



(86) Date de dépôt PCT/PCT Filing Date: 2009/11/25
(87) Date publication PCT/PCT Publication Date: 2010/06/03
(85) Entrée phase nationale/National Entry: 2011/04/29
(86) N° demande PCT/PCT Application No.: US 2009/065847
(87) N° publication PCT/PCT Publication No.: 2010/062927
(30) Priorité/Priority: 2008/11/26 (US61/117,995)

(51) Cl.Int./Int.Cl. *C07D 209/02* (2006.01),
A61K 31/403 (2006.01)


(71) Demandeur/Applicant:
ABBOTT LABORATORIES, US

(72) Inventeurs/Inventors:
STEWART, ANDREW, US;
SEARLE, XENIA, US;
DARCZAK, DARIA, US;
YEUNG, MING, US;
DIDOMENICO, STANLEY, US

(74) Agent: TORYS LLP

(54) Titre : NOUVELLES OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES SUBSTITUEES EN TANT QUE
BLOQUEURS DES CANAUX CALCIQUES

(54) Title: NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL
BLOCKERS



(57) Abrégé/Abstract:

The present application relates to calcium channel inhibitors containing compounds of formula (I), wherein L¹, L², R¹, R², and R³ are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 June 2010 (03.06.2010)



(10) International Publication Number
WO 2010/062927 A3

(51) International Patent Classification:

C07D 209/02 (2006.01) **A61K 31/403** (2006.01)

(21) International Application Number:

PCT/US2009/065847

(22) International Filing Date:

25 November 2009 (25.11.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/117,995 26 November 2008 (26.11.2008) US

(71) Applicant (for all designated States except US): **ABBOTT LABORATORIES** [US/US]; 100 Abbott Park Road, D-377 AP6A-1, Abbott Park, IL 60064-6008 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STEWART, Andrew** [US/US]; 1289 Thornbury Lane, Libertyville, IL 60048 (US). **SEARLE, Xenia** [US/US]; 38 N. Alleghany, Grayslake, IL 60030 (US). **DARCZAK, Daria** [US/US]; 3943 N. Kenneth Ave., Chicago, IL 60641 (US). **YE-UNG, Ming** [US/US]; 34422 N. Tanageray Drive, Grayslake, IL 60030 (US). **DIDOMENICO, Stanley** [US/US]; 10109 West Street, Richmond, IL 60071 (US).

(74) Agent: **MUELLER, Lisa**; Polsinelli Shughart PC, 700 W. 47th Street, Suite 1000, Kansas City, MO 64112 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

22 July 2010

(54) Title: SUBSTITUTED OCTAHYDROCYCLOPNTA (C) PYRROL-4 -AMINES AS CALCIUM CHANNEL BLOCKERS



(57) Abstract: The present application relates to calcium channel inhibitors containing compounds of formula (I), wherein L¹, L², R¹, R², and R³ are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

WO 2010/062927 A3

DEMANDE OU BREVET VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME.

CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 À 313

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets

JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE VOLUME

THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 313

NOTE: For additional volumes, please contact the Canadian Patent Office

NOM DU FICHER / FILE NAME :

NOTE POUR LE TOME / VOLUME NOTE:

NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS

TECHNICAL FIELD AND BACKGROUND

5 The present application relates to compounds that are calcium channel blockers, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

 Voltage-gated calcium channels (VGCC) play an integral role in the regulation of membrane ion conductance, neurotransmitter release, and cellular excitability. VGCC are
10 composed of the pore-forming α_1 subunit and auxiliary $\alpha_2\delta$ and β subunits that modulate channel expression and functional properties (Dolphin, A. C. A short history of voltage-gated calcium channels. *British Journal of Pharmacology* 2006, 147 (Suppl. 1), S56-S62.). These channels can be classified into low-voltage activated (LVA; T-type or $\text{Ca}_v3.x$) and high-voltage activated (HVA; L-type or $\text{Ca}_v1.x$ and N-, P/Q- and R-types or $\text{Ca}_v2.x$)
15 channels. N-, P/Q and R channels typically activate at more positive membrane potentials (~ -30 mV) and are involved in “presynaptic” neurotransmission (McGivern J. G. Targeting N-type and T-type calcium channels for the treatment of pain. *Drug Discovery Today* 2006, 11, 245-253.). T-type channels are activated at relatively negative membrane potentials (~ -60 mV) and are primarily involved in “postsynaptic” excitability (Shin, H.-S.; et al. T-type Ca^{2+}
20 channels as therapeutic targets in the nervous system. *Curr. Opin. in Pharmacology* 2008, 8, 33-41.).

 N-type channel α_δ subunits are encoded by a single gene (α_{1B} or $\text{Ca}_v2.2$) in contrast to pharmacologically defined L- and T-type currents that are encoded by multiple α_1 -subunit genes. A diversity of N-type channels arises due to extensive alternative splicing of the α
25 subunit gene that generates variants with different expression patterns and GPCR-modulated biophysical properties (Gray, A. C.; et al. Neuronal calcium channels: splicing for optimal performance. *Cell Calcium*, 2007, 42(4-5), 409-417.). The primary sequence for $\text{Ca}_v2.2$ is highly conserved across species (rat and human share 91% identity at the amino acid level).

 N-type channels are widely expressed in the central nervous system (CNS) (cortex,
30 hippocampus, striatum, thalamus, brain stem nuclei and spinal cord) and in the peripheral nervous system (PNS) (adult sympathetic nervous system and dorsal root ganglia) (Ino, M.; et al. Functional disorders of the sympathetic nervous system in mice lacking the α_{1B} subunit ($\text{Ca}_v2.2$) of N-type calcium channels. *Proc. Natl. Acad. Sci. USA* 2001, 98(9), 5323-5328). In pain pathways, N-type channels are expressed in the rostral ventral medulla, an important

site of descending pain modulation (Urban, M. O.; et al. Medullary N-type and P/Q-type calcium channels contribute to neuropathy-induced allodynia. *Neuroreport* 2005, 16(6), 563-566.) and are a major contributor to the synaptic neurotransmission that occurs between C/A δ nociceptors and spinal lamina I neurons (Bao, J.; et al. Differences in Ca²⁺ channels governing generation of miniature and evoked excitatory synaptic currents in spinal laminae I and II. *J Neurosci.* 1998, 18(21), 8740-50. Heinke, B.; et al. Pre- and postsynaptic contributions of voltage-dependent Ca²⁺ channels to nociceptive transmission in rat spinal lamina I neurons. *Eur. J. Neurosci.* 2004, 19(1), 103-111.). In contrast, P/Q type channels are expressed almost exclusively in laminae II-IV of the spinal cord and show little co-localization with Substance P and N-type channels (Westenbroek, R. E.; et al. Localization of Ca²⁺ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. *J. Neurosci.* 1998, 18(16), 6319-6330.).

Following nerve injury there is increased expression of Ca_v2.2 (Westenbroek, R. E.; et al. Localization of Ca²⁺ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. *J. Neurosci.* 1998, 18(16), 6319-6330. Cizkova, D.; et al. Localization of N-type Ca²⁺ channels in the rat spinal cord following chronic constrictive nerve injury. *Exp. Brain Res.* 2002, 147, 456-463. Yokoyama, K.; et al. Plastic change of N-type calcium channel expression after preconditioning is responsible for prostaglandin E2-induced long-lasting allodynia. *Anesthesiology* 2003, 99(6), 1364-1370.) and α 2 δ 1 subunits (Luo, Z. D.; et al. Upregulation of dorsal root ganglion α 2 δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. *J. Neurosci.* 2001, 21(6), 1868-1875. Newton, R. A.; et al. Dorsal root ganglion neurons show increased expression of the calcium channel α 2 δ -1 subunit following partial sciatic nerve injury. *Mol. Brain Res.* 2001, 95(1-2), 1-8.) in addition to increases in the superficial layers of the dorsal horn of the spinal cord supporting a role for N-type channels in neuropathic pain. Recently a nociceptor-specific Ca_v2.2 splice variant has been identified in the dorsal root ganglion (Bell, T. J.; et al. Cell specific alternative splicing increases calcium channel density in the pain pathway. *Neuron* 2004, 41(1), 127-138.). These channels have distinct electrophysiological properties and current densities (Castiglioni, A. J.; et al. Alternative splicing in the C-terminus of Ca_v2.2 controls expression and gating of N-type calcium channels. *J. Physiol.* 2006, 576(Pt 1), 119-134.) compared to wildtype Ca_v2.2 channels. While G-protein coupled receptor inhibition of wildtype N-type channels is typically mediated by G $\beta\gamma$ and is voltage-dependent, the nociceptor specific splice variant is inhibited by GPCR activation (e.g. opioids) in a voltage-

independent fashion (Raingo, J.; et al. Alternative splicing controls G protein-dependent inhibition of N-type calcium channels in nociceptors. *Nat. Neurosci.* 2007, 10(3), 285-292.). This mechanism substantially increases the sensitivity of $\text{Ca}_v2.2$ channels to opiates and gamma-aminobutyric acid (GABA) suggesting that cell-specific alternative splicing of mRNA for $\text{Ca}_v2.2$ channels serves as a molecular switch that controls the sensitivity of N-type channels to neurotransmitters and drugs that modulate nociception. Collectively these data provide further support for the role of $\text{Ca}_v2.2$ channels in pain states.

The relative contributions of various HVA Ca^{2+} channels in nociceptive signaling have been evaluated using knockout mice studies. $\text{Ca}_v2.2$ knockout mice are healthy, fertile, and do not display overt neurological deficits (Ino, M.; et al. Functional disorders of the sympathetic nervous system in mice lacking the α_{1B} subunit ($\text{Ca}_v2.2$) of N-type calcium channels. *Proc. Natl. Acad. Sci. USA* 2001, 98(9), 5323-5328. Kim, C.; et al. Altered nociceptive response in mice deficient in the α_{1B} subunit of the voltage-dependent calcium channel. *Mol. Cell. Neurosci.* 2001, 18(2), 235-245. Hatakeyama, S.; et al. Differential nociceptive responses in mice lacking the α_{1B} subunit of N-type Ca^{2+} channels. *Neuroreport* 2001, 12(11), 2423-2427. Liu; L.; et al. In vivo analysis of voltage-dependent calcium channels. *J. Bioenerg. Biomembr.* 2003, 35(6), 671-685.). This finding suggests that other types of Ca_v channels are able to compensate for the lack of $\text{Ca}_v2.2$ channels at most synapses in these mice (Pietrobon, D. Function and dysfunction of synaptic calcium channels: insights from mouse models. *Curr. Opin. Neurobiol.* 2005, 15(3), 257-265.). $\text{Ca}_v2.2$ deficient mice are resistant to the development of inflammatory and neuropathic pain (Kim, C.; et al. Altered nociceptive response in mice deficient in the α_{1B} subunit of the voltage-dependent calcium channel. *Mol. Cell. Neurosci.* 2001, 18(2), 235-245. Hatakeyama, S.; et al. Differential nociceptive responses in mice lacking the α_{1B} subunit of N-type Ca^{2+} channels. *Neuroreport* 2001, 12(11), 2423-2427. Saegusa, H.; et al. Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type calcium channel. *EMBO J.* 2001, 20(10), 2349-2356.), have decreased sympathetic nervous system function (Ino, M.; et al. Functional disorders of the sympathetic nervous system in mice lacking the α_{1B} subunit ($\text{Ca}_v2.2$) of N-type calcium channels. *Proc. Natl. Acad. Sci. USA* 2001, 98(9), 5323-5328.), and altered responses to both ethanol and anesthetics (Newton, R. A.; et al. Dorsal root ganglion neurons show increased expression of the calcium channel $\alpha_{2\delta-1}$ subunit following partial sciatic nerve injury. *Brain Res. Mol. Brain Res.* 2001, 95(1-2), 1-8. Takei, R. et al. Increased sensitivity to halothane but decreased sensitivity to propofol in mice lacking the N-type Ca^{2+} channel. *Neurosci. Lett.*

2003, 350(1), 41-45.). Additional behavioral studies indicate that Ca_v2.2 knockout mice are less anxious, are hyperactive, and show enhanced vigilance compared to wild-type littermates (Beuckmann, C. T.; et al. N-type calcium channel α_{1B} subunit(Ca_v2.2) knock-out mice display hyperactivity and vigilance state differences. J. Neurosci. 2003, 23(17), 6793-6797.).

N- and P/Q-type channels are localized at neuronal synaptic junctions and contribute significantly to neurotransmitter release (Olivera, B. M.; et al. Calcium channel diversity and neurotransmitter release: the omega-conotoxins and omega agatoxins. Annu. Rev. Biochem. 1994, 63, 823-867. Miljanich, G. P.; et al. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 1995, 35, 707-734.). N-type channels play a major role in the release of glutamate, acetylcholine, dopamine, norepinephrine, GABA and calcitonin gene-related protein (CGRP). P/Q-type channels may be involved in the release of glutamate, aspartate, 5HT, GABA and probably glycine (Pietrobon, D. Function and dysfunction of synaptic calcium channels: insights from mouse models. Curr. Opin. Neurobiol. 2005, 15(3), 257-265.).

L, P/Q and N-type channels are blocked by channel specific antagonists i.e., dihydropyridines, ω -agatoxin IVA and ω -conotoxin MVIIA/ ziconotide, respectively. Agatoxin IVa has been shown to block excitatory (Luebke, J. I.; et al. Multiple calcium channel types control glutamatergic synaptic transmission in the hippocampus. Neuron 1993, 11(5), 895-902.) as well as inhibitory neurotransmission (Takahashi, T.; et al. Different types of calcium channels mediate central synaptic transmission. Nature 1993, 366(6451), 156-158.). Intrathecal injection of selective N-type channel blockers (e.g. conotoxin-derived peptides such as GVIA, MVIIA (ziconotide), and CVID) significantly attenuates pain responses in animal models of neuropathic pain, formalin-induced pain, and post-operative pain (Chaplan, S. R.; et al. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J. Pharmacol. Exp. Ther. 1994, 269(3), 1117-1123. Malmberg, A. B.; et al. Voltage-sensitive calcium channels in spinal nociceptive processing: blockade of N-and P-type channels inhibits formalin-induced nociception. J. Neurosci. 1994, 14(8), 4882-4890. Bowersox, S. S.; et al. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produced spinal antinociception in rat models of acute, persistent and neuropathic pain. J. Pharmacol. Exp. Ther. 1996, 279(3), 1243-1249. Wang, Y. X.; et al. Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat

hyperalgesia in a rat model of postoperative pain. *Pain* 2000, 84(2-3), 151-158. Scott, D. A.; et al. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. *Eur. J. Pharmacol.* 2002, 451(3), 279-286.). These peptide blockers bind to the pore region of the channel, do not show voltage- or frequency-

5 dependent activity, and show irreversible channel block (Feng, Z. P.; et al. Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA. *J. Biol. Chem.* 2003, 278(22), 20171-20178.). Ziconotide potently blocks neurotransmitter release in the spinal cord dorsal horn (Matthews, E. A.; et al. Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal

10 horn neuronal responses in a rat model of neuropathy. *Pain* 2001, 92(1-2), 235-246. Smith, M. T.; et al. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. *Pain* 2002, 96(1-2), 119-127. Heinke, B.; et al. Pre- and postsynaptic contributions of voltage-dependent Ca^{2+} channels to nociceptive transmission in rat spinal

15 lamina I neurons. *Eur. J. Neurosci.* 2004, 19(1), 103-111.) and in dorsal root ganglion (DRG) neurons (Evans, A. R.; et al. Differential regulation of evoked peptide release by voltage-sensitive calcium channels in rat sensory neurons. *Brain Res.* 1996, 712(2), 265-273. Smith, M. T.; et al. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P

20 release in rat spinal cord slices. *Pain* 2002, 96(1-2), 119-127.). It also potently and fully blocks depolarization-induced release of substance P from rat spinal cord slices. In contrast, intrathecal delivery of the selective P/Q type blocker ω -agatoxin IVA had no effects on mechanical allodynia in the spinal nerve ligation model (Chaplan, S. R.; et al. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. *J. Pharmacol. Exp. Ther.* 1994, 269(3), 1117-1123.) or thermal hyperalgesia in the chronic constriction

25 injury model (Yamamoto, T.; et al. Differential effects of intrathecally administered N- and P-type voltage-sensitive calcium channel blockers upon two models of experimental mononeuropathy in the rat. *Brain Res.* 1998, 794(2), 329-332.) of neuropathic pain.

Pain is the most common symptom of disease and the most frequent complaint with


30 which patients present to physicians. Inadequate pain management across the spectrum of pain etiologies remains a major public health problem. Going forward, the development of novel therapeutics with new mechanisms of action for the treatment of pain including calcium channel blockade will have a significant impact on the ongoing struggle to balance

efficacy and safety for those patients most in need. The compounds of the present invention are novel calcium channel blockers that have utility in treating pain, amongst other conditions.

5

SUMMARY OF THE INVENTION

The invention is directed to compounds of formula (I)



(I),

or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination

10 thereof, wherein

L¹ is C(O), S(O)₂, SO₂N(R⁴), C(O)O or -(CR^aR^b)_m-;

R¹ is alkyl, G¹, -CH(G¹)₂, -(CR^aR^b)_m-G¹, -(CR^aR^b)_m-CH(G¹)₂, -(CR^eR^f)_n-N(R⁵)₂,
 -(CR^eR^f)_n-N(R⁵)-C(O)O(alkyl), -(CR^eR^f)_n-N(R⁵)-C(O)(alkyl), or -(CR^eR^f)_n-N(R⁵)-SO₂R⁶; or

L¹-R¹ taken together are hydrogen, alkyl, hydroxyalkyl, G¹, or -CH(G¹)₂;

15 L² is -(CR^cR^d)_p-, C(O), C(O)N(R⁴), S(O)₂, SO₂N(R⁵), or C(O)O;

R² is alkyl, G², -C(R^c)(G²)(G³), -(CR^cR^d)_p-G², -(CR^cR^d)_p-CH(G²)(G³),
 -(CR^gR^h)_q-N(R⁵)-C(O)O(alkyl), -(CR^gR^h)_q-N(R⁵)-C(O)O-G², -(CR^gR^h)_q-N(R⁵)-C(O)(alkyl),
 -(CR^gR^h)_q-N(R⁵)-SO₂R⁶, -(CR^gR^h)_q-N(R⁴)(R⁵), -(CR^gR^h)_q-N(R⁵)-C(O)N(R⁵)-(alkyl), or
 -(CR^gR^h)_q-N(R⁵)-C(O)N(R⁵)-G²; or

20 L²-R² taken together are alkyl, G², or -C(R^c)(G²)(G³);

m and p, at each occurrence, are each independently 1, 2, 3, 4, 5, or 6;

n and q, at each occurrence, are each independently 1, 2, 3, 4, or 5;

R^a, R^b, R^c, and R^d, at each occurrence, are each independently hydrogen, alkyl,
 arylalkyl, halogen, haloalkyl or OR⁷; or

25 R^a and R^b, or R^c and R^d, together with the carbon atom to which they are attached,
 optionally form a C₃₋₆ cycloalkyl ring;

R^e, R^f, R^g, and R^h, at each occurrence, are each independently hydrogen, alkyl,
 halogen, haloalkyl, OR⁷, cycloalkylalkyl, heteroaryl, arylalkyl, or heteroarylalkyl; wherein
 the aryl, cycloalkyl and heteroaryl groups of aryl, cycloalkyl and heteroaryl are each

independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of alkyl and haloalkyl;

G^1 , G^2 , and G^3 at each occurrence, are each independently aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; wherein G^1 , G^2 , and G^3 at each occurrence are each
 5 independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cyano, haloalkyl, halogen, nitro, oxo, phenyl, $N(R^7)_2$, $N(R^7)C(O)R^7$, OR^7 , $C(O)R^7$, $C(O)OR^7$, $C(O)N(R^7)_2$, SO_2R^8 , and $SO_2N(R^7)_2$; and wherein G^1 is other than quinoline, quinazolidinedione, or pyridopyrimidinedione;

R^3 is hydrogen, alkyl, haloalkyl, cycloalkyl, or cycloalkylalkyl;

10 R^4 , R^5 , and R^7 , at each occurrence, are each independently hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, or haloalkyl; wherein said aryl, the aryl of arylalkyl and cycloalkyl are independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of alkyl, haloalkyl, and halogen;

R^6 is alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; wherein said
 15 aryl, heteroaryl, and heterocycle are independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of alkyl, haloalkyl, and halogen;

R^8 is alkyl or haloalkyl;

with the proviso that L^1-R^1 and L^2-R^2 are not both alkyl at the same time;

20 and with the proviso that when L^1-R^1 is alkyl, L^2-R^2 is other than $C(O)N(R^4)$, wherein R^4 is alkyl;

and with the further proviso that the compound is other than:

N-(2-trityloctahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

N-(octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide

25 *N*-methyl-*N*-(2-trityloctahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

N-methyl-*N*-(octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

6-(2-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)methyl-2*H*-pyrido[3,2-*b*][1,4]thiazin-3(4*H*)-one;

30 *tert*-butyl 2-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)octahydrocyclopenta[*c*]pyrrol-4-ylcarbamate;

tert-butyl 2-benzyl octahydrocyclopenta[*c*]pyrrol-4-ylcarbamate; or

tert-butyl octahydrocyclopenta[*c*]pyrrol-4-ylcarbamate.

Another aspect of the invention relates to pharmaceutical compositions comprising therapeutically effective amount of compound(s) of the invention or pharmaceutically acceptable salts thereof, in combination with one or more pharmaceutically acceptable carrier. Such compositions can be administered in accordance with a method of the invention, typically as part of a therapeutic regimen for treatment or prevention of conditions and disorders related to calcium channels. More particularly, the method is useful for treating conditions related to a method of treating pain in a subject in need thereof. The method comprises administering to the subject a therapeutically suitable amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. Conditions related to pain include acute pain, chronic pain, neuropathic pain, inflammatory pain, visceral pain, cancer pain, allodynia, fibromyalgia, sciatica, back pain, and headache pain including migraine, or combinations thereof.


Another aspect of the invention provides a method of treating disorders of the central nervous system in a subject in need thereof. The method comprising the step of: administering a therapeutically suitable amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. The disorders of the central nervous system include stroke, epilepsy, manic depression, bipolar disorders, depression, anxiety, schizophrenia, migraine, and psychoses; neural degenerative disorders including Alzheimer's disease, AIDS related dementia, Parkinson's disease, neuropathy caused by head injury, and dementia caused by cerebrovascular disorders; disorders of the lower urinary tract including overactive bladder, prostatitis, prostatic hyperplasia, and benign prostatic hyperplasia; disorders caused by psychogenic stress including bronchial asthma, unstable angina, and hypersensitive colon inflammation; cardiovascular disorders including hypertension, atherosclerosis, heart failure, and cardiac arrhythmias; drug addiction withdrawal symptoms, including ethanol addiction withdrawal symptoms; skin disorders including pruritis and allergic dermatitis, inflammatory bowel disease; cancer; diabetes; and infertility and sexual dysfunction, or combinations thereof.

The compounds, compositions comprising the compounds, and methods for treating or preventing conditions and disorders by administering the compounds are further described herein.

These and other objects of the invention are described in the following paragraphs. These objects should not be deemed to narrow the scope of the invention.

DETAILED DESCRIPTION

Compounds of formula (I) are disclosed in this invention



(I),

wherein L¹, L², R¹, R², and R³ are as defined above in the Summary of the Invention.

Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

In various embodiments, the present invention provides at least one variable that occurs more than one time in any substituent or in the compound of the invention or any other formulae herein. Definition of a variable on each occurrence is independent of its definition at another occurrence. Further, combinations of substituents are permissible only if such combinations result in stable compounds. Stable compounds are compounds, which can be isolated from a reaction mixture.

a. Definitions

As used in the specification and the appended claims, unless specified to the contrary, the following terms have the meaning indicated:

The term "alkenyl" as used herein, means a straight or branched hydrocarbon chain containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.

The term "alkenylene" denotes a divalent group derived from a straight or branched chain hydrocarbon of 2 to 4 carbon atoms and contains at least one carbon-carbon double. Representative examples of alkenylene include, but are not limited to, -CH=CH- and -CH₂CH=CH-.

The term "alkyl" as used herein, means a straight or branched, saturated hydrocarbon chain containing from 1 to 10 carbon atoms. The term "lower alkyl" or "C₁₋₆ alkyl" means a straight or branched chain hydrocarbon containing 1 to 6 carbon atoms. The term "C₁₋₃ alkyl" means a straight or branched chain hydrocarbon containing 1 to 3 carbon atoms.

5 Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, *tert*-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.

The term "alkylene" denotes a divalent group derived from a straight or branched chain hydrocarbon 1 to 10 carbon atoms. Representative examples of alkylene include, but
10 are not limited to, -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH₂CH₂CH₂CH₂-, and -CH₂CH(CH₃)CH₂-.

The term "alkynyl" as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-
15 propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.

The term "aryl" as used herein, means phenyl or a bicyclic aryl. The bicyclic aryl is naphthyl, or a phenyl fused to a monocyclic cycloalkyl, or a phenyl fused to a monocyclic cycloalkenyl. Representative examples of the aryl groups include, but are not limited to, dihydroindenyl, indenyl, naphthyl, dihydronaphthalenyl, and tetrahydronaphthalenyl. The
20 bicyclic aryl is attached to the parent molecular moiety through any carbon atom contained within the bicyclic ring system. The aryl groups of the present invention can be unsubstituted or substituted.

The term "arylalkyl" as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkylene group, as defined herein. Representative
25 examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, and 2-naphth-2-ylethyl.

The term "cyano" as used herein, means a -CN group.

The term "cycloalkyl" or "cycloalkane" as used herein, means a monocyclic, a bicyclic, or a tricyclic cycloalkyl. The monocyclic cycloalkyl is a carbocyclic ring system
30 containing three to eight carbon atoms, zero heteroatoms and zero double bonds. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The bicyclic cycloalkyl is a monocyclic cycloalkyl fused to a monocyclic cycloalkyl ring, or a bridged monocyclic ring system in which two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge containing one, two,

three, or four carbon atoms. Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. Tricyclic cycloalkyls are exemplified by a bicyclic cycloalkyl fused to a monocyclic cycloalkyl, or a bicyclic cycloalkyl in which two non-adjacent carbon atoms of the ring systems are linked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms. Representative examples of tricyclic-ring systems include, but are not limited to, tricyclo[3.3.1.0^{3,7}]nonane (octahydro-2,5-methanopentalene or noradamantane), and tricyclo[3.3.1.1^{3,7}]decane (adamantane). The monocyclic, bicyclic, and tricyclic cycloalkyls can be unsubstituted or substituted, and are attached to the parent molecular moiety through any substitutable atom contained within the ring system.

The term "cycloalkylalkyl" as used herein, means a cycloalkyl group appended to the parent molecular moiety through an alkyl group, as defined herein.

The term "cycloalkenyl" or "cycloalkene" as used herein, means a monocyclic or a bicyclic hydrocarbon ring system. The monocyclic cycloalkenyl has four-, five-, six-, seven- or eight carbon atoms and zero heteroatoms. The four-membered ring systems have one double bond, the five- or six-membered ring systems have one or two double bonds, and the seven- or eight-membered ring systems have one, two or three double bonds. Representative examples of monocyclic cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. The bicyclic cycloalkenyl is a monocyclic cycloalkenyl fused to a monocyclic cycloalkyl group, or a monocyclic cycloalkenyl fused to a monocyclic cycloalkenyl group. The monocyclic or bicyclic cycloalkenyl ring may contain one or two alkylene bridges, each consisting of one, two or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system.

Representative examples of the bicyclic cycloalkenyl groups include, but are not limited to, 4,5,6,7-tetrahydro-3aH-indene, octahydronaphthalenyl and 1,6-dihydro-pentalene. The monocyclic and bicyclic cycloalkenyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring systems, and can be unsubstituted or substituted.

The term "halo" or "halogen" as used herein, means Cl, Br, I, or F.

The term "haloalkyl" as used herein, means an alkyl group, as defined herein, in which one, two, three, four, five or six hydrogen atoms are replaced by halogen. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-

fluoroethyl, 2,2,2-trifluoroethyl, trifluoromethyl, difluoromethyl, pentafluoroethyl, 2-chloro-3-fluoropentyl, and trifluoropropyl such as 3,3,3-trifluoropropyl.

The term "heterocycle" or "heterocyclic" as used herein, means a monocyclic heterocycle, a bicyclic heterocycle, or a tricyclic heterocycle. The monocyclic heterocycle is a three-, four-, five-, six-, seven-, or eight-membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S. The three- or four-membered ring contains zero or one double bond, and one heteroatom selected from the group consisting of O, N, and S. The five-membered ring contains zero or one double bond and one, two or three heteroatoms selected from the group consisting of O, N and S. The six-membered ring contains zero, one or two double bonds and one, two, or three heteroatoms selected from the group consisting of O, N, and S. The seven- and eight-membered rings contains zero, one, two, or three double bonds and one, two, or three heteroatoms selected from the group consisting of O, N, and S. Representative examples of monocyclic heterocycles include, but are not limited to, azetidiny, azepanyl, aziridiny, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperaziny, piperidiny, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, 1,2-thiazinanyl, 1,3-thiazinanyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl. The bicyclic heterocycle is a monocyclic heterocycle fused to a phenyl group, or a monocyclic heterocycle fused to a monocyclic cycloalkyl, or a monocyclic heterocycle fused to a monocyclic cycloalkenyl, or a monocyclic heterocycle fused to a monocyclic heterocycle, or a bridged monocyclic heterocycle ring system in which two non adjacent atoms of the ring are linked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms, or an alkenylene bridge of two, three, or four carbon atoms. Representative examples of bicyclic heterocycles include, but are not limited to, benzopyranyl, benzothiopyranyl, chromanyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, 2,3-dihydroisoquinoline, azabicyclo[2.2.1]heptyl (including 2-azabicyclo[2.2.1]hept-2-yl), 2,3-dihydro-1H-indolyl, isoindolyl, octahydrocyclopenta[*c*]pyrrolyl, octahydropyrrolopyridinyl, and tetrahydroisoquinolyl. Tricyclic heterocycles are exemplified by a bicyclic heterocycle fused to a phenyl group, or a bicyclic heterocycle fused to a monocyclic cycloalkyl, or a bicyclic heterocycle fused to a monocyclic cycloalkenyl, or a bicyclic heterocycle fused to a monocyclic heterocycle, or a

bicyclic heterocycle in which two non adjacent atoms of the bicyclic ring are linked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms, or an alkenylene bridge of two, three, or four carbon atoms. Examples of tricyclic heterocycles include, but not limited to, octahydro-2,5-epoxypentalene, hexahydro-2*H*-2,5-methanocyclopenta[*b*]furan, hexahydro-1*H*-1,4-methanocyclopenta[*c*]furan, aza-adamantane (1-azatricyclo[3.3.1.1^{3,7}]decane), and oxa-adamantane (2-oxatricyclo[3.3.1.1^{3,7}]decane). The monocyclic, bicyclic, and tricyclic heterocycles are connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the rings, and can be unsubstituted or substituted.

The term "heteroaryl" as used herein, means a monocyclic heteroaryl or a bicyclic heteroaryl. The monocyclic heteroaryl is a five- or six-membered ring. The five-membered ring contains two double bonds. The five-membered ring may contain one heteroatom selected from O or S; or one, two, three, or four nitrogen atoms and optionally one oxygen or sulfur atom. The six-membered ring contains three double bonds and one, two, three or four nitrogen atoms. Representative examples of monocyclic heteroaryl include, but are not limited to, furanyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, 1,3-oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, 1,3-thiazolyl, thienyl, triazolyl, and triazinyl. The bicyclic heteroaryl consists of a monocyclic heteroaryl fused to a phenyl, or a monocyclic heteroaryl fused to a monocyclic cycloalkyl, or a monocyclic heteroaryl fused to a monocyclic cycloalkenyl, or a monocyclic heteroaryl fused to a monocyclic heteroaryl, or a monocyclic heteroaryl fused to a monocyclic heterocycle. Representative examples of bicyclic heteroaryl groups include, but are not limited to, benzofuranyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzoxadiazolyl, 6,7-dihydro-1,3-benzothiazolyl, imidazo[1,2-*a*]pyridinyl, indazolyl, indolyl, isoindolyl, isoquinolinyl, naphthyridinyl, pyridoimidazolyl, quinolinyl, thiazolo[5,4-*b*]pyridin-2-yl, thiazolo[5,4-*d*]pyrimidin-2-yl, and 5,6,7,8-tetrahydroquinolin-5-yl. The monocyclic and bicyclic heteroaryl groups of the present invention can be substituted or unsubstituted and are connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the ring systems.

The term "heteroarylalkyl," as used herein, means a heteroaryl group appended to the parent molecular moiety through an alkyl group, as defined herein.

The term "heteroatom" as used herein, means a nitrogen, oxygen, or sulfur atom.

The term "hydroxyl" or "hydroxy" as used herein, means an -OH group.

The term "hydroxyalkyl" as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkylene group, as defined

herein. Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4-hydroxyheptyl.

The term "nitro" as used herein, means a $-\text{NO}_2$ group.

5 The term "oxo" as used herein, means a $=\text{O}$ group.

b. Compounds

Compounds of the invention have the formula (I) as described above.

10 Particular values of variable groups in compounds of formula (I) are as follows. Such values may be used where appropriate with any of the other values, definitions, claims or embodiments defined hereinbefore or hereinafter.

More particularly, compound of formula (I) can include, but are not limited to compounds wherein $\text{L}^1\text{-R}^1$ taken together are hydrogen, alkyl, hydroxyalkyl, G^1 , or $\text{CH}(\text{G}^1)_2$.

15 In another embodiment, compound of formula (I) can include, but are not limited to compounds wherein L^1 is $\text{C}(\text{O})$, $\text{S}(\text{O})_2$, $\text{SO}_2\text{N}(\text{R}^4)$, $\text{C}(\text{O})\text{O}$ or $-(\text{CR}^a\text{R}^b)_m-$; wherein m is 1, 2, 3, 4, 5, or 6.

In a further embodiment, compound of formula (I) can include, but are not limited to compounds wherein L^1 is $\text{C}(\text{O})$, $\text{S}(\text{O})_2$, or $-(\text{CR}^a\text{R}^b)_m-$.

20 In another embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^1 is alkyl, G^1 , $\text{CH}(\text{G}^1)_2$, $-(\text{CR}^a\text{R}^b)_m\text{-G}^1$, $-(\text{CR}^a\text{R}^b)_m\text{-CH}(\text{G}^1)_2$, $-(\text{CR}^e\text{R}^f)_n\text{-N}(\text{R}^5)_2$, $-(\text{CR}^e\text{R}^f)_n\text{-N}(\text{R}^5)\text{-C}(\text{O})\text{O}(\text{alkyl})$, $-(\text{CR}^e\text{R}^f)_n\text{-N}(\text{R}^5)\text{-C}(\text{O})(\text{alkyl})$, or $-(\text{CR}^e\text{R}^f)_n\text{-N}(\text{R}^5)\text{-SO}_2\text{R}^6$; wherein m is 1, 2, 3, 4, 5, or 6; and wherein n is 1, 2, 3, 4, or 5.

In a further embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^1 is G^1 , $\text{CH}(\text{G}^1)_2$, $-(\text{CR}^a\text{R}^b)_m\text{-G}^1$, $-(\text{CR}^a\text{R}^b)_m\text{-CH}(\text{G}^1)_2$.

25 In one embodiment, compound of formula (I) can include, but are not limited to compounds wherein $\text{L}^2\text{-R}^2$ taken together are alkyl, G^2 , or $\text{C}(\text{R}^c)(\text{G}^2)(\text{G}^3)$.

In a further embodiment, compound of formula (I) can include, but are not limited to compounds wherein $\text{L}^2\text{-R}^2$ together are alkyl, aryl, cycloalkyl, heteroaryl or $-\text{C}(\text{R}^c)(\text{G}^2)(\text{G}^3)$, wherein R^c is hydrogen and G^2 and G^3 are each aryl or heteroaryl.

30 In another embodiment, compound of formula (I) can include, but are not limited to compounds wherein L^2 is $-(\text{CR}^c\text{R}^d)_p-$, $\text{C}(\text{O})$, $\text{C}(\text{O})\text{N}(\text{R}^4)$, $\text{S}(\text{O})_2$, $\text{SO}_2\text{N}(\text{R}^5)$, or $\text{C}(\text{O})\text{O}$; wherein p is 1, 2, 3, 4, 5, or 6.

In a further embodiment, compound of formula (I) can include, but are not limited to compounds wherein L^2 is $-(\text{CR}^c\text{R}^d)_p-$, $\text{C}(\text{O})$, $\text{C}(\text{O})\text{N}(\text{R}^4)$, or $\text{S}(\text{O})_2$, wherein p is 1.

In another embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^2 is alkyl, G^2 , $-C(R^c)(G^2)(G^3)$, $-(CR^cR^d)_p-G^2$, $-(CR^cR^d)_p-CH(G^2)(G^3)$, $-(CR^gR^h)_q-N(R^5)-C(O)O(alkyl)$, $-(CR^gR^h)_q-N(R^5)-C(O)O-G^2$, $-(CR^gR^h)_q-N(R^5)-C(O)(alkyl)$, $-(CR^gR^h)_q-N(R^5)-SO_2R^6$, $-(CR^gR^h)_q-N(R^4)(R^5)$, $-(CR^gR^h)_q-N(R^5)-C(O)N(R^5)-(alkyl)$, or
 5 $-(CR^gR^h)_q-N(R^5)-C(O)N(R^5)-G^2$; wherein q is 1, 2, 3, 4, or 5; and wherein p is 1, 2, 3, 4, 5, or 6.

In another embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^a and R^b , at each occurrence, are each independently hydrogen, alkyl, arylalkyl, halogen, or haloalkyl or OR^7 .

10 In a further embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^a and R^b , at each occurrence, are each independently hydrogen, alkyl, or arylalkyl.

In yet another embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^a and R^b , together with the carbon atom to which they are attached,
 15 optionally form a C_{3-6} cycloalkyl ring.

In another embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^c and R^d , at each occurrence, are each independently hydrogen, alkyl, arylalkyl, halogen, or haloalkyl or OR^7 .

In a further embodiment, compound of formula (I) can include, but are not limited to
 20 compounds wherein R^c and R^d , at each occurrence, are each independently hydrogen, alkyl, arylalkyl, or OR^7 , wherein R^7 is hydrogen.

In yet another embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^c and R^d , together with the carbon atom to which they are attached, optionally form a C_{3-6} cycloalkyl ring.

25 In one embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^e and R^f , at each occurrence, are each independently hydrogen, alkyl, halogen, haloalkyl, OR^7 , cycloalkylalkyl, heteroaryl, arylalkyl, or heteroarylalkyl; wherein the aryl, cycloalkyl and heteroaryl groups of aryl, cycloalkyl and heteroaryl are each independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently
 30 selected from the group consisting of alkyl and haloalkyl.

In another embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^g , and R^h , at each occurrence, are each independently hydrogen, alkyl, halogen, haloalkyl, OR^7 , cycloalkylalkyl, heteroaryl, arylalkyl, or heteroarylalkyl; wherein the aryl, cycloalkyl and heteroaryl groups of aryl, cycloalkyl and heteroaryl are each

independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of alkyl and haloalkyl.

In a further embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^g , and R^h , at each occurrence, are each independently hydrogen, alkyl, 5 arylalkyl or cycloalkyl.

In one embodiment, compound of formula (I) can include, but are not limited to compounds wherein G^1 at each occurrence, is independently aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; wherein G^1 at each occurrence is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, 10 alkenyl, alkynyl, cyano, haloalkyl, halogen, nitro, oxo, phenyl, $N(R^7)_2$, $N(R^7)C(O)R^7$, OR^7 , $C(O)R^7$, $C(O)OR^7$, $C(O)N(R^7)_2$, SO_2R^8 , and $SO_2N(R^7)_2$.

In another embodiment, compound of formula (I) can include, but are not limited to compounds wherein G^1 at each occurrence, is independently aryl, cycloalkyl, or heteroaryl; wherein G^1 at each occurrence is independently unsubstituted or substituted with 1, 2, or 3 15 substituents selected from the group consisting of alkyl, cyano, haloalkyl, halogen, or OR^7 .

In one embodiment, compound of formula (I) can include, but are not limited to compounds wherein G^2 at each occurrence, is independently aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; wherein G^2 at each occurrence is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, 20 alkenyl, alkynyl, cyano, haloalkyl, halogen, nitro, oxo, phenyl, $N(R^7)_2$, $N(R^7)C(O)R^7$, OR^7 , $C(O)R^7$, $C(O)OR^7$, $C(O)N(R^7)_2$, SO_2R^8 , and $SO_2N(R^7)_2$.

In a further embodiment, compound of formula (I) can include, but are not limited to compounds wherein G^2 at each occurrence, is independently aryl, cycloalkyl, heteroaryl or heterocycle; wherein G^2 at each occurrence is independently unsubstituted or substituted with 25 1, 2, or 3 substituents selected from the group consisting of alkyl, cyano, haloalkyl, halogen, nitro, oxo, OR^7 , $C(O)R^7$, $C(O)OR^7$ or SO_2R^8 ,

In one embodiment, compound of formula (I) can include, but are not limited to compounds wherein G^3 at each occurrence, is independently aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; wherein G^2 at each occurrence is independently unsubstituted or 30 substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cyano, haloalkyl, halogen, nitro, oxo, phenyl, $N(R^7)_2$, $N(R^7)C(O)R^7$, OR^7 , $C(O)R^7$, $C(O)OR^7$, $C(O)N(R^7)_2$, SO_2R^8 , and $SO_2N(R^7)_2$.

In a further embodiment, compound of formula (I) can include, but are not limited to compounds wherein G^3 at each occurrence, is independently aryl, cycloalkyl, heteroaryl or

heterocycle; wherein G^2 at each occurrence is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of alkyl, cyano, haloalkyl, halogen, nitro, oxo, OR^7 , $C(O)R^7$, $C(O)OR^7$ or SO_2R^8 ,

In one embodiment, compound of formula (I) can include, but are not limited to
5 compounds wherein R^3 is hydrogen, alkyl, haloalkyl, cycloalkyl, or cycloalkylalkyl.

In a further embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^3 is hydrogen, alkyl, or cycloalkyl.

In one embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^4 and R^5 , at each occurrence, are each independently hydrogen, alkyl,
10 aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, or haloalkyl; wherein said aryl, the aryl of arylalkyl and cycloalkyl are independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of alkyl, haloalkyl, and halogen.

In a further embodiment, compound of formula (I) can include, but are not limited to
15 compounds wherein R^4 and R^5 , at each occurrence, are each independently hydrogen, alkyl, arylalkyl, cycloalkyl or cycloalkylalkyl.

In one embodiment; compound of formula (I) can include, but are not limited to compounds wherein R^6 is alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; wherein said aryl, heteroaryl, and heterocycle are independently unsubstituted or substituted
20 with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of alkyl, haloalkyl, and halogen.

In another embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^6 is alkyl or cycloalkyl.

In one embodiment, compound of formula (I) can include, but are not limited to
25 compounds wherein R^7 , at each occurrence, is independently hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, or haloalkyl; wherein said aryl, the aryl of arylalkyl and cycloalkyl are independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of alkyl, haloalkyl, and halogen.

In a further embodiment, compound of formula (I) can include, but are not limited to
30 compounds wherein R^7 , at each occurrence, is independently hydrogen or alkyl.

In one embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^8 is alkyl or haloalkyl.

In a further embodiment, compound of formula (I) can include, but are not limited to compounds wherein R^8 is alkyl.

In one embodiment, in a compound of formula (I), L^1 is $-(CR^aR^b)_m-$; R^a and R^b are each hydrogen; m is 1; R^1 is G^1 , wherein G^1 is aryl; L^2 is $C(O)$; R^2 is $-(CR^cR^d)_p-G^2$, wherein G^2 is aryl and p is 1; R^c and R^d , together with the carbon atom to which they are attached form a C_{3-6} cycloalkyl ring; and R^3 is hydrogen.

5 In another embodiment, in a compound of formula (I), L^1-R^1 together are alkyl; or L^1 is $-(CR^aR^b)_m-$ or $C(O)$; and R^1 is G^1 ; wherein G^1 is aryl, cycloalkyl, or heteroaryl; L^2 is $C(O)$; R^2 is $-(CR^cR^d)_p-G^2$; wherein G^2 is aryl and p is 1 or 2; R^a , R^b , R^c , and R^d , at each occurrence are independently hydrogen, alkyl or arylalkyl; and R^3 is hydrogen or alkyl.

10 In one embodiment, in a compound of formula (I), L^1 is $-(CR^aR^b)_m-$; m is 1 or 2; R^a and R^b are each hydrogen; R^1 is G^1 , wherein G^1 is aryl; L^2 is $C(O)N(R^4)$, wherein R^4 is alkyl; R^2 is G^2 , wherein G^2 is aryl; and R^3 is hydrogen.

In another embodiment, in a compound of formula (I), L^1 is $-(CR^aR^b)_m-$, $C(O)$, or $S(O)_2$; R^a and R^b at each occurrence are each hydrogen; m is 1; R^1 is alkyl or G^1 , wherein G^1 is aryl or cycloalkyl; L^2 is $C(O)$; and R^2 is $-(CR^cR^d)_p-G^2$; wherein R^c and R^d at each
15 occurrence are independently hydrogen, alkyl or OR^7 ; p is 1; G^2 is cycloalkyl or heterocycle; wherein said cycloalkyl or heterocycle is unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of alkyl, haloalkyl, halogen, oxo $C(O)OR^7$; R^7 is hydrogen;; and R^3 is hydrogen.

20 In one embodiment, in a compound of formula (I), L^1 is $-(CR^aR^b)_m-$; R^a and R^b are each hydrogen; m is 1; R^1 is G^1 ; wherein G^1 is aryl; L^2-R^2 together are cycloalkyl; and R^3 is hydrogen or cycloalkyl.

In another embodiment, in a compound of formula (I), L^1 is $-(CR^aR^b)_m-$; R^a and R^b are each hydrogen; m is 1; R^1 is G^1 ; wherein G^1 is aryl; L^2 is $C(O)$; R^2 is $-C(R^c)(G^2)(G^3)$ or $-(CR^cR^d)_p-CH(G^2)(G^3)$; wherein G^2 is aryl and G^3 is aryl or cycloalkyl; R^c and R^d , at each
25 occurrence, are each independently hydrogen; p is 1, 2, 3, 4, or 5; and R^3 is hydrogen.

In a further embodiment, in a compound of formula (I), L^1-R^1 together are hydrogen or $-CH(G^1)_2$; wherein each G^1 is aryl or heteroaryl; or L^1 is $-(CR^aR^b)_m-$, $C(O)$, or $S(O)_2$; and R^1 is G^1 , $-CH(G^1)_2$, $-(CR^aR^b)_m-G^1$, $-(CR^aR^b)_m-CH(G^1)_2$, $-(CR^eR^f)_n-N(R^5)_2$, wherein each G^1 is aryl or heteroaryl; R^a and R^b at each occurrence, are each independently hydrogen; R^e and R^f
30 at each occurrence, are each independently hydrogen or alkyl; m is 1, 2, 3, 4, or 5; n is 1 or 2; R^5 is hydrogen or alkyl; L^2 is $C(O)$; R^2 is $-C(R^c)(G^2)(G^3)$; wherein G^2 and G^3 are each cycloalkyl; R^c is hydrogen or OR^7 , R^7 is hydrogen; and R^3 is hydrogen.

In one embodiment, in a compound of formula (I), L^1 is $-(CR^aR^b)_m-$; R^a and R^b are each hydrogen; m is 1; R^1 is G^1 , wherein G^1 is aryl; L^2 is $C(O)$; R^2 is alkyl or G^2 ; wherein G^2 is cycloalkyl or heterocycle; R^3 is hydrogen.

In another embodiment, in a compound of formula (I), L^1 is $-(CR^aR^b)_m-$, $C(O)$ or $S(O)_2$, wherein R^a and R^b are each hydrogen and m is 1 or 2; R^1 is G^1 , $-\text{CH}(G^1)_2$ or $-(CR^aR^b)_m-G^1$, wherein G^1 at each occurrence is aryl or heteroaryl; L^2 is $C(O)$; R^2 is $-(CR^gR^h)_q-N(R^5)-C(O)O(\text{alkyl})$, $-(CR^gR^h)_q-N(R^5)-C(O)O-G^2$, $-(CR^gR^h)_q-N(R^5)-C(O)(\text{alkyl})$, $-(CR^gR^h)_q-N(R^5)-SO_2R^6$, $-(CR^gR^h)_q-N(R^4)(R^5)$, $-(CR^gR^h)_q-N(R^5)-C(O)N(R^5)-(\text{alkyl})$, or $-(CR^gR^h)_q-N(R^5)-C(O)N(R^5)-G^2$; q is 1 or 2; R^g and R^h , at each occurrence, are each independently hydrogen, alkyl, arylalkyl or cycloalkylalkyl; R^4 and R^5 at each occurrence, are each independently hydrogen, alkyl, arylalkyl, or cycloalkyl; R^6 is alkyl, aryl, or cycloalkyl; G^2 is aryl or cycloalkyl; and R^3 is hydrogen, alkyl, cycloalkyl or cycloalkylalkyl.

In one embodiment, in a compound of formula (I), L^1-R^1 together are hydrogen or hydroxyalkyl; or L^1 is $-(CR^aR^b)_m-$, $C(O)$ or $S(O)_2$; and R^1 is G^1 or $-\text{CH}(G^1)_2$, wherein G^1 is aryl or heteroaryl, and wherein R^a and R^b , at each occurrence, are each independently hydrogen or alkyl; m is 1, 2, 3, 4, or 5; L^2 is $S(O)_2$; R^2 is G^2 , wherein G^2 is aryl or heteroaryl; and R^3 is hydrogen, alkyl or cycloalkyl.

In a further embodiment, in a compound of formula (I), L^1 is $-(CR^aR^b)_m-$; R^a and R^b , at each occurrence, are each independently hydrogen; m is 1, 2, 3, 4, or 5; L^2 is $C(O)$; R^2 is $-(CR^cR^d)_p-G^2$; wherein G^2 is aryl; p is 1; R^c and R^d , at each occurrence, are each independently hydrogen or alkyl; and R^3 is hydrogen.

In another embodiment, in a compound of formula (I), L^1 is $C(O)$, $S(O)_2$ or $-(CR^aR^b)_m-$; R^a and R^b , at each occurrence, are independently hydrogen or alkyl; m is 1; R^1 is G^1 or $-(CR^aR^b)_m-G^1$, wherein G^1 is aryl or heteroaryl; L^2 is $-(CR^cR^d)_p-$; R^c and R^d are each hydrogen; p is 1; R^2 is G^2 , wherein G^2 is aryl, cycloalkyl or heteroaryl; or L^2-R^2 taken together are alkyl, G^2 , or $-C(R^c)(G^2)(G^3)$, wherein G^2 and G^3 are each aryl or heteroaryl and R^c is hydrogen; and R^3 is hydrogen or alkyl.

In a further embodiment, in a compound of formula (I), L^1 is $C(O)$; R^1 is $-(CR^eR^f)_n-N(R^5)_2$; n is 1 or 2; R^e and R^f at each occurrence are each independently hydrogen or alkyl; R^5 at each occurrence is independently hydrogen or alkyl; L^2 is $C(O)$ or $S(O)_2$; R^2 is G^2 or $-C(R^c)(G^2)(G^3)$, wherein G^2 and G^3 are each aryl or heteroaryl and R^c is hydrogen; and R^3 is hydrogen, alkyl, or cycloalkyl. In an additional embodiment, in a compound of formula (I), L^1 is $C(O)$; R^1 is $-(CR^eR^f)_n-N(R^5)_2$ or $-(CR^eR^f)_n-N(R^5)C(O)O(\text{alkyl})$; n is 1 or 2; R^e and R^f at each occurrence are each independently hydrogen, alkyl, or arylalkyl; R^5 at each

occurrence is independently hydrogen, alkyl or cycloalkyl; L^2 is C(O); R^2 is $-(CR^gR^h)_qN(R^4)(R^5)$ or $-(CR^gR^h)_qN(R^5)C(O)O(alkyl)$; q is 1 or 2; R^4 is hydrogen or alkyl; R^g and R^h at each occurrence are each independently hydrogen or alkyl; and R^3 is hydrogen.

In another embodiment, in a compound of formula (I), L^1-R^1 taken together are
 5 hydrogen, G^1 or $CH(G^1)_2$, wherein G^1 is aryl or heteroaryl; L^2 is C(O); R^2 is $-(CR^gR^h)_qN(R^4)(R^5)$ or $-(CR^gR^h)_qN(R^5)C(O)O(alkyl)$; q is 1 or 2; R^4 is hydrogen, alkyl, or cycloalkylalkyl; R^5 is hydrogen or alkyl; R^g and R^h at each occurrence are each independently hydrogen or alkyl; and R^3 is hydrogen. In a further embodiment, in a compound of formula (I), L^1-R^1 taken together are G^1 , wherein G^1 is aryl or heteroaryl; L^2 is C(O); R^2 is
 10 G^2 , wherein G^2 is aryl or heteroaryl; and R^3 is hydrogen or alkyl.

Specific embodiments of compounds contemplated as part of the invention include, but are not limited to:

$N-[(3aS^*,4S^*,6aR^*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-$
 15 phenylcyclopentanecarboxamide;
 $N-[(3aS^*,4R^*,6aR^*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-$
 phenylcyclopentanecarboxamide;
 $N-[(3aR^*,4R^*,6aS^*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclohexyl-2-$
 phenylacetamide;
 20 $N-[(3aS^*,4R^*,6aR^*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclohexyl-2-$
 phenylacetamide;
 $N-[(3aR^*,4R^*,6aS^*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-$
 phenylbutanamide;
 $N-[(3aR^*,4S^*,6aS^*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-$
 25 phenylbutanamide;
 $N-[(3aS^*,4S^*,6aR^*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopentyl-2-$
 phenylacetamide;
 $N-[(3aS^*,4R^*,6aR^*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopentyl-2-$
 phenylacetamide;
 30 $N-[(3aS^*,4S^*,6aR^*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-$
 phenylcyclohexanecarboxamide;
 $N-[(3aS^*,4R^*,6aR^*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-$
 phenylcyclohexanecarboxamide;

N-[(3*aS**,4*S**,6*aR**)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

(2*S*)-2-(3-benzoylphenyl)-*N*-[(3*aS**,4*S**,6*aR**)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]propanamide;

5 (2*S*)-2-(3-benzoylphenyl)-*N*-[(3*aS**,4*R**,6*aR**)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]propanamide;

N-[(3*aS*,4*S*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

10 *N*-[(3*aS*,4*S*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide;

15 *N*-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylpropanamide;

20 *N*-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-propylpentanamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]cycloheptanecarboxamide;

25 (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-(4-isobutylphenyl)propanamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2,3-diphenylpropanamide;

30 *N*-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-methyl-3-phenylpropanamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-methyl-2-phenylpropanamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclopropanecarboxamide;

2-benzyl-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethylbutanamide;

5 *N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;

10 (2*R*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;

(2*S*)-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide;

15 *N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

(2*R*)-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide;

20 (2*R*)-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylpropanamide;

(2*S*)-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylpropanamide;

(2*S*)-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(4-isobutylphenyl)propanamide;

25 *N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclopropyl-2-phenylacetamide;

30 *N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclobutyl-2-phenylacetamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(4-chlorophenyl)-3-methylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-ethyl-2-phenylpentanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-(4-hydroxyphenyl)-3-methylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide;

5 *N*-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-methyl-2-phenylpropanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclopropanecarboxamide;

10 2-benzyl-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2,3-diphenylpropanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-methyl-3-phenylpropanamide;

15 *N*-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;

20 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(2-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

25 2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;

N-{(3*aS*,4*S*,6*aR*)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

30 2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[2-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(3-methylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(4-methylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethoxy)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

5 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(3-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

N-{(3*aS*,4*S*,6*aR*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

10 *N*-{(3*aS*,4*S*,6*aR*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

N-{(3*aS*,4*S*,6*aR*)-2-[3-(3-chlorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(3-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

15 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(3-phenylpropyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-((3*aS*,4*S*,6*aR*)-2-{3-[4-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

20 2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(pyridin-4-ylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(pyridin-3-ylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

25 2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

30 *N*-{(3*aS*,4*R*,6*aR*)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

N-{(3*aS*,4*R*,6*aR*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-2-(3,3-diphenylpropyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

N-{(3*aS*,4*R*,6*aR*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

5 *N*-{(3*aS*,4*R*,6*aR*)-2-[4,4-bis(4-fluorophenyl)butyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

3-methyl-2-phenyl-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;

10 *N*-[(3*aR*,4*S*,6*aS*)-2-(cyclohexylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-2-methyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(2-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

15 *N*-[(3*aR*,4*S*,6*aS*)-2-(3-chlorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(3-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

20 3-methyl-2-phenyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(3-methoxybenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

25 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(3-methylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide;

3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(2-methylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide;

30 *N*-[(3*aR*,4*S*,6*aS*)-2-(2,6-dimethylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(2-methoxybenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(4-*tert*-butylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(4-methoxybenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(3-cyanobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

5 3-methyl-2-phenyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;

3-methyl-2-phenyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[2-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;

10 *N*-{(3*aR*,4*S*,6*aS*)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(thien-2-ylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide;

15 3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(pyridin-4-ylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide;

3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(2-phenylethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide;

20 3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(3-phenylpropyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[3-(4-*tert*-butylphenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

25 3-methyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[3-(2-methylphenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2-phenylbutanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[3-(3-chlorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

30 3-methyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[3-(3-methylphenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2-phenylbutanamide;

3-methyl-2-phenyl-*N*-((3*aR*,4*S*,6*aS*)-2-{3-[3-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[*c*]pyrrol-4-yl)butanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[3-(3-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(4-phenylbutyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[3-(3-chloro-5-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

5 3-methyl-2-phenyl-*N*-((3*aR*,4*S*,6*aS*)-2-{3-[4-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[*c*]pyrrol-4-yl)butanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(3,3-diphenylpropyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

10 *N*-{(3*aR*,4*S*,6*aS*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[4,4-bis(4-fluorophenyl)butyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[5,5-bis(4-fluorophenyl)pentyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

15 *N*-[(3*aS*,4*S*,6*aR*)-2-benzhydryloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzhydryloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

20 3-methyl-2-phenyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;

3,3-dimethyl-2-phenyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;

2,2-dicyclohexyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

25 2-ethyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;

2-propyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} pentanamide;

30 *N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} cyclohexanecarboxamide;

N-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} cycloheptanecarboxamide;

N-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} cyclopentanecarboxamide;

- 6,6-bis(4-fluorophenyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} hexanamide;
- 3,3-diphenyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} propanamide;
- 5 5,5-bis(4-fluorophenyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} pentanamide;
- 3,3-bis(4-fluorophenyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} propanamide;
- 4,4-bis(4-fluorophenyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;
- 10 2,2-diphenyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;
- 2,2-bis(4-fluorophenyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;
- 15 *N*²-(*tert*-butoxycarbonyl)-*N*¹-{(3*aR**,4*R**,6*aS**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} -L-leucinamide;
- N*²-(*tert*-butoxycarbonyl)-*N*¹-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} -D-leucinamide;
- N*²-(*tert*-butoxycarbonyl)-*N*²-methyl-*N*¹-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} -D-leucinamide;
- 20 6,6-bis(4-fluorophenyl)-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} hexanamide;
- 3,3-diphenyl-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} propanamide;
- 25 5,5-bis(4-fluorophenyl)-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} pentanamide;
- 3,3-bis(4-fluorophenyl)-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} propanamide;
- 4,4-bis(4-fluorophenyl)-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;
- 30 2,2-diphenyl-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;
- 2,2-bis(4-fluorophenyl)-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

3,3-dimethyl-2-phenyl-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;

*N*²-(*tert*-butyloxycarbonyl)-*N*¹-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

5 *N*²-(*tert*-butyloxycarbonyl)-*N*¹-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;

*N*²-(*tert*-butyloxycarbonyl)-*N*²-methyl-*N*¹-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;

10 *N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-(*tert*-butyloxycarbonyl)-*N*²-methyl-L-leucinamide;

2,2-dicyclohexyl-2-hydroxy-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

*N*²-(*tert*-butyloxycarbonyl)-*N*²-methyl-*N*¹-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

15 2,2-dicyclohexyl-2-hydroxy-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

*N*²-(*tert*-butyloxycarbonyl)-*N*²-methyl-*N*¹-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

20 2,2-dicyclohexyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

2,2-dicyclohexyl-*N*-{(3*aR*,4*R*,6*aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

*N*¹-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

25 *N*¹-{(3*aR**,4*R**,6*aS**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;

*N*²-methyl-*N*¹-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;

30 *N*¹-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

*N*¹-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;

*N*²-methyl-*N*¹-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;

N^2 -methyl- N^1 -{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^1 -[(3*aS*,4*R*,6*aR*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-leucinamide;

5 N^2 -methyl- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^2 -methyl- N^2 -(methylsulfonyl)- N^1 -{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

10 N^1 -[(3*aS*,4*R*,6*aR*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl- N^2 -(methylsulfonyl)-L-leucinamide;

N^2 -methyl- N^2 -(methylsulfonyl)- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^2 -(methylsulfonyl)- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

15 N^2 -(methylsulfonyl)- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;

N^2 -(cyclopropylsulfonyl)- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

20 N^2 -(isobutylsulfonyl)- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^2 -(cyclopropylsulfonyl)- N^1 -{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^2 -acetyl- N^2 -methyl- N^1 -{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

25 N^2 -(2,2-dimethylpropanoyl)- N^2 -methyl- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^2 -(2,2-dimethylpropanoyl)- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

30 isobutyl (*S*)-4-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

cyclopentyl (*S*)-4-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

N^2 -[(*tert*-butylamino)carbonyl]- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

- N^2 -[(cyclopentylamino)carbonyl]- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
- N^2 -methyl- N^1 -((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
- 5 N^2 -methyl- N^1 -((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
- N^1 -((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
- 3-(trifluoromethyl)- N -{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} benzenesulfonamide;
- 10 3-(trifluoromethyl)- N -{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} benzenesulfonamide;
- 3-(trifluoromethyl)- N -{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} benzenesulfonamide;
- 15 3-(trifluoromethyl)- N -{(3*aR*,4*R*,6*aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} benzenesulfonamide;
- 3-(trifluoromethyl)- N -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} benzenesulfonamide;
- N -[(3*aS*,4*R*,6*aR*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;
- 20 N -{(3*aS*,4*R*,6*aR*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;
- N -{(3*aS*,4*R*,6*aR*)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;
- 25 N -{(3*aS*,4*R*,6*aR*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;
- N -{(3*aS*,4*R*,6*aR*)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;
- 30 N -[(3*aS*,4*S*,6*aR*)-2-(4-hydroxybutyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;
- (3*aS**,4*S**,6*aR**)- N,N -dicyclopropyl-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-amine;
- (3*aS**,4*R**,6*aR**)-2-benzyl- N -cyclopropyloctahydrocyclopenta[*c*]pyrrol-4-amine;

(3a*S**,4*S**,6a*R**)-2-benzyl-*N*-cyclopropyloctahydrocyclopenta[*c*]pyrrol-4-amine;
N-[(3a*S**,4*S**,6a*R**)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-[(3a*S**,4*R**,6a*R**)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-cyclopropyl-*N*-[(3a*S**,4*S**,6a*R**)-octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;

N-{(3a*S**,4*S**,6a*R**)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-{(3a*S**,4*S**,6a*R**)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-cyclopropyl-3-(trifluoromethyl)-*N*-{(3a*S**,4*S**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}benzenesulfonamide;

2,2-dicyclohexyl-*N*-((3a*S*,4*S*,6a*R*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

2,2-dicyclohexyl-*N*-{(3a*S*,4*S*,6a*R*)-2-[(2-phenylethyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-*N*-((3a*S*,4*S*,6a*R*)-2-{[2-(1-naphthyl)ethyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

2,2-dicyclohexyl-*N*-((3a*S*,4*S*,6a*R*)-2-{[3-(trifluoromethyl)benzyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

2,2-dicyclohexyl-*N*-((3a*S*,4*S*,6a*R*)-2-{[2-(4-fluorophenyl)ethyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

(2*S*)-2-phenyl-*N*-{(3a*R*,4*R*,6a*S*)-2-[(1*S*)-1-phenylethyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

(2*S*)-2-phenyl-*N*-{(3a*R*,4*S*,6a*S*)-2-[(1*S*)-1-phenylethyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

(2*S*)-2-phenyl-*N*-{(3a*S*,4*S*,6a*R*)-2-[(1*S*)-1-phenylethyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

(2*S*)-2-phenyl-*N*-{(3a*S*,4*R*,6a*R*)-2-[(1*S*)-1-phenylethyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

N-[(3a*R*,4*S*,6a*S*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*,3-dimethyl-2-phenylbutanamide;

N-[(3*aS**,4*R**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*,3-dimethyl-2-phenylbutanamide;

(3*aR**,4*S**,6*aS**)-*N*-benzyl-2-(3-methyl-2-phenylbutanoyl)octahydrocyclopenta[*c*]pyrrol-4-amine;

5 2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-2-(*N,N*-dimethyl-D-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

10 *N*'-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*-isopropyl-*N*-phenylurea;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-ylcarbamate;

15 *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(ethyl)carbamate;

20 *tert*-butyl (2*S*,3*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamate;

25 *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxohexan-2-yl(methyl)carbamate;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-bis(4-fluorophenyl)acetamide;

30 *N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-isopropyl-3-methylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methylbutanamide;
tert-butyl (2*S*)-2-({[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]amino } carbonyl)piperidine-1-carboxylate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

5 *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-isopropyl-3-methylbutanamide;

10 *N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methylbutanamide;
2-cyclohexyl-2-hydroxy-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;

tert-butyl (*S*)-1-((3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

15 *tert*-butyl (*S*)-1-((3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

20 *S*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-(methylsulfonyl)-L-leucinamide;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-(methylsulfonyl)-L-leucinamide;

25 *N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-neopentyl-L-leucinamide;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-neopentyl-L-leucinamide;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-neopentyl-L-norvalinamide;

30 *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-morpholin-4-ylpentanamide;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide;

5 (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-piperidin-1-ylpentanamide;

*N*²-neopentyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

10 *N*²-neopentyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

*N*²-neopentyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

*N*²-neopentyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

15 *N*²-neopentyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

*N*²-neopentyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

20 *N*-(*tert*-butoxycarbonyl)-*N*-methyl-*N*-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-phenylalaninamide;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

25 *N*²-neopentyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

*N*¹-{(3*aR*,4*S*,6*aS*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*²-neopentyl-L-leucinamide;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

30 isopropyl (*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(6-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

tert-butyl (*S*)-4,4-dimethyl-1-((3*aR*,4*S*,6*aS*)-2-(2-(methylsulfonyl)pyrimidin-5-yl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-ylcarbamate;

(*S*)-*tert*-butyl 2-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylate;

tert-butyl (1*R*)-1-isopropyl-3-oxo-3-(((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]propylcarbamate;

tert-butyl (2*S*)-2-{[(3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate;

N-(*tert*-butoxycarbonyl)-*N*-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-phenylalaninamide;

N-(*tert*-butoxycarbonyl)-*N*-methyl-*N*-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-phenylalaninamide;

(*S*)-*tert*-butyl 2-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylate;

tert-butyl (1*R*)-1-isopropyl-3-oxo-3-(((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]propylcarbamate;

tert-butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate;

tert-butyl (2*S*)-2-{[(3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate;

tert-butyl (3*S*)-3-{[(3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]carbonyl}-3,4-dihydroisoquinoline-2(1*H*)-carboxylate;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)hexan-2-yl)carbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

isopropyl (*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

isopropyl (*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

(3*aS*,4*R*,6*aR*)-*N*-neopentyl-2-{[3-

10 (trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-neopentyl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-isopropyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

15 (3*aR*,4*S*,6*aS*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-*N*-isopropyloctahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aS*,4*R*,6*aR*)-*N*-(4-fluorobenzyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-(4-fluorobenzyl)-2-{[3-

20 (trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-(4-fluorobenzyl)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-ethyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

25 (3*aR*,4*S*,6*aS*)-*N,N*-diethyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-propyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N,N*-dipropyl-2-{[4-

30 (trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-(cyclopropylmethyl)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-*N*-ethyloctahydrocyclopenta[*c*]pyrrol-4-amine;

(3a*R*,4*S*,6a*S*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-*N,N*-diethyloctahydrocyclopenta[*c*]pyrrol-4-amine;

(3a*R*,4*S*,6a*S*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-*N*-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-amine;

5 *tert*-butyl (*S*)-1-(ethyl((3a*R*,4*S*,6a*S*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-(propyl((3a*R*,4*S*,6a*S*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl)amino)pentan-2-yl(methyl)carbamate;

10 *tert*-butyl (*S*)-1-((cyclopropylmethyl)((3a*R*,4*S*,6a*S*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;

2-nitro-*N*-((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)benzenesulfonamide;

N-methyl-2-nitro-*N*-((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)benzenesulfonamide;

(3a*R*,4*S*,6a*S*)-*N*-methyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

20 *tert*-butyl (*S*)-4,4-dimethyl-1-(methyl((3a*R*,4*S*,6a*S*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl)amino)-1-oxopentan-2-yl(methyl)carbamate;

(2*S*)-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methyl-*N*-{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}pentanamide;

25 2-isopropyl-3-methyl-*N*-{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

2-isopropyl-3-methyl-*N*-{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

30 *tert*-butyl (*S*)-4-methyl-1-oxo-1-((3a*R*,4*S*,6a*S*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

tert-butyl methyl((*S*)-4-methyl-1-oxo-1-((3a*R*,4*S*,6a*S*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((*S*)-4-methyl-1-oxo-1-((3a*R*,4*S*,6a*S*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl ethyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

5 *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(3-fluoro-4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluoro-3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

15 *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

(2*S*)-4-methyl-2-morpholin-4-yl-*N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide;

25 (2*S*)-4-methyl-2-pyrrolidin-1-yl-*N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide;

(2*S*)-4-methyl-2-piperidin-1-yl-*N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide;

tert-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl ethyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

5 *tert*-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

10 *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluoro-3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*R*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*R*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

20 *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

25 *tert*-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

30 *tert*-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

5 *tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;

10 *tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;

tert-butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate;

20 *tert*-butyl (*S*)-3,3-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-ylcarbamate;

tert-butyl (*S*)-3,3-dimethyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-ylcarbamate;

25 *tert*-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)hexan-2-yl)carbamate;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

(2*S*)-4-methyl-2-pyrrolidin-1-yl-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzoyl]octahydrocyclopenta[*c*]pyrrol-4-yl}pentanamide;

(2*S*)-4-methyl-*N*-[(3*aS*,4*R*,6*aR*)-2-(methylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-pyrrolidin-1-ylpentanamide;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-(cyclopropylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide;

*N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-leucinamide;

5 *tert*-butyl methyl((*S*)-4-methyl-1-((3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl)carbamate;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]piperidine-2-carboxamide;

10 *N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-valinamide;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-norvalinamide;

*N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-isoleucinamide;

15 *N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-isoleucinamide;

*N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²,4-dimethyl-L-leucinamide;

20 *N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-L-valinamide;

*N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-L-valinamide;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²,4-dimethyl-L-leucinamide;

25 *N*¹-[(3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-norvalinamide;

*N*¹-[(3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-leucinamide;

30 *N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-L-leucinamide;

*N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-norleucinamide;

*N*¹-[(3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-norvalinamide;

N^1 -[(3a*R*,4*R*,6a*S*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-leucinamide;

N^1 -[(3a*R*,4*S*,6a*S*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-norvalinamide;

5 N^2 -ethyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^2 -methyl- N^1 -{(3a*S*,4*R*,6a*R*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-valinamide;

10 (2*S*)- N -[(3a*S*,4*R*,6a*R*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]piperidine-2-carboxamide;

N^1 -[(3a*S*,4*R*,6a*R*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-valinamide;

(2*S*)- N -{(3a*S*,4*R*,6a*R*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}piperidine-2-carboxamide;

15 N^2 -methyl- N^1 -{(3a*S*,4*R*,6a*R*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide;

N^1 -[(3a*S*,4*R*,6a*R*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-norvalinamide;

20 N^2 -methyl- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-valinamide;

N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

N^1 -{(3a*S*,4*R*,6a*R*)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

25 N^2 -methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide;

N^2 -methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide;

30 N^1 -[(3a*R*,4*S*,6a*S*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-norvalinamide;

N^2 -methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^2 -methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^1 -[(3a*R*,4*S*,6a*S*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-leucinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide;

5 N^2 -ethyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

10 N -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-phenylalaninamide;

N -methyl- N -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-phenylalaninamide;

N -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-prolinamide;

15 (3*R*)-3-amino-4-methyl- N -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide;

N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide;

20 (2*S*)- N -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)piperidine-2-carboxamide;

(3*S*)- N -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;

25 4-methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norleucinamide;

30 N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N -((3a*S*,4*R*,6a*R*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-prolinamide;

(3*R*)-3-amino-4-methyl-*N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide;

(2*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)piperidine-2-

5 carboxamide;

(2*S*)-*N*-{(3*aS*,4*R*,6*aR*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}piperidine-2-carboxamide;

*N*¹-{(3*aS*,4*R*,6*aR*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*²-methyl-L-valinamide;

10 (2*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)piperidine-2-carboxamide;

*N*²-methyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide;

15 *N*¹-{(3*aS*,4*R*,6*aR*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*²-methyl-L-norvalinamide;

*N*²-methyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

20 *N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

*N*²-methyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide;

25 *N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-fluoro-3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*N*²-methyl-L-leucinamide;

3-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide;

3-methyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide;

30 *N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-isoleucinamide;

*N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-isoleucinamide;

- N^2 -methyl- N^1 -((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-isoleucinamide;
- N^2 -methyl- N^1 -((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-isoleucinamide;
- 5 N^2 ,4-dimethyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
- N^2 ,4-dimethyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
- 10 N^2 ,4-dimethyl- N^1 -((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
- N^2 ,4-dimethyl- N^1 -((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
- N^2 -methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norleucinamide;
- 15 4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
- N^2 -methyl- N^1 -((3*aR*,4*R*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
- 20 N^2 -methyl- N^1 -((3*aR*,4*R*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
- N^1 -((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
- 25 N^1 -((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
- N^1 -((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
- 30 3-cyclohexyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-alaninamide;
- 3-cyclohexyl- N^2 -methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-alaninamide;

N^1 -((3*aR*,4*S*,6*aS*)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-L-leucinamide;

5 N^1 -((3*aR*,4*S*,6*aS*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-L-leucinamide;

N -methyl- N -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-phenylalaninamide;

10 N^1 -((3*aR*,4*S*,6*aS*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^2 ,4-dimethyl-L-leucinamide;

N -((3*aR*,4*S*,6*aS*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N -methyl-L-phenylalaninamide;

15 N^1 -cyclopropyl- N^2 ,4-dimethyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^1 -ethyl- N^2 ,4-dimethyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

20 N^2 ,4-dimethyl- N^1 -propyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^1 -(cyclopropylmethyl)- N^2 ,4-dimethyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

25 N^1 , N^2 ,4-trimethyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^1 , N^2 -dimethyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

N^1 -((3*aR*,4*S*,6*aS*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^1 , N^2 ,4-trimethyl-L-leucinamide;

30 4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

4-methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[2-(methylsulfonyl)pyrimidin-5-yl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^1 -{(3a*S*,4*R*,6a*R*)-2-[(3-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

5 N^1 -{(3a*S*,4*R*,6a*R*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

N^1 -{(3a*S*,4*R*,6a*R*)-2-[(3,4-difluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

10 N^1 -{(3a*S*,4*R*,6a*R*)-2-[(3,5-difluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

N^1 -{(3a*S*,4*R*,6a*R*)-2-[(4-chlorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

N^2 -methyl- N^1 -[(3a*S*,4*R*,6a*R*)-2-(phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-L-leucinamide;

15 N^2 -methyl- N^1 -{(3a*S*,4*R*,6a*R*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^1 -[(3a*S*,4*R*,6a*R*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-leucinamide;

20 N^2 -methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-valinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-4-methyl-L-leucinamide;

25 N^1 -{(3a*R*,4*S*,6a*S*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norleucinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

30 N^2 -methyl- N^1 -{(3a*S*,4*S*,6a*R*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

N^2 -methyl- N^1 -{(3a*S*,4*S*,6a*R*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;

2,2-bis(4-fluorophenyl)-*N*-[(3*aR*,4*S*,6*aS*)-2-(*N*-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-bis(4-fluorophenyl)-*N*-[(3*aR*,4*S*,6*aS*)-2-(*N*-methyl-L-norvalyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

5 *N*-[(3*aR*,4*S*,6*aS*)-2-(*N*,4-dimethyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-bis(4-fluorophenyl)acetamide;

2,2-bis(4-fluorophenyl)-*N*-[(3*aR*,4*S*,6*aS*)-2-(4-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

10 *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-4-((*S*)-2-(*tert*-butoxycarbonylamino)-4,4-dimethylpentanamido)hexahydrocyclopenta[*c*]pyrrol-2(1*H*)-yl)-4,4-dimethyl-1-oxopentan-2-ylcarbamate;

4-methyl-*N*¹-[(3*aR*,4*S*,6*aS*)-2-(4-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-L-leucinamide;

15 4-methyl-*N*¹-[(3*aR*,4*S*,6*aS*)-2-L-phenylalanyloctahydrocyclopenta[*c*]pyrrol-4-yl]-L-leucinamide;

(3*aR*,4*S*,6*aS*)-*N*-benzhydryl-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aS*,4*R*,6*aR*)-*N*-benzhydryl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

20 (3*aR*,4*S*,6*aS*)-*N*-benzhydryl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzhydryloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-leucinamide;

25 4-methyl-*N*²-propyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

*N*²-(cyclopropylmethyl)-4-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

*N*²-(cyclobutylmethyl)-4-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

30 *N*²-isobutyl-4-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

*N*²-(cyclopentylmethyl)-4-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

- N^2 -(cyclohexylmethyl)-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
- N^2 -butyl-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
- 5 N^2 -ethyl-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
- N^2 -(cyclopropylmethyl)-4-methyl- N^1 -{(3*aR*,4*S*,6*aS*)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
- N^2 -(cyclopropylmethyl)-4-methyl- N^1 -{(3*aR*,4*S*,6*aS*)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
- 10 N^2 -isopropyl-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
- N^2 -isopropyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
- 15 N^2 -isopropyl- N^1 -((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
- N^2 -isopropyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
- N^2 -isopropyl- N^1 -((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
- 20 3-cyclohexyl- N^2 -isopropyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-alaninamide;
- N^1 -((3*aR*,4*S*,6*aS*)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^2 -isopropyl-4-methyl-
- 25 L-leucinamide;
- N^1 -((3*aR*,4*S*,6*aS*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^2 -isopropyl-4-methyl-L-leucinamide;
- N^2 -isopropyl- N^1 -[(3*aR*,4*S*,6*aS*)-2-(*N*-isopropyl-4-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-L-leucinamide;
- 30 N^2 -isopropyl- N^1 -[(3*aR*,4*S*,6*aS*)-2-(*N*-isopropyl-L-phenylalanyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-L-leucinamide;
- N^2 -isopropyl-4-methyl- N^1 -{(3*aR*,4*S*,6*aS*)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^2 -isopropyl-4-methyl- N^1 -{(3*aR*,4*S*,6*aS*)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

2,2-bis(4-fluorophenyl)-*N*-[(3*aR*,4*S*,6*aS*)-2-(*N*-isopropyl-4-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

5 N^2 -isopropyl-4-methyl- N^1 -{(3*aR*,4*S*,6*aS*)-2-[2-(methylsulfonyl)pyrimidin-5-yl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^1 -[(3*aR*,4*S*,6*aS*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -isopropyl-L-norvalinamide;

10 N^1 -[(3*aS*,4*R*,6*aR*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -isopropyl-L-norvalinamide;

N^2 -isopropyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^2 , N^2 -dimethyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

15 (3*R*)-3-(dimethylamino)-4-methyl-*N*-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide;

N^2 -cyclopropyl-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

20 N^2 , N^2 -dicyclopropyl-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^2 -cyclopentyl-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^2 -cyclohexyl-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

25 N^2 -(1-ethylpropyl)-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^2 -cyclobutyl-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

30 4-methyl- N^2 -neopentyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^2 -cyclopentyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

N^2 -cyclohexyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

N^2 -cyclopentyl- N^1 -[(3a*R*,4*S*,6a*S*)-2-(*N*-cyclopentyl-4-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-L-leucinamide;

N^2,N^2 -dimethyl- N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

5 N^1 -[(3a*S*,4*R*,6a*R*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl- N^2 -neopentyl-L-leucinamide;

N^1 -[(3a*S*,4*R*,6a*R*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -(3,3-dimethylbutyl)- N^2 -methyl-L-leucinamide;

10 N^2,N^2 -dimethyl- N^1 -((3a*S*,4*R*,6a*R*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^1 -[(3a*S*,4*R*,6a*R*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -(4-fluorobenzyl)- N^2 -methyl-L-leucinamide;

(2*S*)-*N*-[(3a*S*,4*R*,6a*R*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-1-(methylsulfonyl)piperidine-2-carboxamide;

15 (3*R*)-4-methyl-3-[(methylsulfonyl)amino]-*N*-((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide;

N^2 -(methylsulfonyl)- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

20 N^2 -(methylsulfonyl)- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;

N^2 -ethyl- N^2 -(methylsulfonyl)- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

4-methyl- N^2 -(methylsulfonyl)- N^1 -{(3a*R*,4*S*,6a*S*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

25 3-methyl- N^2 -(methylsulfonyl)- N^1 -{(3a*R*,4*S*,6a*S*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-valinamide;

N^2 -(methylsulfonyl)- N^1 -{(3a*R*,4*S*,6a*S*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide;

30 N^2 -(isopropylsulfonyl)- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^2 -(phenylsulfonyl)- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^2 -(cyclopentylsulfonyl)- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

- isopropyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;
- isopropyl (*S*)-3,3-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-ylcarbamate;
- 5 cyclopentyl (*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;
- N^2 -(2,2-dimethylpropanoyl)- N^1 -{(3*aR*,4*S*,6*aS*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide;
- tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-(3-chloro-4-fluorophenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;
- 10 *tert*-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(pyridin-3-ylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;
- tert*-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(thiophen-2-ylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;
- 15 N^2 -methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethoxy)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
- N^2 -methyl- N^1 -[(3*aR*,4*S*,6*aS*)-2-(thien-2-ylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-L-norvalinamide;
- 20 N^1 -{(3*aR*,4*S*,6*aS*)-2-[(3-chloro-4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;
- N^2 -methyl- N^1 -[(3*aR*,4*S*,6*aS*)-2-(pyridin-3-ylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-L-norvalinamide;
- N^1 -{(3*aR*,4*S*,6*aS*)-2-[(4-cyanophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;
- 25 N^1 -{(3*aR*,4*S*,6*aS*)-2-[(4-methoxyphenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;
- N^1 -((3*aR*,4*S*,6*aS*)-2-{[3,5-bis(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^2 -methyl-L-norvalinamide;
- 30 N^1 -{(3*aR*,4*S*,6*aS*)-2-[(2-chloro-4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;
- N^2 -methyl- N^1 -[(3*aR*,4*S*,6*aS*)-2-(1-naphthylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-L-norvalinamide;

N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-bromo-3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^2 -methyl-L-norvalinamide;

5 N^1 -{(3a*R*,4*S*,6a*S*)-2-[(3,4-dichlorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(4-*tert*-butylphenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;

N^1 -[(3a*R*,4*S*,6a*S*)-2-(1,1'-biphenyl-4-ylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-norvalinamide;

10 N^1 -{(3a*R*,4*S*,6a*S*)-2-[(3,4-dimethoxyphenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(3-cyanophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;

15 N^1 -[(3a*R*,4*S*,6a*S*)-2-(2-furylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-norvalinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(2,3-dichlorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;

N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)benzyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

20 N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[2-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(3-bromophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;

25 N^1 -((3a*R*,4*S*,6a*S*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^2 -methyl-L-norvalinamide;

N^1 -((3a*R*,4*S*,6a*S*)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^2 -methyl-L-norvalinamide;

30 N^2 -methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzoyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide;

N -[(3a*R*,4*S*,6a*S*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N -isopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;

N-isopropyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(*N*-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;

5 *N*-[(3*aR*,4*S*,6*aS*)-2-(*N*-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;

N-cyclopropyl-*N*-[(3*aS**,4*S**,6*aR**)-[2-(*N*-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide; and

10 4-fluoro-*N*-{(3*aR*,4*S*,6*aS*)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-yl} benzamide.

Compounds of the present application may exist as stereoisomers wherein, asymmetric or chiral centers are present. These stereoisomers are "*R*" or "*S*" depending on the configuration of substituents around the chiral carbon atom. The terms "*R*" and "*S*" used
15 herein are configurations as defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem., 1976, 45: 13-30.

On occasion, the relative stereochemistry of an enantiomeric pair is known, however, the absolute configuration is not known. In that circumstance, the relative stereochemistry descriptor terms "*R**" and "*S**" are used. The terms "*R**" and "*S**" used herein are defined in
20 Eliel, E. L.; Wilen, S. H. Stereochemistry of Organic Compounds; John Wiley & Sons, Inc.: New York, 1994; pp 119-120 and 1206. In a particular enantiomeric pair, the relative descriptors are reversed to indicate that this pair of enantiomers is of unknown absolute stereochemistry.

The present application contemplates various stereoisomers and mixtures thereof and
25 these are specifically included within the scope of this application. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers. Individual stereoisomers of compounds of the present application may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution which is well known to those of
30 ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns.

Geometric isomers may exist in the present compounds. The invention contemplates the various geometric isomers and mixtures thereof resulting from the disposition of substituents around a carbon-carbon double bond, a carbon-nitrogen double bond, a cycloalkyl group, or a heterocycle group. Substituents around a carbon-carbon double bond or a carbon-nitrogen bond are designated as being of *Z* or *E* configuration and substituents around a cycloalkyl or a heterocycle are designated as being of *cis* or *trans* configuration.

Within the present invention it is to be understood that compounds disclosed herein may exhibit the phenomenon of tautomerism.

Thus, the formulae drawings within this specification can represent only one of the possible tautomeric or stereoisomeric forms. It is to be understood that the invention encompasses any tautomeric or stereoisomeric form, and mixtures thereof, and is not to be limited merely to any one tautomeric or stereoisomeric form utilized within the naming of the compounds or formulae drawings.

Compounds of this invention can exist in an isotopic form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most abundantly found in nature. Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur fluorine, chlorine, and iodine include, but are not limited to ^2H , ^3H , ^{11}C , ^{14}C , ^{32}P , ^{35}S , ^{18}F , ^{36}Cl , and ^{125}I , respectively. Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention. Compounds containing tritium (^3H) and ^{14}C radioisotopes are preferred in general for their ease in preparation and detectability for radiolabeled compounds. Isotopically labeled compounds of this invention can be prepared by the general methods well known to persons having ordinary skill in the art. Such Isotopically labeled compounds can be conveniently prepared by carrying out the procedures disclosed in the Examples and Schemes below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

c. Biological Data

Abbreviations which have been used in the descriptions of Biological Data that follow are: EDTA for ethylenediaminetetraacetic acid; FBS for fetal bovine serum; FLIPR for fluorometric imaging plate reader; HBSS for Hank's balanced salt solution; HEPES for 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; i.p. for intraperitoneal; MEM for minimum essential medium; MEM NEAA for minimum essential medium non-essential amino acid; p.o. for per orem (by mouth).

(i) In Vitro Methods--Assessment of calcium channel activity using FLIPR:

IMR32 cells endogenously expressing human $\text{Ca}_v2.2$ were assayed for Ca^{2+} influx using a no-wash calcium indicator dye (Calcium 4 dye: Molecular Probes) and FLIPR technology (Lubin, M. L.; Reitz, T. L.; Todd, M. J.; Flores, C. M.; Qin, N.; Xin, H. A nonadherent cell-based HTS assay for N-type calcium channel using calcium 3 dye. Assay and Drug Development Technologies 2006, 4(6), 689-694.). The IMR32 cells were maintained in MEM media containing 10% (v/v) FBS, 1% (v/v) antibiotic/antimitotic, 1% (v/v) sodium pyruvate and 1% (v/v) MEM NEAA. Following dissociation in 0.05% (v/v) trypsin/EDTA, cells were seeded into black 1 x 96-well plates (Corning Cellbind) at a density of $1-1.2 \times 10^5$ cells/well and incubated in the maintenance media above for 48 hours at 37 °C. Immediately prior to performing the assay the media was removed and cells were loaded for 1.5 hours with 1 x Calcium 4 dye prepared in HBSS (137 mM NaCl, 5.4 mM KCl, 0.25 mM Na_2HPO_4 , 0.44 mM KH_2PO_4 , 1.3 mM CaCl_2 , 1mM MgSO_4 , 4.2 mM NaHCO_3) containing HEPES pH 7.4 at room temperature. After dye loading and a subsequent 3 minute or 60 minute pre-incubation with compounds (full log dilutions from 10 μM to 0.1 nM) in the presence of 1.3 mM CaCl_2 and 2 μM nifedipine to block endogenous L-type channels, the external Ca^{2+} concentration was increased to 5 mM CaCl_2 and the cells concomitantly depolarized with 80 mM KCl to assay channel activity. To determine the IC_{50} values, the percent inhibition of the compound at each concentration was determined relative to the activity in the absence of inhibitor, and data was fitted using non-linear regression sigmoidal dose response curve analysis with GraphPad Prism®.

Example	IC_{50} (μM) or percent inhibition (* indicates 3 minute incubation, otherwise 60 minute)	Example	IC_{50} (μM) or percent inhibition (* indicates 3 minute incubation, otherwise 60 minute)
1	3.5*	271	3.41
2	4.2*	272	5.14
3	91% @ 10 μM	273	0.18
4	3.5*	274	1.38
5	3.8*	275	0.92
6	2.2*	276	0.38
7	1.8*	277	0.72
8	1.1	278	0.34

9	1.8*	280	5.04
10	1.3*	281	4.18
11	4	282	5.24
13	23	283	8.69
14	3.8	284	3.71
15	15.7	285	0.48
16	9.8	286	0.38
17	1.6	287	3.09
18	2.7	288	10.36
19	25% @ 10 μ M *	289	9.74
20	1.8	290	7.80
21	10.1*	291	4.40
22	14.7*	292	3.91
23	2.5	293	4.82
24	2.9*	294	7.81
25	3.7*	295	2.97
26	17.3*	296	2.14
27	9.7*	297	7.88
28	13.9*	298	9.00
29	5.6*	299	3.68
30	1.8	300	1.54
31	1.6	302	1.14
32	1.4	303	3.11
33	7.4	304	3.78
34	1.5	305	3.51
35	3.3	306	0.50
36	44% @ 10 μ M*	307	1.54
37	15% @ 10 μ M*	308	1.93
38	27% @ 10 μ M*	309	1.74
39	92% @ 10 μ M*	310	0.68
40	3.6*	311	2.05
41	56% @ 10 μ M*	312	1.59

43	1.5	313	2.10
44	1.7*	314	2.15
46	3.1*	315	5.36
47	15.6*	316	2.02
48	10.5*	317	0.90
49	4.6*	318	1.07
50	5.0*	319	1.21
51	15.2*	320	0.70
52	3.4	321	0.44
53	8.6	322	0.70
54	0.5	323	0.20
55	0.8	324	0.69
56	1	325	0.25
57	0.3	326	1.46
58	1.4	327	1.83
59	0.5	328	1.38
60	1.5	329	2.60
61	1.5	330	1.11
62	1.6	331	0.75
63	0.6	332	0.48
64	1.3	333	0.57
65	4.5	334	0.69
66	0.9	335	0.83
67	1.3	336	0.48
68	1.7	337	0.78
69	1.7	338	0.23
70	1.9	339	1.11
71	1.2	340	1.03
72	3.2	341	2.01
73	3.3	342	2.17
74	11.2*	343	1.01
75	0.5	344	0.99

76	5.7	345	4.32
77	9.4	349	17.65
78	0.4	358	9.00
79	0.9	361	24.74
80	1.7	364	8.12
81	1.1	366	5.28
82	1.5	367	7.00
83	2.6*	368	12.42
84	5.8% @ 10 μ M*	370	6.02
85	3.6	371	8.89
86	1.6	373	7.58
87	3.1	374	5.36
88	1.2	375	8.22
89	2	376	10.63
90	83% @ 10 μ M*	377	13.37
91	1.8	379	8.59
92	2	380	9.73
93	3.3	382	14.42
94	2.3	383	0.80
95	1	384	1.14
96	2.4*	385	1.85
97	5.3*	386	1.62
98	4.9*	387	5.88
99	4.8*	388	4.53
100	4.2*	389	1.48
101	4.7*	390	2.46
102	2.8	391	1.46
103	31*	392	0.95
104	79% @ 10 μ M*	393	1.08
105	1.5	394	0.98
106	5.8*	395	2.12
107	1.1	396	3.55

108	11.3*	397	1.45
109	9.0*	398	3.25
110	2.0*	399	15.29
111	2.2*	400	6.86
112	2.8*	401	2.96
113	3.1*	402	2.06
114	2.8*	403	8.66
115	1.2	404	1.02
116	1.2	405	3.84
117	0.9	406	3.69
118	1	407	5.43
119	1.1	408	5.11
120	3.4	409	5.02
121	14.3	410	1.80
122	0.6	411	4.22
123	0.6	412	4.72
124	0.7	413	0.78
125	2.8	414	0.90
126	1	415	2.97
127	1.5	416	1.33
128	1	417	1.16
129	2.9	418	0.82
130	0.8	419	0.80
131	0.7	420	5.70
132	1.1	421	2.56
133	0.7	422	7.83
134	1.2	423	6.46
135	0.9	424	3.11
136	1.1	425	3.21
137	0.6	426	1.79
138	0.8	427	6.45
139	1	428	2.31

140	0.6	429	0.96
141	0.6	430	1.75
142	0.9	431	0.58
143	0.6	432	1.67
144	1	433	1.26
145	1.2	434	2.70
146	0.8	435	2.32
147	0.5	436	1.77
148	0.8	437	2.43
149	0.6	438	5.70
150	0.5	439	1.43
151	0.7	440	3.19
152	0.8	441	0.37
153	0.4	442	7.18
154	1.3	443	7.68
155	0.7	444	2.11
156	0.8	445	7.96
157	2.1	446	4.96
158	3.5	447	2.71
159	5.6	448	12.35
160	3.8	449	4.06
161	3.9	450	9.25
162	3.9	451	0.80
163	4.6	452	9.12
164	1.6	453	4.23
165	33.3	454	2.03
166	2.7	455	3.03
167	1.2	456	5.33
168	12.9	457	3.07
169	0.9	458	3.08
170	4.6	459	1.62
171	6.2	460	2.69

WO 2010/062927

PCT/US2009/065847

172	2	461	1.88
173	1.8	462	2.96
174	1	463	2.03
175	1.5	466	2.33
176	0.9	467	3.49
177	2.6	468	2.25
178	1	469	2.24
179	0.9	470	1.03
180	1.8	471	0.65
181	0.9	472	1.27
182	1.5	473	2.66
183	1.4	474	1.74
184	1.5	475	1.84
185	0.9	476	1.31
186	0.6	477	1.88
187	1.2	478	0.75
188	0.8	479	0.25
189	1	480	1.31
190	1.3	481	2.28
191	0.5	482	1.97
192	2.3	483	0.49
193	0.6	484	0.97
194	1.4	485	1.50
195	22.1	486	1.21
196	3.2	487	0.56
197	69.7	488	7.43
198	40.4	489	9.76
199	2.2	490	3.12
200	1	491	0.26
201	5.2	492	2.00
202	0.8	493	5.08
203	1.6	496	0.53

204	1.3	497	0.57
205	3.4	498	1.58
206	>100	499	2.70
207	>100	500	1.70
208	>100	501	0.82
209	>100	502	0.97
210	76% @ 10 μ M*	503	0.89
211	3.8	504	0.91
212	4.1	505	2.24
213	60% @ 10 μ M*	506	1.72
215	2	507	0.87
216	85% @ 10 μ M*	508	8.60
217	1.3	509	4.56
218	56% @ 10 μ M*	510	1.68
219	63% @ 10 μ M*	511	2.12
220	>9	512	0.47
221	3.93	513	2.15
222	2.05	515	3.17
223	2.06	516	2.99
224	4.64	517	4.45
225	9.38	518	0.81
226	4.06	519	5.14
227	3.17	520	12.82
228	2.09	521	9.60
229	13.10	522	2.90
231	6.14	523	4.43
232	3.60	524	2.07
233	2.81	525	1.39
234	7.40	526	2.77
235	14.23	527	2.29
237	1.88	528	7.23
238	5.73	529	0.96

239	3.31	530	7.63
240	2.67	531	3.49
241	2.09	532	3.16
242	7.92	533	9.69
243	8.59	534	6.38
244	9.10	536	8.38
245	8.08	537	11.32
246	8.39	538	3.76
247	3.62	539	4.39
248	1.67	540	1.67
252	0.64	541	2.57
253	0.36	542	2.36
254	0.72	543	3.21
255	0.55	544	2.15
256	1.38	546	6.32
257	0.70	548	1.05
258	0.85	549	2.74
259	1.14	550	2.57
260	1.11	551	2.49
261	1.26	552	0.78
262	1.80	553	1.94
264	0.28	554	10.32
265	2.62	555	2.51
266	0.87	556	2.58
267	14.06	557	1.14
268	0.73	558	4.88
269	1.90	559	1.68
270	0.77	560	1.45

(ii) In Vivo Data-- Capsaicin induced secondary mechanical hyperalgesia model:

Sprague Dawley rats were briefly restrained, and capsaicin was administered at 10 µg in 10 µL of vehicle by intraplantar injection into the center of the right hind paw. Secondary mechanical hyperalgesia (SMH) was measured at the heel away from the site of injection 180

minutes following capsaicin exposure. Compounds and gabapentin (positive control), were administered p.o. 60 minutes before testing (2 hours after capsaicin) or i.p. 30 minutes before testing (2.5 hours after capsaicin). SMH was measured using calibrated von Frey filaments (Stoelting, Woodale, IL). Following the 1 hour habituation in the testing room, rats were

5 moved to individual plexiglass chambers that sit on top of a wire mesh to allow for access for stimulation of the plantar surface of the hind paws. Rats were allowed to acclimate to the new chambers for 15 minutes before the onset of testing. The paw withdrawal threshold was determined by increasing and decreasing stimulus intensity (force: g) and calculated using Dixon's up-down method (Chaplan, S. R.; Bach, F. W.; Pogrel, J. W.; Chung, J. M.; Yaksh,

10 T. L.; Quantitative assessment of tactile allodynia in the rat paw. J. Neuroscience Methods 1994, 53(1), 55-63.). The filaments (maximum force of 15.0 g) were held in place for 8 seconds or until there was a withdrawal response from the mechanical stimulation.

Example	% inhibition @ 30 mg/kg p.o.	Example	% inhibition @ 30 mg/kg p.o.
54	38	405	32
75	85	415	52
156	67	461	43
157	57	478	57
165	92	479	40
170	57	480	64
172	85	488	55
183	78	489	47
220	76	560	42
280	38		

d. Methods of Using the Compounds

15 One embodiment of the present invention provides a method of treating pain in a subject in need thereof. The method comprises administering to the subject, including a mammal, such as a human, a therapeutically suitable amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. Conditions related to pain include acute pain, chronic pain, neuropathic pain, inflammatory pain, visceral pain, cancer pain, allodynia,

20 fibromyalgia, sciatica, back pain, and headache pain including migraine, or combinations thereof. Preferably, the method comprises administering to the mammal a therapeutically

effective amount of any of the compounds as described herein, or a pharmaceutically acceptable salt thereof. In certain embodiments, the method comprises administering to the mammal a therapeutically effective amount of any of the compounds as described herein, or a pharmaceutically acceptable salt thereof, in combination with one or more of the following:

- 5 nonsteroidal anti-inflammatory drug (NSAID), opioid analgesic, barbiturate, benzodiazapine, histamine antagonist, sedative, skeletal muscle relaxant, transient receptor potential ion channel antagonist, α -adrenergic, tricyclic antidepressant, anticonvulsant, tachykinin antagonist, muscarinic antagonist, cyclooxygenase-2 selective inhibitor, neuroleptic, vanilloid receptor agonist, vanilloid receptor antagonist, β -adrenergic, local anesthetic, corticosteroid, 10 5-HT receptor agonist, 5-HT receptor antagonist, 5-HT_{2A} receptor antagonist, cholinergic analgesic, $\alpha_2\delta$ ligand such as gabapentin or pregabalin, cannabinoid receptor ligand, metabotropic glutamate subtype 1 receptor antagonist, serotonin reuptake inhibitor, norepinephrine reuptake inhibitor, dual serotonin-noradrenaline reuptake inhibitor, Rho kinase inhibitor, inducible nitric oxide synthase inhibitor, acetylcholinesterase inhibitor, 15 prostaglandin E₂ subtype 4 antagonist, leukotriene B₄ antagonist, 5-lipoxygenase inhibitor, sodium channel blocker, 5-HT₃ antagonist, N-methyl-D-aspartic acid receptor antagonist, and phosphodiesterase V inhibitor.

Yet another embodiment of the present invention relates to a method for providing a method for treating disorders of the central nervous system including stroke, epilepsy, manic 20 depression, bipolar disorders, depression, anxiety, schizophrenia, migraine, and psychoses; neural degenerative disorders including Alzheimer's disease, AIDS related dementia, Parkinson's disease, neuropathy caused by head injury, and dementia caused by cerebrovascular disorders; disorders of the lower urinary tract including overactive bladder, prostatitis, prostatic dysplasia, interstitial cystitis, and benign prostatic hyperplasia; disorders caused 25 by psychogenic stress including bronchial asthma, unstable angina, and hypersensitive colon inflammation; cardiovascular disorders including hypertension, atherosclerosis, heart failure, and cardiac arrhythmias; drug addiction withdrawal symptoms, including ethanol addiction withdrawal symptoms; skin disorders including pruritis and allergic dermatitis, inflammatory bowel disease; cancer; diabetes; and infertility and sexual dysfunction in a mammal in need 30 of such treatment. This method comprises administering to the mammal (including human) a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.

Calcium channel blockers have been associated with a slightly greater decreased risk of stroke compared to other types of antihypertensive agents (Angeli, F.; et al. Calcium channel blockade to prevent stroke in hypertension. *American Journal of Hypertension* 2004, 17(9), 817-822). The enhanced effect did not correlate with differences in systolic
5 blood pressure and the mechanism of action remains unknown. However, calcium channel blockers have been associated with blockade of central neuronal calcium influx and subsequent ischemic injury in two rodent models (Barone, F. C.; et al. SB 201823-A antagonizes calcium currents in central neurons and reduces the effects of focal ischemia in rats and mice. *Stroke* 1995, 26, 1683-1690.). In another model of global ischemia, a
10 calcium channel blocker offered neuroprotection although not permanently (Colbourne, F.; et al. Continuing postischemic neuronal death in CA1: Influence of ischemia duration and cytoprotective doses of NBQX and SNX-111 in rats. *Stroke* 1999, 30(3), 662-668.). Additionally, diminished progression of carotid atherosclerosis has been observed with calcium channel blocker use (Zanchetti, A.; et al. Calcium antagonist lacidipine slows down
15 progression of asymptomatic carotid atherosclerosis. Principal results of the European lacidipine study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial. *Circulation* 2002, 106, r47-r52.).

An increase in intracellular calcium concentration has been correlated with seizure activity (Heinemann, U.; et al. Extracellular free calcium and potassium during paroxysmal
20 activity in the cerebral cortex of the cat. *Exp. Brain Res.* 1977, 27, 237-243.). Several studies have indicated that calcium channel blockers produce anticonvulsant activity (Vezzani, A.; et al. Effects of various calcium channel blockers on three different models of limbic seizures in rats. *Neuropharmacology* 1988, 27(5), 451-458. Ootom, S.; et al. Nifedipine inhibits picrotoxin-induced seizure activity: further evidence on the involvement
25 of L-type calcium channel blockers in epilepsy. *Fundamental & Clinical Pharmacology* 2006, 20, 115-119.).

Calcium channel blockers have been evaluated in the treatment of bipolar disorders and manic depression for decades. There are suggestions that the calcium channel subtype has influence on efficacy of these disorders (Gitlin, M. Treatment-resistant bipolar disorder.
30 *Molecular Psychiatry* 2006, 11, 227-240. Levy, N. A.; Janicak, P. G. *Bipolar Disorders* 2000, 2, 108-119.).

Calcium channel blockers have also been associated with the treatment of anxiety and depression (Saade, S.; et al. The L-type calcium channel blocker nimodipine mitigates

"learned helplessness" in rats. *Pharmacology, Biochemistry and Behavior* 2003, 74, 269-278.).

Antischizophrenic drugs have been found to be calcium channel antagonists (Gould, R. J.; et al. Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium
5 channel antagonists. *Proc. Natl. Acad. Sci. USA* 1983, 80, 5122-5125.). Other calcium channel blockers have been suggested for the treatment of schizophrenia (Tort, A. B. L.; et al. Atypical antipsychotic profile of flunarizine in animal models. *Psychopharmacology* 2005, 177, 344-348.).

Migraines are treated with calcium channel blockers (Arulmoshi, D. K.; et al.
10 Migraine: Current concepts and emerging therapies. *Vascular Pharmacology* 2005, 43, 176-187. Gladstone, J. P.; et al. Current and emerging treatment options for migraine and other primary headache disorders. *Expert Rev. Neurotherapeutics* 2003, 3(6), 845-872.).

Disorders of the lower urinary tract including overactive bladder, prostatitis, prostatic dysplasia, interstitial cystitis, and benign prostatic hyperplasia can be treated with calcium
15 channel blockers (Fraser, M. O.; et al. US20050148587, 2005).

Ethanol withdrawal syndrome is decreased with calcium channel blockers (Little, H. J.; et al. Calcium channel antagonists decrease the ethanol withdrawal syndrome. *Life Sciences* 1986, 39, 2059-2065.).

Several cardiac disorders are treated with calcium channel blockers. Atherosclerosis
20 may be reduced by a decrease in free radical-mediated damage as a result of influence on the biophysical properties of membranes (Mason, R. P.; et al. Antioxidant and cytoprotective activities of the calcium channel blocker mibefradil. *Biochemical Pharmacology* 1998, 55, 1843-1852.). Hypertension and angina are both successfully treated with calcium channel blockers (Croom, K. F.; et al. Modified-release nifedipine: A review of the use of modified-
25 release formulations in the treatment of hypertension and angina pectoris. *Drugs* 2006, 66(4), 497-528.).

There is data suggesting that calcium channel blockers inhibit the proliferation of cancer cells (Gray, L. S.; et al.. International Publication No. WO200059882, 2000.).

Calcium channels have been suggested as a target for the treatment of diabetes
30 (Bhattacharjee, A.; et al. T-Type calcium channels facilitate insulin secretion by enhancing general excitability in the insulin-secreting β -cell line, INS-1. *Endocrinology* 1997, 138(9), 3735-3740.).

Ion channels including calcium channels play an important role in sperm physiology and fertilization (Darszon, A.; et al. Ion channels in sperm physiology. Physiological Reviews 1999, 79(2), 481-510).

Calcium channel blockers modulate inflammation (Bilici, D.; et al. Protective effect of T-type calcium channel blocker in histamine-induced paw inflammation in rat. Pharmacological Research 2001, 44(6), 527-531.).

Increased calcium levels in neurones has been implicated in Alzheimer's disease. Two suggested mechanisms of increased calcium influx are that β -amyloid may form calcium permeable channels (Bhatia, R.; et al. Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for A β P channel-mediated cellular toxicity. FASEB J. 2000, 14(9), 1233-1243.) or a G-protein-coupled receptor may be activated by β -amyloid (Lorton, D. β -Amyloid induced IL-1 β release from an activated human monocyte cell line is calcium- and G-protein-dependent. Mech. Ageing Dev. 1997, 94(1-3), 199-211.).

Neurodegenerative diseases, including Parkinson's and Alzheimer's diseases can be modulated by calcium channel blockers (Rodnitzky, R. L. Can calcium antagonists provide a neuroprotective effect in Parkinson's disease. Drugs 1999, 57(6), 845-849. Vagnucci, A. H., Jr.; et al. Alzheimer's disease and angiogenesis. The Lancet 2003, 361(9357), 605-608. Veng, L. M.; et al. Age-related working memory impairment is correlated with increases in the L-type calcium channel protein α_{1D} ($Ca_v1.3$) in area CA1 of the hippocampus and both are ameliorated by chronic nimodipine treatment. Molecular Brain Research 2203, 110, 193-202. Geldenhuys, W. J.; et al. Structure-activity relationships of pentacycloundecylamines at the N-methyl-D-aspartate receptor. Bioorganic and Medicinal Chemistry 2007, 15, 1525-1532. Cavalli, A.; et al. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008, 51(3), 347-372.)

Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention can be varied so as to obtain an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

Compounds of the invention can also be administered as a pharmaceutical composition comprising the compounds of interest in combination with one or more pharmaceutically acceptable carriers. The phrase "therapeutically effective amount" of the compound of the invention means a sufficient amount of the compound to treat disorders, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well-known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

The total daily dose of the compounds of this invention administered to a human or other animal range from about 0.01 mg/kg body weight to about 100 mg/kg body weight. More preferable doses can be in the range of from about 0.01 mg/kg body weight to about 30 mg/kg body weight. If desired, the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.

e. Pharmaceutical Compositions

The present invention further provides pharmaceutical compositions that comprise compounds of the present invention or a pharmaceutically acceptable salt or solvate thereof. The pharmaceutical compositions comprise compounds of the present invention that may be formulated together with one or more non-toxic pharmaceutically acceptable carriers.

Another aspect of the present invention is a pharmaceutical composition comprising compounds of the invention, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, alone or in combination with one or more nonsteroidal anti-inflammatory drugs (NSAID), opioid analgesics, barbiturates, benzodiazepines,

histamine antagonists, sedatives, skeletal muscle relaxants, transient receptor potential ion channel antagonists, α -adrenergics, tricyclic antidepressants, anticonvulsants, tachykinin antagonists, muscarinic antagonists, cyclooxygenase-2 selective inhibitors, neuroleptics, vanilloid receptor agonists, vanilloid receptor antagonists, β -adrenergics, local anesthetics, corticosteroids, 5-HT receptor agonists, 5-HT receptor antagonists, 5-HT_{2A} receptor antagonists, cholinergic analgesics, $\alpha_2\delta$ ligands such as gabapentin or pregabalin, cannabinoid receptor ligands, metabotropic glutamate subtype 1 receptor antagonists, serotonin reuptake inhibitors, norepinephrine reuptake inhibitors, dual serotonin-noradrenaline reuptake inhibitors, Rho kinase inhibitors, inducible nitric oxide synthase inhibitors, acetylcholinesterase inhibitors, prostaglandin E₂ subtype 4 antagonists, leukotriene B₄ antagonists, 5-lipoxygenase inhibitors, sodium channel blockers, 5-HT₃ antagonists, N-methyl-D-aspartic acid receptor antagonists, and phosphodiesterase V inhibitors.

The pharmaceutical compositions of this invention can be administered to humans and other mammals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments or drops), buccally or as an oral or nasal spray. The term "parenterally" as used herein, refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The term "pharmaceutically acceptable carrier" as used herein, means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as, but not limited to, lactose, glucose and sucrose; starches such as, but not limited to, corn starch and potato starch; cellulose and its derivatives such as, but not limited to, sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as, but not limited to, cocoa butter and suppository waxes; oils such as, but not limited to, peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols; such as propylene glycol; esters such as, but not limited to, ethyl oleate and ethyl laurate; agar; buffering agents such as, but not limited to, magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as, but not limited to, sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening,

flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.

Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions,
5 suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), vegetable oils (such as olive oil), injectable organic esters (such as ethyl oleate) and suitable mixtures thereof. Proper fluidity
10 can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms can be
15 ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

20 In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively,
25 delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be
30 controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid

compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound may be mixed with at least one inert, pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such carriers as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They may optionally contain opacifying agents and may also be of a composition such that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned carriers.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan and mixtures thereof.

Besides inert diluents, the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth and mixtures thereof.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating carriers or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals which are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients and the like. The preferred lipids are natural and synthetic phospholipids and phosphatidyl cholines (lecithins) used separately or together.

Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq.

Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers or propellants which may be required. Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

The compounds of the present invention can be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. The phrase "pharmaceutically acceptable salt" means those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio.

Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in (J. Pharmaceutical Sciences, 1977, 66: 1 et seq). The salts can be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function
5 with a suitable organic acid. Representative acid addition salts include, but are not limited to acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isothionate), lactate, malate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate,
10 oxalate, palmitoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as, but not limited to, methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates;
15 long chain halides such as, but not limited to, decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained. Examples of acids which can be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid
20 and such organic acids as acetic acid, fumaric acid, maleic acid, 4-methylbenzenesulfonic acid, succinic acid and citric acid.

Basic addition salts can be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as, but not limited to, the hydroxide, carbonate or bicarbonate of a
25 pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as, but not limited to, lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium,
30 tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine and the like. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine and the like.

The term "pharmaceutically acceptable prodrug" or "prodrug" as used herein, represents those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like,

5 commensurate with a reasonable benefit/risk ratio, and effective for their intended use.

The present invention contemplates compounds of the invention formed by synthetic means or formed by *in vivo* biotransformation of a prodrug.

The compounds of the invention can exist in unsolvated as well as solvated forms, including hydrated forms, such as hemi-hydrates. In general, the solvated forms, with
10 pharmaceutically acceptable solvents such as water and ethanol among others are equivalent to the unsolvated forms for the purposes of the invention.


f. General Synthesis

This invention is intended to encompass compounds of the invention when prepared
15 by synthetic processes or by metabolic processes. Preparation of the compounds by metabolic processes includes those occurring in the human or animal body (*in vivo*) or processes occurring *in vitro*.

The compounds of the invention may be prepared by a variety of processes well known for the preparation of compounds of this class. For example, the compounds of the
20 invention wherein the groups L^1 , L^2 , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^e , R^f , R^g , R^h , n , q , and G^1 , have the meanings as set forth in the Summary of the Invention section unless otherwise noted, can be synthesized as shown in Schemes 1-20.


Abbreviations which have been used in the descriptions of the Schemes and the Examples that follow are: Ac for acetyl; $AlMe_3$ for trimethylaluminum; Boc for *t*-butoxy
25 carbonyl; Boc_2O for di-*tert*-butyl dicarbonate; Bu for butyl; Et for ethyl, EtOH for ethanol; DMF or *N,N*-dimethylformamide; DMSO for dimethyl sulfoxide; lcms for liquid chromatography/mass spec; MeOH for methanol; MsCl for methanesulfonyl chloride; NEt_3 for triethylamine; OAc for acetate; Ph for phenyl; PPh_3 for triphenylphosphine; PS-cyanoborohydride for polymer-supported cyanoborohydride; psi for pounds per square inch;
30 *t*Bu for *tert*-butyl; THF for tetrahydrofuran, and tlc for thin layer chromatography.

Scheme 1



Compounds of formula (1-3) and (1-4), wherein L^1 and R^1 are as defined in the Summary of the Invention, may be prepared as illustrated in Scheme 1. Compounds of formula (1-1) can be treated with hydroxylamine hydrochloride in the presence of a base such as sodium carbonate, sodium bicarbonate, or sodium acetate in a solvent such as water or aqueous methanol and optionally heated to furnish oximes of formula (1-2). Oximes of formula (1-2) can then be reduced in the presence of hydrogen (30 psi) in the presence of Raney®-nickel in a solvent such as 20% ammonia in methanol at ambient temperature over 1 to 24 hours to provide a diastereomeric mixture of amines, compounds of formulas (1-3) and (1-4). The diastereomeric amines can be separated by techniques known to one skilled in the art such as chromatography.

Scheme 2



15


Compounds of formula (2-2) which are representative of compounds of formula (I), wherein L^1 , R^1 , R^2 and R^3 are as described in the Summary of the Invention, are prepared by reacting compounds of formula (2-1) with carboxylic acids of formula R^2CO_2H under amide bond coupling conditions. Examples of conditions known to generate amides from a mixture of a carboxylic acid and an amine include but are not limited to adding a coupling reagent such as but not limited to *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide (EDC or EDCI), 1,3-dicyclohexylcarbodiimide (DCC), bis(2-oxo-3-oxazolidinyl)phosphinic chloride

20

(BOPCl), O-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HATU), O-benzotriazol-1-yl-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (TBTU), and 2-(1*H*-benzo[*d*][1,2,3]triazol-1-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (HBTU). The coupling reagents may be added as a solid, a solution or as the reagent bound to a solid support resin. In addition to the coupling reagents, auxiliary-coupling reagents may facilitate the coupling reaction. Auxiliary coupling reagents that are often used in the coupling reactions include but are not limited to (dimethylamino)pyridine (DMAP), 1-hydroxy-7-azabenzotriazole (HOAT) and 1-hydroxybenzotriazole (HOBt). The reaction may be carried out optionally in the presence of a base such as triethylamine or diisopropylethylamine. The coupling reaction may be carried out in solvents such as but not limited to tetrahydrofuran, *N,N*-dimethylformamide, dichloromethane, and ethyl acetate. The reaction may be conducted at ambient or elevated temperatures.


Alternatively, compounds of formula (2-2) may be prepared from compounds of formula (2-1) by reacting with an acid chloride of formula $R^2C(O)Cl$. Compounds of formula (2-1), may be treated $R_2C(O)Cl$ in a solvent such as dichloromethane in the presence of an amine such as triethylamine or diisopropylethylamine at room temperature over 1 to 24 hours to afford compounds of formula (2-2).

Scheme 3




As illustrated in Scheme 3, compounds of formulas (3-3), (3-4), and (3-5) which are representative of compounds of formula (I), and wherein R^1 , R^2 and R^3 are as defined in the Summary of the Invention, can be obtained from compounds of formula (3-1). Compounds of formula (3-1) can be converted to compounds of formula (3-2) by treatment with hydrogen (15-60 psi) in the presence of a catalyst such as palladium hydroxide on carbon or palladium on carbon in a solvent such as methanol or ethanol at ambient temperature over 3-36 hours. Compounds of formula (3-2) can then be reductively aminated with aldehydes of formula R^1CHO in the presence of a reducing agent such as PS-cyanoborohydride, sodium cyanoborohydride, or sodium triacetoxyborohydride and acetic acid in a solvent such as methanol or dichloromethane at room temperature over 4-24 hours to supply compounds of formula (3-3). Alternatively, compounds of formula (3-2) can be reacted with a sulfonyl chloride of formula R^1SO_2Cl in the presence of a base such as triethylamine or diisopropylamine optionally in the presence of (dimethylamino)pyridine in a solvent such as dichloromethane at ambient temperature over 4-24 hours to supply compounds of formula (3-4). Compounds of formula (3-5) can also be prepared from compounds of formula (3-2). Compounds of formula (3-2) can be treated with a carboxylic acid of formula R^1CO_2H or and acid chloride of formula $R^1C(O)Cl$ under the amide bond forming conditions described in Scheme 2 to give compounds of formula (3-5).

Scheme 4




As illustrated in Scheme 4, compounds of formulas (4-2), (4-3), (4-4) and (4-5) which are representative of compounds of formula (I), wherein R^1 , R^2 and R^3 are as defined in the Summary of the Invention, can be obtained from compounds of formula (4-1). Accordingly, compounds of formula (4-1) can be treated with sulfonyl chlorides of formula R_2SO_2Cl using the conditions described in Scheme 3 to give compounds of formula (4-2). The benzyl group can be reductively cleaved with hydrogen and a palladium catalyst as described in Scheme 3 to deliver compounds of formula (4-3). Compounds of formula (4-3) can be reductively alkylated with aldehydes of formula R^1CHO under the reaction conditions described in Scheme 3 to give compounds of formula (4-4). The secondary amine of compounds of formula (4-3) can be coupled with a carboxylic acid or acid chloride with the conditions described in Scheme 2 to give amides of formula (4-5).

Scheme 5




Compounds of formula (5-4) and (5-5), wherein G^1 is aryl or heteroaryl and unsubstituted or substituted as described in the Summary of the Invention, can be prepared from compounds of formula (5-1) as described in Scheme 5. Compounds of formula (5-1) can be combined with chloromethyltrimethylsilane and triethylamine and refluxed for 8-24 hours. The intermediate can then be reacted with formaldehyde in the presence of potassium carbonate and in methanol to give compounds of formula (5-2). Compounds of formula (5-2) can be reacted with cyclopent-2-enone at room temperature in the presence of trifluoroacetic acid in a solvent such as dichloromethane to give compounds of formula (5-3). Compounds of formula (5-3) can be transformed to compounds of formulas (5-4) and (5-5) upon treatment first with hydroxylamine hydrochloride and subsequently with hydrogen in the presence of Raney®-nickel as described in Scheme 1.

Scheme 6




Chiral compounds of formulas (6-3) and (6-4), wherein L^1 and R^1 are as defined in the Summary of the Invention, can be synthesized as described in Scheme 6. To this end, compounds of formula (1-1) can be treated with a chiral sulfinamide such as (*S*)-2-methylpropane-2-sulfinamide in the presence of titanium tetraethoxide in a solvent such as tetrahydrofuran and heated to 30-65 °C for 4 to 24 hours to give the diastereomeric compounds (6-1) and (6-2). The chiral diastereomers can be chromatographically separated and then treated individually in the following sequence. Chiral compounds of formula (6-1) can be reduced with sodium borohydride in methanol at -78 °C with gradual warming to room temperature over 8 to 20 hours. Subsequent hydrolysis with hydrochloric acid in methanol delivers chiral compounds of formula (6-3). In similar fashion, chiral compounds of formula (6-2) can be converted to chiral compounds of formula (6-4).

Scheme 7




As illustrated in Scheme 7, chiral compounds of formulas (7-2), wherein L^1 and R^1 are as defined in the Summary of the Invention, can be obtained from chiral compounds of formula (6-2). Chiral compounds of formula (6-2) can be hydrolyzed with hydrochloric acid in tetrahydrofuran at room temperature over 1-8 hours. Subsequent reduction with sodium borohydride in methanol at -40 °C to room temperature over 8-24 hours supplies chiral alcohols (7-1). Alcohols (7-1) can be transformed to chiral amines (7-2) in a three-step process. Compounds of formula (7-1) can be treated with methanesulfonyl chloride in the presence of triethylamine in dichloromethane at ambient temperature for 10 minutes to 2 hours. The sulfonates can then be displaced with inversion with sodium azide in heated *N,N*-dimethylacetamide over 8-24 hours. The derived azides can finally be reduced with triphenylphosphine in a heated mixture of water and tetrahydrofuran to give chiral compounds of formula (7-2).

Scheme 8

As described in Scheme 8, compounds of formula (8-1) can be converted to compounds of formula (8-2) wherein R^3 is alkyl, haloalkyl, cycloalkyl, or cycloalkylalkyl.

- 5 Compounds of formula (8-1) can be treated with amines of formula R^3NH_2 in the presence of PS-cyanoborohydride, sodium cyanoborohydride, or triacetoxy borohydride and acetic acid in dichloromethane at ambient temperature for 1-6 hours to give compounds of formula (8-2). Compounds of formula (8-2) can be used in Scheme 4 in place of compounds of formula (4-1).


10

Scheme 9

As illustrated in Scheme 9, compounds of formula (9-1), wherein R^2 and R^3 are as defined in the Summary of the Invention, can be obtained from compounds of formula (3-2).


- 15 Compounds of formula (3-2) can be reacted with (bromomethylene)dibenzene in the presence of potassium iodide, and sodium carbonate in methyl ethyl ketone heated to 90 °C for 6 to 24 hours to give compounds of formula (9-1) which are representative of compounds of formula (I).

20

Scheme 10

As illustrated in Scheme 10, compounds of formula (10-2) which are representative of compounds of formula (I) and wherein L^1 , R^1 , R^3 , R^5 , R^g , R^h , and q are as defined in the Summary of the Invention can be obtained from compounds of formula (10-1). Compounds of formula (10-1) can be treated with an acid such as hydrochloric acid or trifluoroacetic acid at room temperature in a solvent such as ether, dioxane, or dichloromethane for 2-24 hours to supply compounds of formula (10-2).

Scheme 11




As illustrated in Scheme 11, compounds of formula (11-1), (11-2), (11-3), (11-4), and (11-5) which are representative of compounds of formula (I) and wherein L^1 , R^1 , R^3 , R^5 , R^g , R^h , q , and G^2 are as defined in the Summary of the Invention can be obtained from compounds of formula (10-2). Compounds of formula (10-2) can be treated with a sulfonyl chloride of formula R^6SO_2Cl in dichloromethane in the presence of diisopropylethylamine at room temperature for 2-24 hours to provide compounds of formula (11-1). Similarly, compounds of formula (11-2) can be obtained upon treatment of compounds of formula (10-2) with an anhydride or acid chloride in dichloromethane at ambient temperature in the presence of diisopropylethylamine over 2-24 hours. Compounds of formula (11-3) are obtained from compounds of formula (10-2) upon treatment with a carbonochloridate in the presence of diisopropylethylamine in dichloromethane at room temperature over 2-24 hours.

In like manner, compounds of formula (11-4) are made from compounds of formula (10-2) by reacting with an isocyanate in dichloromethane at room temperature over 2-24 hours.

Compounds of formula (11-5), wherein R^B is alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, or heteroarylalkyl can be prepared either by alkylation or reductive amination of compounds of


5 formula (10-2) using methodology known to one skilled in the art.

Scheme 12



As illustrated in Scheme 12, compounds of formula (12-5) which are representative of
 10 compounds of formula (I) and wherein R^1 and R^2 are as defined in the Summary of the
 Invention can be obtained from compound of formula (12-1). Compound (12-1) can be reacted
 with di-*tert*-butyl dicarbonate in the presence of (dimethylamino)pyridine in a solvent such as
 dichloromethane or dioxane at room temperature for 20 minutes to 4 hours to provide
 15 compound of formula (12-2). The benzyl group of compound of formula (12-2) can be
 removed with hydrogen in the presence of a palladium catalyst as described and then coupled
 with a carboxylic acid or acid chloride as described in the methods of Scheme 3 to provide
 compounds of formula (12-3). Removal of the *tert*-butoxy carbonyl group from compounds
 of formula (12-3) with the acid conditions described in Scheme 10 supplies compounds of
 formula (12-4). Compounds of formula (12-4) can be reductively aminated with aldehydes of
 20 formula $\text{R}^2\text{-CHO}$ using the conditions described in Scheme 3 to give compounds of formula
 (12-5).


Scheme 13



As illustrated in Scheme 13, compounds of formula (13-2) which are representative of compounds of formula (I), wherein R^2 and R^4 are as defined in the Summary of the Invention, and compound of formula (13-1) can be obtained from compound of formula (12-2).

Compound of formula (12-2) can be treated with lithium aluminum hydride in tetrahydrofuran initially at room temperature and then heated to reflux to afford compound of formula (13-1). Compound of formula (13-1) can be used in the methods described in Schemes 2 and 4. Compound of formula (12-2) can be treated with an amine in the presence of trimethylaluminum in toluene initially at 0 °C and then at 90 °C for 6 to 24 hours to provide urea compounds of formula (13-2).


Scheme 14



As shown in Scheme 14, compounds of formulas (14-2), (14-3), (14-4), and (14-5), wherein R^4 , R^6 , R^g , R^h , and q are as defined in the Summary of the Invention can be obtained from compounds of formula (14-1). Compounds of formula (14-1) can be treated with a sulfonyl chloride of formula $\text{R}^6\text{SO}_2\text{Cl}$ in the presence of a base such as triethylamine or diisopropylethylamine in a solvent such as dichloromethane. Subsequent removal of the *t*-butyl group under acidic conditions deliver compounds of formula (14-2). Compounds of formula (14-1) can also be reductively aminated with an aldehyde of formula R^4CHO and a reductant such as sodium cyanoborohydride, polymer supported cyanoborohydride resin, or sodium triacetoxyborohydride optionally in the presence of an acid such as acetic acid in solvents such as dichloromethane or methanol. Acidic removal of the *t*-butyl group supplies compounds of formula (14-3). Compounds of formula (14-1) can also be dialkylated with dibromo compounds. Accordingly, alkylation of (14-1) with 1-bromo-2-(2-bromoethoxy)ethane in heated acetonitrile in the presence of a base followed by acid catalyzed *t*-butyl removal delivers compounds of formula (14-4). Alkylation with 1,4-dibromobutane or 1,5-dibromopentane under similar conditions followed by acid catalyzed *t*-

butyl removal delivers compounds of formula (14-5). Compounds of formulas (14-2), (14-3), (14-4), and (14-5) can be used in Schemes 2, 3, 4 and 12.

Scheme 15




5

As illustrated in Scheme 15, compounds of formula (15-3) which are representative of compounds of formula (I) and wherein R^1 and R^2 are as defined in the Summary of the Invention can be obtained from compound of formula (12-2). The benzyl group of compound of formula (12-2) can be removed with hydrogen in the presence of a palladium catalyst as described in Scheme 3 and then coupled with a sulfonyl chloride of formula $\text{R}^1\text{SO}_2\text{Cl}$ as described in the methods of Scheme 3 to provide compounds of formula (15-1). Removal of the *tert*-butoxy carbonyl group from compounds of formula (15-1) with the acid conditions described in Scheme 10 supplies compounds of formula (15-2). Compounds of formula (15-2) can be coupled with carboxylic acids of formula $\text{R}^2\text{-CO}_2\text{H}$ or acid chlorides of formula $\text{R}^2\text{-C(O)Cl}$ under the reaction conditions described in Scheme 2 to give compounds of formula (15-3).

10


15

Scheme 16




As illustrated in Scheme 17, compounds of formulas (16-3) which are representative of compounds of formula (I), wherein L^2 , R^1 , R^2 and R^3 are as defined in the Summary of the Invention, can be obtained from compounds of formula (12-2). Compounds of formula (12-2) can be converted to compounds of formula (16-1) by treatment with hydrogen (15-60 psi) in the presence of a catalyst such as palladium hydroxide on carbon or palladium on carbon in a solvent such as methanol or ethanol at ambient temperature over 3-36 hours. Compounds of formula (16-1) can then be reacted with an aryl halide or heteroaryl halide suitable for a nucleophilic aromatic substitution reaction to furnish compounds of formula (16-2). For example, a compound of formula (16-1) can be heated in a solvent such as ethanol in the presence of a base and heteroaryl bromide to supply compounds of formula (16-2). Compounds of formula (16-2) can then be deprotected under acidic conditions and further functionalized as described in but not limited to Schemes 2, 4, 10, 11, 12, 13 or 17 to give compounds of formula (16-3).

Scheme 17




- As illustrated in Scheme 17, compounds of formula (17-1) can be transformed into
- 5 compounds of formulas (17-2), (17-3), (17-4), (17-5), and (17-6) which are representative of compounds of formula (I), wherein L¹, R¹, and R² are as defined in the Summary of the Invention. Compounds of formula (17-1) can be converted to compounds of formula (17-2) through either a nucleophilic aromatic substitution reaction under conditions described in Scheme 16 or under cross-coupling reaction conditions known to one skilled in the art.
- 10 Compounds of formula (17-1) can also be reductively aminated with an aldehyde to give compounds of formula (17-3) or a ketone to give compounds of formula (17-4), wherein R^A is alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, or heteroarylalkyl. Alternatively, in compounds of formula (17-4), R^A and R² together with the atom to which they are attached may be joined to form a cyclic group. Reductive amination conditions are
- 15 described in but not limited to those in Schemes 3, 4, 8, 12, and 14. Compounds of formula (17-1) can be mono-alkylated to give compounds of formula (17-5) or di-alkylated to give compounds of formula (17-6). Compounds of formula (17-1) can be treated with an alkyl-, arylalkyl-, cycloalkyl-, cycloalkylalkyl-, or heteroarylalkyl-halide or sulfonate optionally in the presence of a base in an optionally heated solvent such as tetrahydrofuran or *N,N*-
- 20 dimethylformamide to give compounds of formula (17-5), wherein R^B is alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, or heteroarylalkyl. Excess alkylating agent leads to compounds of formula (17-6).

Scheme 18




As illustrated in Scheme 18, compounds of formula (17-1) can be converted to
 5 compounds of formulas (18-1), (18-2), and (18-3) which are representative of compounds of
 formula (I), wherein, L^1 , L^2 , R^1 , and R^2 are as defined in the Summary of the Invention and
 R^{B} is alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, or heteroarylalkyl. Compounds of formula
 (17-1) can be reacted with 2-nitrobenzene-1-sulfonyl chloride in the presence of a base. The
 resultant sulfonamide can then be alkylated under conditions known to one skilled in the art
 10 to give compounds of formula (18-1). Treatment with 2-mercaptoethanol in the presence of a
 base in a solvent such as *N,N*-dimethylformamide gives compounds of formula (18-2).
 Compounds of formula (18-2) can be reacted as described in Schemes 2, 4, 10, 11, 12, 13, or
 17 to give compounds of formula (18-3).

Scheme 19



As illustrated in Scheme 19, compounds of formula (19-2) which are representative of compounds of formula (I), wherein L^1 , L^2 , R^1 and R^2 are as defined in the Summary of the Invention, can be obtained from compound of formula (17-1). Compound of formula (17-1) can be treated with lithium aluminum hydride in tetrahydrofuran initially at room temperature and then heated to reflux to afford compound of formula (19-1). Compound of formula (19-1) can be used in the methods described in Schemes 2, 4, 10, 11, 12, 13, 17 or 18 to give compounds of formula (19-2).

Scheme 20



As illustrated in Scheme 20, compounds of formula (20-3), (20-4), (20-5), (20-6) and (20-7) which are representative of compounds of formula (I) and wherein L^2 , R^2 , R^3 , R^4 , R^5 , R^6 , R^e , R^f , and n are as defined in the Summary of the Invention can be obtained from compounds of formula (20-2). Compounds of formula (20-2) are obtained from compounds of formula (20-1) upon treatment with an acid such as trifluoroacetic acid in dichloromethane or hydrochloric acid in dioxane. Compounds of formula (20-2) can be treated with a sulfonyl chloride of formula R^6SO_2Cl in dichloromethane in the presence of diisopropylethylamine at room temperature for 2-24 hours to provide compounds of formula (20-3). Similarly, compounds of formula (20-4) can be obtained upon treatment of compounds of formula (20-2) with an anhydride or acid chloride in dichloromethane at ambient temperature in the

presence of diisopropylethylamine over 2-24 hours. Compounds of formula (20-5) are obtained from compounds of formula (20-2) upon treatment with a carbonochloridate in the presence of diisopropylethylamine in dichloromethane at room temperature over 2-24 hours. In like manner, compounds of formula (20-6) are made from compounds of formula (20-2) by reacting with an isocyanate in dichloromethane at room temperature over 2-24 hours. Compounds of formula (20-7), wherein R^B is alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, or heteroarylalkyl can be prepared either by alkylation or reductive amination of compounds of formula (20-2) using methodology known to one skilled in the art.

It will be appreciated that the synthetic schemes and specific examples as illustrated in the Examples section are illustrative and are not to be read as limiting the scope of the invention as it is defined in the appended claims. All alternatives, modifications, and equivalents of the synthetic methods and specific examples are included within the scope of the claims.

Optimum reaction conditions and reaction times for each individual step may vary depending on the particular reactants employed and substituents present in the reactants used. Unless otherwise specified, solvents, temperatures and other reaction conditions may be readily selected by one of ordinary skill in the art. Specific procedures are provided in the Examples section. Reactions may be worked up in the conventional manner, e.g. by eliminating the solvent from the residue and further purified according to methodologies generally known in the art such as, but not limited to, crystallization, distillation, extraction, trituration and chromatography. Unless otherwise described, the starting materials and reagents are either commercially available or may be prepared by one skilled in the art from commercially available materials using methods described in the chemical literature.

Routine experimentations, including appropriate manipulation of the reaction conditions, reagents and sequence of the synthetic route, protection of any chemical functionality that may not be compatible with the reaction conditions, and deprotection at a suitable point in the reaction sequence of the method are included in the scope of the invention. Suitable protecting groups and the methods for protecting and deprotecting different substituents using such suitable protecting groups are well known to those skilled in the art; examples of which may be found in T. Greene and P. Wuts, *Protecting Groups in Chemical Synthesis* (3rd ed.), John Wiley & Sons, NY (1999), which is incorporated herein by reference in its entirety. Synthesis of the compounds of the invention may be

accomplished by methods analogous to those described in the synthetic schemes described hereinabove and in specific examples.

Starting materials, if not commercially available, may be prepared by procedures selected from standard organic chemical techniques, techniques that are analogous to the synthesis of known, structurally similar compounds, or techniques that are analogous to the above described schemes or the procedures described in the synthetic examples section.

When an optically active form of a compound of the invention is required, it may be obtained by carrying out one of the procedures described herein using an optically active starting material (prepared, for example, by asymmetric induction of a suitable reaction step), or by resolution of a mixture of the stereoisomers of the compound or intermediates using a standard procedure (such as chromatographic separation, recrystallization or enzymatic resolution).

Similarly, when a pure geometric isomer of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using a pure geometric isomer as a starting material, or by resolution of a mixture of the geometric isomers of the compound or intermediates using a standard procedure such as chromatographic separation.

g. Examples

Example 1 and Example 2

N-[(3*aS**,4*S**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclopentanecarboxamide (Example 1) and
N-[(3*aS**,4*R**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclopentanecarboxamide (Example 2)

1-Hydroxybenzotriazole (33 mg, 0.24 mmol) and *N*-(3-dimethylaminopropyl)-*N*'-ethylcarbodiimide (43 μ L, 0.24 mmol) were added to a solution of 1-phenylcyclopentanecarboxylic acid (46 mg, 0.24 mmol) in dichloromethane (2 mL). The reaction was stirred at room temperature for 10 minutes, then (3*aS**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine (52 mg, 0.24 mmol) was added and the reaction stirred at room temperature overnight. The reaction was quenched with water, and extracted with dichloromethane, then purified by silica gel chromatography using 1-10% methanol (2 *N* ammonia)/chloroform as eluent to give the title compounds.

Example 1: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 7.52 – 7.28 (m, 9H), 7.25 (d, $J = 7.7$, 1H), 4.43 – 4.34 (m, 1H), 3.56 (d, $J = 12.9$, 1H), 3.17 (d, $J = 12.9$, 1H), 2.83 – 2.67 (m, 2H), 2.59 – 2.50 (m, 1H), 2.50 – 2.44 (m, 1H), 2.35 – 2.29 (m, 2H), 2.04 – 1.87 (m, 4H), 1.84 – 1.54 (m, 6H), 1.43 – 1.26 (m, 1H), 1.04 – 0.94 (m, 1H); MS (ESI+) m/z 389 ($\text{M}+\text{H}$) $^+$.

5 **Example 2:** ^1H NMR (500 MHz, pyridine- d_5) δ ppm 7.52 – 7.47 (m, 2H), 7.41 (d, $J = 7.4$, 2H), 7.38 – 7.29 (m, 4H), 7.25 (q, $J = 7.3$, 2H), 4.36 (m, 1H), 3.57 (d, $J = 13.2$, 1H), 3.40 (d, $J = 13.2$, 1H), 2.78 (m, 3H), 2.33 (m, 3H), 2.27 (d, $J = 8.7$, 1H), 2.21 – 2.13 (m, 1H), 1.99 (dt, $J = 5.8$, 11.7, 3H), 1.87 – 1.75 (m, 2H), 1.71 – 1.60 (m, 3H), 1.44 (ddd, $J = 7.7$, 12.1, 14.5, 1H), 1.31 (m, 1H); MS (ESI+) m/z 389 ($\text{M}+\text{H}$) $^+$.

10

Example 3 and Example 4

N-[(3a*R**,4*R**,6a*S**)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclohexyl-2-phenylacetamide (Example 3) and

15 *N*-[(3a*S**,4*R**,6a*R**)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclohexyl-2-phenylacetamide (Example 4)

The title compounds were prepared by substituting 2-cyclohexyl-2-phenylacetic acid for 1-phenylcyclopentanecarboxylic acid in the procedure that describes the preparation of Examples 1 and 2.

20 **Example 3:** ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.10 (s, 1H), 7.67 (d, $J = 7.2$, 1H), 7.44 (dd, $J = 5.7$, 12.3, 3H), 7.40 – 7.35 (m, 3H), 7.33 (t, $J = 7.4$, 1H), 7.27 (dd, $J = 7.6$, 16.2, 1H), 4.43 – 4.37 (m, 0.5H), 4.36 – 4.29 (m, 0.5H), 3.56 (d, $J = 12.6$, 0.5H), 3.42 (t, $J = 11.7$, 1H), 3.26 (dd, $J = 6.6$, 11.7, 1H), 3.14 (d, $J = 10.5$, 0.5H), 2.80 (d, $J = 8.3$, 1H), 2.63 (d, $J = 6.9$, 0.5H), 2.24 – 2.13 (m, 1.5H), 2.02 (d, $J = 12.5$, 0.5H), 1.91 (d, $J = 7.0$, 1H), 1.74 – 1.59 (m, 2.5H), 1.58 – 1.34 (m, 4H), 1.33 – 1.19 (m, 1.5H), 1.18 – 0.99 (m, 3H), 0.87 (d, $J = 14.3$, 0.5H), 0.81 – 0.68 (m, 1H); MS (ESI+) m/z 417 ($\text{M}+\text{H}$) $^+$.

25 **Example 4:** ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.65 – 8.56 (m, 1H), 7.66 (dd, $J = 3.1$, 7.3, 2H), 7.43 (d, $J = 7.4$, 1H), 7.39 – 7.30 (m, 5H), 7.27 (dd, $J = 5.0$, 7.6, 2H), 4.35 (s, 1H), 3.59 (d, $J = 13.1$, 0.5H), 3.52 (d, $J = 13.2$, 0.5H), 3.44 (d, $J = 13.1$, 0.5H), 3.33 (dd, $J = 8.2$, 11.7, 1.5H), 2.89 (dd, $J = 3.1$, 9.1, 0.5H), 2.63 – 2.54 (m, 1H), 2.53 – 2.45 (m, 1H), 2.36 (m, 2H), 2.28 (t, $J = 8.0$, 1H), 2.22 (t, $J = 7.0$, 2H), 2.16 (dd, $J = 6.0$, 12.2, 1H), 1.92 (dd, $J = 6.1$, 12.2, 0.5H), 1.84 (dd, $J = 7.5$, 12.6, 0.5H), 1.71 (dd, $J = 6.2$, 12.8, 2H), 1.44 (dd, $J = 20.6$, 55.0, 4H), 1.29 (m, 1.5H), 1.18 (m, 1H), 1.06 (m, 2H), 0.70 (m, 1H); MS (ESI+) m/z 389 ($\text{M}+\text{H}$) $^+$.

30

Example 5 and Example 6

***N*-[*(3aR*,4R*,6aS*)*]-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide (Example 5) and**

***N*-[*(3aR*,4S*,6aS*)*]-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide (Example 6)**

The title compounds were prepared by substituting 3-methyl-2-phenylbutanoic acid for 1-phenylcyclopentanecarboxylic acid in the procedure that describes the preparation of Examples 1 and 2.

Example 5: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.13 – 8.03 (m, 1H), 7.65 (d, *J* = 7.2, 1H), 7.55 (d, *J* = 7.3, 1H), 7.44 (d, *J* = 4.3, 2H), 7.41 (d, *J* = 7.0, 1H), 7.36 (t, *J* = 6.9, 3H), 7.28 (ddd, *J* = 7.3, 14.7, 17.5, 2H), 4.40 (dd, *J* = 6.7, 13.3, 0.5H), 4.35 – 4.27 (m, 0.5H), 3.55 (d, *J* = 12.7, 0.5H), 3.40 (dd, *J* = 4.5, 12.8, 1H), 3.26 (d, *J* = 12.9, 0.5H), 3.16 (d, *J* = 10.5, 0.5H), 3.05 (d, *J* = 10.5, 0.5H), 2.78 (dd, *J* = 8.1, 15.8, 1H), 2.69 – 2.54 (m, 1.5H), 2.43 – 2.26 (m, 3H), 2.23 – 2.13 (m, 1H), 1.94 – 1.82 (m, 1H), 1.73 – 1.57 (m, 1.5H), 1.50 (dt, *J* = 7.1, 15.0, 0.5H), 1.38 (td, *J* = 6.4, 12.2, 0.5H), 1.27 (m, 0.5H), 1.19 (d, *J* = 6.4, 1.5H), 1.11 (dd, *J* = 5.7, 12.0, 0.5H), 1.03 (d, *J* = 6.5, 1.5H), 0.73 (dd, *J* = 6.7, 10.7, 3H); MS (ESI+) *m/z* 377 (M+H)⁺.

Example 6: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.56 (d, *J* = 12.9, 1H), 7.67 – 7.61 (m, 2H), 7.43 (d, *J* = 7.1, 1H), 7.39 – 7.31 (m, 5H), 7.29 – 7.24 (m, 2H), 4.40 – 4.28 (m, 1H), 3.60 (d, *J* = 13.1, 0.5H), 3.52 (d, *J* = 13.1, 0.5H), 3.44 (d, *J* = 13.2, 0.5H), 3.33 (d, *J* = 13.2, 0.5H), 3.22 (d, *J* = 10.4, 1H), 2.89 (dd, *J* = 3.0, 9.1, 0.5H), 2.64 (m, 1H), 2.55 (m, 1H), 2.51 – 2.44 (m, 1H), 2.36 (s, 1H), 2.28 (t, *J* = 8.3, 1H), 2.24 – 2.10 (m, 2H), 1.95 – 1.87 (m, 0.5H), 1.81 (d, *J* = 8.1, 0.5H), 1.77 – 1.62 (m, 1H), 1.36 (m, 1.5H), 1.20 (dt, *J* = 5.3, 10.6, 3H), 0.70 (dd, *J* = 1.6, 6.7, 3H); MS (ESI+) *m/z* 377 (M+H)⁺.

Example 7 and Example 8

***N*-[*(3aS*,4S*,6aR*)*]-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide (Example 7) and**

***N*-[*(3aS*,4R*,6aR*)*]-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide (Example 8)**

The title compounds were prepared by substituting 2-cyclopentyl-2-phenylacetic acid for 1-phenylcyclopentanecarboxylic acid in the procedure that describes the preparation of Examples 1 and 2.

Example 7: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.06 (dd, $J = 6.8, 23.5$, 1H), 7.67 (d, $J = 7.2$, 1H), 7.46 – 7.39 (m, 3H), 7.40 – 7.29 (m, 4H), 7.29 – 7.22 (m, 1H), 4.45 – 4.37 (m, 0.5H), 4.35 – 4.27 (m, 0.5H), 3.54 (d, $J = 12.7$, 0.5H), 3.42 (dd, $J = 4.0, 12.8$, 1H), 3.34 – 3.19 (m, 1.5H), 2.97 – 2.77 (m, 2.5H), 2.63 (d, $J = 7.2$, 0.5H), 2.46 – 2.27 (m, 3H), 2.26 – 2.05 (m, 1.5H), 2.03 – 1.84 (m, 1.5H), 1.71 (dt, $J = 7.0, 14.1$, 0.5H), 1.65 – 1.36 (m, 8H), 1.33 – 1.22 (m, 0.5H), 1.20 – 0.98 (m, 2H); MS (ESI+) m/z 403 ($\text{M}+\text{H}$) $^+$.

Example 8: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.60 – 8.49 (m, 1H), 7.67 (dd, $J = 2.3, 7.6$, 2H), 7.44 (d, $J = 7.2$, 1H), 7.36 (dt, $J = 5.0, 7.6$, 5H), 7.26 (t, $J = 6.9$, 2H), 4.36 (m, 1H), 3.61 (d, $J = 13.1$, 0.5H), 3.52 (d, $J = 13.1$, 0.5H), 3.45 (d, $J = 13.2$, 0.5H), 3.36 (dd, $J = 12.0, 16.0$, 1.5H), 2.95 – 2.83 (m, 1.5H), 2.63 – 2.55 (m, 1H), 2.53 – 2.46 (m, 1H), 2.38 (s, 1H), 2.29 (dd, $J = 7.0, 12.8$, 1.5H), 2.22 (dd, $J = 6.1, 12.3$, 1H), 2.18 – 2.504 (m, 1.5H), 1.94 (dd, $J = 6.1, 12.2$, 0.5H), 1.84 (dd, $J = 7.5, 12.7$, 0.5H), 1.79 – 1.66 (m, 1H), 1.65 – 1.24 (m, 8.5H), 1.09 – 0.92 (m, 1H); MS (ESI+) m/z 403 ($\text{M}+\text{H}$) $^+$.

Example 9 and Example 10

***N*–[(3a*S**,4*S**,6a*R**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide (Example 9) and**
***N*–[(3a*S**,4*R**,6a*R**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide (Example 10)**

The title compounds were prepared by substituting 1-phenylcyclohexanecarboxylic acid for 1-phenylcyclopentanecarboxylic acid in the procedure that describes the preparation of Examples 1 and 2.

Example 9: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 7.57 – 7.54 (m, 2H), 7.45 (t, $J = 7.3$, 2H), 7.37 (dd, $J = 7.6, 15.3$, 5H), 7.29 (d, $J = 6.9$, 1H), 7.25 (t, $J = 7.3$, 1H), 4.41 (m, 1H), 3.59 (d, $J = 12.9$, 1H), 3.18 (d, $J = 12.9$, 1H), 2.52 (dd, $J = 8.9, 17.6$, 4H), 2.34 (dd, $J = 8.5, 15.2$, 2H), 2.01 – 1.92 (m, 2H), 1.91 – 1.80 (m, 2H), 1.79 – 1.68 (m, 3H), 1.61 (d, $J = 25.2$, 4H), 1.43 – 1.33 (m, 1H), 1.27 (d, $J = 8.7$, 1H), 1.04 – 0.93 (m, 1H); MS (ESI+) m/z 403 ($\text{M}+\text{H}$) $^+$.

Example 10: ^1H NMR (400 MHz, pyridine- d_5) δ ppm 7.60 (s, 1H), 7.42 (d, $J = 7.2$, 2H), 7.36 (t, $J = 6.7$, 4H), 7.27 (d, $J = 7.5$, 2H), 4.42 (m, 1H), 3.58 (d, $J = 13.2$, 1H), 3.40 (d, $J = 13.1$, 1H), 2.81 (d, $J = 8.1$, 1H), 2.68 (m, 2H), 1.41 – 2.24 (m, 4H), 2.18 (m, 1H), 2.00 (m, 1H), 1.80 (m, 4H), 1.73 – 1.54 (m, 4H), 1.52 – 1.39 (m, 1H), 1.36 – 1.18 (m, 2H); MS (ESI+) m/z 403 ($\text{M}+\text{H}$) $^+$.

Example 11***N*-[(3*aS**,4*S**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide**

(3*aS**,6*aR**)-2-Benzyloctahydrocyclopenta[*c*]pyrrol-4-amine (500 mg, 2.311 mmol),
 5 2,2-dicyclohexylacetic acid (570 mg, 2.54 mmol), and 1-hydroxybenzotriazole (389 mg, 2.54 mmol) were combined in dichloromethane (20 mL). The reaction was stirred at room temperature for 10 minutes, then *N*-(3-dimethylaminopropyl)-*N*'-ethylcarbodiimide (0.449 mL, 2.54 mmol) was added dropwise. The reaction was stirred at room temperature for 20 hours, and then the reaction was quenched with 10 mL of water. The reaction was extracted
 10 with 2×20 mL of dichloromethane, the solvent was removed in vacuo, and the crude material was chromatographed over a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-40) eluting with 30-50% ethyl acetate/hexanes to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.60 (d, *J* = 5.1, 1H), 7.45 – 7.38 (m, 4H), 7.35 (m, 1H), 4.49 – 4.41 (m, 1H), 3.57 (d, *J* = 12.6, 1H), 3.37 (d, *J* = 12.5, 1H), 2.76 (d, *J* = 9.6, 1H), 2.69 (dd, *J* = 7.9,
 15 15.7, 1H), 2.50 (d, *J* = 9.1, 1H), 2.48 – 2.41 (m, 1H), 2.28 (t, *J* = 8.2, 1H), 2.15 – 2.08 (m, 1H), 1.99 – 1.06 (m, 26H), 1.04 – 0.92 (m, 1H); MS (ESI+) *m/z* 423 (M+H)⁺.

Example 12 and Example 13

(2*S*)-2-(3-benzoylphenyl)-*N*-[(3*aS,4*S**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]propanamide (Example 12) and**
 20 **(2*S*)-2-(3-benzoylphenyl)-*N*-[(3*aS**,4*R**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]propanamide (Example 13)**

The title compounds were prepared by substituting (*S*)-2-(3-benzoylphenyl)propanoic acid for 1-phenylcyclopentanecarboxylic acid in the procedure that describes the preparation
 25 of Examples 1 and 2.

Example 12: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.28 (d, *J* = 6.9, 0.5H), 8.21 (d, *J* = 7.1, 0.5H), 8.13 (d, *J* = 15.9, 1H), 7.92 – 7.82 (m, 2H), 7.75 (t, *J* = 9.1, 2H), 7.56 – 7.52 (m, 1H), 7.50 – 7.25 (m, 8H), 4.49 – 4.32 (m, 1H), 3.90 (q, *J* = 7.1, 0.5H), 3.81 (t, *J* = 7.0, 0.5H), 3.45 (q, *J* = 12.8, 1.5H), 3.25 (d, *J* = 13.0, 0.5H), 2.75 (d, *J* = 9.2, 1.5H), 2.49 (dd, *J* = 2.9,
 30 9.5, 0.5H), 2.44 – 2.31 (m, 1.5H), 2.24 (dt, *J* = 7.7, 16.5, 1.5H), 2.14 (d, *J* = 9.6, 0.5H), 2.09 – 2.01 (m, 0.5H), 1.90 – 1.71 (m, 1H), 1.66 – 1.44 (m, 5H), 1.20 (dd, *J* = 5.4, 28.1, 1H); MS (ESI+) *m/z* 453 (M+H)⁺.

Example 13: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.67 (d, *J* = 7.1, 1H), 8.10 (s, 1H), 7.91 – 7.86 (m, 2H), 7.83 (d, *J* = 7.7, 1H), 7.74 (d, *J* = 7.6, 1H), 7.56 – 7.51 (m, 1H), 7.47 –

7.32 (m, 7H), 7.30 – 7.24 (m, 1H), 4.47 – 4.29 (m, 1H), 3.93 (q, $J = 6.9$, 1H), 3.56 (t, $J = 12.3$, 1H), 3.44 (d, $J = 13.1$, 0.5H), 3.37 (d, $J = 13.1$, 0.5H), 2.81 (dd, $J = 3.0, 9.1$, 0.5H), 2.72 (d, $J = 7.0$, 0.5H), 2.53 (m, 0.5H), 2.49 – 2.39 (m, 2H), 2.37 – 2.32 (m, 0.5H), 2.31 – 2.18 (m, 2H), 2.12 (dd, $J = 6.0, 12.1$, 0.5H), 2.03 (dd, $J = 6.0, 12.2$, 0.5H), 1.86 – 1.71 (m, 1H), 1.63 (t, $J = 9.9$, 3H), 1.57 – 1.47 (m, 1H), 1.40 – 1.27 (m, 1H); MS (ESI+) m/z 453 (M+H)⁺.

Example 14

N-[(3*aS*,4*S*,6*aR*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

Step A: 2-Benzylhexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one (16.28 g, 76 mmol), titanium tetraethoxide (28.5 mL, 137 mmol), and (*S*)-2-methylpropane-2-sulfinamide (10.452 g, 86 mmol) were combined in tetrahydrofuran (200 mL). The reaction was heated at 60 °C overnight. The reaction was then reduced in volume to about half and poured into 150 mL of saturated aqueous ammonium chloride. The precipitate was collected by filtration and washed with ethyl acetate. The filtrate was poured into a separatory funnel and the organic layer was removed. The aqueous layer was extracted with ethyl acetate (3×100 mL). The organic washes were combined and washed with brine, dried (Na₂SO₄) and concentrated. The crude material was chromatographed using silica gel cartridge (Analogix®, Burlington, Wisconsin, RS65-400) eluting with 5-100% ethyl acetate/hexanes to give (*S,E*)-*N*-((3*aR*,6*aS*)-2-benzylhexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)-2-methylpropane-2-sulfinamide and (*S,E*)-*N*-((3*aS*,6*aR*)-2-benzylhexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)-2-methylpropane-2-sulfinamide.

Step B: A mixture of (*S,E*)-*N*-((3*aS*,6*aR*)-2-benzylhexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)-2-methylpropane-2-sulfinamide (0.940 g, 2.95 mmol) from Step A in methanol (20 mL) was cooled to -78 °C in a dry ice/acetone bath. Sodium borohydride (0.335 g, 8.85 mmol) was added, and the reaction was allowed to warm to room temperature overnight. The reaction was quenched with saturated aqueous ammonium chloride, diluted with water, and extracted with 3×100 mL of ethyl acetate. The extracts were dried (Na₂SO₄) and filtered. The solvent was removed in vacuo, and the crude material was chromatographed using a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-40) with 5-50% acetone/hexanes to give (*S*)-*N*-((3*aS*,4*S*,6*aR*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-yl)-2-methylpropane-2-sulfinamide: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.37 – 7.11 (m, 5H), 4.85 (d, $J = 7.0$, 1H), 3.90 – 3.71 (m, 2H), 3.28 (d, $J = 13.0$, 1H), 3.09 (d, $J = 9.8$, 1H), 2.72 – 2.50 (m, 2H), 2.46 (d, $J = 9.6$, 1H), 2.32 – 2.12

(m, 2H), 1.82 (td, $J = 5.5, 12.7$, 1H), 1.68 – 1.60 (m, $J = 10.6$, 2H), 1.35 – 1.24 (m, 1H), 1.20 (s, $J = 5.5$, 9H).

Step C: (*S*)-*N*-((3*aS*,4*S*,6*aR*)-2-Benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl)-2-methylpropane-2-sulfinamide (855 mg, 2.67 mmol) from Step B and 2 *N* HCl (10 mL, 40.0 mmol) were combined in methanol (10 mL). After 30 minutes, the solvent was removed and the crude material was purified on a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-25) loading with 10% methanol(2 *N* ammonia)/dichloromethane solution and eluting with 2-10% methanol (2 *N* ammonia)/dichloromethane to give (3*aS*,4*S*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-amine: ^1H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.44 (d, $J = 7.4$, 2H), 7.36 (t, $J = 7.5$, 2H), 7.28 (t, $J = 7.3$, 1H), 3.52 (q, $J = 13.0$, 2H), 3.29 (q, $J = 7.3$, 1H), 2.84 (dd, $J = 3.7, 9.3$, 1H), 2.55 – 2.43 (m, 3H), 2.37 – 2.30 (m, 1H), 2.24 (d, $J = 5.3$, 1H), 1.74 – 1.64 (m, 2H), 1.62 – 1.53 (m, 1H), 1.34 (dd, $J = 5.0, 10.1$, 1H).

Step D: 3-Methyl-2-phenylbutanoic acid (1.049 mmol), 1-hydroxybenzotriazole hydrate (1.049 mmol), and *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide (185 μL , 1.049 mmol) were combined in dichloromethane (4 mL). The mixture was stirred at room temperature for 10 minutes, then (3*aS*,4*S*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-amine (1.049 mmol) from Step C was added in 2 mL of dichloromethane. The reaction was stirred at room temperature for 3.5 hours, and then quenched with 0.5 mL of water. The organic layer was separated and chromatographed using a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-12) eluting with 1-10% methanol(ammonia)/dichloromethane to give the title compound: ^1H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.08 (dd, $J = 7.2, 14.4$, 1H), 7.64 (dd, $J = 7.5, 14.5$, 1H), 7.56 – 7.52 (m, 1H), 7.43 (d, $J = 4.4$, 2H), 7.42 – 7.40 (m, 1H), 7.38 – 7.22 (m, 5H), 4.40 (dt, $J = 7.2, 14.3$, 0.5H), 4.35 – 4.28 (m, 0.5H), 3.55 (d, $J = 12.7, 0.5\text{H}$), 3.40 (dd, $J = 4.5, 12.8$, 1H), 3.26 (d, $J = 12.9, 0.5\text{H}$), 3.15 (d, $J = 10.5, 0.5\text{H}$), 3.05 (d, $J = 10.5, 0.5\text{H}$), 2.83 – 2.74 (m, 1H), 2.70 – 2.55 (m, 1.5H), 2.43 – 2.26 (m, 3H), 2.23 – 2.13 (m, 1H), 1.94 – 1.83 (m, 1H), 1.74 – 1.57 (m, 1.5H), 1.50 (dt, $J = 7.1, 15.3$, 0.5H), 1.37 (td, $J = 6.5, 12.1$, 0.5H), 1.31 – 1.23 (m, 0.5H), 1.18 (d, $J = 6.5, 1.5\text{H}$), 1.10 (dt, $J = 6.5, 11.5$, 0.5H), 1.03 (d, $J = 6.5, 1.5\text{H}$), 0.73 (dd, $J = 6.7, 10.7$, 3H); MS (ESI+) m/z 377 ($\text{M}+\text{H}$)⁺.

Example 15

N-[(3*aS*,4*S*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide

The title compound was prepared by substituting 2,2-dicyclohexylacetic acid for 3-methyl-2-phenylbutanoic acid in the procedure used to prepare Example 14: ^1H NMR (500

MHz, pyridine-*d*₅) δ ppm 7.44 – 7.38 (m, 4H), 7.37 – 7.32 (m, 1H), 4.49 – 4.38 (m, 1H), 3.57 (d, *J* = 12.6, 1H), 3.37 (d, *J* = 12.5, 1H), 2.77 (dd, *J* = 1.7, 9.6, 1H), 2.68 (td, *J* = 2.0, 9.3, 1H), 2.51 (dd, *J* = 1.9, 9.0, 1H), 2.45 (dd, *J* = 7.1, 15.9, 1H), 2.30 – 2.25 (m, 1H), 2.11 (dd, *J* = 7.1, 9.6, 1H), 1.98 – 1.83 (m, 3H), 1.83 – 1.58 (m, 12H), 1.57 – 1.51 (m, 1H), 1.48 (d, *J* = 13.0, 1H), 1.44 – 1.37 (m, 1H), 1.36 – 1.09 (m, 9H), 1.04 – 0.94 (m, 1H); MS (ESI+) *m/z* 423 (M+H)⁺.

Example 16

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide

Step A: (*S,E*)-*N*-((3*aS*,6*aR*)-2-Benzylhexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)-2-methylpropane-2-sulfinamide (2.67 g, 8.38 mmol) from Example 14 Step A and 2.0 *N* aqueous HCl (18.86 mL, 37.7 mmol) were combined in tetrahydrofuran (25 mL). The reaction was stirred at room temperature for 2 hours and the tetrahydrofuran was removed in vacuo and the remaining aqueous portion was made slightly basic with aqueous sodium bicarbonate solution. The aqueous layer was extracted with 3×200 mL of dichloromethane. The combined organic layers were separated, and the solvent was removed in vacuo. The crude material was purified on a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS25-25) eluting with ethyl acetate/hexanes to give (3*aS*,6*aR*)-2-benzylhexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.35 – 7.16 (m, 5H), 3.61 (d, *J* = 13.1, 1H), 3.48 (d, *J* = 13.1, 1H), 3.02 (dd, *J* = 1.8, 9.1, 1H), 2.96 – 2.82 (m, 1H), 2.71 – 2.56 (m, 2H), 2.43 (dt, *J* = 8.2, 17.4, 3H), 2.34 – 2.21 (m, 1H), 2.12 (ddd, *J* = 8.3, 13.0, 16.9, 1H), 1.79 (dddd, *J* = 4.2, 6.4, 9.2, 13.2, 1H).

Step B: A mixture of (3*aS*,6*aR*)-2-benzylhexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one (1.462 g, 6.79 mmol) from Step A in methanol (20mL) was cooled in an dry ice/acetone bath to -40 °C. Sodium borohydride (0.514 g, 13.58 mmol) was added in portions over 5 minutes. The reaction allowed to warm to room temperature overnight, then it was quenched with saturated aqueous ammonium chloride, diluted with water, and extracted with 3×150 mL of ethyl acetate. The combined extracts were dried (Na₂SO₄) and the solvent was removed in vacuo to give (3*aS*,4*S*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-ol: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.38 – 7.16 (m, 5H), 4.21 – 4.04 (m, 1H), 3.66 (d, *J* = 12.8, 1H), 3.51 (d, *J* = 12.8, 1H), 3.07 (d, *J* = 9.3, 1H), 2.65 – 2.53 (m, *J* = 11.8, 2H), 2.52 – 2.43 (m, 1H), 2.18 – 2.07 (m, *J* = 7.5, 16.3, 2H), 2.05 – 1.94 (m, *J* = 8.7, 12.6, 1H), 1.84 – 1.74 (m, *J* = 6.2, 1H), 1.49 – 1.34 (m, 3H).

Step C: (3a*S*,4*S*,6a*R*)-2-Benzyl-octahydrocyclopenta[*c*]pyrrol-4-ol (1.476 g, 6.79 mmol) from Step B and triethylamine (1.420 mL, 10.19 mmol) were combined in dichloromethane (30 mL). Methanesulfonyl chloride (0.635 mL, 8.15 mmol) was added as a solution in 20 mL of dichloromethane dropwise via addition funnel. The reaction was stirred at room temperature for 30 minutes and concentrated. The crude material was absorbed onto silica gel and chromatographed on a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS25-25) eluting with 20-100% ethyl acetate/hexanes to give (3a*S*,4*S*,6a*R*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl methanesulfonate: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.35 – 7.27 (m, 4H), 7.27 – 7.20 (m, 1H), 4.96 (ddd, *J* = 6.1, 7.6, 9.1, 1H), 3.71 – 3.44 (m, 1H), 2.94 (s, *J* = 13.5, 3H), 2.85 (ddd, *J* = 4.9, 8.1, 16.0, 1H), 2.75 – 2.68 (m, 2H), 2.67 – 2.55 (m, 1H), 2.54 – 2.44 (m, 1H), 2.31 (dd, *J* = 4.1, 8.7, 1H), 2.20 – 2.04 (m, 1H), 1.97 (dtd, *J* = 3.4, 6.2, 9.6, 1H), 1.79 – 1.63 (m, 1H), 1.61 – 1.49 (m, 2H).

Step D: (3a*S*,4*S*,6a*R*)-2-Benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl methanesulfonate (1.686 g, 5.71 mmol) from Step C and sodium azide (0.557 g, 8.56 mmol) were combined in *N,N*-dimethylacetamide (10 mL). The reaction was heated at 90 °C for 15 hours. The reaction was cooled and diluted with 200 mL of ethyl acetate and then quenched with 30 mL water. The organic layer was removed and washed with 2×20 mL of water, then 20 mL of brine. The solvent was removed in vacuo to give (3a*S*,4*R*,6a*R*)-4-azido-2-benzyl-octahydrocyclopenta[*c*]pyrrole: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.36 – 7.27 (m, 4H), 7.22 (dd, *J* = 2.9, 5.8, 1H), 3.72 – 3.61 (m, 1H), 3.54 (s, 2H), 2.76 – 2.60 (m, 1H), 2.55 – 2.40 (m, 4H), 2.35 (dd, *J* = 3.5, 9.1, 1H), 2.07 – 1.86 (m, 2H), 1.72 – 1.60 (m, 1H), 1.49 – 1.38 (m, 1H).

Step E: Triphenylphosphine (4.49 g, 17.13 mmol) and water (1.234 mL, 68.5 mmol) were added successively to a mixture of (3a*S*,4*R*,6a*R*)-4-azido-2-benzyl-octahydrocyclopenta[*c*]pyrrole (1.384 g, 5.71 mmol) in tetrahydrofuran (30 mL). The reaction was refluxed at 80 °C for 2 hours. The crude material was adsorbed onto silica gel and applied to a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-40) and eluted with 1-10% methanol (2 *N* ammonia)/chloroform to give (3a*S*,4*R*,6a*R*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-amine: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.45 (d, *J* = 7.4, 2H), 7.38 (t, *J* = 7.5, 2H), 7.29 (t, *J* = 7.3, 1H), 3.52 (s, 2H), 3.14 (dd, *J* = 5.7, 10.7, 1H), 2.62 – 2.55 (m, 1H), 2.52 (dd, *J* = 3.2, 9.0, 1H), 2.38 – 2.29 (m, 3H), 2.20 – 2.13 (m, 1H), 2.01 – 1.84 (m, 2H), 1.40 – 1.29 (m, 2H).

Step F: (*S*)-2-Phenylbutanoic acid (41.7 mg, 0.254 mmol), 1-hydroxybenzotriazole (38.9 mg, 0.254 mmol), and *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide (0.045 mL,

0.254 mmol) were combined in dichloromethane (1 mL). The reaction was stirred at room temperature for 10 minutes, and then (3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine (50 mg, 0.231 mmol) from Step E was added in 0.5 mL of dichloromethane. The reaction was stirred at room temperature for 20 hours, and then quenched with 0.5 mL of water. The organic layer was separated. The crude material was chromatographed using a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-4) eluting with 1-10% methanol(ammonia)/dichloromethane to give the title compound: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.47 (d, *J* = 7.0, 1H), 7.59 (m, 2H), 7.42 (d, *J* = 7.1, 2H), 7.34 (dd, *J* = 7.6, 16.5, 4H), 7.25 (dt, *J* = 5.0, 10.1, 2H), 4.45 – 4.29 (m, 1H), 3.62 – 3.51 (m, 2H), 3.44 (d, *J* = 13.2, 1H), 2.85 (dd, *J* = 2.7, 9.0, 1H), 2.58 – 2.50 (m, 1H), 2.50 – 2.42 (m, 2H), 2.40 – 2.31 (m, 1H), 2.31 – 2.22 (m, 2H), 1.97 (dq, *J* = 6.1, 12.1, 1H), 1.85 (td, *J* = 6.9, 13.6, 1H), 1.74 (dt, *J* = 6.4, 14.3, 1H), 1.46 (dt, *J* = 7.1, 19.2, 1H), 1.31 (dt, *J* = 6.2, 20.5, 1H), 0.96 (dd, *J* = 5.5, 9.1, 3H); MS (ESI+) *m/z* 363 (M+H)⁺.

Example 17

N-[(3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide

The title compound was prepared by substituting 2-cyclopentyl-2-phenylacetic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.61 (dd, *J* = 7.4, 10.6, 1H), 7.69 (dd, *J* = 1.5, 8.1, 2H), 7.44 (d, *J* = 7.3, 1H), 7.36 (dt, *J* = 7.2, 15.3, 5H), 7.30 – 7.25 (m, 2H), 4.42 – 4.29 (m, 1H), 3.61 (d, *J* = 13.1, 0.5H), 3.52 (d, *J* = 13.2, 0.5H), 3.43 (dd, *J* = 12.0, 18.8, 1.5H), 3.34 (d, *J* = 13.2, 0.5H), 2.96 – 2.83 (m, 1.5H), 2.55 (dt, *J* = 15.9, 16.3, 2H), 2.41 (t, *J* = 18.3, 1H), 2.31 (d, *J* = 9.0, 0.5H), 2.28 (d, *J* = 6.3, 1H), 2.23 (d, *J* = 5.0, 1H), 2.20 – 2.04 (m, 1.5H), 1.94 (dt, *J* = 7.1, 12.1, 0.5H), 1.89 – 1.81 (m, 0.5H), 1.80 – 1.67 (m, 1H), 1.65 – 1.26 (m, 7H), 1.05 – 0.94 (m, 1H); MS (ESI+) *m/z* 403 (M+H)⁺.

Example 18

N-[(3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 3-methyl-2-phenylbutanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.64 (dd, *J* = 7.3, 11.3, 1H), 7.66 (dd, *J* = 2.4, 7.5, 2H), 7.43 (d, *J* = 7.5, 1H), 7.40 – 7.30 (m, 5H), 7.29 – 7.23 (m, 2H), 4.40 – 4.28 (m, 1H), 3.60 (d, *J* =

13.2, 0.5H), 3.52 (d, $J = 13.1$, 0.5H), 3.44 (d, $J = 13.1$, 0.5H), 3.33 (d, $J = 13.1$, 0.5H), 3.25 (d, $J = 10.5$, 1H), 2.88 (dd, $J = 3.1$, 9.1, 0.5H), 2.66 (s, 1H), 2.60 – 2.56 (m, 0.5H), 2.55 – 2.46 (m, 1.5H), 2.39 (t, $J = 18.7$, 1H), 2.28 (t, $J = 8.0$, 1.5H), 2.22 (d, $J = 5.1$, 1H), 2.18 – 2.09 (m, 0.5H), 1.91 (dd, $J = 6.0$, 12.0, 0.5H), 1.84 (dd, $J = 7.1$, 13.4, 0.5H), 1.72 (ddd, $J =$
 5 6.5, 12.3, 25.1, 1H), 1.49 – 1.40 (m, 0.5H), 1.33 (ddd, $J = 13.3$, 19.9, 32.3, 1H), 1.20 (dd, $J =$ 5.0, 6.4, 3H), 0.70 (dd, $J = 1.7$, 6.7, 3H); MS (ESI+) m/z 377 (M+H)⁺.

Example 19

10 (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylpropanamide

The title compound was prepared by substituting (*S*)-2-phenylpropanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.41 (d, $J = 6.8$, 1H), 7.54 (d, $J = 7.0$, 2H), 7.41 (t, $J = 9.7$, 2H), 7.38 – 7.30 (m, 4H), 7.26 (dd, $J = 5.3$, 16.7, 2H), 4.43 – 4.32 (m, 1H), 3.84 (q, $J = 7.0$, 1H),
 15 3.56 (t, $J = 12.3$, 1H), 3.40 (dd, $J = 13.1$, 33.2, 1H), 2.81 (dd, $J = 2.9$, 9.0, 1H), 2.51 (m, 1H), 2.48 – 2.36 (m, 2H), 2.33 – 2.17 (m, 2H), 2.14 (s, 3H, OAc), 2.00 (dq, $J = 6.1$, 12.1, 1H), 1.73 (dt, $J = 6.3$, 14.2, 1H), 1.60 (d, $J = 7.0$, 3H), 1.47 (dt, $J = 7.1$, 14.8, 1H), 1.39 – 1.24 (m, 1H); MS (ESI+) m/z 349 (M+H)⁺.

20 Example 20

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide

The title compound was prepared by substituting 2,2-dicyclohexylacetic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.12 (d, $J = 7.2$, 1H), 7.45 (d, $J = 7.4$, 2H), 7.36 (t, $J = 7.5$, 2H),
 25 7.27 (t, $J = 7.3$, 1H), 4.52 – 4.43 (m, 1H), 3.63 (d, $J = 13.1$, 1H), 3.48 (d, $J = 13.1$, 1H), 2.89 (dd, $J = 2.7$, 8.9, 1H), 2.65 – 2.50 (m, 3H), 2.35 (d, $J = 4.5$, 2H), 2.18 – 2.10 (m, 1H), 2.03 (t, $J = 7.4$, 1H), 1.96 (d, $J = 13.0$, 2H), 1.87 (dt, $J = 7.4$, 13.9, 3H), 1.80 (d, $J = 12.6$, 2H), 1.76 – 1.64 (m, 5H), 1.60 (d, $J = 10.7$, 2H), 1.51 – 1.38 (m, 3H), 1.30 – 1.05 (m, 8H); MS (ESI+) m/z 423 (M+H)⁺.

30

Example 21

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-propylpentanamide

The title compound was prepared by substituting 2-propylpentanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500

MHz, pyridine-*d*₅) δ ppm 8.36 (d, *J* = 7.2, 1H), 7.43 (d, *J* = 7.4, 2H), 7.36 (t, *J* = 7.5, 2H), 7.27 (t, *J* = 7.3, 1H), 4.56 – 4.38 (m, 1H), 3.60 (d, *J* = 11.8, 1H), 3.45 (d, *J* = 13.1, 1H), 2.85 (dd, *J* = 2.8, 9.0, 1H), 2.61 – 2.50 (m, 2H), 2.50 – 2.45 (m, 1H), 2.39 – 2.25 (m, 3H), 2.20 – 2.09 (m, 1H), 1.93 – 1.79 (m, 3H), 1.66 (dd, *J* = 7.7, 12.2, 1H), 1.53 – 1.29 (m, 7H), 0.87 (td, *J* = 3.1, 7.2, 6H); MS (ESI+) *m/z* 343 (M+H)⁺.

Example 22

***N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]cycloheptanecarboxamide**

The title compound was prepared by substituting cycloheptanecarboxylic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.08 (d, *J* = 7.2, 1H), 7.44 (d, *J* = 7.4, 2H), 7.36 (t, *J* = 7.6, 2H), 7.27 (t, *J* = 7.3, 1H), 4.50 – 4.34 (m, 1H), 3.60 (d, *J* = 13.7, 1H), 3.44 (d, *J* = 13.1, 1H), 2.83 (d, *J* = 9.0, 1H), 2.54 (s, 2H), 2.49 – 2.41 (m, 2H), 2.33 (d, *J* = 6.8, 1H), 2.30 – 2.25 (m, 1H), 2.19 – 2.10 (m, 1H), 2.01 – 1.81 (m, 5H), 1.74 – 1.58 (m, 3H), 1.47 – 1.37 (m, 5H), 1.31 (s, 2H); MS (ESI+) *m/z* 341 (M+H)⁺.

Example 23

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(4-isobutylphenyl)propanamide

The title compound was prepared by substituting (*S*)-2-(3-isobutylphenyl)propanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.37 (d, *J* = 7.2, 1H), 7.49 (d, *J* = 8.0, 2H), 7.42 (d, *J* = 7.5, 2H), 7.36 (t, *J* = 7.5, 2H), 7.27 (t, *J* = 7.3, 1H), 7.14 (d, *J* = 8.0, 2H), 4.43 – 4.31 (m, 1H), 3.84 (q, *J* = 7.0, 1H), 3.58 (d, *J* = 13.1, 1H), 3.44 (d, *J* = 13.1, 1H), 2.82 (dd, *J* = 2.8, 9.1, 1H), 2.55 – 2.48 (m, 1H), 2.48 – 2.42 (m, 2H), 2.39 (d, *J* = 7.2, 2H), 2.31 – 2.21 (m, 2H), 2.00 (dt, *J* = 6.0, 12.1, 1H), 1.83 – 1.69 (m, 2H), 1.63 (d, *J* = 7.0, 3H), 1.48 (dt, *J* = 7.0, 19.1, 1H), 1.36 – 1.25 (m, 1H), 0.86 – 0.77 (m, 6H); MS (ESI+) *m/z* 405 (M+H)⁺.

Example 24

***N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide**

The title compound was prepared by substituting 1-phenylcyclohexanecarboxylic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.73 (d, *J* = 7.8, 1H), 7.63 – 7.59 (m, 1H), 7.41 (d, *J* =

7.3, 2H), 7.39 – 7.31 (m, 4H), 7.29 – 7.23 (m, 3H), 4.45 – 4.35 (m, 1H), 3.58 (d, $J = 13.2$, 1H), 3.40 (d, $J = 13.2$, 1H), 2.80 (d, $J = 7.7$, 1H), 2.69 – 2.59 (m, 2H), 2.41 – 2.31 (m, 3H), 2.28 (d, $J = 8.6$, 1H), 2.20 – 2.13 (m, 1H), 2.00 (td, $J = 5.7, 11.7$, 1H), 1.87 – 1.75 (m, 4H), 1.74 – 1.54 (m, $J = 9.1, 18.8, 38.4$, 4H), 1.46 (dt, $J = 7.8, 14.8$, 1H), 1.36 – 1.19 (m, 2H); MS (ESI+) m/z 403 (M+H)⁺.

Example 25

***N*-[*(3aS,4R,6aR)*-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2,3-diphenylpropanamide**

The title compound was prepared by substituting 2,3-diphenylpropanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.52 (dd, $J = 7.3, 13.3$, 1H), 7.65 (d, $J = 7.4$, 2H), 7.44 (d, $J = 7.1$, 1H), 7.41 – 7.29 (m, 8H), 7.26 (dt, $J = 4.8, 10.9$, 4H), 4.35 – 4.22 (m, 1H), 3.96 (dt, $J = 5.0, 10.0$, 1H), 3.77 (ddd, $J = 3.7, 10.1, 13.5$, 1H), 3.52 (dt, $J = 13.2, 18.8$, 1.5H), 3.33 (d, $J = 13.1$, 0.5H), 3.05 (dt, $J = 4.7, 13.0$, 1H), 2.77 (d, $J = 8.9$, 0.5H), 2.56 (d, $J = 6.2$, 0.5H), 2.38 – 2.23 (m, 3H), 2.23 – 2.17 (m, $J = 8.7$, 1H), 1.94 (ddd, $J = 5.7, 11.8, 23.8$, 1H), 1.72 – 1.57 (m, $J = 6.0$, 1H), 1.51 – 1.19 (m, 3H); MS (ESI+) m/z 425 (M+H)⁺.

Example 26

***N*-[*(3aS,4R,6aR)*-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-methyl-3-phenylpropanamide**

The title compound was prepared by substituting 2-methyl-3-phenylpropanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.12 (dd, $J = 7.0, 21.5$, 1H), 7.47 – 7.22 (m, 10H), 4.43 – 4.29 (m, 1H), 3.58 (dd, $J = 6.6, 13.2$, 1H), 3.45 (dd, $J = 13.2, 21.2$, 1H), 3.20 (ddd, $J = 4.6, 10.8, 15.0$, 1H), 2.81 – 2.66 (m, 3H), 2.48 – 2.19 (m, 5H), 2.04 (ddt, $J = 6.0, 12.1, 24.4$, 1H), 1.82 – 1.63 (m, 1H), 1.47 (ddd, $J = 7.1, 15.9, 18.8$, 1H), 1.39 – 1.30 (m, 1H), 1.28 (d, $J = 6.3$, 3H); MS (ESI+) m/z 363 (M+H)⁺.

Example 27

***N*-[*(3aS,4R,6aR)*-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-methyl-2-phenylpropanamide**

The title compound was prepared by substituting 2-methyl-2-phenylpropanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 7.44 (dd, $J = 7.9, 16.1$, 4H), 7.31 (ddd, $J = 7.7, 14.5$,

22.6, 6H), 7.12 – 7.03 (m, 1H), 4.46 – 4.36 (m, 1H), 3.58 (d, $J = 13.2$, 1H), 3.43 (d, $J = 13.2$, 1H), 2.84 (d, $J = 6.5$, 1H), 2.39 – 2.26 (m, $J = 6.9$, 20.1, 4H), 2.23 – 2.14 (m, $J = 6.7$, 1H), 2.04 (dd, $J = 5.8$, 11.8, 1H), 1.67 (s, 7H), 1.54 – 1.40 (m, 1H), 1.38 – 1.24 (m, 1H); MS (ESI+) m/z 363 (M+H)⁺.

5

Example 28

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclopropanecarboxamide

The title compound was prepared by substituting 1-phenylcyclopropanecarboxylic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.42 (dd, $J = 7.2$, 16.3, 4H), 7.33 (dt, $J = 7.6$, 17.1, 4H), 7.25 (dd, $J = 5.8$, 13.1, 2H), 6.27 (d, $J = 7.5$, 1H), 4.41 – 4.24 (m, $J = 5.8$, 1H), 3.56 (d, $J = 13.2$, 1H), 3.40 (d, $J = 13.2$, 1H), 2.87 – 2.74 (m, 1H), 2.37 – 2.19 (m, 4H), 2.12 (t, $J = 8.0$, 1H), 2.03 – 1.94 (m, 1H), 1.75 (dd, $J = 3.5$, 6.6, 2H), 1.68 – 1.58 (m, $J = 8.7$, 16.8, 1H), 1.37 – 1.23 (m, 2H), 1.01 (dd, $J = 3.5$, 6.6, 2H); MS (ESI+) m/z 361 (M+H)⁺.

15

Example 29

2-benzyl-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethylbutanamide

The title compound was prepared by substituting 2-benzyl-3,3-dimethylbutanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.08 (dd, $J = 7.4$, 13.5, 1H), 7.46 (d, $J = 7.3$, 1H), 7.44 – 7.32 (m, 5H), 7.32 – 7.23 (m, 4H), 4.33 (s, 1H), 3.58 (dd, $J = 13.2$, 16.9, 1H), 3.50 (d, $J = 13.1$, 0.5H), 3.40 (d, $J = 13.1$, 0.5H), 3.25 (q, $J = 11.9$, 1H), 2.80 – 2.66 (m, 2H), 2.45 (d, $J = 6.9$, 1H), 2.41 – 2.23 (m, 3.5H), 2.20 (t, $J = 8.3$, 0.5H), 2.16 – 2.09 (m, 0.5H), 2.06 (dd, $J = 5.8$, 11.6, 0.5H), 1.89 (dd, $J = 5.8$, 11.8, 0.5H), 1.75 (s, 0.5H), 1.61 (s, 0.5H), 1.47 (s, 0.5H), 1.38 – 1.20 (m, 2H), 1.16 (s, 9H); MS (ESI+) m/z 405 (M+H)⁺.

25

Example 30

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide

The title compound was prepared by substituting 3,3-dimethyl-2-phenylbutanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.57 – 8.49 (m, 1H), 7.73 (dd, $J = 3.3$, 5.3, 2H), 7.44 (d,

30

$J = 7.1$, 1H), 7.41 – 7.24 (m, 7H), 4.41 – 4.29 (m, $J = 6.9$, 13.0, 1H), 3.62 (d, $J = 13.2$, 0.5H), 3.53 (d, $J = 13.1$, 0.5H), 3.43 (s, 0.5H), 3.35 (d, $J = 13.1$, 0.5H), 2.90 (dd, $J = 3.1$, 8.9, 1H), 2.63 – 2.46 (m, 2H), 2.44 – 2.37 (m, 0.5H), 2.36 – 2.30 (m, $J = 8.3$, 1H), 2.28 (d, $J = 5.3$, 1H), 2.23 (d, $J = 5.5$, 1H), 2.15 (dt, $J = 6.2$, 12.5, 0.5H), 1.91 (dt, $J = 6.1$, 12.2, 0.5H), 1.88 – 1.79 (m, 0.5H), 1.77 – 1.66 (m, 1H), 1.46 – 1.35 (m, 1H), 1.34 – 1.23 (m, 1H), 1.15 (s, 4.5H), 1.14 (s, 4.5H); MS (ESI+) m/z 391 ($M+H$)⁺.

Example 31 and Example 32

(2S)-N-[(3aS,4R,6aR)-2-benzyl-octahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide (Example 31) and
(2R)-N-[(3aS,4R,6aR)-2-benzyl-octahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide (Example 32)

The material from example 30 was subjected to separation by chiral supercritical fluid chromatography on a ChiralCel® OD-H column (21×250 mm, 5 μm, Chiral Technologies, Inc.), 5-50% methanol:CO₂ (100 bar), at 40 mL/minute over 10 minutes to give the title compounds.

Example 31: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.50 (d, $J = 7.1$, 1H), 7.74 – 7.70 (m, 1H), 7.44 (d, $J = 7.2$, 2H), 7.40 – 7.24 (m, $J = 8.0$, 15.4, 18.2, 7H), 4.43 – 4.31 (m, 1H), 3.63 (d, $J = 13.1$, 1H), 3.49 – 3.41 (m, $J = 6.6$, 2H), 2.91 (dd, $J = 3.0$, 8.9, 1H), 2.63 – 2.43 (m, 3H), 2.28 (d, $J = 5.3$, 2H), 1.92 (dq, $J = 6.1$, 12.1, 1H), 1.78 – 1.68 (m, 1H), 1.41 (dt, $J = 7.0$, 18.9, 1H), 1.30 (dt, $J = 6.4$, 14.5, 1H), 1.14 (s, 9H); MS (ESI+) m/z 391 ($M+H$)⁺.

Example 32: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.52 (d, $J = 7.0$, 1H), 7.72 (d, $J = 7.0$, 2H), 7.41 – 7.24 (m, $J = 7.2$, 21.5, 29.9, 8H), 4.41 – 4.25 (m, 1H), 3.53 (d, $J = 13.1$, 1H), 3.45 (s, 1H), 3.35 (d, $J = 13.1$, 1H), 2.57 (d, $J = 5.7$, 1H), 2.45 – 2.36 (m, 1H), 2.31 (dd, $J = 5.1$, 10.5, 2H), 2.25 – 2.20 (m, 2H), 2.15 (td, $J = 6.4$, 12.4, 1H), 1.83 (td, $J = 6.8$, 14.8, 1H), 1.69 (td, $J = 6.7$, 13.4, 1H), 1.38 (td, $J = 6.7$, 12.4, 1H), 1.14 (s, 9H); MS (ESI+) m/z 391 ($M+H$)⁺.

Example 33

(2S)-N-[(3aR,4S,6aS)-2-benzyl-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide
Step A: (3aR,4S,6aS)-2-Benzyl-octahydrocyclopenta[c]pyrrol-4-amine was prepared according to the procedure described in Example 16 Steps A-E substituting (*S,E*)-*N*-((3aR,6aS)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5*H*)-ylidene)-2-methylpropane-2-sulfonamide from Step A in Example 14 for (*S,E*)-*N*-((3aS,6aR)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5*H*)-ylidene)-2-methylpropane-2-sulfonamide in Step

A of Example 16 to give (3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.34 – 7.28 (m, 4H), 7.25 – 7.18 (m, 1H), 3.54 (s, 2H), 3.09 (dd, *J* = 4.8, 10.9, 1H), 2.75 – 2.58 (m, 1H), 2.48 (dd, *J* = 8.6, 16.5, 2H), 2.40 (dd, *J* = 3.9, 9.3, 1H), 2.30 (dd, *J* = 3.9, 9.0, 1H), 2.21 – 2.09 (m, 1H), 2.01 – 1.84 (m, *J* = 6.9, 12.0, 2H), 1.47 – 1.25 (m, 4H).

Step B: The title compound was prepared by substituting (3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A for (3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.55 (d, *J* = 4.5, 1H), 7.59 (s, *J* = 5.1, 1H), 7.39 (d, *J* = 7.2, 2H), 7.34 (dd, *J* = 7.7, 16.5, 4H), 7.25 (dd, *J* = 7.6, 16.2, 3H), 4.43 – 4.33 (m, 1H), 3.59 – 3.50 (m, 2H), 3.36 (d, *J* = 13.1, 1H), 2.69 – 2.61 (m, 1H), 2.43 – 2.28 (m, 4H), 2.28 – 2.23 (m, 1H), 2.22 – 2.18 (m, 1H), 2.13 (dq, *J* = 6.3, 12.3, 1H), 1.89 – 1.77 (m, 2H), 1.65 (td, *J* = 7.0, 14.2, 1H), 1.40 – 1.32 (m, 1H), 0.97 (t, *J* = 7.3, 3H); MS (ESI+) *m/z* 363 (M+H)⁺.

Example 34

N-[(3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide

The title compound was prepared by substituting (3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and substituting 2-cyclopentyl-2-phenylacetic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.54 (d, *J* = 14.7, 1H), 7.66 (dd, *J* = 2.5, 7.5, 2H), 7.43 (d, *J* = 7.4, 1H), 7.40 – 7.31 (m, 5H), 7.26 (t, *J* = 6.9, 2H), 4.41 – 4.30 (m, 1H), 3.61 (d, *J* = 13.1, 0.5H), 3.52 (d, *J* = 13.1, 0.5H), 3.45 (d, *J* = 13.2, 0.5H), 3.36 (app. t, *J* = 12.7, 1.5H), 2.89 (d, *J* = 9.0, 1H), 2.61 – 2.55 (m, 1H), 2.53 – 2.46 (m, 1H), 2.44 – 2.33 (m, 1H), 2.29 (dd, *J* = 7.3, 12.8, 1.5H), 2.22 (t, *J* = 4.9, 1H), 2.19 – 2.04 (m, 1.5H), 1.98 – 1.89 (m, 0.5H), 1.88 – 1.80 (m, 0.5H), 1.79 – 1.65 (m, 1H), 1.65 – 1.25 (m, 8H), 1.05 – 0.95 (m, 1H); MS (ESI+) *m/z* 403 (M+H)⁺.

Example 35***N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide**

The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and substituting 3-methyl-2-phenylbutanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.64 – 8.49 (m, *J* = 20.1, 1H), 7.67 – 7.61 (m, 2H), 7.43 (d, *J* = 7.0, 1H), 7.39 – 7.30 (m, 5H), 7.29 – 7.24 (m, 2H), 4.41 – 4.27 (m, 1H), 3.60 (d, *J* = 13.1, 0.5H), 3.52 (d, *J* = 13.1, 0.5H), 3.44 (d, *J* = 13.2, 0.5H), 3.33 (d, *J* = 13.2, 0.5H), 3.23 (d, *J* = 10.5, 1H), 2.89 (dd, *J* = 3.0, 9.1, 0.5H), 2.69 – 2.60 (m, *J* = 10.0, 1H), 2.59 – 2.53 (m, *J* = 3.0, 9.0, 1H), 2.52 – 2.44 (m, 1H), 2.44 – 2.33 (m, 1H), 2.30 – 2.25 (m, *J* = 6.4, 10.0, 1.5H), 2.25 – 2.20 (m, 1H), 2.14 (dd, *J* = 5.9, 12.3, 0.5H), 1.91 (dd, *J* = 6.1, 12.1, 0.5H), 1.86 – 1.79 (m, *J* = 4.7, 0.5H), 1.78 – 1.64 (m, 1H), 1.47 – 1.24 (m, *J* = 30.2, 37.0, 1.5H), 1.20 (dd, *J* = 4.9, 6.4, 3H), 0.70 (dd, *J* = 1.6, 6.7, 3H); MS (ESI+) *m/z* 377 (M+H)⁺.

Example 36**(2*R*)-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide**

The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and substituting (*R*)-2-phenylbutanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.38 – 7.21 (m, 10H), 5.29 (d, *J* = 6.9, 1H), 4.04 – 3.90 (m, 1H), 3.65 (d, *J* = 12.9, 1H), 3.52 (d, *J* = 12.9, 1H), 3.15 (t, *J* = 7.6, 1H), 2.68 (t, *J* = 8.6, 1H), 2.64 – 2.48 (m, *J* = 8.5, 3H), 2.30 – 2.22 (m, *J* = 3.7, 8.3, 1.5H), 2.14 (ddd, *J* = 7.4, 13.9, 19.9, 1.5H), 1.93 (dt, *J* = 6.2, 12.5, 1H), 1.84 – 1.62 (m, *J* = 7.6, 14.5, 20.6, 2H), 1.45 – 1.27 (m, 2H), 0.95 – 0.80 (m, 4H); MS (ESI+) *m/z* 363 (M+H)⁺.

Example 37**(2*R*)-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylpropanamide**

The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and substituting (*R*)-2-phenylpropanoic acid for

(*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.37 – 7.26 (m, $J = 5.5, 7.5, 8\text{H}$), 7.25 – 7.18 (m, 2H), 5.19 (d, $J = 5.9, 1\text{H}$), 4.06 – 3.89 (m, 1H), 3.59 (d, $J = 13.0, 1\text{H}$), 3.48 (ddd, $J = 7.6, 13.7, 21.0, 2\text{H}$), 2.60 – 2.46 (m, 3H), 2.43 – 2.33 (m, $J = 7.0, 14.4, 1\text{H}$), 2.26 (dd, $J = 3.8, 9.0, 1\text{H}$), 2.20 – 2.07 (m, $J = 34.2, 1\text{H}$), 2.03 – 1.93 (m, 1H), 1.49 (d, $J = 7.2, 3\text{H}$), 1.44 – 1.22 (m, 3H); MS (ESI+) m/z 349 ($\text{M}+\text{H}$) $^+$.

Example 38

(2*S*)-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylpropanamide

The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and substituting (*S*)-2-phenylpropanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.38 – 7.26 (m, 8H), 7.25 – 7.20 (m, 2H), 5.20 (d, $J = 6.7, 1\text{H}$), 4.03 – 3.91 (m, 1H), 3.60 (d, $J = 13.0, 1\text{H}$), 3.52 – 3.43 (m, 2H), 2.54 (dd, $J = 5.7, 13.8, 2\text{H}$), 2.43 (dd, $J = 7.1, 16.0, 1\text{H}$), 2.29 – 2.23 (m, 1H), 2.22 – 2.08 (m, 2H), 1.98 (ddd, $J = 5.8, 11.9, 15.7, 1\text{H}$), 1.74 – 1.60 (m, 1H), 1.50 (t, $J = 6.4, 3\text{H}$), 1.44 – 1.30 (m, 2H); MS (ESI+) m/z 349 ($\text{M}+\text{H}$) $^+$.

Example 39

(2*S*)-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(4-isobutylphenyl)propanamide

The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and substituting (*S*)-2-(4-isobutylphenyl)propanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ^1H NMR (400 MHz, CDCl_3) δ ppm 7.28 (d, $J = 4.4, 3\text{H}$), 7.25 – 7.18 (m, 1H), 7.15 (dd, $J = 2.3, 8.2, 2\text{H}$), 7.09 (dd, $J = 1.8, 8.2, 2\text{H}$), 5.17 (d, $J = 7.2, 1\text{H}$), 4.03 – 3.89 (m, 1H), 3.58 (d, $J = 13.0, 1\text{H}$), 3.51 – 3.41 (m, 2H), 2.55 – 2.48 (m, 3H), 2.45 (d, $J = 7.2, 2\text{H}$), 2.39 (dd, $J = 7.3, 9.0, 1\text{H}$), 2.27 – 2.20 (m, 1H), 2.19 – 2.06 (m, 1H), 2.05 – 1.91 (m, 1H), 1.85 (dt, $J = 6.8, 13.5, 1\text{H}$), 1.72 – 1.61 (m, 2H), 1.48 (d, $J = 7.2, 3\text{H}$), 1.44 – 1.28 (m, 2H), 0.89 (d, $J = 6.6, 6\text{H}$); MS (ESI+) m/z 405 ($\text{M}+\text{H}$) $^+$.

Example 40***N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide**

The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and substituting 2,2-dicyclohexylacetic acid for (S)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (400 MHz, CDCl₃) δ ppm 7.32 – 7.27 (m, *J* = 6.3, 4H), 7.24 – 7.18 (m, 1H), 5.22 (d, *J* = 6.9, 1H), 4.11 – 3.99 (m, 1H), 3.62 (d, *J* = 13.0, 1H), 3.46 (d, *J* = 13.0, 1H), 2.67 – 2.58 (m, 2H), 2.54 (dd, *J* = 4.2, 9.4, 1H), 2.51 – 2.43 (m, 1H), 2.31 (dt, *J* = 4.0, 7.6, 1H), 2.25 (dd, *J* = 4.2, 9.0, 1H), 2.08 – 1.99 (m, 1H), 1.87 – 1.76 (m, 1H), 1.67 (dd, *J* = 15.7, 26.7, 10H), 1.55 (s, 3H), 1.50 – 1.38 (m, 2H), 1.31 – 1.02 (m, 8H), 1.00 – 0.85 (m, 2H); MS (ESI+) *m/z* 423 (M+H)⁺.

Example 41***N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclopropyl-2-phenylacetamide**

The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and substituting 2-cyclopropyl-2-phenylacetic acid for (S)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.36 – 7.26 (m, 8H), 7.25 – 7.18 (m, 2H), 5.57 – 5.40 (m, 1H), 4.08 – 3.97 (m, 1H), 3.60 (dd, *J* = 5.8, 13.0, 1H), 3.46 (dd, *J* = 3.0, 13.0, 1H), 2.65 (d, *J* = 9.5, 1H), 2.62 – 2.50 (m, 2H), 2.46 – 2.38 (m, 1H), 2.30 – 2.18 (m, 2H), 2.03 (ddd, *J* = 6.0, 12.1, 18.9, 1H), 1.80 – 1.69 (m, 1H), 1.49 – 1.30 (m, 4H), 0.71 (ddd, *J* = 5.7, 9.1, 10.4, 1H), 0.60 – 0.51 (m, 1H), 0.38 (td, *J* = 4.7, 9.0, 1H), 0.19 (dq, *J* = 4.7, 9.4, 1H); MS (ESI+) *m/z* 375 (M+H)⁺.

Example 42***N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclobutyl-2-phenylacetamide**

The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and substituting 2-cyclobutyl-2-phenylacetic acid for (S)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16:

¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.51 (t, *J* = 6.2, 1H), 7.61 (d, *J* = 7.7, 2H), 7.43 (dd, *J* = 7.3, 16.6, 2H), 7.38 – 7.30 (m, 4H), 7.30 – 7.23 (m, 2H), 4.42 – 4.31 (m, 1H), 3.67 (d, *J* = 10.7, 1H), 3.59 (dd, *J* = 13.1, 28.6, 1H), 3.43 (dd, *J* = 13.0, 35.2, 1H), 3.34 – 3.23 (m, 1H), 2.85 (d, *J* = 7.5, 0.5H), 2.67 (d, *J* = 7.1, 0.5H), 2.61 – 2.47 (m, *J* = 9.6, 29.9, 1.5H), 2.46 – 2.33 (m, 1.5H), 2.28 (d, *J* = 17.6, 3H), 2.12 (dt, *J* = 4.5, 12.2, 0.5H), 2.03 – 1.91 (m, 1.5H), 1.87 – 1.55 (m, *J* = 7.8, 17.0, 28.7, 5H), 1.47 (dt, *J* = 7.8, 14.5, 0.5H), 1.42 – 1.26 (m, *J* = 16.4, 37.6, 1.5H); MS (ESI+) *m/z* 389 (M+H)⁺.

Example 43

10 *N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(4-chlorophenyl)-3-methylbutanamide

The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and substituting 2-(4-chlorophenyl)-3-methylbutanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.69 (s, 1H), 7.54 (dd, *J* = 2.9, 8.4, 2H), 7.47 (d, *J* = 7.5, 1H), 7.42 (d, *J* = 7.3, 1H), 7.38 – 7.31 (m, 4H), 7.28 (t, *J* = 7.5, 1H), 4.36 (s, 1H), 3.66 (d, *J* = 13.1, 0.5H), 3.58 (d, *J* = 13.1, 0.5H), 3.51 (d, *J* = 13.1, 0.5H), 3.42 (d, *J* = 13.1, 0.5H), 3.19 (d, *J* = 10.4, 1H), 2.94 (d, *J* = 5.0, 0.5H), 2.66 (d, *J* = 5.0, 0.5H), 2.62 – 2.49 (m, 2.5H), 2.40 (m, 1.5H), 2.34 (m, 1H), 2.31 – 2.25 (m, 1H), 2.14 (dt, *J* = 6.2, 12.3, 0.5H), 2.01 – 1.91 (m, *J* = 4.7, 13.4, 0.5H), 1.87 – 1.62 (m, 1.5H), 1.52 – 1.43 (m, 0.5H), 1.42 – 1.33 (m, *J* = 10.3, 30.3, 1H), 1.17 (t, *J* = 5.9, 3H), 0.67 (dd, *J* = 2.2, 6.7, 3H); MS (ESI+) *m/z* 411 (M+H)⁺.

25 Example 44

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-ethyl-2-phenylpentanamide

The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and substituting 3-ethyl-2-phenylpentanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.69 – 8.62 (m, 1H), 7.65 (s, 2H), 7.45 (s, 1H), 7.41 (d, *J* = 7.8, 1H), 7.38 – 7.31 (m, 4H), 7.27 (d, *J* = 7.0, 2H), 4.34 (dd, *J* = 5.5, 10.8, 1H), 3.68 – 3.62 (m, 0.5H), 3.60 – 3.47 (m, 2H), 3.45 – 3.32 (m, 0.5H), 2.97 – 2.86 (m, 0.5H), 2.67 –

2.21 (m, 5H), 2.19 – 2.08 (m, 0.5H), 1.94 – 1.55 (m, 4H), 1.48 – 1.38 (m, 2H), 1.12 – 1.00 (m, 1H), 0.97 (q, $J = 7.5$, 3H), 0.93 – 0.84 (m, 1.5H), 0.83 – 0.74 (m, 0.5H), 0.61 (t, $J = 6.6$, 3H); MS (ESI+) m/z 405 (M+H)⁺.

5

Example 45***N*-[**(3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl**]-2-(4-hydroxyphenyl)-3-methylbutanamide**

The title compound was prepared by substituting (3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and 2-(4-hydroxyphenyl)-3-methylbutanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.53 – 8.46 (m, 1H), 7.56 (d, $J = 2.8$, 1H), 7.43 (d, $J = 7.2$, 1H), 7.36 (dt, $J = 7.5$, 18.2, 4H), 7.26 (q, $J = 7.1$, 1H), 7.16 (dd, $J = 3.0$, 8.6, 2H), 4.44 – 4.32 (m, 1H), 3.60 (d, $J = 13.1$, 0.5H), 3.53 (d, $J = 13.1$, 0.5H), 3.44 (d, $J = 13.2$, 0.5H), 3.33 (d, $J = 13.1$, 0.5H), 3.18 (d, $J = 10.4$, 1H), 2.90 (dd, $J = 3.0$, 9.1, 0.5H), 2.66 (s, 1H), 2.58 (d, $J = 8.8$, 1H), 2.49 (t, $J = 10.5$, 1H), 2.44 – 2.35 (m, $J = 10.0$, 1H), 2.33 – 2.11 (m, 2H), 1.99 – 1.89 (m, 0.5H), 1.88 – 1.63 (m, 1.5H), 1.53 – 1.42 (m, 0.5H), 1.41 – 1.24 (m, 2H), 1.22 (dd, $J = 4.4$, 6.3, 3H), 0.97 – 0.82 (m, $J = 21.9$, 35.1, 1H), 0.79 (d, $J = 6.7$, 3H); MS (ESI+) m/z 393 (M+H)⁺.

20

Example 46***N*-[**(3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl**]-1-phenylcyclohexanecarboxamide**

The title compound was prepared by substituting (3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and 1-phenylcyclohexanecarboxylic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.73 (d, $J = 8.2$, 1H), 7.59 (s, 1H), 7.41 (d, $J = 7.4$, 2H), 7.36 (td, $J = 2.7$, 7.6, 4H), 7.26 (dd, $J = 6.0$, 8.7, 2H), 4.45 – 4.33 (m, 1H), 3.58 (d, $J = 13.2$, 1H), 3.40 (d, $J = 13.2$, 1H), 2.81 (d, $J = 7.3$, 1H), 2.68 – 2.59 (m, $J = 10.2$, 2H), 2.41 – 2.31 (m, $J = 6.2$, 14.8, 3H), 2.28 (d, $J = 8.8$, 1H), 2.20 – 2.13 (m, 1H), 1.99 (dt, $J = 7.4$, 14.8, 1H), 1.88 – 1.75 (m, $J = 9.0$, 4H), 1.74 – 1.53 (m, $J = 8.8$, 36.2, 4H), 1.50 – 1.40 (m, 1H), 1.36 – 1.20 (m, 2H); MS (ESI+) m/z 403 (M+H)⁺.

30

Example 47***N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-methyl-2-phenylpropanamide**

The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and 2-methyl-2-phenylpropanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 7.49 – 7.38 (m, 4H), 7.31 (ddd, *J* = 7.3, 14.4, 22.5, 5H), 7.08 (d, *J* = 7.3, 1H), 4.46 – 4.35 (m, 1H), 3.58 (d, *J* = 13.2, 1H), 3.43 (d, *J* = 13.2, 1H), 2.84 (d, *J* = 6.7, 1H), 2.36 (d, *J* = 4.8, 3H), 2.31 (d, *J* = 9.6, 1H), 2.21 – 2.13 (m, 1H), 2.04 (td, *J* = 5.9, 11.7, 1H), 1.70 (dd, *J* = 6.7, 12.3, 1H), 1.67 (s, 6H), 1.53 – 1.41 (m, 1H), 1.38 – 1.26 (m, 1H); MS (ESI+) *m/z* 363 (M+H)⁺.

Example 48***N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclopropanecarboxamide**

The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and 1-phenylcyclopropanecarboxylic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 7.46 – 7.37 (m, 4H), 7.33 (dt, *J* = 7.5, 11.5, 4H), 7.28 – 7.22 (m, 2H), 6.22 (d, *J* = 7.3, 1H), 4.31 (dd, *J* = 6.7, 12.7, 1H), 3.56 (d, *J* = 13.2, 1H), 3.40 (d, *J* = 13.2, 1H), 2.81 (dd, *J* = 2.1, 8.9, 1H), 2.39 – 2.18 (m, *J* = 7.3, 12.5, 18.1, 4H), 2.13 (dd, *J* = 7.3, 8.9, 1H), 1.99 (dt, *J* = 5.6, 11.0, 1H), 1.75 (q, *J* = 3.6, 2H), 1.67 – 1.58 (m, *J* = 8.3, 16.6, 1H), 1.38 – 1.22 (m, 2H), 1.01 (q, *J* = 3.6, 2H); MS (ESI+) *m/z* 361 (M+H)⁺.

Example 49**2-benzyl-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethylbutanamide**

The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and 2-benzyl-3,3-dimethylbutanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.08 (dd, *J* = 7.4, 13.6, 1H), 7.46 (d, *J* = 7.3, 1H), 7.44 – 7.40 (m,

1H), 7.38 (dd, $J = 7.6, 15.7$, 2H), 7.34 (d, $J = 4.3$, 2H), 7.31 – 7.23 (m, 4H), 4.36 – 4.29 (m, 1H), 3.59 (d, $J = 13.1$, 0.5H), 3.53 (dd, $J = 13.2, 32.6$, 1H), 3.40 (d, $J = 13.1$, 0.5H), 3.25 (q, $J = 12.0$, 1H), 2.79 – 2.67 (m, 2H), 2.48 – 2.42 (m, $J = 7.0$, 1H), 2.41 – 2.23 (m, 3.5H), 2.20 (t, $J = 8.3$, 0.5H), 2.12 (d, $J = 6.7$, 0.5H), 2.06 (dd, $J = 5.9, 11.7$, 0.5H), 1.88 (dd, $J = 5.8, 11.7$, 0.5H), 1.74 (dd, $J = 9.4, 16.4$, 0.5H), 1.60 (dd, $J = 7.0, 13.2$, 0.5H), 1.51 – 1.42 (m, 0.5H), 1.37 – 1.21 (m, 2H), 1.15 (s, 9H); MS (ESI+) m/z 405 (M+H)⁺.

Example 50

***N*-[*(3aR,4S,6aS)*-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,3-diphenylpropanamide**

The title compound was prepared by substituting (*3aR,4S,6aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (*3aS,4R,6aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and 2,3-diphenylpropanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.53 (dd, $J = 7.3, 13.7$, 1H), 7.66 (d, $J = 7.4$, 2H), 7.44 (d, $J = 7.1$, 1H), 7.41 – 7.22 (m, 12H), 4.36 – 4.23 (m, $J = 7.5, 14.9$, 1H), 3.97 (dt, $J = 4.9, 9.9$, 1H), 3.77 (ddd, $J = 3.7, 10.1, 13.5$, 1H), 3.52 (dt, $J = 13.1, 18.6$, 1H), 3.33 (d, $J = 13.1$, 0.5H), 3.05 (dt, $J = 4.7, 13.0$, 1H), 2.77 (dd, $J = 2.6, 9.0$, 0.5H), 2.55 (d, $J = 6.3$, 0.5H), 2.38 – 2.24 (m, 3H), 2.21 (d, $J = 9.2$, 1.5H), 2.03 – 1.86 (m, 1.5H), 1.72 – 1.56 (m, 1H), 1.52 – 1.20 (m, 2.5H); MS (ESI+) m/z 425 (M+H)⁺.

Example 51

***N*-[*(3aR,4S,6aS)*-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-methyl-3-phenylpropanamide**

The title compound was prepared by substituting (*3aR,4S,6aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (*3aS,4R,6aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and 2-methyl-3-phenylpropanoic acid for (*S*)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.13 (dd, $J = 7.0, 21.3$, 1H), 7.40 (ddd, $J = 7.5, 15.5, 25.3$, 4H), 7.31 – 7.22 (m, 6H), 4.42 – 4.27 (m, 1H), 3.58 (dd, $J = 6.6, 13.1$, 1H), 3.45 (dd, $J = 13.1, 21.0$, 1H), 3.25 – 3.15 (m, 1H), 2.81 – 2.67 (m, 3H), 2.49 – 2.19 (m, 5H), 2.04 (ddd, $J = 6.0, 12.1, 24.6$, 1H), 1.82 – 1.64 (m, 1H), 1.57 – 1.40 (m, 1H), 1.40 – 1.30 (m, 1H), 1.28 (d, $J = 6.4$, 3H); MS (ESI+) m/z 363 (M+H)⁺.

Example 52***N*-[(3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide**

The title compound was prepared by substituting (3a*R*,4*S*,6a*S*)-2-

5 benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 for (3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and 3,3-dimethyl-2-phenylbutanoic acid for (S)-2-phenylbutanoic acid in Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.53 (dd, *J* = 7.4, 10.9, 1H), 7.73 (dd, *J* = 3.3, 5.3, 2H), 7.44 (d, *J* = 7.0, 1H), 7.41 – 7.24 (m, 7H), 4.41 – 4.30 (m, 1H), 3.62 (d, *J* = 13.1, 0.5H), 3.53 (d, *J* = 13.1, 0.5H), 3.45 (d, *J* = 15.0, 0.5H), 3.35 (d, *J* = 13.1, 0.5H), 2.90 (dd, *J* = 3.1, 8.9, 0.5H), 2.63 – 2.45 (m, 2.5H), 2.44 – 2.36 (m, 0.5H), 2.31 (d, *J* = 6.5, 1H), 2.28 (d, *J* = 5.3, 1H), 2.23 (d, *J* = 5.8, 1H), 2.15 (dd, *J* = 5.9, 12.3, 0.5H), 1.92 (dd, *J* = 6.1, 12.2, 0.5H), 1.84 (dd, *J* = 8.1, 12.6, 0.5H), 1.72 (ddd, *J* = 6.5, 12.5, 18.9, 1H), 1.46 – 1.25 (m, 2H), 1.14 (d, *J* = 1.8, 9H); MS (ESI+) *m/z* 391 (M+H)⁺.

15

Example 53**2,2-dicyclohexyl-*N*-[(3a*S*,4*S*,6a*R*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide**

N-[(3a*S*,4*S*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-

dicyclohexylacetamide (2.65 g, 6.27 mmol) from Example 15 and methanol 60 mL were
20 added to 20% palladium hydroxide on carbon, (wet, 0.530 g, 3.77 mmol) in a 250 mL pressure bottle. The reaction was stirred for 16 hours under hydrogen (30 psi) at room temperature. The mixture was filtered through a nylon membrane and the solvent removed in vacuo. The crude material was chromatographed on a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS25-25) eluting with 1-10% methanol (2 *N*
25 ammonia)/dichloromethane to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.97 (d, *J* = 7.1, 1H), 4.57 (dt, *J* = 7.0, 13.8, 1H), 3.03 (dd, *J* = 3.2, 10.1, 1H), 2.89 (dd, *J* = 7.8, 9.7, 1H), 2.78 (dd, *J* = 7.4, 10.1, 1H), 2.71 (ddd, *J* = 3.2, 7.5, 16.7, 1H), 2.58 (dd, *J* = 3.2, 9.8, 1H), 2.50 – 2.39 (m, *J* = 8.3, 1H), 1.98 – 1.89 (m, 3H), 1.89 – 1.80 (m, 3H), 1.79 – 1.67 (m, *J* = 6.4, 14.9, 7H), 1.66 – 1.56 (m, 3H), 1.49 – 1.36 (m, 2H), 1.36 – 1.28 (m, 1H),
30 1.28 – 1.02 (m, 8H); MS (ESI+) *m/z* 333 (M+H)⁺.

Example 54**2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide**

2,2-Dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide (154
 5 mg, 0.463 mmol) from Example 53 and 3-(trifluoromethyl)benzaldehyde (0.062 mL, 0.463
 mmol) were combined in dichloromethane (5 mL), and then 2 mL of acetic acid was added.
 The reaction was stirred at room temperature for 20 minutes, and then PS-cyanoborohydride
 (396 mg, 0.926 mmol) was added. The reaction was stirred at room temperature overnight,
 then filtered and the resin was washed with dichloromethane. The solvent was removed in
 10 vacuo, and the crude material was purified using a silica gel cartridge (Analogix®,
 Burlington, Wisconsin, RS-25) eluting with 1-10% methanol (2 *N*
 ammonia)/dichloromethane to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ
 ppm 7.73 (s, 1H), 7.66 (d, *J* = 7.7, 1H), 7.56 (s, 1H), 7.50 (t, *J* = 7.7, 1H), 4.51 – 4.43 (m,
 1H), 3.55 (d, *J* = 12.9, 1H), 3.46 (d, *J* = 12.9, 1H), 2.75 (d, *J* = 8.6, 2H), 2.52 – 2.41 (m, *J* =
 15 8.5, 19.1, 2H), 2.34 – 2.29 (m, 1H), 2.20 (dd, *J* = 7.7, 9.8, 1H), 2.14 (s, 3H, OAc), 1.96 – 1.54
 (m, 15H), 1.49 – 1.05 (m, 12H), 1.03 – 0.93 (m, *J* = 11.7, 21.1, 1H); MS (ESI+) *m/z* 491
 (M+H)⁺.

Example 55

20 **2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(2-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-
 yl]acetamide**

The title compound was prepared by substituting 2-fluorobenzaldehyde for 3-
 (trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.55
 (s, 1H), 7.36 (dt, *J* = 6.6, 24.8, 2H), 7.20 – 7.15 (m, 2H), 4.44 (s, 1H), 3.68 (d, *J* = 12.6, 1H),
 25 3.44 (d, *J* = 12.6, 1H), 2.77 (d, *J* = 9.6, 1H), 2.64 (dd, *J* = 7.5, 15.0, 1H), 2.53 (d, *J* = 9.0, 1H),
 2.49 – 2.40 (m, 1H), 2.29 (t, *J* = 8.3, 1H), 2.16 – 2.09 (m, 1H), 1.98 – 1.64 (m, 12H), 1.61 (d,
J = 11.4, 2H), 1.55 – 1.37 (m, *J* = 13.8, 20.5, 31.3, 3H), 1.34 – 1.08 (m, 9H), 1.00 (dd, *J* =
 13.4, 22.1, 1H); MS (ESI+) *m/z* 441 (M+H)⁺.

30 **Example 56**

**2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-
 yl]acetamide**

The title compound was prepared by substituting 4-fluorobenzaldehyde for 3-
 (trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.54

(d, $J = 6.0$, 1H), 7.40 – 7.29 (m, 2H), 7.18 (d, $J = 8.7$, 2H), 4.53 – 4.38 (m, 1H), 3.55 (d, $J = 12.5$, 1H), 3.29 (d, $J = 12.6$, 1H), 2.72 (dd, $J = 8.6$, 17.7, 2H), 2.56 – 2.39 (m, 2H), 2.29 (t, $J = 8.3$, 1H), 2.10 (t, $J = 8.1$, 1H), 1.98 – 1.07 (m, 26H), 0.99 (dd, $J = 10.2$, 22.0, 1H); MS (ESI+) m/z 441 (M+H)⁺.

5

Example 57

2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide

The title compound was prepared by substituting 4-fluoro-3-

10 (trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.69 (d, $J = 6.9$, 1H), 7.56 – 7.54 (m, 1H), 7.36 – 7.28 (m, 1H), 4.52 – 4.42 (m, 1H), 3.53 (d, $J = 12.9$, 1H), 3.39 (d, $J = 12.9$, 1H), 2.85 – 2.68 (m, 2H), 2.53 – 2.41 (m, 2H), 2.34 (t, $J = 8.3$, 1H), 2.24 – 2.16 (m, 1H), 1.96 – 1.56 (m, 16H), 1.49 (d, $J = 12.4$, 1H), 1.44 – 1.05 (m, 10H), 1.05 – 0.94 (m, 1H); MS (ESI+) m/z 509 (M+H)⁺.

15

Example 58

2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide

The title compound was prepared by substituting 3-fluoro-4-

20 (trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 7.62 (d, $J = 7.5$, 2H), 7.32 (d, $J = 11.8$, 1H), 7.25 (d, $J = 8.0$, 1H), 4.51 – 4.40 (m, 1H), 3.54 (d, $J = 13.5$, 1H), 3.42 (d, $J = 13.5$, 1H), 2.84 (dd, $J = 7.5$, 16.5, 1H), 2.76 (dd, $J = 2.6$, 9.5, 1H), 2.56 – 2.47 (m, 1H), 2.44 (dd, $J = 2.6$, 8.8, 1H), 2.40 – 2.34 (m, 1H), 2.23 (dd, $J = 7.7$, 9.3, 1H), 1.97 – 1.52 (m, 16H), 1.45 – 0.97 (m, $J = 14.9$, 40.1, 25 72.1, 11H); MS (ESI+) m/z 509 (M+H)⁺.

Example 59

***N*-{(3*aS*,4*S*,6*aR*)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide**

30 The title compound was prepared by substituting 3,5-bis(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.10 (s, 1H), 7.97 (s, 2H), 4.53 – 4.44 (m, 1H), 3.64 – 3.55 (m, 2H), 2.85 – 2.75 (m, 2H), 2.55 – 2.46 (m, 1H), 2.45 – 2.35 (m, 2H), 2.31 (t, $J = 8.3$,

1H), 1.95 – 1.55 (m, 15H), 1.48 (d, $J = 12.6$, 1H), 1.44 – 0.92 (m, 12H); MS (ESI+) m/z 559 (M+H)⁺.

Example 60

5 **2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[2-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide**

The title compound was prepared by substituting 2-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.74 (d, $J = 7.8$, 1H), 7.64 (d, $J = 7.7$, 1H), 7.55 (d, $J = 7.6$, 1H), 7.43 (dd, $J = 7.0$, 13.9, 2H), 4.51 – 4.43 (m, 1H), 3.82 (d, $J = 13.7$, 1H), 3.54 (d, $J = 13.7$, 1H), 2.81 – 2.70 (m, 2H), 2.53 – 2.43 (m, 2H), 2.35 (t, $J = 8.1$, 1H), 2.23 – 2.17 (m, 1H), 1.95 – 1.68 (m, 10H), 1.67 – 1.52 (m, 5H), 1.46 – 1.04 (m, 11H), 0.97 – 0.86 (m, 1H); MS (ESI+) m/z 491 (M+H)⁺.

Example 61

15 **2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(3-methylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide**

The title compound was prepared by substituting 3-methylbenzaldehyde for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.53 (d, $J = 5.8$, 1H), 7.32 (t, $J = 7.5$, 1H), 7.24 – 7.22 (m, 1H), 7.20 – 7.14 (m, 2H), 4.50 – 4.42 (m, 1H), 3.57 (d, $J = 12.4$, 1H), 3.34 (d, $J = 12.3$, 1H), 2.78 (d, $J = 9.4$, 1H), 2.66 (dd, $J = 7.5$, 15.1, 1H), 2.55 (d, $J = 8.8$, 1H), 2.50 – 2.42 (m, 1H), 2.33 (s, 3H), 2.31 – 2.24 (m, 1H), 2.14 – 2.07 (m, 1H), 1.98 – 1.57 (m, 13H), 1.53 (ddd, $J = 6.4$, 11.9, 18.4, 1H), 1.42 (t, $J = 10.0$, 2H), 1.38 – 1.08 (m, 10H), 1.02 – 0.92 (m, 1H); MS (ESI+) m/z 437 (M+H)⁺.

Example 62

25 **2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(4-methylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide**

The title compound was prepared by substituting 4-methylbenzaldehyde for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.54 (d, $J = 7.8$, 1H), 7.30 (d, $J = 7.7$, 2H), 7.21 – 7.18 (m, 2H), 4.49 – 4.42 (m, 1H), 3.58 (d, $J = 12.3$, 1H), 3.31 (d, $J = 12.4$, 1H), 2.77 (d, $J = 9.5$, 1H), 2.66 (dd, $J = 8.3$, 15.9, 1H), 2.54 (d, $J = 8.8$, 1H), 2.50 – 2.41 (m, 1H), 2.32 (s, 3H), 2.30 – 2.23 (m, 2H), 2.11 – 2.03 (m, 1H), 1.99 – 1.58 (m, 13H), 1.57 – 1.08 (m, 12H), 1.03 – 0.90 (m, 1H); MS (ESI+) m/z 437 (M+H)⁺.

Example 63**2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-****(trifluoromethoxy)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide**

The title compound was prepared by substituting 3-(trifluoromethoxy)benzaldehyde for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.60 (d, *J* = 7.3, 1H), 7.42 (t, *J* = 7.9, 1H), 7.37 (s, 1H), 7.30 (dd, *J* = 7.9, 16.8, 2H), 4.51 – 4.44 (m, 1H), 3.50 (d, *J* = 13.0, 1H), 3.45 (d, *J* = 13.0, 1H), 2.80 – 2.72 (m, *J* = 4.8, 16.2, 2H), 2.51 – 2.42 (m, *J* = 8.7, 2H), 2.29 (t, *J* = 8.3, 1H), 2.20 (dd, *J* = 7.2, 9.2, 1H), 1.96 – 1.89 (m, 2H), 1.89 – 1.78 (m, 4H), 1.77 – 1.65 (m, 5H), 1.64 – 1.51 (m, 4H), 1.42 (dd, *J* = 9.4, 23.0, 1H), 1.36 – 1.09 (m, 10H), 1.08 – 0.98 (m, 1H); MS (ESI+) *m/z* 507 (M+H)⁺.

Example 64**2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(3-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide**

The title compound was prepared by substituting 3-fluorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.36 (dd, *J* = 7.8, 13.9, 1H), 7.19 – 7.11 (m, 3H), 4.49 – 4.42 (m, 1H), 3.55 (d, *J* = 12.8, 1H), 3.34 (d, *J* = 12.8, 1H), 2.78 – 2.69 (m, *J* = 8.0, 15.6, 2H), 2.51 – 2.43 (m, *J* = 10.6, 2H), 2.29 (t, *J* = 8.4, 1H), 2.13 (dd, *J* = 7.2, 9.5, 1H), 1.97 – 1.77 (m, 7H), 1.77 – 1.64 (m, 5H), 1.63 – 1.47 (m, 4H), 1.42 (ddd, *J* = 3.0, 12.2, 23.0, 1H), 1.33 (dd, *J* = 9.7, 23.2, 1H), 1.29 – 1.08 (m, 8H), 1.02 (dd, *J* = 11.8, 22.6, 1H); MS (ESI+) *m/z* 441 (M+H)⁺.

Example 65***N*-{(3*aS*,4*S*,6*aR*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide**

The title compound was prepared by substituting 3,3-bis(4-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.77 (d, *J* = 7.3, 1H), 7.39 – 7.31 (m, 4H), 7.20 – 7.13 (m, 4H), 4.58 – 4.50 (m, 1H), 4.13 (d, *J* = 7.5, 1H), 2.85 (dd, *J* = 2.2, 9.4, 1H), 2.74 (dd, *J* = 7.2, 14.4, 1H), 2.47 (d, *J* = 7.4, 2H), 2.38 – 2.26 (m, 4H), 2.22 (t, *J* = 8.6, 1H), 2.12 (dd, *J* = 7.4, 9.3, 1H), 1.98 – 1.90 (m, 4H), 1.90 – 1.82 (m, 2H), 1.82 – 1.76 (m, *J* = 8.6, 2H), 1.76 – 1.66 (m, 5H), 1.65 – 1.57 (m, 3H), 1.47 – 1.33 (m, 3H), 1.30 – 1.18 (m, 4H), 1.18 – 1.03 (m, 4H); MS (ESI+) *m/z* 563 (M+H)⁺.

Example 66***N*-{(3*aS*,4*S*,6*aR*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide**

The title compound was prepared by substituting 6,6-bis(4-fluorophenyl)hexanal for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.80 (d, *J* = 6.7, 1H), 7.35 (ddd, *J* = 2.1, 5.4, 7.9, 4H), 7.16 (td, *J* = 3.1, 8.8, 4H), 4.56 – 4.47 (m, 1H), 3.99 (t, *J* = 7.8, 1H), 2.82 (d, *J* = 9.3, 1H), 2.65 (d, *J* = 7.7, 1H), 2.49 (dd, *J* = 8.5, 19.2, 2H), 2.30 (d, *J* = 31.9, 2H), 2.16 – 2.01 (m, 4H), 1.99 – 1.68 (m, 11H), 1.67 – 1.57 (m, 2H), 1.57 – 1.04 (m, 14H); MS (ESI+) *m/z* 605 (M+H)⁺.

Example 67***N*-{(3*aS*,4*S*,6*aR*)-2-[3-(3-chlorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide**

The title compound was prepared by substituting 3-(3-chlorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.87 (s, 1H), 7.31 (d, *J* = 13.4, 2H), 7.27 (t, *J* = 7.6, 1H), 7.13 (d, *J* = 7.3, 1H), 4.57 – 4.49 (m, 1H), 2.86 (d, *J* = 8.6, 1H), 2.74 (dd, *J* = 7.3, 14.6, 1H), 2.62 (dd, *J* = 7.0, 15.3, 2H), 2.53 – 2.45 (m, *J* = 6.7, 2H), 2.39 – 2.32 (m, *J* = 6.1, 2H), 2.23 (t, *J* = 8.0, 1H), 2.01 – 1.68 (m, 16H), 1.65 – 1.56 (m, 3H), 1.48 – 1.33 (m, 3H), 1.32 – 1.18 (m, 4H), 1.17 – 1.04 (m, *J* = 12.5, 25.1, 4H); MS (ESI+) *m/z* 485 (M+H)⁺.

Example 68**2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(3-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide**

The title compound was prepared by substituting 3-(3-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.81 (d, *J* = 3.1, 1H), 7.31 (dd, *J* = 7.3, 14.5, 1H), 7.10 – 7.02 (m, *J* = 11.5, 3H), 4.60 – 4.46 (m, 1H), 2.85 (d, *J* = 8.2, 1H), 2.76 – 2.59 (m, 3H), 2.55 – 2.43 (m, 2H), 2.41 – 2.28 (m, 2H), 2.25 – 2.16 (m, 1H), 2.15 – 2.06 (m, 1H), 2.00 – 1.90 (m, 4H), 1.89 – 1.67 (m, *J* = 37.4, 11H), 1.67 – 1.54 (m, 3H), 1.49 – 1.33 (m, 3H), 1.30 – 1.18 (m, *J* = 10.6, 4H), 1.17 – 1.05 (m, 4H); MS (ESI+) *m/z* 469 (M+H)⁺.

Example 69**2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(3-phenylpropyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide**

The title compound was prepared by substituting 3-phenylpropanal for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.83 (d, *J* = 5.1, 1H), 7.38 (t, *J* = 7.6, 2H), 7.28 (d, *J* = 7.4, 3H), 4.57 – 4.48 (m, 1H), 2.85 (d, *J* = 8.7, 1H), 2.75 – 2.61 (m, 3H), 2.48 (dd, *J* = 8.7, 19.0, 2H), 2.35 (dd, *J* = 7.0, 17.3, 2H), 2.17 (t, *J* = 7.8, 1H), 2.12 – 2.07 (m, 1H), 1.93 (dd, *J* = 8.6, 14.2, 4H), 1.89 – 1.75 (m, 7H), 1.71 (d, *J* = 10.9, 4H), 1.65 – 1.53 (m, *J* = 6.0, 14.1, 3H), 1.49 – 1.32 (m, 3H), 1.30 – 1.18 (m, 4H), 1.17 – 1.04 (m, *J* = 9.5, 21.4, 4H); MS (ESI+) *m/z* 451 (M+H)⁺.

Example 70**2,2-dicyclohexyl-*N*-((3*aS*,4*S*,6*aR*)-2-{3-[4-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide**

The title compound was prepared by substituting 3-(4-(trifluoromethyl)phenyl)propanal for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.82 (d, *J* = 7.1, 1H), 7.67 (d, *J* = 8.1, 2H), 7.36 (d, *J* = 8.1, 2H), 4.57 – 4.50 (m, 1H), 2.85 (d, *J* = 9.5, 1H), 2.70 (tt, *J* = 7.0, 14.1, 3H), 2.49 (d, *J* = 7.5, 2H), 2.35 (t, *J* = 6.4, 2H), 2.22 (t, *J* = 8.5, 1H), 2.16 – 2.09 (m, 1H), 1.98 – 1.89 (m, 4H), 1.89 – 1.74 (m, 7H), 1.70 (d, *J* = 8.5, 4H), 1.60 (dd, *J* = 4.9, 12.1, 3H), 1.41 (dt, *J* = 9.0, 20.3, 3H), 1.30 – 1.17 (m, 4H), 1.10 (dt, *J* = 10.4, 12.0, 4H); MS (ESI+) *m/z* 519 (M+H)⁺.

Example 71**2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide**

The title compound was prepared by substituting 3-(4-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.94 – 7.77 (m, 1H), 7.25 – 7.20 (m, 2H), 7.14 (t, *J* = 8.7, 2H), 4.61 – 4.47 (m, 1H), 2.93 – 2.80 (m, 1H), 2.79 – 2.69 (m, 1H), 2.62 (dd, *J* = 7.6, 15.5, 2H), 2.55 – 2.44 (m, 2H), 2.43 – 2.29 (m, 2H), 2.27 – 2.08 (m, 2H), 2.02 – 1.90 (m, 4H), 1.89 – 1.75 (m, 7H), 1.70 (d, *J* = 11.2, 4H), 1.60 (d, *J* = 6.9, 3H), 1.49 – 1.32 (m, 3H), 1.30 – 1.17 (m, 4H), 1.12 (dd, *J* = 12.0, 24.1, 4H); MS (ESI+) *m/z* 469 (M+H)⁺.

Example 72**2,2-dicyclohexyl-*N*-[(3a*S*,4*S*,6a*R*)-2-(pyridin-4-ylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide**

The title compound was prepared by substituting isonicotinaldehyde for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.76 (d, *J* = 5.7, 2H), 7.75 – 7.69 (m, 1H), 7.31 (d, *J* = 5.5, 2H), 4.48 (dd, *J* = 6.9, 13.1, 1H), 3.47 (d, *J* = 13.5, 1H), 3.39 (d, *J* = 13.5, 1H), 2.87 – 2.75 (m, *J* = 9.2, 21.0, 2H), 2.53 – 2.45 (m, 1H), 2.43 (d, *J* = 9.0, 1H), 2.34 (t, *J* = 8.3, 1H), 2.26 – 2.20 (m, 1H), 1.97 – 1.87 (m, 4H), 1.87 – 1.76 (m, 4H), 1.75 – 1.64 (m, *J* = 6.5, 12.2, 17.6, 5H), 1.63 – 1.56 (m, *J* = 13.2, 3H), 1.43 (dd, *J* = 10.1, 22.9, 1H), 1.35 (dd, *J* = 5.6, 12.1, 1H), 1.30 – 1.18 (m, *J* = 12.4, 24.4, 4H), 1.17 – 1.08 (m, *J* = 10.1, 19.2, 4H), 1.09 – 0.99 (m, 1H); MS (ESI+) *m/z* 424 (M+H)⁺.

Example 73**2,2-dicyclohexyl-*N*-[(3a*S*,4*S*,6a*R*)-2-(pyridin-3-ylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide**

The title compound was prepared by substituting nicotinaldehyde for 3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.80 (d, *J* = 1.7, 1H), 7.64 (d, *J* = 6.4, 2H), 7.30 (dd, *J* = 4.8, 7.7, 1H), 4.49 – 4.41 (m, 1H), 3.54 (d, *J* = 12.9, 1H), 3.35 (d, *J* = 12.8, 1H), 2.80 – 2.71 (m, *J* = 7.7, 2H), 2.51 – 2.42 (m, *J* = 8.7, 2H), 2.31 (t, *J* = 8.3, 1H), 2.16 (t, *J* = 8.8, 1H), 1.91 (dd, *J* = 6.4, 11.9, 2H), 1.86 – 1.64 (m, 10H), 1.57 (dd, *J* = 11.4, 24.2, 4H), 1.42 (d, *J* = 12.8, 1H), 1.35 – 1.08 (m, 10H), 1.03 (d, *J* = 14.0, 1H); MS (ESI+) *m/z* 424 (M+H)⁺.

Example 74**2,2-dicyclohexyl-*N*-[(3a*S*,4*R*,6a*R*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide**

The title compound was prepared by substituting *N*-[(3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide from Example 20 for *N*-[(3a*S*,4*S*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide in Example 53: ¹H NMR (300 MHz, CDCl₃) δ ppm 5.31 (d, *J* = 7.5, 1H), 3.97 – 3.82 (m, 1H), 3.09 – 2.85 (m, 3H), 2.66 (dd, *J* = 3.7, 12.5, 2H), 2.40 – 2.26 (m, 1H), 2.10 – 1.80 (m, 6H), 1.79 – 1.53 (m, 11H), 1.52 – 1.30 (m, *J* = 21.5, 31.0, 2H), 1.29 – 1.03 (m, 7H), 0.93 (dd, *J* = 11.9, 23.1, 2H); MS (ESI+) *m/z* 333 (M+H)⁺.

Example 75**2,2-dicyclohexyl-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide**

The title compound was prepared by substituting 2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide from Example 74 for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.07 (d, *J* = 7.2, 1H), 7.75 (s, 1H), 7.63 – 7.54 (m, 2H), 7.43 (t, *J* = 7.8, 1H), 4.51 – 4.42 (m, 1H), 3.61 (d, *J* = 13.6, 1H), 3.46 (d, *J* = 13.5, 1H), 2.87 (dd, *J* = 2.4, 8.9, 1H), 2.64 – 2.52 (m, 2H), 2.52 – 2.46 (m, 1H), 2.30 (s, 2H), 2.18 – 2.08 (m, 1H), 2.03 (t, *J* = 7.3, 1H), 1.99 – 1.76 (m, 7H), 1.75 – 1.55 (m, 7H), 1.51 – 1.35 (m, 3H), 1.31 – 1.03 (m, 8H); MS (ESI+) *m/z* 491 (M+H)⁺.

Example 76**2,2-dicyclohexyl-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-fluoro-4-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide**

The title compound was prepared by substituting 3-fluoro-4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde and 2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide from Example 74 for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.16 (d, *J* = 7.3, 1H), 7.59 (d, *J* = 10.3, 1H), 7.33 (d, *J* = 11.7, 1H), 7.28 (d, *J* = 8.0, 1H), 4.52 – 4.44 (m, 1H), 3.56 (d, *J* = 14.2, 1H), 3.45 (d, *J* = 14.2, 1H), 2.92 (dd, *J* = 1.8, 8.9, 1H), 2.63 – 2.52 (m, *J* = 11.3, 2H), 2.43 (dd, *J* = 6.9, 8.8, 1H), 2.34 (dd, *J* = 2.0, 9.0, 1H), 2.29 – 2.23 (m, 1H), 2.13 (dq, *J* = 5.9, 11.8, 1H), 2.04 (t, *J* = 7.4, 1H), 2.00 – 1.84 (m, 5H), 1.80 (d, *J* = 12.4, 2H), 1.76 – 1.56 (m, 7H), 1.46 (dd, *J* = 10.4, 23.5, 3H), 1.30 – 1.18 (m, 4H), 1.17 – 1.05 (m, 4H); MS (ESI+) *m/z* 509 (M+H)⁺.

Example 77***N*-{(3*aS*,4*R*,6*aR*)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-****2,2-dicyclohexylacetamide**

The title compound was prepared by substituting 3,5-bis(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde and 2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide from Example 74 for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure

described for Example 54: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.16 (d, $J = 7.1$, 1H), 7.99 (s, 3H), 4.50 – 4.42 (m, 1H), 3.69 (d, $J = 13.9$, 1H), 3.54 (d, $J = 13.9$, 1H), 2.92 (dd, $J = 2.7$, 9.0, 1H), 2.65 – 2.56 (m, $J = 10.2$, 15.6, 2H), 2.55 – 2.50 (m, 1H), 2.31 (d, $J = 4.2$, 2H), 2.10 (dq, $J = 5.9$, 11.8, 1H), 2.03 (t, $J = 7.4$, 1H), 1.99 – 1.83 (m, 5H), 1.80 (d, $J = 12.4$, 2H), 1.75 – 1.64 (m, $J = 12.4$, 18.4, 5H), 1.63 – 1.56 (m, $J = 8.7$, 2H), 1.44 (td, $J = 7.6$, 21.0, 3H), 1.31 – 1.16 (m, 4H), 1.16 – 1.04 (m, 4H); MS (ESI+) m/z 559 ($\text{M} + \text{H}$) $^+$.

Example 78

N-{(3*aS*,4*R*,6*aR*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide

The title compound was prepared by substituting 6,6-bis(4-fluorophenyl)hexanal for 3-(trifluoromethyl)benzaldehyde and 2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide from Example 74 for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.14 (d, $J = 7.3$, 1H), 7.33 (dd, $J = 5.6$, 8.5, 4H), 7.14 (t, $J = 8.7$, 4H), 4.52 – 4.44 (m, 1H), 3.96 (t, $J = 7.8$, 1H), 2.94 (d, $J = 8.8$, 1H), 2.58 (s, 2H), 2.42 (d, $J = 8.1$, 2H), 2.31 (d, $J = 22.9$, 3H), 2.17 – 2.09 (m, 1H), 2.08 – 1.85 (m, 8H), 1.85 – 1.77 (m, 2H), 1.76 – 1.64 (m, 5H), 1.61 (d, $J = 12.0$, 2H), 1.52 – 1.42 (m, 5H), 1.41 – 1.34 (m, 2H), 1.31 – 1.19 (m, 5H), 1.18 – 1.07 (m, 5H); MS (ESI+) m/z 605 ($\text{M} + \text{H}$) $^+$.

Example 79

2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-2-(3,3-diphenylpropyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide

The title compound was prepared by substituting 3,3-diphenylpropanal for 3-(trifluoromethyl)benzaldehyde and 2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide from Example 74 for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.10 (d, $J = 7.7$, 1H), 7.45 (d, $J = 7.3$, 2H), 7.42 (d, $J = 7.1$, 3H), 7.38 – 7.30 (m, 5H), 4.56 – 4.48 (m, 1H), 4.27 (t, $J = 7.5$, 1H), 2.92 – 2.86 (m, 1H), 2.59 – 2.48 (m, $J = 6.7$, 14.0, 2H), 2.38 – 2.26 (m, 5H), 2.21 – 2.12 (m, 2H), 2.05 (t, $J = 7.4$, 1H), 1.97 (dd, $J = 8.3$, 17.0, 2H), 1.94 – 1.85 (m, 4H), 1.81 (d, $J = 11.8$, 2H), 1.72 (d, $J = 13.2$, 4H), 1.66 (dd, $J = 7.4$, 11.8, 1H), 1.61 (d, $J = 12.6$, 2H), 1.48 (ddd, $J = 3.4$, 12.8, 15.5, 3H), 1.30 – 1.19 (m, 4H), 1.19 – 1.06 (m, 4H); MS (ESI+) m/z 527 ($\text{M} + \text{H}$) $^+$.

Example 80***N*-{(3*aS*,4*R*,6*aR*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide**

The title compound was prepared by substituting 3,3-bis(4-fluorophenyl)propanal for
5 3-(trifluoromethyl)benzaldehyde and 2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-
octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide from Example 74 for 2,2-dicyclohexyl-*N*-
[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for
Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.13 (s, 1H), 7.41 (dd, *J* = 5.5, 8.7,
2H), 7.35 (dd, *J* = 5.1, 13.8, 3H), 7.14 (dt, *J* = 8.8, 14.7, 4H), 4.60 – 4.51 (m, *J* = 21.3, 1H),
10 4.30 (t, *J* = 7.7, 1H), 2.95 (d, *J* = 8.9, 1H), 2.57 – 2.51 (m, 2H), 2.40 (d, *J* = 8.7, 1H), 2.30 (d,
J = 7.0, 3H), 2.26 – 2.12 (m, 4H), 2.05 (t, *J* = 7.4, 1H), 2.02 – 1.94 (m, *J* = 12.5, 2H), 1.94 –
1.85 (m, *J* = 6.7, 18.0, 2H), 1.82 (d, *J* = 11.7, 2H), 1.72 (d, *J* = 11.8, 4H), 1.67 – 1.57 (m, *J* =
10.6, 16.3, 3H), 1.48 (qd, *J* = 3.3, 12.7, 3H), 1.25 (dd, *J* = 15.5, 28.8, 4H), 1.13 (t, *J* = 18.3,
4H); MS (ESI+) *m/z* 563 (M+H)⁺.

15

Example 81***N*-{(3*aS*,4*R*,6*aR*)-2-[4,4-bis(4-fluorophenyl)butyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide**

The title compound was prepared by substituting 4,4-bis(4-fluorophenyl)butanal for
20 3-(trifluoromethyl)benzaldehyde and 2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-
octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide from Example 74 for 2,2-dicyclohexyl-*N*-
[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for
Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.12 (d, *J* = 7.5, 1H), 7.36 (ddd, *J* =
5.5, 8.6, 16.2, 4H), 7.17 (t, *J* = 8.8, 2H), 7.11 (t, *J* = 8.8, 2H), 4.52 – 4.45 (m, 1H), 3.99 (t, *J* =
25 7.9, 1H), 2.91 (d, *J* = 9.1, 1H), 2.59 – 2.50 (m, 2H), 2.36 (t, *J* = 7.1, 3H), 2.24 – 2.16 (m, *J* =
6.6, 13.0, 2H), 2.14 – 2.02 (m, *J* = 9.6, 17.5, 3H), 2.02 – 1.86 (m, *J* = 9.2, 27.4, 5H), 1.81 (t, *J* =
10.7, 2H), 1.73 (d, *J* = 9.6, 4H), 1.68 – 1.57 (m, *J* = 13.6, 3H), 1.53 – 1.37 (m, 6H), 1.31 –
1.19 (m, *J* = 11.2, 23.8, 4H), 1.18 – 1.07 (m, *J* = 10.5, 22.1, 4H); MS (ESI+) *m/z* 577
(M+H)⁺.

30

Example 82**3-methyl-2-phenyl-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide****Step A:** 3-Methyl-*N*-[(3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-

5 phenylbutanamide was prepared by substituting *N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide from Example 18 for *N*-[(3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide in the procedure described for Example 53: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.31 (dd, *J* = 1.5, 6.6, 2H), 5.50 – 5.38 (m, *J* = 3.8, 9.7, 1H), 3.84 (dd, *J* = 4.1, 13.5, 1H), 2.92 (ddd, *J* = 10.1, 15.8, 20.7, 3H), 2.76 (dt, *J* = 3.7, 11.5, 2H), 2.65 – 2.53 (m, *J* = 7.9, 12.1, 3H), 2.47 – 2.25 (m, *J* = 9.8, 17.7, 31.5, 2H), 2.20 – 2.07 (m, *J* = 9.3, 17.5, 1H), 2.05 – 1.80 (m, 2H), 1.53 – 1.39 (m, 1H), 1.27 (s, 2H), 1.03 (dd, *J* = 3.4, 6.5, 3H), 0.70 (d, *J* = 6.7, 3H); MS (ESI+) *m/z* 287 (M+H)⁺.

Step B: The title compound was prepared by substituting 3-methyl-*N*-[(3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.60 (t, *J* = 7.9, 1H), 7.73 (d, *J* = 26.6, 1H), 7.63 (dd, *J* = 2.0, 7.5, 1H), 7.57 – 7.52 (m, 2H), 7.43 (dd, *J* = 7.7, 17.9, 1H), 7.33 (td, *J* = 4.1, 7.5, 2H), 7.26 (dt, *J* = 3.6, 7.2, 1H), 4.38 – 4.28 (m, 1H), 3.60 (d, *J* = 13.6, 0.5H), 3.52 (d, *J* = 13.5, 0.5H), 3.46 (d, *J* = 13.6, 0.5H), 3.35 (d, *J* = 13.5, 0.5H), 3.22 (dd, *J* = 1.4, 10.4, 1H), 2.90 (dd, *J* = 3.0, 9.1, 0.5H), 2.70 – 2.60 (m, *J* = 5.3, 11.8, 1H), 2.59 – 2.53 (m, 1H), 2.52 – 2.46 (m, 1H), 2.44 – 2.32 (m, 1H), 2.28 (d, *J* = 9.1, 0.5H), 2.25 (d, *J* = 5.1, 1H), 2.20 (dd, *J* = 2.4, 4.7, 1H), 2.13 – 2.07 (m, 1.5H), 1.92 – 1.80 (m, 1H), 1.75 (dt, *J* = 6.3, 18.8, 0.5H), 1.71 – 1.64 (m, 0.5H), 1.47 – 1.39 (m, 0.5H), 1.39 – 1.32 (m, 0.5H), 1.32 – 1.24 (m, *J* = 4.2, 16.6, 0.5H), 1.20 (dd, *J* = 4.3, 6.4, 3H), 0.70 (d, *J* = 6.7, 3H); MS (ESI+) *m/z* 445 (M+H)⁺.

Example 83***N*-[(3*aR*,4*S*,6*aS*)-2-(cyclohexylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide**

Step A: 3-Methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide was prepared by substituting *N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide from Example 35 for *N*-[(3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide

in Example 53: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.61 (d, $J = 6.9$, 1H), 7.65 (dd, $J = 4.6, 6.9$, 2H), 7.34 (t, $J = 7.5$, 2H), 7.26 (t, $J = 7.3$, 1H), 4.24 (tt, $J = 6.2, 12.6$, 1H), 3.23 (d, $J = 10.4$, 1H), 3.19 (dd, $J = 2.7, 10.8$, 0.5H), 2.99 (dd, $J = 7.2, 10.9$, 0.5H), 2.84 – 2.72 (m, 2H), 2.70 – 2.61 (m, 1H), 2.58 (dd, $J = 2.8, 10.7$, 0.5H), 2.53 (dd, $J = 3.3, 10.5$, 1H), 2.49 – 2.44 (m, 0.5H), 2.43 – 2.35 (m, $J = 10.5$, 0.5H), 2.35 – 2.28 (m, $J = 12.5$, 0.5H), 2.06 (dq, $J = 6.1, 12.2$, 0.5H), 1.91 – 1.72 (m, 1.5H), 1.66 (dt, $J = 7.2, 19.4$, 0.5H), 1.42 (dd, $J = 7.9, 19.3$, 0.5H), 1.30 – 1.13 (m, 4 H), 0.71 (d, $J = 6.7$, 3H); MS (ESI+) m/z 287 (M+H) $^+$.

Step B: The title compound was prepared by substituting cyclohexanecarbaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.57 (dd, $J = 7.0, 10.9$, 1H), 7.64 (dd, $J = 4.9, 7.0$, 2H), 7.34 (t, $J = 7.6$, 2H), 7.25 (t, $J = 7.4$, 1H), 4.37 – 4.28 (m, 1H), 3.23 (d, $J = 10.4$, 1H), 2.85 (dd, $J = 2.8, 9.0$, 0.5H), 2.70 – 2.60 (m, 1H), 2.59 – 2.53 (m, $J = 4.6, 11.8$, 0.5H), 2.51 (dd, $J = 3.1, 9.1$, 1H), 2.44 – 2.38 (m, 1H), 2.37 – 2.32 (m, 0.5H), 2.31 – 2.28 (m, 0.5H), 2.27 – 2.08 (m, 3.5H), 2.08 – 1.99 (m, 1H), 1.93 – 1.73 (m, 3.5H), 1.73 – 1.54 (m, 3.5H), 1.47 – 1.27 (m, 2.5H), 1.22 (dd, $J = 6.5, 10.5$, 3H), 1.19 – 1.06 (m, 3H), 0.90 – 0.75 (m, 2H), 0.71 (dd, $J = 2.2, 6.7$, 3H); MS (ESI+) m/z 383 (M+H) $^+$.

Example 84

3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-2-methyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide

The title compound was prepared by substituting formaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.55 (t, $J = 5.4$, 1H), 7.65 (t, $J = 6.5$, 2H), 7.34 (ddd, $J = 3.7, 7.6, 10.9$, 2H), 7.29 – 7.25 (m, 1H), 4.42 – 4.28 (m, 1H), 3.22 (d, $J = 10.5$, 1H), 2.91 (dd, $J = 2.2, 9.0$, 0.5H), 2.65 (dt, $J = 6.7, 17.3$, 1H), 2.53 (dd, $J = 2.5, 9.2$, 1H), 2.46 (dd, $J = 4.4, 10.2$, 0.5H), 2.42 – 2.35 (m, 0.5H), 2.30 (d, $J = 8.8$, 1.5H), 2.25 (dd, $J = 2.8, 9.0$, 0.5H), 2.19 (s, 1.5H), 2.16 – 2.05 (m, 3.5H), 1.85 (td, $J = 6.2, 12.0$, 1H), 1.75 (dd, $J = 6.6, 13.8$, 0.5H), 1.63 (dt, $J = 7.0, 15.3$, 0.5H), 1.39 (dt, $J = 8.1, 14.4$, 1H), 1.31 (dt, $J = 2.9, 9.4$, 0.5H), 1.22 (dd, $J = 6.5, 11.7$, 3H), 0.71 (dd, $J = 2.9, 6.7$, 3H); MS (ESI+) m/z 301 (M+H) $^+$.

Example 85***N*-[(3*aR*,4*S*,6*aS*)-2-(2-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide**

The title compound was prepared by substituting 2-fluorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.66 – 8.58 (m, 1H), 7.63 (dd, *J* = 3.1, 7.4, 2H), 7.53 (t, *J* = 7.4, 1H), 7.33 (td, *J* = 2.2, 7.6, 2H), 7.28 – 7.22 (m, *J* = 7.4, 9.9, 2H), 7.17 – 7.06 (m, *J* = 8.2, 14.8, 26.9, 2H), 4.34 (dd, *J* = 6.0, 11.5, 1H), 3.75 (d, *J* = 13.6, 0.5H), 3.71 – 3.62 (m, 1H), 3.57 (d, *J* = 13.6, 0.5H), 3.22 (dd, *J* = 2.2, 10.4, 1H), 3.00 (d, *J* = 6.7, 0.5H), 2.69 – 2.48 (m, *J* = 23.7, 34.8, 3H), 2.47 – 2.28 (m, 3.5H), 2.17 – 2.07 (m, 0.5H), 1.93 – 1.78 (m, *J* = 6.7, 12.4, 20.1, 1H), 1.78 – 1.62 (m, 1H), 1.49 – 1.27 (m, *J* = 10.3, 19.5, 26.3, 1.5H), 1.20 (dd, *J* = 2.9, 6.4, 3H), 0.70 (dd, *J* = 1.4, 6.6, 3H); MS (ESI+) *m/z* 395 (M+H)⁺.

Example 86***N*-[(3*aR*,4*S*,6*aS*)-2-(3-chlorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide**

The title compound was prepared by substituting 3-chlorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.62 (t, *J* = 6.5, 1H), 7.64 (dd, *J* = 4.3, 7.0, 2H), 7.51 (s, 0.5H), 7.46 (s, 0.5H), 7.33 (td, *J* = 2.5, 7.5, 3H), 7.30 – 7.28 (m, 1H), 7.28 – 7.23 (m, 2H), 4.37 – 4.28 (m, 1H), 3.60 (d, *J* = 13.4, 0.5H), 3.51 (d, *J* = 13.4, 0.5H), 3.45 (d, *J* = 13.4, 0.5H), 3.33 (d, *J* = 13.4, 0.5H), 3.22 (dd, *J* = 2.2, 10.4, 1H), 2.93 (d, *J* = 6.3, 0.5H), 2.69 – 2.48 (m, 3H), 2.31 (dddd, *J* = 8.9, 13.2, 14.5, 20.2, 3H), 2.16 – 2.05 (m, 1H), 1.92 – 1.79 (m, 1H), 1.78 – 1.62 (m, 1H), 1.49 – 1.40 (m, 0.5H), 1.37 (dd, *J* = 5.8, 12.6, 0.5H), 1.30 (dd, *J* = 7.2, 13.5, 0.5H), 1.20 (dd, *J* = 3.0, 6.5, 3H), 0.70 (dd, *J* = 1.5, 6.7, 3H); MS (ESI+) *m/z* 411 (M+H)⁺.

Example 87***N*-[(3*aR*,4*S*,6*aS*)-2-(3-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide**

The title compound was prepared by substituting 3-fluorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.61 (t, *J* = 8.0, 1H), 7.64 (dd, *J* = 4.1, 7.0, 2H), 7.37 – 7.16 (m, 5H), 7.13 (d, *J* = 7.6, 1H), 7.04 (s, 1H), 4.33 (dd, *J* = 5.7, 12.4, 1H), 3.57 (d, *J* = 13.5, 0.5H), 3.48 (d, *J* = 13.4, 0.5H), 3.42 (d, *J* = 13.5, 0.5H), 3.30 (d, *J* = 13.5, 0.5H), 3.23 (d, *J* = 10.5, 1H), 2.90 (dd, *J* = 2.9, 9.1, 0.5H), 2.70 – 2.61 (m, 1H), 2.59 – 2.53 (m, 1H), 2.53 – 2.45 (m, 1H), 2.44 – 2.31 (m, *J* = 18.5, 1H), 2.27 (t, *J* = 7.7, 1H), 2.19 (dd, *J* = 6.3, 13.0, 1H), 2.12 (dd, *J* = 6.0, 12.3, 0.5H), 1.93 – 1.80 (m, *J* = 6.9, 12.4, 20.6, 1H), 1.79 – 1.64 (m, 1H), 1.47 – 1.24 (m, 2H), 1.20 (dd, *J* = 3.1, 6.4, 3H), 0.70 (d, *J* = 6.7, 3H); MS (ESI+) *m/z* 395 (M+H)⁺.

Example 88**3-methyl-2-phenyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide**

The title compound was prepared by substituting 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.60 (t, *J* = 7.6, 1H), 7.76 (s, 0.5H), 7.71 (s, 0.5H), 7.64 (d, *J* = 7.8, 2H), 7.57 – 7.53 (m, *J* = 7.1, 2H), 7.43 (dd, *J* = 7.8, 17.8, 1H), 7.36 – 7.30 (m, 2H), 7.28 – 7.23 (m, 1H), 4.33 (dd, *J* = 5.8, 12.3, 1H), 3.61 (d, *J* = 13.6, 0.5H), 3.53 (d, *J* = 13.5, 0.5H), 3.47 (d, *J* = 13.5, 0.5H), 3.36 (d, *J* = 13.5, 0.5H), 3.22 (dd, *J* = 1.5, 10.4, 1H), 2.91 (dd, *J* = 3.0, 9.0, 0.5H), 2.69 – 2.59 (m, 1H), 2.55 (dd, *J* = 3.0, 9.0, 1H), 2.52 – 2.47 (m, 1H), 2.44 – 2.32 (m, *J* = 10.5, 32.1, 1H), 2.29 (d, *J* = 8.9, 0.5H), 2.26 (d, *J* = 5.2, 1H), 2.22 – 2.18 (m, 1H), 2.16 – 2.06 (m, 0.5H), 1.92 – 1.79 (m, 1H), 1.79 – 1.63 (m, 1H), 1.48 – 1.25 (m, 1.5H), 1.20 (dd, *J* = 4.5, 6.4, 3H), 0.70 (d, *J* = 5.8, 3H); MS (ESI+) *m/z* 445 (M+H)⁺.

Example 89***N*-[(3*aR*,4*S*,6*aS*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide**

The title compound was prepared by substituting 4-fluorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.61 (t, *J* = 7.2, 1H), 7.64 (dd, *J* = 2.4, 7.5, 2H), 7.39 (dd, *J* = 5.8, 8.2, 1H), 7.33 (dt, *J* = 5.8, 11.6, 3H), 7.28 – 7.23 (m, 1H), 7.11 (dd, *J* = 8.8, 19.1, 2H), 4.34 (dd, *J* = 5.8, 12.6, 1H), 3.56 (d, *J* = 13.3, 0.5H), 3.45 (dd, *J* = 13.3, 16.8, 1H), 3.31 (d, *J* = 13.1, 0.5H), 3.22 (dd, *J* = 2.3, 10.5, 1H), 2.92 (d, *J* = 6.5, 0.5H), 2.69 – 2.60 (m, 1H), 2.57 (d, *J* = 6.6, 1H), 2.51 (d, *J* = 8.4, 1H), 2.46 – 2.33 (m, 1H), 2.29 (d, *J* = 4.4, 1H), 2.22 (d, *J* = 6.5, 1H), 2.14 (dq, *J* = 6.2, 12.2, 0.5H), 1.95 – 1.80 (m, *J* = 7.1, 12.4, 20.7, 1H), 1.79 – 1.72 (m, 0.5H), 1.71 – 1.64 (m, 1H), 1.48 – 1.23 (m, 1.5H), 1.20 (t, *J* = 6.1, 3H), 0.70 (dd, *J* = 2.1, 6.7, 3H); MS (ESI+) *m/z* 395 (M+H)⁺.

Example 90***N*-[(3*aR*,4*S*,6*aS*)-2-(3-methoxybenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide**

The title compound was prepared by substituting 3-methoxybenzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.61 – 8.54 (m, 1H), 7.63 (d, *J* = 7.6, 2H), 7.36 – 7.24 (m, *J* = 5.6, 12.0, 20.6, 4H), 7.17 (s, 0.5H), 7.11 (s, 0.5H), 7.06 (d, *J* = 7.8, 0.5H), 7.00 (d, *J* = 7.5, 0.5H), 6.95 – 6.88 (m, 1H), 4.42 – 4.29 (m, 1H), 3.72 (s, 1.5H), 3.70 (s, 1.5H), 3.60 (d, *J* = 13.3, 0.5H), 3.52 (d, *J* = 13.2, 0.5H), 3.48 (d, *J* = 13.3, 0.5H), 3.36 (d, *J* = 13.2, 0.5H), 3.23 – 3.19 (m, 1H), 2.93 (dd, *J* = 2.7, 9.0, 0.5H), 2.68 – 2.61 (m, 1H), 2.58 (dd, *J* = 3.0, 8.9, 1H), 2.52 – 2.46 (m, 1H), 2.45 – 2.20 (m, 3H), 2.18 – 2.11 (m, 1H), 1.91 (dd, *J* = 6.0, 12.0, 0.5H), 1.87 – 1.80 (m, 0.5H), 1.78 – 1.64 (m, 1H), 1.48 – 1.26 (m, *J* = 28.4, 35.4, 1.5H), 1.20 (t, *J* = 6.7, 3H), 0.70 (dd, *J* = 2.8, 6.7, 3H); MS (ESI+) *m/z* 407 (M+H)⁺.

Example 91**3-methyl-*N*-[(3a*R*,4*S*,6a*S*)-2-(3-methylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide**

The title compound was prepared by substituting 3-methylbenzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3a*R*,4*S*,6a*S*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3a*S*,4*S*,6a*R*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.62 – 8.50 (m, 1H), 7.64 (d, *J* = 7.5, 2H), 7.33 (td, *J* = 3.7, 7.5, 2H), 7.29 – 7.23 (m, *J* = 5.5, 11.0, 3H), 7.18 (s, 1H), 7.07 (d, *J* = 7.0, 1H), 4.42 – 4.29 (m, 1H), 3.60 (d, *J* = 13.1, 0.5H), 3.51 (d, *J* = 13.0, 0.5H), 3.45 (d, *J* = 13.1, 0.5H), 3.33 (d, *J* = 13.0, 0.5H), 3.22 (d, *J* = 10.4, 1H), 2.90 (dd, *J* = 2.9, 8.9, 0.5H), 2.64 (tt, *J* = 6.8, 13.6, 1H), 2.59 – 2.46 (m, *J* = 5.3, 12.0, 23.8, 2H), 2.44 – 2.34 (m, 1H), 2.30 (d, *J* = 5.3, 1H), 2.28 – 2.23 (m, *J* = 8.0, 4H), 2.13 (dt, *J* = 6.3, 12.4, 1H), 1.94 – 1.78 (m, 1H), 1.78 – 1.64 (m, 1H), 1.48 – 1.25 (m, 1.5H), 1.20 (t, *J* = 6.1, 3H), 0.70 (dd, *J* = 1.9, 6.7, 3H); MS (ESI+) *m/z* 391 (M+H)⁺.

Example 92**3-methyl-*N*-[(3a*R*,4*S*,6a*S*)-2-(2-methylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide**

The title compound was prepared by substituting 2-methylbenzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3a*R*,4*S*,6a*S*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3a*S*,4*S*,6a*R*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.57 – 8.51 (m, 1H), 7.63 (dd, *J* = 3.5, 7.1, 2H), 7.43 – 7.36 (m, 1H), 7.36 – 7.30 (m, 3H), 7.25 (dd, *J* = 6.9, 9.6, 2H), 7.20 – 7.13 (m, *J* = 10.0, 2H), 4.31 (dd, *J* = 5.5, 11.3, 1H), 3.57 (d, *J* = 13.1, 0.5H), 3.48 (d, *J* = 13.0, 0.5H), 3.39 (d, *J* = 13.0, 0.5H), 3.29 (d, *J* = 13.0, 0.5H), 3.21 (d, *J* = 10.3, 1H), 2.92 (dd, *J* = 2.8, 9.0, 0.5H), 2.68 – 2.60 (m, 1H), 2.60 – 2.53 (m, 1H), 2.51 – 2.45 (m, 1H), 2.35 (s, 1.5H), 2.30 (s, 1.5H), 2.28 – 2.17 (m, 2H), 2.15 – 2.06 (m, 1H), 1.84 (ddd, *J* = 6.8, 12.4, 20.0, 1H), 1.76 – 1.62 (m, 1H), 1.42 (dt, *J* = 7.2, 19.2, 0.5H), 1.33 (dt, *J* = 7.0, 12.5, 0.5H), 1.29 – 1.22 (m, 0.5H), 1.20 (d, *J* = 6.5, 3H), 0.70 (d, *J* = 6.7, 3H); MS (ESI+) *m/z* 391 (M+H)⁺.

Example 93***N*-[(3*aR*,4*S*,6*aS*)-2-(2,6-dimethylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide**

The title compound was prepared by substituting 2,6-dimethylbenzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.54 – 8.50 (m, *J* = 6.7, 1H), 7.65 – 7.60 (m, 2H), 7.32 (t, *J* = 7.1, 2H), 7.28 – 7.23 (m, 1H), 7.11 (dd, *J* = 6.2, 14.3, 1H), 7.04 (t, *J* = 8.3, 2H), 4.27 – 4.19 (m, 1H), 3.57 (d, *J* = 12.5, 0.5H), 3.44 (dd, *J* = 12.5, 15.5, 1H), 3.34 (d, *J* = 12.5, 0.5H), 3.20 (d, *J* = 10.4, 1H), 2.92 (d, *J* = 5.9, 0.5H), 2.68 – 2.58 (m, *J* = 10.2, 18.3, 1H), 2.55 – 2.51 (m, *J* = 4.5, 1H), 2.48 – 2.42 (m, 0.5H), 2.39 (s, 3H), 2.34 (s, 3H), 2.32 – 2.18 (m, 3H), 2.07 (td, *J* = 6.6, 12.6, 0.5H), 1.87 – 1.73 (m, 1H), 1.72 – 1.62 (m, 1H), 1.33 (dd, *J* = 19.1, 78.6, 2.5H), 1.19 (dd, *J* = 4.9, 6.3, 3H), 0.69 (d, *J* = 6.6, 3H); MS (ESI+) *m/z* 405 (M+H)⁺.

Example 94***N*-[(3*aR*,4*S*,6*aS*)-2-(2-methoxybenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide**

The title compound was prepared by substituting 2-methoxybenzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.50 (t, *J* = 7.3, 1H), 7.62 (d, *J* = 7.3, 2H), 7.55 (d, *J* = 7.8, 1H), 7.32 (dq, *J* = 3.8, 11.6, 2H), 7.25 (dd, *J* = 3.6, 7.5, 2H), 7.04 (dt, *J* = 7.4, 11.4, 1H), 6.89 (t, *J* = 8.3, 1H), 4.43 – 4.31 (m, 1H), 3.80 – 3.57 (m, 5H), 3.21 (d, *J* = 10.4, 1H), 2.99 (d, *J* = 6.2, 0.5H), 2.61 (ddd, *J* = 4.5, 12.6, 15.9, 2.5H), 2.52 – 2.45 (m, 0.5H), 2.45 – 2.31 (m, 3.5H), 2.19 – 2.09 (m, 0.5H), 2.00 – 1.80 (m, 1H), 1.72 (ddd, *J* = 6.5, 12.3, 19.3, 1H), 1.47 – 1.25 (m, 2.5H), 1.20 (dd, *J* = 3.0, 6.4, 3H), 0.70 (d, *J* = 6.7, 3H); MS (ESI+) *m/z* 407 (M+H)⁺.

Example 95***N*-[(3*aR*,4*S*,6*aS*)-2-(4-*tert*-butylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide**

The title compound was prepared by substituting 4-*tert*-butylbenzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-

4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.57 (dd, *J* = 6.7, 11.0, 1H), 7.63 (dd, *J* = 3.4, 7.1, 2H), 7.44 – 7.30 (m, 6H), 7.25 (t, *J* = 7.4, 1H), 4.36 (tt, *J* = 6.3, 12.6, 1H), 3.63 (d, *J* = 13.1, 0.5H), 3.55 (d, *J* = 13.0, 0.5H), 3.46 (d, *J* = 13.0, 0.5H), 3.35 (d, *J* = 13.0, 0.5H), 3.21 (d, *J* = 10.4, 1H), 2.90 (dd, *J* = 2.7, 8.7, 0.5H), 2.65 (dt, *J* = 6.6, 16.9, 1H), 2.58 – 2.44 (m, 2H), 2.44 – 2.34 (m, 1H), 2.32 (d, *J* = 8.6, 0.5H), 2.30 (d, *J* = 5.2, 1H), 2.24 (d, *J* = 5.0, 1H), 2.19 – 2.12 (m, 1H), 1.92 (dq, *J* = 6.1, 12.1, 0.5H), 1.82 (td, *J* = 7.3, 14.3, 0.5H), 1.70 (dq, *J* = 8.1, 14.7, 1H), 1.48 – 1.30 (m, *J* = 22.3, 41.1, 1H), 1.27 (s, *J* = 1.6, 9H), 1.20 (dd, *J* = 3.5, 6.4, 3H), 0.70 (d, *J* = 6.4, 3H); MS (ESI+) *m/z* 433 (M+H)⁺.

Example 96

N-[(3*aR*,4*S*,6*aS*)-2-(4-methoxybenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 4-methoxybenzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.57 (dd, *J* = 8.3, 10.9, 1H), 7.63 (dd, *J* = 2.8, 7.4, 2H), 7.39 – 7.28 (m, 4H), 7.28 – 7.23 (m, 1H), 6.98 (dd, *J* = 8.7, 10.2, 2H), 4.41 – 4.30 (m, 1H), 3.68 (s, 3H), 3.57 (d, *J* = 12.9, 0.5H), 3.48 (d, *J* = 12.9, 0.5H), 3.42 (d, *J* = 12.9, 0.5H), 3.31 (d, *J* = 12.8, 0.5H), 3.21 (d, *J* = 10.4, 1H), 2.90 (dd, *J* = 2.8, 8.9, 0.5H), 2.69 – 2.59 (m, 1H), 2.56 (dd, *J* = 2.9, 9.0, 1H), 2.53 – 2.46 (m, 1H), 2.45 – 2.33 (m, 1H), 2.32 – 2.26 (m, *J* = 10.0, 1H), 2.24 (t, *J* = 5.2, 1H), 2.15 (dt, *J* = 6.3, 12.3, 0.5H), 1.96 – 1.88 (m, 0.5H), 1.88 – 1.79 (m, 0.5H), 1.79 – 1.65 (m, 1H), 1.48 – 1.24 (m, *J* = 19.9, 48.8, 3H), 1.20 (dd, *J* = 4.3, 6.4, 3H), 0.70 (dd, *J* = 2.0, 6.7, 2H); MS (ESI+) *m/z* 407 (M+H)⁺.

Example 97

N-[(3*aR*,4*S*,6*aS*)-2-(3-cyanobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 3-formylbenzonitrile for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H

NMR (500 MHz, pyridine-*d*₅) δ ppm 8.60 (t, *J* = 7.1, 1H), 7.63 (d, *J* = 5.9, 2H), 7.56 – 7.50 (m, 2H), 7.39 – 7.30 (m, 3H), 7.29 – 7.23 (m, *J* = 8.9, 13.2, 2H), 4.32 (dd, *J* = 5.7, 11.2, 1H), 3.53 (d, *J* = 13.6, 0.5H), 3.44 (d, *J* = 13.5, 0.5H), 3.40 (d, *J* = 13.6, 0.5H), 3.28 (d, *J* = 13.6, 0.5H), 3.21 (dd, *J* = 1.3, 10.4, 1H), 2.90 (dd, *J* = 2.8, 9.1, 0.5H), 2.64 (qd, *J* = 6.6, 13.2, 1H), 2.59 – 2.47 (m, 1H), 2.46 – 2.37 (m, 1H), 2.37 – 2.30 (m, 0.5H), 2.26 – 2.20 (m, 1H), 2.19 – 2.13 (m, 1H), 2.10 (dt, *J* = 6.2, 12.3, 0.5H), 1.89 – 1.79 (m, 1H), 1.75 (dt, *J* = 6.1, 20.0, 0.5H), 1.66 (dt, *J* = 7.0, 19.3, 0.5H), 1.47 – 1.38 (m, 0.5H), 1.38 – 1.23 (m, 2H), 1.20 (dd, *J* = 3.6, 6.4, 3H), 0.70 (d, *J* = 6.7, 3H); MS (ESI+) *m/z* 402 (M+H)⁺.

10

Example 98**3-methyl-2-phenyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[4-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide**

The title compound was prepared by substituting 4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-

15

octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.62 (t, *J* = 7.8, 1H), 7.64 (dd, *J* = 7.0, 11.8, 4H), 7.51 (d, *J* = 8.0, 1H), 7.46 (d, *J* = 7.9, 1H), 7.33 (dd, *J* = 7.4, 12.1, 2H), 7.29 – 7.24 (m, 1H), 4.40 – 4.30 (m, 1H), 3.58 (d, *J* = 13.7, 0.5H), 3.48 (t, *J* = 13.8, 1H), 3.35 (d, *J* = 13.7, 0.5H), 3.23 (dd, *J* = 1.4, 10.4, 1H), 2.92 (dd, *J* = 2.7, 9.0, 0.5H), 2.69 – 2.60 (m, 1H), 2.57 (dd, *J* = 2.7, 9.1, 1H), 2.54 – 2.47 (m, 0.5H), 2.47 – 2.39 (m, 1H), 2.39 – 2.32 (m, 0.5H), 2.31 – 2.20 (m, 2H), 2.19 – 2.11 (m, 1H), 1.95 – 1.82 (m, *J* = 6.4, 37.0, 1H), 1.77 (dt, *J* = 6.4, 13.8, 0.5H), 1.69 (dt, *J* = 6.9, 19.1, 0.5H), 1.50 – 1.25 (m, *J* = 34.6, 62.0, 1.5H), 1.21 (t, *J* = 6.4, 3H), 0.70 (d, *J* = 5.1, 3H); MS (ESI+) *m/z* 445 (M+H)⁺.

25

Example 99**3-methyl-2-phenyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[2-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide**

The title compound was prepared by substituting 2-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-

30

octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.61 (d, *J* = 6.0, 1H), 7.93 (d, *J* = 7.6, 0.5H), 7.85 (d, *J* = 7.8, 0.5H), 7.63 (t, *J* = 5.8, 3H), 7.53 (dd, *J* = 7.9, 16.0,

1H), 7.38 – 7.23 (m, 5H), 4.36 (dd, $J = 5.7, 13.2$, 1H), 3.76 (q, $J = 14.5$, 1H), 3.66 (q, $J = 15.0$, 1H), 3.23 (dd, $J = 2.2, 10.5$, 1H), 3.03 (dd, $J = 2.2, 9.0$, 0.5H), 2.69 – 2.60 (m, $J = 5.6, 17.6$, 1H), 2.59 – 2.47 (m, 1H), 2.47 – 2.40 (m, $J = 10.2, 17.4$, 1H), 2.39 – 2.12 (m, 3H), 1.96 – 1.82 (m, 1H), 1.78 (dt, $J = 6.2, 20.1$, 0.5H), 1.68 (dt, $J = 7.2, 13.8$, 0.5H), 1.48 – 1.24 (m, 1.5H), 1.20 (t, $J = 6.7$, 3H), 0.70 (dd, $J = 1.7, 6.7$, 3H); MS (ESI+) m/z 445 (M+H)⁺.

Example 100

***N*-{(3*aR*,4*S*,6*aS*)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide**

10 The title compound was prepared by substituting 4-fluoro-3-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.63 (t, $J = 7.0$, 1H), 7.69 (d, $J = 6.3$, 1H), 7.64 (d, $J = 7.6$, 2H), 7.55 – 7.49 (m, 1H), 7.33 (dd, $J = 7.2, 13.6$, 2H), 7.25 (dd, $J = 7.6, 15.5$, 2H), 4.33 (dd, $J = 5.7, 11.4$, 1H), 3.54 (d, $J = 13.5$, 0.5H), 3.44 (t, $J = 14.0$, 1H), 3.31 (d, $J = 13.4$, 0.5H), 3.22 (d, $J = 10.4$, 1H), 2.91 (dd, $J = 2.6, 9.0, 0.5H$), 2.69 – 2.60 (m, $J = 7.5, 13.7$, 1H), 2.55 (dd, $J = 3.1, 9.1$, 1H), 2.53 – 2.39 (m, 2H), 2.38 – 2.32 (m, $J = 8.0$, 0.5H), 2.29 – 2.21 (m, 1H), 2.19 (d, $J = 4.0$, 1H), 2.12 (dd, $J = 6.1, 12.1$, 0.5H), 1.91 – 1.81 (m, $J = 10.9, 16.7$, 1H), 1.77 (dt, $J = 6.3, 19.8$, 0.5H), 1.68 (td, $J = 7.0, 14.0$, 0.5H), 1.44 (dt, $J = 7.6, 14.7$, 0.5H), 1.40 – 1.25 (m, 1H), 1.20 (t, $J = 5.7$, 3H), 0.70 (d, $J = 6.4$, 3H); MS (ESI+) m/z 463 (M+H)⁺.

Example 101

***N*-{(3*aR*,4*S*,6*aS*)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide**

25 The title compound was prepared by substituting 3-fluoro-4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.63 (t, $J = 6.6$, 1H), 7.64 (dd, $J = 3.0, 7.5$, 2H), 7.37 – 7.30 (m, 3H), 7.30 – 7.23 (m, 3H), 4.38 – 4.30 (m, 1H), 3.56 (d, $J = 14.1$, 0.5H), 3.46 (t, $J = 13.4$, 1H), 3.33 (d, $J = 14.1$, 0.5H), 3.23 (d, $J = 10.4$, 1H), 2.94 (dd, $J = 2.5, 9.0$, 0.5H), 2.65 (dt, $J = 6.2, 10.9$, 1H), 2.58 (dd, $J = 2.8, 9.2$,

1H), 2.54 – 2.48 (m, 0.5H), 2.47 – 2.39 (m, 1H), 2.39 – 2.32 (m, 0.5H), 2.28 (dd, $J = 2.7, 8.9$, 0.5H), 2.26 – 2.20 (m, 1H), 2.19 – 2.09 (m, 1H), 1.87 (ddd, $J = 6.4, 12.3, 18.7$, 1H), 1.78 (dt, $J = 6.2, 19.6$, 0.5H), 1.68 (dt, $J = 7.5, 14.6$, 0.5H), 1.49 – 1.24 (m, 2H), 1.21 (dd, $J = 4.3, 6.2$, 3H), 0.70 (d, $J = 6.7$, 3H); MS (ESI+) m/z 463 (M+H)⁺.

5

Example 102

3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(thien-2-ylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide

The title compound was prepared by substituting thiophene-2-carbaldehyde for 3-
10 (trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H
NMR (500 MHz, pyridine-*d*₅) δ ppm 8.62 – 8.53 (m, 1H), 7.63 (dd, $J = 4.4, 7.0$, 2H), 7.33 (t, $J = 7.6$, 3H), 7.28 – 7.23 (m, 1H), 6.98 (dd, $J = 4.8, 9.3$, 1H), 6.94 (d, $J = 3.0$, 1H), 4.33 (dd, J
15 = 7.7, 13.5, 1H), 3.77 (d, $J = 13.7$, 0.5H), 3.68 (dd, $J = 4.6, 13.7$, 1H), 3.57 (d, $J = 13.7$, 0.5H), 3.21 (d, $J = 10.4$, 1H), 2.94 (d, $J = 8.5$, 0.5H), 2.69 – 2.44 (m, 3H), 2.44 – 2.28 (m, 3H), 2.28 – 2.22 (m, 0.5H), 2.18 – 2.09 (m, 0.5H), 1.90 (td, $J = 6.1, 12.1$, 0.5H), 1.86 – 1.79 (m, 0.5H), 1.78 – 1.63 (m, 1H), 1.47 – 1.35 (m, 1H), 1.32 (dd, $J = 7.1, 13.2$, 0.5H), 1.20 (dd, $J = 2.0, 6.4$, 3H), 0.70 (d, $J = 6.7$, 3H); MS (ESI+) m/z 383 (M+H)⁺.

20

Example 103

3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(pyridin-4-ylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide

The title compound was prepared by substituting isonicotinaldehyde for 3-
25 (trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H
NMR (500 MHz, pyridine-*d*₅) δ ppm 8.70 (d, $J = 5.9$, 2H), 8.62 (s, 1H), 7.64 (dd, $J = 3.0, 7.5$, 2H), 7.36 – 7.30 (m, 2H), 7.25 (dd, $J = 7.0, 12.4$, 3H), 4.39 – 4.30 (m, 1H), 3.51 (d, $J = 14.2$,
30 0.5H), 3.41 (dd, $J = 11.5, 14.2$, 1H), 3.28 (d, $J = 14.3$, 0.5H), 3.23 (dd, $J = 1.8, 10.5$, 1H), 2.94 (dd, $J = 2.6, 9.2$, 0.5H), 2.69 – 2.60 (m, 1H), 2.57 (dd, $J = 2.9, 9.2$, 1H), 2.52 – 2.46 (m, 0.5H), 2.42 (dd, $J = 7.2, 8.8$, 1H), 2.38 – 2.31 (m, 0.5H), 2.28 (dd, $J = 2.7, 9.0$, 0.5H), 2.24 – 2.18 (m, 1H), 2.17 – 2.11 (m, 1H), 1.95 – 1.82 (m, 1H), 1.77 (dt, $J = 5.8, 12.3$, 0.5H), 1.73 –

1.64 (m, 0.5H), 1.49 – 1.25 (m, 2H), 1.23 – 1.17 (m, 3H), 0.70 (d, $J = 6.5$, 3H); MS (ESI+) m/z 378 (M+H)⁺.

Example 104

5 **3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(2-phenylethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide**

The title compound was prepared by substituting 2-phenylacetaldehyde for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.57 (dd, $J = 5.2, 12.0$, 1H), 7.65 (t, $J = 7.1$, 2H), 7.38 – 7.23 (m, 8H), 4.40 – 4.29 (m, 1H), 3.23 (d, $J = 10.5$, 1H), 3.00 (dd, $J = 2.6, 9.0$, 0.5H), 2.80 (t, $J = 7.8$, 1H), 2.75 – 2.70 (m, 1H), 2.70 – 2.61 (m, 1H), 2.61 – 2.52 (m, 1H), 2.52 – 2.46 (m, 1H), 2.43 (dd, $J = 7.6, 8.7$, 0.5H), 2.38 (dd, $J = 2.7, 8.8$, 1H), 2.34 (dd, $J = 2.7, 8.5$, 1H), 15 2.26 (d, $J = 8.3$, 0.5H), 2.24 – 2.18 (m, 1H), 2.12 (td, $J = 6.4, 12.4$, 0.5H), 1.91 – 1.82 (m, 1H), 1.76 (dt, $J = 6.2, 18.7$, 0.5H), 1.70 – 1.61 (m, 0.5H), 1.46 – 1.26 (m, 2H), 1.23 (dd, $J = 6.5, 13.5$, 3H), 0.97 – 0.83 (m, 1H), 0.71 (dd, $J = 2.7, 6.7$, 3H); MS (ESI+) m/z 391 (M+H)⁺.

Example 105

20 **3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(3-phenylpropyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide**

The title compound was prepared by substituting 3-phenylpropanal for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.60 (t, $J = 6.8$, 1H), 7.69 – 7.63 (m, 2H), 7.39 – 7.22 (m, 8H), 4.41 – 4.31 (m, 1H), 3.25 (d, $J = 10.4$, 1H), 2.95 (dd, $J = 2.5, 8.9$, 0.5H), 2.68 (td, $J = 2.7, 7.2$, 2H), 2.65 – 2.60 (m, 1H), 2.58 (dd, $J = 2.8, 9.2$, 0.5H), 2.56 – 2.52 (m, 0.5H), 2.51 – 2.46 (m, 0.5H), 2.44 – 2.38 (m, 0.5H), 2.37 – 2.26 (m, 3H), 2.23 (t, $J = 7.2$, 1H), 2.18 (d, $J = 7.3$, 0.5H), 2.13 (t, $J = 8.8$, 1.5H), 1.88 (dd, $J = 6.1, 12.1$, 1H), 1.79 (dd, $J = 7.2, 14.5$, 1.5H), 1.74 – 1.64 (m, 1.5H), 1.48 – 1.37 (m, 1H), 1.37 – 1.28 (m, 0.5H), 1.23 (dd, $J = 6.5, 12.2$, 3H), 0.71 (dd, $J = 3.0, 6.7$, 3H); MS (ESI+) m/z 405 (M+H)⁺.

Example 106***N*-{(3*aR*,4*S*,6*aS*)-2-[3-(4-*tert*-butylphenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide**

The title compound was prepared by substituting 3-(4-*tert*-butylphenyl)propanal for
5 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-
octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-
dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure
described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.57 (t, *J* = 8.5, 1H), 7.65
(t, *J* = 6.6, 2H), 7.40 (dd, *J* = 5.4, 8.0, 2H), 7.34 (t, *J* = 7.4, 2H), 7.30 – 7.23 (m, 3H), 4.37 (dt,
10 *J* = 6.1, 11.1, 1H), 3.23 (d, *J* = 10.4, 1H), 2.96 (dd, *J* = 1.9, 8.9, 0.5H), 2.67 (ddd, *J* = 6.7,
11.6, 23.3, 2H), 2.59 (dd, *J* = 2.6, 9.3, 0.5H), 2.57 – 2.51 (m, 0.5H), 2.50 – 2.44 (m, 0.5H),
2.43 – 2.38 (m, 0.5H), 2.35 (t, *J* = 8.1, 2H), 2.29 (dd, *J* = 2.6, 8.8, 0.5H), 2.25 (t, *J* = 7.1, 1H),
2.19 (d, *J* = 7.2, 0.5H), 2.17 – 2.11 (m, 1H), 1.92 – 1.85 (m, 1H), 1.81 (dt, *J* = 7.7, 15.5, 1H),
1.74 (dt, *J* = 7.9, 15.9, 1H), 1.69 – 1.63 (m, 0.5H), 1.46 – 1.31 (m, 2H), 1.28 (s, 9H), 1.23 (dd,
15 *J* = 6.5, 13.4, 3H), 0.94 – 0.84 (m, 2H), 0.71 (dd, *J* = 3.2, 6.6, 3H); MS (ESI+) *m/z* 461
(*M*+H)⁺.

Example 107***N*-{(3*aR*,4*S*,6*aS*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-
20 methyl-2-phenylbutanamide**

The title compound was prepared by substituting 6,6-bis(4-fluorophenyl)hexanal for
3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-
octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-
dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure
25 described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.59 (t, *J* = 6.4, 1H), 7.65
(dd, *J* = 4.9, 6.9, 2H), 7.33 (dd, *J* = 6.8, 11.6, 6H), 7.25 (dd, *J* = 6.5, 8.2, 1H), 7.14 (dd, *J* =
1.4, 8.7, 4H), 4.40 – 4.30 (m, 1H), 3.97 (q, *J* = 7.7, 1H), 3.23 (d, *J* = 10.4, 1H), 2.96 (d, *J* =
6.8, 0.5H), 2.71 – 2.61 (m, 1H), 2.59 (dd, *J* = 2.5, 9.0, 0.5H), 2.56 – 2.46 (m, 1H), 2.40 (dd, *J* =
8.4, 16.1, 1H), 2.37 – 2.33 (m, 1H), 2.30 (dd, *J* = 4.4, 8.1, 1H), 2.20 (t, *J* = 6.2, 2H), 2.17 –
30 2.10 (m, 1H), 2.01 (ddd, *J* = 7.8, 11.6, 15.5, 2H), 1.88 (dq, *J* = 6.0, 11.8, 1H), 1.78 (dt, *J* =
6.3, 20.2, 0.5H), 1.67 (td, *J* = 7.1, 14.5, 0.5H), 1.49 – 1.30 (m, 6H), 1.29 – 1.25 (m, 2H), 1.22
(dd, *J* = 6.5, 11.0, 3H), 0.71 (dd, *J* = 3.2, 6.7, 3H); MS (ESI+) *m/z* 559 (*M*+H)⁺.

Example 108**3-methyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[3-(2-methylphenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2-phenylbutanamide**

The title compound was prepared by substituting 3-*o*-tolylpropanal for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.57 (dd, *J* = 7.2, 14.2, 1H), 7.68 – 7.62 (m, 2H), 7.34 (t, *J* = 7.5, 2H), 7.29 – 7.23 (m, 2H), 7.23 – 7.22 (m, 1H), 7.17 (dd, *J* = 2.6, 3.9, 2H), 4.42 – 4.31 (m, 1H), 3.23 (d, *J* = 10.4, 1H), 2.98 (dd, *J* = 2.3, 8.8, 0.5H), 2.69 – 2.64 (m, 2H), 2.64 – 2.59 (m, 2H), 2.58 – 2.51 (m, 0.5H), 2.51 – 2.45 (m, 0.5H), 2.45 – 2.39 (m, 0.5H), 2.39 – 2.34 (m, 2H), 2.32 (dd, *J* = 2.7, 8.9, 1H), 2.28 (s, 1.5H), 2.25 (s, 1.5H), 2.19 (d, *J* = 8.1, 0.5H), 2.17 – 2.11 (m, 1.5H), 1.93 – 1.85 (m, 1H), 1.84 – 1.77 (m, 0.5H), 1.73 (dd, *J* = 7.6, 15.1, 1H), 1.66 (dt, *J* = 7.4, 9.4, 1.5H), 1.43 (dt, *J* = 7.5, 13.8, 1H), 1.38 – 1.30 (m, 1H), 1.23 (dd, *J* = 6.5, 12.1, 3H), 0.71 (dd, *J* = 2.8, 6.7, 3H); MS (ESI+) *m/z* 419 (M+H)⁺.

Example 109***N*-{(3*aR*,4*S*,6*aS*)-2-[3-(3-chlorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide**

The title compound was prepared by substituting 3-(3-chlorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.60 (d, *J* = 4.6, 1H), 7.66 (dd, *J* = 4.3, 7.0, 2H), 7.35 (dd, *J* = 10.9, 18.3, 3H), 7.29 – 7.23 (m, 3H), 7.16 (d, *J* = 6.8, 0.5H), 7.12 (d, *J* = 7.0, 0.5H), 4.41 – 4.31 (m, 1H), 3.24 (d, *J* = 10.4, 1H), 2.98 (d, *J* = 8.9, 0.5H), 2.72 – 2.62 (m, 2H), 2.62 – 2.55 (m, 2H), 2.55 – 2.51 (m, 0.5H), 2.50 – 2.45 (m, 0.5H), 2.43 – 2.37 (m, 0.5H), 2.31 (ddd, *J* = 2.6, 7.2, 12.1, 3H), 2.23 – 2.16 (m, 1H), 2.15 – 2.09 (m, 1H), 1.91 – 1.84 (m, 1H), 1.80 (td, *J* = 6.3, 12.5, 1H), 1.72 (dd, *J* = 7.5, 14.5, 1H), 1.69 – 1.61 (m, 1H), 1.46 – 1.37 (m, 1H), 1.37 – 1.28 (m, 1H), 1.23 (dd, *J* = 6.5, 13.3, 3H), 0.71 (dd, *J* = 3.9, 6.7, 3H); MS (ESI+) *m/z* 439 (M+H)⁺.

Example 110**3-methyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[3-(3-methylphenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2-phenylbutanamide**

The title compound was prepared by substituting 3-*m*-tolylpropanal for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.57 (dd, *J* = 7.1, 13.5, 1H), 7.65 (dd, *J* = 4.8, 7.0, 2H), 7.34 (t, *J* = 7.5, 2H), 7.29 – 7.22 (m, 2H), 7.12 (d, *J* = 5.9, 1H), 7.09 (d, *J* = 7.1, 1H), 7.06 – 7.02 (m, 1H), 4.42 – 4.31 (m, 1H), 3.24 (d, *J* = 10.4, 1H), 2.97 (d, *J* = 6.8, 0.5H), 2.71 – 2.58 (m, 4H), 2.56 – 2.44 (m, 1H), 2.43 – 2.38 (m, 0.5H), 2.35 (t, *J* = 6.6, 3H), 2.29 (s, 1.5H), 2.27 (s, 1.5H), 2.27 – 2.23 (m, 1H), 2.17 – 2.11 (m, 1.5H), 1.89 (dt, *J* = 6.1, 11.8, 1H), 1.79 (dd, *J* = 7.4, 14.7, 1.5H), 1.72 (dt, *J* = 7.6, 15.1, 1H), 1.66 (dd, *J* = 5.9, 13.1, 0.5H), 1.42 (dt, *J* = 7.5, 12.0, 1H), 1.37 – 1.30 (m, 0.5H), 1.23 (dd, *J* = 6.5, 11.7, 3H), 0.71 (dd, *J* = 3.0, 6.6, 3H); MS (ESI+) *m/z* 419 (M+H)⁺.

Example 111**3-methyl-2-phenyl-*N*-((3*aR*,4*S*,6*aS*)-2-{3-[3-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[*c*]pyrrol-4-yl)butanamide**

The title compound was prepared by substituting 3-(3-(trifluoromethyl)phenyl)propanal for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.61 (d, *J* = 6.4, 1H), 7.69 – 7.62 (m, 3H), 7.53 (d, *J* = 6.5, 1H), 7.46 (t, *J* = 7.8, 1H), 7.42 (d, *J* = 5.5, 1H), 7.34 (t, *J* = 7.5, 2H), 7.26 (t, *J* = 7.3, 1H), 4.37 (tt, *J* = 6.4, 12.7, 1H), 3.24 (d, *J* = 10.5, 1H), 3.00 (dd, *J* = 1.9, 8.9, 0.5H), 2.78 – 2.63 (m, 3H), 2.61 (dd, *J* = 2.3, 9.1, 0.5H), 2.57 – 2.45 (m, 1H), 2.40 (dd, *J* = 7.1, 14.3, 0.5H), 2.37 – 2.26 (m, 3H), 2.24 – 2.07 (m, 3H), 1.93 – 1.83 (m, 1H), 1.83 – 1.71 (m, 2H), 1.71 – 1.63 (m, 1H), 1.48 – 1.37 (m, 1H), 1.37 – 1.30 (m, 0.5H), 1.23 (dd, *J* = 6.5, 13.6, 3H), 0.72 (dd, *J* = 4.4, 6.6, 3H); MS (ESI+) *m/z* 473 (M+H)⁺.

Example 112***N*-{(3*aR*,4*S*,6*aS*)-2-[3-(3-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide**

The title compound was prepared by substituting 3-(3-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.52 (s, 1H), 7.69 – 7.61 (m, 2H), 7.33 (t, *J* = 7.5, 2H), 7.27 (ddd, *J* = 3.5, 7.6, 10.6, 2H), 7.14 – 6.95 (m, 3H), 4.43 – 4.29 (m, 1H), 3.23 (d, *J* = 10.4, 1H), 2.97 (dd, *J* = 2.2, 8.8, 0.5H), 2.72 – 2.58 (m, 3H), 2.57 – 2.44 (m, 1H), 2.44 – 2.38 (m, 0.5H), 2.36 – 2.26 (m, 3H), 2.25 – 2.16 (m, 1H), 2.16 – 2.09 (m, 1H), 1.93 – 1.83 (m, 1H), 1.77 (dt, *J* = 7.2, 14.6, 1.5H), 1.72 – 1.63 (m, 1.5H), 1.47 – 1.27 (m, 2H), 1.22 (dd, *J* = 6.5, 10.4, 3H), 0.94 – 0.83 (m, 1H), 0.71 (dd, *J* = 2.7, 6.7, 3H); MS (ESI+) *m/z* 423 (M+H)⁺.

Example 113**3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(4-phenylbutyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide**

The title compound was prepared by substituting 4-phenylbutanal for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.58 (dd, *J* = 9.0, 16.5, 1H), 7.66 (t, *J* = 6.4, 2H), 7.34 (t, *J* = 5.6, 4H), 7.29 – 7.22 (m, 4H), 4.39 – 4.29 (m, 1H), 3.24 (d, *J* = 10.4, 1H), 2.91 (dd, *J* = 2.4, 9.0, 0.5H), 2.66 (ddd, *J* = 6.5, 10.6, 13.1, 1H), 2.57 (ddd, *J* = 5.3, 12.3, 17.7, 3H), 2.51 – 2.45 (m, 1H), 2.43 – 2.29 (m, 3H), 2.26 (dd, *J* = 3.0, 8.8, 0.5H), 2.24 – 2.08 (m, 2H), 1.91 – 1.83 (m, 1H), 1.81 – 1.72 (m, 1H), 1.71 – 1.58 (m, 2H), 1.49 (dt, *J* = 7.8, 15.9, 1H), 1.41 (dt, *J* = 6.9, 17.2, 2H), 1.31 (ddd, *J* = 6.7, 13.2, 20.5, 1H), 1.23 (dd, *J* = 6.5, 13.0, 3H), 0.71 (dd, *J* = 2.6, 6.6, 3H); MS (ESI+) *m/z* 419 (M+H)⁺.

Example 114***N*-{(3*aR*,4*S*,6*aS*)-2-[3-(3-chloro-5-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide**

The title compound was prepared by substituting 3-(3-chloro-5-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-

octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.61 (d, *J* = 7.4, 1H), 7.66 (dd, *J* = 3.2, 7.5, 2H), 7.35 (dd, *J* = 7.5, 15.0, 2H), 7.25 (dd, *J* = 6.1, 13.7, 2H), 7.12 (d, *J* = 7.5, 1H), 7.06 – 6.95 (m, 1H), 4.43 – 4.31 (m, 1H), 3.24 (d, *J* = 10.4, 1H), 3.01 (dd, *J* = 1.3, 8.7, 0.5H), 2.73 – 2.64 (m, 1H), 2.62 (dd, *J* = 6.0, 9.0, 1H), 2.59 – 2.54 (m, 1H), 2.53 – 2.45 (m, 1H), 2.43 – 2.38 (m, 0.5H), 2.37 – 2.25 (m, 3H), 2.24 – 2.06 (m, 3H), 1.93 – 1.76 (m, 2H), 1.75 – 1.58 (m, 2H), 1.47 – 1.28 (m, 2H), 1.23 (dd, *J* = 6.5, 14.4, 3H), 0.72 (dd, *J* = 5.0, 6.2, 3H); MS (ESI+) *m/z* 457 (M+H)⁺.

10

Example 115

3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-{3-[4-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide

The title compound was prepared by substituting 3-(4-(trifluoromethyl)phenyl)propanal for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.69 – 7.62 (m, 4H), 7.39 (d, *J* = 8.0, 1H), 7.37 – 7.32 (m, 3H), 7.26 (t, *J* = 7.3, 1H), 4.41 – 4.33 (m, 1H), 3.25 (d, *J* = 10.5, 1H), 3.00 (dd, *J* = 2.2, 9.0, 0.5H), 2.76 – 2.59 (m, 3H), 2.56 – 2.46 (m, 1H), 2.44 – 2.39 (m, 0.5H), 2.37 (dd, *J* = 2.1, 8.9, 0.5H), 2.31 (dt, *J* = 5.8, 14.1, 2H), 2.23 – 2.07 (m, 3H), 1.94 – 1.71 (m, 2.5H), 1.67 (ddd, *J* = 5.6, 7.9, 11.8, 1H), 1.47 – 1.28 (m, 2H), 1.23 (dd, *J* = 6.5, 13.1, 3H), 0.89 (dt, *J* = 7.2, 24.8, 1H), 0.72 (dd, *J* = 3.7, 6.7, 3H); MS (ESI+) *m/z* 473 (M+H)⁺.

25

Example 116

N-[(3*aR*,4*S*,6*aS*)-2-(3,3-diphenylpropyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 3,3-diphenylpropanal for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.59 (dd, *J* = 2.9, 7.0, 1H), 7.65 (d, *J* = 8.1, 2H), 7.46 (d, *J* = 7.2, 1H), 7.44 – 7.37 (m, 4H), 7.33 (tt, *J* = 3.7, 7.7, 6H), 7.28 – 7.24 (m, 1H), 7.23 –

30

7.18 (m, 1H), 4.44 – 4.34 (m, 1H), 4.28 (d, $J = 7.2$, 1H), 4.20 (dd, $J = 5.4$, 9.1, 1H), 3.24 (d, $J = 10.4$, 1H), 2.93 (dd, $J = 2.4$, 9.0, 0.5H), 2.71 – 2.61 (m, 1H), 2.56 (dd, $J = 2.7$, 9.2, 0.5H), 2.54 – 2.50 (m, 0.5H), 2.50 – 2.43 (m, 0.5H), 2.43 – 2.36 (m, 0.5H), 2.35 – 2.28 (m, 3H), 2.24 (tt, $J = 5.1$, 10.0, 2H), 2.18 – 2.07 (m, 2H), 1.94 – 1.83 (m, 1H), 1.82 – 1.74 (m, 0.5H),
 5 1.68 (td, $J = 7.0$, 14.3, 0.5H), 1.47 – 1.37 (m, 1H), 1.37 – 1.29 (m, 0.5H), 1.22 (dd, $J = 4.6$, 6.4, 3H), 0.71 (dd, $J = 1.7$, 6.7, 3H); MS (ESI+) m/z 481 (M+H)⁺.

Example 117

10 *N*-{(3*aR*,4*S*,6*aS*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 3,3-bis(4-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure
 15 described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.62 (d, $J = 5.3$, 1H), 7.65 (d, $J = 7.3$, 2H), 7.42 (dd, $J = 5.6$, 8.6, 1H), 7.39 – 7.29 (m, 5H), 7.26 (td, $J = 5.3$, 7.2, 1H), 7.19 – 7.09 (m, 4H), 4.47 – 4.37 (m, 1H), 4.29 (t, $J = 7.7$, 0.5H), 4.21 (t, $J = 7.6$, 0.5H), 3.24 (d, $J = 10.4$, 1H), 3.02 (dd, $J = 1.2$, 8.9, 0.5H), 2.71 – 2.60 (m, 1H), 2.57 – 2.46 (m, 1H), 2.44 – 2.30 (m, 3H), 2.27 – 2.20 (m, 2H), 2.19 – 2.09 (m, 4H), 1.90 (dq, $J = 6.0$, 17.7, 1H),
 20 1.81 (dq, $J = 6.2$, 18.7, 0.5H), 1.67 (ddd, $J = 7.6$, 12.3, 14.8, 0.5H), 1.48 – 1.38 (m, 1H), 1.38 – 1.30 (m, 0.5H), 1.22 (dd, $J = 2.5$, 6.5, 3H), 0.71 (dd, $J = 1.4$, 6.7, 3H); MS (ESI+) m/z 517 (M+H)⁺.

Example 118

25 *N*-{(3*aR*,4*S*,6*aS*)-2-[4,4-bis(4-fluorophenyl)butyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 4,4-bis(4-fluorophenyl)butanal for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure
 30 described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.61 (d, $J = 7.0$, 1H), 7.66 (dd, $J = 5.3$, 7.0, 2H), 7.44 – 7.31 (m, 6H), 7.26 (t, $J = 7.4$, 1H), 7.19 – 7.08 (m, 4H), 4.41 – 4.30 (m, 1H), 4.03 – 3.92 (m, 1H), 3.24 (d, $J = 10.4$, 1H), 2.95 (dd, $J = 2.3$, 8.9, 0.5H), 2.67 (ddd, $J = 6.6$, 13.3, 17.1, 1H), 2.56 (dd, $J = 2.8$, 9.1, 0.5H), 2.54 – 2.43 (m, 1H), 2.42 –

2.30 (m, 2H), 2.29 – 2.20 (m, 2.5H), 2.19 – 2.02 (m, 4H), 1.90 – 1.72 (m, 1.5H), 1.65 (dt, $J = 7.1, 19.2, 0.5\text{H}$), 1.52 – 1.34 (m, 3H), 1.34 – 1.26 (m, 0.5H), 1.23 (dd, $J = 6.5, 15.3, 3\text{H}$), 0.71 (dd, $J = 5.0, 6.5, 3\text{H}$); MS (ESI+) m/z 531 ($\text{M}+\text{H}$)⁺.

5

Example 119

***N*-{(3*aR*,4*S*,6*aS*)-2-[5,5-bis(4-fluorophenyl)pentyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide**

The title compound was prepared by substituting 5,5-bis(4-fluorophenyl)pentanal for 3-(trifluoromethyl)benzaldehyde and 3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide from Example 83 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.61 (s, 1H), 7.66 (dd, $J = 4.3, 7.3, 2\text{H}$), 7.37 – 7.30 (m, 5H), 7.25 (dd, $J = 5.6, 13.1, 2\text{H}$), 7.19 – 7.11 (m, 4H), 4.38 – 4.29 (m, 1H), 3.96 (dd, $J = 7.9, 18.0, 1\text{H}$), 3.25 (d, $J = 10.5, 1\text{H}$), 2.96 (d, $J = 10.4, 0.5\text{H}$), 2.72 – 2.62 (m, 1H), 2.62 – 2.57 (m, .50H), 2.56 – 2.51 (m, 0.5H), 2.50 – 2.45 (m, 0.5H), 2.43 – 2.36 (m, 1H), 2.36 – 2.31 (m, 1H), 2.30 – 2.26 (m, 1H), 2.23 – 2.06 (m, 3H), 2.07 – 1.96 (m, 2H), 1.86 (dt, $J = 6.0, 12.2, 1\text{H}$), 1.81 – 1.72 (m, 1H), 1.66 (dt, $J = 7.0, 19.1, 1\text{H}$), 1.56 – 1.49 (m, 1H), 1.48 – 1.40 (m, 1H), 1.38 – 1.26 (m, 3H), 1.23 (dd, $J = 6.5, 9.7, 3\text{H}$), 0.71 (dd, $J = 2.5, 6.7, 3\text{H}$); MS (ESI+) m/z 545 ($\text{M}+\text{H}$)⁺.

20

Example 120

***N*-[(3*aS*,4*S*,6*aR*)-2-benzhydryloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide**

Potassium iodide (12.48 mg, 0.075 mmol) and sodium carbonate (80 mg, 0.752 mmol) were combined with methyl ethyl ketone (5mL) and then 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide (200 mg, 0.601 mmol) from Example 53 was added followed by the addition of (bromomethylene)dibenzene (124 mg, 0.501 mmol). The reaction was heated overnight at 90 °C. The reaction mixture was concentrated with a stream of nitrogen and then purified by silica gel chromatography eluting with 2-10% methanol (2 *N* ammonia)/dichloromethane to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.74 (dd, $J = 6.7, 15.4, 1\text{H}$), 7.61 (t, $J = 6.7, 3\text{H}$), 7.35 (t, $J = 7.6, 4\text{H}$), 7.28 – 7.23 (m, 3H), 4.42 (dt, $J = 7.4, 14.4, 1\text{H}$), 4.16 (s, 1H), 2.96 (qd, $J = 4.2, 8.0, 1\text{H}$), 2.63 (dd, $J = 4.1, 9.8, 1\text{H}$), 2.57 – 2.48 (m, 1H), 2.42 (dt, $J = 9.4, 14.6, 2\text{H}$), 2.33 (dd, $J = 3.7, 9.3, 1\text{H}$), 2.09 – 1.90 (m, 3H), 1.90 – 1.80 (m, 3H), 1.79 – 1.70 (m, 4H), 1.69 – 1.55

30

(m, 6H), 1.46 (d, $J = 14.7$, 1H), 1.39 (s, 1H), 1.33 – 1.00 (m, 8H), 1.00 – 0.89 (m, 1H); MS (ESI+) m/z 499 (M+H)⁺.

Example 121

5 ***N*-[(3*aS*,4*R*,6*aR*)-2-benzhydryloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide**

The title compound was prepared by substituting 2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide from Example 74 for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for
 10 Example 120: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.11 (d, $J = 7.2$, 1H), 7.64 (d, $J = 7.1$, 2H), 7.32 (t, $J = 7.6$, 4H), 7.20 – 7.15 (m, 4H), 4.55 – 4.48 (m, 1H), 4.21 (s, 1H), 2.81 (dd, $J = 2.9$, 9.4, 1H), 2.63 – 2.57 (m, 1H), 2.57 – 2.51 (m, 1H), 2.41 (dd, $J = 7.0$, 9.2, 1H), 2.36 – 2.24 (m, 3H), 2.01 (t, $J = 7.4$, 1H), 1.99 – 1.90 (m, 3H), 1.86 (ddd, $J = 3.3$, 8.1, 15.4, 2H), 1.82 – 1.76 (m, 2H), 1.70 (ddd, $J = 8.9$, 13.9, 15.3, 5H), 1.63 – 1.55 (m, 2H), 1.51 – 1.37 (m,
 15 3H), 1.28 – 1.01 (m, 8H); MS (ESI+) m/z 499 (M+H)⁺.

Example 122

3-methyl-2-phenyl-*N*-{(3*aS,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide**

Step A: (3-(Trifluoromethyl)phenyl)methanamine (25 g, 143 mmol),
 20 (chloromethyl)trimethylsilane (19.92 mL, 143 mmol), and triethylamine (23.87 mL, 171 mmol) were combined neat and the resultant mixture was refluxed overnight. The reaction was cooled to room temperature and 150 mL of heptane was added. The HCl salts were removed by filtration and washed with heptane. The solvent was removed by placing under
 25 house vacuum and then high vacuum. *N*-(3-(Trifluoromethyl)benzyl)-1-(trimethylsilyl)methanamine was isolated by vacuum distillation (bp 70-90 °C/3.2 torr): ¹H NMR (300 MHz, CDCl₃) δ ppm 7.59 (s, 1H), 7.53 – 7.38 (m, 3H), 3.86 (s, 2H), 2.04 (s, 2H), 1.34 (s, 1H), 0.06 (s, 9H).

Step B: Formaldehyde (4.08 g, 50.2 mmol) and methanol (2.032 mL, 50.2 mmol)
 30 were combined, and the mixture was cooled to 0 °C (ice bath). *N*-(3-(trifluoromethyl)benzyl)-1-(trimethylsilyl)methanamine (10.94 g, 41.9 mmol) was added dropwise via addition funnel over 30 minutes. Potassium carbonate (4.63 g, 33.5 mmol) was added, and the reaction stirred at 0 °C for 2 additional hours. The reaction product was decanted from the potassium carbonate, treated with more potassium carbonate, and decanted

again. The potassium carbonate solids were washed several times with ether, and these washes were added to the product solution. The solvent was removed in vacuo to give 1-methoxy-*N*-(3-(trifluoromethyl)benzyl)-*N*-((trimethylsilyl)methyl)methanamine which was used directly in the next step.

5 **Step C:** Cyclopent-2-enone (3.31 g, 40.4 mmol) and trifluoroacetic acid (0.031 mL, 0.404 mmol) were combined in dichloromethane (40 mL). 1-Methoxy-*N*-(3-(trifluoromethyl)benzyl)-*N*-((trimethylsilyl)methyl)methanamine (12.33 g, 40.4 mmol) from Step B was added as a solution in 10 mL of dichloromethane dropwise via addition funnel over 45 minutes at room temperature under nitrogen. The reaction was quenched with
10 aqueous sodium bicarbonate and extracted with 2×100 mL of dichloromethane. The organic washes were combined and washed with brine. The solvent was removed in vacuo to give 2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.54 – 7.34 (m, 4H), 3.66 (d, *J* = 13.4, 1H), 3.52 (d, *J* = 13.4, 1H), 3.04 (dd, *J* = 1.8, 8.9, 1H), 2.91 (ddd, *J* = 2.8, 7.4, 11.7, 1H), 2.72 – 2.65 (m, 1H), 2.62 (d, *J* = 8.9, 1H),
15 2.52 – 2.23 (m, 4H), 2.15 (ddd, *J* = 8.1, 12.9, 17.1, 1H), 1.85 – 1.70 (m, 1H).

Step D: Hydroxylamine hydrochloride (3.47 g, 50.0 mmol) and sodium acetate (4.27 g, 52.0 mmol) were dissolved in 15 mL of water and added to a solution of 2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one (11.33 g, 40 mmol) from Step C in ethanol (80 mL). The reaction was brought to reflux for 5 minutes and allowed to
20 cool to 70 °C. After 1 hour, the reaction mixture was cooled, and the solvent was removed in vacuo to give (*E*)-2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one oxime which was used without additional purification in the next step.

Step E: (*E*)-2-(3-(Trifluoromethyl)benzyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one oxime (11.9 g, 39.9 mmol) from Step D in 20% ammonia-methanol (115 mL) was added to
25 methanol-washed Raney®-nickel, (water-wet, 38.52 g, 295 mmol) in a 500 mL pressure bottle. The vessel was pressurized with hydrogen (30 psi), and the mixture was shaken for 16 hours at ambient temperature. The mixture was filtered through a nylon membrane, the solvent was removed in vacuo, and the crude material was adsorbed onto silica gel. Silica gel chromatography using a cartridge (Analogix®, Burlington, Wisconsin, SF65-400) eluting
30 with 1-10% methanol (2 *N* ammonia)/dichloromethane gave the following diastereomers. (3*aS**,4*R**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine: ¹H NMR (300 MHz, pyridine-*d*₅) δ ppm 7.58 (s, 1H), 7.50 (t, *J* = 6.7, 2H), 7.45 – 7.37 (m, 1H), 3.59 (s, 2H), 3.26 (dt, *J* = 6.3, 12.6, 1H), 2.67 – 2.50 (m, 4H), 2.38 (dd, *J* = 6.6, 8.4, 1H), 2.31 – 2.20 (m, 1H), 1.79 – 1.62 (m, 2H), 1.60 – 1.33 (m, 4H); and

(3a*S**,4*S**,6a*R**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine: ¹H NMR (300 MHz, pyridine-*d*₅) δ ppm 7.58 (s, 1H), 7.50 (t, *J* = 7.2, 2H), 7.45 – 7.37 (m, 1H), 3.59 (s, 2H), 3.09 (dd, *J* = 4.9, 11.4, 1H), 2.77 – 2.57 (m, *J* = 3.9, 1H), 2.52 – 2.38 (m, 3H), 2.34 (dd, *J* = 3.7, 9.0, 1H), 2.22 – 2.09 (m, 1H), 2.03 – 1.85 (m, *J* = 4.7, 7.0, 10.8, 2H), 1.42 – 1.21 (m, 4H).

Step F: The title compound was prepared by substituting 3-methyl-2-phenylbutanoic acid for 1-phenylcyclopentanecarboxylic acid and (3a*S**,4*S**,6a*R**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step E for (3a*S**,6a*R**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.23 (d, *J* = 6.9, 0.5H), 8.13 (d, *J* = 7.1, 0.5H), 7.73 (s, 0.5H), 7.67 (s, 0.5H), 7.63 (dd, *J* = 6.7, 8.0, 2H), 7.56 – 7.53 (m, 1H), 7.50 (t, *J* = 8.5, 2H), 7.38 – 7.22 (m, 3H), 4.45 – 4.38 (m, 0.5H), 4.33 – 4.26 (m, 0.5H), 3.50 (s, 1H), 3.44 (d, *J* = 13.4, 0.5H), 3.21 (d, *J* = 13.4, 0.5H), 3.17 (d, *J* = 10.5, 0.5H), 3.10 (d, *J* = 10.5, 0.5H), 2.91 (qd, *J* = 3.4, 7.9, 0.5H), 2.79 (dd, *J* = 3.4, 9.5, 0.5H), 2.74 – 2.56 (m, 1.5H), 2.47 – 2.31 (m, 2.5H), 2.27 (dd, *J* = 3.1, 8.9, 0.5H), 2.21 (d, *J* = 2.7, 0.5H), 1.98 – 1.93 (m, 0.5H), 1.89 – 1.79 (m, 0.5H), 1.74 – 1.56 (m, 1.5H), 1.53 – 1.46 (m, 0.5H), 1.46 – 1.39 (m, 0.5H), 1.30 – 1.23 (m, 1H), 1.19 (d, *J* = 6.5, 1.5H), 1.17 – 1.11 (m, 0.5H), 1.08 (d, *J* = 6.5, 1.5H), 0.72 (dd, *J* = 6.7, 9.6, 3H); MS (ESI+) *m/z* 445 (M+H)⁺.

Example 123

3,3-dimethyl-2-phenyl-*N*-{(3a*S**,4*S**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide

The title compound was prepared by substituting 3,3-dimethyl-2-phenylbutanoic acid for 1-phenylcyclopentanecarboxylic acid and (3a*S**,4*S**,6a*R**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3a*S**,6a*R**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.32 (d, *J* = 6.7, 0.5H), 8.13 (d, *J* = 7.1, 0.5H), 7.74 – 7.70 (m, 1H), 7.69 – 7.66 (m, 1H), 7.61 (t, *J* = 8.6, 3H), 7.48 – 7.43 (m, 1H), 7.37 – 7.24 (m, 3H), 4.48 – 4.39 (m, 0.5H), 4.36 – 4.28 (m, 0.5H), 3.51 (q, *J* = 13.1, 0.5H), 3.41 (d, *J* = 17.1, 1H), 3.35 (d, *J* = 13.3, 0.5H), 3.13 (d, *J* = 13.4, 0.5H), 2.98 (qd, *J* = 4.0, 8.2, 0.5H), 2.81 (dd, *J* = 3.9, 9.5, 0.5H), 2.74 (ddd, *J* = 3.4, 7.8, 16.6, 0.5H), 2.49 – 2.37 (m, 2H), 2.31 (dd, *J* = 3.4, 9.6, 0.5H), 2.24 – 2.15 (m, 2H), 2.01 – 1.94 (m, 0.5H), 1.84 (ddd, *J* = 8.1, 11.7, 14.5, 0.5H), 1.73 – 1.65 (m, 1H), 1.64 – 1.56 (m, 0.5H), 1.52 – 1.38 (m, 1H), 1.27 (dt, *J* = 5.6, 12.2, 1H), 1.16 (s, 4.5H), 1.11 (s, 4.5H); MS (ESI+) *m/z* 459 (M+H)⁺.

Example 124**2,2-dicyclohexyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide**

5 The title compound was prepared by substituting 2,2-dicyclohexylacetic acid for 1-phenylcyclopentanecarboxylic acid and (3*aS**,4*S**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3*aS**,6*aR**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 7.73 (s, 1H), 7.65 (d, *J* = 7.6, 1H), 7.57
10 – 7.44 (m, 3H), 4.46 (dt, *J* = 6.4, 12.6, 1H), 3.55 (d, *J* = 12.9, 1H), 3.47 (d, *J* = 12.8, 1H), 2.75 (d, *J* = 8.1, 2H), 2.53 – 2.39 (m, 2H), 2.32 (t, *J* = 8.2, 1H), 2.21 (t, *J* = 8.3, 1H), 1.97 – 1.53 (m, 15H), 1.50 – 1.04 (m, 11H), 0.98 (dd, *J* = 11.3, 23.1, 1H); MS (ESI+) *m/z* 491 (M+H)⁺.

15

Example 125**2-ethyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide**

The title compound was prepared by substituting 2-ethylbutanoic acid for 1-phenylcyclopentanecarboxylic acid and (3*aS**,4*S**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3*aS**,6*aR**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.90 (d, *J* = 6.7, 1H), 7.71 (s, 1H), 7.61
20 (d, *J* = 7.7, 1H), 7.54 (d, *J* = 7.7, 1H), 7.46 (t, *J* = 7.7, 1H), 4.51 – 4.43 (m, 1H), 3.49 (s, 2H), 2.83 (ddd, *J* = 2.9, 7.8, 16.8, 1H), 2.75 (dd, *J* = 2.9, 9.5, 1H), 2.52 – 2.43 (m, 1H), 2.37 (dd, *J* = 2.9, 9.1, 1H), 2.35 – 2.30 (m, 1H), 2.25 (dd, *J* = 7.6, 9.4, 1H), 2.01 (tt, *J* = 4.8, 9.5, 1H),
25 1.89 (dt, *J* = 7.3, 11.6, 1H), 1.77 (ddt, *J* = 7.5, 9.3, 15.2, 2H), 1.70 – 1.60 (m, 2H), 1.51 – 1.37 (m, 2H), 1.34 – 1.26 (m, 1H), 0.95 (t, *J* = 7.4, 3H), 0.83 (t, *J* = 7.4, 3H); MS (ESI+) *m/z* 383 (M+H)⁺.

30

Example 126**2-propyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}pentanamide**

The title compound was prepared by substituting 2-propylpentanoic acid for 1-phenylcyclopentanecarboxylic acid and (3*aS**,4*S**,6*aR**)-2-(3-

(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3a*S**,6a*R**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.94 (d, *J* = 6.9, 1H), 7.72 (s, 1H), 7.62 (d, *J* = 7.7, 1H), 7.56 (d, *J* = 7.7, 1H), 7.47 (t, *J* = 7.7, 1H), 4.48 (dt, *J* = 7.3, 14.6, 1H), 3.52 (d, *J* = 13.0, 1H), 3.48 (d, *J* = 13.0, 1H), 2.84 (ddd, *J* = 3.0, 7.7, 16.7, 1H), 2.74 (dd, *J* = 3.1, 9.5, 1H), 2.52 – 2.45 (m, 1H), 2.38 – 2.34 (m, 2H), 2.27 (dd, *J* = 7.6, 9.5, 1H), 2.22 (td, *J* = 4.6, 9.5, 1H), 1.90 (dt, *J* = 7.3, 11.5, 1H), 1.84 – 1.75 (m, 2H), 1.73 – 1.61 (m, 2H), 1.48 – 1.27 (m, 6H), 1.20 – 1.08 (m, 1H), 0.88 (t, *J* = 7.0, 3H), 0.83 (t, *J* = 7.1, 3H); MS (ESI+) *m/z* 411 (M+H)⁺.

10

Example 127

N-{(3a*S**,4*S**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}cyclohexanecarboxamide

The title compound was prepared by substituting cyclohexanecarboxylic acid for 1-phenylcyclopentanecarboxylic acid and (3a*S**,4*S**,6a*R**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3a*S**,6a*R**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.74 (d, *J* = 6.1, 1H), 7.71 (s, 1H), 7.62 (d, *J* = 7.7, 1H), 7.57 (d, *J* = 9.2, 1H), 7.47 (t, *J* = 7.7, 1H), 4.48 – 4.41 (m, 1H), 3.53 (d, *J* = 13.2, 1H), 3.47 (d, *J* = 13.2, 1H), 2.84 (ddd, *J* = 2.8, 7.9, 10.3, 1H), 2.75 (dd, *J* = 2.8, 9.5, 1H), 2.51 – 2.43 (m, 1H), 2.37 (dd, *J* = 2.8, 9.1, 1H), 2.34 – 2.29 (m, 1H), 2.27 – 2.19 (m, 2H), 1.94 – 1.83 (m, 2H), 1.80 (d, *J* = 12.9, 1H), 1.73 – 1.60 (m, 6H), 1.57 – 1.51 (m, 1H), 1.35 – 1.27 (m, 1H), 1.22 – 1.10 (m, 3H); MS (ESI+) *m/z* 395 (M+H)⁺.

25

Example 128

N-{(3a*S**,4*S**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}cycloheptanecarboxamide

The title compound was prepared by substituting cycloheptanecarboxylic acid for 1-phenylcyclopentanecarboxylic acid and (3a*S**,4*S**,6a*R**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3a*S**,6a*R**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.79 (d, *J* = 6.9, 1H), 7.71 (s, 1H), 7.62 (d, *J* = 7.7, 1H), 7.56 (s, 1H), 7.47 (t, *J* = 7.7, 1H), 4.48 – 4.40 (m, 1H), 3.54 (d, *J* = 13.2, 1H), 3.46 (d, *J* = 13.2, 1H), 2.86 (ddd, *J* = 3.0, 7.8, 16.6, 1H), 2.76 (dd, *J* = 3.0, 9.5, 1H), 2.51

30

– 2.39 (m, 2H), 2.37 – 2.30 (m, 2H), 2.26 (dd, $J = 7.5, 9.4$, 1H), 2.00 – 1.80 (m, 5H), 1.75 – 1.60 (m, 4H), 1.49 – 1.41 (m, 4H), 1.33 (ddt, $J = 7.2, 8.9, 12.1$, 3H); MS (ESI+) m/z 409 (M+H)⁺.

5

Example 129***N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}cyclopentanecarboxamide**

The title compound was prepared by substituting cyclopentanecarboxylic acid for 1-phenylcyclopentanecarboxylic acid and (3*aS**,4*S**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3*aS**,6*aR**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.82 (d, $J = 6.9$, 1H), 7.71 (s, 1H), 7.61 (d, $J = 7.7$, 1H), 7.55 (d, $J = 7.7$, 1H), 7.46 (t, $J = 7.7$, 1H), 4.48 – 4.41 (m, 1H), 4.07 (q, $J = 7.1$, 1H), 2.82 (ddd, $J = 2.9, 7.8, 16.7$, 1H), 2.72 (dd, $J = 2.9, 9.5$, 1H), 2.66 (p, $J = 7.9$, 1H), 2.50 – 2.42 (m, 1H), 2.37 (dd, $J = 2.9, 9.0$, 1H), 2.34 – 2.29 (m, 1H), 2.21 (dd, $J = 7.5, 9.4$, 1H), 2.03 (dt, $J = 7.0, 15.3$, 1H), 1.86 (dddd, $J = 7.4, 12.3, 20.5, 23.4$, 3H), 1.75 – 1.60 (m, 5H), 1.53 – 1.41 (m, 2H), 1.30 (td, $J = 4.7, 11.1$, 1H), 1.11 (t, $J = 7.1$, 1H); MS (ESI+) m/z 381 (M+H)⁺.

20

Example 130**6,6-bis(4-fluorophenyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}hexanamide**

The title compound was prepared by substituting 6,6-bis(4-fluorophenyl)hexanoic acid for 1-phenylcyclopentanecarboxylic acid and (3*aS**,4*S**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3*aS**,6*aR**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.99 (d, $J = 7.1$, 1H), 7.69 (s, 1H), 7.58 (s, 1H), 7.54 (d, $J = 7.6$, 1H), 7.42 (dd, $J = 6.9, 14.5$, 1H), 7.26 (dd, $J = 5.5, 8.6$, 4H), 7.14 – 7.08 (m, 4H), 4.51 – 4.41 (m, 1H), 3.91 (t, $J = 7.8$, 1H), 3.47 (d, $J = 2.3$, 2H), 2.84 (qd, $J = 3.0, 8.0$, 1H), 2.69 (dd, $J = 3.1, 9.5$, 1H), 2.53 – 2.43 (m, 1H), 2.38 – 2.20 (m, 5H), 1.99 (dd, $J = 7.8, 15.6$, 2H), 1.89 – 1.78 (m, 3H), 1.70 – 1.59 (m, 2H), 1.37 – 1.25 (m, 3H); MS (ESI+) m/z 571 (M+H)⁺.

Example 131**3,3-diphenyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}propanamide**

The title compound was prepared by substituting 3,3-diphenylpropanoic acid for 1-phenylcyclopentanecarboxylic acid and (3*aS**,4*S**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3*aS**,6*aR**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.10 (d, *J* = 7.0, 1H), 7.72 (s, 1H), 7.62 (d, *J* = 7.8, 1H), 7.48 (t, *J* = 7.7, 1H), 7.39 (dd, *J* = 2.6, 7.5, 5H), 7.26 (dt, *J* = 7.6, 15.1, 5H), 7.17 (dd, *J* = 6.2, 13.5, 2H), 4.38 – 4.27 (m, 1H), 3.54 (d, *J* = 13.4, 1H), 3.38 (d, *J* = 13.4, 1H), 3.15 – 3.09 (m, 2H), 2.75 (qd, *J* = 3.6, 7.9, 1H), 2.44 – 2.35 (m, 2H), 2.32 (t, *J* = 8.3, 1H), 2.20 (dd, *J* = 3.3, 8.9, 1H), 2.08 (dd, *J* = 7.8, 9.5, 1H), 1.70 (t, *J* = 7.9, 1H), 1.58 – 1.46 (m, 2H), 1.18 – 1.10 (m, 1H); MS (ESI+) *m/z* 493 (M+H)⁺.

Example 132**5,5-bis(4-fluorophenyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}pentanamide**

The title compound was prepared by substituting 5,5-bis(4-fluorophenyl)pentanoic acid for 1-phenylcyclopentanecarboxylic acid and (3*aS**,4*S**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3*aS**,6*aR**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.06 (d, *J* = 7.0, 1H), 7.70 (s, 1H), 7.60 (d, *J* = 8.0, 1H), 7.54 (d, *J* = 7.7, 1H), 7.44 (t, *J* = 7.7, 1H), 7.26 (dd, *J* = 5.6, 8.4, 4H), 7.08 (td, *J* = 1.2, 8.8, 4H), 4.51 – 4.42 (m, 1H), 3.96 (t, *J* = 7.8, 1H), 2.86 (qd, *J* = 3.2, 7.9, 1H), 2.69 (dd, *J* = 3.2, 9.5, 1H), 2.52 – 2.43 (m, 1H), 2.43 – 2.29 (m, 5H), 2.24 (dd, *J* = 7.7, 9.4, 1H), 2.15 – 2.06 (m, 3H), 1.85 (dt, *J* = 9.9, 17.8, 1H), 1.76 (dt, *J* = 7.3, 15.3, 2H), 1.70 – 1.59 (m, 2H), 1.33 – 1.26 (m, 1H); MS (ESI+) *m/z* 557 (M+H)⁺.

Example 133**3,3-bis(4-fluorophenyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}propanamide**

The title compound was prepared by substituting 3,3-bis(4-fluorophenyl)propanoic acid for 1-phenylcyclopentanecarboxylic acid and (3*aS**,4*S**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for

(3a*S**,6a*R**)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.13 (d, *J* = 7.0, 1H), 7.71 (s, 1H), 7.61 (d, *J* = 7.7, 1H), 7.56 (s, 1H), 7.47 (t, *J* = 7.7, 1H), 7.32 (ddd, *J* = 3.7, 5.4, 8.8, 4H), 7.11 – 7.02 (m, 4H), 4.94 (d, *J* = 8.0, 1H), 4.39 – 4.25 (m, 1H), 3.52 (d, *J* = 13.4, 1H), 3.41 (d, *J* = 13.4, 1H), 3.06 (d, *J* = 7.9, 2H), 2.76 (qd, *J* = 3.4, 7.9, 1H), 2.43 (dd, *J* = 3.3, 9.5, 2H), 2.31 (t, *J* = 8.3, 1H), 2.23 (dd, *J* = 3.1, 9.0, 1H), 2.10 (dd, *J* = 7.8, 9.4, 1H), 1.76 – 1.67 (m, 1H), 1.59 – 1.49 (m, 2H), 1.22 – 1.11 (m, 1H); MS (ESI+) *m/z* 529 (M+H)⁺.

Example 134

10 4,4-bis(4-fluorophenyl)-*N*-{(3a*S**,4*S**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide

The title compound was prepared by substituting 4,4-bis(4-fluorophenyl)butanoic acid for 1-phenylcyclopentanecarboxylic acid and (3a*S**,4*S**,6a*R**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3a*S**,6a*R**)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.16 (d, *J* = 6.9, 1H), 7.66 (s, 1H), 7.58 (s, 1H), 7.50 (d, *J* = 7.7, 1H), 7.38 (t, *J* = 7.7, 1H), 7.28 (dd, *J* = 5.5, 7.3, 4H), 7.10 – 7.02 (m, 4H), 4.49 (dt, *J* = 7.6, 14.7, 1H), 4.10 (t, *J* = 7.9, 1H), 3.50 (d, *J* = 13.4, 1H), 3.42 (d, *J* = 13.4, 1H), 2.92 (qd, *J* = 3.6, 7.9, 1H), 2.67 (dd, *J* = 3.5, 9.5, 1H), 2.55 (dd, *J* = 7.2, 15.0, 2H), 2.52 – 2.46 (m, 1H), 2.40 (t, *J* = 8.3, 1H), 2.36 – 2.24 (m, 4H), 1.91 – 1.82 (m, 1H), 1.71 (td, *J* = 5.8, 11.3, 1H), 1.67 – 1.60 (m, 1H), 1.35 – 1.27 (m, 1H); MS (ESI+) *m/z* 543 (M+H)⁺.

Example 135

25 2,2-diphenyl-*N*-{(3a*S**,4*S**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide

The title compound was prepared by substituting 2,2-diphenylacetic acid for 1-phenylcyclopentanecarboxylic acid and (3a*S**,4*S**,6a*R**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3a*S**,6a*R**)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.50 (s, 1H), 7.71 (d, *J* = 7.5, 2H), 7.63 (d, *J* = 7.2, 2H), 7.45 (d, *J* = 7.4, 2H), 7.39 – 7.28 (m, 5H), 7.25 (dd, *J* = 5.8, 8.9, 3H), 4.51 – 4.42 (m, 1H), 3.44 (d, *J* = 13.3, 1H), 3.25 (d, *J* = 13.3, 1H), 2.85 (qd, *J* = 3.2, 7.9, 1H), 2.59 (dd, *J* = 3.4, 9.5, 1H), 2.47 – 2.37 (m, 1H), 2.26 (t, *J* = 8.3, 1H), 2.21 – 2.13 (m, 2H), 1.85 – 1.76 (m, 1H), 1.67 – 1.52 (m, 3H), 1.27 – 1.18 (m, 1H); MS (ESI+) *m/z* 479 (M+H)⁺.

Example 136**2,2-bis(4-fluorophenyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide**

The title compound was prepared by substituting 2,2-bis(4-fluorophenyl)acetic acid for 1-phenylcyclopentanecarboxylic acid and (3*aS**,4*S**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3*aS**,6*aR**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.68 (d, *J* = 7.0, 1H), 7.64 (s, 1H), 7.60 (t, *J* = 6.4, 1H), 7.57 – 7.54 (m, 2H), 7.52 – 7.43 (m, 4H), 7.17 – 7.07 (m, 4H), 4.48 – 4.41 (m, 1H), 3.46 (d, *J* = 13.3, 1H), 3.30 (d, *J* = 13.3, 1H), 2.90 (qd, *J* = 3.5, 8.0, 1H), 2.59 (dd, *J* = 3.5, 9.5, 1H), 2.50 – 2.42 (m, 1H), 2.32 (t, *J* = 8.3, 1H), 2.25 – 2.19 (m, 3H), 1.87 – 1.77 (m, 1H), 1.66 (td, *J* = 5.7, 11.4, 1H), 1.62 – 1.54 (m, 1H), 1.29 – 1.20 (m, 1H); MS (ESI+) *m/z* 515 (M+H)⁺.

Example 137***N*²-(*tert*-butoxycarbonyl)-*N*¹-{(3*aR**,4*R**,6*aS**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-L-leucine for 1-phenylcyclopentanecarboxylic acid and (3*aS**,4*S**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3*aS**,6*aR**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in Example the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.50 (d, *J* = 7.1, 0.5H), 8.46 (d, *J* = 6.8, 0.5H), 8.03 (dd, *J* = 8.2, 17.0, 1H), 7.74 (s, 1H), 7.71 (d, *J* = 7.7, 0.5H), 7.61 (d, *J* = 6.5, 0.5H), 7.47 (t, *J* = 7.7, 1H), 4.67 (dd, *J* = 8.2, 14.1, 0.5H), 4.61 (dd, *J* = 8.1, 14.7, 0.5H), 4.53 – 4.39 (m, 1H), 3.81 (d, *J* = 13.1, 0.5H), 3.70 (d, *J* = 13.3, 0.5H), 3.44 (d, *J* = 13.3, 0.5H), 3.29 (d, *J* = 13.2, 0.5H), 2.93 – 2.86 (m, 1H), 2.85 – 2.74 (m, 1H), 2.46 (d, *J* = 4.1, 1H), 2.39 – 2.21 (m, 3H), 1.96 – 1.76 (m, 5H), 1.73 – 1.55 (m, 2H), 1.50 (s, 4.5H), 1.50 (s, 4.5H), 1.34 – 1.23 (m, 1H), 0.91 – 0.82 (m, 6H); MS (ESI+) *m/z* 498 (M+H)⁺.

Example 138 **N^2 -(tert-butyloxycarbonyl)- N^1 -{(3a*S**,4*S**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-D-leucine
 5 for 1-phenylcyclopentanecarboxylic acid and (3a*S**,4*S**,6a*R**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3a*S**,6a*R**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.50 (d, *J* = 7.0, 0.5H), 8.46 (d, *J* = 6.8, 0.5H), 8.03 (dd, *J* = 8.1, 17.2, 1H), 7.74 (s, 1H), 7.71 (d, *J* = 7.7, 1H), 7.61 (d, *J* = 5.8, 1H),
 10 7.48 (t, *J* = 7.7, 1H), 4.67 (dd, *J* = 8.3, 14.3, 0.5H), 4.61 (dd, *J* = 7.9, 14.5, 0.5H), 4.47 (ddd, *J* = 7.0, 13.9, 17.8, 1H), 3.81 (d, *J* = 13.1, 0.5H), 3.70 (d, *J* = 13.1, 0.5H), 3.44 (d, *J* = 13.3, 0.5H), 3.29 (d, *J* = 13.2, 0.5H), 2.89 (t, *J* = 13.2, 1H), 2.85 – 2.75 (m, 1H), 2.51 – 2.42 (m, 1H), 2.39 – 2.30 (m, 1H), 2.28 (dd, *J* = 6.1, 15.3, 2H), 1.97 – 1.77 (m, 4H), 1.73 – 1.55 (m, 2H), 1.50 (s, 4.5H), 1.50 (s, 4.5H), 1.34 – 1.22 (m, 1H), 0.91 – 0.81 (m, 6H); MS (ESI+) *m/z*
 15 498 (M+H)⁺.

Example 139 **N^2 -(tert-butyloxycarbonyl)- N^2 -methyl- N^1 -{(3a*S**,4*S**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-D-leucine for 1-phenylcyclopentanecarboxylic acid and (3a*S**,4*S**,6a*R**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3a*S**,6a*R**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 1: ¹H NMR (300 MHz, pyridine-*d*₅) δ ppm 7.76 (d, *J* = 15.9, 2H), 7.57 (s, 3H), 7.54 – 7.43 (m, 1H), 7.42 – 7.36 (m, 0.5H), 7.34 – 7.21 (m, 1H), 4.86 (t, *J* = 9.6, 0.5H), 4.48 – 4.35 (m, 0.5H), 3.71 (d, *J* = 13.3, 0.5H), 3.52 (d, *J* = 13.4, 0.5H), 3.40 (d, *J* = 13.2, 0.5H),
 25 2.98 (s, 1.5H), 2.97 (s, 1.5H), 2.77 (ddd, *J* = 2.0, 7.2, 9.8, 2H), 2.57 – 2.46 (m, 1H), 2.43 (dd, *J* = 2.9, 9.2, 0.5H), 2.36 (dd, *J* = 2.3, 6.4, 0.5H), 2.34 – 2.22 (m, 2H), 1.93 (dddd, *J* = 2.0, 6.2, 8.1, 14.3, 1H), 1.85 – 1.59 (m, 4H), 1.52 (s, 4.5H), 1.50 (s, 4.5H), 1.39 – 1.28 (m, 1H), 0.96 –
 30 0.89 (m, 6H); MS (ESI+) *m/z* 512 (M+H)⁺.

Example 140**6,6-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}hexanamide**

The title compound was prepared by substituting 6,6-bis(4-fluorophenyl)hexanoic acid for 1-phenylcyclopentanecarboxylic acid and (3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-amine from Example 122 Step E for (3aS*,6aR*)-2-benzyl octahydrocyclopenta[c]pyrrol-4-amine in the procedure described for Example 2: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.31 (d, *J* = 7.3, 1H), 7.77 (s, 1H), 7.61 (t, *J* = 7.4, 1H), 7.57 (d, *J* = 7.2, 1H), 7.45 (t, *J* = 7.7, 1H), 7.25 (dd, *J* = 5.6, 8.2, 4H), 7.10 (t, *J* = 8.7, 4H), 4.46 – 4.37 (m, 1H), 3.90 (t, *J* = 7.8, 1H), 3.61 (d, *J* = 13.5, 1H), 3.47 (d, *J* = 13.5, 1H), 2.85 – 2.79 (m, 1H), 2.49 (d, *J* = 16.3, 2H), 2.47 – 2.41 (m, 1H), 2.30 (ddd, *J* = 8.1, 15.0, 20.0, 4H), 2.15 – 2.06 (m, 1H), 1.98 (dd, *J* = 7.8, 15.5, 2H), 1.90 – 1.79 (m, 3H), 1.60 (dt, *J* = 7.4, 19.3, 1H), 1.44 – 1.36 (m, 1H), 1.32 (dq, *J* = 7.8, 15.3, 2H); MS (ESI+) *m/z* 571 (M+H)⁺.

Example 141**3,3-diphenyl-N-{(3aS*,4R*,6aR*)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}propanamide**

The title compound was prepared by substituting 3,3-diphenylpropanoic acid for 1-phenylcyclopentanecarboxylic acid and (3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-amine from Example 122 Step E for (3aS*,6aR*)-2-benzyl octahydrocyclopenta[c]pyrrol-4-amine in the procedure described for Example 2: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.28 (d, *J* = 7.4, 1H), 7.74 (s, 1H), 7.45 (t, *J* = 7.7, 1H), 7.38 (dd, *J* = 1.8, 7.4, 4H), 7.28 (dt, *J* = 7.6, 9.4, 4H), 7.20 – 7.17 (m, 4H), 5.00 (t, *J* = 7.8, 1H), 4.34 – 4.26 (m, 1H), 3.56 (d, *J* = 13.5, 1H), 3.43 (d, *J* = 13.5, 1H), 3.14 (d, *J* = 7.9, 2H), 2.65 (dd, *J* = 2.1, 8.3, 1H), 2.45 – 2.36 (m, 1H), 2.36 – 2.28 (m, 2H), 2.26 – 2.19 (m, 2H), 1.98 – 1.89 (m, 1H), 1.72 (ddd, *J* = 6.3, 12.5, 14.5, 1H), 1.43 (dt, *J* = 7.4, 14.1, 1H), 1.34 – 1.25 (m, 1H); MS (ESI+) *m/z* 493 (M+H)⁺.

Example 142**5,5-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide**

The title compound was prepared by substituting 5,5-bis(4-fluorophenyl)pentanoic acid for 1-phenylcyclopentanecarboxylic acid and (3aS*,4R*,6aR*)-2-(3-

(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3a*S**,6a*R**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 2: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.36 (d, *J* = 7.2, 1H), 7.75 (s, 1H), 7.62 – 7.54 (m, 2H), 7.44 (t, *J* = 7.7, 1H), 7.24 (dt, *J* = 5.7, 11.3, 4H), 7.07 (t, *J* = 8.7, 4H), 4.47 – 4.39 (m, 1H), 3.96 (t, *J* = 7.8, 1H), 3.59 (d, *J* = 13.5, 1H), 3.46 (d, *J* = 13.5, 1H), 2.84 (d, *J* = 9.0, 1H), 2.51 (s, 2H), 2.42 (dd, *J* = 7.0, 14.2, 3H), 2.30 (d, *J* = 7.1, 1H), 2.27 – 2.22 (m, 1H), 2.15 – 2.06 (m, 3H), 1.85 (dd, *J* = 6.2, 13.9, 1H), 1.78 (dt, *J* = 7.4, 15.1, 2H), 1.60 (dt, *J* = 7.6, 14.6, 1H), 1.43 – 1.34 (m, 1H); MS (ESI+) *m/z* 557 (M+H)⁺.

10

Example 143**3,3-bis(4-fluorophenyl)-*N*-{(3a*S**,4*R**,6a*R**)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}propanamide**

The title compound was prepared by substituting 3,3-bis(4-fluorophenyl)propanoic acid for 1-phenylcyclopentanecarboxylic acid and (3a*S**,4*R**,6a*R**)-2-(3-

15

(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3a*S**,6a*R**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 2: : ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.36 (d, *J* = 7.4, 1H), 7.74 (s, 1H), 7.62 – 7.56 (m, 2H), 7.45 (t, *J* = 7.7, 1H), 7.32 (ddd, *J* = 2.0, 5.4, 7.8, 4H), 7.07 (dt, *J* = 8.7, 11.2, 4H), 4.36 – 4.26 (m, 1H), 3.56 (d, *J* = 13.5, 1H), 3.45 (d, *J* = 13.5, 1H), 3.09 (d, *J* = 7.9, 2H), 2.70 – 2.63 (m, 1H), 2.47 – 2.37 (m, 1H), 2.33 (t, *J* = 6.7, 3H), 2.26 (dd, *J* = 3.0, 9.0, 1H), 2.24 – 2.18 (m, 1H), 1.96 (tt, *J* = 6.0, 11.8, 1H), 1.79 – 1.70 (m, 1H), 1.44 (dt, *J* = 7.6, 14.4, 1H), 1.35 – 1.26 (m, 1H); MS (ESI+) *m/z* 529 (M+H)⁺.

20

Example 144**4,4-bis(4-fluorophenyl)-*N*-{(3a*S**,4*R**,6a*R**)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide**

The title compound was prepared by substituting 4,4-bis(4-fluorophenyl)butanoic acid for 1-phenylcyclopentanecarboxylic acid and (3a*S**,4*R**,6a*R**)-2-(3-

(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3a*S**,6a*R**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for

30

Example 2: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.39 (d, *J* = 7.2, 1H), 7.77 (s, 1H), 7.62 (d, *J* = 7.9, 2H), 7.45 (t, *J* = 7.7, 1H), 7.25 (dd, *J* = 5.5, 7.3, 4H), 7.05 (t, *J* = 8.7, 4H), 4.50 – 4.40 (m, 1H), 4.08 (t, *J* = 7.9, 1H), 3.61 (d, *J* = 13.5, 1H), 3.49 (d, *J* = 13.5, 1H), 2.87 (dd, *J* = 1.4, 8.8, 1H), 2.56 (dd, *J* = 7.7, 15.3, 4H), 2.48 (d, *J* = 8.8, 1H), 2.31 (dd, *J* = 8.0, 15.4, 4H),

2.13 (dq, $J = 6.0, 12.0$, 1H), 1.87 (td, $J = 6.3, 12.5$, 1H), 1.62 (dt, $J = 7.4, 14.3$, 1H), 1.41 (dd, $J = 11.7, 20.8$, 1H); MS (ESI+) m/z 543 (M+H)⁺.

Example 145

5 **2,2-diphenyl-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide**

The title compound was prepared by substituting 2,2-diphenylacetic acid for 1-phenylcyclopentanecarboxylic acid and (3*aS**,4*R**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for
 10 (3*aS**,6*aR**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 2: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.94 (d, $J = 6.8$, 1H), 7.74 (s, 2H), 7.64 (d, $J = 7.8$, 4H), 7.47 – 7.40 (m, 1H), 7.38 – 7.29 (m, 5H), 7.28 – 7.23 (m, 3H), 4.45 – 4.37 (m, 1H), 3.57 (d, $J = 13.5$, 1H), 3.42 (d, $J = 13.5$, 1H), 2.76 (dd, $J = 3.0, 9.1$, 1H), 2.54 – 2.47 (m, 1H), 2.47 – 2.42 (m, 1H), 2.39 (dd, $J = 7.3, 9.0$, 1H), 2.23 (d, $J = 3.0$, 2H), 2.06 (dq, $J =$
 15 6.2, 12.2, 1H), 1.83 – 1.74 (m, 1H), 1.59 (dt, $J = 6.9, 14.5$, 1H), 1.33 (dt, $J = 6.3, 19.6$, 1H); MS (ESI+) m/z 479 (M+H)⁺.

Example 146

20 **2,2-bis(4-fluorophenyl)-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide**

The title compound was prepared by substituting 2,2-bis(4-fluorophenyl)acetic acid for 1-phenylcyclopentanecarboxylic acid and (3*aS**,4*R**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for
 25 (3*aS**,6*aR**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 2: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.07 (d, $J = 7.1$, 1H), 7.74 (s, 1H), 7.59 (s, 1H), 7.56 (d, $J = 5.3$, 5H), 7.44 (t, $J = 7.7$, 1H), 7.12 (q, $J = 8.6$, 4H), 5.23 (s, 1H), 4.45 – 4.36 (m, 1H), 3.57 (d, $J = 13.5$, 1H), 3.44 (d, $J = 13.5$, 1H), 2.78 (dd, $J = 2.9, 9.1$, 1H), 2.56 – 2.49 (m, 1H), 2.49 – 2.44 (m, 1H), 2.41 (dd, $J = 7.3, 8.9$, 1H), 2.27 – 2.22 (m, 2H), 2.07 (dq, $J = 6.1, 12.1$, 1H), 1.86 – 1.76 (m, 1H), 1.60 (td, $J = 7.2, 14.6$, 1H), 1.35 (td, $J = 6.3, 12.6$,
 30 1H); MS (ESI+) m/z 515 (M+H)⁺.

Example 147**3,3-dimethyl-2-phenyl-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide**

The title compound was prepared by substituting 3,3-dimethyl-2-phenylbutanoic acid for 1-phenylcyclopentanecarboxylic acid and (3*aS**,4*R**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3*aS**,6*aR**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 2: ¹H NMR (400 MHz,) δ ppm 8.47 (t, *J* = 6.7, 1H), 7.77 (s, 0.5H), 7.71 (d, *J* = 7.3, 2H), 7.60 (d, *J* = 7.7, 0.5H), 7.54 (s, 1H), 7.43 (dd, *J* = 8.1, 16.6, 1H), 7.35 – 7.24 (m, 4H), 4.39 – 4.29 (m, 1H), 3.62 (d, *J* = 13.6, 0.5H), 3.53 (d, *J* = 13.5, 0.5H), 3.47 (d, *J* = 13.6, 0.5H), 3.44 (s, 1H), 3.38 (d, *J* = 13.5, 0.5H), 2.92 (dd, *J* = 2.9, 9.0, 0.5H), 2.62 – 2.54 (m, 1H), 2.54 – 2.46 (m, 1H), 2.46 – 2.36 (m, 0.5H), 2.32 (dd, *J* = 9.1, 12.0, 1H), 2.27 (d, *J* = 5.2, 1H), 2.21 (d, *J* = 5.6, 1H), 2.17 – 2.07 (m, 0.5H), 1.86 (ddd, *J* = 6.4, 13.3, 21.3, 1H), 1.71 (tdd, *J* = 6.4, 13.0, 19.3, 1H), 1.36 (ddt, *J* = 8.2, 14.4, 20.6, 1.5H), 1.14 (d, *J* = 1.3, 9H); MS (ESI+) *m/z* 459 (M+H)⁺.

Example 148***N*²-(*tert*-butoxycarbonyl)-*N*¹-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-L-leucine for 1-phenylcyclopentanecarboxylic acid and (3*aS**,4*R**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E for (3*aS**,6*aR**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described for Example 2: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.66 (dd, *J* = 7.6, 11.3, 1H), 7.98 (d, *J* = 6.0, 1H), 7.74 (d, *J* = 7.5, 1H), 7.58 (d, *J* = 21.6, 2H), 7.44 (t, *J* = 7.8, 1H), 4.74 – 4.66 (m, 1H), 4.45 – 4.36 (m, 1H), 3.58 (t, *J* = 13.6, 1H), 3.43 (dd, *J* = 13.6, 20.1, 1H), 2.81 (s, 0.5H), 2.73 (s, 0.5H), 2.57 (s, 0.5H), 2.47 (d, *J* = 9.1, 2H), 2.34 (s, 0.5H), 2.26 (d, *J* = 6.7, 1H), 2.24 – 2.20 (m, 0.5H), 2.11 (s, 1H), 2.07 – 1.99 (m, 0.5H), 1.87 (s, 4H), 1.71 – 1.62 (m, 0.5H), 1.61 – 1.55 (m, 0.5H), 1.50 (d, *J* = 2.8, 9H), 1.40 (s, 1H), 0.87 (d, *J* = 5.8, 3H), 0.84 (d, *J* = 5.5, 3H); MS (ESI+) *m/z* 498 (M+H)⁺.

Example 149 **N^2 -(tert-butyloxycarbonyl)- N^1 -{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-D-leucine
 5 for 1-phenylcyclopentanecarboxylic acid and (3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-amine from Example 122 Step E for (3aS*,6aR*)-2-benzyl octahydrocyclopenta[c]pyrrol-4-amine in the procedure described for Example 2: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.66 (dd, *J* = 7.4, 11.1, 1H), 7.97 (d, *J* = 6.0, 1H), 7.74 (d, *J* = 7.6, 1H), 7.57 (d, *J* = 10.9, 2H), 7.44 (dd, *J* = 5.9, 13.6, 1H), 4.74 – 4.66
 10 (m, 1H), 4.41 (dd, *J* = 6.2, 11.5, 1H), 3.58 (t, *J* = 13.4, 1H), 3.43 (dd, *J* = 13.6, 19.7, 1H), 2.82 (dd, *J* = 2.4, 9.0, 0.5H), 2.74 (d, *J* = 8.7, 0.5H), 2.62 – 2.54 (m, 0.5H), 2.54 – 2.43 (m, 2H), 2.37 – 2.32 (m, 0.5H), 2.27 (d, *J* = 6.7, 1H), 2.24 – 2.19 (m, 0.5H), 2.16 – 2.08 (m, 0.5H), 2.06 – 1.99 (m, 0.5H), 1.94 – 1.78 (m, 4.5H), 1.66 (dt, *J* = 7.2, 19.6, 0.5H), 1.62 – 1.56 (m, 0.5H), 1.50 (d, *J* = 2.9, 9H), 1.43 – 1.31 (m, 1H), 0.86 (dd, *J* = 5.7, 13.5, 6H); MS (ESI+) *m/z* 498 (M+H)⁺.
 15

Example 150 **N^2 -(tert-butyloxycarbonyl)- N^2 -methyl- N^1 -{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-D-leucine for 1-phenylcyclopentanecarboxylic acid and (3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-amine from Example 122 Step E for (3aS*,6aR*)-2-benzyl octahydrocyclopenta[c]pyrrol-4-amine in the procedure described for Example 2: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.31 (s, 1H), 7.75 (s, 1H), 7.57 (d, *J* = 11.6, 2H), 7.44 (t, *J* = 7.7, 1H), 5.18 – 5.09 (m, 0.5H), 4.84 – 4.73 (m, 0.5H), 4.44 – 4.32 (m, 1H), 3.59 (d, *J* = 13.5, 1H), 3.47 (d, *J* = 13.6, 1H), 3.07 (d, *J* = 25.1, 2.5H), 2.83 (d, *J* = 8.5, 0.5H), 2.79 – 2.72 (m, 0.5H), 2.55 – 2.44 (m, 2H), 2.44 – 2.39 (m, 1H), 2.37 – 2.33 (m, 0.5H), 2.29 (d, *J* = 7.4, 1H), 2.23 (dd, *J* = 7.9, 15.2, 1H), 2.08 (dt, *J* = 5.2, 11.8, 1H), 1.88 – 1.78 (m, 3H), 1.64 – 1.51 (m, 2H), 1.46 (s, 9H), 1.41 – 1.33 (m, 1H), 0.88 (d, *J* = 6.4, 3H),
 25 0.84 (d, *J* = 6.5, 3H); MS (ESI+) *m/z* 512 (M+H)⁺.
 30

Example 151***N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-(*tert*-butyloxycarbonyl)-*N*²-methyl-L-leucinamide**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-leucine for 1-phenylcyclopentanecarboxylic acid in the procedure described for Example 2:

¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.28 (d, *J* = 6.6, 1H), 7.41 (s, 2H), 7.38 – 7.34 (m, 2H), 7.27 (t, *J* = 7.3, 1H), 5.16 – 5.11 (m, 0.5H), 4.82 – 4.74 (m, 0.5H), 4.44 – 4.33 (m, 1H), 3.57 (s, 1H), 3.46 – 3.38 (m, 1H), 3.07 (d, *J* = 26.9, 3H), 2.89 – 2.82 (m, 0.5H), 2.80 – 2.73 (m, 1H), 2.50 – 2.43 (m, 2H), 2.40 – 2.29 (m, 2H), 2.24 – 2.19 (m, 1H), 2.10 (dq, *J* = 5.8, 11.6, 1H), 1.92 – 1.87 (m, 0.5H), 1.83 (dd, *J* = 5.2, 9.3, 2H), 1.64 – 1.51 (m, 2H), 1.46 (s, 9H), 1.42 – 1.35 (m, 1H), 0.88 (d, *J* = 6.3, 3H), 0.84 (d, *J* = 6.6, 3H); MS (ESI+) *m/z* 444 (M+H)⁺.

Example 152**2,2-dicyclohexyl-2-hydroxy-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide**

Step A: (3*aS*,4*S*,6*aR*)-2-(3-(Trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine was prepared according to the procedure described in Example 14 Step A-C. Substituting 2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one from Steps A-C in Example 122 for 2-benzylhexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one in Step A of Example 14 gave (*S,E*)-2-methyl-*N*-((3*aR*,6*aS*)-2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)propane-2-sulfinamide and (*S,E*)-2-methyl-*N*-((3*aS*,6*aR*)-2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)propane-2-sulfinamide.

(*S,E*)-2-Methyl-*N*-((3*aS*,6*aR*)-2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)propane-2-sulfinamide was used as described in Example 14 Steps B-C to give (3*aS*,4*S*,6*aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.72 (s, 1H), 7.59 (d, *J* = 12.2, 1H), 7.54 (d, *J* = 7.7, 1H), 7.39 (t, *J* = 7.7, 1H), 3.71 – 3.66 (m, 1H), 3.64 (d, *J* = 13.3, 1H), 3.49 (d, *J* = 13.3, 1H), 3.22 (dd, *J* = 3.7, 9.9, 1H), 2.77 (qd, *J* = 3.8, 7.9, 1H), 2.49 (dd, *J* = 8.9, 16.7, 2H), 2.39 (t, *J* = 8.3, 1H), 2.29 (dd, *J* = 3.4, 9.0, 1H), 2.10 (ddd, *J* = 6.1, 9.7, 15.6, 1H), 1.90 (td, *J* = 5.9, 12.0, 1H), 1.69 – 1.60 (m, 1H), 1.42 (dt, *J* = 5.6, 12.2, 1H); MS (ESI+) *m/z* 284 (M+H)⁺.

Step B: The title compound was prepared by substituting 2,2-dicyclohexyl-2-hydroxyacetic acid for 3-methyl-2-phenylbutanoic acid and (3*aS*,4*S*,6*aR*)-2-(3-

(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step A for (3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Step D of Example 14: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.45 (br s, 1H), 7.85 (s, 1H), 7.75 (d, *J* = 7.4, 1H), 7.54 (d, *J* = 7.6, 1H), 7.36 (dd, *J* = 5.4, 13.2, 1H), 5.93 (br s, 1H), 4.64 – 4.57 (m, 1H), 3.85 (d, *J* = 13.2, 1H), 3.29 (d, *J* = 13.2, 1H), 2.92 (d, *J* = 9.5, 1H), 2.66 (dd, *J* = 7.4, 15.2, 1H), 2.49 – 2.41 (m, 1H), 2.39 (d, *J* = 9.1, 1H), 2.24 – 2.01 (m, 5H), 1.96 – 1.83 (m, 4H), 1.83 – 1.70 (m, 6H), 1.63 (t, *J* = 13.2, 2H), 1.58 – 1.49 (m, 1H), 1.45 – 1.08 (m, 10H); MS (ESI+) *m/z* 507 (M+H)⁺.

10

Example 153

***N*²-(*tert*-butoxycarbonyl)-*N*²-methyl-*N*¹-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-L-leucinamide**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-leucine for 3-methyl-2-phenylbutanoic acid and (3*aS*,4*S*,6*aR*)-2-(3-

15

(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from 152 Step A for (3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Step D of Example 14: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.01 (s, 1H), 7.83 (s, 1H), 7.76 (s, 1H), 7.64 (d, *J* = 7.7, 2H), 5.12 – 5.04 (m, 1H), 4.42 (s, 1H), 3.61 (s, 1H), 3.52 (s, 1H), 3.12 – 2.97 (m, 3H), 2.78 (s, 1H), 2.72 (d, *J* = 9.5, 1H), 2.50 – 2.41 (m, 1H), 2.37 (d, *J* = 7.3, 1H), 2.32 – 2.16 (m, 2H), 1.98 – 1.72 (m, 3H), 1.64 (dt, *J* = 6.8, 14.9, 1H), 1.60 – 1.53 (m, 2H), 1.50 (s, 9H), 1.33 – 1.20 (m, 1H), 0.89 (d, *J* = 6.5, 6H); MS (ESI+) *m/z* 512 (M+H)⁺.

20

Example 154

2,2-dicyclohexyl-2-hydroxy-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide

25

Step A: (3*aS*,4*R*,6*aR*)-2-(3-(Trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine was prepared according to the procedure described in Example 16 Steps A-E substituting (*S,E*)-2-methyl-*N*-((3*aS*,6*aR*)-2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)propane-2-sulfinamide from Step A in Example 152 for (*S,E*)-*N*-((3*aS*,6*aR*)-2-benzylhexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)-2-methylpropane-2-sulfinamide in Step A-E of Example 16 to give (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.78 (s, 1H), 7.59 (d, *J* = 6.0, 2H), 7.45 (t, *J* = 7.7, 1H), 4.94 (br s, 2H), 3.53 (s, 2H), 3.13 (dd, *J* = 5.1, 11.6, 1H), 2.63 – 2.54 (m, 1H), 2.49 (dd, *J* = 3.3,

30

9.0, 1H), 2.35 (dd, $J = 7.5$, 9.0, 1H), 2.32 (d, $J = 5.9$, 2H), 2.21 – 2.13 (m, 1H), 1.96 (dt, $J = 6.0$, 8.7, 1H), 1.88 (td, $J = 3.9$, 9.7, 1H), 1.38 – 1.29 (m, 2H); MS (ESI+) m/z 284 (M+H)⁺.

Step B: The title compound was prepared by substituting (3a*S*,4*R*,6a*R*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step A for

5 (3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and 2,2-dicyclohexyl-2-hydroxyacetic acid for (*S*)-2-phenylbutanoic acid in the procedure described in Step F of Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.75 (s, 1H), 7.70 (d, $J = 7.8$, 1H), 7.63 – 7.54 (m, 1H), 7.44 (t, $J = 7.7$, 1H), 6.25 – 6.09 (m, 1H), 4.45 – 4.37 (m, 1H), 3.61 (d, $J = 13.5$, 1H), 3.44 (d, $J = 13.5$, 1H), 2.91 (dd, $J = 2.1$, 9.0, 1H), 2.58 – 2.46 (m, 1H), 2.40 (dd, $J = 7.1$, 8.8, 1H), 2.33 (dd, $J = 2.3$, 8.9, 1H), 2.22 (dd, $J = 7.0$, 8.7, 1H), 2.19 – 2.04 (m, 5H), 1.94 – 1.82 (m, 4H), 1.82 – 1.71 (m, 4H), 1.63 (s, 3H), 1.58 – 1.46 (m, 1H), 1.37 (s, 4H), 1.25 (s, 7H); MS (ESI+) m/z 507 (M+H)⁺.

Example 155

15 ***N*²-(tert-butyloxycarbonyl)-*N*²-methyl-*N*¹-{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide**

The title compound was prepared by substituting (3a*S*,4*R*,6a*R*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 154 Step A for (3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine and *N*-(tert-butoxycarbonyl)-*N*-methyl-L-leucine for (*S*)-2-phenylbutanoic acid in the procedure described in Step F of Example 16: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.30 (s, 1H), 7.74 (s, 1H), 7.57 (d, $J = 9.4$, 2H), 7.44 (t, $J = 7.7$, 1H), 5.21 – 5.04 (m, 1H), 4.37 (s, 1H), 3.58 (d, $J = 12.2$, 1H), 3.44 (d, $J = 13.8$, 1H), 3.07 (d, $J = 25.6$, 3H), 2.77 (d, $J = 8.6$, 1H), 2.47 (s, 2H), 2.41 – 2.32 (m, 1H), 2.29 (d, $J = 7.2$, 1H), 2.25 – 2.18 (m, 1H), 2.08 (dq, $J = 5.8$, 11.7, 1H), 1.83 (dd, $J = 5.4$, 9.0, 3H), 1.64 – 1.52 (m, 2H), 1.46 (s, 9H), 1.41 – 1.32 (m, 1H), 0.88 (d, $J = 6.3$, 3H), 0.84 (d, $J = 6.5$, 3H); MS (ESI+) m/z 512 (M+H)⁺.

Example 156

30 **2,2-dicyclohexyl-*N*-{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide**

Step A: (3a*R*,4*S*,6a*S*)-2-(3-(Trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine was prepared according to the procedure described in Example 16 Step A-E substituting (*S,E*)-2-methyl-*N*-((3a*R*,6a*S*)-2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)propane-2-sulfinamide

from Example 152 Step A for (*S,E*)-*N*-((3*aS*,6*aR*)-2-benzylhexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)-2-methylpropane-2-sulfinamide prepared in Step A of Example 14 to give (3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.78 (s, 1H), 7.59 (d, *J* = 11.1, 2H), 7.45 (t, *J* = 7.7, 1H), 4.94 (br s, 2H), 3.14 (dd, *J* = 5.2, 11.5, 1H), 2.58 (tt, *J* = 5.1, 10.1, 1H), 2.49 (dd, *J* = 3.3, 9.0, 1H), 2.35 (dd, *J* = 7.5, 9.0, 1H), 2.31 (d, *J* = 5.8, 2H), 2.21 – 2.14 (m, 1H), 2.01 – 1.91 (m, 1H), 1.88 (td, *J* = 4.2, 9.9, 1H), 1.38 – 1.29 (m, 2H).

Step B: The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step A for (3*aS*,4*R*,6*aR*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine and 2,2-dicyclohexylacetic acid for (*S*)-2-phenylbutanoic acid in the procedure described for Example 16 Step F: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.13 (d, *J* = 7.2, 1H), 7.76 (s, 1H), 7.63 – 7.53 (m, 2H), 7.44 (t, *J* = 7.9, 1H), 4.51 – 4.43 (m, 1H), 3.61 (d, *J* = 13.5, 1H), 3.46 (d, *J* = 13.5, 1H), 2.88 (dd, *J* = 2.8, 9.0, 1H), 2.63 – 2.52 (m, 2H), 2.49 (dd, *J* = 7.1, 8.9, 1H), 2.32 – 2.27 (m, 2H), 2.13 (dq, *J* = 6.1, 11.9, 1H), 2.03 (t, *J* = 7.4, 1H), 1.96 (d, *J* = 13.0, 2H), 1.92 – 1.83 (m, 3H), 1.80 (d, *J* = 12.2, 2H), 1.75 – 1.68 (m, 4H), 1.67 – 1.63 (m, 1H), 1.63 – 1.57 (m, 2H), 1.50 – 1.37 (m, 3H), 1.30 – 1.18 (m, 4H), 1.12 (dtd, *J* = 2.7, 12.5, 24.6, 4H); MS (ESI+) *m/z* 491 (M+H)⁺.

Example 157

2,2-dicyclohexyl-*N*-{(3*aR*,4*R*,6*aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide

Step A: (3*aR*,4*R*,6*aS*)-2-(3-(Trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine was prepared according to the procedure described in Example 14 Steps B-C substituting (*S,E*)-2-methyl-*N*-((3*aR*,6*aS*)-2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)propane-2-sulfinamide from Example 152 Step A for (*S,E*)-*N*-((3*aS*,6*aR*)-2-benzylhexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)-2-methylpropane-2-sulfinamide prepared in Step A of Example 14 to give (3*aR*,4*R*,6*aS*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.78 (s, 1H), 7.59 (d, *J* = 11.1, 2H), 7.45 (t, *J* = 7.7, 1H), 4.94 (br s, 2H), 3.14 (dd, *J* = 5.2, 11.5, 1H), 2.58 (tt, *J* = 5.1, 10.1, 1H), 2.49 (dd, *J* = 3.3, 9.0, 1H), 2.35 (dd, *J* = 7.5, 9.0, 1H), 2.31 (d, *J* = 5.8, 2H), 2.21 – 2.14 (m, 1H), 2.00 – 1.92 (m, 1H), 1.88 (td, *J* = 4.2, 9.9, 1H), 1.39 – 1.29 (m, 2H); MS (ESI+) *m/z* 284 (M+H)⁺.

Step B: The title compound was prepared by substituting 2,2-dicyclohexylacetic acid for 3-methyl-2-phenylbutanoic acid in and (3*aR*,4*R*,6*aS*)-2-(3-

(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step A for (3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Step D of Example 14: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.73 (s, 1H), 7.66 (d, *J* = 7.7, 1H), 7.55 (d, *J* = 7.3, 2H), 7.50 (t, *J* = 7.7, 1H), 4.50 – 4.43 (m, 1H), 3.54 (d, *J* = 12.9, 1H), 3.46 (d, *J* = 12.9, 1H), 2.74 (td, *J* = 2.6, 10.5, 2H), 2.51 – 2.42 (m, 2H), 2.31 (t, *J* = 8.3, 1H), 2.20 (dd, *J* = 7.8, 9.8, 1H), 1.94 – 1.54 (m, 15H), 1.46 (d, *J* = 13.0, 1H), 1.40 (d, *J* = 14.4, 1H), 1.35 – 1.07 (m, 9H), 0.98 (qd, *J* = 3.0, 12.3, 1H); MS (ESI+) *m/z* 491 (M+H)⁺.

Example 158

10 *N*¹-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide

*N*²-(*tert*-butyloxycarbonyl)-*N*¹-{(3*aR**,4*R**,6*aS**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide (140 mg, 0.281 mmol) from Example 137 and 2 *N* HCl (2.5 mL, 5.00 mmol) were combined in ether, and the reaction was stirred at room temperature overnight. The solids were collected and dried to give the title compound as the hydrochloride salt: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.59 (s, 0.5H), 8.48 (s, 0.5H), 7.89 (s, 0.5H), 7.83 (s, 0.5H), 7.69 (t, *J* = 6.8, 1H), 7.60 (d, *J* = 7.8, 1H), 7.50 – 7.44 (m, 1H), 4.96 (br s, 2H), 4.57 – 4.48 (m, 1H), 3.73 (d, *J* = 13.2, 0.5H), 3.67 (s, 1H), 3.64 (d, *J* = 13.2, 1H), 3.39 (d, *J* = 13.1, 0.5H), 3.35 (d, *J* = 13.2, 0.5H), 2.81 – 2.70 (m, 2H), 2.45 (dd, *J* = 7.5, 15.3, 1H), 2.39 – 2.31 (m, 1H), 2.27 – 2.14 (m, 2H), 1.95 – 1.79 (m, 2.5H), 1.72 – 1.56 (m, 2H), 1.53 – 1.46 (m, 0.5H), 1.33 – 1.23 (m, 1.5H), 0.90 (dt, *J* = 6.2, 14.1, 6H); MS (ESI+) *m/z* 398 (M+H)⁺.

Example 159

25 *N*¹-{(3*aR**,4*R**,6*aS**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide

The title compound was prepared by substituting *N*²-(*tert*-butyloxycarbonyl)-*N*¹-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide from Example 138 for *N*²-(*tert*-butyloxycarbonyl)-*N*¹-{(3*aR**,4*R**,6*aS**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide in the procedure described for Example 158: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.67 (d, *J* = 7.4, 0.5H), 8.57 (d, *J* = 7.6, 0.5H), 7.88 (s, 0.5H), 7.81 (s, 0.5H), 7.68 (d, *J* = 7.3, 1H), 7.61 (s, 1H), 7.48 (dd, *J* = 7.3, 14.5, 1H), 4.56 – 4.47 (m, 1H), 3.79 – 3.70 (m, 1H), 3.65 (d, *J* = 13.2, 0.5H), 3.38 (t, *J* = 13.5, 1H), 2.82 – 2.71 (m, 2H), 2.50 – 2.42 (m, 1H), 2.38 – 2.31 (m, 1H), 2.27 –

2.16 (m, 2H), 2.08 (dt, $J = 6.8, 19.9, 0.5\text{H}$), 1.96 – 1.88 (m, 1.5H), 1.88 – 1.80 (m, 1H), 1.70 – 1.59 (m, 2H), 1.58 – 1.52 (m, 0.5H), 1.42 – 1.20 (m, 4H), 0.90 (dt, $J = 6.1, 13.2, 6\text{H}$); MS (ESI+) m/z 398 (M+H)⁺.

5

Example 160

N^2 -methyl- N^1 -{(3a*S,4*S**,6a*R**)-2-[3-**

(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide

The title compound was prepared by substituting N^2 -(*tert*-butyloxycarbonyl)- N^2 -methyl- N^1 -{(3a*S**,4*S**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide from Example 139 for N^2 -(*tert*-butyloxycarbonyl)- N^1 -{(3a*R**,4*R**,6a*S**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide in the procedure described for Example 158: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.52 (s, 0.5H), 8.29 (s, 0.5H), 7.92 (s, 0.5H), 7.79 (s, 0.5H), 7.69 (dd, $J = 7.6, 18.7, 1\text{H}$), 7.62 (d, $J = 7.6, 1\text{H}$), 7.48 (dd, $J = 7.8, 18.2, 1\text{H}$), 4.59 – 4.48 (m, 1H), 3.82 (d, $J = 13.2, 0.5\text{H}$), 3.63 (d, $J = 13.1, 0.5\text{H}$), 3.42 (d, $J = 13.1, 0.5\text{H}$), 3.31 – 3.18 (m, 1H), 2.81 (dd, $J = 1.9, 9.4, 0.5\text{H}$), 2.74 (dd, $J = 8.5, 18.2, 1\text{H}$), 2.50 – 2.43 (m, 1H), 2.41 (s, 1.5H), 2.40 (s, 1.5H), 2.33 (dd, $J = 1.9, 9.0, 0.5\text{H}$), 2.25 (dd, $J = 7.3, 9.4, 0.5\text{H}$), 2.21 – 2.03 (m, 1.5H), 1.92 – 1.81 (m, 2H), 1.80 – 1.48 (m, 4H), 1.42 – 1.21 (m, 3.5H), 0.94 (d, $J = 6.6, 1.5\text{H}$), 0.93 (d, $J = 6.6, 1.5\text{H}$), 0.90 (d, $J = 6.6, 1.5\text{H}$), 0.87 (d, $J = 6.6, 1.5\text{H}$); MS (ESI+) m/z 412 (M+H)⁺.

20

Example 161

N^1 -{(3a*S,4*R**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide**

The title compound was prepared by substituting N^2 -(*tert*-butyloxycarbonyl)- N^1 -{(3a*S**,4*R**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide from Example 148 for N^2 -(*tert*-butyloxycarbonyl)- N^1 -{(3a*R**,4*R**,6a*S**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide in the procedure described for Example 158: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.33 (s, 1H), 7.76 (s, 1H), 7.63 – 7.58 (m, 2H), 7.45 (d, $J = 4.3, 1\text{H}$), 4.40 (dd, $J = 6.5, 12.5, 1\text{H}$), 3.63 – 3.53 (m, 1H), 3.46 (dd, $J = 6.1, 13.6, 1\text{H}$), 2.82 – 2.73 (m, 1H), 2.69 – 2.51 (m, 2H), 2.48 – 2.38 (m, 1H), 2.33 (dd, $J = 8.8, 16.3, 1\text{H}$), 2.24 (dd, $J = 7.6, 16.5, 1\text{H}$), 2.16 – 1.88 (m, 5H), 1.85 (dt, $J = 7.8, 15.2, 0.5\text{H}$), 1.76 – 1.62 (m, 1H), 1.39 (qd, $J = 6.6, 14.9, 1.5\text{H}$), 1.31 – 1.20 (m, 2H), 0.95 (d, $J = 6.0, 3\text{H}$), 0.91 (dd, $J = 3.2, 5.6, 3\text{H}$); MS (ESI+) m/z 398 (M+H)⁺.

30

Example 162 **N^1 -{(3a*S**,4*R**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-
D-leucinamide**

The title compound was prepared by substituting N^2 -(*tert*-butyloxycarbonyl)- N^1 -
 5 {(3a*S**,4*R**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-
 leucinamide from Example 149 for N^2 -(*tert*-butyloxycarbonyl)- N^1 -{(3a*R**,4*R**,6a*S**)-2-[3-
 (trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide in the procedure
 described for Example 158: ^1H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.31 (s, 1H), 7.75 (s,
 1H), 7.62 – 7.53 (m, 2H), 7.44 (dd, $J = 7.4, 15.0$, 1H), 4.44 – 4.35 (m, 1H), 3.60 (d, $J = 13.5$,
 10 2H), 3.46 (dd, $J = 5.5, 13.5$, 1H), 2.87 – 2.79 (m, 1H), 2.57 – 2.43 (m, 2H), 2.42 – 2.37 (m,
 1H), 2.32 (dt, $J = 3.0, 8.8$, 1H), 2.27 – 2.20 (m, 1H), 2.08 (td, $J = 6.0, 12.2$, 1H), 1.96 – 1.80
 (m, 3H), 1.61 – 1.50 (m, 2H), 1.44 – 1.35 (m, 1H), 1.30 – 1.19 (m, 2H), 0.90 (d, $J = 6.2$, 3H),
 0.85 (d, $J = 6.2$, 3H); MS (ESI+) m/z 398 (M+H)⁺.

15

Example 163 **N^2 -methyl- N^1 -{(3a*S**,4*R**,6a*R**)-2-[3-
(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide**

The title compound was prepared by substituting N^2 -(*tert*-butyloxycarbonyl)- N^2 -
 methyl- N^1 -{(3a*S**,4*R**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-
 20 yl}-D-leucinamide from Example 150 for N^2 -(*tert*-butyloxycarbonyl)- N^1 -{(3a*R**,4*R**,6a*S**)-
 2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide in the
 procedure described for Example 158: ^1H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.32 (d, $J =$
 6.0, 1H), 7.76 (s, 1H), 7.61 (d, $J = 7.6$, 1H), 7.55 (d, $J = 14.8$, 1H), 7.45 (t, $J = 7.7$, 1H), 4.47
 – 4.40 (m, 1H), 3.61 (d, $J = 13.5$, 1H), 3.47 (dd, $J = 3.1, 13.6$, 1H), 3.30 (t, $J = 6.7$, 1H), 2.86
 25 (d, $J = 8.9$, 1H), 2.59 – 2.51 (m, 1H), 2.46 (d, $J = 2.5$, 3H), 2.42 (dd, $J = 8.5, 15.4$, 1H), 2.35 –
 2.30 (m, 1H), 2.28 – 2.23 (m, 1H), 2.14 – 2.05 (m, 1H), 1.93 – 1.82 (m, 2H), 1.74 (ddd, $J =$
 4.0, 9.7, 13.7, 1H), 1.62 (dt, $J = 7.4, 15.4$, 1H), 1.40 (dt, $J = 14.2, 15.7$, 1H), 1.3 – 1.22 (m,
 3H), 0.91 (dt, $J = 3.0, 6.0$, 3H), 0.85 (d, $J = 6.7$, 3H); MS (ESI+) m/z 412 (M+H)⁺.

30

Example 164 **N^2 -methyl- N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-
(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide**

The title compound was prepared by substituting N^2 -(*tert*-butyloxycarbonyl)- N^2 -
 methyl- N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-

L-leucinamide from Example 153 for N^2 -(*tert*-butyloxycarbonyl)- N^1 -{(3*aR**,4*R**,6*aS**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide in the procedure described for Example 158: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.56 (d, $J = 7.4$, 1H), 7.91 (s, 1H), 7.67 (d, $J = 7.6$, 1H), 7.61 (d, $J = 7.8$, 1H), 7.47 (t, $J = 7.7$, 1H), 4.54 (dt, $J = 6.6$, 13.2, 1H), 3.81 (d, $J = 13.2$, 1H), 3.32 (dd, $J = 6.0$, 7.9, 1H), 3.28 (d, $J = 13.2$, 1H), 2.81 (d, $J = 9.5$, 1H), 2.78 – 2.71 (m, 1H), 2.48 – 2.44 (m, 1H), 2.42 (s, 3H), 2.33 (d, $J = 9.1$, 1H), 2.26 (dd, $J = 7.4$, 9.3, 1H), 2.16 – 2.11 (m, 1H), 1.91 – 1.83 (m, 2H), 1.82 – 1.75 (m, 1H), 1.65 (ddq, $J = 6.3$, 12.1, 18.8, 3H), 1.26 (td, $J = 6.2$, 12.7, 1H), 0.95 (d, $J = 6.5$, 3H), 0.90 (d, $J = 6.6$, 3H); MS (ESI+) m/z 412 ($\text{M}+\text{H}$) $^+$.

10

Example 165 **N^1 -[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-leucinamide**

The title compound was prepared by substituting N^1 -[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -(*tert*-butyloxycarbonyl)- N^2 -methyl-L-leucinamide from Example 151 for N^2 -(*tert*-butyloxycarbonyl)- N^1 -{(3*aR**,4*R**,6*aS**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide in the procedure described for Example 158: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.35 (d, $J = 6.9$, 1H), 7.44 (d, $J = 7.4$, 2H), 7.37 (t, $J = 7.6$, 2H), 7.27 (t, $J = 7.3$, 1H), 4.50 – 4.42 (m, 1H), 3.61 (d, $J = 13.1$, 1H), 3.45 (d, $J = 13.2$, 1H), 3.33 (t, $J = 7.0$, 1H), 2.87 (d, $J = 8.7$, 1H), 2.56 – 2.50 (m, 1H), 2.47 (s, 3H), 2.43 (dd, $J = 5.5$, 14.6, 1H), 2.37 (d, $J = 8.7$, 1H), 2.29 – 2.23 (m, 1H), 2.17 – 2.04 (m, 1H), 1.94 – 1.82 (m, 2H), 1.79 – 1.73 (m, 1H), 1.68 – 1.57 (m, 1H), 1.41 (dd, $J = 7.2$, 13.5, 1H), 1.27 (s, 2H), 0.92 (d, $J = 6.6$, 3H), 0.85 (d, $J = 6.6$, 3H); MS (ESI+) m/z 344 ($\text{M}+\text{H}$) $^+$.

25

Example 166 **N^2 -methyl- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide**

The title compound was prepared by substituting N^2 -(*tert*-butyloxycarbonyl)- N^2 -methyl- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide from Example 155 for N^2 -(*tert*-butyloxycarbonyl)- N^1 -{(3*aR**,4*R**,6*aS**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide in the procedure described for Example 158: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.09 – 7.97 (m, 1H), 7.76 (s, 1H), 7.63 – 7.61 (m, 1H), 7.45 (d, $J = 7.6$, 1H), 7.42 (d, $J = 7.6$, 1H), 4.49 – 4.40 (m, 1H), 3.60 (d, $J = 12.4$, 1H), 3.47 (d, $J = 13.6$, 1H), 2.87 (d, $J = 7.6$, 1H), 2.59 (d, $J = 9.4$, 4H),

30

2.43 (dt, $J = 7.2, 9.1$, 1H), 2.34 (dd, $J = 1.7, 8.9$, 1H), 2.28 – 2.23 (m, 1H), 2.16 – 2.03 (m, 2H), 1.98 – 1.77 (m, 3H), 1.70 – 1.61 (m, 1H), 1.46 – 1.33 (m, 1H), 1.32 – 1.21 (m, 2H), 0.93 (d, $J = 6.4$, 3H), 0.86 (d, $J = 6.4$, 3H); MS (ESI+) m/z 412 (M+H)⁺.

5

Example 167

***N*²-methyl-*N*²-(methylsulfonyl)-*N*¹-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide**

To *N*²-methyl-*N*¹-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide from Example 164 (122 mg, 0.296 mmol) in dichloromethane (0.5 mL) was added *N,N*-diisopropylethylamine (78 μ L, 0.445 mmol) followed by methanesulfonyl chloride (25.4 μ L, 0.326 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction was reduced in volume and loaded onto a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-12). The title compound was eluted with a gradient of 0% to 5% methanol (2 *N* ammonia)/dichloromethane over 20 minutes: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.59 (d, $J = 6.7$, 1H), 7.73 (s, 1H), 7.66 (d, $J = 7.6$, 1H), 7.62 (d, $J = 7.8$, 1H), 7.51 (t, $J = 7.7$, 1H), 4.78 (dd, $J = 6.2, 9.5$, 1H), 4.41 – 4.33 (m, 1H), 3.67 (d, $J = 13.3$, 1H), 3.16 (s, 3H), 3.15 (s, 3H), 2.90 (qd, $J = 3.3, 7.9$, 1H), 2.75 (dd, $J = 3.3, 9.6$, 1H), 2.53 – 2.44 (m, 1H), 2.38 – 2.29 (m, 3H), 1.89 – 1.70 (m, 4H), 1.70 – 1.58 (m, 3H), 1.36 – 1.26 (m, 1H), 0.83 (d, $J = 6.6$, 3H), 0.81 (d, $J = 6.5$, 3H); MS (ESI+) m/z 490 (M+H)⁺.

20

Example 168

***N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-*N*²-(methylsulfonyl)-L-leucinamide**

The title compound was prepared by substituting *N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-leucinamide from Example 165 for *N*²-methyl-*N*¹-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide in the procedure described in Example 167: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.97 (d, $J = 7.0$, 1H), 7.43 (d, $J = 7.3$, 2H), 7.37 (d, $J = 7.3$, 2H), 7.30 – 7.25 (m, 1H), 4.78 (dd, $J = 5.1, 10.2$, 1H), 4.42 – 4.35 (m, 1H), 3.58 (d, $J = 13.1$, 1H), 3.46 (d, $J = 13.2$, 1H), 3.21 (s, 3H), 3.12 (s, 3H), 2.83 (d, $J = 8.7$, 1H), 2.55 – 2.47 (m, 2H), 2.36 (dd, $J = 8.1, 14.7$, 2H), 2.26 – 2.22 (m, 1H), 2.13 (dt, $J = 5.9, 11.7$, 1H), 1.93 – 1.82 (m, 2H), 1.70 – 1.61 (m, 2H), 1.44 – 1.36 (m, 1H), 0.82 (d, $J = 6.2$, 3H), 0.73 (d, $J = 5.9$, 3H); MS (ESI+) m/z 422 (M+H)⁺.

30

Example 169***N*²-methyl-*N*²-(methylsulfonyl)-*N*¹-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide**

5 The title compound was prepared by substituting *N*²-methyl-*N*¹-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide from Example 166 for *N*²-methyl-*N*¹-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide in the procedure described in Example 167: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.98 (d, *J* = 7.4, 1H),
 10 7.77 (s, 1H), 7.62 – 7.58 (m, 2H), 7.45 (t, *J* = 7.7, 1H), 4.78 (dd, *J* = 5.0, 10.2, 1H), 4.41 – 4.33 (m, 1H), 3.59 (d, *J* = 13.5, 1H), 3.48 (d, *J* = 13.6, 1H), 3.21 (s, 3H), 3.12 (s, 3H), 2.84 (d, *J* = 7.4, 1H), 2.51 (t, *J* = 5.4, 2H), 2.37 (dd, *J* = 6.9, 8.9, 1H), 2.32 (d, *J* = 7.1, 1H), 2.23 (dd, *J* = 6.8, 8.9, 1H), 2.11 (dd, *J* = 5.8, 11.8, 1H), 1.93 – 1.82 (m, 2H), 1.70 – 1.61 (m, 3H), 1.44 – 1.35 (m, 1H), 0.82 (d, *J* = 6.2, 3H), 0.73 (d, *J* = 6.0, 3H); MS (ESI+) *m/z* 490 (M+H)⁺.

15

Example 170***N*²-(methylsulfonyl)-*N*¹-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide**

Step A: *N*-(*tert*-Butoxycarbonyl)-L-leucine (180 mg, 0.778 mmol),
 20 hydroxybenzotriazole (119 mg, 0.778 mmol), and (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine (201 mg, 0.707 mmol) from Example 154 Step A were combined in dichloromethane (1 mL). After 20 minutes, *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide (0.138 mL, 0.778 mmol) was added and the reaction stirred at room temperature for 24 hours. The reaction was quenched with water,
 25 and the layers were separated. The aqueous layer extracted with 1 mL of dichloromethane. The combined organic layers were applied to a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS15-24) and eluted with 1-10% methanol (2 *N* ammonia)/dichloromethane to give *N*²-(*tert*-butoxycarbonyl)-*N*¹-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide: ¹H NMR (500
 30 MHz, pyridine-*d*₅) δ ppm 8.66 (d, *J* = 7.1, 1H), 7.97 (d, *J* = 8.5, 1H), 7.73 (s, 1H), 7.56 (s, 2H), 7.44 (t, *J* = 7.7, 1H), 4.70 (dd, *J* = 5.9, 11.0, 1H), 4.40 (br s, 1H), 3.56 (d, *J* = 13.5, 1H), 3.41 (d, *J* = 13.5, 1H), 2.74 (d, *J* = 8.9, 1H), 2.48 (s, 2H), 2.37 – 2.31 (m, 1H), 2.27 (d, *J* = 8.4, 1H), 2.24 – 2.19 (m, 1H), 2.12 (dq, *J* = 6.0, 12.0, 1H), 1.91 – 1.81 (m, 4H), 1.66 (td, *J* =

7.4, 14.7, 1H), 1.50 (s, 9H), 1.43 – 1.35 (m, 1H), 0.87 (d, $J = 5.9$, 3H), 0.84 (d, $J = 5.6$, 3H); MS (ESI+) m/z 498 (M+H)⁺.

Step B: N^2 -(*tert*-Butyloxycarbonyl)- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide from Step A

5 (0.731 g, 1.469 mmol) in ethanol (5 mL) was treated with HCl (4 *N* in dioxane, 10.0 mL, 40.0 mmol). The reaction was stirred at room temperature for 2 hours and the solvent removed in vacuo. The reaction was quenched with saturated aqueous sodium bicarbonate and extracted with 3×50 mL of dichloromethane. The solvent was removed in vacuo to give N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.27 (d, $J = 7.6$, 1H), 7.75 (s, 1H), 7.63 – 7.54 (m, 2H), 7.44 (dd, $J = 6.9$, 14.6, 1H), 4.44 – 4.33 (m, 1H), 3.62 – 3.53 (m, 2H), 3.45 (d, $J = 13.5$, 1H), 2.84 (dd, $J = 2.5$, 8.9, 1H), 2.52 (dd, $J = 7.2$, 14.0, 1H), 2.50 – 2.43 (m, 1H), 2.42 – 2.37 (m, 1H), 2.32 (dd, $J = 2.8$, 9.0, 1H), 2.23 (dd, $J = 7.2$, 8.8, 1H), 2.09 (td, $J = 6.0$, 12.0, 2H), 1.94 – 1.81 (m, 4H), 1.61 – 1.50 (m, 2H), 1.39 (ddt, $J = 6.3$, 8.7, 12.6, 1H), 15 0.90 (d, $J = 6.4$, 3H), 0.84 (d, $J = 6.3$, 3H); MS (ESI+) m/z 398 (M+H)⁺.

Step C: The title compound was prepared by substituting N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide from Step B for N^2 -methyl- N^1 -{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide in the procedure described in Example 167: ¹H NMR (500 MHz, 20 pyridine-*d*₅) δ ppm 9.41 (d, $J = 9.4$, 1H), 9.22 (d, $J = 7.3$, 1H), 7.76 (s, 1H), 7.59 (d, $J = 14.0$, 2H), 7.43 (dd, $J = 6.2$, 13.9, 1H), 4.47 (tt, $J = 6.3$, 12.5, 2H), 3.59 (d, $J = 13.5$, 1H), 3.48 (d, $J = 13.6$, 1H), 3.17 (s, 3H), 2.87 (dd, $J = 2.3$, 9.1, 1H), 2.59 – 2.50 (m, 2H), 2.38 (dd, $J = 7.0$, 9.0, 1H), 2.34 (dd, $J = 2.3$, 9.0, 1H), 2.24 (dd, $J = 6.9$, 8.8, 1H), 2.20 – 2.12 (m, 1H), 1.99 (dq, $J = 6.7$, 20.2, 1H), 1.89 (ddd, $J = 6.0$, 10.8, 15.0, 2H), 1.80 – 1.66 (m, 2H), 1.43 (ddd, $J = 6.3$, 25 10.7, 12.2, 1H), 0.82 (d, $J = 6.7$, 3H), 0.79 (d, $J = 6.6$, 3H); MS (ESI+) m/z 476 (M+H)⁺.

Example 171

N^2 -(methylsulfonyl)- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide

30 The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-D-leucine for *N*-(*tert*-butoxycarbonyl)-L-leucine in the procedure described in Step A and then following the procedures described in Steps B and C of Example 170: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.42 (d, $J = 9.3$, 1H), 9.22 (d, $J = 7.3$, 1H), 7.78 (s, 1H), 7.61 (d, $J = 7.7$, 2H), 7.44 (dd, $J = 8.7$, 16.4, 1H), 4.51 – 4.41 (m, 2H), 3.62 (d, $J = 13.5$, 1H), 3.49 (d, $J =$

13.6, 1H), 3.19 (s, 3H), 2.87 (dd, $J = 2.8, 9.1$, 1H), 2.66 – 2.60 (m, 1H), 2.55 (dd, $J = 9.0$, 15.6, 1H), 2.49 (dd, $J = 7.3, 9.0$, 1H), 2.33 (dd, $J = 3.0, 9.0$, 1H), 2.30 – 2.25 (m, 1H), 2.12 (dq, $J = 5.8, 11.9$, 1H), 1.98 (td, $J = 6.7, 13.5$, 1H), 1.93 – 1.83 (m, 2H), 1.77 (ddd, $J = 5.6$, 8.5, 13.8, 1H), 1.63 (dt, $J = 7.5, 19.4$, 1H), 1.45 – 1.36 (m, 1H), 0.82 (d, $J = 6.7$, 3H), 0.78 (d, $J = 6.5$, 3H); MS (ESI+) m/z 476 (M+H)⁺.

Example 172

*N*²-(cyclopropylsulfonyl)-*N*¹-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-L-leucinamide

10 The title compound was prepared by substituting cyclopropanesulfonyl chloride for methanesulfonyl chloride and *N*¹-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-L-leucinamide from Example 170 Step B for *N*²-methyl-*N*¹-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-L-leucinamide in the procedure
15 described in Example 167: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.34 (d, $J = 9.4$, 1H), 9.03 (d, $J = 7.2$, 1H), 7.76 (s, 1H), 7.60 (d, $J = 10.5$, 2H), 7.44 (dd, $J = 6.1, 13.8$, 1H), 4.45 (dd, $J = 6.4, 11.7$, 2H), 3.57 (d, $J = 13.5$, 1H), 3.49 (d, $J = 13.5$, 1H), 2.84 (dd, $J = 2.4, 9.1$, 1H), 2.80 – 2.73 (m, 1H), 2.61 – 2.50 (m, 2H), 2.38 (dd, $J = 7.0, 8.9$, 1H), 2.34 (dd, $J = 2.5$, 9.0, 1H), 2.28 – 2.23 (m, 1H), 2.18 (td, $J = 5.8, 11.9$, 1H), 2.04 (dt, $J = 6.9, 20.3$, 1H), 1.91
20 (ddd, $J = 4.1, 7.2, 14.3$, 2H), 1.77 (ddd, $J = 5.3, 8.7, 13.8$, 1H), 1.73 – 1.65 (m, 1H), 1.44 (ddd, $J = 6.1, 12.3, 18.6$, 1H), 1.33 (td, $J = 4.7, 11.0$, 1H), 1.22 – 1.16 (m, 1H), 0.91 (ddd, $J = 4.5, 8.5, 11.2$, 1H), 0.88 – 0.85 (m, 1H), 0.84 (d, $J = 6.7$, 3H), 0.82 (d, $J = 6.6$, 3H); MS (ESI+) m/z 502 (M+H)⁺.

25

Example 173

*N*²-(isobutylsulfonyl)-*N*¹-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-L-leucinamide

The title compound was prepared by substituting 2-methylpropane-1-sulfonyl chloride for methanesulfonyl chloride and *N*¹-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-L-leucinamide from Example 170 Step B for *N*²-methyl-*N*¹-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-L-leucinamide in the procedure
30 described in Example 167: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.34 (d, $J = 9.3$, 1H), 9.20 (d, $J = 7.4$, 1H), 7.77 (s, 1H), 7.62 (d, $J = 7.6$, 1H), 7.60 – 7.55 (m, 1H), 7.45 (t, $J = 7.7$,

1H), 4.52 – 4.43 (m, 2H), 3.61 (d, $J = 13.5$, 1H), 3.52 (d, $J = 13.6$, 1H), 3.19 – 3.16 (m, 2H), 2.91 (dd, $J = 2.0, 9.0$, 1H), 2.63 – 2.46 (m, 3H), 2.42 (dd, $J = 6.8, 8.9$, 1H), 2.37 (dd, $J = 2.1, 9.0$, 1H), 2.27 (dd, $J = 6.9, 8.8$, 1H), 2.18 (td, $J = 5.8, 11.7$, 1H), 2.01 (tt, $J = 6.7, 13.4$, 1H), 1.96 – 1.85 (m, 2H), 1.73 (tdd, $J = 6.3, 10.3, 14.9$, 2H), 1.45 (ddt, $J = 6.2, 9.0, 12.2$, 1H), 1.08
 5 (d, $J = 6.7$, 3H), 1.04 (d, $J = 6.7$, 3H), 0.81 (app t, $J = 7.0$, 6H); MS (ESI+) m/z 518 (M+H)⁺.

Example 174

N^2 -(cyclopropylsulfonyl)- N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide

10 **Step A:** N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide was prepared as described in the procedures in Example 170 Steps A-B by substituting (3a*S*,4*S*,6a*R*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from 152 Step A for (3a*S*,4*R*,6a*R*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine: ¹H NMR
 15 (500 MHz, pyridine-*d*₅) δ ppm 8.57 - 8.51 (m, 1H), 7.90 (bs, 1H), 7.71 - 7.65 (m, 1H), 7.47 (t, $J = 7.7$, 1H), 4.57 - 4.49 (m, 1H), 3.73 (d, $J = 13.1$, 1H), 3.66 - 3.59 (m, 1H), 3.35 (d, $J = 13.1$, 1H), 2.80 (dd, $J = 2.6, 9.4$, 1H), 2.78 - 2.69 (m, 1H), 2.49 - 2.40 (m, 1H), 2.35 (dd, $J = 2.5, 9.0$, 1H), 2.24 - 1.79 (m, 7H), 1.73 - 1.50 (m, 3H), 1.47 - 1.21 (m, 2H), 0.95 - 0.85 (m, 6H).

20 **Step B:** To N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide from Step A (80 mg, 0.184 mmol) in dichloromethane (0.5 mL) was added triethylamine (0.064 mL, 0.461 mmol) followed by cyclopropanesulfonyl chloride (38.9 mg, 0.277 mmol) in a solution of 300 μ L dichloromethane and the reaction mixture was stirred at room temperature overnight.
 25 The reaction was reduced in volume and loaded onto a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-12). The title compound was eluted with a gradient of 20% to 100% ethyl acetate/hexanes over 20 minutes to give N^2 -(cyclopropylsulfonyl)- N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.34 (d, $J = 9.0$, 1H), 8.84 (d, $J = 6.8$, 1H), 7.73 (s, 1H), 7.64 (d, $J = 7.5$, 1H), 7.59 (d, $J = 12.3$, 1H), 7.43 (dd, $J = 6.6, 14.3$, 1H), 4.53 – 4.42 (m, 2H), 3.76 (d, $J = 13.2$, 1H), 3.41 (d, $J = 13.2$, 1H), 2.99 (qd, $J = 4.2, 8.0$, 1H), 2.90 (dd, $J = 3.6, 9.5$, 1H), 2.82 – 2.74 (m, 1H), 2.57 – 2.48 (m, 1H), 2.40 (dd, $J = 8.5, 19.8$, 2H), 2.30 (dd, $J = 3.4, 9.2$, 1H), 2.02 (td, $J = 6.5, 13.7$, 1H), 1.94 – 1.85 (m, 2H), 1.85 – 1.78
 30

(m, 1H), 1.71 (td, $J = 6.2, 11.6$, 1H), 1.67 – 1.58 (m, 1H), 1.40 – 1.28 (m, 2H), 1.22 (dt, $J = 4.7, 10.8$, 1H), 0.93 (ddd, $J = 6.6, 12.3, 14.0$, 2H), 0.87 (d, $J = 6.5$, 3H), 0.84 (d, $J = 6.7$, 3H); MS (ESI+) m/z 502 (M+H)⁺.

5

Example 175

N^2 -acetyl- N^2 -methyl- N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide

To N^2 -methyl- N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide (123 mg, 0.299 mmol) from Example 164 in dichloromethane (0.5 mL) was added *N,N*-diisopropylethylamine (78 μ L, 0.448 mmol) followed by acetic anhydride (33.9 μ L, 0.359 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction was reduced in volume and loaded onto a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-12), and the product was eluted with a gradient of 0% to 5% methanol (2 *N* ammonia)/dichloromethane over 20 minutes. The solvent was removed in vacuo to supply the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.10 (d, $J = 7.1$, 1H), 7.81 (d, $J = 7.5$, 1H), 7.76 (s, 1H), 7.63 (d, $J = 7.8$, 1H), 7.56 (d, $J = 7.7$, 1H), 5.54 (dd, $J = 6.5, 9.2$, 1H), 4.41 (dt, $J = 7.3, 14.5$, 1H), 3.62 (d, $J = 13.2$, 1H), 3.49 (d, $J = 13.2$, 1H), 3.01 (s, 3H), 2.84 – 2.77 (m, 1H), 2.73 (dd, $J = 2.8, 9.5$, 1H), 2.48 – 2.41 (m, 1H), 2.34 (dd, $J = 2.8, 9.0$, 1H), 2.25 (dt, $J = 7.7, 17.0$, 2H), 2.09 (s, 3H), 1.85 (ddd, $J = 5.6, 9.9, 13.2$, 1H), 1.81 – 1.70 (m, 2H), 1.66 – 1.46 (m, 3H), 1.30 – 1.23 (m, 1H), 0.87 (d, $J = 2.7$, 3H), 0.85 (d, $J = 2.6$, 3H); MS (ESI+) m/z 454 (M+H)⁺.

25

Example 176

N^2 -(2,2-dimethylpropanoyl)- N^2 -methyl- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide

To N^2 -methyl- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide (38.9 mg, 0.095 mmol) from Example 166 in dichloromethane (0.5 mL) was added *N,N*-diisopropylethylamine (24.77 μ L, 0.142 mmol) followed by pivaloyl chloride (12.79 μ L, 0.104 mmol), and the resultant reaction mixture was stirred at room temperature overnight. The reaction was reduced in volume and loaded onto a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-4). The title compound was eluted with a gradient of 0% to 100% ethyl acetate/hexanes over 15 minutes: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.81 (d, $J =$

7.4, 1H), 7.74 (s, 1H), 7.60 – 7.55 (m, 2H), 7.43 (dd, $J = 6.6, 14.3$, 1H), 5.45 (dd, $J = 7.0, 8.7$, 1H), 4.35 – 4.29 (m, 1H), 3.57 (d, $J = 13.5$, 1H), 3.44 (d, $J = 13.5$, 1H), 3.13 (s, 3H), 2.73 (dd, $J = 2.6, 8.9$, 1H), 2.53 – 2.45 (m, 1H), 2.41 (ddd, $J = 2.7, 8.3, 12.0$, 1H), 2.37 – 2.32 (m, 1H), 2.29 (dd, $J = 3.0, 9.0$, 1H), 2.26 – 2.21 (m, 1H), 2.05 (dq, $J = 6.0, 12.0$, 1H), 1.86 – 1.80 (m, 3H), 1.55 (ddd, $J = 6.9, 12.8, 19.6$, 2H), 1.41 – 1.31 (m, 1H), 1.30 (s, 9H), 0.88 (d, $J = 6.7, 3H$), 0.82 (d, $J = 6.6, 3H$); MS (ESI+) m/z 496 ($M+H$)⁺.

Example 177

N^2 -(2,2-dimethylpropanoyl)- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide

The title compound was prepared as described in Example 176 substituting N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide from Example 170 Step B for N^2 -methyl- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.77 (d, $J = 7.3$, 1H), 7.86 (d, $J = 8.4$, 1H), 7.73 (s, 1H), 7.60 – 7.55 (m, $J = 10.6$, 2H), 7.45 (t, $J = 7.7$, 1H), 4.42 – 4.35 (m, 1H), 3.55 (d, $J = 13.5$, 1H), 3.41 (d, $J = 13.5$, 1H), 2.71 (d, $J = 9.0$, 1H), 2.50 (s, 2H), 2.34 (dd, $J = 6.9, 8.9$, 1H), 2.29 – 2.20 (m, 2H), 2.12 (dq, $J = 6.1, 12.3$, 1H), 1.94 – 1.74 (m, 5H), 1.66 (dt, $J = 7.1, 19.3$, 1H), 1.39 (d, $J = 6.9$, 1H), 1.33 (s, 9H), 0.84 (d, $J = 6.1$, 3H), 0.82 (d, $J = 6.1$, 3H); MS (ESI+) m/z 482 ($M+H$)⁺.

Example 178

isobutyl (*S*)-4-methyl-1-oxo-1-((3a*S*,4*R*,6a*R*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate

The title compound was prepared by substituting isobutyl carbonochloridate for methanesulfonyl chloride and N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide from Example 170 Step B for N^2 -methyl- N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide in the procedure described in Example 167: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.83 (d, $J = 6.8$, 1H), 8.42 (d, $J = 8.5$, 1H), 7.73 (s, 1H), 7.65 – 7.53 (m, 2H), 7.46 – 7.40 (m, 1H), 4.77 (dd, $J = 7.5, 15.2$, 1H), 4.48 – 4.39 (m, 1H), 4.01 (dd, $J = 6.7, 10.3$, 1H), 3.92 (dd, $J = 6.7, 10.4$, 1H), 3.56 (d, $J = 13.4$, 1H), 3.40 (d, $J = 13.5$, 1H), 2.77 (d, $J = 7.0$, 1H), 2.57 – 2.45 (m, 2H), 2.38 – 2.32 (m, 1H), 2.30 – 2.24 (m, 1H), 2.23 – 2.19 (m, 1H), 2.14 (td, $J = 5.9, 11.9$, 1H), 1.95 –

1.79 (m, 5H), 1.73 – 1.63 (m, 1H), 1.45 – 1.34 (m, 1H), 0.87 (d, $J = 5.9$, 3H), 0.84 (d, $J = 5.8$, 3H), 0.82 (d, $J = 4.3$, 3H), 0.80 (d, $J = 4.3$, 3H); MS (ESI+) m/z 498 (M+H)⁺.

Example 179

5 **cyclopentyl (S)-4-methyl-1-oxo-1-((3a*S*,4*R*,6a*R*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate**

The title compound was prepared by substituting cyclopentyl carbonochloridate for methanesulfonyl chloride and N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide from Example 10 170 Step B for N^2 -methyl- N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide in the procedure describe in Example 167: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.82 (d, $J = 7.0$, 1H), 8.26 (d, $J = 8.6$, 1H), 7.73 (s, 1H), 7.62 – 7.53 (m, 2H), 7.43 (t, $J = 7.8$, 1H), 5.32 – 5.24 (m, 1H), 4.77 (dd, $J = 7.0$, 15.0, 1H), 4.47 – 4.36 (m, 1H), 3.56 (d, $J = 13.4$, 1H), 3.40 (d, $J = 13.6$, 15 1H), 2.76 (d, $J = 9.0$, 1H), 2.55 – 2.46 (m, 2H), 2.38 – 2.31 (m, 1H), 2.27 (d, $J = 7.2$, 1H), 2.21 (t, $J = 7.9$, 1H), 2.13 (dq, $J = 6.2$, 12.5, 1H), 1.94 – 1.83 (m, 4H), 1.77 (dd, $J = 6.9$, 12.4, 2H), 1.73 – 1.64 (m, 3H), 1.58 (dt, $J = 8.0$, 14.7, 2H), 1.39 (td, $J = 9.0$, 14.1, 3H), 0.87 (d, $J = 5.9$, 3H), 0.84 (d, $J = 5.3$, 3H); MS (ESI+) m/z 510 (M+H)⁺.

20

Example 180

N^2 -[(tert-butylamino)carbonyl]- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide

To N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide (113 mg, 0.284 mmol) from Example 170 Step B in dichloromethane (0.5 25 mL) was added 2-isocyanato-2-methylpropane (35.1 μ L, 0.313 mmol) and the reaction mixture was stirred at room temperature overnight. The reaction was reduced in volume and loaded onto a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-12). The title compound was eluted with a gradient of 0% to 10% methanol (2 *N* ammonia)/dichloromethane over 20 minutes: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.74 30 (d, $J = 8.3$, 1H), 7.73 (s, 1H), 7.57 (d, $J = 9.5$, 2H), 7.44 (t, $J = 7.7$, 1H), 6.56 (d, $J = 8.6$, 1H), 6.33 (s, 1H), 4.88 (td, $J = 5.6$, 8.9, 1H), 4.41 – 4.33 (m, 1H), 3.56 (d, $J = 13.5$, 1H), 3.41 (d, $J = 13.6$, 1H), 2.71 (dd, $J = 1.7$, 9.2, 1H), 2.55 – 2.45 (m, 2H), 2.35 (dd, $J = 6.9$, 8.9, 1H), 2.29 – 2.20 (m, 2H), 2.11 (dq, $J = 6.1$, 12.1, 1H), 1.92 – 1.77 (m, 3H), 1.73 – 1.64 (m, 2H), 1.44 (s,

9H), 1.43 – 1.35 (m, 1H), 0.85 (d, $J = 3.3$, 3H), 0.84 (d, $J = 3.2$, 3H); MS (ESI+) m/z 497 (M+H)⁺.

Example 181

5 **N^2 -[(cyclopentylamino)carbonyl]- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-L-leucinamide**

The title compound was prepared by substituting isocyanatocyclopentane for 2-isocyanato-2-methylpropane as described in the procedure in Example 180: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.84 (d, $J = 7.2$, 1H), 7.73 (s, 1H), 7.64 – 7.53 (m, 2H), 7.44 (t, $J =$
10 9.1, 2H), 6.60 (d, $J = 7.4$, 1H), 6.57 (d, $J = 8.8$, 1H), 4.42 – 4.36 (m, 2H), 3.56 (d, $J = 13.7$, 1H), 3.40 (d, $J = 13.6$, 1H), 2.73 (dd, $J = 1.9$, 9.3, 1H), 2.53 – 2.49 (m, 2H), 2.34 (dd, $J = 7.0$, 9.0, 1H), 2.26 (dd, $J = 1.8$, 8.9, 1H), 2.24 – 2.20 (m, 1H), 2.16 – 2.09 (m, 1H), 1.90 (tdd, $J =$ 5.7, 12.5, 18.4, 4H), 1.80 (ddd, $J = 5.7$, 7.9, 13.6, 1H), 1.76 – 1.65 (m, 2H), 1.51 (dt, $J = 6.3$, 14.9, 3H), 1.41 (tt, $J = 7.2$, 11.8, 4H), 0.85 (d, $J = 6.5$, 6H); MS (ESI+) m/z 509 (M+H)⁺.

15

Example 182

N^2 -methyl- N^1 -((3a*S*,4*R*,6a*R*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide

Step A: N^1 -[(3a*S*,4*R*,6a*R*)-Octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -(*tert*-
20 butyloxycarbonyl)- N^2 -methyl-L-leucinamide was prepared by substituting N^1 -[(3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -(*tert*-butyloxycarbonyl)- N^2 -methyl-L-leucinamide from Example 151 for N -[(3a*S*,4*S*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide in Example 53.

Step B: To N^1 -[(3a*S*,4*R*,6a*R*)-Octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -(*tert*-
25 butyloxycarbonyl)- N^2 -methyl-L-leucinamide from Step A (220 mg, 0.622 mmol) in dichloromethane (5.0 mL) was added triethylamine (0.130 mL, 0.934 mmol) followed by 3-(trifluoromethyl)benzene-1-sulfonyl chloride (0.110 mL, 0.685 mmol) and the reaction mixture was stirred at room temperature overnight. The reaction was reduced in volume and loaded onto a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-24). The title
30 compound was eluted with a gradient of 0% to 10% methanol (2 *N* ammonia)/dichloromethane over 20 minutes to give N^2 -(*tert*-butyloxycarbonyl)- N^2 -methyl- N^1 -((3a*S*,4*R*,6a*R*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.32 (bs, 1H), 8.18 – 8.13 (m, 1H), 8.02 – 7.95 (m, 1H), 7.90 – 7.84 (m, 1H), 7.68 (t, $J = 7.9$, 1H), 4.17 – 4.09 (m, 1H), 3.77

– 3.69 (m, 1H), 3.20 – 3.11 (m, 2H), 3.05 – 2.97 (m, 4H), 2.53 – 2.47 (m, 2H), 1.98 – 1.88 (m, 1H), 1.87 – 1.71 (m, 3H), 1.62 – 1.48 (m, 3H), 1.46 (s, 9H), 1.32 – 1.22 (m, 1H), 0.87 (dd, $J = 6.6, 15.5, 6\text{H}$).

Step C: The title compound was prepared by substituting N^2 -(*tert*-butyloxycarbonyl)- N^2 -methyl- N^1 -((3*aS*,4*R*,6*aR*)-2-{{3-(trifluoromethyl)phenyl}sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide for N^2 -(*tert*-butyloxycarbonyl)- N^1 -{{(3*aR**,4*R**,6*aS**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}}-L-leucinamide in the procedure described in Example 158: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.38 (s, 1H), 8.30 (d, $J = 6.8, 1\text{H}$), 8.20 (d, $J = 7.8, 1\text{H}$), 7.91 (d, $J = 8.0, 1\text{H}$), 7.72 (t, $J = 7.8, 1\text{H}$), 4.31 – 4.24 (m, 1H), 3.87 (dd, $J = 2.2, 10.0, 1\text{H}$), 3.21 – 3.17 (m, 2H), 3.15 (dd, $J = 7.4, 9.9, 1\text{H}$), 2.95 (dd, $J = 7.2, 9.6, 1\text{H}$), 2.60 – 2.49 (m, 2H), 2.38 (s, 3H), 2.00 – 1.92 (m, 2H), 1.91 – 1.80 (m, 2H), 1.68 (ddd, $J = 5.8, 7.9, 13.6, 1\text{H}$), 1.60 – 1.52 (m, 2H), 1.29 (ddd, $J = 6.4, 12.8, 16.2, 1\text{H}$), 0.89 (d, $J = 6.6, 3\text{H}$), 0.84 (d, $J = 6.6, 3\text{H}$); MS (ESI+) m/z 462 ($\text{M}+\text{H}$) $^+$.

15

Example 183

N^2 -methyl- N^1 -((3*aS*,4*R*,6*aR*)-2-{{4-(trifluoromethyl)phenyl}sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide

The title compound was prepared as described in Example 182 substituting 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in Step B: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.30 (d, $J = 7.1, 1\text{H}$), 8.14 (d, $J = 8.2, 2\text{H}$), 7.90 (d, $J = 8.3, 2\text{H}$), 4.30 – 4.23 (m, 1H), 3.86 (dd, $J = 2.6, 10.0, 1\text{H}$), 3.22 – 3.13 (m, 3H), 2.97 (dd, $J = 7.3, 9.6, 1\text{H}$), 2.61 – 2.50 (m, 2H), 2.39 (s, 3H), 2.00 – 1.92 (m, 2H), 1.91 – 1.80 (m, 2H), 1.68 (ddd, $J = 5.9, 7.9, 13.7, 1\text{H}$), 1.61 – 1.52 (m, 2H), 1.30 (ddt, $J = 6.7, 9.9, 13.4, 1\text{H}$), 0.90 (d, $J = 6.6, 3\text{H}$), 0.84 (d, $J = 6.6, 3\text{H}$); MS (ESI+) m/z 462 ($\text{M}+\text{H}$) $^+$.

25

Example 184

N^1 -((3*aS*,4*R*,6*aR*)-2-{{3-(trifluoromethyl)phenyl}sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide

Step A: N^1 -[(3*aS*,4*R*,6*aR*)-2-Benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -(*tert*-butyloxycarbonyl)-L-leucinamide was prepared by substituting *N*-(*tert*-butoxycarbonyl)-L-leucine for (S)-2-phenylbutanoic acid in the procedure described in Example 16 Step F: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.64 (d, $J = 7.1, 1\text{H}$), 7.97 (d, $J = 8.5, 1\text{H}$), 7.41 (d, $J = 7.3, 2\text{H}$), 7.36 (t, $J = 7.5, 2\text{H}$), 7.27 (t, $J = 7.3, 1\text{H}$), 4.71 (s, 1H), 4.41 (s, 1H), 3.56 (d, $J =$

30

13.1, 1H), 3.39 (d, $J = 13.1$, 1H), 2.74 (d, $J = 8.9$, 1H), 2.48 (s, 2H), 2.39 - 2.19 (m, 3H), 2.14 (td, $J = 6.3, 12.4$, 1H), 2.00 - 1.78 (m, 4H), 1.73 - 1.55 (m, 1H), 1.50 (s, 9H), 1.39 (d, $J = 7.0$, 1H), 0.86 (dd, $J = 5.8, 13.4$, 6H).

Step B: The title compound was prepared as described with the procedures in

5 Example 182 Steps A-C substituting N^1 -[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -(*tert*-butyloxycarbonyl)-L-leucinamide from Step A for N^1 -[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -(*tert*-butyloxycarbonyl)- N^2 -methyl-L-leucinamide: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.37 (s, 1H), 8.33 (d, $J = 6.9$, 1H), 8.18 (d, $J = 7.9$, 1H), 7.91 (d, $J = 7.8$, 1H), 7.72 (t, $J = 7.9$, 1H),
10 4.27 - 4.19 (m, 1H), 3.84 (dd, $J = 2.5, 9.9$, 1H), 3.55 (dd, $J = 4.4, 9.3$, 1H), 3.17 (dd, $J = 2.7, 9.7$, 1H), 3.07 (dd, $J = 7.6, 9.8$, 1H), 2.91 (dd, $J = 7.3, 9.6$, 1H), 2.55 - 2.45 (m, 2H), 2.09 (s, 1H), 1.97 - 1.78 (m, 5H), 1.52 (ddd, $J = 4.5, 9.5, 18.5$, 2H), 1.27 (ddt, $J = 6.7, 9.6, 13.2$, 1H), 0.89 (d, $J = 6.4$, 3H), 0.83 (d, $J = 6.3$, 3H); MS (ESI+) m/z 448 ($M+H$) $^+$.

15

Example 185 and Example 186

3-(trifluoromethyl)- N -{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}benzenesulfonamide
(Example 185) and
3-(trifluoromethyl)- N -{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}benzenesulfonamide
(Example 186)

20

To (3aS*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 122 Step E (200 mg, 0.703 mmol) in dichloromethane (2 mL) was added triethylamine (0.147 mL, 1.055 mmol) followed by 3-(trifluoromethyl)benzene-1-sulfonyl
25 chloride (0.124 mL, 0.774 mmol), and the reaction mixture was stirred at room temperature overnight. The reaction was quenched with water and extracted with dichloromethane. The organics were reduced in volume and loaded onto a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-24). The title compounds were eluted with a gradient of 0% to 10% methanol (2 *N* ammonia)/dichloromethane over 20 minutes.

30

Example 185: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.42 (s, 1H), 8.27 (d, $J = 7.9$, 1H), 7.82 (d, $J = 7.8$, 1H), 7.64 (s, 1H), 7.61 (d, $J = 7.8$, 1H), 7.57 (d, $J = 8.2$, 2H), 7.50 (d, $J = 7.7$, 1H), 7.40 (t, $J = 7.7$, 1H), 3.91 - 3.84 (m, 1H), 3.47 (d, $J = 13.4$, 1H), 3.37 (d, $J = 13.4$, 1H), 2.78 (dd, $J = 4.3, 9.6$, 1H), 2.69 (dd, $J = 4.4, 7.7$, 1H), 2.47 - 2.39 (m, 2H), 2.22 (dt, $J = 8.0$,

12.6, 2H), 1.89 (qd, $J = 7.1, 11.0$, 1H), 1.65 (dtd, $J = 2.9, 6.2, 8.9$, 1H), 1.57 – 1.47 (m, 1H), 1.34 – 1.26 (m, 1H); MS (ESI+) m/z 493 (M+H)⁺.

Example 186: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.51 (d, $J = 7.3$, 1H), 8.43 (s, 1H), 8.30 (d, $J = 7.9$, 1H), 7.81 (d, $J = 7.7$, 1H), 7.72 (s, 1H), 7.60 (dd, $J = 3.2, 7.9$, 2H), 7.55 (d, $J = 7.7$, 1H), 7.46 (t, $J = 7.7$, 1H), 3.82 – 3.74 (m, 1H), 3.54 – 3.44 (m, 2H), 2.61 (dd, $J = 1.9, 9.2$, 1H), 2.57 – 2.44 (m, 2H), 2.33 (dd, $J = 2.0, 9.0$, 1H), 2.18 (ddd, $J = 6.8, 9.0, 12.7$, 2H), 1.96 (td, $J = 5.9, 11.8$, 1H), 1.89 – 1.79 (m, 1H), 1.64 – 1.54 (m, 1H), 1.29 (ddt, $J = 6.4, 10.0, 12.6$, 1H); MS (ESI+) m/z 493 (M+H)⁺.

10

Example 187**3-(trifluoromethyl)-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}benzenesulfonamide**

The title compound was prepared by substituting (3*aS*,4*S*,6*aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 152 Step A for (3*aS**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 185: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.26 (s, 1H), 8.41 (s, 1H), 8.27 (d, $J = 7.9$, 1H), 7.82 (d, $J = 7.8$, 1H), 7.62 (d, $J = 7.9$, 1H), 7.57 (d, $J = 9.8$, 2H), 7.50 (d, $J = 7.7$, 1H), 7.40 (t, $J = 7.7$, 1H), 3.87 (dd, $J = 7.1, 16.1$, 1H), 3.48 (d, $J = 13.4$, 1H), 3.38 (d, $J = 13.4$, 1H), 2.77 (dd, $J = 4.3, 9.6$, 1H), 2.73 – 2.65 (m, 1H), 2.47 – 2.41 (m, 2H), 2.26 – 2.19 (m, 2H), 1.89 (qd, $J = 7.1, 10.9$, 1H), 1.65 (dtd, $J = 2.9, 6.2, 8.9$, 1H), 1.52 (dq, $J = 8.3, 12.8$, 1H), 1.34 – 1.26 (m, 1H); MS (ESI+) m/z 493 (M+H)⁺.

15

20

Example 188**3-(trifluoromethyl)-*N*-{(3*aR*,4*R*,6*aS*)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}benzenesulfonamide**

The title compound was prepared by substituting (3*aR*,4*R*,6*aS*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 157 Step A for (3*aS**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 185: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.27 (s, 1H), 8.42 (s, 1H), 8.27 (d, $J = 7.9$, 1H), 7.82 (d, $J = 7.8$, 1H), 7.64 (s, 1H), 7.62 (d, $J = 7.9$, 1H), 7.57 (d, $J = 9.2$, 1H), 7.50 (d, $J = 7.6$, 1H), 7.40 (t, $J = 7.7$, 1H), 3.87 (dd, $J = 7.1, 16.2$, 1H), 3.47 (d, $J = 13.4$, 1H), 3.37 (d, $J = 13.4$, 1H), 2.77 (dd, $J = 4.3, 9.6$, 1H), 2.73 – 2.66 (m, 1H), 2.47 – 2.41 (m, 2H), 2.26 – 2.19 (m, 2H), 1.89 (qd, $J = 7.1, 11.0$, 1H), 1.65 (dtd, $J = 2.9, 6.2, 8.9$, 1H), 1.52 (dq, $J = 8.4, 12.9$, 1H), 1.33 – 1.26 (m, 1H); MS (ESI+) m/z 493 (M+H)⁺.

30

Example 189**3-(trifluoromethyl)-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}benzenesulfonamide**

5 The title compound was prepared by substituting (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 154 Step A for (3*aS**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 185: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.51 (d, *J* = 6.7, 1H), 8.43 (s, 1H), 8.30 (d, *J* = 7.8, 1H), 7.81 (d, *J* = 7.9, 1H), 7.72 (s, 1H), 7.62 – 7.52
 10 (m, 3H), 7.45 (t, *J* = 7.6, 1H), 3.82 – 3.74 (m, 1H), 3.54 – 3.44 (m, 2H), 2.61 (d, *J* = 9.4, 1H), 2.57 – 2.44 (m, 2H), 2.33 (dd, *J* = 1.9, 9.0, 1H), 2.18 (ddd, *J* = 6.9, 9.0, 13.4, 2H), 1.96 (ddd, *J* = 5.1, 11.0, 16.3, 1H), 1.84 (dt, *J* = 7.5, 12.3, 1H), 1.58 (dt, *J* = 9.3, 12.1, 1H), 1.35 – 1.25 (m, 1H); MS (ESI+) *m/z* 493 (M+H)⁺.

15

Example 190***N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide**

The title compound was prepared by substituting (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Example 16 Step E for (3*aS**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in
 20 Example 185: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.49 (d, *J* = 7.0, 1H), 8.43 (s, 1H), 8.29 (d, *J* = 7.9, 1H), 7.81 (d, *J* = 7.8, 1H), 7.60 (d, *J* = 8.0, 1H), 7.38 (d, *J* = 4.7, 4H), 7.33 – 7.27 (m, 1H), 3.84 – 3.75 (m, 1H), 3.47 (q, *J* = 13.1, 2H), 2.61 (dd, *J* = 2.0, 9.2, 1H), 2.56 – 2.43 (m, 2H), 2.35 (dd, *J* = 2.0, 9.0, 1H), 2.21 – 2.12 (m, 2H), 1.99 (td, *J* = 5.9, 11.7, 1H),
 25 1.87 – 1.77 (m, 1H), 1.64 – 1.53 (m, 1H), 1.29 (ddt, *J* = 6.4, 10.0, 12.6, 1H); MS (ESI+) *m/z* 425 (M+H)⁺.

Example 191***N*-{(3*aS*,4*R*,6*aR*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide**

30

Step A: *N*-((3*aS*,4*R*,6*aR*)-Octahydrocyclopenta[*c*]pyrrol-4-yl)-3-(trifluoromethyl)benzenesulfonamide was prepared by substituting *N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide from

Example 190 for *N*-[(3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide in the procedure described in Example 53.

Step B: The title compound was prepared by substituting 6,6-bis(4-fluorophenyl)hexanal for 3-(trifluoromethyl)benzaldehyde and *N*-((3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl)-3-(trifluoromethyl)benzenesulfonamide from Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.53 (d, *J* = 6.8, 1H), 8.46 (s, 1H), 8.33 (d, *J* = 7.9, 1H), 7.82 (d, *J* = 7.8, 1H), 7.63 (t, *J* = 7.8, 1H), 7.36 – 7.31 (m, 4H), 7.15 (t, *J* = 8.7, 4H), 3.97 (t, *J* = 7.8, 1H), 3.83 – 3.74 (m, 1H), 2.66 (d, *J* = 9.4, 1H), 2.56 – 2.43 (m, 2H), 2.39 (d, *J* = 8.5, 1H), 2.24 (dt, *J* = 5.8, 12.0, 2H), 2.10 – 2.04 (m, 2H), 2.04 – 1.99 (m, 2H), 1.99 – 1.91 (m, 1H), 1.87 (dt, *J* = 6.8, 11.4, 1H), 1.62 – 1.52 (m, 1H), 1.34 (ddd, *J* = 6.9, 17.6, 29.2, 7H); MS (ESI+) *m/z* 607 (M+H)⁺.

Example 192

***N*-{(3*aS*,4*R*,6*aR*)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide**

The title compound was prepared by substituting 3,5-bis(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde and *N*-((3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl)-3-(trifluoromethyl)benzenesulfonamide from Example 191 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.53 (d, *J* = 7.4, 1H), 8.42 (s, 1H), 8.30 (d, *J* = 7.9, 1H), 8.03 (s, 1H), 7.96 (s, 2H), 7.81 (d, *J* = 7.8, 1H), 7.60 (t, *J* = 7.9, 1H), 3.82 – 3.74 (m, 1H), 3.59 (s, 2H), 2.68 – 2.64 (m, 1H), 2.59 – 2.49 (m, 2H), 2.38 – 2.33 (m, 1H), 2.23 (dt, *J* = 5.9, 8.9, 2H), 1.97 – 1.81 (m, 2H), 1.59 (ddd, *J* = 8.2, 11.8, 13.0, 1H), 1.35 – 1.24 (m, 1H); MS (ESI+) *m/z* 561 (M+H)⁺.

Example 193

***N*-{(3*aS*,4*R*,6*aR*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide**

The title compound was prepared by substituting 3,3-bis(4-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde and *N*-((3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl)-3-(trifluoromethyl)benzenesulfonamide from Example 191 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.56 (d, *J* = 7.4, 1H), 8.46 (s, 1H), 8.35

(d, $J = 7.9$, 1H), 7.80 (d, $J = 7.8$, 1H), 7.61 (d, $J = 7.8$, 1H), 7.37 (dd, $J = 5.6$, 8.4, 2H), 7.34 – 7.30 (m, 2H), 7.16 (dt, $J = 8.7$, 12.8, 4H), 4.19 (t, $J = 7.7$, 1H), 3.87 – 3.78 (m, 1H), 2.69 (d, $J = 9.1$, 1H), 2.55 – 2.44 (m, 2H), 2.39 (d, $J = 8.7$, 1H), 2.28 – 2.24 (m, 2H), 2.17 (dd, $J = 7.8$, 15.3, 2H), 2.06 (dd, $J = 9.2$, 16.3, 2H), 1.98 (dt, $J = 5.7$, 16.5, 1H), 1.89 (dd, $J = 12.0$, 19.0, 1H), 1.64 – 1.53 (m, 1H), 1.38 – 1.23 (m, 1H); MS (ESI+) m/z 565 (M+H)⁺.

Example 194

***N*-{(3*aS*,4*R*,6*aR*)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide**

The title compound was prepared by substituting 3-fluoro-4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde and *N*-((3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl)-3-(trifluoromethyl)benzenesulfonamide from Example 191 Step A for 2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide in the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.56 (d, $J = 6.8$, 1H), 8.44 (s, 1H), 8.33 (d, $J = 7.9$, 1H), 7.82 (d, $J = 7.6$, 1H), 7.65 – 7.59 (m, 2H), 7.29 (d, $J = 11.8$, 1H), 7.21 (s, 1H), 3.81 – 3.74 (m, 1H), 3.46 (s, 2H), 2.64 (d, $J = 9.3$, 1H), 2.55 (ddd, $J = 8.5$, 13.8, 27.5, 2H), 2.35 (d, $J = 8.7$, 1H), 2.17 (dd, $J = 7.9$, 15.7, 2H), 1.99 (dt, $J = 5.9$, 16.5, 1H), 1.87 (dt, $J = 7.3$, 12.1, 1H), 1.60 (dt, $J = 8.3$, 10.0, 1H), 1.35 – 1.26 (m, 1H); MS (ESI+) m/z 510 (M+H)⁺.

Example 195

***N*-[(3*aS*,4*S*,6*aR*)-2-(4-hydroxybutyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide**

Step A: *N*-((3*aS*,4*S*,6*aR*)-2-Benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl)-3-(trifluoromethyl)benzenesulfonamide was prepared by substituting (3*aS*,4*S*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-amine from Example 14 Step C for (3*aS**,6*aR**)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 185.

Step B: *N*-((3*aS*,4*S*,6*aR*)-2-Benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl)-3-(trifluoromethyl)benzenesulfonamide (0.4237 g, 0.998 mmol) from Step A in tetrahydrofuran (10 mL) was added to 20% palladium hydroxide on carbon (wet, 0.085 g, 0.603 mmol) in a 50 mL pressure bottle under nitrogen. The reaction mixture was then placed under a hydrogen atmosphere (30 psi) and shaken at 50 °C for 18 hours. The mixture was filtered through a nylon membrane and the solvent was removed in vacuo. The crude material was

purified by silica gel chromatography using 1-10% methanol (2 *N* ammonia)/dichloromethane supplied the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.50 (s, 1H), 8.38 (d, *J* = 7.9, 1H), 7.85 (d, *J* = 7.8, 1H), 7.68 (t, *J* = 7.8, 1H), 3.89 (dd, *J* = 8.4, 14.2, 1H), 3.82 (t, *J* = 6.2, 2H), 2.82 (dd, *J* = 3.3, 9.7, 1H), 2.62 (qd, *J* = 3.4, 7.9, 1H), 2.42 – 2.36 (m, 1H), 2.32 (d, *J* = 4.5, 2H), 2.26 (dd, *J* = 6.8, 11.7, 2H), 2.10 (t, *J* = 8.7, 1H), 1.91 – 1.82 (m, 1H), 1.74 – 1.67 (m, 2H), 1.64 – 1.49 (m, 5H), 1.32 (dd, *J* = 6.1, 9.6, 1H); MS (ESI+) *m/z* 407 (M+H)⁺.

Example 196

(3a*S**,4*S**,6a*R**)-*N,N*-dicyclopropyl-2-[3-

(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-amine

(3a*S**,4*S**,6a*R**)-2-(3-(Trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-amine (228 mg, 0.802 mmol) from Example 122 Step E and (1-ethoxycyclopropoxy)trimethylsilane (140 mg, 0.802 mmol) were combined in dichloromethane (1.5 mL) and 5 mL of acetic acid was added. The reaction was stirred at room temperature for 20 minutes, and then PS-cyanoborohydride (343 mg, 0.802 mmol) was added. The reaction was heated to 40 °C overnight. Silica gel chromatography eluting with 1-10% methanol (2 *N* ammonia)/dichloromethane to gave the title compound: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.58 (s, 1H), 7.48 (d, *J* = 7.6, 2H), 7.42 (d, *J* = 7.6, 1H), 3.64 (d, *J* = 13.6, 1H), 3.51 (d, *J* = 13.6, 1H), 2.94 – 2.82 (m, 3H), 2.80 – 2.71 (m, 2H), 2.55 (dd, *J* = 5.4, 9.4, 3H), 2.41 (t, *J* = 8.3, 1H), 2.16 (dd, *J* = 4.7, 8.7, 1H), 1.97 – 1.70 (m, 7H), 1.70 – 1.59 (m, 3H), 1.40 (dd, *J* = 6.7, 12.6, 1H); MS (ESI+) *m/z* 365 (M+H)⁺.

Example 197 and Example 198

(3a*S**,4*R**,6a*R**)-2-benzyl-*N*-cyclopropyloctahydrocyclopenta[*c*]pyrrol-4-amine

(Example 197) and

(3a*S**,4*S**,6a*R**)-2-benzyl-*N*-cyclopropyloctahydrocyclopenta[*c*]pyrrol-4-amine

(Example 198)

2-Benzylhexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one (0.578 g, 2.68 mmol), cyclopropylamine (0.189 mL, 2.68 mmol), and acetic acid (10 mL) were combined in dichloromethane (20 mL). PS-Cyanoborohydride (1.147 g, 2.68 mmol) was added. The reaction was stirred at room temperature for 2 hours, then filtered and the resin was washed with dichloromethane. The solvent was removed in vacuo, and the crude material was

applied to a silica gel column and was eluted with 1-10% methanol(2 *N* ammonia)/dichloromethane to give the title compounds.

(3a*S**,4*R**,6a*R**)-2-benzyl-*N*-cyclopropyloctahydrocyclopenta[*c*]pyrrol-4-amine (Example 197): ¹H NMR (300 MHz, CDCl₃) δ ppm 7.34 – 7.29 (m, 2H), 7.28 – 7.20 (m, 2H), 3.56 (s, 2H), 3.14 (ddd, *J* = 5.7, 7.3, 10.5, 1H), 2.84 (t, *J* = 8.4, 1H), 2.77 – 2.55 (m, 3H), 2.41 (dd, *J* = 6.2, 9.4, 1H), 2.14 – 2.02 (m, 2H), 1.83 – 1.72 (m, 2H), 1.63 – 1.47 (m, 3H), 1.46 – 1.35 (m, 1H), 0.40 (tdd, *J* = 1.3, 3.0, 4.7, 2H), 0.31 (ddd, *J* = 2.8, 4.3, 6.2, 2H); MS (ESI+) *m/z* 256 (M+H)⁺.

(3a*S**,4*S**,6a*R**)-2-benzyl-*N*-cyclopropyloctahydrocyclopenta[*c*]pyrrol-4-amine (Example 198): ¹H NMR (300 MHz, CDCl₃) δ ppm 7.34 – 7.29 (m, 4H), 7.29 – 7.20 (m, 1H), 3.66 – 3.50 (m, 2H), 3.04 – 2.92 (m, 1H), 2.63 (s, 1H), 2.54 – 2.50 (m, 2H), 2.48 – 2.40 (m, 1H), 2.34 (dd, *J* = 3.8, 9.0, 1H), 2.26 (dt, *J* = 5.0, 16.3, 1H), 2.13 – 2.04 (m, 2H), 2.03 – 1.82 (m, 2H), 1.46 – 1.35 (m, 2H), 0.46 – 0.38 (m, 2H), 0.36 – 0.30 (m, 2H); MS (ESI+) *m/z* 256 (M+H)⁺.

Example 199

***N*-[(3a*S**,4*S**,6a*R**)-2-benzyl-*N*-cyclopropyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide**

(3a*S**,4*S**,6a*R**)-2-Benzyl-*N*-cyclopropyloctahydrocyclopenta[*c*]pyrrol-4-amine (382 mg, 1.490 mmol) from Example 198, triethylamine (312 μL, 2.235 mmol), and 3-(trifluoromethyl)benzene-1-sulfonyl chloride (262 μL, 1.639 mmol) were combined in tetrahydrofuran (7 mL). A catalytic amount of (dimethylamino)pyridine was added, and the reaction mixture was stirred at room temperature overnight. The solvent was reduced in volume, and the crude material applied to silica gel and eluted with 20% to 100% ethyl acetate/hexanes to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.46 (s, 1H), 8.31 (d, *J* = 7.9, 1H), 7.93 (d, *J* = 7.8, 1H), 7.74 (t, *J* = 7.9, 1H), 7.41 (d, *J* = 7.2, 2H), 7.36 (t, *J* = 7.4, 2H), 7.29 (t, *J* = 7.2, 1H), 3.97 (ddd, *J* = 6.1, 7.7, 13.5, 1H), 3.54 – 3.45 (m, 2H), 3.17 (dt, *J* = 5.9, 11.8, 1H), 2.82 (dd, *J* = 3.6, 9.7, 1H), 2.55 (t, *J* = 8.2, 1H), 2.51 – 2.43 (m, 2H), 2.36 – 2.22 (m, 2H), 1.88 – 1.82 (m, 1H), 1.57 (dt, *J* = 5.9, 11.6, 1H), 1.43 – 1.32 (m, 3H), 1.05 – 0.98 (m, 1H), 0.80 (ddd, *J* = 6.9, 9.8, 12.4, 1H), 0.73 – 0.65 (m, 1H); MS (ESI+) *m/z* 465 (M+H)⁺.

Example 200***N*-[(3a*S**,4*R**,6a*R**)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide**

The title compound was prepared by substituting (3a*S**,4*R**,6a*R**)-2-benzyl-*N*-cyclopropyloctahydrocyclopenta[*c*]pyrrol-4-amine from Example 197 for (3a*S**,4*S**,6a*R**)-2-benzyl-*N*-cyclopropyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 199: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.45 (s, 1H), 8.29 (d, *J* = 7.8, 1H), 7.92 (d, *J* = 7.8, 1H), 7.69 (t, *J* = 7.9, 1H), 7.49 (d, *J* = 7.4, 2H), 7.41 (t, *J* = 7.6, 2H), 7.31 (t, *J* = 7.3, 1H), 4.41 (dd, *J* = 7.7, 17.3, 1H), 3.63 (d, *J* = 13.2, 1H), 3.53 (d, *J* = 13.2, 1H), 2.87 (d, *J* = 8.9, 1H), 2.70 (dd, *J* = 8.2, 15.9, 1H), 2.49 (d, *J* = 8.9, 1H), 2.46 – 2.37 (m, 1H), 2.16 – 2.07 (m, 2H), 1.99 – 1.94 (m, 1H), 1.84 – 1.77 (m, 1H), 1.73 – 1.65 (m, 1H), 1.65 – 1.57 (m, 1H), 1.35 – 1.25 (m, 1H), 1.18 (ddd, *J* = 5.1, 6.9, 10.5, 1H), 0.99 (dq, *J* = 4.7, 6.7, 1H), 0.81 – 0.74 (m, 1H), 0.69 (ddd, *J* = 6.9, 10.8, 11.8, 1H); MS (ESI+) *m/z* 465 (M+H)⁺.

15

Example 201***N*-cyclopropyl-*N*-[(3a*S**,4*S**,6a*R**)-octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide**

(3a*S**,4*S**,6a*R**)-2-benzyl-*N*-cyclopropyloctahydrocyclopenta[*c*]pyrrol-4-amine (0.308 g, 0.663mmol) from Example 199 and methanol (2mL) were added to 20% palladium hydroxide on carbon (wet, 4 mg) in a 50 mL pressure bottle. The reaction was stirred for 16 hours under hydrogen (30 psi) at room temperature. The mixture was filtered through a nylon membrane and the solvent removed in vacuo. The crude material was chromatographed on a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS15-24) eluting with 1-10% methanol (2 *N* ammonia)/dichloromethane to give the title compound: ¹H NMR (300 MHz, CDCl₃) δ ppm 8.14 (s, 1H), 8.07 (d, *J* = 7.9, 1H), 7.87 (d, *J* = 7.9, 1H), 7.70 (t, *J* = 7.8, 1H), 3.80 – 3.69 (m, 1H), 3.25 (dd, *J* = 7.8, 10.7, 1H), 3.06 – 2.88 (m, 2H), 2.79 – 2.71 (m, 1H), 2.63 – 2.51 (m, 1H), 2.46 (dd, *J* = 5.9, 10.8, 1H), 2.05 (qd, *J* = 7.0, 12.1, 1H), 1.79 (ddd, *J* = 3.9, 6.8, 10.7, 1H), 1.72 – 1.63 (m, 2H), 1.56 (dd, *J* = 4.8, 6.1, 1H), 1.48 (td, *J* = 6.9, 12.8, 1H), 1.31 (ddd, *J* = 2.7, 5.5, 8.8, 1H), 0.92 – 0.70 (m, 3H); MS (ESI+) *m/z* 375 (M+H)⁺.

30

Example 202***N*-{(3*aS**,4*S**,6*aR**)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide***N*-Cyclopropyl-*N*-[(3*aS**,4*S**,6*aR**)-octahydrocyclopenta[*c*]pyrrol-4-yl]-3-

5 (trifluoromethyl)benzenesulfonamide from Example 201 (140mg, 0.374 mmol) and 6,6-bis(4-fluorophenyl)hexanal (108 mg, 0.374 mmol) were combined in dichloromethane (2 mL) and then acetic acid (1 mL) was added. The reaction was stirred at room temperature for 20 minutes, then PS-cyanoborohydride (306 mg, 0.748 mmol) was added. The reaction was stirred at room temperature overnight, then filtered and the resin washed with

10 dichloromethane. The solvent was removed in vacuo and the crude material purified using a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-12) eluting with 1-10% methanol (2 *N* ammonia)/dichloromethane to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.50 (s, 1H), 8.36 (d, *J* = 7.9, 1H), 7.95 (d, *J* = 7.9, 1H), 7.76 (dd, *J* = 6.4, 14.2, 1H), 7.33 (dd, *J* = 5.6, 8.3, 4H), 7.18 – 7.11 (m, 4H), 3.96 (dd, *J* = 8.0, 16.3, 2H), 3.18 – 3.10

15 (m, 1H), 2.82 (dd, *J* = 3.5, 9.5, 1H), 2.50 – 2.44 (m, 2H), 2.39 (t, *J* = 8.0, 1H), 2.31 – 2.21 (m, 4H), 2.03 (dd, *J* = 7.8, 15.3, 2H), 1.91 (dt, *J* = 3.5, 10.4, 1H), 1.59 (dt, *J* = 5.6, 11.5, 1H), 1.51 (dd, *J* = 10.6, 16.2, 1H), 1.46 – 1.33 (m, 6H), 1.28 (dd, *J* = 7.4, 15.1, 2H), 1.08 (td, *J* = 5.0, 10.5, 1H), 0.84 (dt, *J* = 6.9, 12.6, 1H), 0.75 – 0.66 (m, 1H); MS (ESI+) *m/z* 647 (M+H)⁺.

20

Example 203***N*-{(3*aS**,4*S**,6*aR**)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide**

The title compound was prepared by substituting 3,3-bis(4-fluorophenyl)propanal for 6,6-bis(4-fluorophenyl)hexanal in the procedure described for Example 202: ¹H NMR (500

25 MHz, pyridine-*d*₅) δ ppm 8.49 (s, 1H), 8.35 (d, *J* = 7.9, 1H), 7.94 (d, *J* = 7.8, 1H), 7.77 (t, *J* = 7.9, 1H), 7.34 (ddd, *J* = 2.1, 5.5, 8.4, 4H), 7.14 (td, *J* = 2.2, 8.8, 4H), 4.16 (t, *J* = 7.3, 1H), 3.97 – 3.90 (m, 1H), 3.24 – 3.15 (m, 1H), 2.77 (dd, *J* = 4.1, 9.1, 1H), 2.54 (t, *J* = 8.1, 1H), 2.47 (dd, *J* = 7.1, 15.3, 2H), 2.32 – 2.20 (m, 6H), 1.91 (dt, *J* = 3.5, 10.5, 1H), 1.63 (dt, *J* = 5.8, 11.6, 1H), 1.52 – 1.36 (m, 3H), 1.03 (dt, *J* = 4.5, 10.6, 1H), 0.83 (dt, *J* = 6.8, 12.6, 1H), 0.78 –

30 0.70 (m, 1H); MS (ESI+) *m/z* 605 (M+H)⁺.

Example 204***N*-cyclopropyl-3-(trifluoromethyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}benzenesulfonamide**

The title compound was prepared by substituting 3-(trifluoromethyl)benzaldehyde for 5 6,6-bis(4-fluorophenyl)hexanal in the procedure described for Example 202: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.46 (s, 1H), 8.32 (d, *J* = 7.9, 1H), 7.93 (d, *J* = 7.8, 1H), 7.76 – 7.72 (m, 2H), 7.52 (d, *J* = 7.7, 1H), 7.44 (t, *J* = 7.7, 1H), 4.00 – 3.93 (m, 1H), 3.50 (d, *J* = 13.2, 1H), 3.43 (d, *J* = 13.2, 1H), 3.15 (qd, *J* = 3.8, 7.8, 1H), 2.78 (dd, *J* = 3.8, 9.7, 1H), 2.52 – 2.43 (m, 2H), 2.39 (dd, *J* = 8.0, 9.5, 1H), 2.32 – 2.22 (m, 2H), 1.90 – 1.82 (m, 1H), 1.59 (dt, *J* = 10 5.9, 11.5, 1H), 1.48 – 1.32 (m, 4H), 0.99 – 0.93 (m, 1H), 0.81 (ddd, *J* = 6.9, 9.8, 12.4, 1H), 0.75 – 0.67 (m, 1H); MS (ESI+) *m/z* 533 (M+H)⁺.

Example 205**2,2-dicyclohexyl-*N*-((3*aS*,4*S*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide**

2,2-Dicyclohexyl-*N*-((3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide from Example 53 (101 mg, 0.304 mmol), triethylamine (0.042 mL, 0.304 mmol), and 3-(trifluoromethyl)benzene-1-sulfonyl chloride (0.049 mL, 0.304 mmol) were combined in dichloromethane (2 mL). A catalytic amount of *N,N*-dimethylaminopyridine was added. The 20 reaction was stirred at room temperature for 1 hour and lcms showed product, and tlc showed no more starting material. The reaction was quenched with aqueous sodium bicarbonate and the aqueous layer was separated. The organic layers was concentrated to give a precipitate. The precipitate was washed with water and ether and dried under a stream of nitrogen to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.49 (d, *J* = 6.3, 1H), 8.34 (s, 25 1H), 8.19 (d, *J* = 7.9, 1H), 7.93 (d, *J* = 7.8, 1H), 7.73 (t, *J* = 7.8, 1H), 4.46 – 4.38 (m, 1H), 3.73 (dd, *J* = 3.4, 9.3, 1H), 3.17 (dd, *J* = 2.8, 9.7, 1H), 3.07 (ddd, *J* = 6.4, 12.0, 23.6, 3H), 2.49 (dd, *J* = 8.0, 15.9, 1H), 2.12 (t, *J* = 7.2, 1H), 2.02 – 1.77 (m, 8H), 1.73 (dd, *J* = 5.3, 9.0, 4H), 1.68 – 1.58 (m, 3H), 1.52 (ddd, *J* = 3.2, 12.5, 14.7, 1H), 1.43 (ddd, *J* = 3.1, 12.6, 15.0, 1H), 1.37 – 1.03 (m, 9H); MS (ESI+) *m/z* 541 (M+H)⁺.

30

Example 206**2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[(2-phenylethyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide**

The title compound was prepared by substituting 2-phenylethanesulfonyl chloride for
 5 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedure described in Example 205:
¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.35 (d, *J* = 7.0, 1H), 7.33 – 7.25 (m, 4H), 4.60 –
 4.51 (m, 1H), 3.79 (dd, *J* = 4.8, 10.2, 1H), 3.56 – 3.39 (m, 4H), 3.27 (t, *J* = 8.3, 2H), 3.24 –
 3.16 (m, 2H), 2.66 – 2.57 (m, 1H), 2.09 (t, *J* = 7.4, 1H), 2.00 – 1.76 (m, 9H), 1.72 (d, *J* =
 12.9, 4H), 1.67 – 1.64 (m, 1H), 1.59 (t, *J* = 13.7, 2H), 1.54 – 1.36 (m, 3H), 1.30 – 1.18 (m,
 10 4H), 1.18 – 1.06 (m, 4H); MS (ESI+) *m/z* 501 (M+H)⁺.

Example 207**2,2-dicyclohexyl-*N*-((3*aS*,4*S*,6*aR*)-2-{[2-(1-naphthyl)ethyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide**

The title compound was prepared by substituting 2-(naphthalen-1-yl)ethanesulfonyl
 15 chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedure described in
 Example 205: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.37 (d, *J* = 6.8, 1H), 8.13 (d, *J* = 9.0,
 1H), 7.97 – 7.94 (m, 1H), 7.85 (d, *J* = 8.2, 1H), 7.53 (p, *J* = 6.9, 2H), 7.46 – 7.40 (m, 1H),
 7.36 (t, *J* = 7.9, 1H), 4.60 – 4.49 (m, 1H), 3.81 (dd, *J* = 4.8, 10.2, 1H), 3.75 (t, *J* = 8.3, 2H),
 20 3.57 – 3.46 (m, 4H), 3.27 – 3.16 (m, 2H), 2.67 – 2.59 (m, 1H), 2.09 (t, *J* = 7.3, 1H), 1.95 (t, *J*
 = 13.3, 2H), 1.89 – 1.76 (m, 5H), 1.72 (d, *J* = 12.2, 4H), 1.66 (dd, *J* = 5.1, 7.2, 1H), 1.60 (t, *J*
 = 10.5, 2H), 1.46 (dt, *J* = 10.8, 20.4, 3H), 1.29 – 1.18 (m, 4H), 1.18 – 1.03 (m, 5H); MS
 (ESI+) *m/z* 551 (M+H)⁺.

25

Example 208**2,2-dicyclohexyl-*N*-((3*aS*,4*S*,6*aR*)-2-{[3-(trifluoromethyl)benzyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide**

The title compound was prepared by substituting (3-
 (trifluoromethyl)phenyl)methanesulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl
 30 chloride in the procedure described in Example 205: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm
 8.32 (d, *J* = 6.7, 1H), 7.96 (s, 1H), 7.81 (d, *J* = 7.7, 1H), 7.64 (d, *J* = 7.7, 1H), 7.46 (t, *J* = 7.7,
 1H), 4.69 (q, *J* = 13.5, 2H), 4.58 – 4.49 (m, 1H), 3.81 (dd, *J* = 4.9, 10.4, 1H), 3.52 (dd, *J* =
 6.3, 13.7, 2H), 3.26 (dd, *J* = 3.1, 9.9, 1H), 3.23 – 3.15 (m, 1H), 2.65 – 2.58 (m, 1H), 2.06 (t, *J*
 = 7.3, 1H), 1.93 (d, *J* = 13.8, 2H), 1.82 (dt, *J* = 9.9, 14.4, 6H), 1.71 (t, *J* = 10.2, 4H), 1.67 (dd,

$J = 7.0, 11.0, 1\text{H}$), 1.60 (d, $J = 9.5, 2\text{H}$), 1.51 – 1.35 (m, 3H), 1.29 – 1.02 (m, 8H); MS (ESI+) m/z 555 (M+H)⁺.

Example 209

5 **2,2-dicyclohexyl-*N*-((3a*S*,4*S*,6a*R*)-2-{[2-(4-fluorophenyl)ethyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide**

The title compound was prepared by substituting 2-(4-fluorophenyl)ethanesulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedure described in Example 205: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.37 (d, $J = 6.8, 1\text{H}$), 7.18 (dd, $J = 5.6, 8.5, 2\text{H}$), 7.09 (t, $J = 8.7, 2\text{H}$), 4.60 – 4.49 (m, 1H), 3.80 (dd, $J = 4.9, 10.3, 1\text{H}$), 3.57 – 3.39 (m, 4H), 3.27 – 3.16 (m, 4H), 2.67 – 2.59 (m, 1H), 2.09 (t, $J = 7.3, 1\text{H}$), 1.99 – 1.77 (m, 8H), 1.72 (d, $J = 12.4, 4\text{H}$), 1.66 (dd, $J = 3.0, 8.1, 1\text{H}$), 1.59 (t, $J = 14.2, 2\text{H}$), 1.46 (ddd, $J = 7.9, 16.4, 33.2, 3\text{H}$), 1.24 (ddd, $J = 3.2, 12.7, 25.7, 4\text{H}$), 1.18 – 1.03 (m, 4H); MS (ESI+) m/z 519 (M+H)⁺.

15

Examples 210 and Example 211

(2*S*)-2-phenyl-*N*-{(3a*R*,4*R*,6a*S*)-2-[(1*S*)-1-phenylethyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide (Example 210) and

20 **(2*S*)-2-phenyl-*N*-{(3a*R*,4*S*,6a*S*)-2-[(1*S*)-1-phenylethyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide (Example 211)**

Step A: (3a*R*,6a*S*)-2-((*S*)-1-Phenylethyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one and (3a*S*,6a*R*)-2-((*S*)-1-phenylethyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one were prepared as described in the procedure described in Example 122 Step C substituting *S*(-)-*N*-methoxymethyl-*N*-(trifluorosilyl)methyl-1-phenylethyl amine for 1-methoxy-*N*-(3-(trifluoromethyl)benzyl)-*N*-((trimethylsilyl)methyl)methanamine.

25 (3a*R*,6a*S*)-2-((*S*)-1-phenylethyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.34 – 7.16 (m, 5H), 3.23 (d, $J = 8.9, 1\text{H}$), 3.12 (q, $J = 6.6, 1\text{H}$), 2.80 (dt, $J = 7.5, 14.9, 1\text{H}$), 2.60 (t, $J = 8.6, 1\text{H}$), 2.48 (dd, $J = 2.0, 9.5, 1\text{H}$), 2.44 – 2.20 (m, 5H), 2.08 (ddd, $J = 8.2, 13.0, 17.0, 1\text{H}$), 1.72 (ddd, $J = 6.7, 10.1, 17.4, 1\text{H}$), 1.31 (d, $J = 6.6, 3\text{H}$); MS (ESI+) m/z 230 (M+H)⁺.

30 (3a*S*,6a*R*)-2-((*S*)-1-phenylethyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.39 – 7.13 (m, 5H), 3.15 (dd, $J = 6.5, 13.1, 1\text{H}$), 2.88 (dd, $J = 7.1, 13.7, 1\text{H}$), 2.76 (t, $J = 9.0, 3\text{H}$), 2.54 (dd, $J = 9.9, 18.1, 2\text{H}$), 2.45 – 2.35 (m, 2H), 2.34 – 2.26 (m,

1H), 2.13 (ddd, $J = 6.5, 10.8, 17.2$, 1H), 1.91 – 1.77 (m, 1H), 1.33 (d, $J = 6.2$, 3H); MS (ESI+) m/z 230 (M+H)⁺.

Step B: (3a*R*,6a*S*)-2-((*S*)-1-Phenylethyl)octahydrocyclopenta[*c*]pyrrol-4-amine was prepared as described in Example 122 Step D-E substituting (3a*R*,6a*S*)-2-((*S*)-1-phenylethyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one from Step A for 2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.47 – 7.09 (m, 5H), 3.12 (dd, $J = 6.1, 12.5$, 1H), 2.75 (br s, 2H), 2.48 (d, $J = 6.5$, 3H), 2.33 – 2.20 (m, 1H), 2.11 – 1.95 (m, 1H), 1.94 – 1.73 (m, 2H), 1.73 – 1.54 (m, 2H), 1.43 (s, 3H), 1.35 (d, $J = 6.3$, 3H); MS (ESI+) m/z 231 (M+H)⁺.

Step C: The title compounds were prepared by substituting (*S*)-2-phenylbutanoic acid for 1-phenylcyclopentanecarboxylic acid and (3a*R*,6a*S*)-2-((*S*)-1-phenylethyl)octahydrocyclopenta[*c*]pyrrol-4-amine for (3a*S**,6a*R**)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Examples 1 and 2.

Example 210: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 11.04 (d, $J = 6.9$, 1H), 10.39 (d, $J = 7.2$, 2H), 10.16 (q, $J = 8.0$, 4H), 10.13 – 10.04 (m, 4H), 7.19 (dt, $J = 7.1, 14.1$, 1H), 6.36 (dd, $J = 6.3, 8.7$, 1H), 5.82 (q, $J = 6.5$, 1H), 5.69 (dd, $J = 2.5, 9.4$, 1H), 5.56 (qd, $J = 2.7, 7.7$, 1H), 5.22 – 5.07 (m, 2H), 4.99 – 4.92 (m, 2H), 4.90 (dd, $J = 2.7, 9.2$, 1H), 4.65 (td, $J = 6.8, 13.6$, 1H), 4.55 (dt, $J = 7.1, 11.8$, 1H), 4.32 – 4.20 (m, 2H), 4.11 (d, $J = 6.5$, 3H), 3.86 – 3.80 (m, 1H), 3.75 (t, $J = 7.3$, 3H); MS (ESI+) m/z 377 (M+H)⁺.

Example 211: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 11.35 (d, $J = 7.1$, 1H), 10.40 (d, $J = 7.1$, 2H), 10.13 (dt, $J = 7.6, 15.2$, 6H), 10.04 (dt, $J = 4.6, 14.8$, 2H), 7.22 – 7.14 (m, 1H), 6.36 (dd, $J = 6.3, 8.8$, 1H), 5.78 (q, $J = 6.5$, 1H), 5.55 (d, $J = 8.8$, 1H), 5.22 – 5.09 (m, 3H), 5.04 – 4.98 (m, 1H), 4.92 (dd, $J = 8.9, 15.9$, 3H), 4.70 – 4.60 (m, 1H), 4.59 – 4.52 (m, 1H), 4.42 (dt, $J = 6.9, 19.0$, 1H), 4.10 (dd, $J = 6.6, 18.3$, 1H), 4.01 (d, $J = 6.5$, 3H), 3.75 (t, $J = 7.3$, 3H); MS (ESI+) m/z 377 (M+H)⁺.

Example 212 and Example 213

(2*S*)-2-phenyl-*N*-{(3a*S*,4*S*,6a*R*)-2-[(1*S*)-1-phenylethyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide (Example 212) and

(2*S*)-2-phenyl-*N*-{(3a*S*,4*R*,6a*R*)-2-[(1*S*)-1-phenylethyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide (Example 213)

Step A: (3a*S*,6a*R*)-2-((*S*)-1-phenylethyl)octahydrocyclopenta[*c*]pyrrol-4-amine was prepared as described in Example 122 Steps D-E substituting (3a*S*,6a*R*)-2-((*S*)-1-

phenylethyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one from Example 210 Step A for 2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[*c*]pyrrol-4(5*H*)-one: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.47 – 7.09 (m, 5H), 3.12 (dd, *J* = 6.1, 12.5, 1H), 2.75 (br s, 2H), 2.48 (d, *J* = 6.5, 3H), 2.33 – 2.20 (m, 1H), 2.11 – 1.95 (m, 1H), 1.94 – 1.73 (m, 2H), 1.73 – 1.54 (m, 2H),
 5 1.43 (br s, 2H), 1.35 (d, *J* = 6.3, 3H); MS (ESI+) *m/z* 231 (M+H)⁺.

Step B: The title compounds were prepared by substituting (*S*)-2-phenylbutanoic acid for 1-phenylcyclopentanecarboxylic acid and (3*aS*,6*aR*)-2-((*S*)-1-phenylethyl)octahydrocyclopenta[*c*]pyrrol-4-amine for (3*aS**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Examples 1 and
 10 2.

Example 212: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 10.86 (d, *J* = 6.3, 1H), 10.31 (d, *J* = 7.3, 2H), 10.18 – 10.07 (m, 7H), 10.04 (t, *J* = 7.3, 1H), 7.12 (dt, *J* = 7.2, 14.6, 1H), 6.31 (dd, *J* = 6.4, 8.6, 1H), 5.77 (q, *J* = 6.6, 1H), 5.61 – 5.53 (m, 1H), 5.21 – 5.08 (m, 3H), 4.99 (dd, *J* = 4.6, 9.8, 1H), 4.94 (dd, *J* = 8.3, 16.1, 2H), 4.70 – 4.60 (m, 2H), 4.46 (dt, *J* = 5.8, 16.8, 1H),
 15 4.41 – 4.33 (m, 1H), 4.13 – 4.06 (m, 1H), 4.01 (d, *J* = 6.6, 3H), 3.75 (t, *J* = 7.3, 3H); MS (ESI+) *m/z* 377 (M+H)⁺.

Example 213: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.50 (d, *J* = 7.1, 1H), 7.56 (s, 1H), 7.45 (d, *J* = 7.3, 2H), 7.34 (dt, *J* = 7.6, 16.7, 4H), 7.25 (dd, *J* = 7.3, 13.4, 3H), 4.37 – 4.30 (m, 1H), 3.52 (dd, *J* = 6.2, 8.8, 1H), 3.11 (q, *J* = 6.5, 1H), 2.60 (dd, *J* = 2.3, 8.1, 1H), 2.56 – 2.44
 20 (m, 3H), 2.37 – 2.27 (m, 3H), 2.04 – 1.96 (m, 1H), 1.85 – 1.74 (m, 2H), 1.49 (dq, *J* = 6.8, 13.3, 1H), 1.38 – 1.32 (m, 1H), 1.29 (d, *J* = 6.6, 3H), 0.92 (t, *J* = 7.3, 3H); MS (ESI+) *m/z* 377 (M+H)⁺.

Example 214

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*,3-dimethyl-2-phenylbutanamide

Step A: Di-*tert*-butyl dicarbonate (0.429 mL, 1.849 mmol), (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine (200 mg, 0.925 mmol) from Example 33 Step A, and (dimethylamino)pyridine (22.59 mg, 0.185 mmol) were combined in dichloromethane
 30 (5mL). The reaction mixture was stirred at room temperature for 30 minutes. The crude material was purified on a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-4) eluting with ethyl acetate/hexanes to give *tert*-butyl (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylcarbamate: ¹H NMR (400 MHz, CDCl₃) δ ppm 7.39 – 7.12 (m, 5H), 4.47 (s, 1H), 3.74 (s, 1H), 3.61 (s, 1H), 3.52 (s, 1H), 2.55 (t, *J* = 31.6, 4H),

2.31 (s, 2H), 2.03 (d, $J = 6.1$, 1H), 1.83 (d, $J = 8.0$, 1H), 1.58 (s, 1H), 1.43 (s, 9H), 0.98 – 0.79 (m, 1H); MS (ESI+) m/z 317 (M+H)⁺.

Step B: *tert*-Butyl (3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylcarbamate (59 mg, 0.187mmol) from Step A was treated with lithium aluminum hydride (0.374 mmol) in tetrahydrofuran (0.5 mL). The reaction was stirred at room temperature for 1 hour and then heated to reflux for 2 hours. The reaction was cooled to room temperature and quenched with dropwise addition of saturated aqueous sodium sulfate (50 μ L) to give a precipitate. The precipitate was washed with tetrahydrofuran, and then the solvent was removed to give (3a*R*,4*S*,6a*S*)-2-benzyl-*N*-methyloctahydrocyclopenta[*c*]pyrrol-4-amine: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.34 – 7.28 (m, 4H), 7.25 – 7.19 (m, 1H), 3.60 – 3.51 (m, 2H), 2.76 (q, $J = 5.6$, 1H), 2.64 (d, $J = 15.7$, 1H), 2.58 – 2.53 (m, 1H), 2.51 – 2.46 (m, 1H), 2.40 – 2.35 (m, 4H), 2.31 – 2.22 (m, 2H), 1.98 – 1.85 (m, 2H), 1.39 (dt, $J = 5.7$, 10.6, 3H); MS (ESI+) m/z 231 (M+H)⁺.

Step C: The title compound was prepared by substituting 3-methyl-2-phenylbutanoic acid for 1-phenylcyclopentanecarboxylic acid and (3a*R*,4*S*,6a*S*)-2-benzyl-*N*-methyloctahydrocyclopenta[*c*]pyrrol-4-amine for (3a*S**,6a*R**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 2: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.59 – 7.41 (m, 5H), 7.39 – 7.16 (m, 5H), 3.64 (d, $J = 13.2$, 1H), 3.50 (d, $J = 9.5$, 1H), 2.69 – 2.52 (m, 2H), 2.50 – 2.33 (m, 3H), 2.25 – 2.15 (m, 1H), 2.05 (dd, $J = 6.3$, 9.2, 1H), 1.88 – 1.67 (m, 2H), 1.34 (dd, $J = 13.4$, 19.6, 3H), 1.08 (d, $J = 6.4$, 3H), 1.03 – 0.95 (m, 1H), 0.79 – 0.66 (m, 6H); MS (ESI+) m/z 391 (M+H)⁺.

Example 215

N-[(3a*S**,4*R**,6a*R**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*,3-dimethyl-2-phenylbutanamide

The title compound was prepared as described in Example 214 substituting (3a*R**,4*S**,6a*S**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine (International Publication No. WO2006/012396) for (3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in Example 214 Step A: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.61 – 7.41 (m, 5H), 7.26 (dd, $J = 15.4$, 37.9, 5H), 3.65 (d, $J = 13.2$, 1H), 3.54 (dd, $J = 7.6$, 19.9, 2H), 2.70 – 2.53 (m, 2H), 2.50 – 2.36 (m, 2H), 2.25 – 2.15 (m, 1H), 2.07 (s, 1H), 1.87 – 1.66 (m, 2H), 1.43 – 1.26 (m, 3H), 1.19 (d, $J = 6.4$, 2H), 1.08 (d, $J = 6.5$, 2H), 1.01 (d, $J = 6.4$, 1H), 0.79 – 0.63 (m, 5H); MS (ESI+) m/z 391 (M+H)⁺.

Example 216**(3aR*,4S*,6aS*)-N-benzyl-2-(3-methyl-2-phenylbutanoyl)octahydrocyclopenta[c]pyrrol-4-amine**

5 **Step A:** *tert*-Butyl (3aR,4S,6aS)-2-benzyl-4-aminooctahydrocyclopenta[c]pyrrol-4-ylcarbamate was prepared as described in Example 214 Step A substituting (3aR*,4S*,6aS*)-2-benzyl-4-aminooctahydrocyclopenta[c]pyrrol-4-amine (International Publication No. WO2006/012396) for (3aR,4S,6aS)-2-benzyl-4-aminooctahydrocyclopenta[c]pyrrol-4-amine: MS (ESI+) *m/z* 317 (M+H)⁺.

10 **Step B:** *tert*-Butyl (3aR,4S,6aS)-2-benzyl-4-aminooctahydrocyclopenta[c]pyrrol-4-ylcarbamate (100 mg, 0.316 mmol) from Step A and ammonium formate (100 mg, 1.580 mmol) were combined in ethanol. The reaction was deoxygenated at low temperature, and palladium on carbon (3.36 mg, 0.032 mmol) was added. The reaction was heated to reflux under nitrogen. After 3 hours, tlc and lcms showed mostly starting material. Degussa's
15 catalyst and 5 equivalents more ammonium formate were added and the reaction mixture was refluxed under nitrogen overnight. More ammonium formate and Degussa's catalyst were added and the reaction heated to 90 °C. After 2 hours, tlc and lcms show no remaining starting material. The reaction was filtered through diatomaceous earth containing carbonate functionalized silica gel (Silicycle, Quebec, Canada) with methanol. Solvent removal in
20 vacuo gave *tert*-butyl (3aR,4S,6aS)-2-benzyl-4-aminooctahydrocyclopenta[c]pyrrol-4-ylcarbamate: MS (ESI+) *m/z* 226 (M+H)⁺.

Step C: 3-Methyl-2-phenylbutanoic acid (63 mg, 0.353 mmol), 1-hydroxybenzotriazole (54.1 mg, 0.353 mmol), and *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide (0.063 mL, 0.353 mmol) were combined in dichloromethane (5 mL). The
25 reaction was stirred at room temperature for 20 minutes, and then *tert*-butyl (3aR,4S,6aS)-2-benzyl-4-aminooctahydrocyclopenta[c]pyrrol-4-ylcarbamate (80 mg, 0.353 mmol) from Step B was added. After 30 minutes, the reaction was quenched with water and extracted with dichloromethane. The combined extracts were concentrated, and the crude material purified using 10-100% ethyl acetate/hexanes to give *tert*-butyl (3aR,4S,6aS)-2-(3-methyl-2-
30 phenylbutanoyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamate: MS (ESI+) *m/z* 387 (M+H)⁺.

Step D: *tert*-Butyl (3aR,4S,6aS)-2-(3-methyl-2-phenylbutanoyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamate (39 mg, 0.101 mmol) from Step C was combined with 4 M HCl in dioxane (5 mL, 20.00 mmol) in ether (5 mL). After about 2 hours, the solvent was removed in vacuo to give 1-((3aR,4S,6aS)-4-

aminohexahydrocyclopenta[*c*]pyrrol-2(1*H*)-yl)-3-methyl-2-phenylbutan-1-one hydrochloric acid salt which was used in the next step without additional purification: MS (ESI+) *m/z* 287 (M+H)⁺.

Step E: 1-((3*aR*,4*S*,6*aS*)-4-aminohexahydrocyclopenta[*c*]pyrrol-2(1*H*)-yl)-3-methyl-2-phenylbutan-1-one hydrochloric acid salt (49 mg, 0.152 mmol) and benzaldehyde (0.023 mL, 0.228 mmol) were combined in dichloromethane (1.5 mL). Acetic acid (1.5 mL) was added. The reaction was stirred at room temperature for 30 minutes, then PS-cyanoborohydride (64.9 mg, 0.152 mmol) was added. After 72 hours, lcms of the reaction showed no more starting material. The reaction mixture was filtered, and the solvent was removed under a stream of nitrogen. The crude material was purified using a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-4) eluting with 1-10% methanol (2 *N* ammonia)/dichloromethane to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.69 – 7.60 (m, 2H), 7.54 – 7.44 (m, 2H), 7.44 – 7.34 (m, 5H), 7.29 (tdd, *J* = 4.8, 7.8, 13.0, 2H), 3.90 – 3.36 (m, 4H), 3.29 (dd, *J* = 3.8, 10.6, 0.5H), 2.99 (dd, *J* = 5.7, 11.4, 0.5H), 2.93 (dd, *J* = 6.0, 11.3, 0.5H), 2.75 – 2.63 (m, 1H), 2.59 – 2.48 (m, 1H), 2.46 – 2.31 (m, 1H), 2.25 (dt, *J* = 4.1, 8.7, 0.5H), 1.97 (dt, *J* = 9.3, 11.6, 1H), 1.93 – 1.85 (m, 0.5H), 1.84 – 1.74 (m, 1H), 1.65 – 1.55 (m, 0.5H), 1.51 – 1.35 (m, 1H), 1.33 – 1.21 (m, 1H), 1.18 – 1.10 (m, 3H), 1.01 (td, *J* = 7.7, 13.1, 0.5H), 0.87 (dt, *J* = 6.6, 12.9, 0.5H), 0.75 (t, *J* = 7.2, 3H); MS (ESI+) *m/z* 377 (M+H)⁺.

Example 217

2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-2-(*N,N*-dimethyl-D-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide

Step A: *N*-(*tert*-Butoxycarbonyl)-D-leucine (72.7 mg, 0.314 mmol), 2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide (95 mg, 0.286 mmol) from Example 74, and hydroxybenzotriazole (48.1 mg, 0.314 mmol) were combined in dichloromethane (10 mL). After 20 minutes, *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide (0.056 mL, 0.314 mmol) was added, and the reaction mixture was stirred at room temperature for 18 hours. The reaction was quenched with water. The separated organic layer was reduced in volume, and the crude material was applied to a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-12) and eluted first with 10% to 100% ethyl acetate/hexanes and then with 1-10% methanol (2 *N* ammonia)/dichloromethane to give *tert*-butyl (*R*)-1-((3*aS*,4*R*,6*aR*)-4-(2,2-dicyclohexylacetamido)hexahydrocyclopenta[*c*]pyrrol-2(1*H*)-yl)-4-methyl-1-oxopentan-2-ylcarbamate: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm

8.26 (dd, $J = 7.2, 24.0$, 1H), 7.91 (d, $J = 8.6$, 1H), 4.48 – 4.36 (m, 1H), 4.12 – 3.96 (m, 1H), 3.87 (dd, $J = 7.4, 10.3$, 1H), 3.70 (ddd, $J = 8.0, 14.4, 23.7$, 1H), 3.40 (dd, $J = 5.7, 12.3$, 1H), 2.77 (s, 1H), 2.58 (d, $J = 6.1$, 1H), 2.08 (s, 1H), 2.01 (dd, $J = 5.6, 10.4$, 2H), 1.96 – 1.55 (m, 17H), 1.54 – 1.50 (m, 9H), 1.49 – 1.37 (m, 2H), 1.19 (qdd, $J = 12.3, 22.3, 24.7$, 11H), 1.00 (t, $J = 6.6$, 3H), 0.88 (d, $J = 6.6$, 1H).

Step B: *tert*-Butyl (*R*)-1-((3*aS*,4*R*,6*aR*)-4-(2,2-dicyclohexylacetamido)hexahydrocyclopenta[*c*]pyrrol-2(1*H*)-yl)-4-methyl-1-oxopentan-2-ylcarbamate (185 mg, 0.339 mmol) from Step A, and 2 *N* HCl in ether (2.5 mL, 5.00 mmol) were combined in ether (1 mL). The reaction mixture was stirred at room temperature overnight. The solids were collected and dried to give *N*-((3*aS*,4*R*,6*aR*)-2-((*R*)-2-amino-4-methylpentanoyl)octahydrocyclopenta[*c*]pyrrol-4-yl)-2,2-dicyclohexylacetamide: ^1H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.34 – 8.24 (m, 1H), 4.92 (br s, 2H), 4.46 – 4.31 (m, 1H), 4.07 (d, $J = 9.2$, 0.5H), 3.91 – 3.81 (m, 1.5H), 3.77 (dd, $J = 8.8, 12.1$, 1H), 3.72 – 3.64 (m, 0.5H), 3.59 – 3.53 (m, 0.5H), 3.45 (dd, $J = 5.2, 12.2$, 0.5H), 3.32 (d, $J = 6.5$, 0.5H), 2.82 – 2.69 (m, 1H), 2.63 (dd, $J = 8.4, 14.5$, 0.5H), 2.54 (dd, $J = 8.0, 16.4$, 0.5H), 2.21 – 2.06 (m, 2H), 2.02 (q, $J = 7.6$, 1H), 1.99 – 1.55 (m, 15H), 1.50 – 1.38 (m, 3H), 1.37 – 1.12 (m, 9H), 1.09 (d, $J = 6.5$, 3H), 1.01 (d, $J = 6.6$, 2H), 0.96 (d, $J = 6.4$, 1H), 0.91 (d, $J = 6.6$, 1H). MS (ESI+) m/z 466 (M+H)⁺.

Step C: To *N*-((3*aS*,4*R*,6*aR*)-2-((*R*)-2-amino-4-methylpentanoyl)octahydrocyclopenta[*c*]pyrrol-4-yl)-2,2-dicyclohexylacetamide (0.133 g, 0.298 mmol) from Step B was added formaldehyde (0.228 mL, 2.98 mmol) in dichloromethane (0.5 mL). Acetic acid (0.5 mL) was added. The reaction was stirred at room temperature for 30 minutes, PS-cyanoborohydride (0.255 g, 0.597 mmol) was then added, and the reaction mixture was stirred at room temperature overnight. The reaction was filtered, and the solvent was removed in vacuo. The crude material was purified on silica gel chromatography on a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-12) eluting with 1-10% methanol (2 *N* ammonia)/dichloromethane to give the title compound: ^1H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.29 (dd, $J = 7.1, 15.9$, 1H), 4.46 – 4.35 (m, 1H), 4.09 – 3.99 (m, 1H), 3.92 – 3.80 (m, 1H), 3.70 (dd, $J = 8.6, 12.4$, 1H), 3.66 – 3.58 (m, 2H), 3.45 (dd, $J = 4.8, 9.1$, 0.5H), 2.78 – 2.64 (m, 1H), 2.63 – 2.53 (m, 1H), 2.42 (s, 3H), 2.38 (s, 3H), 2.23 – 2.14 (m, 0.5H), 2.13 – 1.99 (m, 2H), 1.99 – 1.82 (m, 5H), 1.82 – 1.63 (m, 8H), 1.60 (d, $J = 14.0$, 1H), 1.57 – 1.51 (m, 1H), 1.45 (ddd, $J = 8.6, 18.8, 29.3$, 3H), 1.36 – 1.05 (m, 9H), 1.01 (d, $J = 6.6$, 3H), 0.91 (dd, $J = 6.6, 19.9$, 3H); MS (ESI+) m/z 474 (M+H)⁺.

Example 218***N*-[(3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide**

3-Methyl-*N*-[(3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide
5 from Example 83 Step A (25 mg, 0.087 mmol), triethylamine (0.018 mL, 0.131 mmol), and
benzoyl chloride (10.12 μ L, 0.087 mmol) were combined in dichloromethane (5 mL). After
5 minutes, tlc shows no more starting material. The crude reaction mixture was concentrated
and applied to a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-4) eluting with
1-10% methanol(2 *N* ammonia)/dichloromethane to give the title compound: ^1H NMR (300
10 MHz, CDCl_3) δ ppm 7.49 – 7.42 (m, 2H), 7.41 – 7.35 (m, 3H), 7.33 – 7.27 (m, 3H), 5.43 (d, J
= 6.7, 1H), 3.97 (m, 1H), 3.74 (m, 2H), 3.56 (m, 2H), 3.39 (m, 1H), 2.74 (m, 2H), 2.48 (m,
1H), 2.38 (m, 2H), 2.07 (dd, J = 4.6, 10.8, 1H), 1.94 (m, 1H), 1.52 – 1.31 (m, 2H), 1.01 (d, J
= 6.3, 3H), 0.68 (d, J = 6.6, 3H); MS (ESI+) m/z 391 ($\text{M}+\text{H}$) $^+$.

15

Example 219***N'*-[(3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*-isopropyl-*N*-phenylurea**

2 *M* Trimethylaluminum in toluene (0.198 mL, 0.395 mmol) was added dropwise to
N-isopropylaniline (0.068 mL, 0.474 mmol) in toluene (2 mL) at 0 °C. The reaction was
20 warmed to room temperature and stirred for 1 hour. The aluminum amide solution was then
added dropwise to a solution of *tert*-butyl (3*aR*,4*S*,6*aS*)-2-
benzoyloctahydrocyclopenta[*c*]pyrrol-4-ylcarbamate from Example 214 Step A (50 mg, 0.158
mmol) in 1 mL of toluene at 0 °C. The reaction was heated at 90 °C overnight, and then the
reaction was quenched with 1 mL of 5% aqueous sodium hydroxide. The separated toluene
25 layer was applied directly to a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS-4)
eluting with 1-10% methanol (2 *N* ammonia)/dichloromethane to give the title compound: ^1H
NMR (300 MHz, CDCl_3) δ ppm 7.40 (ddd, J = 1.8, 3.2, 5.7, 3H), 7.29 (d, J = 4.4, 4H), 7.24 –
7.18 (m, 1H), 7.14 (t, J = 2.0, 1H), 7.13 – 7.10 (m, 1H), 4.87 (dt, J = 6.8, 13.6, 1H), 3.94 –
3.84 (m, 1H), 3.74 (d, J = 7.1, 1H), 3.60 (d, J = 13.0, 1H), 3.44 (d, J = 13.0, 1H), 2.53 (t, J =
30 5.5, 2H), 2.48 – 2.40 (m, 1H), 2.40 – 2.33 (m, 1H), 2.22 (dd, J = 3.7, 8.8, 1H), 2.07 (ddd, J =
5.1, 9.2, 11.7, 1H), 1.95 (td, J = 6.0, 12.0, 1H), 1.63 – 1.52 (m, 1H), 1.40 – 1.30 (m, 1H), 1.29
– 1.17 (m, 1H), 1.05 (d, J = 3.2, 3H), 1.02 (d, J = 3.2, 3H); MS (ESI+) m/z 378 ($\text{M}+\text{H}$) $^+$.

Example 220**(2S)-N-[(3aS,4R,6aR)-2-benzyl-octahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide**

Step A: (*S*)-*tert*-Butyl 2-amino-4-methylpentanoate hydrochloride (0.516 g, 2.306 mmol) were dissolved in dichloromethane (15 mL) and triethylamine (1.061 mL, 7.61 mmol) was added. 3-Chloropropane-1-sulfonyl chloride (0.337 mL, 2.77 mmol) was added dropwise, and the reaction mixture was stirred at room temperature overnight. The solvent was removed in vacuo, and the crude material was taken up in ether, filtered, and concentrated to give (*S*)-*tert*-butyl 2-(3-chloropropylsulfonamido)-4-methylpentanoate: ¹H NMR (300 MHz, CDCl₃) δ ppm 4.70 (d, *J* = 9.7, 1H), 4.02 - 3.91 (m, 1H), 3.77 - 3.60 (m, 2H), 3.25 - 2.96 (m, 3H), 2.31 (tdd, *J* = 2.2, 6.6, 9.2, 2H), 1.83 (dq, *J* = 6.5, 13.0, 1H), 1.58 - 1.53 (m, 8H), 1.38 (t, *J* = 7.3, 1H), 0.96 (dd, *J* = 2.1, 6.6, 6H); MS (ESI+) *m/z* 345 (M+NH₄)⁺.

Step B: (*S*)-*tert*-Butyl 2-(3-chloropropylsulfonamido)-4-methylpentanoate (0.756 g, 2.306 mmol) from Step A was dissolved in tetrahydrofuran and potassium *tert*-butoxide (0.517 g, 4.61 mmol) was added. The reaction was stirred at room temperature overnight. The solvent was removed in vacuo, and the crude material was partitioned between ether and water. The ether layer was separated, washed with brine, dried (Na₂SO₄), and concentrated in vacuo to supply *tert*-butyl (2*S*)-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanoate: ¹H NMR (300 MHz, CDCl₃) δ ppm 4.17 - 4.05 (m, 1H), 3.68 (dd, *J* = 7.9, 16.6, 1H), 3.40 - 3.28 (m, 1H), 3.21 - 3.09 (m, 2H), 2.39 (td, *J* = 5.3, 13.6, 2H), 1.68 (m, 3H), 1.47 (s, 9H), 0.97 (dd, *J* = 3.2, 6.2, 6H).

Step C: *tert*-Butyl (2*S*)-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanoate (0.656 g, 2.251 mmol) from Step B was combined with HCl (4 *N* in dioxane, 5 mL, 20.00 mmol). The reaction mixture was stirred at room temperature for 24 hours, then the solvent removed in vacuo to furnish (2*S*)-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanoic acid: MS (DCI+) *m/z* 253 (M+NH₄)⁺.

Step D: (2*S*)-2-(1,1-Dioxidoisothiazolidin-2-yl)-4-methylpentanoic acid (359 mg, 1.526 mmol) was combined with triethylamine (0.387 mL, 2.77 mmol) in dichloromethane (10 mL). 1-Hydroxybenzotriazole (234 mg, 1.526 mmol) and *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide (0.270 mL, 1.526 mmol) were added, and the reaction mixture was stirred for 15 minutes. Then (3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[c]pyrrol-4-amine (300 mg, 1.387 mmol) from Example 16 Step E was added, and the reaction mixture was stirred at room temperature for 24 hours. The reaction was quenched with 10 mL of aqueous sodium bicarbonate and extracted with 3x20 mL of dichloromethane. The solvent was

removed in vacuo. The crude material was applied to a silica gel cartridge (Analogix®, Burlington, Wisconsin, RS15-24) and eluted with 1-10% methanol (2 *N* ammonia)/dichloromethane to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.76 (d, *J* = 6.9, 1H), 7.46 - 7.39 (m, 2H), 7.40 - 7.33 (m, 2H), 7.26 (dd, *J* = 9.9, 17.2, 1H), 4.52 (t, *J* = 7.7, 1H), 4.44 - 4.34 (m, 1H), 3.93 (dt, *J* = 7.0, 14.5, 1H), 3.57 (dd, *J* = 5.4, 13.1, 1H), 3.49 - 3.36 (m, 2H), 3.30 - 3.20 (m, 2H), 2.83 - 2.74 (m, 1H), 2.62 - 2.45 (m, 2H), 2.44 - 2.37 (m, 1H), 2.33 - 2.17 (m, 4H), 2.11 (qd, *J* = 6.5, 12.5, 1H), 1.92 - 1.78 (m, 3H), 1.77 - 1.59 (m, 2H), 1.45 - 1.32 (m, 1H), 0.88 (d, *J* = 6.6, 3H), 0.83 (dd, *J* = 2.5, 6.5, 3H); MS (ESI+) *m/z* 434 (M+H)⁺.

10

Example 221

***tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-ylcarbamate**

N-(*tert*-Butoxycarbonyl)-L-leucine (0.374 g, 1.617 mmol), 1-hydroxybenzotriazole hydrate (0.248 g, 1.617 mmol), and (3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 33 (0.318g, 1.470 mmol) were combined in dichloromethane (3.0 mL). After 20 minutes, *N*¹-((ethylimino)methylene)-*N*³,*N*³-dimethylpropane-1,3-diamine (0.286 mL, 1.617 mmol) was added, and the reaction was stirred at room temperature overnight. The reaction was quenched with water and extracted with of dichloromethane (2×2mL), and the extracts were applied directly to a 25 g silica gel cartridge and purified with a gradient of 5-40% acetone/hexanes over 30 minutes to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.61-8.64 (m, 1H), 7.96-7.99 (m, 1H), 7.42-7.44 (m, 2H), 7.36 (t, *J* = 7.4 Hz, 2H), 7.28 (d, *J* = 7.3 Hz, 1H), 4.65-4.73 (m, 1H), 4.37-4.45 (m, 1H), 3.59 (d, *J* = 13.1 Hz, 1H), 3.43 (d, *J* = 13.1 Hz, 1H), 2.81-2.84 (m, 1H), 2.55-2.58 (m, 1H), 2.44-2.54 (m, 2H), 2.24-2.36 (m, 2H), 2.02-2.13 (m, 1H), 1.78-1.94 (m, 4H), 1.53-1.66 (m, 1H), 1.50 (s, 9H), 1.26-1.43 (m, 1H), 0.87 (d, *J* = 5.5 Hz, 3H), 0.83-0.85 (m, 3H); MS (ESI+) *m/z* 430 (M+H)⁺.

20

25

Example 222

***tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-leucine for *N*-(*tert*-butoxycarbonyl)-L-leucine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.23-8.32 (m, 1H), 7.42-7.44 (m, 2H), 7.36 (t, *J* =

30

7.5 Hz, 2H), 7.27 (t, $J = 7.4$ Hz, 1H), 5.02 (m, 0.7H), 4.69 (m, 0.3H), 4.37-4.43 (m, 1H), 3.58 (d, $J = 13.1$ Hz, 1H), 3.45 (d, $J = 13.1$ Hz, 1H), 3.04-3.11 (m, 3H), 2.82-2.91 (m, 1H), 2.40-2.52 (m, 3H), 2.31-2.34 (m, 1H), 2.21-2.25 (m, 1H), 1.99-2.14 (m, 1H), 1.77-1.94 (m, 3H), 1.51-1.62 (m, 2H), 1.47 (s, 9H), 1.34-1.37 (m, 1H), 0.88 (d, $J = 6.4$ Hz, 3H), 0.85 (d, $J = 6.4$ Hz, 3H); MS (ESI+) m/z 444 (M+H)⁺.

Example 223

***tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopent-2-yl(ethyl)carbamate**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-ethyl-L-leucine for *N*-(*tert*-butoxycarbonyl)-L-leucine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.11-8.14 (m, 1H), 7.42-7.44 (m, 2H), 7.36 (t, $J = 7.4$ Hz, 2H), 7.27 (t, $J = 7.3$ Hz, 1H), 4.36-4.41 (m, 1H), 3.59 (d, $J = 13.1$ Hz, 1H), 3.43-3.47 (m, 3H), 2.80-2.85 (m, 1H), 2.47-2.51 (m, 2H), 2.39-2.43 (m, 1H), 2.33-2.35 (m, 1H), 2.22-2.25 (m, 1H), 2.05-2.13 (m, 1H), 1.94-2.04 (m, 1H), 1.81-1.84 (m, 1H), 1.72-1.78 (m, 1H), 1.52-1.61 (m, 1H), 1.46-1.49 (m, 9H), 1.34-1.41 (m, 2H), 1.17-1.33 (m, 3H), 0.89-0.91 (m, 6H); MS (ESI+) m/z 458 (M+H)⁺.

Example 224

***tert*-butyl (2*S*,3*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxopent-2-yl(methyl)carbamate**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-isoleucine for *N*-(*tert*-butoxycarbonyl)-L-leucine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.43 (d, $J = 8.7$ Hz, 1H), 7.43 (s, 1H), 7.37 (t, $J = 7.4$ Hz, 2H), 7.25-7.30 (m, 1H), 4.68-4.72 (m, 1H), 4.34-4.44 (m, 1H), 3.61 (d, $J = 13.1$ Hz, 1H), 3.46 (d, $J = 13.1$ Hz, 1H), 3.22-3.26 (m, 1H), 3.13-3.14 (m, 2H), 2.87-2.90 (m, 1H), 2.46-2.54 (m, 3H), 2.25-2.35 (m, 3H), 2.00-2.12 (m, 1H), 1.82 (dq, $J = 12.7, 6.3$ Hz, 1H), 1.52-1.63 (m, 1H), 1.48-1.50 (m, 9H), 1.32-1.43 (m, 3H), 0.96-1.10 (m, 4H), 0.78-0.86 (m, 3H); MS (ESI+) m/z 444 (M+H)⁺.

Example 225***tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-*L*-*tert*-leucine for *N*-(*tert*-butoxycarbonyl)-*L*-leucine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.71 (m, 1H), 7.70 (d, *J* = 9.6 Hz, 1H), 7.43-7.45 (m, 2H), 7.37 (t, *J* = 7.5 Hz, 2H), 7.26-7.30 (m, 1H), 4.61 (d, *J* = 9.7 Hz, 1H), 4.39-4.45 (m, 1H), 3.63 (d, *J* = 13.1 Hz, 1H), 3.44 (d, *J* = 13.1 Hz, 1H), 2.86 (dd, *J* = 9.0, 2.9 Hz, 1H), 2.57-2.63 (m, 1H), 2.45-2.55 (m, 2H), 2.26-2.33 (m, 2H), 2.00 (dd, *J* = 12.1, 6.1 Hz, 1H), 1.77-1.84 (m, 1H), 1.48-1.56 (m, 1H), 1.48 (s, 9H), 1.25-1.38 (m, 1H), 1.18 (s, 9H); MS (ESI+) *m/z* 430 (M+H)⁺.

Example 226***tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamate**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*L*-neopentylglycine for *N*-(*tert*-butoxycarbonyl)-*L*-leucine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.54-8.57 (m, 1H), 8.10-8.13 (m, 1H), 7.41-7.45 (m, 2H), 7.36 (t, *J* = 7.4 Hz, 2H), 7.25-7.29 (m, 1H), 4.72-4.76 (m, 1H), 4.38-4.42 (m, 1H), 3.59 (d, *J* = 13.1 Hz, 1H), 3.43 (d, *J* = 13.1 Hz, 1H), 2.84 (dd, *J* = 9.0, 2.9 Hz, 1H), 2.53-2.60 (m, 1H), 2.46-2.53 (m, 1H), 2.42-2.46 (m, 1H), 2.29-2.32 (m, 1H), 2.22-2.27 (m, 1H), 2.16 (dd, *J* = 14.1, 4.8 Hz, 1H), 2.01-2.07 (m, 1H), 1.77-1.87 (m, 2H), 1.54-1.62 (m, 1H), 1.50 (s, 9H), 1.31-1.41 (m, 1H), 0.98 (s, 9H); MS (ESI+) *m/z* 444 (M+H)⁺.

Example 227***tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxohexan-2-yl(methyl)carbamate**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-*L*-norleucine for *N*-(*tert*-butoxycarbonyl)-*L*-leucine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.21-8.24 (m, 1H), 7.42-7.44 (m, 2H), 7.36 (t, *J* = 7.4 Hz, 2H), 7.24-7.31 (m, 1H), 5.02 (m, 0.7H), 4.66 (m, 0.3H), 4.34-4.47 (m, 1H), 3.59 (d, *J* = 13.1 Hz, 1H), 3.45 (d, *J* = 13.1 Hz, 1H), 3.05-3.10 (m, 3H), 2.82-2.85 (m, 1H), 2.45-2.50 (m, 2H), 2.37-2.45 (m, 1H), 2.31-2.37 (m, 1H), 2.24 (t, *J* = 7.5 Hz, 1H), 2.05-2.12 (m,

2H), 1.79-1.84 (m, 2H), 1.53-1.62 (m, 1H), 1.47 (s, 9H), 1.34-1.38 (m, 1H), 1.21-1.29 (m, 4H), 0.75-0.81 (m, 3H); MS (ESI+) m/z 444 (M+H)⁺.

Example 228

5 ***N*-[(3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-bis(4-fluorophenyl)acetamide**

The title compound was prepared by substituting 2,2-bis(4-fluorophenyl)acetic acid for *N*-(*tert*-butoxycarbonyl)-L-leucine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.04 (d, *J* = 7.0, 1H), 7.57 – 7.52 (m, 4H), 7.42 (d, *J* = 7.1, 2H), 7.36 (t, *J* = 7.5, 2H), 7.27 (t, *J* = 7.3, 1H), 7.12 (dt, *J* = 15.8, 8.0, 4H), 5.23 (s, 1H), 4.45 – 4.37 (m, 1H), 3.57 (d, *J* = 13.1, 1H), 3.43 (d, *J* = 13.1, 1H), 2.78 (dd, *J* = 9.1, 2.9, 1H), 2.54 – 2.47 (m, 1H), 2.47 – 2.43 (m, 1H), 2.40 (dd, *J* = 8.9, 7.3, 1H), 2.29 (dd, *J* = 9.0, 3.0, 1H), 2.27 – 2.21 (m, 1H), 2.10 (dq, *J* = 12.2, 6.2, 1H), 1.84 – 1.75 (m, 1H), 1.60 (td, *J* = 14.6, 7.3, 1H), 1.41 – 1.31 (m, 1H); MS (ESI+) m/z 447 (M+H)⁺.

15

Example 229

***N*-[(3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-isopropyl-3-methylbutanamide**

The title compound was prepared by substituting 2-isopropyl-3-methylbutanoic acid for *N*-(*tert*-butoxycarbonyl)-L-leucine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.18 (d, *J* = 7.5, 1H), 7.44 (d, *J* = 7.5, 2H), 7.37 (t, *J* = 7.6, 2H), 7.27 (t, *J* = 7.3, 1H), 4.52 – 4.37 (m, 1H), 3.62 (d, *J* = 13.2, 1H), 3.44 (d, *J* = 13.1, 1H), 2.83 (dd, *J* = 9.0, 2.8, 1H), 2.62 – 2.51 (m, 2H), 2.48 (dd, *J* = 8.8, 7.1, 1H), 2.34 – 2.26 (m, 2H), 2.17 – 2.05 (m, 3H), 1.92 – 1.81 (m, 2H), 1.64 (dt, *J* = 19.2, 7.1, 1H), 1.44 – 1.34 (m, 2H), 1.13 (dd, *J* = 6.6, 3.9, 6H), 0.98 (d, *J* = 6.8, 6H); MS (ESI+) m/z 343 (M+H)⁺.

25

Example 230

***N*-[(3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methylbutanamide**

The title compound was prepared by substituting 3-methylbutanoic acid for *N*-(*tert*-butoxycarbonyl)-L-leucine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.36 (d, *J* = 7.8, 1H), 7.44 (d, *J* = 7.6, 2H), 7.37 (t, *J* = 7.5, 2H), 7.28 (t, *J* = 7.2, 1H), 4.48 – 4.40 (m, 1H), 3.60 (d, *J* = 13.1, 1H), 3.45 (d, *J* = 13.2, 1H), 2.82 (dd, *J* = 9.0, 2.2, 1H), 2.59 – 2.50 (m, 2H), 2.50 – 2.43 (m, 1H), 2.31 (tt, *J* = 19.8, 7.9, 3H), 2.23 (d, *J*

30

= 7.3, 2H), 2.17 – 2.08 (m, 1H), 1.87 (dd, $J = 13.1, 6.7$, 1H), 1.68 – 1.58 (m, 1H), 1.46 – 1.34 (m, 1H), 0.95 (d, $J = 6.6$, 5H); MS (ESI+) m/z 343 (M+H)⁺.

Example 231

5 ***tert*-butyl (2*S*)-2-([(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylate**

The title compound was prepared by substituting (*S*)-1-(*tert*-butoxycarbonyl)piperidine-2-carboxylic acid for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step E of Example 16 for
 10 (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 7.35-7.39 (m, 2H), 7.30 (t, $J = 7.5$ Hz, 2H), 7.21 (t, $J = 7.2$ Hz, 2H), 4.86-4.88 (m, 1H), 4.25-4.30 (m, 1H), 4.08-4.12 (m, 1H), 3.58 (d, $J = 13.2$ Hz, 1H), 3.47 (d, $J = 13.1$ Hz, 1H), 3.29 (td, $J = 12.8, 3.1$ Hz, 1H), 2.80 (d, $J = 6.1$ Hz, 1H), 2.49-2.56 (m, 1H), 2.42-2.47 (m, 2H), 2.36 (dd, $J = 9.0, 3.2$ Hz, 1H), 2.32 (d, $J = 7.7$ Hz, 1H), 2.22-2.26 (m, 1H), 2.03-2.11 (m, 1H), 1.79-1.93 (m, 1H), 1.49-1.68 (m, 5H), 1.48 (s, 9H), 1.32-1.44 (m, 2H); MS (ESI+) m/z 428 (M+H)⁺.
 15

Example 232

20 ***tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamate**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-valine for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step E of Example 16 for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H
 25 NMR (501 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 7.35-7.39 (m, 3H), 7.29 (t, $J = 7.5$ Hz, 2H), 7.21 (t, $J = 7.3$ Hz, 1H), 4.30-4.38 (m, 1H), 4.20-4.29 (m, 1H), 3.56 (d, $J = 13.0$ Hz, 1H), 3.47 (d, $J = 13.2$ Hz, 1H), 3.00-3.02 (m, 3H), 2.76 (d, $J = 6.5$ Hz, 1H), 2.48-2.55 (m, 1H), 2.33-2.47 (m, 4H), 2.28-2.32 (m, 1H), 2.04-2.12 (m, 1H), 1.81-1.88 (m, 1H), 1.49-1.59 (m, 1H), 1.46 (s, 9H), 1.36-1.45 (m, 1H), 1.00 (d, $J = 6.5$ Hz, 3H), 0.87 (d, $J = 6.7$ Hz, 3H);
 30 MS (ESI+) m/z 430 (M+H)⁺.

Example 233***tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-norvaline for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step E of Example 16 for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 7.36-7.38 (m, 2H), 7.28-7.31 (m, 3H), 7.21 (t, *J* = 7.2 Hz, 1H), 4.70-4.79 (m, 1H), 4.23-4.29 (m, 1H), 3.57 (d, *J* = 13.2 Hz, 1H), 3.47 (d, *J* = 13.2 Hz, 1H), 2.95 (s, 3H), 2.77-2.81 (m, 1H), 2.48-2.52 (m, 1H), 2.39-2.46 (m, 2H), 2.36 (dd, *J* = 9.0, 2.9 Hz, 1H), 2.30 (t, *J* = 8.0 Hz, 1H), 2.07 (dq, *J* = 12.1, 6.1 Hz, 1H), 1.92-2.03 (m, 1H), 1.72-1.86 (m, 2H), 1.50-1.59 (m, 1H), 1.47 (s, 9H), 1.36-1.44 (m, 1H), 1.25-1.35 (m, 2H), 0.86 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z* 430 (M+H)⁺.

Example 234***tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-L-*tert*-leucine for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step E of Example 16 for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.71 (m, 1H), 7.69 (d, *J* = 9.6 Hz, 1H), 7.39-7.42 (m, 2H), 7.36 (t, *J* = 7.5 Hz, 2H), 7.25-7.29 (m, 1H), 4.61 (d, *J* = 9.7 Hz, 1H), 4.32-4.42 (m, 1H), 3.53-3.56 (m, 1H), 3.37-3.40 (m, 1H), 2.63-2.66 (m, 1H), 2.41-2.51 (m, 2H), 2.27-2.33 (m, 2H), 2.20-2.25 (m, 1H), 2.11-2.19 (m, 1H), 1.80-1.91 (m, 1H), 1.61-1.73 (m, 1H), 1.48 (s, 9H), 1.35-1.44 (m, 1H), 1.18 (s, 9H); MS (ESI+) *m/z* 430 (M+H)⁺.

Example 235***N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-isopropyl-3-methylbutanamide**

The title compound was prepared by substituting 2-isopropyl-3-methylbutanoic acid for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step E of Example 16 for (3*aR*,4*S*,6*aS*)-2-

benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.18 (d, *J* = 7.1, 1H), 7.44 (d, *J* = 7.3, 2H), 7.36 (t, *J* = 7.6, 2H), 7.27 (t, *J* = 7.3, 1H), 4.51 – 4.37 (m, 1H), 3.61 (d, *J* = 13.1, 1H), 3.44 (d, *J* = 13.2, 1H), 2.83 (dd, *J* = 9.0, 2.8, 1H), 2.61 – 2.51 (m, 2H), 2.48 (dd, *J* = 8.8, 7.2, 1H), 2.35 – 2.24 (m, 2H), 2.16 – 2.06 (m, 3H), 1.93 – 1.81 (m, 2H), 1.64 (dt, *J* = 14.6, 7.1, 1H), 1.44 – 1.35 (m, 1H), 1.13 (dd, *J* = 6.6, 3.9, 6H), 0.98 (d, *J* = 6.7, 6H); MS (ESI+) *m/z* 343 (M+H)⁺.

Example 236

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methylbutanamide

The title compound was prepared by substituting 3-methylbutanoic acid for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step E of Example 16 for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.30 – 8.17 (m, 1H), 7.43 (dd, *J* = 11.2, 4.2, 2H), 7.37 (t, *J* = 7.5, 2H), 7.27 (t, *J* = 7.3, 1H), 4.49 – 4.39 (m, 1H), 3.60 (d, *J* = 13.1, 1H), 3.45 (d, *J* = 13.1, 1H), 2.89 – 2.78 (m, 1H), 2.55 – 2.49 (m, 2H), 2.45 (dd, *J* = 10.4, 5.3, 1H), 2.36 – 2.24 (m, 3H), 2.21 (d, *J* = 7.1, 2H), 2.17 – 2.08 (m, 1H), 1.90 – 1.79 (m, 1H), 1.62 (ddd, *J* = 15.1, 12.3, 7.2, 1H), 1.40 (dtd, *J* = 9.2, 8.2, 6.1, 1H), 0.95 (d, *J* = 6.6, 6H); MS (ESI+) *m/z* 301 (M+H)⁺.

Example 237

2-cyclohexyl-2-hydroxy-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-

(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide

The title compound was prepared by substituting 2-cyclohexyl-2-hydroxyacetic acid for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*S*,6*aR*)-2-(3-trifluoromethyl)benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 152 for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.59 (d, *J* = 7.9, 0.5H), 8.40 – 8.33 (m, 0.5H), 7.97 (s, 0.5H), 7.77 (dd, *J* = 42.9, 9.6, 1.5H), 7.48 – 7.39 (m, 1.5H), 7.29 (d, *J* = 5.3, 0.5H), 4.67 – 4.57 (m, 1H), 4.37 (t, *J* = 3.8, 1H), 3.80 (dd, *J* = 21.0, 13.1, 1H), 3.27 (dd, *J* = 64.7, 13.0, 1H), 2.86 (dd, *J* = 13.0, 4.7, 1H), 2.73 – 2.61 (m, 1H), 2.50 – 2.40 (m, 1H), 2.36 (d, *J* = 9.1, 1H), 2.28 – 2.08 (m, 3H), 2.03 (dd, *J* = 14.3, 6.2, 0.5H), 2.00 – 1.93 (m, 0.5H), 1.92 – 1.88 (m, 0.5H), 1.86 – 1.45 (m, 9.5H), 1.35 – 1.06 (m, 4H); MS (ESI+) *m/z* 425(M+H)⁺.

Example 238***tert*-butyl (*S*)-1-((3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate**

5 The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-norvaline for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step C of Example 14 for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (501 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 7.44-7.45 (bs, 2H), 7.35-7.40 (m, 2H), 7.30-7.37 (m, 1H), 7.25-7.29 (m, 1H), 4.70-4.75 (bs, 1H), 4.37-4.43 (m, 1H), 3.56 (d, *J* = 12.9 Hz, 1H), 3.52 (d, *J* = 12.8 Hz, 1H), 2.95 (s, 3H), 2.71 (d, *J* = 8.9 Hz, 1H), 2.62-2.68 (m, 1H), 2.44-2.48 (m, 2H), 2.25 (t, *J* = 8.5 Hz, 1H), 2.14 (t, *J* = 8.3 Hz, 1H), 1.91-1.99 (m, 1H), 1.66-1.80 (m, 3H), 1.56-1.63 (m, 1H), 1.50 (s, 9H), 1.26-1.38 (m, 3H), 0.88 (t, *J* = 7.4 Hz, 3H); MS (ESI+) *m/z* 430 (M+H)⁺.

Example 239***tert*-butyl (*S*)-1-((3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate**

20 The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-leucine for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step C of Example 14 for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (501 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 7.44-7.49 (m, 2H), 7.36-7.40 (m, 2H), 7.32-7.39 (m, 1H), 7.27 (t, *J* = 7.4 Hz, 1H), 4.82-4.89 (m, 1H), 4.37-4.43 (m, 1H), 3.63 (d, *J* = 13.2 Hz, 1H), 3.50 (d, *J* = 13.0 Hz, 1H), 2.94 (s, 3H), 2.73 (dd, *J* = 9.7, 1.8 Hz, 1H), 2.64-2.70 (m, 1H), 2.44-2.47 (m, 2H), 2.22-2.28 (m, 1H), 2.15-2.19 (m, 1H), 1.88 (ddd, *J* = 14.1, 8.2, 6.0 Hz, 1H), 1.64-1.81 (m, 3H), 1.55-1.65 (m, 2H), 1.50 (s, 9H), 1.28-1.38 (m, 1H), 0.90-0.93 (m, 6H); MS (ESI+) *m/z* 444 (M+H)⁺.

Example 240***tert*-butyl (*S*)-1-((3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate**

Step A: (3*aR*,4*R*,6*aS*)-2-Benzyloctahydrocyclopenta[*c*]pyrrol-4-amine was prepared according to the procedure described in Example 14 Steps B-C substituting (*S,E*)-*N*-((3*aR*,6*aS*)-2-benzylhexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)-2-methylpropane-2-sulfinamide from Example 14 Step A for (*S,E*)-*N*-((3*aS*,6*aR*)-2-benzylhexahydrocyclopenta[*c*]pyrrol-4(5*H*)-ylidene)-2-methylpropane-2-sulfinamide prepared in Step A of Example 14 to give (3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.44 (d, *J* = 7.4, 2H), 7.36 (t, *J* = 7.5, 2H), 7.28 (t, *J* = 7.3, 1H), 3.52 (q, *J* = 13.0, 2H), 3.29 (q, *J* = 7.3, 1H), 2.84 (dd, *J* = 3.7, 9.3, 1H), 2.55 – 2.43 (m, 3H), 2.37 – 2.30 (m, 1H), 2.24 (d, *J* = 5.3, 1H), 1.74 – 1.64 (m, 2H), 1.62 – 1.53 (m, 1H), 1.34 (dd, *J* = 5.0, 10.1, 1H).

Step B: The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-norvaline for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 7.40 (d, *J* = 7.4, 2H), 7.34 (t, *J* = 7.5, 2H), 7.25 (t, *J* = 7.3, 1H), 4.79 – 4.68 (m, 1H), 4.44 – 4.32 (m, 1H), 3.82 (d, *J* = 13.2, 1H), 3.36 (d, *J* = 13.0, 1H), 2.94 (s, 3H), 2.80 – 2.65 (m, 2H), 2.46 (s, 1H), 2.35 (dd, *J* = 9.2, 2.7, 1H), 2.31 – 2.25 (m, 2H), 1.99 (dt, *J* = 14.0, 7.0, 1H), 1.83 – 1.72 (m, 2H), 1.70 – 1.56 (m, 2H), 1.49 (d, *J* = 4.5, 1H), 1.48 (s, 9H), 1.41 – 1.23 (m, 3H), 0.89 (t, *J* = 7.4, 3H); MS (ESI+) *m/z* 430 (M+H)⁺.

Example 241***tert*-butyl (*S*)-1-((3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-leucine for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 240 for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (400 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 7.40-7.43 (m, 2H), 7.31-7.37 (m, 3H), 7.23-7.30 (m, 1H), 4.82-4.89 (m, 1H), 4.35-4.42 (m, 1H), 3.35 (d, *J* = 12.9 Hz, 1H), 2.95 (s, 3H), 2.68-2.78 (m, 2H), 2.42-2.50 (m, 1H), 2.26-2.36 (m, 3H), 1.89 (ddd, *J* = 14.1, 8.2, 5.9

Hz, 1H), 1.71-1.82 (m, 2H), 1.60-1.70 (m, 3H), 1.48-1.51 (m, 1H), 1.48 (s, 9H), 1.22-1.35 (m, 1H), 0.88-0.98 (m, 6H); MS (ESI+) m/z 444 (M+H)⁺.

Example 242

5 N^1 -[(3a*R*,4*S*,6a*S*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -(methylsulfonyl)-L-leucinamide

Step A: (*S*)-*tert*-Butyl 2-amino-4-methylpentanoate hydrochloride (1.53 g, 6.84 mmol) was dissolved in dichloromethane and triethylamine (3.15 mL, 22.57 mmol).

Methanesulfonyl chloride (0.638 mL, 8.21 mmol) was added dropwise, and the reaction
10 stirred at room temperature for 1 hour. The reaction was quenched with saturated aqueous NaHCO₃ and extracted with dichloromethane (3×50mL). The solvent was removed in vacuo to give (*S*)-*tert*-butyl 4-methyl-2-(methylsulfonamido)pentanoate: ¹H NMR (300 MHz, CDCl₃) δ ppm 4.71 (d, J = 9.7, 1H), 3.98 (td, J = 9.5, 5.5, 1H), 2.92 (s, 3H), 1.84 (dt, J = 13.1, 6.6, 1H), 1.54 (s, 9H), 1.44-1.48 br s, 1H), 0.96 (dd, J = 6.6, 2.4, 6H); MS (ESI-) m/z
15 264(M-H)⁻. (*S*)-*tert*-Butyl 4-methyl-2-(methylsulfonamido)pentanoate was dissolved in 10 mL of 4 *N* HCl in dioxane and stirred at room temperature overnight. The solvent was removed under a stream of nitrogen and under high vacuum to give (*S*)-4-methyl-2-(methylsulfonamido)pentanoic acid: ¹H NMR (300 MHz, CDCl₃) δ ppm 4.86 (d, J = 9.6, 1H), 4.17 (td, J = 9.6, 4.8, 1H), 3.18 – 3.07 (m, 1H), 2.99 (s, 3H), 1.96 – 1.80 (m, 1H), 1.64
20 (dddd, J = 23.4, 13.9, 9.1, 5.0, 2H), 1.40 (t, J = 7.3, 1H), 0.98 (dd, J = 6.6, 3.3, 6H).

Step B: The title compound was prepared by substituting (*S*)-4-methyl-2-(methylsulfonamido)pentanoic acid from Step A for *N*-(*tert*-butoxycarbonyl)-L-leucine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.41 (d, J = 9.4, 1H), 9.21 (d, J = 7.3, 1H), 7.45 (d, J = 7.2, 2H), 7.37 (t, J = 7.5, 2H), 7.29 (t, J = 7.3, 1H), 4.53 – 4.42 (m, 2H), 3.62 (d, J = 13.1, 1H), 3.47 (d, J = 13.1, 1H), 3.19 (s, 3H), 2.87
25 (dd, J = 9.1, 2.9, 1H), 2.66 – 2.58 (m, 1H), 2.57 – 2.45 (m, 2H), 2.35 (dd, J = 9.0, 3.0, 1H), 2.31 – 2.25 (m, 1H), 2.14 (dq, J = 12.0, 6.0, 1H), 1.99 (dq, J = 13.2, 6.5, 1H), 1.93 – 1.82 (m, 2H), 1.77 (ddd, J = 13.8, 8.5, 5.6, 1H), 1.63 (dt, J = 19.3, 7.2, 1H), 1.46 – 1.35 (m, 1H), 0.82 (d, J = 6.7, 3H), 0.79 (d, J = 6.5, 3H); MS (ESI+) m/z 408 (M+H)⁺.

Example 243***N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-(methylsulfonyl)-L-leucinamide**

The title compound was prepared by substituting (*S*)-4-methyl-2-(methylsulfonylamido)pentanoic acid from Step A of Example 242 for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step E of Example 16 for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.40 (d, *J* = 9.4, 1H), 9.21 (d, *J* = 7.2, 1H), 7.43 (d, *J* = 7.5, 2H), 7.36 (t, *J* = 7.6, 2H), 7.27 (t, *J* = 7.3, 1H), 4.52 – 4.38 (m, 2H), 3.57 (d, *J* = 13.1, 1H), 3.47 (d, *J* = 13.1, 1H), 3.17 (s, 3H), 2.85 (dd, *J* = 9.1, 2.2, 1H), 2.59 – 2.48 (m, 2H), 2.37 (dd, *J* = 9.0, 6.8, 2H), 2.25 (dd, *J* = 8.7, 7.1, 1H), 2.19 (dq, *J* = 11.9, 5.9, 1H), 1.99 (dq, *J* = 13.1, 6.5, 1H), 1.94 – 1.84 (m, 2H), 1.80 – 1.66 (m, 2H), 1.44 (ddd, *J* = 18.9, 12.5, 6.2, 1H), 0.82 (d, *J* = 6.7, 3H), 0.79 (d, *J* = 6.5, 3H). ; MS (ESI+) *m/z* 408 (M+H)⁺.

Example 244***N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-neopentyl-L-leucinamide**

Step A: (*S*)-*tert*-Butyl 2-amino-4-methylpentanoate hydrochloride (1.022 g, 4.57 mmol) and pivalaldehyde (0.502 mL, 4.57 mmol) were combined in dichloromethane (25 mL). Acetic acid (1.0 mL) was added. The reaction was stirred at room temperature for 5 minutes, then PS-cyanoborohydride (3.90 g, 9.14 mmol) was added. The reaction was stirred at room temperature overnight, then filtered and the solvent was removed in vacuo. The crude material was diluted with dichloromethane and basified using saturated aqueous sodium bicarbonate to give (*S*)-*tert*-butyl 4-methyl-2-(neopentylamino)pentanoate: ¹H NMR (300 MHz, CDCl₃) δ ppm 3.04 (t, *J* = 7.4, 1H), 2.40 (d, *J* = 11.1, 1H), 2.09 (d, *J* = 11.1, 1H), 1.86 – 1.70 (m, 1H), 1.46 (s, 10H), 1.40 (t, *J* = 7.2, 3H), 0.95 – 0.89 (m, 6H), 0.89 (s, 9H). (*S*)-*tert*-butyl 4-methyl-2-(neopentylamino)pentanoate was dissolved in 10 mL of 4 *N* HCl in dioxane and stirred at room temperature overnight. The solvent was removed under a stream of nitrogen and under high vacuum to give (*S*)-4-methyl-2-(neopentylamino)pentanoic acid: ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 8.89 – 8.37 (m, 1H), 8.34 – 8.03 (m, 1H), 3.82 (t, *J* = 6.5, 1H), 2.88 (d, *J* = 12.3, 1H), 2.62 (d, *J* = 12.2, 1H), 1.83 – 1.67 (m, 2H), 1.67 – 1.56 (m, 1H), 1.00 (s, 9H), 0.97 – 0.88 (m, 6H).

Step B: The title compound was prepared by substituting (*S*)-4-methyl-2-(neopentylamino)pentanoic acid from Step A for *N*-(*tert*-butoxycarbonyl)-L-leucine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.06-8.08 (m, 1H), 7.43-7.46 (m, 2H), 7.37 (t, *J* = 7.5 Hz, 2H), 7.28 (t, *J* = 7.3 Hz, 1H), 4.39-4.46 (m, 1H), 3.61 (d, *J* = 13.1 Hz, 1H), 3.46 (d, *J* = 13.1 Hz, 1H), 3.27 (dd, *J* = 8.5, 5.6 Hz, 1H), 2.84 (dd, *J* = 8.7, 2.5 Hz, 1H), 2.49-2.61 (m, 2H), 2.43-2.49 (m, 2H), 2.36 (dd, *J* = 9.1, 2.9 Hz, 1H), 2.32-2.36 (m, 1H), 2.30 (dd, *J* = 8.8, 7.0 Hz, 1H), 2.15 (dq, *J* = 12.1, 6.1 Hz, 1H), 1.80-1.96 (m, 2H), 1.55-1.76 (m, 4H), 1.39-1.46 (m, 1H), 0.94 (s, 9H), 0.93 (d, *J* = 6.8 Hz, 3H), 0.87 (d, *J* = 6.5 Hz, 3H); MS (ESI+) *m/z* 400 (M+H)⁺.

10

Example 245***N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-neopentyl-L-leucinamide**

The title compound was prepared by substituting (*S*)-4-methyl-2-(neopentylamino)pentanoic acid from Step A of Example 244 for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine of Step E from Example 16 for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.07-8.09 (m, 1H), 7.43-7.45 (m, 2H), 7.37 (t, *J* = 7.5 Hz, 2H), 7.28 (t, *J* = 7.3 Hz, 1H), 4.43 (p, *J* = 6.2 Hz, 1H), 3.60 (d, *J* = 13.1 Hz, 1H), 3.45 (d, *J* = 13.1 Hz, 1H), 3.26 (dd, *J* = 8.6, 5.6 Hz, 1H), 2.86 (dd, *J* = 8.9, 2.6 Hz, 1H), 2.47-2.60 (m, 2H), 2.42-2.47 (m, 2H), 2.36 (dd, *J* = 9.1, 3.0 Hz, 1H), 2.29-2.35 (m, 1H), 2.29 (dd, *J* = 8.7, 7.3 Hz, 1H), 2.14 (dq, *J* = 12.1, 6.0 Hz, 1H), 1.81-1.95 (m, 2H), 1.52-1.76 (m, 4H), 1.44 (dq, *J* = 13.2, 6.6 Hz, 1H), 0.94 (s, 9H), 0.93 (d, *J* = 6.6 Hz, 3H), 0.87 (d, *J* = 6.5 Hz, 3H); MS (ESI+) *m/z* 400 (M+H)⁺.

25

Example 246***N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-neopentyl-L-norvalinamide**

Step A: (*S*)-2-(Neopentylamino)pentanoic acid hydrochloride was prepared by substituting (*S*)-*tert*-butyl 2-amino pentanoate for (*S*)-*tert*-butyl 2-amino-4-methylpentanoate in the procedure described in Step A of Example 244: ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 8.49 (ddd, *J* = 34.9, 23.2, 14.1, 2H), 3.84 (dd, *J* = 8.0, 5.2, 1H), 2.86 (d, *J* = 12.3, 1H),

30

2.66 (d, $J = 12.3$, 1H), 1.99 – 1.73 (m, 2H), 1.58 – 1.42 (m, 1H), 1.41 – 1.26 (m, 1H), 1.00 (s, 9H), 0.92 (t, $J = 7.3$, 3H); MS (ESI+) m/z 188 (M+H)⁺.

Step B: The title compound was prepared by substituting (S)-2-(neopentylamino)pentanoic acid from Step A for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step E of Example 16 for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.00-8.03 (m, 1H), 7.43-7.45 (m, 2H), 7.37 (t, $J = 7.5$ Hz, 2H), 7.28 (t, $J = 7.3$ Hz, 1H), 4.40-4.45 (m, 1H), 3.60 (d, $J = 13.1$ Hz, 1H), 3.45 (d, $J = 13.1$ Hz, 1H), 3.20 (t, $J = 6.5$ Hz, 1H), 2.85 (dd, $J = 8.8$, 2.6 Hz, 1H), 2.52-2.60 (m, 1H), 2.46-2.52 (m, 1H), 2.38-2.46 (m, 2H), 2.31-2.38 (m, 2H), 2.28 (dd, $J = 8.8$, 7.3 Hz, 1H), 2.13 (dq, $J = 12.1$, 6.0 Hz, 1H), 1.79-1.92 (m, 2H), 1.71-1.80 (m, 1H), 1.65-1.73 (m, 1H), 1.57-1.65 (m, 1H), 1.39-1.57 (m, 3H), 0.93 (s, 9H), 0.86 (t, $J = 7.3$ Hz, 3H); MS (ESI-) m/z 384 (M-H)⁻.

Example 247

***tert*-butyl (S)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate**

Step A: (S)-2-(*tert*-Butoxycarbonylamino)-4,4-dimethylpentanoic acid (50 mg, 0.204 mmol) and iodomethane (0.102 mL, 1.631 mmol) were dissolved in tetrahydrofuran (2 mL) at 0 °C and sodium hydride (24.46 mg, 0.611 mmol) was added. The reaction was stirred at 0 °C for a half hour and at room temperature overnight. The reaction was cooled to 0 °C and ethyl acetate (1 mL) was added followed by dropwise quenching with water (2 mL). The solvent was removed in vacuo and the crude material was partitioned between ether and water. The ether layer was separated. The aqueous layer was acidified to pH~5 using 1 *N* citric acid and extracted with ethyl acetate. The organic layer was washed with 1 *N* sodium thiosulfate and brine, dried (Na₂SO₄) and concentrated in vacuo. The compound was purified using a 4 g silica gel cartridge with a gradient of 0-3% methanol/dichloromethane over 20 minutes to give (S)-2-(*tert*-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid: ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 12.63 (s, 1H), 4.57 (ddd, $J = 74.4$, 9.5, 3.1, 1H), 2.69 (s, 3H), 1.83 – 1.53 (m, 2H), 1.39 (s, 9H), 0.89 (s, 9H); MS (ESI+) m/z 260(M+H)⁺.

Step B: The title compound was prepared by substituting (S)-2-(*tert*-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid from Step A for *N*-(*tert*-butoxycarbonyl)-L-leucine in the procedure described in Example 221: ¹H NMR (400 MHz,

pyridine-*d*₅, temperature 90 °C) δ ppm 7.35-7.38 (m, 2H), 7.29 (t, *J* = 7.5 Hz, 2H), 7.20 (t, *J* = 7.3 Hz, 1H), 6.98-7.02 (m, 1H), 4.85-4.90 (m, 1H), 4.20-4.26 (m, 1H), 3.56 (d, *J* = 13.2 Hz, 1H), 3.48 (d, *J* = 13.2 Hz, 1H), 2.92 (s, 3H), 2.79 (d, *J* = 6.5 Hz, 1H), 2.51-2.55 (m, 1H), 2.39-2.47 (m, 2H), 2.37 (dd, *J* = 9.0, 3.1 Hz, 1H), 2.32 (dd, *J* = 8.9, 7.2 Hz, 1H), 2.19 (dd, *J* = 14.3, 5.6 Hz, 1H), 2.00-2.08 (m, 1H), 1.77-1.86 (m, 1H), 1.62 (dd, *J* = 14.3, 6.9 Hz, 1H), 1.50-1.56 (m, 1H), 1.48 (s, 9H), 1.35-1.47 (m, 1H), 0.95 (s, 9H); MS (DSI+) *m/z* 458(M+H)⁺.

Example 248

***tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate**

The title compound was prepared by substituting (*S*)-2-(*tert*-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid from Step A of Example 247 for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step E of Example 16 for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.41-7.43 (m, 2H), 7.36 (t, *J* = 7.5 Hz, 2H), 7.25-7.29 (m, 1H), 5.14 (m, 0.7H), 4.79 (m, 0.2H), 4.35 (dd, *J* = 5.6, 2.9 Hz, 1H), 3.56-3.60 (m, 1H), 3.40-3.44 (m, 1H), 3.02-3.09 (m, 3H), 2.76-2.84 (m, 1H), 2.42-2.51 (m, 2H), 2.31-2.40 (m, 2H), 2.17-2.24 (m, 2H), 2.06-2.15 (m, 1H), 1.79-1.83 (m, 1H), 1.62-1.70 (m, 1H), 1.51-1.63 (m, 2H), 1.47 (s, 9H), 1.32-1.42 (m, 1H), 0.94 (s, 9H); MS (ESI+) *m/z* 458 (M+H)⁺.

Example 249

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-morpholin-4-ylpentanamide

Step A: (*S*)-*tert*-Butyl 2-amino-4-methylpentanoate (1.0042 g, 5.36 mmol), potassium carbonate (2.446 g, 17.69 mmol), and 1-bromo-2-(2-bromoethoxy)ethane (1.368 g, 5.90 mmol) were combined in acetonitrile (30 mL). The reaction was heated at 80 °C overnight. The reaction was cooled and filtered and the solvent removed in vacuo. The crude material was purified by silica gel chromatography using 5-50% ethyl acetate/hexanes to give (*S*)-*tert*-butyl 4-methyl-2-morpholinopentanoate: ¹H NMR (300 MHz, CDCl₃) δ ppm 3.76 - 3.58 (m, 4H), 3.11 (dd, *J* = 6.9, 8.1, 1H), 2.74 - 2.53 (m, 4H), 1.71 - 1.55 (m, 2H), 1.51 - 1.34 (m, 10H), 0.92 (dd, *J* = 6.6, 7.3, 6H). (*S*)-*tert*-Butyl 4-methyl-2-morpholinopentanoate (0.637 g, 2.475 mmol) and 4 *N* hydrochloric acid in dioxane (5 mL) were combined. The

reaction mixture was stirred at ambient temperature for 24 hours, then the solvent removed in vacuo to give (*S*)-4-methyl-2-morpholinopentanoic acid hydrochloride: MS (DCI+) m/z 202(M+H)⁺.

Step B: (*S*)-4-Methyl-2-morpholinopentanoic acid hydrochloride (363 mg, 1.526 mmol) and triethylamine (0.387 mL, 2.77 mmol) were combined in dichloromethane (10 mL). 1-Hydroxybenzotriazole hydrate (234 mg, 1.526 mmol) and *N*¹-((ethylimino)methylene)-*N*³,*N*³-dimethylpropane-1,3-diamine (0.270 mL, 1.526 mmol) were added, and the reaction was stirred for 15 minutes. Then (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine (300 mg, 1.387 mmol) from Example 16 Step E was added, and the reaction mixture was stirred at ambient temperature for 24 hours. The reaction was quenched with aqueous sodium bicarbonate and extracted with dichloromethane. The solvent was removed in vacuo and the crude material was purified by silica gel chromatography using 1-10% methanol (2 *N* ammonia)/dichloromethane to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.27 (d, *J* = 7.3, 1H), 7.44 (d, *J* = 7.4, 2H), 7.37 (t, *J* = 7.5, 2H), 7.27 (dd, *J* = 9.8, 17.3, 1H), 4.51 - 4.39 (m, 1H), 3.74 (t, *J* = 4.5, 4H), 3.62 (d, *J* = 13.1, 1H), 3.45 (d, *J* = 13.1, 1H), 3.29 - 3.21 (m, 1H), 2.87 (dd, *J* = 2.4, 9.0, 1H), 2.79 (dt, *J* = 4.5, 9.3, 2H), 2.75 - 2.68 (m, 2H), 2.55 (d, *J* = 14.8, 2H), 2.49 - 2.43 (m, 1H), 2.35 (dd, *J* = 2.6, 8.9, 1H), 2.32 - 2.26 (m, 1H), 2.11 (dq, *J* = 6.1, 12.1, 1H), 1.86 (dd, *J* = 6.6, 12.2, 3H), 1.67 - 1.55 (m, 2H), 1.41 (dt, *J* = 6.2, 20.1, 1H), 0.94 (dd, *J* = 6.2, 11.1, 6H); MS (ESI+) m/z 400(M+H)⁺.

Example 250

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide

The title compound was prepared by substituting 1,4-dibromobutane for 1-bromo-2-(2-bromoethoxy)ethane in Step A of Example 249: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.98 - 7.93 (m, 1H), 7.47 - 7.41 (m, 2H), 7.36 (t, *J* = 7.4, 2H), 7.31 - 7.24 (m, 1H), 4.45 (t, *J* = 5.2, 1H), 3.61 (d, *J* = 13.1, 1H), 3.45 (d, *J* = 13.1, 1H), 3.16 (dd, *J* = 5.1, 9.3, 1H), 2.87 (d, *J* = 7.9, 1H), 2.73 - 2.65 (m, 2H), 2.66 - 2.52 (m, 4H), 2.44 (dd, *J* = 6.2, 8.9, 1H), 2.36 (dd, *J* = 2.1, 9.0, 1H), 2.30 - 2.23 (m, 1H), 2.12 (dq, *J* = 6.0, 11.9, 1H), 1.95 - 1.78 (m, 3H), 1.66 - 1.54 (m, 6H), 1.47 - 1.36 (m, 1H), 1.00 (d, *J* = 6.4, 3H), 0.91 (d, *J* = 6.4, 3H); MS (ESI+) m/z 384(M+H)⁺.

Example 251**(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-piperidin-1-ylpentanamide**

The title compound was prepared by substituting 1,5-dibromopentane for 1-bromo-2-(2-bromoethoxy)ethane in Step A of Example 249: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.09 (d, *J* = 7.5, 1H), 7.44 (d, *J* = 7.3, 2H), 7.36 (d, *J* = 7.7, 2H), 7.28 (t, *J* = 7.3, 1H), 4.46 – 4.36 (m, 1H), 3.61 (d, *J* = 13.1, 1H), 3.45 (d, *J* = 13.1, 1H), 3.21 (dd, *J* = 8.1, 5.4, 1H), 2.85 (d, *J* = 8.8, 1H), 2.70 – 2.50 (m, 6H), 2.49 – 2.44 (m, 1H), 2.32 (dt, *J* = 27.0, 7.9, 2H), 2.11 (dq, *J* = 12.1, 6.1, 1H), 1.95 – 1.79 (m, 3H), 1.63 – 1.47 (m, 6H), 1.45 – 1.32 (m, 3H), 0.94 (d, *J* = 5.8, 6H); MS (ESI+) *m/z* 398(M+H)⁺.

Example 252***N*²-neopentyl-*N*¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide**

Step A: (3aR,4S,6aS)-2-Benzyl-octahydrocyclopenta[c]pyrrol-4-amine (0.83 g, 3.84 mmol) from Step A of Example 33 was dissolved in anhydrous dichloromethane (5 mL) under nitrogen and triethylamine (0.588 mL, 4.22 mmol) was added followed by di-*tert*-butyl dicarbonate (1.010 mL, 4.22 mmol). The reaction was stirred at 25 °C for 1 hour. Thin-layer chromatography (SiO₂, 5% methanol/dichloromethane) showed complete reaction. The volatiles were removed in vacuo, and the crude material was purified using a 24 g silica gel cartridge eluting with a gradient of 1-5% methanol (2 *N* ammonia)/dichloromethane over 20 minutes to give *tert*-butyl (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylcarbamate: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.54 (d, *J* = 6.3, 1H), 7.43 (d, *J* = 7.3, 2H), 7.36 (t, *J* = 7.4, 2H), 7.27 (t, *J* = 7.2, 1H), 4.12 (q, *J* = 12.1, 1H), 3.59 (d, *J* = 12.9, 1H), 3.43 (d, *J* = 13.0, 1H), 2.78 (s, 1H), 2.59 – 2.49 (m, 2H), 2.49 – 2.41 (m, 1H), 2.37 – 2.25 (m, 2H), 2.16 – 2.05 (m, 1H), 1.88 (td, *J* = 13.1, 6.1, 1H), 1.65 (td, *J* = 14.8, 7.3, 1H), 1.52 (s, 9H), 1.43 – 1.35 (m, 1H); MS (ESI+) *m/z* 317(M+H)⁺.

Step B: *tert*-Butyl (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylcarbamate (1.06 g, 3.35 mmol) from Step A and ethanol (20 mL) were added to 20% Pd(OH)₂ on carbon, wet (212.0 mg, 1.51 mmol) in a 250 mL stainless steel pressure bottle. The reaction mixture was stirred for 16 hours under 30 psi hydrogen at room temperature. The mixture was filtered through a nylon membrane and the solvent was removed in vacuo to give *tert*-butyl (3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-ylcarbamate: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 4.02-3.99 (m, 1H), 3.03 (d, *J* = 10.4, 1H), 2.98 – 2.89 (m, 1H), 2.84

(dd, $J = 10.1, 6.4$, 1H), 2.61-2.50 (m, 3H), 2.06 – 1.98 (m, 1H), 1.91 (td, $J = 12.9, 6.7$, 1H), 1.63 (dt, $J = 19.5, 7.6$, 1H), 1.53 (s, 9H), 1.29-1.23 (m, 1H); MS (ESI+) m/z 227(M+H)⁺.

Step C: *tert*-Butyl (3a*R*,4*S*,6a*S*)-octahydrocyclopenta[*c*]pyrrol-4-ylcarbamate (0.71 g, 3.14 mmol) from Step B, triethylamine (0.656 mL, 4.71 mmol), and 3-

5 (trifluoromethyl)benzene-1-sulfonyl chloride (0.552 mL, 3.45 mmol) were combined in dichloromethane (10.0 mL). The reaction was stirred at room temperature for 16 hours and quenched with saturated aqueous NaHCO₃. The organic layer was separated and concentrated in vacuo. The resultant crude material was applied to a SF-25-60g cartridge (Analogix®, Burlington, Wisconsin) and purified with a gradient of 0-2% methanol/dichloromethane over 20 minutes to give *tert*-butyl (3a*R*,4*S*,6a*S*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylcarbamate: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.30 (s, 1H), 8.14 (d, $J = 7.8$, 1H), 7.84 (d, $J = 7.8$, 1H), 7.65 (t, $J = 7.8$, 1H), 6.83 – 6.71 (m, 1H), 3.88 – 3.76 (m, 1H), 3.61 (dd, $J = 10.1, 3.3$, 1H), 3.24 (dd, $J = 9.8, 8.1$, 1H), 3.12 (d, $J = 5.6$, 2H), 2.64 – 2.44 (m, 2H), 1.99 – 1.78 (m, 2H), 1.55 (tt, $J = 12.4, 7.7$, 1H), 1.48 (s, 9H), 1.38 – 1.20 (m, 1H); MS (ESI-) m/z 433(M-H)⁻.

Step D: *tert*-Butyl (3a*R*,4*S*,6a*S*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylcarbamate (0.814 g, 1.874 mmol) from Step C and HCl (26.2 mL, 52.5 mmol, 2 *M* in ether) in ethanol (3 mL) were combined. The reaction was stirred at room temperature overnight and then the volatiles were removed. The compound was purified using a 24 g silica gel cartridge with a gradient of 1-10% methanol (2 *N* ammonia)/dichloromethane over 20 minutes to give (3a*R*,4*S*,6a*S*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.37 (s, 1H), 8.21 (d, $J = 7.9$, 1H), 7.93 (d, $J = 7.9$, 1H), 7.75 (t, $J = 7.9$, 1H), 3.41 (dd, $J = 9.8, 2.8$, 1H), 3.13 (dd, $J = 9.7, 3.1$, 1H), 3.03 – 2.98 (m, 1H), 2.97 – 2.89 (m, 2H), 2.56 – 2.45 (m, 1H), 2.14 (tdd, $J = 8.7, 5.9, 2.9$, 1H), 1.5-2.0 (m, 2H) 1.95 – 1.85 (m, 1H), 1.79 – 1.69 (m, 1H), 1.32 – 1.15 (m, 2H); MS (ESI+) m/z 335(M+H)⁺.

Step E: The title compound was prepared by substituting (*S*)-4-methyl-2-(neopentylamino)pentanoic acid from Step A of Example 244 for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3a*R*,4*S*,6a*S*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step D for (3a*R*,4*S*,6a*S*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.38 (s, 1H), 8.19-8.22 (m, 2H), 7.90-7.93 (m, 1H), 7.72 (t, $J = 7.8$ Hz, 1H), 4.21-4.29 (m, 1H), 3.87 (dd, $J = 9.9, 2.6$ Hz, 1H), 3.25

(dd, $J = 8.6, 5.6$ Hz, 1H), 3.15-3.21 (m, 2H), 2.97 (dd, $J = 9.6, 7.0$ Hz, 1H), 2.43-2.60 (m, 3H), 2.28-2.32 (m, 1H), 1.79-2.01 (m, 3H), 1.67-1.78 (m, 1H), 1.69 (ddd, $J = 13.6, 7.9, 5.7$ Hz, 1H), 1.51-1.60 (m, 2H), 1.32 (ddt, $J = 9.3, 12.8, 6.4$ Hz, 1H), 0.93 (d, $J = 6.6$ Hz, 3H), 0.93 (s, 9H), 0.86 (d, $J = 6.5$ Hz, 3H); MS (ESI+) m/z 518 (M+H)⁺.

5

Example 253

***N*²-neopentyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide**

The title compound was prepared by substituting (*S*)-2-(Neopentylamino)pentanoic acid from Step A of Example 246 for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step D of Example 252 for (3*aR*,4*S*,6*aS*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.38-8.39 (bs, 1H), 8.19-8.21 (m, 1H), 8.13-8.16 (m, 1H), 7.90-7.93 (m, 1H), 7.72 (t, $J = 7.8$ Hz, 1H), 4.21-4.28 (m, 1H), 3.87 (dd, $J = 9.9, 2.8$ Hz, 1H), 3.15-3.21 (m, 3H), 2.97 (dd, $J = 9.6, 7.3$ Hz, 1H), 2.45-2.59 (m, 2H), 2.40 (d, $J = 11.2$ Hz, 1H), 2.31 (d, $J = 11.2$ Hz, 1H), 1.93-2.00 (m, 1H), 1.76-1.89 (m, 2H), 1.61-1.93 (m, 1H), 1.61-1.70 (m, 1H), 1.41-1.58 (m, 3H), 1.31 (ddt, $J = 9.4, 13.0, 6.5$ Hz, 1H), 0.92 (s, 9H), 0.86 (t, $J = 7.3$ Hz, 3H); MS (ESI+) m/z 504 (M+H)⁺.

20

Example 254

***N*²-neopentyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide**

Step A: (3*aS*,4*R*,6*aR*)-2-(3-

(Trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine was prepared by substituting (3*aS*,4*R*,6*aR*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine from Step E of Example 16 for (3*aR*,4*S*,6*aS*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in Step A of Example 252 and following steps B-D in Example 252: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.37 (s, 1H), 8.20 (d, $J = 7.9$, 1H), 7.93 (d, $J = 7.8$, 1H), 7.74 (t, $J = 7.8$, 1H), 3.40 (dd, $J = 9.8, 2.8$, 1H), 3.13 (dd, $J = 9.7, 3.1$, 1H), 3.00 (dd, $J = 12.9, 5.7$, 1H), 2.93 (ddd, $J = 12.0, 9.7, 7.9$, 2H), 2.52 (qd, $J = 8.6, 4.3$, 1H), 2.17 – 2.09 (m, 1H), 1.94 – 1.84 (m, 1H), 1.78 – 1.69 (m, 1H), 1.67 – 1.33 (m, 2H), 1.30 – 1.15 (m, 2H); MS (ESI+) m/z 335(M+H)⁺.

30

Step B: The title compound was prepared by substituting (*S*)-4-methyl-2-(neopentylamino)pentanoic acid from Step A of Example 244 for *N*-(*tert*-butoxycarbonyl)-L-

leucine and (3a*S*,4*R*,6a*R*)-2-(3-

(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step A for (3a*R*,4*S*,6a*S*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in

Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.37-8.38 (bs, 1H), 8.15-8.19 (m, 2H), 7.90-7.92 (m, 1H), 7.71 (t, *J* = 7.8 Hz, 1H), 4.22-4.28 (m, 1H), 3.88 (dd, *J* = 9.9, 2.8 Hz, 1H), 3.23 (dd, *J* = 8.5, 5.7 Hz, 1H), 3.19 (dd, *J* = 9.7, 2.8 Hz, 1H), 3.15 (dd, *J* = 9.9, 7.6 Hz, 1H), 2.96 (dd, *J* = 9.6, 7.2 Hz, 1H), 2.50-2.59 (m, 2H), 2.41-2.44 (m, 1H), 2.32 (d, *J* = 11.2 Hz, 1H), 1.92-2.01 (m, 1H), 1.82-1.92 (m, 2H), 1.60-1.78 (m, 1H), 1.69 (ddd, *J* = 13.5, 7.8, 5.7 Hz, 1H), 1.50-1.59 (m, 2H), 1.32 (ddt, *J* = 9.4, 13.0, 6.5 Hz, 1H), 0.92 (s, 9H), 0.92 (d, *J* = 6.6 Hz, 3H), 0.86 (d, *J* = 6.5 Hz, 3H); MS (ESI+) *m/z* 518 (M+H)⁺.

Example 255

***N*²-neopentyl-*N*¹-((3a*S*,4*R*,6a*R*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide**

The title compound was prepared by substituting (*S*)-2-(neopentylamino)pentanoic acid from Step A of Example 246 for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3a*S*,4*R*,6a*R*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 254 for (3a*R*,4*S*,6a*S*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.37-8.38 (bs, 1H), 8.18 (d, *J* = 7.9 Hz, 1H), 8.09-8.11 (m, 1H), 7.90-7.92 (m, 1H), 7.71 (t, *J* = 7.8 Hz, 1H), 4.20-4.27 (m, 1H), 3.88 (dd, *J* = 9.9, 2.8 Hz, 1H), 3.20 (dd, *J* = 6.6, 3.1 Hz, 1H), 3.16-3.20 (m, 1H), 3.14 (dd, *J* = 9.9, 7.8 Hz, 1H), 2.96 (dd, *J* = 9.6, 7.3 Hz, 1H), 2.46-2.61 (m, 2H), 2.38 (d, *J* = 11.3 Hz, 1H), 2.33 (d, *J* = 11.3 Hz, 1H), 1.92-1.99 (m, 1H), 1.83-1.90 (m, 1H), 1.76-1.83 (m, 1H), 1.66-1.87 (m, 1H), 1.61-1.70 (m, 1H), 1.38-1.58 (m, 3H), 1.26-1.37 (m, 1H), 0.92 (s, 9H), 0.85 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z* 504 (M+H)⁺.

Example 256

***N*²-neopentyl-*N*¹-((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide**

Step A: (3a*R*,4*S*,6a*S*)-2-(4-(Trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine was prepared by substituting 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in Step C of Example 252 and following the procedure of Step D in

Example 252: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.15 (d, $J = 8.2$, 2H), 7.92 (d, $J = 8.3$, 2H), 3.40 (dd, $J = 9.8$, 2.9, 1H), 3.13 (dd, $J = 9.7$, 3.2, 1H), 3.06 – 2.93 (m, 3H), 2.54 (s, 1H), 2.21 – 2.12 (m, 1H), 1.93 – 1.85 (m, 1H), 1.78 – 1.69 (m, 1H), 1.67 – 1.33 (m, 2H), 1.33 – 1.15 (m, 2H); MS (ESI+) m/z 335(M+H) $^+$.

Step B: The title compound was prepared by substituting (*S*)-4-methyl-2-(neopentylamino)pentanoic acid from Step A of Example 244 for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step A for (3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in

Example 221: ^1H NMR (400 MHz, pyridine- d_5) δ ppm 8.20-8.23 (m, 1H), 8.13-8.16 (m, 2H), 7.89-7.92 (m, 2H), 4.21-4.29 (m, 1H), 3.86 (dd, $J = 9.9$, 2.8 Hz, 1H), 3.22-3.28 (m, 1H), 3.15-3.22 (m, 2H), 2.99 (dd, $J = 9.6$, 7.0 Hz, 1H), 2.50-2.62 (m, 2H), 2.43-2.47 (m, 1H), 2.28-2.32 (m, 1H), 1.92-2.02 (m, 1H), 1.80-1.92 (m, 2H), 1.64-1.76 (m, 1H), 1.69 (ddd, $J = 13.5$, 7.7, 5.8 Hz, 1H), 1.50-1.61 (m, 2H), 1.25-1.40 (m, 1H), 0.93 (d, $J = 6.8$ Hz, 3H), 0.93 (s, 9H), 0.86 (d, $J = 6.5$ Hz, 3H); MS (ESI+) m/z 518 (M+H) $^+$.

Example 257

***N*²-neopentyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide**

The title compound was prepared by substituting (*S*)-2-(neopentylamino)pentanoic acid from Step A of Example 246 for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 256 for (3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.37-8.38 (bs, 1H), 8.13-8.18 (m, 3H), 7.89-7.91 (m, 2H), 4.21-4.28 (m, 1H), 3.86 (dd, $J = 9.9$, 2.9 Hz, 1H), 3.16-3.22 (m, 3H), 2.98 (dd, $J = 9.6$, 7.3 Hz, 1H), 2.47-2.61 (m, 2H), 2.41 (d, $J = 11.2$ Hz, 1H), 2.32 (d, $J = 11.2$ Hz, 1H), 1.93-2.00 (m, 1H), 1.78-1.88 (m, 2H), 1.63-1.70 (m, 1H), 1.41-1.58 (m, 3H), 1.28-1.36 (m, 1H), 0.93 (s, 9H), 0.86 (t, $J = 7.3$ Hz, 3H); MS (ESI+) m/z 504 (M+H) $^+$.

Example 258***N*-(*tert*-butoxycarbonyl)-*N*-methyl-*N*-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-phenylalaninamide**

5 The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-phenylalanine for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 256 for (3*aR*,4*S*,6*aS*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (400 MHz, pyridine-*d*₅, temperature 90 °C) δ

10 ppm 8.09-8.12 (m, 2H), 7.83-7.86 (m, 2H), 7.52-7.59 (bs, 1H), 7.28-7.32 (m, 2H), 7.23-7.28 (m, 2H), 7.15-7.21 (m, 1H), 4.95-5.12 (m, 1H), 4.09 (p, *J* = 6.9 Hz, 1H), 3.62 (dd, *J* = 10.4, 3.4 Hz, 1H), 3.48 (dd, *J* = 14.0, 7.0 Hz, 1H), 3.26 (dd, *J* = 10.1, 7.9 Hz, 1H), 3.10-3.18 (m, 1H), 3.04-3.13 (m, 1H), 2.97 (s, 3H), 2.46-2.57 (m, 1H), 2.36-2.46 (m, 1H), 1.86-1.96 (m, 1H), 1.74-1.83 (m, 1H), 1.44-1.55 (m, 1H), 1.42-1.46 (m, 1H), 1.38 (s, 9H), 1.21-1.32 (m,

15 1H); MS (ESI+) *m/z* 596 (M+H)⁺.

Example 259***tert*-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

20 The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-norvaline for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step A of Example 256 for (3*aR*,4*S*,6*aS*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (400 MHz, pyridine-*d*₅, temperature 90 °C) δ

25 ppm 8.06-8.09 (m, 2H), 7.79-7.82 (m, 2H), 7.40 (d, *J* = 3.1 Hz, 1H), 4.66-4.76 (m, 1H), 4.07 (p, *J* = 6.8 Hz, 1H), 3.65 (dd, *J* = 10.2, 3.4 Hz, 1H), 3.28 (dd, *J* = 10.2, 7.7 Hz, 1H), 3.06-3.17 (m, 2H), 2.93 (s, 3H), 2.53-2.62 (m, 1H), 2.45-2.53 (m, 1H), 1.93-2.02 (m, 1H), 1.86-1.95 (m, 1H), 1.70-1.85 (m, 2H), 1.47-1.57 (m, 1H), 1.45 (s, 9H), 1.27-1.37 (m, 2H), 1.22-1.32

30 (m, 1H), 0.86 (t, *J* = 7.4 Hz, 3H); MS (ESI+) *m/z* 548 (M+H)⁺.

Example 260

***N*²-neopentyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide**

Step A: (3*aS*,4*R*,6*aR*)-2-(4-

5 (Trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine was prepared by following the procedures described in Example 252 Steps A-D substituting (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Step E of Example 16 for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in Step A of Example 252 and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl
10 chloride in the procedure described in Step C of Example 252: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.15 (d, *J* = 8.2, 2H), 7.92 (d, *J* = 8.3, 2H), 3.40 (dd, *J* = 9.8, 2.9, 1H), 3.13 (dd, *J* = 9.7, 3.2, 1H), 3.06 – 2.93 (m, 3H), 2.54 (s, 1H), 2.21 – 2.12 (m, 1H), 1.93 – 1.85 (m, 1H), 1.78 – 1.69 (m, 1H), 1.67 – 1.33 (m, 2H), 1.33 – 1.15 (m, 2H); MS (ESI+) *m/z* 335(M+H)⁺.

15 **Step B:** The title compound was prepared by substituting (*S*)-2-(neopentylamino)pentanoic acid from Step A of Example 246 for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step A for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in
20 Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.09-8.14 (m, 3H), 7.88-7.91 (m, 2H), 4.20-4.26 (m, 1H), 3.88 (dd, *J* = 9.9, 2.9 Hz, 1H), 3.13-3.21 (m, 3H), 2.98 (dd, *J* = 9.6, 7.4 Hz, 1H), 2.49-2.64 (m, 2H), 2.38 (d, *J* = 11.2 Hz, 1H), 2.33 (d, *J* = 11.2 Hz, 1H), 1.91-1.99 (m, 1H), 1.76-1.90 (m, 2H), 1.66-1.95 (m, 1H), 1.62-1.71 (m, 1H), 1.41-1.58 (m, 3H), 1.33 (ddt, *J* = 9.5, 13.0, 6.5 Hz, 1H), 0.92 (s, 9H), 0.86 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z*
25 504 (M+H)⁺.

Example 261

***N*¹-{(3*aR*,4*S*,6*aS*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*²-neopentyl-L-leucinamide**

30 **Step A:** (3*aR*,4*S*,6*aS*)-2-(4-Fluorophenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine was prepared by substituting 4-fluorobenzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in Step C of Example 252 and following Step D in Example 252: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.05 – 7.96 (m, 2H), 7.38 – 7.31

(m, 2H), 3.34 (dd, $J = 9.8, 3.0$, 1H), 3.08 (dd, $J = 9.7, 3.3$, 1H), 3.05 – 2.98 (m, 1H), 2.97 – 2.89 (m, 2H), 2.59 – 2.49 (m, 1H), 2.20 – 2.10 (m, 1H), 1.95 – 1.85 (m, 1H), 1.79 – 1.69 (m, 1H), 1.67 – 1.33 (m, 2H) 1.31 – 1.15 (m, 2H); MS (ESI+) m/z 285(M+H)⁺.

Step B: The title compound was prepared by substituting (S)-4-methyl-2-

5 (neopentylamino)pentanoic acid from Step A of Example 244 for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aR*,4*S*,6*aS*)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step A for (3*aR*,4*S*,6*aS*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.21-8.23 (m, 1H), 7.99-8.02 (m, 2H), 7.32 (t, $J = 8.5$ Hz, 2H), 4.23-4.29 (m, 1H), 3.78 (dd, $J = 9.9, 2.9$ Hz, 1H), 3.26 (dd, $J = 8.5, 5.7$ Hz, 1H), 3.12-3.18 (m, 2H), 2.96 (dd, $J = 9.6, 7.1$ Hz, 1H), 2.51-2.60 (m, 2H), 2.44-2.47 (m, 1H), 2.29-2.32 (m, 1H), 1.93-2.01 (m, 1H), 1.81-1.93 (m, 2H), 1.67-1.79 (m, 1H), 1.70 (ddd, $J = 13.5, 7.8, 5.7$ Hz, 1H), 1.53-1.60 (m, 2H), 1.23-1.36 (m, 1H), 0.93 (d, $J = 6.7$ Hz, 3H), 0.93 (s, 9H), 0.87 (d, $J = 6.5$ Hz, 3H); MS (ESI+) m/z 468 (M+H)⁺.

15

Example 262

***tert*-butyl (S)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate**

Step A: *tert*-Butyl (3*aR*,4*S*,6*aS*)-octahydrocyclopenta[*c*]pyrrol-4-ylcarbamate from
20 Step B of Example 252 (250 mg, 1.105 mmol), 2-bromo-5-(trifluoromethyl)pyridine (250 mg, 1.105 mmol), and triethylamine (0.462 mL, 3.31 mmol) were combined in ethanol (0.6 mL). The reaction was heated at 81 °C for 16 hours. To the reaction mixture was added 50% water/ethanol (5 mL), and the precipitate was collected by filtration. This crude material was purified using a 12 g silica gel cartridge with a gradient of 0-1.5% methanol (2 *N*
25 ammonia)/dichloromethane over 20 minutes to give *tert*-butyl (3*aR*,4*S*,6*aS*)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-ylcarbamate: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.62 (s, 1H), 7.76 (d, $J = 6.4$, 1H), 7.68 (d, $J = 8.6$, 1H), 6.38 (d, $J = 8.8$, 1H), 4.10 (s, 1H), 3.73 (d, $J = 10.4$, 1H), 3.65 (s, 1H), 3.61 – 3.53 (m, 1H), 3.32 (d, $J = 10.1$, 1H), 2.82 – 2.71 (m, 2H), 2.15 (td, $J = 12.6, 6.8$, 1H), 1.97 (dt, $J = 13.1, 6.4$, 1H), 1.74
30 (dq, $J = 15.6, 7.9$, 1H), 1.54 (s, 9H), 1.45 – 1.34 (m, 1H); MS(DCI+) m/z 372(M+H)⁺.

Step B: *tert*-Butyl (3*aR*,4*S*,6*aS*)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-ylcarbamate (282 mg, 0.759 mmol) from Step A was combined with 4 *N* HCl in 1,4-dioxane (2.5 mL, 9.87 mmol). The reaction was stirred at

room temperature overnight and then the volatiles were removed in vacuo. The compound was purified using a 12 g silica gel cartridge eluting with a gradient of 0-7.5% methanol (2 *N* ammonia)/dichloromethane over 20 minutes to give (3a*R*,4*S*,6a*S*)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-amine: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.64 (s, 1H), 7.69 (dd, *J* = 8.9, 2.5, 1H), 6.38 (d, *J* = 8.9, 1H), 4.95 (s, 2H), 3.56 (dd, *J* = 23.7, 14.1, 3H), 3.25 (d, *J* = 6.2, 1H), 3.11 (q, *J* = 6.0, 1H), 2.83 – 2.68 (m, 1H), 2.35 (ddd, *J* = 13.1, 7.9, 5.3, 1H), 2.02 (dtd, *J* = 13.5, 8.3, 5.5, 1H), 1.92 (ddd, *J* = 18.3, 7.4, 5.6, 1H), 1.46 – 1.30 (m, 2H); MS (ESI+) *m/z* 272(M+H)⁺.

Step C: The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-L-neopentylglycine for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3a*R*,4*S*,6a*S*)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step B for (3a*R*,4*S*,6a*S*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.52 (s, 1H), 7.81 (d, *J* = 5.8, 1H), 7.60 (dd, *J* = 8.9, 2.5, 1H), 7.07 (d, *J* = 7.0, 1H), 6.35 (d, *J* = 8.9, 1H), 4.53 (td, *J* = 8.3, 4.7, 1H), 4.30 – 4.18 (m, 1H), 3.72 (dd, *J* = 11.3, 3.5, 1H), 3.65 (dd, *J* = 11.3, 7.6, 1H), 3.57 (dd, *J* = 11.1, 7.8, 1H), 3.31 (dd, *J* = 11.2, 3.9, 1H), 2.80 – 2.67 (m, 2H), 2.10 (ddd, *J* = 19.9, 13.5, 5.8, 2H), 1.93 (td, *J* = 13.1, 7.7, 1H), 1.74 (dd, *J* = 14.3, 8.0, 1H), 1.64 (dq, *J* = 12.9, 7.8, 1H), 1.50 (s, 9H), 1.44 – 1.33 (m, 1H), 1.00 (s, 9H); MS (ESI+) *m/z* 499(M+H)⁺.

Example 263

isopropyl (*S*)-1-oxo-1-((3a*R*,4*S*,6a*S*)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate

Step A: (*S*)-2-Aminopentanoic acid (1.874 g, 16mmol) was dissolved in dioxane (16 mL) and 16 mL of 1 *N* NaOH at 0 °C. 1 *M* Isopropyl carbonochloridate in toluene (16.00 mL, 16.00 mmol) was added simultaneously with 16 mL of 1 *N* NaOH dropwise using addition funnels. The reaction was stirred at 0 °C for 3 hours and allowed to warm to room temperature overnight to give a biphasic solution pH 8-9. The solvent was reduced in volume. The aqueous layer was washed with ether, acidified with 1 *M* KHSO₄, and extracted with ethyl acetate to give (*S*)-2-(isopropoxycarbonylamino)pentanoic acid: ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 12.43 (s, 1H), 7.25 (d, *J* = 8.0, 1H), 4.73 (hept, *J* = 6.3, 1H), 3.89 (td, *J* = 8.6, 5.2, 1H), 1.68 – 1.46 (m, 2H), 1.41 – 1.22 (m, 2H), 1.16 (d, *J* = 6.2, 6H), 0.85 (t, *J* = 7.3, 3H); MS (DCI+) *m/z* 204(M+H)⁺.

Step B: The title compound was prepared by substituting (*S*)-2-(isopropoxycarbonylamino)pentanoic acid from Step A for *N*-(*tert*-butoxycarbonyl)-L-

leucine and (3a*R*,4*S*,6a*S*)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step B of Example 262 for (3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.52 (d, *J* = 1.0, 1H), 7.94 (dd, *J* = 4.3, 2.4, 1H), 7.60 (dd, *J* = 8.9, 2.5, 1H), 7.07 (d, *J* = 7.0, 1H), 6.35 (d, *J* = 8.9, 1H), 5.03 (dt, *J* = 12.5, 6.2, 1H), 4.49 (dd, *J* = 13.9, 8.0, 1H), 4.35 – 4.19 (m, 1H), 3.73 (dd, *J* = 11.3, 3.6, 1H), 3.66 (dd, *J* = 11.3, 7.6, 1H), 3.57 (dd, *J* = 11.0, 8.0, 1H), 3.32 (dd, *J* = 11.2, 3.9, 1H), 2.81 – 2.66 (m, 2H), 2.10 (dt, *J* = 12.4, 7.0, 1H), 2.04 – 1.88 (m, 2H), 1.86 – 1.75 (m, 1H), 1.72 – 1.60 (m, 1H), 1.57 – 1.46 (m, 2H), 1.45 – 1.33 (m, 1H), 1.21 (d, *J* = 6.2, 3H), 1.18 (d, *J* = 6.2, 3H), 0.87 (t, *J* = 7.4, 3H). ;MS (ESI+) *m/z* 457(M+H)⁺.

10

Example 264

***tert*-butyl (S)-4,4-dimethyl-1-oxo-1-((3a*R*,4*S*,6a*S*)-2-(6-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate**

Step A: (3a*R*,4*S*,6a*S*)-2-(6-(Trifluoromethyl)pyridin-2-

yl)octahydrocyclopenta[*c*]pyrrol-4-amine was prepared as described for Example 262 Steps A-B substituting 2-bromo-6-(trifluoromethyl)pyridine for 2-bromo-5-(trifluoromethyl)pyridine in Step A of Example 262: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.53 (t, *J* = 7.9, 1H), 6.98 (d, *J* = 7.2, 1H), 6.51 (d, *J* = 8.6, 1H), 3.49 (dd, *J* = 20.2, 8.4, 3H), 3.19 (dd, *J* = 10.7, 4.8, 1H), 3.08 (q, *J* = 6.0, 1H), 2.78 – 2.69 (m, 1H), 2.32 (td, *J* = 12.2, 5.8, 1H), 2.04 – 1.95 (m, 1H), 1.89 (dt, *J* = 12.7, 5.7, 1H), 1.80 – 1.49 (m, 2H), 1.44 – 1.36 (m, 1H), 1.35 – 1.27 (m, 1H); MS (ESI+) *m/z* 272(M+H)⁺.

Step B: The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-L-neopentylglycine for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3a*R*,4*S*,6a*S*)-2-(6-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step A for (3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 7.78 (s, 1H), 7.45 (s, 1H), 7.05 (s, 1H), 6.91 (d, *J* = 7.3, 1H), 6.47 (d, *J* = 8.6, 1H), 4.53 (td, *J* = 8.3, 4.7, 1H), 4.28 – 4.19 (m, 1H), 3.67 – 3.56 (m, 2H), 3.52 (dd, *J* = 10.9, 7.9, 1H), 3.27 (dd, *J* = 11.0, 3.7, 1H), 2.76 – 2.66 (m, 2H), 2.13 (dd, *J* = 14.3, 4.6, 1H), 2.06 (dt, *J* = 12.8, 6.4, 1H), 1.91 (td, *J* = 13.3, 7.9, 1H), 1.73 (dd, *J* = 14.3, 8.0, 1H), 1.62 (dq, *J* = 15.1, 7.7, 1H), 1.50 (s, 9H), 1.37 (qd, *J* = 7.9, 4.9, 1H), 1.00 (s, 9H). ;MS (ESI+) *m/z* 499(M+H)⁺.

30

Example 265

***tert*-butyl (*S*)-4,4-dimethyl-1-((3*aR*,4*S*,6*aS*)-2-(2-(methylsulfonyl)pyrimidin-5-yl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-ylcarbamate**

Step A: (3*aR*,4*S*,6*aS*)-2-(2-(Methylsulfonyl)pyrimidin-5-

5 yl)octahydrocyclopenta[*c*]pyrrol-4-amine was prepared as described in Example 262 Steps A-B substituting 5-bromo-2-(methylsulfonyl)pyrimidine for 2-bromo-5-(trifluoromethyl)pyridine in Step A of Example 262: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.48 (s, 2H), 4.96 (s, 3H), 3.71 (dd, *J* = 11.6, 8.6, 1H), 3.66 (d, *J* = 6.1, 2H), 3.41 (dd, *J* = 11.7, 4.9, 1H), 3.11 (q, *J* = 6.0, 1H), 2.80 – 2.71 (m, 1H), 2.37 – 2.30 (m, 1H), 2.00 (ddd, *J* = 21.4, 10.5, 6.5, 1H), 1.90 (td, *J* = 12.5, 5.6, 1H), 1.82 – 1.51 (m, 2H), 1.44 – 1.29 (m, 2H); MS (ESI+) *m/z* 283(M+H)⁺.

Step B: The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-L-neopentylglycine for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aR*,4*S*,6*aS*)-2-(2-(methylsulfonyl)pyrimidin-5-yl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step A for
 15 (3*aR*,4*S*,6*aS*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.34 (s, 2H), 7.79 (ddd, *J* = 3.5, 1.7, 0.7, 1H), 7.10 – 6.93 (m, 1H), 4.52 (td, *J* = 8.2, 4.7, 1H), 4.27 (qd, *J* = 7.1, 5.4, 1H), 3.90 (d, *J* = 11.1, 3H), 3.85 (dd, *J* = 8.1, 3.9, 1H), 3.77 (dd, *J* = 12.1, 7.6, 1H), 3.67 (dd, *J* = 11.8, 7.9, 1H), 3.42 (dd, *J* = 11.8, 4.1, 1H), 2.79 – 2.63 (m, 2H), 2.16 – 2.02 (m, 2H), 1.97 – 1.83 (m, 20 1H), 1.72 (dd, *J* = 14.3, 8.0, 1H), 1.68 – 1.56 (m, 1H), 1.49 (s, 9H), 1.44 – 1.30 (m, 1H), 0.99 (s, 9H); MS (ESI+) *m/z* 510(M+H)⁺.

Example 266

(*S*)-*tert*-butyl 2-((3*aS*,4*R*,6*aR*)-2-(3-

25 **(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylate**

(*S*)-1-(*tert*-Butoxycarbonyl)pyrrolidine-2-carboxylic acid (53.1 mg, 0.247 mmol), and 2-(3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (94 mg, 0.247 mmol) were combined in dichloromethane (2 mL).
 30 After 10 minutes, (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine (75 mg, 0.224 mmol) from Step A of Example 254 was added. After stirring for 10 more minutes, *N*-ethyl-*N*-isopropylpropan-2-amine (0.098 mL, 0.561 mmol) was added and the reaction mixture was stirred at room temperature overnight. The reaction was quenched with saturated NaHCO₃

solution, extracted with 2 mL of dichloromethane, washed with 0.1 N HCl, and concentrated in vacuo. The crude material was purified using a 12 g silica gel cartridge with a gradient of

1-5% methanol (2 N ammonia)/dichloromethane over 20 minutes to give the title compound: ¹H NMR (501 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.29-8.30 (bs, 1H), 8.13 (d, *J* = 7.9 Hz, 1H), 7.83 (d, *J* = 7.8 Hz, 1H), 7.66-7.72 (m, 1H), 7.64 (t, *J* = 7.9 Hz, 1H), 4.29-4.32 (m, 1H), 4.06-4.10 (m, 1H), 3.68-3.71 (m, 1H), 3.46-3.51 (m, 1H), 3.34-3.42 (m, 1H), 3.26 (dd, *J* = 9.9, 7.4 Hz, 1H), 3.06-3.17 (m, 2H), 2.55-2.57 (m, 2H), 2.09 (d, *J* = 3.0 Hz, 1H), 1.88-1.98 (m, 3H), 1.80-1.88 (m, 1H), 1.59-1.68 (m, 1H), 1.55 (dd, *J* = 13.2, 8.7 Hz, 1H), 1.50 (s, 9H), 1.25-1.37 (m, 1H); MS (ESI+) *m/z* 532 (M+H)⁺.

Example 267

***tert*-butyl (1*R*)-1-isopropyl-3-oxo-3-(((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]propylcarbamate**

The title compound was prepared by substituting (*R*)-3-(*tert*-butoxycarbonylamino)-4-methylpentanoic acid for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid in the procedure described in Example 266: ¹H NMR (501 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.29-8.31 (bs, 1H), 8.14 (d, *J* = 7.8 Hz, 1H), 7.83 (d, *J* = 7.8 Hz, 1H), 7.76-7.80 (bs, 1H), 7.65 (t, *J* = 7.9 Hz, 1H), 6.53-6.62 (m, 1H), 4.08-4.15 (m, 1H), 4.02-4.08 (m, 1H), 3.67 (dd, *J* = 10.1, 3.2 Hz, 1H), 3.28 (dd, *J* = 9.9, 7.9 Hz, 1H), 3.08-3.16 (m, 2H), 2.46-2.59 (m, 4H), 1.87-1.98 (m, 2H), 1.79-1.87 (m, 1H), 1.50-1.62 (m, 1H), 1.48 (s, 9H), 1.24-1.36 (m, 1H), 0.89-0.93 (m, 6H); MS (ESI+) *m/z* 548 (M+H)⁺.

Example 268

***tert*-butyl (2*S*)-2-(((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate**

The title compound was prepared by substituting (*S*)-1-(*tert*-butoxycarbonyl)piperidine-2-carboxylic acid for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid in the procedure described in Example 266: ¹H NMR (501 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.29-8.30 (bs, 1H), 8.14 (d, *J* = 7.8 Hz, 1H), 7.83 (d, *J* = 7.9 Hz, 1H), 7.64 (t, *J* = 7.9 Hz, 1H), 7.39-7.43 (bs, 1H), 4.82-4.84 (m, 1H), 4.04-4.12 (m, 2H), 3.68 (dd, *J* = 10.1, 3.3 Hz, 1H), 3.28-3.32 (m, 1H), 3.23-3.28 (m, 1H), 3.08-3.16 (m, 2H), 2.48-

2.58 (m, 2H), 2.16-2.21 (m, 1H), 1.89-1.96 (m, 1H), 1.78-1.85 (m, 1H), 1.49-1.63 (m, 5H), 1.47 (s, 9H), 1.32-1.39 (m, 1H), 1.23-1.32 (m, 1H); MS (ESI+) m/z 544 (M+H)⁺.

Example 269

5 ***N*-(*tert*-butoxycarbonyl)-*N*-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-phenylalaninamide**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-L-phenylalanine for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and (3*aR*,4*S*,6*aS*)-
 10 2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step D of Example 252 for (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.28-8.32 (m, 1H), 8.11-8.17 (m, 1H), 7.82-7.93 (m, 2H), 7.63-7.69 (m, 1H), 7.21-7.29 (m, 4H),
 15 7.16-7.21 (m, 1H), 7.07-7.15 (m, 1H), 4.65-4.70 (m, 1H), 4.0 (m, 1H), 3.52-3.62 (m, 1H), 3.26-3.31 (m, 1H), 3.12-3.21 (m, 2H), 3.03-3.11 (m, 2H), 2.42-2.48 (m, 1H), 2.31-2.36 (m, 1H), 1.81-1.88 (m, 1H), 1.69-1.77 (m, 1H), 1.37-1.48 (m, 1H), 1.42 (s, 9H), 1.16-1.26 (m, 1H); MS (ESI+) m/z 599 (M+H)⁺.

20 Example 270

***N*-(*tert*-butoxycarbonyl)-*N*-methyl-*N*-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-phenylalaninamide**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-phenylalanine for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and
 25 (3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step D of Example 252 for (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.65 – 8.52 (m, 1H),
 30 8.38 (s, 1H), 8.22 (d, *J* = 7.8, 1H), 7.93 (d, *J* = 7.8, 1H), 7.75 (t, *J* = 7.8, 1H), 7.39 – 7.23 (m, 5H), 5.40 – 5.29 (m, 1H), 4.30 – 4.14 (m, 1H), 3.84 – 3.72 (m, 1H), 3.65 – 3.45 (m, 1H), 3.13 (d, *J* = 5.4, 2H), 3.06 (s, 3H), 3.03 (dd, *J* = 9.7, 7.6, 1H), 2.89 (dd, *J* = 9.5, 7.5, 1H), 2.41 (dd,

$J = 13.4, 6.1, 1\text{H}$), 2.39 – 2.30 (m, 1H), 1.95-1.80 (m, 1H), 1.74 (s, 1H), 1.55 – 1.40 (m, 1H), 1.36 (s, 5H), 1.25 (s, 4H), 1.22 – 1.15 (m, 1H); MS (ESI+) m/z 596 (M+H)⁺.

Example 271

5 **(*S*)-*tert*-butyl 2-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylate**

The title compound was prepared by substituting (3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step D of
10 Example 252 for (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.42-8.59 (m, 1H), 8.36-8.38 (bs, 1H), 8.16-8.22 (m, 1H), 7.92 (d, $J = 7.3$ Hz, 1H), 7.74 (t, $J = 7.5$ Hz, 1H), 4.31-4.55 (m, 1H), 4.09-4.31 (m, 1H), 3.73-3.90 (m, 1H), 3.48-3.68 (m, 1H), 3.27-3.48 (m, 1H), 3.06-
15 3.25 (m, 2H), 2.85-3.03 (m, 1H), 2.42-2.65 (m, 2H), 1.72-2.22 (m, 5H), 1.60-1.72 (m, 1H), 1.53-1.57 (bs, 5H), 1.49-1.54 (bs, 4H), 1.4 (m, 1H), 1.13-1.26 (m, 1H); MS (ESI+) m/z 532 (M+H)⁺, 549 (M+NH₄)⁺.

Example 272

20 ***tert*-butyl (1*R*)-1-isopropyl-3-oxo-3-(((3*aR*,4*S*,6*aS*)-2-([3-(trifluoromethyl)phenyl]sulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl)amino]propylcarbamate**

The title compound was prepared by substituting (*R*)-3-(*tert*-butoxycarbonylamino)-4-methylpentanoic acid for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and
25 (3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step D of Example 252 for (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.30-8.31 (bs, 1H), 8.14 (d, $J = 7.8$ Hz, 1H), 7.84 (d, $J = 7.6$ Hz, 1H), 7.76-7.85 (bs, 1H), 7.66 (t, $J = 7.8$ Hz, 1H), 6.50-6.69 (bs, 1H), 4.08-4.16 (m, 1H), 3.64-3.72 (m, 1H), 3.24-3.33 (m, 1H),
30 3.12 (d, $J = 5.2$ Hz, 2H), 2.42-2.63 (m, 4H), 1.89-2.00 (m, 2H), 1.79-1.89 (m, 1H), 1.49-1.63 (m, 1H), 1.48 (s, 9H), 1.23-1.33 (m, 2H), 0.88-0.95 (m, 6H); MS (ESI+) m/z 570 (M+Na)⁺.

Example 273***tert*-butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate**

5 The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-valine for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and (3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step D of Example 252 for (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure

10 described in Example 266: ¹H NMR (500 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.30-8.32 (bs, 1H), 8.14 (d, *J* = 7.8 Hz, 1H), 7.84 (d, *J* = 7.8 Hz, 1H), 7.64 (t, *J* = 7.8 Hz, 1H), 7.58-7.69 (bs, 1H), 4.32 (d, *J* = 9.5 Hz, 1H), 4.03-4.12 (m, 1H), 3.68 (dd, *J* = 10.2, 3.3 Hz, 1H), 3.27-3.31 (m, 1H), 3.08-3.16 (m, 2H), 3.00 (s, 3H), 2.53-2.61 (m, 1H), 2.46-2.53 (m, 1H), 2.33-2.43 (m, 1H), 1.85-1.93 (m, 1H), 1.77-1.85 (m, 1H), 1.47-1.54 (m, 1H), 1.45 (s, 9H), 1.21-1.30 (m, 1H), 0.97 (d, *J* = 6.5 Hz, 3H), 0.86 (d, *J* = 6.7 Hz, 3H); MS (ESI+) *m/z* 570 (M+Na)⁺.

15

Example 274

20 ***tert*-butyl (2*S*)-2-[[[(3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]carbonyl]piperidine-1-carboxylate**

The title compound was prepared by substituting (*S*)-1-(*tert*-butoxycarbonyl)piperidine-2-carboxylic acid for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and (3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step D of Example 252D for (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure

25 described in Example 266: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.37-8.38 (bs, 1H), 8.32 (d, *J* = 5.2 Hz, 1H), 8.19 (d, *J* = 7.9 Hz, 1H), 7.91 (d, *J* = 7.9 Hz, 1H), 7.71 (t, *J* = 7.8 Hz, 1H), 4.07-4.23 (m, 2H), 3.84 (dd, *J* = 9.9, 2.2 Hz, 1H), 3.46 (td, *J* = 12.9, 2.8 Hz, 1H), 3.16 (d, *J* = 9.2 Hz, 1H), 3.12 (dd, *J* = 9.5, 7.6 Hz, 1H), 2.90-2.94 (m, 1H), 2.41-2.57 (bs, 2H), 2.24-2.29 (m, 1H), 1.75-1.97 (m, 2H), 1.53-1.65 (m, 3H), 1.49-1.55 (m, 2H), 1.48 (s, 9H), 1.42-1.51 (m, 1H), 1.29-1.39 (m, 1H), 1.17-1.29 (m, 1H); MS (ESI+) *m/z* 563 (M+H)⁺.

30

Example 275

***tert*-butyl (3*S*)-3-[[[(3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]carbonyl]-3,4-dihydroisoquinoline-2(1*H*)-carboxylate**

The title compound was prepared by substituting (*S*)-2-(*tert*-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and (3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step D of Example 252 for (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.26-8.27 (bs, 1H), 8.08-8.10 (m, 1H), 7.81-7.84 (m, 1H), 7.62 (t, *J* = 7.8 Hz, 1H), 7.29-7.36 (m, 1H), 7.12-7.14 (m, 2H), 7.08-7.11 (m, 2H), 4.83-5.02 (m, 1H), 4.78 (d, *J* = 15.6 Hz, 1H), 4.67 (d, *J* = 15.6 Hz, 1H), 3.90-3.97 (m, 1H), 3.52 (dd, *J* = 10.1, 3.3 Hz, 1H), 3.30 (dd, *J* = 15.3, 4.8 Hz, 1H), 3.14 (dd, *J* = 9.9, 7.8 Hz, 1H), 3.11 (dd, *J* = 15.4, 6.3 Hz, 1H), 3.04-3.08 (m, 2H), 2.45-2.53 (m, 1H), 2.38-2.45 (m, 1H), 1.64-1.75 (m, 2H), 1.50 (s, 9H), 1.35-1.46 (m, 1H), 1.15-1.25 (m, 1H); MS (ESI+) *m/z* 594 (M+H)⁺, 611 (M+NH₄)⁺.

Example 276

***tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-L-neopentylglycine for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and (3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step D of Example 252D for (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.29-8.30 (bs, 1H), 8.14 (d, *J* = 7.9 Hz, 1H), 7.83 (d, *J* = 7.9 Hz, 1H), 7.79-7.87 (bs, 1H), 7.64 (t, *J* = 7.8 Hz, 1H), 7.05-7.18 (bs, 1H), 4.46-4.51 (m, 1H), 4.06-4.14 (m, 1H), 3.67 (dd, *J* = 10.2, 2.8 Hz, 1H), 3.27 (dd, *J* = 10.1, 7.6 Hz, 1H), 3.07-3.15 (m, 2H), 2.50-2.59 (m, 2H), 2.08 (dd,

$J = 14.2, 4.6$ Hz, 1H), 1.85-1.92 (m, 1H), 1.77-1.85 (m, 1H), 1.70 (dd, $J = 14.2, 8.0$ Hz, 1H), 1.48-1.54 (m, 1H), 1.47 (s, 9H), 1.21-1.30 (m, 1H), 0.96 (s, 9H); MS (ESI+) m/z 562 (M+H)⁺.

Example 277

5 ***tert*-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)hexan-2-yl)carbamate**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-norleucine for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and (3*aR*,4*S*,6*aS*)-
10 2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step D of Example 252 for (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.44 (d, $J = 6.9$ Hz, 1H), 8.36-8.38 (bs, 1H), 8.19 (d, $J = 7.9$ Hz, 1H), 7.91 (d, $J = 7.6$ Hz, 1H), 7.72 (t, $J = 7.8$ Hz, 1H),
15 5.0 (m, 0.7H), 4.6 (m, 0.3H), 4.18-4.24 (m, 1H), 3.83-3.86 (m, 1H), 3.13-3.19 (m, 1H), 3.08-3.13 (m, 1H), 2.97-3.10 (bs, 3H), 2.91 (dd, $J = 9.4, 7.4$ Hz, 1H), 2.44-2.59 (m, 2H), 1.98-2.19 (m, 1H), 1.84-1.98 (m, 1H), 1.72-1.85 (m, 2H), 1.47-1.60 (m, 1H), 1.44-1.46 (m, 9H), 1.22-1.34 (m, 1H), 1.15-1.34 (m, 4H), 0.76-0.81 (m, 3H); MS (ESI+) m/z 562 (M+H)⁺, 579 (M+NH₄)⁺.

20

Example 278

***tert*-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

25 The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-norvaline for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and (3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step D of Example 252 for (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure
30 described in Example 266: ¹H NMR (500 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.30-8.31 (bs, 1H), 8.14 (d, $J = 7.9$ Hz, 1H), 7.84 (d, $J = 7.8$ Hz, 1H), 7.64 (t, $J = 7.8$ Hz, 1H), 7.49 (d, $J = 5.6$ Hz, 1H), 4.72-4.73 (m, 1H), 4.04-4.11 (m, 1H), 3.67 (dd, $J = 10.1, 3.3$ Hz, 1H), 3.26 (dd, $J = 10.1, 7.7$ Hz, 1H), 3.10-3.13 (m, 2H), 2.93 (s, 3H), 2.46-2.59 (m, 2H), 1.86-2.01

(m, 1H), 0.86 (t, $J = 7.3$ Hz, 3H); MS (ESI+) m/z 548 (M+H)⁺.

Example 279

5 isopropyl (*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate

The title compound was prepared by substituting (S)-2-(isopropoxycarbonylamino)pentanoic acid from Step A of Example 263 for (S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and (3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amine from Step A of Example 256 for (3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amine in the procedure described in Example 266: ¹H NMR (501 MHz, pyridine-*d*₅) δ ppm 8.08 (d, *J* = 8.2, 2H), 7.96 (d, *J* = 4.8, 1H), 7.82 (d, *J* = 8.3, 2H), 7.18 (d, *J* = 4.5, 2H), 5.01 (hept, *J* = 6.2, 1H), 4.45 (dd, *J* = 14.0, 7.7, 1H), 4.11 (dt, *J* = 13.0, 6.7, 1H), 3.67 (dd, *J* = 10.2, 3.0, 1H), 3.30 (dd, *J* = 10.2, 7.6, 1H), 3.16 – 3.07 (m, 2H), 2.57 (h, *J* = 9.3, 2H), 1.99 – 1.85 (m, 2H), 1.86 – 1.72 (m, 2H), 1.58 – 1.50 (m, 1H), 1.45 (ddd, *J* = 20.8, 11.7, 7.2, 2H), 1.26 (ddd, *J* = 13.1, 10.9, 6.6, 1H), 1.19 (d, *J* = 6.2, 3H), 1.16 (d, *J* = 6.2, 3H), 0.84 (t, *J* = 7.4, 3H); MS (ESI+) *m/z* 520 (M+H)⁺.

Example 280

isopropyl (*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate

25 The title compound was prepared by substituting N^1 -{(3a*R*,4*S*,6a*S*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide from Example 382 for (*S*)-tert-butyl 2-amino-4-methylpentanoate and isopropyl carbonochloridate for methanesulfonyl chloride in the procedure described in Example 242: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.22 – 8.15 (m, 1H), 7.65 (d, $J = 8.0$, 2H), 7.51 (d, $J = 7.9$, 2H), 7.39 – 7.34 (m, 1H), 5.11 – 5.02 (m, 1H), 4.74 – 4.64 (m, 1H), 4.48 – 4.40 (m, 1H), 3.57 (d, $J = 13.7$, 1H), 3.46 (d, $J = 13.6$, 1H), 2.90 – 2.82 (m, 1H), 2.62 – 2.49 (m, 2H), 2.44 – 2.38 (m, 1H), 2.34 – 2.28 (m, 1H), 2.24 (dd, $J = 9.7, 6.3$, 1H), 2.10 – 2.00 (m, 2H), 1.92 – 1.81 (m, 2H), 1.65 – 1.57 (m, 1H), 1.55 – 1.45 (m, 2H), 1.42 – 1.33 (m, 1H), 1.22 (d, $J = 6.2$, 3H), 1.15 (d, $J = 6.2$, 3H), 0.81 (t, $J = 7.4$, 3H); MS (ESI+) m/z 470 ($\text{M}+\text{H}$) $^+$.

Example 281**(3a*S*,4*R*,6a*R*)-*N*-neopentyl-2-{[3-****(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine**

5 (3a*S*,4*R*,6a*R*)-2-(3-(Trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine (100 mg, 0.299 mmol) from Step A of Example 254 and pivalaldehyde (0.043 mL, 0.389 mmol) were combined in dichloromethane (1 mL). Acetic acid (0.3 mL) was added. The reaction was stirred at room temperature for 20 minutes, then PS-cyanoborohydride (147 mg, 0.359 mmol) was added. The reaction was stirred at room temperature for 72 hours, then
 10 filtered. The reaction mixture was washed with 1 *N* NaHCO₃ and concentrate in vacuo. The crude material was purified using a 12 g silica gel cartridge with a gradient of 0-4% methanol (2 *N* ammonia)/dichloromethane to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.40-8.41 (bs, 1H), 8.22-8.25 (m, 1H), 7.92-7.95 (m, 1H), 7.75 (t, *J* = 7.8 Hz, 1H), 3.42 (dd, *J* = 9.8, 3.1 Hz, 1H), 3.17 (dd, *J* = 9.6, 3.1 Hz, 1H), 3.06-3.10 (m, 1H), 2.96 (dd, *J* =
 15 9.6, 7.7 Hz, 1H), 2.74-2.77 (m, 1H), 2.48-2.53 (m, 1H), 2.30 (d, *J* = 11.3 Hz, 1H), 2.22-2.27 (m, 1H), 2.22 (d, *J* = 7.9 Hz, 1H), 1.78-1.92 (m, 2H), 1.18-1.31 (m, 3H), 0.90 (s, 9H); MS (ESI+) *m/z* 405 (M+H)⁺.

Example 282**(3a*R*,4*S*,6a*S*)-*N*-neopentyl-2-{[3-****(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine**

20 The title compound was prepared by substituting (3a*R*,4*S*,6a*S*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step D of Example 252 for (3a*S*,4*R*,6a*R*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure
 25 described in Example 281: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.40-8.41 (bs, 1H), 8.22-8.25 (m, 1H), 7.92-7.95 (m, 1H), 7.75 (t, *J* = 7.9 Hz, 1H), 3.42 (dd, *J* = 9.8, 3.1 Hz, 1H), 3.17 (dd, *J* = 9.6, 3.0 Hz, 1H), 3.05-3.09 (m, 1H), 2.96 (dd, *J* = 9.6, 7.7 Hz, 1H), 2.73-2.77 (m, 1H), 2.48-2.53 (m, 1H), 2.30 (d, *J* = 11.3 Hz, 1H), 2.22-2.27 (m, 1H), 2.21 (d, *J* = 11.0 Hz,
 30 1H), 1.78-1.93 (m, 2H), 1.18-1.32 (m, 3H), 0.90 (s, 9H); MS (ESI+) *m/z* 405 (M+H)⁺.

Example 283

(3aR,4S,6aS)-N-isopropyl-2-[[4-(trifluoromethyl)phenyl]sulfonyl]octahydrocyclopenta[c]pyrrol-4-amine

The title compound was prepared by substituting (3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amine from Step A of Example 256 for (3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amine and acetone for pivalaldehyde in the procedure described in Example 281: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.14-8.22 (m, 2H), 7.91-7.98 (m, 2H), 3.40 (dd, *J* = 9.7, 3.0 Hz, 1H), 3.16 (dd, *J* = 9.6, 3.3 Hz, 1H), 3.06 (dd, *J* = 9.7, 7.8 Hz, 1H), 2.99 (dd, *J* = 9.6, 7.7 Hz, 1H), 2.85-2.90 (m, 1H), 2.74 (hept, *J* = 6.2 Hz, 1H), 2.46-2.53 (m, 1H), 2.14-2.25 (m, 1H), 1.80-1.91 (m, 2H), 1.07-1.43 (m, 3H), 1.00 (d, *J* = 6.2 Hz, 3H), 0.96 (d, *J* = 6.1 Hz, 3H); MS (ESI+) *m/z* 377 (M+H)⁺.

Example 284

(3aR,4S,6aS)-2-[[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl]-N-isopropyloctahydrocyclopenta[c]pyrrol-4-amine

Step A: *tert*-Butyl (3aR,4S,6aS)-2-(2-chloro-4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamate was prepared by substituting 2-chloro-4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in Step C of Example 252: ¹H NMR (500 MHz, pyridine-*d*₅) δ 8.33 (d, *J* = 8.0, 1H), 8.00 (s, 1H), 7.77 – 7.68 (m, 2H), 4.04 – 3.96 (m, 1H), 3.83 (d, *J* = 9.5, 1H), 3.48 (dd, *J* = 10.2, 7.5, 1H), 3.41 – 3.29 (m, 2H), 2.72 – 2.59 (m, 2H), 2.02 (td, *J* = 12.0, 6.4, 1H), 1.90 (qd, *J* = 7.1, 4.5, 1H), 1.64 (ddd, *J* = 16.1, 12.4, 8.8, 1H), 1.50 (s, 9H), 1.41 – 1.32 (m, 1H); MS (ESI+) *m/z* 486 (M+NH₄)⁺.

Step B: (3aR,4S,6aS)-2-[[2-Chloro-4-(trifluoromethyl)phenyl]sulfonyl]octahydrocyclopenta[c]pyrrol-4-amine was prepared by substituting *tert*-butyl (3aR,4S,6aS)-2-(2-chloro-4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamate from Step A for *tert*-butyl (3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamate in the procedure described in Step D of Example 252: ¹H NMR (500 MHz, pyridine-*d*₅) δ 8.34 (d, *J* = 8.2, 1H), 8.01 (s, 1H), 7.75 (d, *J* = 8.3, 1H), 3.55 (dd, *J* = 10.1, 3.1, 1H), 3.38 – 3.31 (m, 2H), 3.28 (dd, *J* = 9.9, 3.7, 1H), 3.10 (q, *J* = 6.1, 1H), 2.70 – 2.60 (m, 1H), 2.31 – 2.22 (m,

1H), 1.93 (ddd, $J = 11.1, 8.2, 5.7$, 1H), 1.87 – 1.76 (m, 1H), 1.74 – 1.49 (m, 2H), 1.37 – 1.24 (m, 2H); MS (ESI+) m/z 369(M+H)⁺.

Step C: The title compound was prepared by substituting (3a*R*,4*S*,6a*S*)-2- {[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine from Step A for
 5 (3a*S*,4*R*,6a*R*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine and acetone for pivalaldehyde in the procedure described in Example 281: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.37 (d, $J = 8.2$ Hz, 1H), 8.03 (d, $J = 1.7$ Hz, 1H), 7.77 (d, $J = 9.0$ Hz, 1H), 3.56 (dd, $J = 10.0, 3.1$ Hz, 1H), 3.41 (dd, $J = 10.1, 7.8$ Hz, 1H), 3.31-3.38 (m, 2H),
 2.97 (q, $J = 6.3$ Hz, 1H), 2.78 (hept, $J = 6.2$ Hz, 1H), 2.58-2.63 (m, 1H), 2.30-2.35 (m, 1H),
 10 1.87-1.96 (m, 2H), 1.05-1.67 (m, 1H), 1.21-1.37 (m, 2H), 1.01 (d, $J = 6.2$ Hz, 3H), 0.98 (d, $J = 6.1$ Hz, 3H); MS (ESI+) m/z 411 (M+H)⁺.

Example 285

(3a*S*,4*R*,6a*R*)-*N*-(4-fluorobenzyl)-2- {[3-
 15 (trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine

The title compound was prepared by substituting 4-fluorobenzaldehyde for pivalaldehyde in the procedure described in Example 281: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.39-8.40 (bs, 1H), 8.23 (d, $J = 7.9$ Hz, 1H), 7.94 (d, $J = 7.9$ Hz, 1H), 7.76 (t, $J = 7.8$ Hz, 1H), 7.41 (dd, $J = 8.3, 5.5$ Hz, 2H), 7.11-7.15 (m, 2H), 3.71 (d, $J = 13.2$ Hz, 1H), 3.67 (d,
 20 $J = 13.2$ Hz, 1H), 3.39 (dd, $J = 9.8, 3.1$ Hz, 1H), 3.16 (dd, $J = 9.6, 3.0$ Hz, 1H), 3.06 (dd, $J = 9.8, 8.0$ Hz, 1H), 2.96 (dd, $J = 9.6, 7.6$ Hz, 1H), 2.83-2.88 (m, 1H), 2.47-2.56 (m, 1H), 2.30-2.36 (m, 1H), 1.92-2.09 (m, 1H), 1.87-1.94 (m, 1H), 1.80-1.88 (m, 1H), 1.29-1.37 (m, 1H), 1.20-1.29 (m, 1H); MS (ESI+) m/z 443 (M+H)⁺.

Example 286

(3a*R*,4*S*,6a*S*)-*N*-(4-fluorobenzyl)-2- {[3-
 (trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine

The title compound was prepared by substituting (3a*R*,4*S*,6a*S*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Step D of
 30 Example 252 for (3a*S*,4*R*,6a*R*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine and 4-fluorobenzaldehyde for pivalaldehyde in the procedure described in Example 281: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.39-8.40 (bs, 1H), 8.22-8.24 (m, 1H), 7.93-7.95 (m, 1H), 7.75

(t, $J = 7.8$ Hz, 1H), 7.41 (dd, $J = 8.3, 5.5$ Hz, 2H), 7.13 (t, $J = 8.7$ Hz, 2H), 3.71 (d, $J = 13.3$ Hz, 1H), 3.67 (d, $J = 13.2$ Hz, 1H), 3.39 (dd, $J = 9.8, 3.1$ Hz, 1H), 3.16 (dd, $J = 9.6, 3.0$ Hz, 1H), 3.06 (dd, $J = 9.8, 8.0$ Hz, 1H), 2.96 (dd, $J = 9.6, 7.6$ Hz, 1H), 2.85 (q, $J = 6.1$ Hz, 1H), 2.47-2.56 (m, 1H), 2.30-2.35 (m, 1H), 1.93-2.07 (m, 1H), 1.87-1.94 (m, 1H), 1.79-1.87 (m, 1H), 1.29-1.38 (m, 1H), 1.20-1.29 (m, 1H); MS (ESI+) m/z 443 (M+H)⁺.

Example 287

(3a*R*,4*S*,6a*S*)-*N*-(4-fluorobenzyl)-2-[3-

(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-amine

The title compound was prepared by substituting (3a*R*,4*S*,6a*S*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-amine (0.83 g, 3.84 mmol) from Step A of Example 33 for (3a*S*,4*R*,6a*R*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine and 4-fluorobenzaldehyde for pivalaldehyde in the procedure described in Example 281: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.79-7.80 (bs, 1H), 7.58-7.61 (m, 1H), 7.60 (s, 1H), 7.44-7.49 (m, 1H), 7.39-7.44 (m, 2H), 7.12 (t, $J = 8.6$ Hz, 2H), 3.71-3.79 (m, 2H), 3.55-3.56 (bs, 2H), 2.96 (q, $J = 5.1$ Hz, 1H), 2.57-2.63 (m, 1H), 2.51 (dd, $J = 8.8, 3.2$ Hz, 1H), 2.39-2.43 (m, 1H), 2.31-2.39 (m, 3H), 1.91-1.98 (m, 2H), 1.72-1.93 (m, 1H), 1.34-1.48 (m, 2H); MS (ESI+) m/z 393 (M+H)⁺.

Example 288

(3a*R*,4*S*,6a*S*)-*N*-ethyl-2-[4-

(trifluoromethyl)phenyl]sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-amine

(3a*R*,4*S*,6a*S*)-2-(4-(Trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine (120 mg, 0.359 mmol) from Step A of Example 256, iodoethane (0.287 mL, 3.59 mmol), and triethylamine (0.750 mL, 5.38 mmol) were in tetrahydrofuran (1 mL). The reaction was stirred at 65 °C for 3 days, and then the solvent was removed in vacuo. The residue was diluted with dichloromethane (5 mL), and addition of saturated aqueous sodium bicarbonate gave the products as a solid. This material was purified using a 12 g silica gel cartridge with a gradient of 0-5% methanol (2 *N* ammonia)/dichloromethane over 20 minutes to give two products. The second product was further purified on 4×0.25 mm preparative thin-layer chromatography plate eluting with 6% methanol (2 *N* ammonia)/dichloromethane to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.17-8.19 (m, 2H), 7.93-7.95 (m, 2H), 3.38 (dd, $J = 9.8, 3.1$ Hz, 1H), 3.15 (dd, $J = 9.6, 3.2$ Hz, 1H), 3.06 (dd, $J = 9.8,$

8.0 Hz, 1H), 2.96 (dd, $J = 9.6, 7.7$ Hz, 1H), 2.78 (q, $J = 6.1$ Hz, 1H), 2.44-2.58 (m, 4H), 2.25-2.33 (m, 1H), 1.85-1.92 (m, 1H), 1.75-1.85 (m, 1H), 1.16-1.34 (m, 2H), 1.05 (t, $J = 7.1$ Hz, 3H); MS (ESI+) m/z 363 (M+H)⁺.

5

Example 289**(3a*R*,4*S*,6a*S*)-*N,N*-diethyl-2-{{4-****(trifluoromethyl)phenyl}sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine**

The first product from Example 288 was purified on a 2×0.25 mm preparative thin-layer chromatography plate eluting with acetone to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.18-8.20 (m, 2H), 7.94-7.97 (m, 2H), 3.43 (dd, $J = 9.6, 2.6$ Hz, 1H), 3.22 (dd, $J = 9.5, 2.6$ Hz, 1H), 2.98 (dd, $J = 9.6, 7.8$ Hz, 1H), 2.88 (dd, $J = 9.5, 7.4$ Hz, 1H), 2.70-2.75 (m, 1H), 2.30-2.50 (m, 5H), 2.22-2.29 (m, 1H), 1.75-1.81 (m, 1H), 1.62-1.68 (m, 1H), 1.25-1.34 (m, 1H), 1.16-1.25 (m, 1H), 0.92 (t, $J = 7.0$ Hz, 6H); MS (ESI+) m/z 391 (M+H)⁺.

15

Example 290**(3a*R*,4*S*,6a*S*)-*N*-propyl-2-{{4-****(trifluoromethyl)phenyl}sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine**

The title compound was prepared by substituting 1-iodopropane for iodoethane in the procedure described in Example 288: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.17-8.19 (m, 2H), 7.93-7.95 (m, 2H), 3.39 (dd, $J = 9.8, 3.1$ Hz, 1H), 3.16 (dd, $J = 9.6, 3.2$ Hz, 1H), 3.07 (dd, $J = 9.8, 8.0$ Hz, 1H), 2.98 (dd, $J = 9.6, 7.7$ Hz, 1H), 2.77 (q, $J = 5.9$ Hz, 1H), 2.50-2.58 (m, 1H), 2.39-2.51 (m, 2H), 2.24-2.30 (m, 1H), 1.77-1.92 (m, 2H), 1.36-1.50 (m, 2H), 1.16-1.57 (m, 1H), 1.19-1.34 (m, 2H), 0.88 (t, $J = 7.4$ Hz, 3H); MS (ESI+) m/z 377 (M+H)⁺.

25

Example 291**(3a*R*,4*S*,6a*S*)-*N,N*-dipropyl-2-{{4-****(trifluoromethyl)phenyl}sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine**

The title compound was prepared as described in Example 290 following the procedures described in Examples 288 and 289: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.18-8.20 (m, 2H), 7.93-7.95 (m, 2H), 3.48 (dd, $J = 9.5, 2.3$ Hz, 1H), 3.23 (dd, $J = 9.5, 2.8$ Hz, 1H), 2.99 (dd, $J = 9.4, 7.7$ Hz, 1H), 2.92 (dd, $J = 9.3, 7.8$ Hz, 1H), 2.74-2.80 (m, 1H),

30

2.37-2.48 (m, 1H), 2.19-2.35 (m, 5H), 1.78-1.84 (m, 1H), 1.61-1.66 (m, 1H), 1.16-1.39 (m, 6H), 0.84 (t, $J = 7.3$ Hz, 6H); MS (ESI+) m/z 419 (M+H)⁺.

Example 292

5 **(3aR,4S,6aS)-N-(cyclopropylmethyl)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine**

The title compound was prepared by substituting (bromomethyl)cyclopropane for iodoethane in the procedure described in Example 288: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.17-8.19 (m, 2H), 7.93-7.95 (m, 2H), 3.38 (dd, $J = 9.8, 3.2$ Hz, 1H), 3.16 (dd, $J = 9.6, 3.2$ Hz, 1H), 3.07 (dd, $J = 9.8, 8.0$ Hz, 1H), 2.98 (dd, $J = 9.6, 7.6$ Hz, 1H), 2.79-2.84 (m, 1H), 2.51-2.58 (m, 1H), 2.36-2.50 (m, 2H), 2.26-2.32 (m, 1H), 1.85-1.93 (m, 1H), 1.78-1.85 (m, 1H), 1.35-1.78 (m, 1H), 1.22-1.33 (m, 2H), 0.89-0.98 (m, 1H), 0.36-0.44 (m, 2H), 0.11-0.13 (m, 2H); MS (ESI+) m/z 389 (M+H)⁺.

15 Example 293

(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-N-ethyloctahydrocyclopenta[c]pyrrol-4-amine

The title compound was prepared by substituting (3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine from Step B of Example 284 for (3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amine in the procedure described in Example 288: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.37 (d, $J = 8.2$ Hz, 1H), 8.03 (s, 1H), 7.78 (dd, $J = 8.3, 1.7$ Hz, 1H), 3.54 (dd, $J = 10.0, 3.5$ Hz, 1H), 3.43 (dd, $J = 10.0, 8.0$ Hz, 1H), 3.27-3.36 (m, 2H), 2.86 (q, $J = 5.9$ Hz, 1H), 2.59-2.65 (m, 1H), 2.47-2.58 (m, 2H), 2.35-2.41 (m, 1H), 1.82-1.95 (m, 2H), 1.04-1.73 (m, 1H), 1.25-1.40 (m, 2H), 1.05 (t, $J = 7.1$ Hz, 3H); MS (ESI+) m/z 397 (M+H)⁺.

Example 294

30 **(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-N,N-diethyloctahydrocyclopenta[c]pyrrol-4-amine**

The title compound was prepared as described in Example 293 following the procedures described in Examples 288 and 289: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.38 (d, $J = 8.2$ Hz, 1H), 8.04 (d, $J = 1.7$ Hz, 1H), 7.77-7.79 (m, 1H), 3.57 (dd, $J = 9.9, 2.7$

Hz, 1H), 3.34-3.41 (m, 2H), 3.29 (dd, $J = 9.9, 7.3$ Hz, 1H), 2.81-2.87 (m, 1H), 2.33-2.57 (m, 6H), 1.80-1.86 (m, 1H), 1.68-1.74 (m, 1H), 1.22-1.43 (m, 2H), 0.94 (t, $J = 7.1$ Hz, 6H); MS (ESI+) m/z 442 ($M+NH_4$)⁺.

5

Example 295

(3a*R*,4*S*,6a*S*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-*N*-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-amine

(3a*R*,4*S*,6a*S*)-2-{[2-Chloro-4-

(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine (70 mg, 0.190 mmol) from Step B of Example 284, 2-bromo-5-(trifluoromethyl)pyridine (42.9 mg, 0.190 mmol), and triethylamine (0.079 mL, 0.569 mmol) were combined in ethanol (0.6 mL). The reaction was heated at 86 °C for 5 days and the solvent was evaporated in vacuo. The resultant material was purified using a 12 g silica gel cartridge with a gradient of 0-0.8% methanol (2 *N* ammonia)/dichloromethane over 20 minutes to give crude product. It was further purified by loading it onto 2×0.25 mm preparative thin-layer chromatography plate and eluted with 30% acetone/hexanes to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.50-8.52 (bs, 1H), 8.40 (d, $J = 8.2$ Hz, 1H), 8.03 (s, 1H), 7.96-7.98 (m, 1H), 7.75-7.78 (m, 1H), 7.54-7.59 (m, 1H), 6.59 (d, $J = 8.8$ Hz, 1H), 4.30-4.42 (m, 1H), 3.89 (dd, $J = 10.2, 2.7$ Hz, 1H), 3.57 (dd, $J = 10.2, 7.0$ Hz, 1H), 3.43 (dd, $J = 9.9, 6.7$ Hz, 1H), 3.39 (dd, $J = 10.0, 2.9$ Hz, 1H), 2.68 (d, $J = 3.5$ Hz, 2H), 2.13-2.20 (m, 1H), 1.90-1.97 (m, 1H), 1.59-1.66 (m, 1H), 1.40-1.48 (m, 1H); MS (ESI+) m/z 514 ($M+H$)⁺.

Example 296

***tert*-butyl (*S*)-1-(ethyl((3a*R*,4*S*,6a*S*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate**

The title compound was prepared by substituting (*S*)-2-(*tert*-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid from Step A of Example 247 for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and (3a*R*,4*S*,6a*S*)-*N*-ethyl-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 288 for (3a*S*,4*R*,6a*R*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 266: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.11 (d, $J = 8.3$, 2H), 7.83 (d, $J = 8.4$, 2H), 5.44 – 4.96 (m, 2H), 4.20 – 3.97 (m, 1H), 3.57 –

3.39 (m, 2H), 3.38 – 3.23 (m, 2H), 3.19 (d, $J = 4.1$, 2H), 2.89 (s, 3H), 2.85 – 2.73 (m, 1H), 2.72 – 2.59 (m, 1H), 2.25 – 2.08 (m, 1H), 1.97 – 1.73 (m, 3H), 1.52 (s, 9H), 1.35 – 1.21 (m, 1H), 1.17 (t, $J = 7.0$, 3H), 0.97 (s, 9H); MS (ESI+) m/z 604(M+H)⁺.

5

Example 297

***tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-(propyl((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl)amino)pentan-2-yl(methyl)carbamate**

The title compound was prepared by substituting (*S*)-2-(*tert*-
10 butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid from Step A of Example 247 for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and (3*aR*,4*S*,6*aS*)-*N*-propyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine from Example 290 for (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 266: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm
15 8.11 (d, $J = 8.2$, 2H), 7.83 (d, $J = 8.4$, 2H), 5.37 – 5.09 (m, 1H), 4.15 – 3.99 (m, 1H), 3.54 (dd, $J = 10.1$, 3.2, 1H), 3.48 – 3.35 (m, 1H), 3.29 (dt, $J = 9.1$, 8.7, 1H), 3.18 (dd, $J = 9.1$, 4.5, 3H), 2.90 (s, 3H), 2.86 – 2.77 (m, 1H), 2.74 – 2.64 (m, 1H), 2.24 – 2.09 (m, 1H), 1.96 – 1.86 (m, 2H), 1.85 – 1.75 (m, 1H), 1.59 (dt, $J = 15.2$, 7.5, 3H), 1.52 (s, 9H), 1.34 – 1.22 (m, 1H), 0.98 (s, 9H), 0.90 (t, $J = 7.3$, 3H); MS (ESI+) m/z 618(M+H)⁺.

20

Example 298

***tert*-butyl (*S*)-1-((cyclopropylmethyl)((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate**

25 The title compound was prepared by substituting (*S*)-2-(*tert*-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid from Step A of Example 247 for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and (3*aR*,4*S*,6*aS*)-*N*-(cyclopropylmethyl)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine from Example 292 for (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure
30 described in Example 266: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.11 (d, $J = 8.2$, 2H), 7.83 (d, $J = 8.3$, 2H), 5.39 – 5.07 (m, 1H), 4.12 – 3.95 (m, 1H), 3.58 (dd, $J = 9.9$, 3.4, 1H), 3.44 – 3.24 (m, 3H), 3.20 (d, $J = 4.7$, 2H), 3.11 – 2.96 (m, 1H), 2.88 (s, 3H), 2.80 – 2.65 (m, 1H), 2.32 – 2.16 (m, 1H), 2.13 – 2.00 (m, 1H), 1.99 – 1.90 (m, 1H), 1.90 – 1.80 (m, 1H), 1.51

(m, 10H), 1.31 (ddd, $J = 20.7, 12.5, 7.9$, 1H), 1.03 – 0.92 (m, 10H), 0.55 (tt, $J = 14.1, 7.5$, 2H), 0.47 – 0.36 (m, 1H), 0.32 – 0.22 (m, 1H); MS (ESI+) m/z 630(M+H)⁺.

Example 299

5 **2-nitro-*N*-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)benzenesulfonamide**

(3*aR*,4*S*,6*aS*)-2-(4-(Trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine (300 mg, 0.897 mmol) from Step A of Example 256 and triethylamine (0.313 mL, 2.243 mmol) were combined in dichloromethane (20 mL). 2-Nitrobenzene-1-sulfonyl chloride (258 mg, 1.166 mmol) in dichloromethane (5 mL) was added dropwise. The reaction mixture was stirred at room temperature for 16 hours. The reaction was quenched with water, and the organic layer was separated and concentrated. The resulted crude material was triturated with 50% diethyl ether/hexane, collected by filtration, washed with water then hexane to yield a solid. The crude solid was purified using a 12 g silica gel cartridge with a gradient of 10-100% ethyl acetate/hexane over 20 minutes to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 9.69 (s, 1H), 8.31 (dd, $J = 6.0, 3.3$, 1H), 8.12 (d, $J = 8.2$, 2H), 7.92 (dd, $J = 8.6, 2.1$, 3H), 7.67 (dd, $J = 5.9, 3.3$, 2H), 4.94 (s, 2H), 3.84 (dd, $J = 15.0, 6.2$, 1H), 3.58 (dd, $J = 10.0, 2.4$, 1H), 3.17 (dd, $J = 9.7, 2.7$, 1H), 2.94 (dd, $J = 10.0, 7.7$, 1H), 2.87 (dd, $J = 9.6, 7.7$, 1H), 2.71 (td, $J = 9.3, 2.4$, 1H), 2.60 – 2.50 (m, 1H), 1.94 – 1.80 (m, 2H), 1.71 – 1.58 (m, 1H), 1.23 (tt, $J = 10.5, 6.5$, 1H); MS (ESI+) m/z 518(M+H)⁺.

Example 300

25 ***N*-methyl-2-nitro-*N*-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)benzenesulfonamide**

2-Nitro-*N*-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl)benzenesulfonamide (250 mg, 0.481 mmol) from Example 299 and dimethyl sulfate (0.138 mL, 1.444 mmol) were combined in *N,N*-dimethylformamide (3 mL) at 0 °C and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.145 mL, 0.962 mmol) was added dropwise. The reaction mixture was stirred for 0.5 hours, water was added, and the precipitate was collected by filtration. The resultant crude material was purified using a 12 g silica gel cartridge eluting with a gradient of 0-60% ethyl

acetate/hexane over 20 minutes to give the title compound: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.15 (dd, $J = 12.1, 4.7, 3\text{H}$), 7.94 (d, $J = 8.3, 2\text{H}$), 7.88 (dd, $J = 7.7, 1.3, 1\text{H}$), 7.68 (dtd, $J = 19.1, 7.5, 1.3, 2\text{H}$), 4.29 (dt, $J = 10.8, 7.0, 1\text{H}$), 3.63 (dd, $J = 9.9, 1.5, 1\text{H}$), 3.21 (dd, $J = 9.7, 2.3, 1\text{H}$), 2.90 (s, 3H), 2.89 – 2.81 (m, 2H), 2.58 – 2.39 (m, 2H), 1.83 – 1.72 (m, 1H),
 5 1.68 – 1.58 (m, 1H), 1.50 (qd, $J = 11.8, 7.3, 1\text{H}$), 1.21 (ddd, $J = 19.4, 12.4, 7.1, 1\text{H}$); MS (ESI+) m/z 551(M+NH $_4$) $^+$.

Example 301

(3aR,4S,6aS)-N-methyl-2-{[4-

(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine

2-Mercaptoethanol (0.056 mL, 0.793 mmol) was added dropwise to a mixture of *N*-methyl-2-nitro-*N*-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)benzenesulfonamide (235 mg, 0.440 mmol) from Example 300 and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.166 mL, 1.101 mmol) in *N,N*-dimethylformamide (1mL) at room temperature. The reaction mixture was stirred for 30 minutes, and 1 *N* NaHCO $_3$ solution was added. The mixture was extracted with dichloromethane, and the separated the organic layer was concentrated. The resultant crude material was purified using a SF15-12g cartridge (Analogix®, Burlington, Wisconsin) with a gradient of 0-5.5% methanol (2 *N* NH $_3$)/dichloromethane over 20 minutes to give the
 20 title compound: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.17 (d, $J = 8.1, 2\text{H}$), 7.94 (d, $J = 8.2, 2\text{H}$), 4.93 – 4.86 (m, 1H), 3.34 (dd, $J = 9.8, 3.3, 1\text{H}$), 3.14 (dd, $J = 9.7, 3.2, 1\text{H}$), 3.06 (dd, $J = 9.7, 8.2, 1\text{H}$), 2.65 (q, $J = 5.7, 1\text{H}$), 2.57 – 2.46 (m, 1H), 2.29 (s, 3H), 2.25 (ddd, $J = 8.6, 5.0, 2.5, 1\text{H}$), 1.86 (ddd, $J = 12.0, 8.6, 6.1, 1\text{H}$), 1.80 – 1.72 (m, 1H), 1.61 – 1.32 (m, 1H), 1.32 – 1.19 (m, 2H); MS (ESI+) m/z 349(M+H) $^+$.

Example 302

tert-butyl (*S*)-4,4-dimethyl-1-(methyl((3aR,4S,6aS)-2-(4-

(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-1-

oxopentan-2-yl(methyl)carbamate

30 The title compound was prepared by substituting (*S*)-2-(*tert*-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid from Step A of Example 247 for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and (3aR,4S,6aS)-*N*-methyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine from Example 301 for (3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-

amine in the procedure described in Example 266: ^1H NMR (400 MHz, pyridine- d_5) δ ppm 8.11 (d, $J = 8.2$, 2H), 7.83 (d, $J = 8.3$, 2H), 5.37 – 5.10 (m, 1H), 4.73 – 4.53 (m, 1H), 3.57 (d, $J = 9.1$, 1H), 3.24 (dd, $J = 16.5$, 7.2, 2H), 3.16 (dd, $J = 9.9$, 3.4, 1H), 2.94 (s, 3H), 2.88 (s, 3H), 2.64 – 2.51 (m, 2H), 2.25 – 2.09 (m, 1H), 1.89 – 1.78 (m, 1H), 1.77 – 1.54 (m, 3H), 1.52 (s, 9H), 1.26 (dt, $J = 17.5$, 7.1, 1H), 0.96 (s, 9H); MS (ESI+) m/z 590(M+H) $^+$.

Example 303

(2S)-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methyl-N-[(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl]pentanamide

Step A: (2S)-N-[(3aS,4R,6aR)-2-Benzyl-octahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide (265 mg, 0.611 mmol) from Example 220 Step D and ethanol (20 mL) were added to 20% Pd(OH) $_2$ on carbon, wet (53.0 mg, 0.377 mmol) in a 50 mL pressure bottle and stirred for 48 hours under 30 psi hydrogen at 50 °C. The mixture was filtered through a nylon membrane and the solvent removed in vacuo to give (2S)-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]pentanamide: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.89 (dd, $J = 6.6$, 18.9, 1H), 4.55 - 4.50 (m, 1H), 4.42 - 4.31 (m, 1H), 3.99 - 3.91 (m, 1H), 3.44 - 3.39 (m, 1H), 3.34 (dd, $J = 2.8$, 11.4, 0.5H), 3.29 - 3.25 (m, 2H), 3.21 (dd, $J = 5.4$, 13.2, 1H), 3.13 (dd, $J = 7.7$, 11.2, 0.5H), 2.99 (td, $J = 7.5$, 10.8, 1H), 2.79 (dd, $J = 3.3$, 10.9, 0.5H), 2.73 (dd, $J = 3.3$, 10.9, 0.5H), 2.69 - 2.55 (m, 2H), 2.31 - 2.16 (m, 2H), 2.12 - 2.00 (m, 1H), 1.94 - 1.78 (m, 4H), 1.69 (dddd, $J = 5.2$, 11.0, 16.7, 19.8, 2H), 1.49 - 1.29 (m, 1H), 0.88 (t, $J = 6.5$, 3H), 0.83 (t, $J = 6.4$, 3H); MS (ESI+) m/z 344(M+H) $^+$

Step B: (2S)-2-(1,1-Dioxidoisothiazolidin-2-yl)-4-methyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]pentanamide (204 mg, 0.594 mmol) and 3-(trifluoromethyl)benzaldehyde (0.158 mL, 1.188 mmol) were dissolved in dichloromethane (3 mL). Acetic acid (1 mL) was added. The reaction was stirred at ambient temperature for 20 min, then PS-cyanoborohydride (487 mg, 1.188 mmol) was added. The reaction was stirred at room temperature overnight, then filtered, and the solvent was removed in vacuo. The crude material was purified by silica gel chromatography using 1-10% methanol (2 N ammonia)/dichloromethane to the title compound: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.79 (d, $J = 7.0$, 1H), 7.75 (d, $J = 10.3$, 1H), 7.61 - 7.54 (m, 2H), 7.44 (t, $J = 7.7$, 1H), 4.52 (dd, $J = 6.6$, 8.9, 1H), 4.38 (dq, $J = 6.4$, 12.6, 1H), 3.94 (dd, $J = 7.3$, 16.2, 1H), 3.57 (dd, $J = 9.1$, 13.5, 1H), 3.50 - 3.37 (m, 2H), 3.31 - 3.19 (m, 2H), 2.79 (ddd, $J = 3.0$, 9.1, 19.0, 1H), 2.62 - 2.54 (m, 1H), 2.54 - 2.45 (m, 1H), 2.43 - 2.36 (m, 1H), 2.31 - 2.16 (m, 4H), 2.13 - 2.03

(m, 1H), 1.94 - 1.78 (m, 3H), 1.77 - 1.59 (m, 2H), 1.39 (dt, $J = 6.5, 19.8$, 1H), 0.88 (d, $J = 6.6$, 3H), 0.82 (dd, $J = 2.3, 6.5$, 3H); MS (ESI+) m/z 502(M+H)⁺.

Example 304

5 **2-isopropyl-3-methyl-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide**

The title compound was prepared by substituting *N*-[(3*aS*,4*R*,6*aR*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-2-isopropyl-3-methylbutanamide from Example 235 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide in the procedures described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.12-8.14 (m, 1H), 7.75-7.76 (bs, 1H), 7.55-7.63 (m, 2H), 7.44 (t, $J = 7.8$ Hz, 1H), 4.42-4.48 (m, 1H), 3.62 (d, $J = 13.5$ Hz, 1H), 3.46 (d, $J = 13.5$ Hz, 1H), 2.86 (dd, $J = 9.0, 2.4$ Hz, 1H), 2.50-2.57 (m, 2H), 2.44-2.49 (m, 1H), 2.25-2.31 (m, 2H), 2.06-2.15 (m, 3H), 1.83-1.90 (m, 2H), 1.58-1.65 (m, 1H), 1.35-1.42 (m, 1H), 1.14 (d, $J = 6.7$ Hz, 3H), 1.13 (d, $J = 6.6$ Hz, 3H), 0.98 (d, $J = 6.8$ Hz, 6H); MS (ESI+) m/z 411 (M+H)⁺.

Example 305

20 **2-isopropyl-3-methyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide**

The title compound was prepared by substituting *N*-[(3*aR*,4*S*,6*aS*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-2-isopropyl-3-methylbutanamide from Example 229 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide in the procedures described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.12-8.14 (m, 1H), 7.75-7.77 (bs, 1H), 7.58-7.63 (m, 1H), 7.42-7.47 (m, 1H), 4.42-4.48 (m, 1H), 3.62 (d, $J = 13.5$ Hz, 1H), 3.46 (d, $J = 13.5$ Hz, 1H), 2.85 (dd, $J = 8.9, 2.5$ Hz, 1H), 2.50-2.58 (m, 2H), 2.45-2.49 (m, 1H), 2.28 (d, $J = 6.6$ Hz, 2H), 2.06-2.16 (m, 4H), 1.84-1.90 (m, 2H), 1.58-1.66 (m, 1H), 1.35-1.42 (m, 1H), 1.14 (d, $J = 6.6$ Hz, 3H), 1.13 (d, $J = 6.6$ Hz, 3H), 0.98 (d, $J = 6.8$ Hz, 6H); MS (ESI-) m/z 409 (M-H)⁻.

Example 306

***tert*-butyl (*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-ylcarbamate from Example 221 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide in the procedures described in Example 303: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.64 (d, *J* = 7.2 Hz, 1H), 7.96-7.99 (m, 1H), 7.72-7.77 (m, 1H), 7.55-7.63 (m, 2H), 7.44 (t, *J* = 7.7 Hz, 1H), 4.66-4.75 (m, 1H), 4.35-4.44 (m, 1H), 3.59 (d, *J* = 13.5 Hz, 1H), 3.46 (d, *J* = 13.6 Hz, 1H), 2.81-2.84 (m, 1H), 2.44-2.59 (m, 3H), 2.22-2.31 (m, 2H), 2.14 (s, 3H, OAc), 1.96-2.07 (m, 1H), 1.79-1.91 (m, 4H), 1.55-1.70 (m, 1H), 1.50 (s, 9H), 1.27-1.41 (m, 1H), 0.82-0.89 (m, 6H); MS (ESI+) *m/z* 498 (M+H)⁺.

Example 307

***tert*-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate from Example 222 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide in the procedures described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.27-8.34 (m, 1H), 7.75-7.76 (bs, 1H), 7.52-7.63 (m, 2H), 7.42-7.47 (m, 1H), 5.1 (m, 0.7H), 4.7 (0.3H), 4.35-4.41 (m, 1H), 3.59 (d, *J* = 13.5 Hz, 1H), 3.45-3.49 (m, 1H), 3.04-3.13 (m, 3H), 2.82-2.85 (m, 1H), 2.42-2.54 (m, 3H), 2.22-2.31 (m, 2H), 1.98-2.11 (m, 1H), 1.80-2.11 (m, 1H), 1.79-1.87 (m, 2H), 1.53-1.62 (m, 2H), 1.46-1.48 (m, 9H), 1.33-1.38 (m, 1H), 0.88 (d, *J* = 6.4 Hz, 3H), 0.85 (d, *J* = 6.6 Hz, 3H); MS (ESI+) *m/z* 512 (M+H)⁺.

Example 308***tert*-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

5 The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate from Example 222 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide and 4-(trifluoromethyl)benzaldehyde for 3-

10 (trifluoromethyl)benzaldehyde in the procedures described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.31-8.36 (bs, 1H), 7.64-7.66 (m, 2H), 7.50-7.53 (m, 2H), 5.1 (m, 0.7H) 4.7 (0.3H), 4.38-4.43 (m, 1H), 3.57 (d, *J* = 13.7 Hz, 1H), 3.45-3.49 (m, 1H), 3.04-3.12 (m, 3H), 2.84-2.87 (m, 1H), 2.51-2.56 (m, 2H), 2.35-2.42 (m, 1H), 2.30-2.35 (m, 1H), 2.20-2.24 (m, 1H), 2.05-2.10 (m, 1H), 1.81-1.93 (m, 3H), 1.55-1.61 (m, 2H), 1.46-1.48 (m, 9H),

15 1.35-1.40 (m, 1H), 0.88 (d, *J* = 6.3 Hz, 3H), 0.85 (d, *J* = 6.6 Hz, 3H); MS (ESI+) *m/z* 512 (M+H)⁺.

Example 309***tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate**

20 The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate from Example 222 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-

25 methylpentanamide and 4-fluorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde in the procedures described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.30-8.32 (m, 1H), 7.35-7.38 (m, 2H), 7.12 (t, *J* = 8.6 Hz, 2H), 5.1 (m, 0.7H) 4.7 (0.3H), 4.37-4.41 (m, 1H), 3.50 (d, *J* = 13.1 Hz, 1H), 3.40 (d, *J* = 13.1 Hz, 1H), 3.04-3.11 (m, 3H), 2.81-2.84 (m, 1H), 2.47-2.53 (m, 2H), 2.29-2.39 (m, 2H), 2.19-2.23 (m, 1H), 2.02-2.11 (m, 1H), 1.79-1.94 (m,

30 3H), 1.53-1.62 (m, 2H), 1.46-1.48 (m, 9H), 1.34-1.39 (m, 1H), 0.89 (d, *J* = 6.4 Hz, 3H), 0.85 (d, *J* = 6.6 Hz, 3H); MS (ESI+) *m/z* 462 (M+H)⁺.

Example 310***tert*-butyl ethyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

5 The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(ethyl)carbamate from Example 223 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide in the procedures described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.14-8.17 (m, 1H), 7.74-7.77 (m, 1H), 7.55-7.61 (m, 2H), 7.41-7.46 (m, 1H), 5.1 (m, 0.7H) 4.7 (0.3H), 4.32-4.42 (m, 1H), 3.59 (d, *J* = 13.4 Hz, 1H), 3.38-3.53 (m, 3H), 2.78-2.87 (m, 1H), 2.44-2.54 (m, 2H), 2.36-2.44 (m, 1H), 2.28-2.35 (m, 1H), 2.20-2.27 (m, 1H), 2.01-2.13 (m, 1H), 1.91-2.01 (m, 1H), 1.79-1.88 (m, 1H), 1.71-1.79 (m, 1H), 1.62-1.71 (m, 1H), 1.53-1.62 (m, 1H), 1.48 (s, 9H), 1.33-1.42 (m, 1H), 1.17-1.33 (m, 3H), 0.83-0.97 (m, 6H); MS (ESI+) *m/z* 526 (M+H)⁺.

15

Example 311***tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(3-fluoro-4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate**

20 The title compound was prepared by substituting *N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-(*tert*-butoxycarbonyl)-*N*²-methyl-L-leucinamide from Example 151 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide and 3-fluoro-4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde in the procedures described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.33-8.42 (m, 1H), 7.31-7.35 (m, 1H), 7.24-7.29 (m, 1H), 5.1 (m, 0.7H) 4.7 (0.3H), 4.35-4.42 (m, 1H), 3.51-3.56 (m, 1H), 3.41-3.45 (m, 1H), 3.04-3.12 (m, 3H), 2.77-2.97 (m, 1H), 2.47-2.52 (m, 2H), 2.29-2.35 (m, 2H), 2.19-2.22 (m, 1H), 2.06-2.15 (m, 1H), 1.83-1.89 (m, 3H), 1.53-1.66 (m, 2H), 1.47 (s, 9H), 1.32-1.41 (m, 2H), 0.88-0.90 (m, 3H), 0.85 (d, *J* = 6.6 Hz, 3H); MS (ESI+) *m/z* 530 (M+H)⁺.

30

Example 312***tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluoro-3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate**

5 The title compound was prepared by substituting *N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-(*tert*-butoxycarbonyl)-*N*²-methyl-L-leucinamide from Example 151 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide and 4-fluoro-3-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde in the procedures
 10 described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.32-8.39 (m, 1H), 7.62-7.75 (m, 1H), 7.20-7.27 (m, 2H), 5.1 (m, 0.7H) 4.7 (0.3H), 4.29-4.47 (m, 1H), 3.49-3.54 (m, 1H), 3.38-3.43 (m, 1H), 3.04-3.12 (m, 3H), 2.74-2.89 (m, 1H), 2.47-2.51 (m, 2H), 2.19-2.38 (m, 3H), 2.05-2.15 (m, 1H), 1.84 (dd, *J* = 9.0, 5.2 Hz, 3H), 1.54-1.65 (m, 2H), 1.46 (s, 9H), 1.26-1.42 (m, 1H), 0.89 (d, *J* = 6.4 Hz, 3H), 0.85 (d, *J* = 6.6 Hz, 3H); MS (ESI+) *m/z* 530
 15 (M+H)⁺.

Example 313***tert*-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

20 **Step A:** *tert*-Butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-norvaline for *N*-(*tert*-butoxycarbonyl)-L-leucine in the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm
 25 8.26 – 8.15 (m, 1H), 7.43 (d, *J* = 7.4, 2H), 7.36 (t, *J* = 7.5, 2H), 7.27 (t, *J* = 7.3, 1H), 5.07 – 5.00 (m, 1H), 4.72 – 4.58 (m, 1H), 4.46 – 4.31 (m, 1H), 3.59 (d, *J* = 13.1, 1H), 3.44 (d, *J* = 13.1, 1H), 3.12 – 2.99 (m, 3H), 2.83 (d, *J* = 8.9, 1H), 2.53 – 2.44 (m, 2H), 2.44 – 2.37 (m, 1H), 2.33 (d, *J* = 7.9, 1H), 2.26 – 2.19 (m, 1H), 2.14 – 1.95 (m, 2H), 1.79 (ddt, *J* = 7.1, 5.2, 4.2, 2H), 1.62 – 1.51 (m, 1H), 1.46 (s, 9H), 1.40 – 1.24 (m, 2H), 0.83 (t, *J* = 6.7, 3H); MS
 30 (ESI+) *m/z* 430(M+H)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Step A for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-

yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide in the procedures described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.24-8.26 (m, 1H), 7.75-7.76 (bs, 1H), 7.54-7.62 (m, 2H), 7.44 (t, *J* = 7.7 Hz, 1H), 5.1 (m, 0.7H), 4.7 (0.3H), 4.33-4.44 (m, 1H), 3.59 (d, *J* = 13.5 Hz, 1H), 3.45-3.48 (m, 1H), 3.02-3.10 (m, 3H), 2.82-2.85 (m, 1H),
 5 2.46-2.54 (m, 2H), 2.40-2.43 (m, 1H), 2.28-2.32 (m, 1H), 2.21-2.25 (m, 1H), 1.99-2.04 (m, 2H), 1.76-1.86 (m, 2H), 1.48-1.63 (m, 1H), 1.46 (s, 9H), 1.20-1.41 (m, 3H), 0.80-0.86 (m, 3H); MS (ESI+) *m/z* 498 (M+H)⁺.

Example 314

10 ***tert*-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from
 15 Step A of Example 313 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide and 4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde in the procedures described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.25-8.29 (bs, 1H), 7.64-7.66 (m, 2H), 7.50-7.52 (m, 2H), 5.1 (m, 0.7H), 4.7 (0.3H), 4.37-4.43 (m, 1H), 3.55-3.59 (m,
 20 1H), 3.45-3.48 (m, 1H), 3.02-3.11 (m, 3H), 2.84-2.87 (m, 1H), 2.45-2.54 (m, 2H), 2.30-2.39 (m, 2H), 2.20-2.23 (m, 1H), 2.02-2.15 (m, 2H), 1.77-1.87 (m, 2H), 1.52-1.59 (m, 1H), 1.46-1.47 (m, 9H), 1.28-1.39 (m, 3H), 0.81-0.85 (m, 3H); MS (ESI+) *m/z* 498 (M+H)⁺.

Example 315

25 ***tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from
 30 Step A of Example 313 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide and 4-fluorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde in the procedures described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.23-8.27 (m, 1H), 7.34-7.38 (m, 2H), 7.12 (t, *J* = 8.5 Hz, 2H), 5.1 (m, 0.7H), 4.7 (0.3H), 4.33-4.45 (m, 1H), 3.50 (d, *J* = 13.1 Hz, 1H), 3.38-3.41 (m, 1H), 3.02-

3.11 (m, 3H), 2.81-2.84 (m, 1H), 2.44-2.53 (m, 2H), 2.29-2.39 (m, 2H), 2.19-2.23 (m, 1H), 2.02-2.04 (m, 2H), 1.81-1.84 (m, 2H), 1.55-1.59 (m, 1H), 1.46-1.47 (m, 9H), 1.28-1.38 (m, 3H), 0.81-0.85 (m, 3H); MS (ESI+) m/z 448 (M+H)⁺.

5

Example 316

***tert*-butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamate from Example 232 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide in the procedures described in Example 303: ¹H NMR (400 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 7.69-7.70 (bs, 1H), 7.49-7.57 (m, 2H), 7.32-7.41 (m, 2H), 4.31-4.35 (m, 1H), 4.19-4.29 (m, 1H), 3.57 (d, *J* = 13.5 Hz, 1H), 3.50 (d, *J* = 13.6 Hz, 1H), 3.00 (s, 3H), 2.76 (d, *J* = 6.4 Hz, 1H), 2.50-2.56 (m, 1H), 2.38-2.46 (m, 3H), 2.28-2.37 (m, 2H), 2.06 (dq, *J* = 12.2, 6.1 Hz, 1H), 1.82-1.90 (m, 1H), 1.52-1.62 (m, 1H), 1.46 (s, 9H), 1.35-1.44 (m, 1H), 1.00 (d, *J* = 6.5 Hz, 3H), 0.87 (d, *J* = 6.7 Hz, 3H); MS (ESI+) m/z 498 (M+H)⁺.

20

Example 317

***tert*-butyl methyl((*S*)-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate from Example 233 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide and 4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde in the procedures described in Example 303: ¹H NMR (400 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 7.58-7.61 (m, 2H), 7.45-7.48 (m, 2H), 7.18-7.28 (m, 1H), 4.70-4.75 (m, 1H), 4.22-4.30 (m, 1H), 3.48-3.59 (m, 2H), 2.94 (s, 3H), 2.78-2.81 (m, 1H), 2.52-2.57 (m, 1H), 2.34-2.47 (m, 3H), 2.27-2.32 (m, 1H), 2.04-2.12 (m, 1H), 1.93-2.03 (m, 1H), 1.82-1.91 (m, 1H), 1.71-1.81 (m, 1H), 1.49-1.67 (m, 1H), 1.46-1.47 (m, 9H), 1.37-1.46 (m, 1H), 1.26-1.36 (m, 2H), 0.87 (t, *J* = 7.4 Hz, 3H); MS (ESI+) m/z 498 (M+H)⁺.

30

Example 318***tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate**

5 The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate from Example 233 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide and 4-fluorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde in the procedures described in Example 303: ¹H NMR (400
10 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 7.28-7.32 (m, 2H), 7.16-7.21 (m, 1H), 7.02 (t, *J* = 8.6 Hz, 2H), 4.69-4.77 (m, 1H), 4.21-4.28 (m, 1H), 3.49 (d, *J* = 13.2 Hz, 1H), 3.43 (d, *J* = 13.2 Hz, 1H), 2.94 (s, 3H), 2.76-2.78 (m, 1H), 2.48-2.55 (m, 1H), 2.33-2.46 (m, 3H), 2.25-2.32 (m, 1H), 2.04-2.14 (m, 1H), 1.94-2.03 (m, 1H), 1.82-1.91 (m, 1H), 1.70-1.81 (m, 1H), 1.49-1.58 (m, 1H), 1.46-1.48 (m, 9H), 1.37-1.44 (m, 1H), 1.28-1.36 (m, 2H), 0.87 (t, *J* = 7.4
15 Hz, 3H); MS (ESI+) *m/z* 448 (M+H)⁺.

Example 319**(2*S*)-4-methyl-2-morpholin-4-yl-*N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide**

20 **Step A:** (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-Benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide (0.400 g, 1.001 mmol) from Step B of Example 249 and ethanol (40 mL) were added to 20% Pd(OH)₂ on carbon, wet (0.080 g, 0.570 mmol) in a 250 mL stainless steel pressure bottle and stirred for 16 hours under 30 psi hydrogen at 55 °C. The mixture was filtered through a nylon membrane and the solvent removed in vacuo to give (*S*)-
25 4-methyl-2-morpholino-*N*-((3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.46 (d, *J* = 6.9, 1H), 4.46 - 4.38 (m, 1H), 3.74 (s, 4H), 3.45 (dd, *J* = 2.0, 11.3, 1H), 3.31 - 3.21 (m, 2H), 3.10 (dd, *J* = 7.0, 11.0, 1H), 2.89 (dd, *J* = 2.3, 11.0, 1H), 2.83 - 2.77 (m, 2H), 2.76 - 2.67 (m, 4H), 2.09 (td, *J* = 6.0, 11.8, 1H), 1.95 - 1.87 (m, 1H), 1.84 (dq, *J* = 6.0, 9.7, 2H), 1.71 - 1.57 (m, 2H), 1.49 (ddt, *J* = 6.3, 9.1, 12.5,
30 1H), 0.94 (dd, *J* = 6.3, 11.2, 6H); MS (ESI+) *m/z* 310(M+H)⁺

Step B: (*S*)-4-Methyl-2-morpholino-*N*-((3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide (191mg, 0.617 mmol), triethylamine (0.129 mL, 0.926 mmol), and 3-(trifluoromethyl)benzene-1-sulfonyl chloride (0.109 mL, 0.679 mmol) were combined in

dichloromethane (0.5 mL). The reaction was stirred at room temperature for 3 hours. The crude material was purified by silica gel chromatography using 1-10% methanol (2 *N* ammonia)/dichloromethane to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.44 (d, *J* = 6.2, 1H), 8.38 (s, 1H), 8.19 (d, *J* = 7.9, 1H), 7.92 (d, *J* = 7.8, 1H), 7.72 (t, *J* = 7.9, 1H), 4.27 - 4.20 (m, 1H), 3.90 (dd, *J* = 2.3, 10.0, 1H), 3.76 - 3.67 (m, 4H), 3.20 (ddd, *J* = 3.9, 9.4, 10.9, 3H), 2.97 (dd, *J* = 7.1, 9.6, 1H), 2.78 - 2.72 (m, 2H), 2.72 - 2.67 (m, 2H), 2.62 - 2.53 (m, 2H), 1.94 (dt, *J* = 6.2, 12.1, 1H), 1.89 - 1.77 (m, 3H), 1.64 - 1.54 (m, 2H), 1.30 (ddt, *J* = 6.5, 9.3, 12.8, 1H), 0.92 (d, *J* = 4.4, 3H), 0.91 (d, *J* = 4.4, 3H); MS (ESI+) *m/z* 518(M+H)⁺.

10

Example 320

(2*S*)-4-methyl-2-pyrrolidin-1-yl-*N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide

The title compound was prepared by substituting (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide from Example 250 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-morpholinopentanamide in the procedures described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.37-8.39 (m, 1H), 8.17-8.20 (m, 1H), 8.12-8.15 (m, 1H), 7.89-7.92 (m, 1H), 7.71 (t, *J* = 7.8 Hz, 1H), 4.23-4.29 (m, 1H), 3.86 (dd, *J* = 9.9, 2.4 Hz, 1H), 3.16-3.20 (m, 2H), 3.13-3.15 (m, 1H), 2.97 (dd, *J* = 9.6, 6.8 Hz, 1H), 2.65-2.69 (m, 2H), 2.55-2.61 (m, 4H), 1.90-2.00 (m, 1H), 1.76-1.90 (m, 3H), 1.54-1.62 (m, 6H), 1.25-1.34 (m, 1H), 0.98 (d, *J* = 6.3 Hz, 3H), 0.91 (d, *J* = 6.3 Hz, 3H); MS (ESI+) *m/z* 502 (M+H)⁺.

20

Example 321

(2*S*)-4-methyl-2-piperidin-1-yl-*N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide

The title compound was prepared by substituting (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-piperidin-1-ylpentanamide from Example 251 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-morpholinopentanamide in the procedures described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.38-8.39 (bs, 1H), 8.18-8.20 (m, 2H), 7.90-7.92 (m, 1H), 7.71 (t, *J* = 7.8 Hz, 1H), 4.20-4.26 (m, 1H), 3.87 (dd, *J* = 9.9, 2.1 Hz, 1H), 3.16-3.20 (m, 3H), 2.97 (dd, *J* =

25

30

9.5, 6.3 Hz, 1H), 2.56-2.64 (m, 6H), 1.80-1.97 (m, 4H), 1.46-1.59 (m, 6H), 1.23-1.37 (m, 3H), 0.93 (d, $J = 6.6$ Hz, 3H), 0.92 (d, $J = 6.7$ Hz, 3H); MS (ESI+) m/z 516 (M+H)⁺.

Example 322

5 ***tert*-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate from Example 222 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide in the procedures described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.48-8.50 (m, 1H), 8.36-8.37 (bs, 1H), 8.19 (d, $J = 7.9$ Hz, 1H), 7.91 (d, $J = 7.9$ Hz, 1H), 7.72 (t, $J = 7.8$ Hz, 1H), 5.13 (m, 0.7H), 4.78 (m, 0.3H), 4.15-4.29 (m, 1H), 3.84 (dd, $J = 9.9, 2.1$ Hz, 1H), 3.13-3.16 (m, 1H), 3.02-3.12 (m, 4H), 2.91 (dd, $J = 9.6, 6.9$ Hz, 1H), 2.48-2.52 (m, 2H), 1.74-1.90 (m, 4H), 1.49-1.67 (m, 2H), 1.44-1.46 (m, 9H), 1.16-1.29 (m, 1H), 0.89 (d, $J = 6.4$ Hz, 3H), 0.84 (d, $J = 6.4$ Hz, 3H); MS (ESI+) m/z 562 (M+H)⁺.

Example 323

20 ***tert*-butyl ethyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(ethyl)carbamate from Example 223 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide in the procedures described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.37-8.40 (m, 2H), 8.19 (d, $J = 7.9$ Hz, 1H), 7.91 (d, $J = 7.9$ Hz, 1H), 7.72 (t, $J = 7.9$ Hz, 1H), 5.0 (m, 0.7H), 4.7 (m, 0.3H), 4.16-4.27 (m, 1H), 3.83-3.86 (m, 1H), 3.43-3.49 (m, 2H), 3.09-3.18 (m, 2H), 2.90-2.94 (m, 1H), 2.43-2.58 (m, 2H), 1.90-2.02 (m, 2H), 1.71-1.84 (m, 2H), 1.62-1.67 (m, 1H), 1.34-1.59 (m, 10H), 1.21-1.31 (m, 4H), 0.88-0.91 (m, 6H); MS (ESI+) m/z 576 (M+H)⁺.

Example 324

***tert*-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

5 The title compound was prepared by substituting *N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-(*tert*-butoxycarbonyl)-*N*²-methyl-L-leucinamide from Example 151 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319:

10 ¹H NMR (501 MHz, pyridine-*d*₅, temperature 60 °C) δ ppm 8.08-8.11 (m, 2H), 7.99-8.03 (bs, 1H), 7.84-7.87 (m, 2H), 4.95 (m, 0.7H), 4.4 (m, 0.3H), 4.11-4.17 (m, 1H), 3.70-3.74 (m, 1H), 3.15-3.21 (m, 1H), 3.13 (dd, *J* = 9.8, 2.8 Hz, 1H), 3.03 (dd, *J* = 9.7, 7.3 Hz, 1H), 3.00 (s, 3H), 2.50-2.54 (m, 2H), 1.89-1.97 (m, 1H), 1.72-1.89 (m, 3H), 1.50-1.61 (m, 2H), 1.45 (s, 9H), 1.28 (ddt, *J* = 9.5, 12.9, 6.5 Hz, 1H), 0.89 (d, *J* = 6.8 Hz, 3H), 0.85 (d, *J* = 6.5 Hz, 3H); MS

15 (DCI+) *m/z* 562 (M+H)⁺, 579 (M+NH₄)⁺.

Example 325

***tert*-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

20 The title compound was prepared by substituting *N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-(*tert*-butoxycarbonyl)-*N*²-methyl-L-leucinamide from Example 151 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide in the procedures described in Example 319: ¹H NMR (501 MHz, pyridine-*d*₅, temperature 60 °C) δ ppm 8.32-8.33 (bs, 1H), 8.15 (d, *J* = 8.1 Hz, 1H), 7.97-8.01 (m, 1H), 7.87 (d, *J* = 7.7 Hz, 1H), 7.68 (t, *J* = 7.9 Hz, 1H), 4.95 (m, 0.7H), 4.4 (m, 0.3H), 4.11-4.15 (m, 1H), 3.71-3.75 (m, 1H), 3.12-3.18 (m, 2H), 3.00-3.04 (m, 1H), 2.99 (s, 3H), 2.48-2.52 (m, 2H), 1.90-1.96 (m, 1H), 1.73-1.86 (m, 3H), 1.50-1.60 (m, 2H), 1.46 (s, 9H), 1.24-1.30 (m, 1H), 0.88 (d, *J* = 6.6 Hz, 3H), 0.85 (d, *J* = 6.5 Hz, 3H); MS (ESI+) *m/z* 579

25

30 (M+NH₄)⁺.

Example 326***tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate**

The title compound was prepared by substituting *N*¹-[(3*aS*,4*R*,6*aR*)-2-

5 benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-(*tert*-butoxycarbonyl)-*N*²-methyl-L-leucinamide from Example 151 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-fluorobenzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319:
¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.51-8.58 (m, 1H), 7.97-7.99 (m, 2H), 7.29-7.35 (m,
10 2H), 5.13 (m, 0.7H), 4.8 (m, 0.3H), 4.20-4.23 (m, 1H), 3.70-3.81 (m, 1H), 3.00-3.11 (m, 5H), 2.86-2.91 (m, 1H), 2.42-2.53 (m, 2H), 1.75-1.96 (m, 4H), 1.49-1.62 (m, 2H), 1.41-1.50 (bs, 9H), 1.23-1.39 (m, 1H), 0.81-0.88 (m, 6H); MS (ESI+) *m/z* 512 (M+H)⁺.

Example 327

15 ***tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluoro-3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate**

The title compound was prepared by substituting *N*¹-[(3*aS*,4*R*,6*aR*)-2-

benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-(*tert*-butoxycarbonyl)-*N*²-methyl-L-leucinamide from
20 Example 151 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-fluoro-3-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319:
¹H NMR (501 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.28 (dd, *J* = 6.6, 2.3 Hz, 1H), 8.16-8.20 (m, 1H), 7.54-7.59 (m, 1H), 7.44 (t, *J* = 9.4 Hz, 1H), 4.79-4.84 (m, 1H), 4.08 (p, *J*
25 = 6.9 Hz, 1H), 3.67 (dd, *J* = 10.1, 3.3 Hz, 1H), 3.25 (dd, *J* = 10.1, 7.7 Hz, 1H), 3.09-3.17 (m, 2H), 2.94 (s, 3H), 2.53-2.61 (m, 1H), 2.46-2.53 (m, 1H), 1.91-1.98 (m, 1H), 1.79-1.87 (m, 2H), 1.73 (ddd, *J* = 14.1, 9.1, 5.1 Hz, 1H), 1.56-1.64 (m, 1H), 1.48-1.56 (m, 1H), 1.46 (s, 9H), 1.26-1.33 (m, 1H), 0.89 (d, *J* = 6.6 Hz, 3H), 0.87 (d, *J* = 6.6 Hz, 3H); MS (ESI+) *m/z* 580 (M+H)⁺.

30

Example 328

***tert*-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*R*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

5 The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate from Example 240 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319:

10 ¹H NMR (400 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.04-8.07 (m, 2H), 7.80-7.83 (m, 2H), 7.54-7.57 (m, 1H), 4.79 (dd, *J* = 9.4, 6.0 Hz, 1H), 4.29 (dq, *J* = 9.8, 7.0 Hz, 1H), 3.49 (dd, *J* = 10.3, 4.7 Hz, 1H), 3.21 (dd, *J* = 9.9, 7.8 Hz, 1H), 3.07-3.13 (m, 2H), 3.01 (s, 3H), 2.92-3.01 (m, 1H), 2.46-2.54 (m, 1H), 1.95-2.07 (m, 1H), 1.75-1.85 (m, 1H), 1.68-1.77 (m, 1H), 1.55-1.66 (m, 2H), 1.54 (s, 9H), 1.25-1.39 (m, 3H), 0.87 (t, *J* = 7.3 Hz, 3H); MS (ESI+)

15 *m/z* 548 (M+H)⁺.

Example 329

***tert*-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*R*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

20 The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate from Example 241 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319: ¹H NMR (400 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.04-8.07 (m, 2H), 7.80-7.83 (m, 2H), 7.54-7.61 (m, 1H), 4.90 (dd, *J* = 9.2, 6.0 Hz, 1H), 4.26-4.34 (m, 1H), 3.49 (dd, *J* = 10.3, 4.7 Hz, 1H), 3.21 (dd, *J* = 9.9, 7.8 Hz, 1H), 3.06-3.14 (m, 2H), 3.02 (s, 3H), 2.94-3.01 (m, 1H), 2.47-2.55 (m, 1H), 1.87 (ddd, *J*

25 = 14.2, 8.5, 5.6 Hz, 1H), 1.69-1.83 (m, 2H), 1.57-1.67 (m, 3H), 1.54 (s, 9H), 1.27-1.39 (m, 1H), 0.90 (d, *J* = 6.9 Hz, 3H), 0.89 (d, *J* = 6.9 Hz, 3H); MS (ESI+) *m/z* 562 (M+H)⁺.

30

Example 330***tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate from Example 233 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-fluorobenzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319:

¹H NMR (400 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 7.90-7.97 (m, 2H), 7.38-7.48 (bs, 1H), 7.18-7.24 (m, 2H), 7.18-7.23 (m, 1H), 4.65-4.75 (m, 1H), 4.03-4.13 (m, 1H), 3.58 (dd, *J* = 10.1, 3.4 Hz, 1H), 3.22 (dd, *J* = 10.1, 7.8 Hz, 1H), 3.03-3.13 (m, 2H), 2.94 (s, 3H), 2.51-2.60 (m, 1H), 2.43-2.51 (m, 1H), 1.89-2.01 (m, 2H), 1.80-1.86 (m, 1H), 1.69-1.81 (m, 1H), 1.47-1.62 (m, 1H), 1.45 (s, 9H), 1.23-1.38 (m, 3H), 0.86 (t, *J* = 7.3 Hz, 2H); MS (ESI+) *m/z* 498 (M+H)⁺.

Example 331***tert*-butyl methyl((*S*)-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate from Example 233 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319:

¹H NMR (400 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.05-8.08 (m, 2H), 7.79-7.83 (m, 2H), 7.43-7.48 (bs, 1H), 4.68-4.72 (m, 1H), 4.01-4.11 (m, 1H), 3.65 (dd, *J* = 10.2, 3.3 Hz, 1H), 3.26 (dd, *J* = 10.1, 7.7 Hz, 1H), 3.07-3.18 (m, 2H), 2.94 (s, 3H), 2.45-2.58 (m, 2H), 1.89-2.00 (m, 2H), 1.70-1.86 (m, 2H), 1.46-1.57 (m, 1H), 1.45 (s, 9H), 1.31 (dt, *J* = 15.2, 7.6 Hz, 2H), 1.23-1.37 (m, 1H), 0.85 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z* 565 (M+NH₄)⁺.

Example 332

***tert*-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

5 The title compound was prepared by substituting *tert*-butyl (2*S*,3*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamate from Example 224 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide in the procedures described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.66 (d, *J* = 6.0 Hz, 1H), 8.39-8.40 (m, 1H), 8.21 (d, *J* = 7.9 Hz, 1H), 7.92 (d, *J* = 7.6 Hz, 1H), 7.72 (t, *J* = 7.9 Hz, 1H), 4.67 (d, *J* = 11.1 Hz, 1H), 4.15-4.25 (m, 1H), 4.15-4.23 (m, 1H), 3.89 (d, *J* = 9.9 Hz, 1H), 3.09-3.26 (m, 5H), 2.88-3.08 (m, 1H), 2.46-2.55 (m, 2H), 2.17-2.31 (m, 1H), 1.74-1.94 (m, 2H), 1.42-1.55 (m, 1H), 1.48 (s, 9H), 1.18-1.30 (m, 1H), 1.00-1.12 (m, 1H), 0.94 (d, *J* = 6.3 Hz, 3H), 0.80 (t, *J* = 7.0 Hz, 3H); MS (ESI+) *m/z* 562 (M+H)⁺.

15

Example 333

***tert*-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

20 The title compound was prepared by substituting *tert*-butyl (2*S*,3*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamate from Example 224 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.68 (d, *J* = 6.3 Hz, 1H), 8.12-8.17 (m, 2H), 7.87-7.95 (m, 2H), 4.68 (d, *J* = 11.0 Hz, 1H), 4.16-4.24 (m, 1H), 3.87 (d, *J* = 9.8 Hz, 1H), 3.09-3.24 (m, 5H), 2.89-3.08 (m, 1H), 2.50-2.58 (m, 2H), 2.22-2.27 (m, 1H), 1.77-1.85 (m, 2H), 1.51-1.66 (m, 1H), 1.48 (s, 9H), 1.34-1.49 (m, 1H), 1.19-1.31 (m, 1H), 0.98-1.13 (m, 1H), 0.95 (d, *J* = 6.1 Hz, 3H), 0.80 (t, *J* = 6.9 Hz, 3H); MS (ESI+) *m/z* 562 (M+H)⁺.

30

Example 334

***tert*-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

5 **Step A:** *tert*-Butyl (2*S*,3*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamate was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-L-isoleucine for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Example 16 Step E for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in
10 Example 221: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.43 (d, *J* = 6.4, 1H), 7.41 (d, *J* = 7.2, 2H), 7.36 (t, *J* = 7.5, 2H), 7.27 (t, *J* = 7.2, 1H), 4.70 (d, *J* = 11.1, 1H), 4.36 (d, *J* = 4.4, 2H), 3.56 (d, *J* = 13.0, 1H), 3.40 (d, *J* = 13.1, 1H), 3.24 (s, 1H), 3.13 (s, 3H), 2.72 (d, *J* = 8.6, 1H), 2.47 (s, 2H), 2.37 – 2.18 (m, 4H), 2.13 (dd, *J* = 11.7, 5.6, 1H), 1.91 – 1.76 (m, 1H), 1.65 (dd, *J* = 11.4, 6.8, 1H), 1.48 (s, 9H), 1.11 – 0.95 (m, 4H), 0.80 (t, *J* = 7.1, 3H); MS (ESI+) *m/z* 444
15 (M+H)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl (2*S*,3*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamate from Step A for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide in the
20 procedures described in Example 319: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.68 (d, *J* = 7.2 Hz, 1H), 8.35-8.40 (m, 1H), 8.15 (d, *J* = 7.8 Hz, 1H), 7.91 (d, *J* = 7.6 Hz, 1H), 7.72 (t, *J* = 7.8 Hz, 1H), 4.68 (d, *J* = 11.3 Hz, 1H), 4.13-4.25 (m, 1H), 3.74-3.88 (m, 1H), 3.15-3.25 (m, 1H), 3.11-3.16 (bs, 3H), 2.95-3.05 (m, 1H), 2.83-2.94 (m, 1H), 2.38-2.61 (m, 2H), 2.17-2.32 (m, 1H), 1.88-2.03 (m, 1H), 1.76-1.88 (m, 1H), 1.52-1.66 (m, 1H), 1.44-1.53 (bs, 9H), 1.33-
25 1.46 (m, 1H), 1.21-1.33 (m, 1H), 0.96-1.12 (m, 1H), 0.94 (d, *J* = 6.4 Hz, 3H), 0.79 (t, *J* = 7.2 Hz, 3H); MS (ESI+) *m/z* 562 (M+H)⁺.

Example 335

30 ***tert*-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate**

 The title compound was prepared by substituting *tert*-butyl (2*S*,3*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-

yl(methyl)carbamate from Step A of Example 334 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.66-8.72 (m, 1H), 8.05-8.13 (m, 2H), 7.88-7.91 (m, 2H), 4.69 (d, *J* = 11.3 Hz, 1H), 4.15-4.22 (m, 1H), 3.73-3.87 (m, 1H), 3.16-3.23 (m, 1H), 3.11-3.18 (bs, 3H), 3.00 (t, *J* = 8.3 Hz, 1H), 2.90 (t, *J* = 8.4 Hz, 1H), 2.42-2.56 (m, 2H), 2.21-2.28 (m, 1H), 1.88-2.03 (m, 1H), 1.73-1.88 (m, 1H), 1.52-1.66 (m, 1H), 1.48 (s, 9H), 1.34-1.46 (m, 1H), 1.21-1.34 (m, 1H), 0.98-1.13 (m, 1H), 0.94 (d, *J* = 6.3 Hz, 3H), 0.76-0.81 (m, 3H); MS (ESI+) *m/z* 562 (M+H)⁺.

10

Example 336

***tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate**

15 The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate from Example 247 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide in the procedures described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.36-8.38 (bs, 1H), 8.30-8.37 (m, 1H), 8.19 (d, *J* = 7.8 Hz, 1H), 7.91 (d, *J* = 7.8 Hz, 1H), 7.72 (t, *J* = 7.8 Hz, 1H), 5.4 (m, 0.7H), 4.7 (m, 0.3H), 4.16-4.20 (m, 1H), 3.86 (d, *J* = 9.8 Hz, 1H), 3.13-3.18 (m, 1H), 3.08-3.13 (m, 1H), 2.96-3.08 (bs, 3H), 2.90-2.93 (m, 1H), 2.41-2.56 (m, 2H), 2.13-2.37 (m, 1H), 1.81-1.92 (m, 1H), 1.72-1.81 (m, 1H), 1.60-1.72 (m, 1H), 1.47-1.60 (m, 1H), 1.41-1.50 (bs, 9H), 1.19-1.33 (m, 1H), 0.87-0.99 (bs, 9H); MS (ESI+) *m/z* 576 (M+H)⁺, 593 (M+NH₄)⁺.

25

Example 337

***tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate**

30

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate from Example 247 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-

benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.35-8.38 (m, 1H), 8.12-8.15 (m, 2H), 7.89-7.91 (m, 2H), 5.11-5.19 (m, 1H), 4.15-4.19 (m, 1H), 3.83-3.86 (m, 1H), 3.13-3.17 (m, 1H), 3.09-3.14 (m, 1H), 2.97-3.09 (bs, 3H), 2.92-2.96 (m, 1H), 2.43-2.57 (m, 2H), 2.15-2.38 (m, 1H), 1.81-1.91 (m, 1H), 1.72-1.81 (m, 1H), 1.61-1.72 (m, 1H), 1.48-1.60 (m, 1H), 1.40-1.51 (bs, 9H), 1.20-1.36 (m, 1H), 0.89-0.99 (bs, 9H); MS (ESI+) *m/z* 576 (M+H)⁺.

10

Example 338

***tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate from Example 248 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide in the procedures described in Example 319: ¹H NMR (400 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.29-8.30 (bs, 1H), 8.13 (d, *J* = 7.9 Hz, 1H), 7.83 (d, *J* = 8.6 Hz, 1H), 7.64 (t, *J* = 7.8 Hz, 1H), 7.29 (d, *J* = 3.9 Hz, 1H), 4.82-4.87 (bs, 1H), 4.05 (p, *J* = 6.7 Hz, 1H), 3.63 (dd, *J* = 10.2, 3.3 Hz, 1H), 3.25 (dd, *J* = 10.1, 7.8 Hz, 1H), 3.07-3.17 (m, 2H), 2.91 (s, 3H), 2.51-2.59 (m, 1H), 2.43-2.50 (m, 1H), 2.15 (dd, *J* = 14.3, 5.6 Hz, 1H), 1.92 (dq, *J* = 12.2, 6.1 Hz, 1H), 1.77-1.85 (m, 1H), 1.61 (dd, *J* = 14.3, 7.2 Hz, 1H), 1.47-1.55 (m, 1H), 1.46 (s, 9H), 1.23-1.36 (m, 1H), 0.93 (s, 9H); MS (ESI+) *m/z* 576 (M+H)⁺.

25

Example 339

***tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate from Example 248 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-

30

(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319: ¹H NMR (400 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.05-8.08 (m, 2H), 7.79-7.82 (m, 2H), 7.28-7.32 (m, 1H), 4.79-4.91 (m, 1H), 4.05 (p, *J* = 6.7 Hz, 1H), 3.62 (dd, *J* = 10.2, 3.4 Hz, 1H), 3.26 (dd, *J* = 10.2, 7.8 Hz, 1H), 3.09-3.17 (m, 2H), 2.92 (s, 3H), 2.51-2.62 (m, 1H), 2.43-2.51 (m, 1H), 2.15 (dd, *J* = 14.3, 5.6 Hz, 1H), 1.88-1.98 (m, 1H), 1.76-1.86 (m, 1H), 1.62 (dd, *J* = 14.3, 7.0 Hz, 1H), 1.47-1.56 (m, 1H), 1.46 (s, 9H), 1.29 (ddt, *J* = 9.0, 13.0, 6.5 Hz, 1H), 0.94 (s, 9H); MS (ESI+) *m/z* 576 (M+H)⁺.

10

Example 340

***tert*-butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamate from Example 232 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide in the procedures described in Example 319: ¹H NMR (501 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.29-8.30 (bs, 1H), 8.13 (d, *J* = 7.8 Hz, 1H), 7.83 (d, *J* = 7.7 Hz, 1H), 7.64 (t, *J* = 7.8 Hz, 1H), 7.59-7.68 (m, 1H), 4.32 (d, *J* = 10.4 Hz, 1H), 4.07 (p, *J* = 6.6 Hz, 1H), 3.64 (dd, *J* = 10.2, 3.3 Hz, 1H), 3.23 (t, *J* = 9.0 Hz, 1H), 3.07-3.15 (m, 2H), 3.00 (s, 3H), 2.49-2.59 (m, 1H), 2.42-2.49 (m, 1H), 2.31-2.42 (m, 1H), 1.90-1.97 (m, 1H), 1.79-1.86 (m, 1H), 1.47-1.59 (m, 1H), 1.45 (s, 9H), 1.24-1.33 (m, 1H), 0.97 (d, *J* = 6.5 Hz, 3H), 0.86 (d, *J* = 6.7 Hz, 3H); MS (ESI+) *m/z* 548 (M+H)⁺.

25

Example 341

***tert*-butyl (*S*)-3,3-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-ylcarbamate**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate from Example 225 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-

30

(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319:

¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.86 (d, *J* = 6.7 Hz, 1H), 8.11-8.18 (m, 2H), 7.89-7.92 (m, 2H), 7.71 (d, *J* = 9.5 Hz, 1H), 4.56 (d, *J* = 9.8 Hz, 1H), 4.20 (p, *J* = 6.4 Hz, 1H), 3.79 (dd, *J* = 10.0, 3.0 Hz, 1H), 3.24 (dd, *J* = 9.9, 7.7 Hz, 1H), 3.14 (d, *J* = 3.2 Hz, 1H), 3.02 (dd, *J* = 9.7, 7.3 Hz, 1H), 2.55-2.65 (m, 2H), 1.76-1.84 (m, 2H), 1.44-1.56 (m, 1H), 1.48 (s, 9H), 1.19-1.27 (m, 1H), 1.16 (s, 9H); MS (ESI+) *m/z* 548 (M+H)⁺, 565 (M+NH₄)⁺.

Example 342

***tert*-butyl (*S*)-3,3-dimethyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-ylcarbamate**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate from Example 234 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319:

¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.89 (d, *J* = 7.4, 1H), 8.10 (d, *J* = 8.1, 2H), 7.90 (d, *J* = 8.3, 2H), 7.73 (s, 1H), 4.55 (d, *J* = 9.8, 1H), 4.27 – 4.16 (m, 1H), 3.70 (dd, *J* = 9.8, 2.2, 1H), 3.14 (dd, *J* = 9.8, 2.5, 1H), 2.98 – 2.92 (m, 1H), 2.91 – 2.85 (m, 1H), 2.53 – 2.39 (m, 2H), 1.99 (td, *J* = 11.5, 5.7, 1H), 1.83 (td, *J* = 12.4, 7.2, 1H), 1.60 (dt, *J* = 12.3, 8.2, 1H), 1.48 (s, 9H), 1.34 – 1.25 (m, 1H), 1.15 (s, 9H); MS (ESI+) *m/z* 548 (M+H)⁺, 565 (M+NH₄)⁺.

Example 343

***tert*-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)hexan-2-yl)carbamate**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxohexan-2-yl(methyl)carbamate from Example 227 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319:

¹H NMR (400 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.06-8.09 (m, 2H), 7.79-7.82 (m, 2H), 7.40 (d, *J* = 5.6 Hz, 1H), 4.68-4.72 (m, 1H), 4.07 (p, *J* = 6.8 Hz, 1H), 3.65 (dd, *J* = 10.2,

3.4 Hz, 1H), 3.28 (dd, $J = 10.2, 7.7$ Hz, 1H), 3.09-3.17 (m, 2H), 2.94 (s, 3H), 2.54-2.59 (m, 1H), 2.47-2.53 (m, 1H), 1.97-2.07 (m, 1H), 1.87-1.96 (m, 1H), 1.72-1.86 (m, 2H), 1.47-1.56 (m, 1H), 1.46 (s, 9H), 1.23-1.35 (m, 1H), 1.27-1.30 (m, 4H), 0.80-0.84 (m, 3H); MS (ESI+) m/z 562 (M+H)⁺, 579 (M+NH₄)⁺, 620 (M+CH₃CN+NH₄)⁺.

5

Example 344

***tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate**

10 The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamate from Example 226 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319:

15 ¹H NMR (400 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.06-8.08 (m, 1H), 8.06 (d, $J = 0.9$ Hz, 1H), 7.79-7.82 (m, 2H), 7.73-7.77 (m, 1H), 7.00-7.05 (m, 1H), 4.47 (td, $J = 8.2, 4.7$ Hz, 1H), 4.04-4.11 (m, 1H), 3.65 (dd, $J = 10.2, 3.0$ Hz, 1H), 3.29 (dd, $J = 10.2, 7.3$ Hz, 1H), 3.15 (dd, $J = 10.0, 6.9$ Hz, 1H), 3.11 (dd, $J = 9.9, 3.4$ Hz, 1H), 2.51-2.59 (m, 2H), 2.08 (dd, $J = 14.2, 4.6$ Hz, 1H), 1.84-1.93 (m, 1H), 1.75-1.83 (m, 1H), 1.69 (dd, $J = 14.2, 8.0$ Hz, 1H),

20 1.48-1.56 (m, 1H), 1.47 (s, 9H), 1.22-1.33 (m, 1H), 0.96 (s, 9H); MS (ESI+) m/z 562 (M+H)⁺.

Example 345

(2*S*)-4-methyl-2-pyrrolidin-1-yl-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzoyl]octahydrocyclopenta[*c*]pyrrol-4-yl}pentanamide

25 The title compound was prepared by substituting (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide from Example 250 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 3-(trifluoromethyl)benzoyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319: ¹H

30 NMR (500 MHz, pyridine-*d*₅) δ ppm 8.41 – 8.17 (m, 1H), 8.14 – 8.05 (m, 1H), 8.01 – 7.78 (m, 1H), 7.76 – 7.66 (m, 1H), 7.53 (t, $J = 7.6$, 1H), 4.51 – 4.29 (m, 1H), 4.20 – 4.00 (m, 1H), 3.89 (ddd, $J = 12.0, 6.6, 1.5$, 1H), 3.74 (tdd, $J = 8.3, 5.2, 2.8$, 1H), 3.67 – 3.45 (m, 1H), 3.32 –

3.13 (m, 2H), 2.87 – 2.57 (m, 6H), 2.23 – 2.02 (m, 1H), 1.96 – 1.78 (m, 2H), 1.73 – 1.55 (m, 6H), 1.47 – 1.24 (m, 1H), 1.04 – 0.79 (m, 6H); MS (ESI+) m/z 466 (M+H)⁺.

Example 346

5 (2*S*)-4-methyl-*N*-[(3*aS*,4*R*,6*aR*)-2-(methylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-pyrrolidin-1-ylpentanamide

The title compound was prepared by substituting (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide from Example 250 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-morpholinopentanamide and methanesulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.24-8.26 (m, 1H), 4.35 (p, *J* = 6.8 Hz, 1H), 3.79 (dd, *J* = 9.9, 2.6 Hz, 1H), 3.50 (dd, *J* = 9.9, 7.0 Hz, 1H), 3.35 (dd, *J* = 9.6, 7.0 Hz, 1H), 3.17-3.21 (m, 2H), 3.04 (s, 3H), 2.67-2.75 (m, 4H), 2.60-2.63 (m, 2H), 1.99-2.07 (m, 1H), 1.78-1.95 (m, 3H), 1.58-1.68 (m, 15 6H), 1.32-1.39 (m, 1H), 0.99 (d, *J* = 6.2 Hz, 3H), 0.92 (d, *J* = 6.3 Hz, 3H); MS (ESI+) m/z 372 (M+H)⁺.

Example 347

20 (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-(cyclopropylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide

The title compound was prepared by substituting (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide from Example 250 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-morpholinopentanamide and cyclopropanesulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedures described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.14 (d, *J* = 7.3 Hz, 1H), 4.33-4.40 (m, 1H), 3.82 (dd, *J* = 9.9, 2.6 Hz, 1H), 3.57 (dd, *J* = 9.9, 7.0 Hz, 1H), 3.41 (dd, *J* = 9.6, 7.0 Hz, 1H), 3.22 (dd, *J* = 9.6, 3.2 Hz, 1H), 3.16 (dd, *J* = 9.2, 5.1 Hz, 1H), 2.60-2.70 (m, 7H), 2.04 (dq, *J* = 11.9, 5.9 Hz, 1H), 1.79-1.97 (m, 3H), 1.56-1.67 (m, 6H), 1.33-1.40 (m, 1H), 1.16-1.23 (m, 30 2H), 0.99 (d, *J* = 6.3 Hz, 3H), 0.92 (d, *J* = 6.4 Hz, 3H), 0.86-0.92 (m, 2H); MS (ESI+) m/z 398 (M+H)⁺.

Example 348

***N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-leucinamide**

tert-Butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate (60 mg, 0.135 mmol) from Example 222 was combined with 4 *N* hydrogen chloride in 1,4-dioxane (0.698 mL, 2.79 mmol). The reaction was stirred at room temperature for 16 hours and then concentrated. The material was purified using a 12 g silica gel cartridge with a gradient of 1-10% methanol (2 *N* ammonia)/dichloromethane over 20 minutes to give the title compound: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.16-8.19 (m, 1H), 7.44-7.46 (m, 2H), 7.37 (t, *J* = 7.5 Hz, 2H), 7.28 (t, *J* = 7.3 Hz, 1H), 4.42-4.48 (m, 1H), 3.61 (d, *J* = 13.1 Hz, 1H), 3.46 (d, *J* = 13.1 Hz, 1H), 3.22 (dd, *J* = 8.2, 5.8 Hz, 1H), 2.87 (d, *J* = 10.3 Hz, 1H), 2.51-2.61 (m, 2H), 2.44 (dd, *J* = 8.8, 7.1 Hz, 1H), 2.43 (s, 3H), 2.37 (dd, *J* = 9.0, 2.0 Hz, 1H), 2.25-2.29 (m, 1H), 2.09-2.17 (m, 1H), 1.95-2.07 (m, 1H), 1.82-1.95 (m, 2H), 1.72 (ddd, *J* = 13.5, 7.8, 5.8 Hz, 1H), 1.55-1.64 (m, 2H), 1.38-1.45 (m, 1H), 0.92 (d, *J* = 6.6 Hz, 3H), 0.86 (d, *J* = 6.6 Hz, 3H); MS (ESI+) *m/z* 344 (M+H)⁺.

Example 349

***tert*-butyl methyl((*S*)-4-methyl-1-((3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl)carbamate**

The title compound was prepared by substituting *N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-(*tert*-butyloxycarbonyl)-*N*²-methyl-L-leucinamide from Example 151 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide in the procedure described in Example 319 Step A: ¹H NMR (500 MHz, pyridine-*d*₅) δ 8.47 – 8.30 (m, 1H), 5.15 (dd, *J* = 6.4, 5.1, 1H), 4.82 – 4.77 (m, 1H), 4.40 – 4.21 (m, 1H), 3.25 – 3.04 (m, 4H), 3.03 – 2.92 (m, 1H), 2.88 (dd, *J* = 10.8, 7.1, 1H), 2.69 (d, *J* = 10.2, 1H), 2.56 – 2.44 (m, 2H), 2.04 (td, *J* = 11.6, 5.8, 1H), 1.93 – 1.78 (m, 3H), 1.64 – 1.53 (m, 2H), 1.47 (s, 9H), 1.34 (ddt, *J* = 11.0, 7.1, 5.5, 1H), 0.89 (d, *J* = 6.3, 3H), 0.85 (d, *J* = 6.5, 3H); MS (ESI+) *m/z* 354 (M+H)⁺.

Example 350**(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]piperidine-2-carboxamide**

The title compound was prepared by substituting *tert*-butyl (2S)-2-({[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylate from Example 231 for *tert*-butyl (S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.67-7.70 (m, 1H), 7.42-7.44 (m, 2H), 7.36 (t, *J* = 7.5 Hz, 2H), 7.27 (t, *J* = 7.3 Hz, 1H), 4.34-4.40 (m, 1H), 3.59 (d, *J* = 13.1 Hz, 1H), 3.41 (d, *J* = 13.1 Hz, 1H), 3.32 (dd, *J* = 10.3, 3.2 Hz, 1H), 2.99-3.02 (m, 1H), 2.83 (dd, *J* = 8.9, 2.5 Hz, 1H), 2.54-2.61 (m, 1H), 2.46-2.54 (m, 1H), 2.40-2.58 (m, 1H), 2.39-2.47 (m, 1H), 2.33-2.39 (m, 2H), 2.21 (dd, *J* = 8.9, 7.2 Hz, 1H), 2.02-2.10 (m, 2H), 1.77-1.84 (m, 1H), 1.64-1.74 (m, 1H), 1.47-1.64 (m, 2H), 1.34-1.45 (m, 2H), 1.25-1.34 (m, 2H); MS (ESI+) *m/z* 328 (M+H)⁺.

Example 351**N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-valinamide**

The title compound was prepared by substituting *tert*-butyl (S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamate from Example 232 for *tert*-butyl (S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.10-8.12 (m, 1H), 7.43-7.45 (m, 2H), 7.37 (t, *J* = 7.5 Hz, 2H), 7.28 (t, *J* = 7.3 Hz, 1H), 4.44-4.50 (m, 1H), 3.62 (d, *J* = 13.1 Hz, 1H), 3.44 (d, *J* = 13.1 Hz, 1H), 2.85-2.90 (m, 2H), 2.47-2.57 (m, 2H), 2.43 (dd, *J* = 8.8, 7.0 Hz, 1H), 2.40 (s, 3H), 2.36 (dd, *J* = 8.9, 2.7 Hz, 1H), 2.26 (dd, *J* = 8.9, 6.8 Hz, 1H), 2.07-2.16 (m, 2H), 1.91-2.06 (m, 1H), 1.81-1.89 (m, 1H), 1.59 (dq, *J* = 12.1, 7.6 Hz, 1H), 1.38-1.45 (m, 1H), 1.06 (d, *J* = 6.9 Hz, 3H), 1.05 (d, *J* = 6.9 Hz, 3H); MS (ESI+) *m/z* 330 (M+H)⁺.

Example 352 **N^1 -[(3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-norvalinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate from Example 233 for *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ^1H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.11-8.14 (m, 1H), 7.43-7.45 (m, 2H), 7.37 (t, *J* = 7.5 Hz, 2H), 7.28 (t, *J* = 7.3 Hz, 1H), 4.42-4.48 (m, 1H), 3.61 (d, *J* = 13.1 Hz, 1H), 3.44 (d, *J* = 13.1 Hz, 1H), 3.16 (t, *J* = 6.5 Hz, 1H), 2.86 (dd, *J* = 8.9, 2.6 Hz, 1H), 2.47-2.57 (m, 2H), 2.42 (dd, *J* = 8.9, 7.2 Hz, 1H), 2.40 (s, 3H), 2.36 (dd, *J* = 8.9, 2.7 Hz, 1H), 2.26 (dd, *J* = 8.9, 7.0 Hz, 1H), 2.12 (dq, *J* = 11.9, 6.0 Hz, 2H), 1.77-1.89 (m, 2H), 1.65-1.73 (m, 1H), 1.54-1.64 (m, 1H), 1.37-1.54 (m, 3H), 0.84 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z* 330 (M+H)⁺.

Example 353 **N^1 -[(3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-isoleucinamide**

The title compound was prepared by substituting *tert*-butyl (2*S*,3*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamate from Example 224 for *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ^1H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.10-8.14 (m, 1H), 7.44-7.46 (m, 2H), 7.37 (t, *J* = 7.5 Hz, 2H), 7.26-7.30 (m, 1H), 4.42-4.50 (m, 1H), 3.61 (d, *J* = 13.1 Hz, 1H), 3.46 (d, *J* = 13.1 Hz, 1H), 2.97 (d, *J* = 6.0 Hz, 1H), 2.87 (d, *J* = 10.2 Hz, 1H), 2.50-2.57 (m, 2H), 2.41-2.45 (m, 1H), 2.41 (s, 3H), 2.35-2.39 (m, 1H), 2.24-2.29 (m, 1H), 2.07-2.16 (m, 1H), 1.89-2.09 (m, 1H), 1.73-1.92 (m, 3H), 1.55-1.68 (m, 1H), 1.26-1.46 (m, 2H), 1.03 (d, *J* = 6.7 Hz, 3H), 0.86 (t, *J* = 7.4 Hz, 3H); MS (ESI+) *m/z* 344 (M+H)⁺.

Example 354 **N^1 -[(3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-isoleucinamide**

The title compound was prepared by substituting *tert*-butyl (2*S*,3*S*)-1-((3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamate from Step A of Example 334 for *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ^1H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.11-8.14 (m, 1H), 7.43-7.46 (m, 2H), 7.37 (t, J = 7.5 Hz, 2H), 7.25-7.30 (m, 1H), 4.44-4.51 (m, 1H), 3.62 (d, J = 13.1 Hz, 1H), 3.44 (d, J = 13.1 Hz, 1H), 2.96 (d, J = 6.0 Hz, 1H), 2.87 (dd, J = 8.9, 2.1 Hz, 1H), 2.47-2.61 (m, 2H), 2.43 (dd, J = 8.8, 7.0 Hz, 1H), 2.40 (s, 3H), 2.36 (dd, J = 8.9, 2.4 Hz, 1H), 2.26 (dd, J = 8.9, 6.6 Hz, 1H), 2.07-2.16 (m, 1H), 1.88-2.02 (m, 1H), 1.73-1.91 (m, 3H), 1.60 (dq, J = 12.1, 7.5 Hz, 1H), 1.25-1.46 (m, 2H), 1.03 (d, J = 6.8 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H); MS (ESI+) m/z 344 ($M+H$)⁺.

Example 355 **N^1 -[(3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 ,4-dimethyl-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate from Example 247 for *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ^1H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.21-8.24 (m, 1H), 7.43-7.46 (m, 2H), 7.37 (t, J = 7.4 Hz, 2H), 7.24-7.30 (m, 1H), 4.42-4.47 (m, 1H), 3.61 (d, J = 13.0 Hz, 1H), 3.46 (d, J = 13.1 Hz, 1H), 3.19-3.22 (m, 1H), 2.88 (d, J = 10.0 Hz, 1H), 2.52 (d, J = 4.7 Hz, 2H), 2.40-2.46 (m, 1H), 2.41 (s, 3H), 2.37 (dd, J = 9.0, 2.4 Hz, 1H), 2.26 (dd, J = 8.7, 6.2 Hz, 1H), 2.07-2.18 (m, 1H), 1.93 (dd, J = 14.1, 5.1 Hz, 1H), 1.80-1.89 (m, 1H), 1.58-1.82 (m, 1H), 1.55-1.65 (m, 1H), 1.51 (dd, J = 14.0, 6.6 Hz, 1H), 1.34-1.46 (m, 1H), 0.98 (s, 9H); MS (ESI+) m/z 358 ($M+H$)⁺.

Example 356***N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-L-valinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate from Example 234 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.09-8.12 (m, 1H), 7.42-7.44 (m, 2H), 7.37 (t, *J* = 7.3 Hz, 2H), 7.25-7.32 (m, 1H), 4.38-4.44 (m, 1H), 3.58 (d, *J* = 13.0 Hz, 1H), 3.44 (d, *J* = 13.1 Hz, 1H), 3.26 (s, 1H), 2.78 (dd, *J* = 8.9, 2.5 Hz, 1H), 2.44-2.52 (m, 2H), 2.38-2.42 (m, 1H), 2.33 (dd, *J* = 9.0, 2.7 Hz, 1H), 2.23-2.27 (m, 1H), 2.07-2.16 (m, 2H), 1.91-2.26 (m, 1H), 1.80-1.88 (m, 1H), 1.55-1.62 (m, 1H), 1.36-1.43 (m, 1H), 1.14 (s, 9H); MS (ESI+) *m/z* 330 (M+H)⁺.

Example 357***N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-L-valinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate from Example 225 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.07-8.10 (m, 1H), 7.43-7.45 (m, 2H), 7.37 (t, *J* = 7.4 Hz, 2H), 7.25-7.31 (m, 1H), 4.42 (t, *J* = 5.0 Hz, 1H), 3.61 (d, *J* = 13.1 Hz, 1H), 3.44 (d, *J* = 13.1 Hz, 1H), 3.26 (s, 1H), 2.84-2.87 (m, 1H), 2.44-2.55 (m, 2H), 2.41-2.44 (m, 1H), 2.33-2.36 (m, 1H), 2.24-2.27 (m, 1H), 1.96-2.20 (m, 1H), 2.03-2.12 (m, 2H), 1.79-1.86 (m, 1H), 1.51-1.59 (m, 1H), 1.35-1.41 (m, 1H), 1.14 (s, 9H); MS (ESI+) *m/z* 330 (M+H)⁺.

Example 358***N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²,4-dimethyl-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate from Example 248 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-

yl(methyl)carbamate in the procedure described in Example 348: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.21-8.24 (m, 1H), 7.43-7.45 (m, 2H), 7.37 (t, $J = 7.4$ Hz, 2H), 7.27 (t, $J = 7.3$ Hz, 1H), 4.42-4.48 (m, 1H), 3.61 (d, $J = 13.1$ Hz, 1H), 3.45 (d, $J = 13.1$ Hz, 1H), 3.19 (t, $J = 5.8$ Hz, 1H), 2.88 (d, $J = 10.3$ Hz, 1H), 2.50-2.55 (m, 2H), 2.42 (dd, $J = 9.0, 7.1$ Hz, 1H),
 5 2.40 (s, 3H), 2.36 (dd, $J = 8.6, 2.6$ Hz, 1H), 2.23-2.27 (m, 1H), 2.12 (dq, $J = 11.9, 5.9$ Hz, 1H), 1.93 (dd, $J = 14.0, 5.2$ Hz, 1H), 1.80-1.90 (m, 2H), 1.68-1.93 (m, 1H), 1.55-1.64 (m, 1H), 1.51 (dd, $J = 14.0, 6.6$ Hz, 1H), 1.36-1.45 (m, 1H), 0.98 (s, 9H); MS (ESI+) m/z 358 (M+H) $^+$.

10

Example 359 **N^1 -[(3a*S*,4*S*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-norvalinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3a*S*,4*S*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate from
 15 Example 238 for *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in
 Example 348: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.37-8.42 (m, 1H), 7.51-7.53 (m, 2H), 7.36-7.41 (m, 2H), 7.31 (t, $J = 7.4$ Hz, 1H), 4.52-4.57 (m, 1H), 3.73 (d, $J = 12.7$ Hz, 1H), 3.30 (d, $J = 12.8$ Hz, 1H), 3.19 (t, $J = 6.2$ Hz, 1H), 2.77-2.82 (m, 1H), 2.67-2.73 (m,
 20 1H), 2.39-2.47 (m, 3H), 2.40 (s, 3H), 2.18 (dd, $J = 9.5, 7.1$ Hz, 1H), 2.07-2.15 (m, 1H), 1.85-1.91 (m, 1H), 1.79-1.83 (m, 1H), 1.63-1.78 (m, 2H), 1.54-1.62 (m, 1H), 1.42-1.52 (m, 2H), 1.23-1.31 (m, 1H), 0.86 (t, $J = 7.3$ Hz, 3H); MS (ESI+) m/z 330 (M+H) $^+$.

Example 360 **N^1 -[(3a*S*,4*S*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3a*S*,4*S*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate from Example 239 for *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.47 (d, $J = 7.3$ Hz, 1H), 7.51-7.53 (m, 2H), 7.39 (t, $J = 7.5$ Hz, 2H), 7.31 (t, $J = 7.3$ Hz, 1H), 4.52-4.58 (m, 1H), 3.77 (d, $J = 12.8$ Hz, 1H), 3.29 (d, $J = 12.8$ Hz, 1H), 3.27 (dd, $J = 8.2, 5.7$ Hz, 1H), 2.82 (dd, $J = 9.5, 2.3$ Hz, 1H), 2.71-2.76 (m, 1H), 2.42-2.49

30

(m, 1H), 2.41 (s, 3H), 2.37-2.42 (m, 1H), 2.22 (dd, $J = 9.4, 7.2$ Hz, 1H), 2.15 (t, $J = 8.3$ Hz, 1H), 1.83-1.96 (m, 2H), 1.72-1.80 (m, 1H), 1.54-1.72 (m, 3H), 1.28 (dq, $J = 12.9, 6.4$ Hz, 1H), 0.92 (d, $J = 6.6$ Hz, 3H), 0.90 (d, $J = 6.6$ Hz, 3H); MS (ESI+) m/z 344 (M+H)⁺.

5

Example 361 **N^1 -[**(3aR,4S,6aS)**-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((**(3aR,4S,6aS)**-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl)carbamate from Example 226 for *tert*-butyl (*S*)-1-((**(3aR,4S,6aS)**-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.27-8.30 (m, 1H), 7.43-7.45 (m, 2H), 7.37 (t, $J = 7.4$ Hz, 2H), 7.25-7.29 (m, 1H), 4.36-4.42 (m, 1H), 3.58-3.61 (m, 2H), 3.45 (d, $J = 13.1$ Hz, 1H), 2.86 (dd, $J = 9.0, 2.4$ Hz, 1H), 2.45-2.54 (m, 2H), 2.39 (dd, $J = 9.0, 7.2$ Hz, 1H), 2.36 (dd, $J = 9.1, 2.5$ Hz, 1H), 2.24 (dd, $J = 8.8, 6.9$ Hz, 1H), 2.18 (dd, $J = 14.0, 4.3$ Hz, 1H), 2.01-2.23 (m, 2H), 2.07-2.14 (m, 1H), 1.79-1.87 (m, 1H), 1.56 (dq, $J = 12.0, 7.7$ Hz, 1H), 1.44 (dd, $J = 14.0, 7.5$ Hz, 1H), 1.35-1.44 (m, 1H), 0.98 (s, 9H); MS (ESI+) m/z 344 (M+H)⁺.

Example 362

20 **N^1 -[**(3aR,4S,6aS)**-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-norleucinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((**(3aR,4S,6aS)**-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxohexan-2-yl(methyl)carbamate from Example 227 for *tert*-butyl (*S*)-1-((**(3aR,4S,6aS)**-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.07-8.10 (m, 1H), 7.43-7.46 (m, 2H), 7.37 (t, $J = 7.5$ Hz, 2H), 7.28 (t, $J = 7.4$ Hz, 1H), 4.42-4.47 (m, 1H), 3.61 (d, $J = 13.1$ Hz, 1H), 3.46 (d, $J = 13.1$ Hz, 1H), 3.15 (t, $J = 6.5$ Hz, 1H), 2.87 (dd, $J = 9.0, 2.5$ Hz, 1H), 2.47-2.58 (m, 2H), 2.40-2.44 (m, 1H), 2.41 (s, 3H), 2.37 (dd, $J = 8.9, 2.6$ Hz, 1H), 2.26 (dd, $J = 8.9, 6.8$ Hz, 1H), 2.08-2.17 (m, 1H), 1.93-2.16 (m, 1H), 1.80-1.89 (m, 2H), 1.67-1.75 (m, 1H), 1.59 (dq, $J = 12.0, 7.6$ Hz, 1H), 1.38-1.50 (m, 3H), 1.20-1.28 (m, 2H), 0.81 (t, $J = 7.3$ Hz, 3H); MS (ESI+) m/z 344 (M+H)⁺.

Example 363***N*¹-[(3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-norvalinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate from Example 240 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.26 (d, *J* = 7.8 Hz, 1H), 7.50-7.52 (m, 2H), 7.39 (t, *J* = 7.5 Hz, 2H), 7.32 (t, *J* = 7.3 Hz, 1H), 4.51-4.57 (m, 1H), 3.57 (d, *J* = 12.7 Hz, 1H), 3.42 (d, *J* = 12.7 Hz, 1H), 3.13-3.16 (m, 1H), 2.75-2.78 (m, 1H), 2.63-2.70 (m, 1H), 2.45-2.49 (m, 1H), 2.39-2.47 (m, 1H), 2.39 (s, 3H), 2.14 (dd, *J* = 8.9, 7.6 Hz, 1H), 2.09 (dd, *J* = 9.5, 7.2 Hz, 1H), 1.82-2.27 (m, 1H), 1.83-1.91 (m, 1H), 1.63-1.81 (m, 3H), 1.54-1.63 (m, 1H), 1.39-1.54 (m, 2H), 1.25-1.33 (m, 1H), 0.86 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z* 330 (M+H)⁺.

Example 364***N*¹-[(3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate from Example 241 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.24-8.27 (m, 1H), 7.50-7.52 (m, 2H), 7.40 (t, *J* = 7.5 Hz, 2H), 7.32 (t, *J* = 7.4 Hz, 1H), 4.50-4.56 (m, 1H), 3.54 (d, *J* = 12.7 Hz, 1H), 3.45 (d, *J* = 12.7 Hz, 1H), 3.20 (dd, *J* = 8.2, 5.7 Hz, 1H), 2.76-2.78 (m, 1H), 2.64-2.71 (m, 1H), 2.46-2.49 (m, 1H), 2.41-2.47 (m, 1H), 2.39 (s, 3H), 2.16 (t, *J* = 8.2 Hz, 1H), 2.06-2.12 (m, 1H), 1.78-2.09 (m, 1H), 1.82-1.93 (m, 2H), 1.63-1.76 (m, 2H), 1.55-1.63 (m, 1H), 1.48-1.56 (m, 1H), 1.25-1.35 (m, 1H), 0.93 (d, *J* = 6.5 Hz, 3H), 0.88 (d, *J* = 6.6 Hz, 3H); MS (ESI+) *m/z* 344 (M+H)⁺.

Example 365***N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-norvalinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-1-oxo-1-
 5 ((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from
 Step A of Example 313 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-
 benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-
 yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz,
 pyridine-*d*₅) δ ppm 8.08-8.10 (m, 1H), 7.43-7.46 (m, 2H), 7.37 (t, *J* = 7.4 Hz, 2H), 7.28 (t, *J* =
 10 7.3 Hz, 1H), 4.41-4.46 (m, 1H), 3.61 (d, *J* = 13.1 Hz, 1H), 3.45 (d, *J* = 13.1 Hz, 1H), 3.15 (t,
J = 6.5 Hz, 1H), 2.86 (dd, *J* = 9.0, 2.5 Hz, 1H), 2.47-2.57 (m, 2H), 2.40-2.44 (m, 1H), 2.40 (s,
 3H), 2.37 (dd, *J* = 9.0, 2.3 Hz, 1H), 2.24-2.27 (m, 1H), 2.07-2.16 (m, 1H), 1.90-2.10 (m, 1H),
 1.77-1.88 (m, 2H), 1.63-1.73 (m, 1H), 1.54-1.63 (m, 1H), 1.36-1.53 (m, 3H), 0.84 (t, *J* = 7.3
 Hz, 3H); MS (ESI+) *m/z* 330 (M+H)⁺.

15

Example 366***N*²-ethyl-*N*¹-{(3*aR*,4*S*,6*aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-
 4-yl}-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl ethyl((*S*)-4-methyl-1-oxo-
 20 1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-
 ylamino)pentan-2-yl)carbamate from Example 310 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-
 benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-
 yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz,
 pyridine-*d*₅) δ ppm 8.23-8.26 (m, 1H), 7.76-7.77 (bs, 1H), 7.55-7.63 (m, 2H), 7.45 (t, *J* = 7.7
 25 Hz, 1H), 4.41-4.45 (m, 1H), 3.61 (d, *J* = 13.5 Hz, 1H), 3.48 (d, *J* = 13.5 Hz, 1H), 3.33 (dd, *J*
 = 8.2, 5.8 Hz, 1H), 2.86 (dd, *J* = 9.0, 2.3 Hz, 1H), 2.70-2.78 (m, 1H), 2.60-2.64 (m, 1H),
 2.53-2.55 (m, 2H), 2.43-2.47 (m, 1H), 2.33 (dd, *J* = 9.0, 2.4 Hz, 1H), 2.28 (dd, *J* = 8.8, 6.3
 Hz, 1H), 2.08-2.12 (m, 1H), 1.80-2.05 (m, 1H), 1.82-1.95 (m, 2H), 1.72 (ddd, *J* = 13.5, 7.8,
 5.8 Hz, 1H), 1.56-1.63 (m, 2H), 1.39-1.45 (m, 1H), 1.08 (t, *J* = 7.1 Hz, 3H), 0.92 (d, *J* = 6.6
 30 Hz, 3H), 0.86 (d, *J* = 6.5 Hz, 3H); MS (ESI+) *m/z* 462 (M+H)⁺.

Example 367***N*²-methyl-*N*¹-{(3*aS*,4*R*,6*aR*)-2-[4-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-valinamide****Step A:** *tert*-Butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-

5 (trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamate from Example 232 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-

10 methylpentanamide and 4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde in the procedures described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.59 (d, *J* = 8.0, 2H), 7.46 (d, *J* = 7.9, 2H), 4.35 (d, *J* = 9.6, 1H), 4.30 – 4.23 (m, 1H), 3.55 (d, *J* = 13.7, 1H), 3.48 (d, *J* = 13.7, 1H), 3.01 (s, 3H), 2.77 (dd, *J* = 8.9, 2.1, 1H), 2.57 – 2.48 (m, 1H), 2.42 (ddd, *J* = 10.7, 9.3, 6.0, 2H), 2.36 (dd, *J* = 14.0, 5.7, 2H), 2.30 – 2.25 (m, 1H), 2.12 – 2.03 (m, 2H), 1.87 (td, *J* = 12.9, 6.3, 1H), 1.57 (dt, *J* = 14.8, 7.9, 1H), 1.45 (s, 9H), 1.43 – 1.35 (m, 1H), 1.01 (d, *J* = 6.5, 3H), 0.87 (d, *J* = 6.7, 3H); MS (ESI+) *m/z* 498 (M+H)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-

20 ylamino)butan-2-yl)carbamate from Step A for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.13-8.16 (m, 1H), 7.65-7.67 (m, 2H), 7.51-7.54 (m, 2H), 4.45-4.51 (m, 1H), 3.60 (d, *J* = 13.7 Hz, 1H), 3.47 (d, *J* = 13.7 Hz, 1H), 2.90 (d, *J* = 13.1 Hz, 1H), 2.88-2.90

25 (m, 1H), 2.48-2.59 (m, 2H), 2.40 (s, 3H), 2.33-2.40 (m, 2H), 2.24 (dd, *J* = 8.9, 7.0 Hz, 1H), 2.08-2.16 (m, 2H), 1.94-2.10 (m, 1H), 1.85-1.93 (m, 1H), 1.60 (dq, *J* = 12.0, 7.7 Hz, 1H), 1.43 (ddt, *J* = 8.9, 12.4, 6.2 Hz, 1H), 1.06 (t, *J* = 6.9 Hz, 6H); MS (ESI+) *m/z* 398 (M+H)⁺.

Example 368

30 (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]piperidine-2-carboxamide

Step A: *tert*-Butyl (2*S*)-2-({[(3*aS*,4*R*,6*aR*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]amino } carbonyl) piperidine-1-carboxylate was

prepared by substituting *tert*-butyl (2*S*)-2-({[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylate from Example 231 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide and 4-fluorobenzaldehyde for 3-

5 (trifluoromethyl)benzaldehyde in the procedures described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.37 (d, *J* = 7.2, 2H), 7.30 (t, *J* = 7.5, 2H), 7.21 (t, *J* = 7.3, 2H), 4.87 (d, *J* = 3.9, 1H), 4.32 – 4.23 (m, 1H), 4.10 (d, *J* = 12.8, 1H), 3.58 (d, *J* = 13.2, 1H), 3.47 (d, *J* = 13.2, 1H), 3.29 (td, *J* = 12.8, 2.9, 1H), 2.83 – 2.76 (m, 1H), 2.52 (td, *J* = 8.1, 3.4, 1H), 2.48 – 2.41 (m, 2H), 2.36 (dd, *J* = 9.0, 3.1, 1H), 2.33 – 2.28 (m, 1H), 2.24 (dd, *J* = 11.7, 1.6, 10 1H), 2.07 (dq, *J* = 12.2, 6.1, 1H), 1.87 – 1.78 (m, 1H), 1.69 – 1.59 (m, 1H), 1.59 – 1.49 (m, 3H), 1.48 (s, 9H), 1.45 – 1.29 (m, 3H); MS (ESI+) *m/z* 428 (M+H)⁺.

Step B: The title compound was prepared by substituting *tert*-Butyl (2*S*)-2-({[(3*aS*,4*R*,6*aR*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylate from Step A for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-15 2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.68-7.70 (m, 1H), 7.35 (dd, *J* = 8.3, 5.6 Hz, 2H), 7.10-7.14 (m, 2H), 4.34-4.40 (m, 1H), 3.51 (d, *J* = 13.1 Hz, 1H), 3.36 (d, *J* = 13.1 Hz, 1H), 3.32 (dd, *J* = 10.4, 3.2 Hz, 1H), 2.98-3.02 (m, 1H), 2.82 (dd, *J* = 9.0, 2.6 Hz, 1H), 2.54-2.61 (m, 1H), 2.48-2.54 20 (m, 1H), 2.39-2.46 (m, 1H), 2.33-2.45 (m, 1H), 2.29-2.35 (m, 2H), 2.16-2.22 (m, 1H), 2.01-2.10 (m, 2H), 1.78-1.87 (m, 1H), 1.65-1.74 (m, 1H), 1.56-1.64 (m, 1H), 1.47-1.56 (m, 1H), 1.34-1.44 (m, 2H), 1.26-1.34 (m, 2H); MS (ESI+) *m/z* 346 (M+H)⁺.

Example 369

25 ***N*¹-[(3*aS*,4*R*,6*aR*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-valinamide**

Step A: *tert*-Butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamate from Example 232 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide and 4-fluorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde in the procedures described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.43 (s, 30

1H), 7.30 (dd, $J = 8.3, 5.7$, 2H), 7.03 (t, $J = 8.8$, 2H), 4.35 (d, $J = 9.5$, 1H), 4.25 (s, 1H), 3.49 (d, $J = 13.2$, 1H), 3.41 (d, $J = 13.2$, 1H), 3.01 (s, 3H), 2.75 (dd, $J = 8.9, 2.3$, 1H), 2.57 – 2.48 (m, 1H), 2.45 – 2.31 (m, 4H), 2.27 (dd, $J = 8.8, 7.4$, 1H), 2.11 – 2.03 (m, 1H), 1.85 (dt, $J = 20.7, 6.5$, 1H), 1.56 (dt, $J = 15.2, 7.3$, 1H), 1.46 (s, 9H), 1.43 – 1.35 (m, 1H), 1.01 (d, $J = 6.5$, 3H), 0.87 (d, $J = 6.7$, 3H); MS (ESI+) m/z 448 (M+H)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate from Step A for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.11-8.14 (m, 1H), 7.37 (dd, $J = 8.3, 5.6$ Hz, 2H), 7.11-7.15 (m, 2H), 4.43-4.49 (m, 1H), 3.54 (d, $J = 13.1$ Hz, 1H), 3.39 (d, $J = 13.1$ Hz, 1H), 2.90 (d, $J = 5.8$ Hz, 1H), 2.86 (dd, $J = 9.0, 2.6$ Hz, 1H), 2.47-2.56 (m, 2H), 2.40 (s, 3H), 2.38 (dd, $J = 9.0, 7.0$ Hz, 1H), 2.34 (dd, $J = 9.0, 2.6$ Hz, 1H), 2.23 (dd, $J = 8.9, 7.0$ Hz, 1H), 2.07-2.16 (m, 2H), 1.93-2.04 (m, 1H), 1.83-1.92 (m, 1H), 1.59 (dq, $J = 12.1, 7.7$ Hz, 1H), 1.41 (ddt, $J = 8.9, 12.4, 6.2$ Hz, 1H), 1.06 (t, $J = 6.8$ Hz, 6H); MS (ESI+) m/z 348 (M+H)⁺.

Example 370

(2*S*)-*N*-{(3*aS*,4*R*,6*aR*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}piperidine-2-carboxamide

Step A: *tert*-Butyl (2*S*)-2-({[(3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylate was prepared by substituting *tert*-butyl (2*S*)-2-({[(3*aS*,4*R*,6*aR*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylate from Example 231 for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide and 4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde in the procedures described in Example 303: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.59 (d, $J = 8.1$, 2H), 7.47 (d, $J = 8.0$, 2H), 7.27 – 7.20 (m, 1H), 4.87 (d, $J = 3.7$, 1H), 4.32 – 4.23 (m, 1H), 3.57 (d, $J = 13.7$, 1H), 3.49 (d, $J = 13.8$, 1H), 3.29 (td, $J = 12.8, 3.0$, 1H), 2.81 (dd, $J = 8.7, 2.0$, 1H), 2.59 – 2.50 (m, 1H), 2.46 (ddd, $J = 12.1, 7.0, 2.8$, 1H), 2.43 – 2.38 (m, 1H), 2.36 (dd, $J = 9.0, 2.9$, 1H), 2.32 – 2.27 (m, 1H), 2.27 – 2.20 (m, 1H), 2.11 – 2.03 (m, 2H), 1.86 (ddd, $J = 12.7, 8.1, 6.3$, 1H), 1.70 – 1.60 (m, 1H), 1.59 – 1.49 (m, 4H), 1.47 (s, 9H), 1.45 – 1.29 (m, 2H); MS (ESI+) m/z 496 (M+H)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl (2*S*)-2-(([(3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylate from Step A for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.71 (d, *J* = 7.5 Hz, 1H), 7.64-7.66 (m, 2H), 7.49-7.52 (m, 2H), 4.36-4.41 (m, 1H), 3.57 (d, *J* = 13.7 Hz, 1H), 3.43 (d, *J* = 13.7 Hz, 1H), 3.33 (dd, *J* = 10.3, 3.2 Hz, 1H), 2.98-3.03 (m, 1H), 2.85 (dd, *J* = 9.0, 2.5 Hz, 1H), 2.50-2.60 (m, 2H), 2.36-2.58 (m, 1H), 2.41-2.46 (m, 1H), 2.34 (d, *J* = 7.6 Hz, 1H), 2.31-2.33 (m, 1H), 2.20 (dd, *J* = 8.9, 7.2 Hz, 1H), 2.02-2.10 (m, 2H), 1.81-1.88 (m, 1H), 1.66-1.71 (m, 1H), 1.50-1.63 (m, 2H), 1.35-1.42 (m, 2H), 1.24-1.34 (m, 2H); MS (ESI+) *m/z* 396 (M+H)⁺.

Example 371

*N*²-methyl-*N*¹-{(3*aS*,4*R*,6*aR*)-2-[4-

(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Example 317 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.14-8.17 (m, 1H), 7.64-7.67 (m, 2H), 7.51-7.54 (m, 2H), 4.43-4.49 (m, 1H), 3.59 (d, *J* = 13.7 Hz, 1H), 3.47 (d, *J* = 13.7 Hz, 1H), 3.16 (t, *J* = 6.5 Hz, 1H), 2.88 (dd, *J* = 9.0, 2.6 Hz, 1H), 2.44-2.58 (m, 2H), 2.40 (s, 3H), 2.34-2.39 (m, 2H), 2.24 (t, *J* = 8.0 Hz, 1H), 2.12 (dq, *J* = 11.8, 5.9 Hz, 1H), 1.95-2.18 (m, 1H), 1.85-1.93 (m, 1H), 1.76-1.85 (m, 1H), 1.66-1.73 (m, 1H), 1.56-1.64 (m, 1H), 1.39-1.53 (m, 3H), 0.84 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z* 398 (M+H)⁺.

Example 372

*N*¹-[(3*aS*,4*R*,6*aR*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-norvalinamide

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate from Example 318 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-

4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.12-8.15 (m, 1H), 7.35-7.39 (m, 2H), 7.11-7.15 (m, 2H), 4.41-4.47 (m, 1H), 3.53 (d, $J = 13.1$ Hz, 1H), 3.39 (d, $J = 13.1$ Hz, 1H), 3.16 (t, $J = 6.5$ Hz, 1H), 2.85 (dd, $J = 9.0, 2.6$ Hz, 1H), 2.46-2.59 (m, 2H), 2.40 (s, 3H), 2.38 (dd, $J = 8.9, 6.8$ Hz, 1H), 2.34 (dd, $J = 8.9, 2.8$ Hz, 1H), 2.23 (dd, $J = 8.9, 7.1$ Hz, 1H), 2.07-2.16 (m, 1H), 1.91-2.12 (m, 1H), 1.84-1.91 (m, 1H), 1.76-1.83 (m, 1H), 1.66-1.73 (m, 1H), 1.54-1.63 (m, 1H), 1.36-1.54 (m, 3H), 0.84 (t, $J = 7.3$ Hz, 3H); MS (ESI+) m/z 348 (M+H) $^+$.

10

Example 373 **N^2 -methyl- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-valinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-3-methyl-1-oxo-1-((3a*S*,4*R*,6a*R*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate from Example 316 for *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.13 (d, $J = 7.6$, 1H), 7.76 (s, 1H), 7.61 (d, $J = 7.6$, 1H), 7.56 (s, 1H), 7.45 (t, $J = 7.7$, 1H), 4.52 – 4.36 (m, 1H), 3.62 (d, $J = 13.6$, 1H), 3.46 (d, $J = 13.6$, 1H), 2.92 – 2.79 (m, 2H), 2.59 – 2.46 (m, 2H), 2.43 (d, $J = 8.8$, 1H), 2.40 (s, 3H), 2.33 (dd, $J = 9.0, 2.5$, 1H), 2.28 – 2.22 (m, 1H), 2.15 – 2.05 (m, 2H), 2.04 – 1.93 (m, 1H), 1.86 (td, $J = 12.9, 6.4$, 1H), 1.59 (dt, $J = 14.9, 7.7$, 1H), 1.44 – 1.36 (m, 1H), 1.05 (t, $J = 7.0$, 6H); MS (ESI+) m/z 398 (M+H) $^+$.

25

Example 374 **N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3a*S*,4*R*,6a*R*)-2-(3-fluoro-4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate from Example 311 for *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.20-8.22 (m, 1H), 7.58-7.61 (m, 1H), 7.32-7.36 (m, 1H), 7.27-7.29 (m,

30

1H), 4.43-4.48 (m, 1H), 3.55-3.62 (m, 1H), 3.45 (d, $J = 14.1$ Hz, 1H), 3.22 (dd, $J = 8.2, 5.8$ Hz, 1H), 2.91 (dd, $J = 9.0, 2.5$ Hz, 1H), 2.48-2.60 (m, 2H), 2.42 (s, 3H), 2.35-2.39 (m, 2H), 2.23 (dd, $J = 8.9, 7.1$ Hz, 1H), 2.07-2.16 (m, 1H), 1.91-2.11 (m, 1H), 1.84-1.95 (m, 2H), 1.71 (ddd, $J = 13.5, 7.8, 5.8$ Hz, 1H), 1.56-1.65 (m, 2H), 1.39-1.46 (m, 1H), 0.91 (d, $J = 6.6$ Hz, 3H), 0.85 (d, $J = 6.5$ Hz, 3H); MS (ESI+) m/z 430 (M+H)⁺.

Example 375

N^1 -{(3a*S*,4*R*,6a*R*)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide

10 The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3a*S*,4*R*,6a*R*)-2-(4-fluoro-3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate from Example 312 for *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.18-8.21 (m, 1H), 7.68-7.71 (m, 1H), 7.57-7.60 (m, 1H), 7.22-7.28 (m, 1H), 4.42-4.46 (m, 1H), 3.55 (d, $J = 13.5$ Hz, 1H), 3.43 (d, $J = 13.4$ Hz, 1H), 3.21 (dd, $J = 8.2, 5.8$ Hz, 1H), 2.88 (dd, $J = 9.0, 2.6$ Hz, 1H), 2.48-2.60 (m, 2H), 2.42 (s, 3H), 2.37-2.42 (m, 1H), 2.34 (dd, $J = 8.8, 2.4$ Hz, 1H), 2.21-2.28 (m, 1H), 2.06-2.14 (m, 1H), 1.90-2.08 (m, 1H), 1.83-1.94 (m, 2H), 1.71 (ddd, $J = 13.5, 7.8, 5.8$ Hz, 1H), 1.55-1.64 (m, 2H), 1.38-1.45 (m, 1H), 0.91 (d, $J = 6.5$ Hz, 3H), 0.85 (d, $J = 6.5$ Hz, 3H); MS (ESI+) m/z 430 (M+H)⁺.

Example 376

N^2 -methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide

25 The title compound was prepared by substituting *tert*-butyl methyl((*S*)-1-oxo-1-((3a*R*,4*S*,6a*S*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Example 313 for *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.09-8.12 (m, 1H), 7.76-7.77 (bs, 1H), 7.60-7.63 (m, 1H), 7.55-7.58 (m, 1H), 7.45 (t, $J = 7.7$ Hz, 1H), 4.40-4.44 (m, 1H), 3.61 (d, $J = 13.5$ Hz, 1H), 3.47 (d, $J = 13.5$ Hz, 1H), 3.15 (t, $J = 6.5$ Hz, 1H), 2.87 (dd, $J = 9.0, 2.6$ Hz, 1H), 2.47-2.57 (m, 2H), 2.40-2.44 (m, 1H), 2.40 (s, 3H), 2.33 (dd, $J = 9.0, 2.7$ Hz, 1H), 2.23-2.27 (m, 1H), 2.05-2.12 (m, 1H),

1.93-2.10 (m, 1H), 1.83-1.90 (m, 1H), 1.76-1.83 (m, 1H), 1.64-1.73 (m, 1H), 1.54-1.63 (m, 1H), 1.36-1.53 (m, 3H), 0.84 (t, $J = 7.3$ Hz, 3H); MS (ESI+) m/z 398 (M+H)⁺.

Example 377

5 **N^2 -methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-1-oxo-1-((3a*R*,4*S*,6a*S*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Example 314 for *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.12-8.15 (m, 1H), 7.64-7.67 (m, 2H), 7.51-7.54 (m, 2H), 4.42-4.47 (m, 1H), 3.57-3.61 (m, 1H), 3.48 (d, $J = 13.7$ Hz, 1H), 3.16 (t, $J = 6.5$ Hz, 1H), 2.89 (dd, $J = 9.0$, 2.5 Hz, 1H), 2.48-2.58 (m, 2H), 2.41 (s, 3H), 2.34-2.41 (m, 2H), 2.24 (dd, $J = 8.9$, 7.0 Hz, 1H), 2.03-2.18 (m, 1H), 1.94-2.26 (m, 1H), 1.77-1.95 (m, 2H), 1.66-1.73 (m, 1H), 1.55-1.64 (m, 1H), 1.38-1.55 (m, 3H), 0.84 (t, $J = 7.3$ Hz, 3H); MS (ESI+) m/z 398 (M+H)⁺.

Example 378

20 **N^1 -[(3a*R*,4*S*,6a*S*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-norvalinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate from Example 315 for *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.12-8.15 (m, 1H), 7.64-7.67 (m, 2H), 7.51-7.54 (m, 2H), 4.42-4.47 (m, 1H), 3.57-3.61 (m, 1H), 3.48 (d, $J = 13.7$ Hz, 1H), 3.16 (t, $J = 6.5$ Hz, 1H), 2.89 (dd, $J = 9.0$, 2.5 Hz, 1H), 2.48-2.58 (m, 2H), 2.41 (s, 3H), 2.34-2.41 (m, 2H), 2.24 (dd, $J = 8.9$, 7.0 Hz, 1H), 2.03-2.18 (m, 1H), 1.94-2.26 (m, 1H), 1.77-1.95 (m, 2H), 1.66-1.73 (m, 1H), 1.55-1.64 (m, 1H), 1.38-1.55 (m, 3H), 0.84 (t, $J = 7.3$ Hz, 3H); MS (ESI+) m/z 398 (M+H)⁺.

Example 379***N*²-methyl-*N*¹-{(3*aR*,4*S*,6*aS*)-2-[3-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Example 307 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.18-8.20 (m, 1H), 7.76-7.77 (bs, 1H), 7.60-7.64 (m, 1H), 7.54-7.59 (m, 1H), 7.45 (t, *J* = 7.7 Hz, 1H), 4.40-4.47 (m, 1H), 3.61 (d, *J* = 13.5 Hz, 1H), 3.47 (d, *J* = 13.5 Hz, 1H), 3.22 (dd, *J* = 8.2, 5.8 Hz, 1H), 2.87 (d, *J* = 10.4 Hz, 1H), 2.49-2.57 (m, 2H), 2.40-2.46 (m, 1H), 2.42 (s, 3H), 2.33 (dd, *J* = 8.9, 2.5 Hz, 1H), 2.26 (dd, *J* = 8.9, 6.5 Hz, 1H), 2.01-2.16 (m, 1H), 1.92-2.12 (m, 1H), 1.83-1.97 (m, 2H), 1.71 (ddd, *J* = 13.5, 7.7, 5.8 Hz, 1H), 1.55-1.64 (m, 2H), 1.37-1.44 (m, 1H), 0.91 (d, *J* = 6.6 Hz, 3H), 0.85 (d, *J* = 6.5 Hz, 3H); MS (ESI+) *m/z* 412 (M+H)⁺.

Example 380***N*²-methyl-*N*¹-{(3*aR*,4*S*,6*aS*)-2-[4-****(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Example 308 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.19-8.22 (m, 1H), 7.64-7.67 (m, 2H), 7.51-7.54 (m, 2H), 4.43-4.48 (m, 1H), 3.59 (d, *J* = 13.7 Hz, 1H), 3.48 (d, *J* = 13.7 Hz, 1H), 3.23 (dd, *J* = 8.2, 5.8 Hz, 1H), 2.90 (dd, *J* = 9.0, 2.4 Hz, 1H), 2.49-2.58 (m, 2H), 2.43 (s, 3H), 2.38-2.42 (m, 1H), 2.37 (dd, *J* = 19.2, 2.5 Hz, 1H), 2.24 (dd, *J* = 8.9, 6.8 Hz, 1H), 2.09-2.17 (m, 1H), 1.95-2.13 (m, 1H), 1.83-1.97 (m, 2H), 1.72 (ddd, *J* = 13.5, 7.8, 5.8 Hz, 1H), 1.56-1.65 (m, 2H), 1.39-1.46 (m, 1H), 0.91 (d, *J* = 6.6 Hz, 3H), 0.85 (d, *J* = 6.5 Hz, 3H); MS (ESI+) *m/z* 412 (M+H)⁺.

Example 381***N*¹-[(3*aR*,4*S*,6*aS*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate from Example 309 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.17-8.20 (m, 1H), 7.37 (dd, *J* = 8.2, 5.6 Hz, 2H), 7.11-7.15 (m, 2H), 4.41-4.47 (m, 1H), 3.52 (d, *J* = 13.1 Hz, 1H), 3.40 (d, *J* = 13.1 Hz, 1H), 3.22 (dd, *J* = 8.2, 5.8 Hz, 1H), 2.86 (dd, *J* = 9.0, 2.4 Hz, 1H), 2.46-2.57 (m, 2H), 2.42 (s, 3H), 2.34-2.41 (m, 2H), 2.24 (dd, *J* = 8.9, 6.7 Hz, 1H), 2.05-2.18 (m, 1H), 1.98-2.11 (m, 1H), 1.83-1.97 (m, 2H), 1.71 (ddd, *J* = 13.5, 7.8, 5.8 Hz, 1H), 1.55-1.64 (m, 2H), 1.41 (ddt, *J* = 8.9, 12.3, 6.2 Hz, 1H), 0.91 (d, *J* = 6.6 Hz, 3H), 0.85 (d, *J* = 6.6 Hz, 3H); MS (ESI+) *m/z* 362 (M+H)⁺.

Example 382***N*¹-{(3*aR*,4*S*,6*aS*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide**

Step A: *tert*-Butyl ((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate was prepared by substituting *N*-(*tert*-butoxycarbonyl)-L-norvaline for *N*-(*tert*-butoxycarbonyl)-L-leucine in the procedure described in Example 221: ¹H NMR (400 MHz, pyridine-*d*₅) δ ppm 8.61 – 8.53 (m, 1H), 7.92 (d, *J* = 8.2, 1H), 7.43 (d, *J* = 7.4, 2H), 7.35 (d, *J* = 7.6, 2H), 7.27 (t, *J* = 7.2, 1H), 4.64 (dd, *J* = 14.4, 7.8, 1H), 4.47 – 4.35 (m, 1H), 3.59 (d, *J* = 13.1, 1H), 3.43 (d, *J* = 13.2, 1H), 2.83 (dd, *J* = 4.7, 4.1, 1H), 2.60 – 2.48 (m, 2H), 2.47 – 2.40 (m, 1H), 2.32 (dd, *J* = 5.0, 3.9, 1H), 2.27 – 2.20 (m, 1H), 2.11 – 1.97 (m, 2H), 1.91 – 1.76 (m, 2H), 1.63 – 1.42 (m, 12H), 1.40 – 1.29 (m, 1H), 0.81 (t, *J* = 7.3, 3H); MS (ESI+) *m/z* 416 (M+H)⁺.

Step B: *tert*-Butyl-((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate was prepared by substituting *tert*-butyl ((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Step A for (2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide and 4-(trifluoromethyl)benzaldehyde for 3-

(trifluoromethyl)benzaldehyde in the procedures described in Example 303: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.60 (d, $J = 7.0$, 1H), 7.93 (d, $J = 8.3$, 1H), 7.65 (d, $J = 8.1$, 2H), 7.51 (d, $J = 7.9$, 2H), 4.64 (dd, $J = 13.0$, 6.5, 1H), 4.47 – 4.37 (m, 1H), 3.57 (d, $J = 13.7$, 1H), 3.45 (d, $J = 13.7$, 1H), 2.86 (d, $J = 8.3$, 1H), 2.55 (dd, $J = 14.1$, 9.2, 2H), 2.43 – 2.36 (m, 1H), 2.31 (d, $J = 7.8$, 1H), 2.26 – 2.20 (m, 1H), 2.14 (s, 1H), 2.04 (dd, $J = 12.1$, 6.0, 2H), 1.90 – 1.80 (m, 2H), 1.59 (s, 1H), 1.49 (d, $J = 11.3$, 10H), 1.37 (s, 1H), 0.81 (t, $J = 7.3$, 3H); MS (ESI+) m/z 484 (M+H) $^+$.

Step C: The title compound was prepared by substituting *tert*-Butyl-((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Step B for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.19-8.22 (m, 1H), 7.64-7.67 (m, 2H), 7.50-7.53 (m, 2H), 4.37-4.43 (m, 1H), 3.53-3.58 (m, 2H), 3.46 (d, $J = 13.7$ Hz, 1H), 2.86 (dd, $J = 9.0$, 2.6 Hz, 1H), 2.49-2.57 (m, 1H), 2.43-2.49 (m, 1H), 2.33-2.36 (m, 2H), 2.19-2.25 (m, 1H), 2.11-2.20 (m, 2H), 2.06-2.14 (m, 1H), 1.91-2.01 (m, 1H), 1.82-1.90 (m, 1H), 1.62-1.69 (m, 1H), 1.38-1.58 (m, 4H), 0.84 (t, $J = 7.3$ Hz, 3H); MS (ESI+) m/z 384 (M+H) $^+$.

Example 383

N^2 -ethyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting *tert*-butyl ethyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Example 323 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ^1H NMR (500 MHz, pyridine- d_5) δ ppm 8.37-8.39 (m, 1H), 8.32-8.37 (m, 1H), 8.19-8.21 (m, 1H), 7.90-7.93 (m, 1H), 7.73 (t, $J = 7.9$ Hz, 1H), 4.23-4.29 (m, 1H), 3.86 (d, $J = 11.2$ Hz, 1H), 3.31 (t, $J = 6.9$ Hz, 1H), 3.18 (dd, $J = 9.7$, 2.1 Hz, 1H), 3.16 (dd, $J = 9.9$, 7.5 Hz, 1H), 2.96 (dd, $J = 9.5$, 6.5 Hz, 1H), 2.68-2.75 (m, 1H), 2.51-2.63 (m, 3H), 1.90-2.12 (m, 1H), 1.91-1.99 (m, 1H), 1.80-1.91 (m, 2H), 1.66-1.72 (m, 1H), 1.52-1.60 (m, 2H), 1.26-1.34 (m, 1H), 1.06 (t, $J = 7.1$ Hz, 3H), 0.92 (d, $J = 6.6$ Hz, 3H), 0.85 (d, $J = 6.5$ Hz, 3H); MS (ESI+) m/z 476 (M+H) $^+$.

Example 384***N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-****(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Example 322 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.38-8.39 (bs, 1H), 8.29-8.31 (m, 1H), 8.19-8.21 (m, 1H), 7.91-7.93 (m, 1H), 7.73 (t, *J* = 7.8 Hz, 1H), 4.24-4.29 (m, 1H), 3.87 (dd, *J* = 9.9, 2.2 Hz, 1H), 3.17-3.22 (m, 2H), 3.15 (dd, *J* = 9.8, 7.4 Hz, 1H), 2.95 (dd, *J* = 9.6, 6.7 Hz, 1H), 2.49-2.60 (m, 2H), 2.39 (s, 3H), 1.93-2.10 (m, 1H), 1.91-1.99 (m, 1H), 1.80-1.91 (m, 2H), 1.68 (ddd, *J* = 13.5, 7.8, 5.8 Hz, 1H), 1.53-1.59 (m, 2H), 1.25-1.33 (m, 1H), 0.91 (d, *J* = 6.6 Hz, 3H), 0.85 (d, *J* = 6.6 Hz, 3H); MS (ESI+) *m/z* 462 (M+H)⁺.

Example 385***N*-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-phenylalaninamide**

The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-phenylalaninamide from Example 269 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.38-8.39 (bs, 1H), 8.19-8.22 (m, 2H), 7.91-7.94 (m, 1H), 7.74 (t, *J* = 7.8 Hz, 1H), 7.29-7.35 (m, 4H), 7.24-7.29 (m, 1H), 4.92-4.95 (m, 1H), 4.16-4.23 (m, 1H), 3.80 (dd, *J* = 7.6, 5.7 Hz, 1H), 3.77 (dd, *J* = 9.8, 2.7 Hz, 1H), 3.32 (dd, *J* = 13.2, 5.7 Hz, 1H), 3.15 (dd, *J* = 9.6, 2.9 Hz, 1H), 2.99-3.03 (m, 2H), 2.89 (dd, *J* = 9.6, 7.6 Hz, 1H), 2.41-2.47 (m, 1H), 2.32-2.37 (m, 1H), 1.98-2.15 (m, 1H), 1.83-1.89 (m, 1H), 1.71-1.77 (m, 1H), 1.35-1.43 (m, 1H), 1.17-1.26 (m, 1H); MS (ESI+) *m/z* 482 (M+H)⁺.

Example 386***N*-methyl-*N*-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*L*-phenylalaninamide**

5 The title compound was prepared by substituting *N*-(*tert*-butoxycarbonyl)-*N*-methyl-*N*-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*L*-phenylalaninamide from Example 270 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.39-8.40 (bs, 1H), 8.25 (d, *J* = 5.1 Hz, 1H), 7.94-7.96 (m, 1H), 7.79 (t, *J* = 7.8 Hz, 1H), 7.31-7.33 (m, 4H), 7.24-7.28 (m, 1H), 4.17-4.24 (m, 1H), 3.73 (dd, *J* = 9.9, 2.8 Hz, 1H), 3.45 (t, *J* = 6.8 Hz, 1H), 3.13-3.20 (m, 2H), 3.01-3.10 (m, 2H), 2.91 (dd, *J* = 9.6, 7.6 Hz, 1H), 2.39-2.50 (m, 1H), 2.36 (s, 3H), 2.28-2.37 (m, 1H), 2.0 (m, 1H), 1.89-2.26 (m, 1H), 1.84-1.92 (m, 1H), 1.72-1.79 (m, 1H), 1.40-1.48 (m, 1H), 1.18-1.26 (m, 1H); MS (ESI+) *m/z* 496 (M+H)⁺.

Example 387***N*-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*L*-prolinamide**

20 The title compound was prepared by substituting (*S*)-*tert*-butyl 2-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylate from Example 271 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.35-8.38 (m, 1H), 8.17-8.19 (m, 2H), 7.90-7.92 (m, 1H), 7.72 (t, *J* = 7.9 Hz, 1H), 4.13-4.19 (m, 1H), 3.86 (dd, *J* = 8.6, 5.8 Hz, 1H), 3.79 (dd, *J* = 9.9, 2.6 Hz, 1H), 3.16 (dd, *J* = 9.6, 2.9 Hz, 1H), 3.02 (dd, *J* = 9.9, 7.8 Hz, 1H), 2.66-3.18 (m, 1H), 2.79-2.91 (m, 3H), 2.48-2.55 (m, 1H), 2.40-2.45 (m, 1H), 1.99-2.10 (m, 2H), 1.76-1.92 (m, 2H), 1.55-1.65 (m, 1H), 1.48-1.56 (m, 1H), 1.39-1.48 (m, 1H), 1.21-1.29 (m, 1H); MS (ESI+) *m/z* 432 (M+H)⁺.

Example 388**(3*R*)-3-amino-4-methyl-*N*-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide**

The title compound was prepared by substituting *tert*-butyl (1*R*)-1-isopropyl-3-oxo-3-
 5 [((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]propylcarbamate from Example 272 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.74-8.76 (bs, 2H), 8.37-8.38 (bs, 1H), 8.19 (d, *J* = 7.9 Hz, 1H), 7.91 (d, *J* = 7.9 Hz, 1H), 7.72 (t, *J* = 7.8 Hz, 1H), 4.23-4.28 (m, 1H), 3.85 (dd, *J* = 9.9, 2.4 Hz, 1H), 3.14-3.19 (m, 2H), 3.12 (dd, *J* = 9.9, 7.6 Hz, 1H), 2.94 (dd, *J* = 9.6, 6.8 Hz, 1H), 2.50-2.55 (m, 2H), 2.43 (dd, *J* = 14.4, 3.2 Hz, 1H), 2.27 (dd, *J* = 14.4, 9.9 Hz, 1H), 1.92-1.99 (m, 1H), 1.80-1.88 (m, 1H), 1.65-1.90 (m, 1H), 1.50-1.61 (m, 2H), 1.25-1.32 (m, 1H), 0.85 (d, *J* = 6.9 Hz, 3H), 0.83 (d, *J* = 6.9 Hz, 3H); MS (ESI-) *m/z* 446 (M-H)⁻.

15

Example 389***N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate from Example 273 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.39-8.40 (bs, 1H), 8.24 (d, *J* = 6.9 Hz, 1H), 8.21 (d, *J* = 7.8 Hz, 1H),
 20 7.91-7.93 (m, 1H), 7.73 (t, *J* = 7.8 Hz, 1H), 4.24-4.28 (m, 1H), 3.86 (dd, *J* = 9.9, 2.4 Hz, 1H), 3.18 (dd, *J* = 9.7, 2.4 Hz, 1H), 3.15 (dd, *J* = 9.9, 7.5 Hz, 1H), 2.96 (dd, *J* = 9.6, 6.9 Hz, 1H), 2.88 (d, *J* = 5.9 Hz, 1H), 2.51-2.56 (m, 2H), 2.38 (s, 3H), 2.04-2.14 (m, 1H), 1.88-2.12 (m, 1H), 1.90-1.98 (m, 1H), 1.80-1.88 (m, 1H), 1.51-1.58 (m, 1H), 1.29 (ddt, *J* = 9.6, 12.8, 6.4 Hz, 1H), 1.04 (d, *J* = 6.9 Hz, 3H), 1.01-1.05 (m, 6H), 1.02 (d, *J* = 6.9 Hz, 3H); MS (ESI+) *m/z* 448 (M+H)⁺.

30

Example 390**(2S)-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)piperidine-2-carboxamide**

5 The title compound was prepared by substituting *tert*-butyl (2S)-2-{[((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate from Example 274 for *tert*-butyl (S)-1-((3aR,4S,6aS)-2-benzyl octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.35-8.36 (bs, 1H), 8.17-8.19 (m, 1H), 7.90-7.92 (m, 1H), 7.78-7.80 (m, 1H), 7.73 (t, *J* = 7.8 Hz, 1H), 4.16-4.23 (m, 1H), 3.79 (dd, *J* = 9.8, 2.6 Hz, 1H), 3.32 (dd, *J* = 10.3, 3.2 Hz, 1H), 3.15 (dd, *J* = 9.6, 2.9 Hz, 1H), 3.02 (dd, *J* = 9.8, 7.7 Hz, 1H), 2.96-3.00 (m, 1H), 2.89 (dd, *J* = 9.6, 7.4 Hz, 1H), 2.49-2.59 (m, 2H), 2.42-2.49 (m, 1H), 2.18-2.71 (m, 1H), 2.01-2.05 (m, 1H), 1.87-1.95 (m, 1H), 1.75-1.83 (m, 1H), 1.65-1.71 (m, 1H), 1.54-1.61 (m, 1H), 1.44-1.52 (m, 1H), 1.35-1.43 (m, 1H), 1.19-1.35 (m, 3H); MS (ESI+) *m/z* 446 (M+H)⁺.

Example 391**(3S)-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide**

20 The title compound was prepared by substituting *tert*-butyl (3S)-3-{[((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}-3,4-dihydroisoquinoline-2(1H)-carboxylate from Example 275 for *tert*-butyl (S)-1-((3aR,4S,6aS)-2-benzyl octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (501 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.30-8.31 (bs, 1H), 8.13-8.16 (m, 1H), 7.83-7.85 (m, 1H), 7.68-7.71 (m, 1H), 7.65 (t, *J* = 7.9 Hz, 1H), 7.08-7.12 (m, 3H), 6.97-7.00 (m, 1H), 4.05-4.15 (m, 2H), 3.94-3.98 (m, 1H), 3.66 (dd, *J* = 10.3, 3.4 Hz, 1H), 3.63 (dd, *J* = 9.8, 5.2 Hz, 1H), 3.21-3.26 (m, 1H), 3.11-3.18 (m, 3H), 2.99-3.06 (m, 1H), 2.54-2.58 (m, 1H), 2.47-2.52 (m, 1H), 1.96 (m, 1H), 1.87-1.94 (m, 1H), 1.78-1.85 (m, 1H), 1.45-1.54 (m, 1H), 1.23-1.31 (m, 1H); MS (ESI-) *m/z* 492 (M-H)⁻.

Example 392**4-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-
 5 ((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate from Example 276 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (501 MHz, pyridine-*d*₅, temperature 90 °C) δ ppm 8.30-8.31 (bs, 1H), 8.13-8.16 (m, 1H), 7.82-7.85 (m, 2H), 7.65 (t, *J* = 7.9 Hz, 1H), 4.03-4.10 (m, 1H), 3.69 (dd, *J* = 10.1, 3.4 Hz, 1H), 3.48 (dd, *J* = 7.5, 4.0 Hz, 1H), 3.23-3.27 (m, 1H), 3.11-3.13 (m, 2H), 2.54-2.59 (m, 1H), 2.46-2.51 (m, 1H), 2.07 (dd, *J* = 14.1, 4.0 Hz, 1H), 2.0 (m, 1H), 1.89-1.96 (m, 1H), 1.78-1.87 (m, 1H), 1.65-1.92 (m, 1H), 1.46-1.55 (m, 1H), 1.34 (dd, *J* = 14.1, 7.6 Hz, 1H), 1.23-1.32 (m, 1H), 0.96 (s, 9H); MS (ESI+) *m/z* 462 (M+H)⁺.

15

Example 393***N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norleucinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-1-oxo-1-
 20 ((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)hexan-2-yl)carbamate from Example 277 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.38-8.39 (bs, 1H), 8.19-8.23 (m, 2H), 7.91-7.93 (m, 1H), 7.73 (t, *J* = 7.8
 25 Hz, 1H), 4.24-4.29 (m, 1H), 3.87 (dd, *J* = 9.9, 2.3 Hz, 1H), 3.18 (dd, *J* = 9.8, 2.3 Hz, 1H), 3.11-3.16 (m, 2H), 2.94 (dd, *J* = 9.6, 6.8 Hz, 1H), 2.53-2.66 (m, 2H), 2.39 (s, 3H), 1.98-2.19 (m, 1H), 1.91-1.99 (m, 1H), 1.78-1.88 (m, 2H), 1.65-1.73 (m, 1H), 1.50-1.59 (m, 1H), 1.35-1.48 (m, 2H), 1.20-1.33 (m, 3H), 0.81 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z* 462 (M+H)⁺.

30

Example 394***N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-****(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-1-oxo-1-
 5 ((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-
 ylamino)pentan-2-yl)carbamate from Example 278 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-
 benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-
 yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz,
 pyridine-*d*₅) δ ppm 8.38-8.39 (bs, 1H), 8.19-8.21 (m, 2H), 7.90-7.93 (m, 1H), 7.72 (t, *J* = 7.9
 10 Hz, 1H), 4.22-4.29 (m, 1H), 3.87 (dd, *J* = 9.9, 2.5 Hz, 1H), 3.18 (dd, *J* = 9.6, 2.4 Hz, 1H),
 3.10-3.15 (m, 2H), 2.94 (dd, *J* = 9.6, 7.0 Hz, 1H), 2.49-2.57 (m, 2H), 2.37 (s, 3H), 1.92-2.22
 (m, 1H), 1.89-1.99 (m, 1H), 1.74-1.87 (m, 2H), 1.62-1.70 (m, 1H), 1.40-1.58 (m, 3H), 1.25-
 1.32 (m, 1H), 0.84 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z* 448 (M+H)⁺.

15

Example 395***N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-****(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide**

Step A: *tert*-Butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-
 (trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-
 20 yl)carbamate was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-
 benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-
 yl(methyl)carbamate from Example 222 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-
 benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-
 (trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl
 25 chloride in the procedure described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm
 8.08 (d, *J* = 8.2, 2H), 7.82 (d, *J* = 8.2, 2H), 7.51 (d, *J* = 2.1, 1H), 4.83 (s, 1H), 4.12 – 4.04 (m,
 1H), 3.67 (dd, *J* = 10.2, 3.4, 1H), 3.27 (dd, *J* = 10.2, 7.8, 1H), 3.14 – 3.09 (m, 2H), 2.94 (s,
 3H), 2.63 – 2.46 (m, 2H), 1.95 – 1.68 (m, 4H), 1.60 (td, *J* = 13.4, 6.8, 1H), 1.54 – 1.47 (m,
 1H), 1.46 (s, 9H), 1.27 (ddt, *J* = 13.3, 9.3, 6.7, 1H), 0.89 (dd, *J* = 10.7, 6.6, 6H); MS (ESI+)
 30 *m/z* 562 (M+H)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl methyl((*S*)-4-
 methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-
 (trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-

yl)carbamate from Step A for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.32-8.34 (m, 1H), 8.13-8.16 (m, 2H), 7.90-7.92 (m, 2H), 4.23-4.30 (m, 1H), 3.86 (dd, *J* = 9.9, 2.4 Hz, 1H), 3.22 (dd, *J* = 8.2, 5.9 Hz, 1H), 3.18 (dd, *J* = 9.8, 2.4 Hz, 1H), 3.15 (dd, *J* = 10.0, 7.6 Hz, 1H), 2.97 (dd, *J* = 9.6, 6.8 Hz, 1H), 2.53-2.60 (m, 2H), 2.41 (s, 3H), 2.0 (m, 1H), 1.91-1.99 (m, 1H), 1.80-1.91 (m, 2H), 1.69 (ddd, *J* = 13.5, 7.7, 5.9 Hz, 1H), 1.52-1.60 (m, 2H), 1.26-1.35 (m, 1H), 0.91 (d, *J* = 6.6 Hz, 3H), 0.85 (d, *J* = 6.5 Hz, 3H); MS (ESI+) *m/z* 462 (M+H)⁺.

10

Example 396

***N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-prolinamide**

The title compound was prepared by substituting (*S*)-*tert*-butyl 2-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylate from Example 266 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.36-8.37 (bs, 1H), 8.17-8.19 (m, 2H), 7.90-7.92 (m, 1H), 7.72 (t, *J* = 7.8 Hz, 1H), 4.13-4.19 (m, 1H), 3.81-3.85 (m, 2H), 3.17 (dd, *J* = 9.6, 2.9 Hz, 1H), 3.05 (dd, *J* = 9.9, 7.8 Hz, 1H), 2.80-2.91 (m, 3H), 2.50-2.55 (m, 1H), 2.39-2.45 (m, 1H), 1.97-2.09 (m, 2H), 1.96 (m, 1H), 1.84-1.91 (m, 1H), 1.76-1.82 (m, 1H), 1.56-1.65 (m, 1H), 1.48-1.56 (m, 1H), 1.40-1.48 (m, 1H), 1.21-1.29 (m, 1H); MS (ESI+) *m/z* 432 (M+H)⁺.

25

Example 397

(3*R*)-3-amino-4-methyl-*N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide

The title compound was prepared by substituting *tert*-butyl (1*R*)-1-isopropyl-3-oxo-3-(((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]propylcarbamate from Example 267 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.37-8.38 (bs, 1H), 8.20 (d, *J* = 7.9 Hz, 1H), 7.90-7.92 (m, 1H), 7.72 (t, *J*

30

= 7.8 Hz, 1H), 4.22-4.27 (m, 1H), 3.86 (dd, $J = 9.9, 2.4$ Hz, 1H), 3.12-3.18 (m, 3H), 2.95 (dd, $J = 9.6, 6.8$ Hz, 1H), 2.51-2.56 (m, 2H), 2.45 (dd, $J = 14.4, 3.2$ Hz, 1H), 2.27 (dd, $J = 14.4, 9.9$ Hz, 1H), 1.90-1.98 (m, 1H), 1.79-1.88 (m, 1H), 1.63-1.83 (m, 3H), 1.49-1.62 (m, 2H), 1.24-1.32 (m, 1H), 0.80-0.95 (m, 6H); MS (ESI+) m/z 448 (M+H)⁺.

5

Example 398

(2S)-N-((3aS,4R,6aR)-2-{[3-

(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)piperidine-2-carboxamide

10 The title compound was prepared by substituting *tert*-butyl (2S)-2-{[((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate from Example 268 for *tert*-butyl (S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.35-8.36 (bs, 1H), 8.17 (d, $J = 7.9$ Hz, 1H), 7.90-7.92 (m, 1H), 7.78-7.80 (m, 1H), 7.72 (t, $J = 7.8$ Hz, 1H), 4.16-4.23 (m, 1H), 3.83 (dd, $J = 9.9, 2.7$ Hz, 1H), 3.30 (dd, $J = 10.3, 3.2$ Hz, 1H), 3.16 (dd, $J = 9.6, 2.8$ Hz, 1H), 3.04 (dd, $J = 9.8, 7.8$ Hz, 1H), 2.95-3.00 (m, 1H), 2.89 (dd, $J = 9.6, 7.4$ Hz, 1H), 2.49-2.59 (m, 2H), 2.41-2.49 (m, 1H), 2.29-2.51 (m, 1H), 1.96-2.04 (m, 1H), 1.86-1.92 (m, 1H), 1.77-1.83 (m, 1H), 1.64-1.70 (m, 1H), 1.52-1.61 (m, 1H), 1.43-1.53 (m, 1H), 1.34-1.43 (m, 1H), 1.20-1.34 (m, 3H); MS (ESI+) m/z 446 (M+H)⁺.

15

20

Example 399

(2S)-N-((3aS,4R,6aR)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl)piperidine-2-carboxamide

25

Step A: *tert*-Butyl (2S)-2-{[((3aS,4R,6aR)-2-{[4-fluorophenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate was prepared by substituting *tert*-butyl (2S)-2-({[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylate from Example 231 for (S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-fluorobenzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedure described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.98 – 7.91 (m, 2H), 7.47 – 7.40 (m, 1H), 7.22 (dd, $J =$

30

12.0, 5.3, 2H), 4.88 – 4.80 (m, 1H), 4.13 – 4.05 (m, 2H), 3.61 (dd, $J = 10.1, 3.3$, 1H), 3.30 (td, $J = 12.8, 3.2$, 1H), 3.23 (dd, $J = 10.0, 7.8$, 1H), 3.07 (dd, $J = 8.6, 5.3$, 2H), 2.60 – 2.46 (m, 2H), 2.19 (dd, $J = 12.5, 1.1$, 1H), 1.97 – 1.89 (m, 1H), 1.85 – 1.77 (m, 1H), 1.66 – 1.49 (m, 5H), 1.47 (s, 9H), 1.31 (dtdd, $J = 13.3, 6.8, 6.0, 3.1$, 2H); MS (ESI+) m/z 513 ($M+NH_4$)⁺.

5 **Step B:** The title compound was prepared by substituting *tert*-butyl (2*S*)-2-
 {[(*(3aS,4R,6aR)*)-2- $\{[4$ -fluorophenyl]sulfonyl $\}$ octahydrocyclopenta[*c*]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate from Step A for *tert*-butyl (*S*)-1-((*(3aR,4S,6aS)*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.96-7.99 (m, 2H), 7.78 (d, $J = 7.0$ Hz, 1H), 7.30-7.34 (m, 2H), 4.20 (p, $J = 7.0$ Hz, 1H), 3.75 (dd, $J = 9.9, 2.9$ Hz, 1H), 3.30 (dd, $J = 10.3, 3.2$ Hz, 1H), 3.11 (dd, $J = 9.6, 2.9$ Hz, 1H), 2.96-3.03 (m, 2H), 2.87 (dd, $J = 9.6, 7.4$ Hz, 1H), 2.48-2.60 (m, 2H), 2.42-2.49 (m, 1H), 2.28-2.46 (m, 1H), 2.00-2.05 (m, 1H), 1.86-1.92 (m, 1H), 1.76-1.83 (m, 1H), 1.66-1.71 (m, 1H), 1.44-1.62 (m, 2H), 1.24-1.41 (m, 4H); MS (ESI+) m/z 396 ($M+H$)⁺.

15

Example 400

*N*¹-{(*(3aS,4R,6aR)*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*²-methyl-L-valinamide

20 **Step A:** *tert*-Butyl methyl((*S*)-3-methyl-1-oxo-1-((*(3aS,4R,6aR)*)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate was prepared by substituting *tert*-butyl (*S*)-1-((*(3aS,4R,6aR)*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamate from Example 232 for (*S*)-*N*-((*(3aS,4R,6aR)*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-
 25 fluorobenzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedure described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 7.97 – 7.89 (m, 2H), 7.74 – 7.63 (m, 1H), 7.25 – 7.18 (m, 2H), 4.34 (d, $J = 10.1$, 1H), 4.08 (dt, $J = 13.5, 6.7$, 1H), 3.57 (dd, $J = 10.1, 3.3$, 1H), 3.22 – 3.16 (m, 1H), 3.07 (d, $J = 5.5$, 2H), 3.01 (s, 3H), 2.57 – 2.50 (m, 1H), 2.50 – 2.43 (m, 1H), 2.38 (qd, $J = 13.2, 6.6$, 1H), 1.94 (td, $J = 12.2, 6.5$,
 30 1H), 1.86 – 1.77 (m, 1H), 1.54 (ddd, $J = 16.4, 12.6, 7.7$, 1H), 1.45 (s, 9H), 1.34 – 1.24 (m, 1H), 0.98 (d, $J = 6.5$, 3H), 0.86 (d, $J = 6.7$, 3H); MS (ESI+) m/z 498 ($M+H$)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl methyl((*S*)-3-methyl-1-oxo-1-((*(3aS,4R,6aR)*)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-

ylamino)butan-2-yl)carbamate from Step A for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.13-8.31 (m, 1H), 7.99-8.02 (m, 2H), 7.30-7.34 (m, 2H), 4.24-4.29 (m, 1H), 3.78 (dd, *J* = 9.9, 2.5 Hz, 1H), 3.11-3.14 (m, 2H), 2.94 (dd, *J* = 9.6, 6.9 Hz, 1H), 2.87 (d, *J* = 5.8 Hz, 1H), 2.47-2.58 (m, 2H), 2.37 (s, 3H), 2.05-2.14 (m, 1H), 1.92-2.08 (m, 1H), 1.91-1.98 (m, 1H), 1.80-1.87 (m, 1H), 1.51-1.59 (m, 1H), 1.25-1.35 (m, 1H), 0.98-1.08 (m, 6H); MS (ESI+) *m/z* 398 (M+H)⁺.

Example 401

(2*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-{[4-

(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)piperidine-2-carboxamide

Step A: *tert*-Butyl (2*S*)-2-{[((3*aS*,4*R*,6*aR*)-2-{[4-

(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate was prepared by substituting *tert*-butyl (2*S*)-2-{[((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]amino}carbonyl}piperidine-1-carboxylate from Example 231 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedure described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.08 (d, *J* = 8.1, 2H), 7.82 (d, *J* = 8.2, 2H), 7.46 (d, *J* = 5.2, 1H), 4.84 (d, *J* = 3.3, 1H), 4.09 (dt, *J* = 13.3, 6.6, 2H), 3.68 (dd, *J* = 10.2, 3.3, 1H), 3.34 – 3.24 (m, 2H), 3.12 (d, *J* = 5.5, 2H), 2.61 – 2.48 (m, 2H), 2.22 – 2.15 (m, 1H), 1.93 (dt, *J* = 11.8, 6.6, 1H), 1.81 (dtd, *J* = 12.7, 7.6, 4.8, 1H), 1.65 – 1.49 (m, 5H), 1.47 (s, 9H), 1.40 – 1.24 (m, 2H); MS (ESI+) *m/z* 563 (M+NH₄)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl (2*S*)-2-{[((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate from Step A for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.10-8.13 (m, 2H), 7.89-7.92 (m, 2H), 7.79 (d, *J* = 7.0 Hz, 1H), 4.17-4.22 (m, 1H), 3.82 (dd, *J* = 9.9, 2.8 Hz, 1H), 3.30 (dd, *J* = 10.3, 3.2 Hz, 1H), 3.16 (dd, *J* = 9.6, 2.9

Hz, 1H), 3.03-3.07 (m, 1H), 2.96-2.99 (m, 1H), 2.92 (dd, $J = 9.6, 7.4$ Hz, 1H), 2.50-2.59 (m, 2H), 2.43-2.50 (m, 1H), 2.27-2.53 (m, 1H), 2.00-2.04 (m, 1H), 1.86-1.92 (m, 1H), 1.76-1.83 (m, 1H), 1.64-1.70 (m, 1H), 1.53-1.63 (m, 1H), 1.43-1.53 (m, 1H), 1.35-1.43 (m, 1H), 1.20-1.35 (m, 3H); MS (ESI+) m/z 446 (M+H)⁺.

5

Example 402

*N*²-methyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-

(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide

Step A: *tert*-Butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-

10 (trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamate from Example 232 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-
15 (trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedure described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.07 (d, $J = 8.2$, 2H), 7.82 (d, $J = 8.2$, 2H), 7.72 (s, 1H), 4.34 (d, $J = 10.4$, 1H), 4.09 (dd, $J = 13.6, 6.7$, 1H), 3.64 (dd, $J = 10.2, 3.3$, 1H), 3.26 – 3.19 (m, 1H), 3.15 – 3.07 (m, 2H), 3.01 (s, 3H), 2.58 – 2.51 (m, 1H), 2.50 – 2.44 (m, 1H), 2.38 (qd, $J = 13.2, 6.6$, 1H), 1.93 (td, $J = 12.1, 6.5$, 1H), 1.82 (td, $J = 12.7, 7.5$, 1H), 1.53 (ddd, $J = 15.6, 12.6, 8.3$, 1H), 1.45 (s, 9H), 1.29
20 (ddd, $J = 15.9, 13.2, 6.7$, 1H), 0.97 (d, $J = 6.5$, 3H), 0.86 (d, $J = 6.7$, 3H); MS (ESI+) m/z 548 (M+H)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-

25 (trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate from Step A for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.22-8.25 (m, 1H), 8.13-8.15 (m, 2H), 7.89-7.92 (m, 2H), 4.23-4.29 (m, 1H), 3.86 (dd, $J = 9.9, 2.6$ Hz, 1H), 3.13-3.20 (m, 2H), 2.98 (dd, $J = 9.6, 7.0$ Hz, 1H), 2.87 (d, $J = 5.8$ Hz, 1H), 2.50-2.59 (m, 2H), 2.37 (s, 3H), 2.05-2.13 (m, 1H), 1.93-2.11 (m, 1H), 1.90-1.98 (m, 1H), 1.80-1.87 (m, 1H), 1.51-1.58 (m, 1H), 1.26-1.34 (m, 1H), 1.04 (d, $J = 6.9$ Hz, 3H), 1.02 (d, $J = 6.9$ Hz, 3H); MS (ESI+) m/z 448 (M+H)⁺.

30

Example 403***N*¹-{(3*aS*,4*R*,6*aR*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*²-methyl-L-norvalinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate from Example 330 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.23 (d, *J* = 7.2 Hz, 1H), 7.98-8.01 (m, 2H), 7.30-7.34 (m, 2H), 4.26 (p, *J* = 6.8 Hz, 1H), 3.77 (dd, *J* = 9.9, 2.7 Hz, 1H), 3.09-3.15 (m, 3H), 2.93 (dd, *J* = 9.6, 7.1 Hz, 1H), 2.47-2.58 (m, 2H), 2.38 (s, 3H), 1.92-2.21 (m, 1H), 1.91-1.99 (m, 1H), 1.75-1.87 (m, 2H), 1.64-1.71 (m, 1H), 1.51-1.60 (m, 1H), 1.38-1.51 (m, 2H), 1.25-1.35 (m, 1H), 0.84 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z* 398 (M+H)⁺.

Example 404***N*²-methyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Example 331 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.24-8.26 (m, 1H), 8.12-8.15 (m, 2H), 7.89-7.92 (m, 2H), 4.26 (p, *J* = 6.9 Hz, 1H), 3.85 (dd, *J* = 9.9, 2.7 Hz, 1H), 3.18 (dd, *J* = 9.6, 2.7 Hz, 1H), 3.15 (dd, *J* = 7.7, 3.9 Hz, 1H), 3.13 (d, *J* = 7.0 Hz, 1H), 2.97 (dd, *J* = 9.6, 7.2 Hz, 1H), 2.51-2.61 (m, 2H), 2.38 (s, 3H), 1.95-2.31 (m, 1H), 1.92-1.98 (m, 1H), 1.75-1.87 (m, 2H), 1.64-1.72 (m, 1H), 1.51-1.59 (m, 1H), 1.39-1.52 (m, 2H), 1.30 (ddt, *J* = 9.7, 13.0, 6.5 Hz, 1H), 0.84 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z* 448 (M+H)⁺.

Example 405***N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-****(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-1-oxo-1-
 5 ((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-
 ylamino)pentan-2-yl)carbamate from Example 259 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-
 benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-
 yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz,
 pyridine-*d*₅) δ ppm 8.20-8.23 (m, 1H), 8.13-8.15 (m, 2H), 7.89-7.92 (m, 2H), 4.22-4.29 (m,
 10 1H), 3.85 (dd, *J* = 9.9, 2.7 Hz, 1H), 3.18 (dd, *J* = 9.7, 2.7 Hz, 1H), 3.11-3.16 (m, 2H), 2.96
 (dd, *J* = 9.6, 7.1 Hz, 1H), 2.50-2.61 (m, 2H), 2.38 (s, 3H), 1.98-2.07 (m, 1H), 1.90-1.98 (m,
 1H), 1.75-1.87 (m, 2H), 1.63-1.70 (m, 1H), 1.41-1.58 (m, 3H), 1.26-1.33 (m, 1H), 0.84 (t, *J* =
 7.3 Hz, 3H); MS (ESI+) *m/z* 448 (M+H)⁺.

15

Example 406***N*²-methyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[3-****(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-3-methyl-1-
 oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-
 20 ylamino)butan-2-yl)carbamate from Example 340 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-
 benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-
 yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz,
 pyridine-*d*₅) δ ppm 8.39-8.40 (bs, 1H), 8.24 (d, *J* = 7.2 Hz, 1H), 8.18-8.22 (m, 1H), 7.90-7.92
 (m, 1H), 7.72 (t, *J* = 7.8 Hz, 1H), 4.24-4.30 (m, 1H), 3.86 (dd, *J* = 9.9, 2.3 Hz, 1H), 3.14-3.20
 25 (m, 2H), 2.96 (dd, *J* = 9.7, 7.1 Hz, 1H), 2.86 (d, *J* = 5.8 Hz, 1H), 2.50-2.57 (m, 2H), 2.37 (s,
 3H), 2.04-2.13 (m, 1H), 1.88-2.08 (m, 1H), 1.89-1.98 (m, 1H), 1.80-1.89 (m, 1H), 1.50-1.59
 (m, 1H), 1.25-1.34 (m, 1H), 1.03 (d, *J* = 6.9 Hz, 3H), 1.01 (d, *J* = 7.0 Hz, 3H); MS (ESI+)
m/z 448 (M+H)⁺.

30

Example 407***N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-fluoro-3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*N*²-methyl-L-leucinamide**

5 The title compound was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluoro-3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate from Example 327 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.35 (dd, *J* = 6.5, 1.9 Hz, 1H), 8.31 (d, *J* = 7.3 Hz, 1H), 8.26 (ddd, *J* = 8.5, 4.7, 2.4 Hz, 1H), 7.53-7.58 (m, 1H), 4.24-4.30 (m, 1H), 3.88 (dd, *J* = 9.9, 2.5 Hz, 1H), 3.16-3.20 (m, 3H), 3.00 (dd, *J* = 9.6, 7.2 Hz, 1H), 2.53-2.62 (m, 2H), 2.38 (s, 3H), 1.82-2.01 (m, 4H), 1.67 (ddd, *J* = 13.5, 7.8, 5.7 Hz, 1H), 1.53-1.59 (m, 2H), 1.32 (ddt, *J* = 9.7, 12.9, 6.5 Hz, 1H), 0.89 (d, *J* = 6.6 Hz, 3H), 0.84 (d, *J* = 6.5 Hz, 3H); MS (ESI+) *m/z* 480 (M+H)⁺.

15

Example 408***N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide**

20 The title compound was prepared by substituting *tert*-butyl (*S*)-3,3-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-ylcarbamate from Example 341 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.25 (d, *J* = 6.7 Hz, 1H), 8.12-8.16 (m, 2H), 7.90-7.92 (m, 2H), 4.18-4.24 (m, 1H), 3.82 (dd, *J* = 10.0, 2.3 Hz, 1H), 3.24 (s, 1H), 3.13-3.18 (m, 2H), 2.98 (dd, *J* = 9.5, 6.5 Hz, 1H), 2.49-2.60 (m, 2H), 1.93-2.29 (m, 2H), 1.85-1.95 (m, 1H), 1.77-1.85 (m, 1H), 1.47-1.55 (m, 1H), 1.22-1.31 (m, 1H), 1.12 (s, 9H); MS (ESI-) *m/z* 446 (M-H)⁻.

25

Example 409***N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide**

30 The title compound was prepared by substituting *tert*-butyl (*S*)-3,3-dimethyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-

ylamino)butan-2-ylcarbamate from Example 342 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.23 (d, *J* = 6.7 Hz, 1H), 8.12-8.14 (m, 2H), 7.89-7.91 (m, 2H), 4.18-4.25 (m, 1H), 3.80 (dd, *J* = 9.9, 2.7 Hz, 1H), 3.24 (s, 1H), 3.16 (dd, *J* = 9.7, 2.8 Hz, 1H), 3.10 (dd, *J* = 9.9, 7.5 Hz, 1H), 2.95 (dd, *J* = 9.6, 7.2 Hz, 1H), 2.45-2.55 (m, 2H), 1.96-2.22 (m, 2H), 1.88-1.96 (m, 1H), 1.78-1.85 (m, 1H), 1.49-1.57 (m, 1H), 1.20-1.32 (m, 1H), 1.11 (s, 9H).

Example 410

10 ***N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-isoleucinamide**

The title compound was prepared by substituting *tert*-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Example 332 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.39-8.40 (bs, 1H), 8.24 (d, *J* = 7.2 Hz, 1H), 8.19-8.22 (m, 1H), 7.91-7.93 (m, 1H), 7.73 (d, *J* = 7.9 Hz, 1H), 4.24-4.30 (m, 1H), 3.87 (dd, *J* = 9.9, 2.3 Hz, 1H), 3.13-3.20 (m, 2H), 2.95 (d, *J* = 6.3 Hz, 2H), 2.50-2.58 (m, 2H), 2.38 (s, 3H), 1.89-2.02 (m, 1H), 1.90-1.98 (m, 1H), 1.79-1.89 (m, 2H), 1.72-1.82 (m, 1H), 1.51-1.59 (m, 1H), 1.23-1.40 (m, 2H), 1.00 (d, *J* = 6.8 Hz, 3H), 0.86 (t, *J* = 7.4 Hz, 3H); MS (ESI+) *m/z* 462 (M+H)⁺.

Example 411

25 ***N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-isoleucinamide**

The title compound was prepared by substituting *tert*-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Example 333 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.24-8.26 (m, 1H), 8.13-8.16 (m, 2H), 7.90-7.92 (m, 2H), 4.23-4.30 (m, 1H), 3.86 (dd, *J* = 9.9, 2.5 Hz, 1H), 3.19 (dd, *J* = 9.6, 2.4 Hz, 1H), 3.15 (dd, *J* = 9.8, 7.6 Hz, 1H), 2.97 (dd, *J* = 9.4, 6.9 Hz, 1H), 2.95 (d, *J* = 6.0 Hz, 1H), 2.52-2.60 (m, 2H), 2.39 (s, 3H),

1.92-2.04 (m, 1H), 1.91-1.97 (m, 1H), 1.80-1.88 (m, 2H), 1.72-1.80 (m, 1H), 1.51-1.60 (m, 1H), 1.25-1.36 (m, 2H), 1.01 (d, $J = 6.9$ Hz, 3H), 0.86 (t, $J = 7.4$ Hz, 3H); MS (ESI+) m/z 462 (M+H)⁺.

5

Example 412

***N*²-methyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[3-**

(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-isoleucinamide

The title compound was prepared by substituting *tert*-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Example 334 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.23-8.26 (m, 1H), 8.12-8.16 (m, 2H), 7.89-7.91 (m, 2H), 4.24-4.29 (m, 1H), 3.86 (dd, $J = 9.9, 2.5$ Hz, 1H), 3.15-3.20 (m, 2H), 2.98 (dd, $J = 9.6, 6.9$ Hz, 1H), 2.94 (d, $J = 6.1$ Hz, 1H), 2.50-2.62 (m, 2H), 2.38 (s, 3H), 1.91-2.04 (m, 1H), 1.91-1.98 (m, 1H), 1.80-1.88 (m, 2H), 1.72-1.80 (m, 1H), 1.51-1.59 (m, 1H), 1.24-1.35 (m, 2H), 1.00 (d, $J = 6.8$ Hz, 3H), 0.85 (t, $J = 7.4$ Hz, 3H); MS (ESI+) m/z 462 (M+H)⁺.

20

Example 413

***N*²-methyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-**

(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-isoleucinamide

The title compound was prepared by substituting *tert*-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Example 335 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.38-8.39 (bs, 1H), 8.24 (d, $J = 7.0$ Hz, 1H), 8.19-8.22 (m, 1H), 7.90-7.92 (m, 1H), 7.72 (t, $J = 7.8$ Hz, 1H), 4.23-4.30 (m, 1H), 3.86 (dd, $J = 9.9, 2.2$ Hz, 1H), 3.14-3.20 (m, 2H), 2.97 (dd, $J = 9.6, 6.6$ Hz, 1H), 2.93 (d, $J = 6.1$ Hz, 1H), 2.55 (t, $J = 4.5$ Hz, 2H), 2.37 (s, 3H), 1.92-2.10 (m, 1H), 1.91-1.99 (m, 1H), 1.80-1.89 (m, 2H), 1.71-1.81 (m, 1H), 1.51-1.59 (m, 1H), 1.24-1.40 (m, 2H), 0.99 (d, $J = 6.8$ Hz, 3H), 0.84 (t, $J = 7.4$ Hz, 3H); MS (ESI+) m/z 462 (M+H)⁺.

Example 414***N*²,4-dimethyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-****(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-
5 ((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-
ylamino)pentan-2-yl(methyl)carbamate from Example 336 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-
2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-
yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz,
pyridine-*d*₅) δ ppm 8.38-8.40 (m, 1H), 8.34 (d, *J* = 6.9 Hz, 1H), 8.20-8.22 (m, 1H), 7.90-7.93
10 (m, 1H), 7.73 (d, *J* = 7.9 Hz, 1H), 4.23-4.28 (m, 1H), 3.89 (dd, *J* = 9.9, 2.1 Hz, 1H), 3.16-
3.21 (m, 2H), 3.15 (dd, *J* = 9.8, 7.4 Hz, 1H), 2.93-2.97 (m, 1H), 2.50-2.58 (m, 2H), 2.38 (s,
3H), 2.00-2.06 (m, 1H), 1.90-1.99 (m, 1H), 1.90 (dd, *J* = 14.1, 5.1 Hz, 1H), 1.79-1.87 (m,
1H), 1.51-1.60 (m, 1H), 1.48 (dd, *J* = 14.0, 6.5 Hz, 1H), 1.25-1.32 (m, 1H), 0.97 (s, 9H); MS
(ESI+) *m/z* 476 (M+H)⁺.

Example 415***N*²,4-dimethyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-****(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-
20 ((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-
ylamino)pentan-2-yl(methyl)carbamate from Example 337 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-
2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-
yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz,
pyridine-*d*₅) δ ppm 8.37-8.40 (m, 1H), 8.14-8.16 (m, 2H), 7.90-7.92 (m, 2H), 4.23-4.27 (m,
25 1H), 3.87 (dd, *J* = 9.9, 2.2 Hz, 1H), 3.22 (t, *J* = 5.9 Hz, 1H), 3.18 (dd, *J* = 9.7, 2.1 Hz, 1H),
3.15 (dd, *J* = 9.9, 7.5 Hz, 1H), 2.95-2.99 (m, 1H), 2.55-2.58 (m, 2H), 2.40 (s, 3H), 1.91-1.98
(m, 1H), 1.92 (dd, *J* = 14.0, 5.1 Hz, 2H), 1.80-1.86 (m, 1H), 1.52-1.61 (m, 1H), 1.50 (dd, *J* =
14.0, 6.4 Hz, 1H), 1.25-1.34 (m, 1H), 0.97 (s, 9H); MS (ESI+) *m/z* 476 (M+H)⁺.

Example 416***N*²,4-dimethyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[3-****(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-
5 ((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-
ylamino)pentan-2-yl(methyl)carbamate from Example 338 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-
2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-
yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz,
pyridine-*d*₅) δ ppm 8.37-8.39 (bs, 1H), 8.33-8.36 (m, 1H), 8.18-8.21 (m, 1H), 7.91 (d, *J* = 7.0
10 Hz, 1H), 7.72 (t, *J* = 7.8 Hz, 1H), 4.23-4.29 (m, 1H), 3.88 (dd, *J* = 9.9, 2.1 Hz, 1H), 3.12-3.20
(m, 3H), 2.94 (dd, *J* = 9.6, 6.6 Hz, 1H), 2.54 (t, *J* = 4.6 Hz, 2H), 2.37 (s, 3H), 1.92-2.00 (m,
1H), 1.75-2.14 (m, 1H), 1.90 (dd, *J* = 14.0, 5.2 Hz, 1H), 1.80-1.87 (m, 1H), 1.51-1.59 (m,
1H), 1.49 (dd, *J* = 14.0, 6.6 Hz, 1H), 1.24-1.33 (m, 1H), 0.96 (s, 9H); MS (ESI+) *m/z* 476
(M+H)⁺.

15

Example 417***N*²,4-dimethyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-****(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-
20 ((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-
ylamino)pentan-2-yl(methyl)carbamate from Example 339 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-
2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-
yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz,
pyridine-*d*₅) δ ppm 8.36-8.38 (m, 1H), 8.13-8.15 (m, 2H), 7.89-7.91 (m, 2H), 4.22-4.29 (m,
25 1H), 3.87 (d, *J* = 10.4 Hz, 1H), 3.16-3.20 (m, 2H), 3.14 (dd, *J* = 9.9, 7.5 Hz, 1H), 2.96 (dd, *J*
= 9.6, 6.8 Hz, 1H), 2.54-2.59 (m, 2H), 2.38 (s, 3H), 1.91-1.99 (m, 1H), 1.95 (m, 1H), 1.91
(dd, *J* = 14.0, 5.2 Hz, 1H), 1.79-1.87 (m, 1H), 1.52-1.60 (m, 1H), 1.50 (dd, *J* = 14.0, 6.6 Hz,
1H), 1.26-1.33 (m, 1H), 0.96 (s, 9H); MS (ESI+) *m/z* 476 (M+H)⁺.

30

Example 418

***N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norleucinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-1-oxo-1-
 5 ((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)hexan-2-yl)carbamate from Example 343 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.21-8.24 (m, 1H), 8.13-8.15 (m, 2H), 7.90-7.92 (m, 2H), 4.23-4.30 (m, 1H), 3.86 (dd, *J* = 9.9, 2.5 Hz, 1H), 3.18 (dd, *J* = 9.6, 2.6 Hz, 1H), 3.12-3.16 (m, 2H), 2.96
 10 (dd, *J* = 9.6, 7.0 Hz, 1H), 2.54-2.61 (m, 2H), 2.40 (s, 3H), 1.94-2.28 (m, 1H), 1.91-1.98 (m, 1H), 1.78-1.87 (m, 2H), 1.65-1.73 (m, 1H), 1.51-1.59 (m, 1H), 1.36-1.50 (m, 2H), 1.27-1.34 (m, 1H), 1.24 (h, *J* = 7.4 Hz, 2H), 0.81 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z* 462 (M+H)⁺.

15

Example 419

4-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting *tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-
 ((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate from Example 344 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.39-8.41 (m, 1H), 8.13-8.15 (m, 2H), 7.90-7.92 (m, 2H), 4.18-4.24 (m, 1H), 3.85 (dd, *J* = 9.9, 2.6 Hz, 1H), 3.59 (dd, *J* = 7.4, 4.3 Hz, 1H), 3.16 (dd, *J* = 9.6, 2.8 Hz,
 20 1H), 3.10 (dd, *J* = 9.9, 7.4 Hz, 1H), 2.95 (dd, *J* = 9.6, 7.1 Hz, 1H), 2.48-2.58 (m, 2H), 2.16 (dd, *J* = 14.0, 4.3 Hz, 1H), 2.06-2.22 (m, 1H), 1.88-1.95 (m, 1H), 1.78-1.83 (m, 1H), 1.47-1.55 (m, 1H), 1.43 (dd, *J* = 13.9, 7.4 Hz, 1H), 1.23-1.31 (m, 1H), 0.98 (s, 9H); MS (ESI+) *m/z* 462 (M+H)⁺.

30

Example 420***N*²-methyl-*N*¹-((3*aR*,4*R*,6*aS*)-2-{[4-****(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-1-oxo-1-
 5 ((3*aR*,4*R*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-
 ylamino)pentan-2-yl)carbamate from Example 328 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-
 benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-
 yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz,
 pyridine-*d*₅) δ ppm 8.52 (d, *J* = 7.9 Hz, 1H), 8.10-8.15 (m, 2H), 7.88-7.91 (m, 2H), 4.44-4.50
 10 (m, 1H), 3.63 (dd, *J* = 9.5, 2.8 Hz, 1H), 3.23-3.26 (m, 1H), 3.14-3.19 (m, 1H), 2.98 (dd, *J* =
 25.4, 9.3 Hz, 3H), 2.49-2.56 (m, 1H), 2.48 (s, 3H), 1.86-1.92 (m, 1H), 1.90 (m, 1H), 1.75-
 1.83 (m, 1H), 1.69-1.75 (m, 2H), 1.59-1.68 (m, 1H), 1.44-1.59 (m, 2H), 1.33-1.39 (m, 1H),
 0.88 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z* 448 (M+H)⁺.

15

Example 421***N*²-methyl-*N*¹-((3*aR*,4*R*,6*aS*)-2-{[4-****(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide**

The title compound was prepared by substituting *tert*-butyl methyl((*S*)-4-methyl-1-
 oxo-1-((3*aR*,4*R*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-
 20 ylamino)pentan-2-yl)carbamate from Example 329 for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-
 benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-
 yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz,
 pyridine-*d*₅) δ ppm 8.60-8.65 (m, 1H), 8.12-8.14 (m, 2H), 7.88-7.91 (m, 2H), 4.45-4.50 (m,
 1H), 3.63-3.66 (m, 1H), 3.33-3.37 (m, 1H), 3.15 (dd, *J* = 9.6, 3.0 Hz, 1H), 2.95-3.05 (m, 3H),
 25 2.51 (s, 3H), 2.46-2.52 (m, 1H), 1.91-1.97 (m, 2H), 1.78-1.83 (m, 1H), 1.72-1.75 (m, 3H),
 1.63 (dq, *J* = 13.0, 8.2 Hz, 1H), 1.34-1.39 (m, 1H), 0.94 (d, *J* = 6.5 Hz, 3H), 0.88 (d, *J* = 6.5
 Hz, 3H); MS (ESI+) *m/z* 462 (M+H)⁺.

Example 422

30 ***N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-
 4-yl)-L-norvalinamide**

Step A: *tert*-Butyl-((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-
 (trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-

yl)carbamate was prepared by substituting *tert*-butyl ((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Example 382 Step A for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-

5 (trifluoromethyl)benzene-1-sulfonyl chloride in the procedure described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.13 (d, *J* = 8.1, 2H), 7.96 (d, *J* = 8.0, 1H), 7.90 (d, *J* = 8.3, 2H), 4.60 (dd, *J* = 14.5, 8.2, 1H), 4.27 – 4.18 (m, 1H), 3.81 (dd, *J* = 9.8, 1.5, 1H), 3.21 – 3.10 (m, 2H), 2.99 – 2.92 (m, 1H), 2.61 – 2.50 (m, 2H), 2.00 (dd, *J* = 14.3, 5.4, 1H), 1.84 (ddd, *J* = 13.4, 11.2, 6.8, 3H), 1.55 – 1.44 (m, 13H), 1.25 (d, *J* = 8.9, 1H), 0.81 (t, *J* = 7.3, 10 3H); MS (ESI+) *m/z* 551 (M+NH₄)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl-((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Step A for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, 15 pyridine-*d*₅) δ ppm 8.28 (d, *J* = 7.0 Hz, 1H), 8.11-8.15 (m, 2H), 7.89-7.92 (m, 2H), 4.17-4.24 (m, 1H), 3.82 (dd, *J* = 9.9, 2.8 Hz, 1H), 3.52 (dd, *J* = 7.9, 4.9 Hz, 1H), 3.16 (dd, *J* = 9.6, 2.9 Hz, 1H), 3.09 (dd, *J* = 9.9, 7.7 Hz, 1H), 2.94 (dd, *J* = 9.6, 7.3 Hz, 1H), 2.46-2.57 (m, 2H), 2.07-2.18 (m, 2H), 1.88-1.96 (m, 2H), 1.77-1.84 (m, 1H), 1.63 (dddd, *J* = 13.1, 8.0, 10.1, 5.1 20 Hz, 1H), 1.40-1.53 (m, 3H), 1.23-1.32 (m, 1H), 0.85 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z* 434 (M+H)⁺.

Example 423

***N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol- 25 4-yl)-L-norvalinamide**

Step A: *tert*-Butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl carbamate was prepared by substituting *N*-(*tert*-butoxycarbonyl) L-norvaline for *N*-(*tert*-butoxycarbonyl)-L-leucine and (3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine from Example 16 Step E for (3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 221: ¹H 30 NMR (400 MHz, pyridine-*d*₅) δ ppm 8.58 (d, *J* = 7.2, 1H), 7.91 (d, *J* = 8.3, 1H), 7.42 (d, *J* = 7.3, 2H), 7.36 (t, *J* = 7.4, 2H), 7.27 (t, *J* = 7.2, 1H), 4.64 (dd, *J* = 14.4, 7.7, 1H), 4.45 – 4.35 (m, 1H), 3.56 (d, *J* = 13.1, 1H), 3.40 (d, *J* = 13.2, 1H), 2.74 (d, *J* = 8.9, 1H), 2.52 – 2.43 (m,

2H), 2.39 – 2.27 (m, 2H), 2.26 – 2.19 (m, 1H), 2.14 (dq, $J = 12.0, 6.0$, 1H), 2.02 (dt, $J = 13.9, 6.7$, 1H), 1.85 (td, $J = 13.8, 8.2$, 2H), 1.65 (td, $J = 14.3, 7.3$, 1H), 1.49 (d, $J = 8.5$, 11H), 1.44 – 1.32 (m, 1H), 0.86 – 0.76 (m, 3H); MS (ESI+) m/z 416 (M+H)⁺.

Step B: *tert*-Butyl-((*S*)-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-

5 (trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl carbamate from Step A for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-
10 (trifluoromethyl)benzene-1-sulfonyl chloride in the procedure described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.79 (d, $J = 6.8$, 1H), 8.11 (d, $J = 8.1$, 2H), 7.98 (d, $J = 8.1$, 1H), 7.90 (d, $J = 8.3$, 2H), 4.59 (dd, $J = 14.4, 7.8$, 1H), 4.28 – 4.20 (m, 1H), 3.78 (d, $J = 9.7$, 1H), 3.14 (d, $J = 9.6$, 1H), 3.05 – 2.98 (m, 1H), 2.93 – 2.86 (m, 1H), 2.50 (d, $J = 2.3$, 2H), 2.02 – 1.92 (m, 2H), 1.88 – 1.77 (m, 2H), 1.63 – 1.53 (m, 1H), 1.53 – 1.38 (m, 11H),
15 1.33 – 1.22 (m, 1H), 0.79 (t, $J = 7.4$, 3H); MS (ESI+) m/z 551 (M+NH₄)⁺.

Step C: The title compound was prepared by substituting *tert*-butyl-((*S*)-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Step B for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.27 (d, $J = 7.2$ Hz, 1H), 8.10-8.14 (m, 2H), 7.89-7.91 (m, 2H), 4.18-4.24 (m, 1H), 3.83 (dd, $J = 9.9, 2.9$ Hz, 1H), 3.51 (dd, $J = 7.9, 4.9$ Hz, 1H), 3.16 (dd, $J = 9.6, 2.9$ Hz, 1H), 3.08 (dd, $J = 9.9, 7.7$ Hz, 1H), 2.93 (dd, $J = 9.6, 7.4$ Hz, 1H), 2.45-2.56 (m, 2H), 2.03-2.23 (m, 2H), 1.88-1.95 (m, 2H), 1.77-1.84 (m, 1H), 1.64 (dddd, $J = 13.1, 8.1, 10.1, 5.1$ Hz, 1H), 1.38-1.54 (m, 3H), 1.24-1.32 (m, 1H), 0.84 (t, $J = 7.3$ Hz, 3H); MS (ESI-) m/z 432 (M-H)⁻.
20
25

Example 424

*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide
30

Step A: *tert*-Butyl-((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate was prepared by substituting *tert*-butyl ((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-

benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Example 382 Step A for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide in the procedure described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.70 (d, *J* = 6.9, 1H), 8.37 (s, 1H), 8.18 (d, *J* = 7.8, 1H), 7.95 (d, *J* = 8.0, 1H), 7.91 (d, *J* = 7.8, 1H), 7.72 (t, *J* = 7.9, 1H), 4.59 (dd, *J* = 14.1, 7.8, 1H), 4.23 (dt, *J* = 13.0, 6.5, 1H), 3.82 (dd, *J* = 9.7, 1.4, 1H), 3.18 – 3.07 (m, 2H), 2.98 – 2.90 (m, 1H), 2.62 – 2.48 (m, 2H), 2.00 (ddd, *J* = 15.3, 11.0, 6.5, 1H), 1.91 – 1.74 (m, 3H), 1.57 – 1.39 (m, 12H), 1.23 (ddd, *J* = 16.9, 12.6, 6.1, 1H), 0.81 (t, *J* = 7.3, 3H); MS (ESI+) *m/z* 551 (M+NH₄)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl-((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Step A for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.36-8.37 (bs, 1H), 8.26 (d, *J* = 6.9 Hz, 1H), 8.17-8.20 (m, 1H), 7.90-7.92 (m, 1H), 7.70-7.74 (m, 1H), 4.18-4.24 (m, 1H), 3.83 (dd, *J* = 9.8, 2.7 Hz, 1H), 3.52 (dd, *J* = 7.9, 4.9 Hz, 1H), 3.16 (dd, *J* = 9.6, 2.8 Hz, 1H), 3.07 (dd, *J* = 9.9, 7.5 Hz, 1H), 2.91 (dd, *J* = 9.6, 7.3 Hz, 1H), 2.44-2.54 (m, 2H), 1.95-2.28 (m, 2H), 1.86-1.99 (m, 2H), 1.77-1.84 (m, 1H), 1.59-1.66 (m, 1H), 1.39-1.54 (m, 3H), 1.22-1.32 (m, 1H), 0.84 (t, *J* = 7.3 Hz, 3H); MS (ESI+) *m/z* 434 (M+H)⁺.

Example 425

***N*¹-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide**

Step A: *tert*-Butyl-((*S*)-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate was prepared by substituting *tert*-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl carbamate from Example 423 Step A for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide in the procedure described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.77 (d, *J* = 6.9, 1H), 8.35 (s, 1H), 8.16 (d, *J* = 7.7, 1H), 7.96 (d, *J* = 8.2, 1H), 7.90 (d, *J* = 8.0, 1H), 7.72 (t, *J* = 7.9, 1H), 4.58 (dd, *J* = 14.4, 8.0, 1H), 4.30 – 4.20 (m, 1H), 3.84 – 3.75 (m, 1H), 3.15 (d, *J* = 9.4, 1H), 3.04 – 2.95 (m, 1H), 2.91 – 2.79 (m, 1H), 2.47 (dd, *J* = 2.3, 1.2, 2H), 2.03 – 1.91 (m, 2H), 1.88 – 1.76 (m, 2H), 1.64 – 1.53 (m, 1H),

1.53 – 1.40 (m, 11H), 1.33 – 1.19 (m, 1H), 0.79 (t, $J = 7.3$, 3H); MS (ESI+) m/z 551 (M+NH₄)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl-((*S*)-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate was prepared by substituting *tert*-butyl-((*S*)-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate from Step A for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.35-8.37 (m, 1H), 8.27 (d, $J = 7.0$ Hz, 1H), 8.17-8.19 (m, 1H), 7.90-7.92 (m, 1H), 7.72 (t, $J = 7.8$ Hz, 1H), 4.18-4.25 (m, 1H), 3.84 (dd, $J = 9.9$, 2.7 Hz, 1H), 3.51 (dd, $J = 7.9$, 4.9 Hz, 1H), 3.17 (dd, $J = 9.6$, 2.8 Hz, 1H), 3.07 (dd, $J = 9.9$, 7.6 Hz, 1H), 2.91 (dd, $J = 9.6$, 7.3 Hz, 1H), 2.43-2.54 (m, 2H), 1.96-2.32 (m, 2H), 1.87-1.95 (m, 2H), 1.78-1.84 (m, 1H), 1.59-1.67 (m, 1H), 1.37-1.53 (m, 3H), 1.23-1.32 (m, 1H), 0.83 (t, $J = 7.3$ Hz, 3H); MS (ESI-) m/z 432 (M-H)⁻.

Example 426

3-cyclohexyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-

(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-alaninamide

Step A: *tert*-Butyl (*S*)-3-cyclohexyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)propan-2-ylcarbamate was prepared by substituting (*S*)-2-(*tert*-butoxycarbonylamino)-3-cyclohexylpropanoic acid for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and (3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 256 Step A for (3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.76 (s, 1H), 8.13 (d, $J = 8.1$, 2H), 8.01 (d, $J = 8.3$, 1H), 7.90 (d, $J = 8.3$, 2H), 4.74 – 4.65 (m, 1H), 4.31 – 4.19 (m, 1H), 3.85 – 3.78 (m, 1H), 3.21 – 3.10 (m, 2H), 3.01 – 2.93 (m, 1H), 2.64 – 2.51 (m, 2H), 1.96 – 1.74 (m, 6H), 1.69 – 1.60 (m, 1H), 1.60 – 1.45 (m, 13H), 1.32 – 1.18 (m, 1H), 1.16 – 0.96 (m, 3H), 0.94 – 0.81 (m, 1H), 0.79 – 0.67 (m, 1H); MS (ESI+) m/z 605 (M+NH₄)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl (*S*)-3-cyclohexyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-

ylamino)propan-2-ylcarbamate from Step A for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.35 (d, *J* = 7.0 Hz, 1H), 8.12-8.15 (m, 2H), 7.90-7.92 (m, 2H), 4.20-4.26 (m, 1H), 3.83 (dd, *J* = 9.9, 2.7 Hz, 1H), 3.63 (dd, *J* = 9.2, 4.7 Hz, 1H), 3.17 (dd, *J* = 9.7, 2.8 Hz, 1H), 3.10 (dd, *J* = 9.8, 7.6 Hz, 1H), 2.96 (dd, *J* = 9.6, 7.2 Hz, 1H), 2.46-2.61 (m, 2H), 1.97-2.47 (m, 2H), 1.86-1.96 (m, 2H), 1.78-1.86 (m, 1H), 1.72-1.78 (m, 1H), 1.65-1.71 (m, 1H), 1.47-1.62 (m, 6H), 1.22-1.33 (m, 1H), 0.99-1.23 (m, 3H), 0.91 (qd, *J* = 12.5, 3.4 Hz, 1H), 0.79 (qd, *J* = 12.0, 3.4 Hz, 1H); MS (ESI+) *m/z* 488 (M+H)⁺.

10

Example 427

3-cyclohexyl-*N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-alaninamide

Step A: *tert*-Butyl (*S*)-3-cyclohexyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-

15 (trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)propan-2-yl(methyl)carbamate was prepared by substituting (*S*)-2-(*tert*-butoxycarbonyl(methyl)amino)-3-cyclohexylpropanoic acid for (*S*)-1-(*tert*-butoxycarbonyl)pyrrolidine-2-carboxylic acid and (3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine from Example 256 Step A for (3*aS*,4*R*,6*aR*)-2-(3-

20 (trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-amine in the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.51 (d, *J* = 6.9, 1H), 8.13 (d, *J* = 8.2, 2H), 7.90 (d, *J* = 8.3, 2H), 5.23 – 5.14 (m, 0.4H), 4.89 – 4.79 (m, 0.6H), 4.28 – 4.15 (m, 1H), 3.83 (d, *J* = 10.6, 1H), 3.17 – 3.01 (m, 5H), 2.94 (dd, *J* = 9.4, 7.2, 1H), 2.57 – 2.48 (m, 2H), 1.99 – 1.74 (m, 5H), 1.67 (d, *J* = 13.1, 1H), 1.62 – 1.48 (m, 4H), 1.45 (s, 9H),

25 1.34 – 1.20 (m, 2H), 1.18 – 1.00 (m, 3H), 0.98 – 0.85 (m, 1H), 0.81 – 0.66 (m, 1H); MS (ESI+) *m/z* 602 (M+H)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl (*S*)-3-cyclohexyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)propan-2-yl(methyl)carbamate from Step A for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.30 (d, *J* = 7.2 Hz, 1H), 8.13-8.16 (m, 2H), 7.89-7.93 (m, 2H), 4.24-4.32 (m, 1H), 3.86 (dd, *J* = 9.9, 2.3 Hz, 1H), 3.25 (dd, *J* = 7.8, 5.6 Hz, 1H), 3.13-3.21 (m, 2H),

30

2.98 (dd, $J = 9.5, 6.8$ Hz, 1H), 2.47-2.63 (m, 2H), 2.41 (s, 3H), 1.95-2.23 (m, 1H), 1.91-1.99 (m, 1H), 1.79-1.90 (m, 1H), 1.66-1.78 (m, 3H), 1.51-1.62 (m, 6H), 1.26-1.35 (m, 1H), 1.00-1.23 (m, 3H), 0.76-0.93 (m, 2H); MS (ESI+) m/z 502 (M+H)⁺.

5

Example 428

N^1 -((3a*R*,4*S*,6a*S*)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-L-leucinamide

Step A: *tert*-Butyl (*S*)-4,4-dimethyl-1-oxo-1-((3a*R*,4*S*,6a*S*)-2-(2-chloro-5-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate was prepared by substituting *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamate from Example 226 for (*S*)-*N*-((3a*S*,4*R*,6a*R*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 2-chloro-5-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedure described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.56 (d, $J = 1.9$, 1H), 8.14 (d, $J = 8.7$, 1H), 7.80 (dd, $J = 8.3, 1.9$, 1H), 7.73 (d, $J = 8.3$, 1H), 4.92 (s, 1H), 4.70 (td, $J = 8.3, 5.1$, 1H), 4.34 – 4.25 (m, 1H), 3.91 (dd, $J = 10.1, 2.9$, 1H), 3.54 (dd, $J = 10.2, 7.7$, 1H), 3.36 (dd, $J = 9.9, 7.5$, 1H), 3.27 (dd, $J = 10.0, 3.3$, 1H), 2.72 – 2.57 (m, 2H), 2.13 (dd, $J = 14.1, 4.8$, 1H), 1.94 (qd, $J = 6.4, 1.2$, 1H), 1.86 – 1.77 (m, 2H), 1.60 – 1.52 (m, 1H), 1.49 (s, 9H), 1.35 – 1.25 (m, 1H), 0.96 (s, 9H); MS (ESI+) m/z 596 (M+H)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3a*R*,4*S*,6a*S*)-2-(2-chloro-5-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate from Step A for *tert*-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.56 (d, $J = 2.2$ Hz, 1H), 8.41 (d, $J = 7.0$ Hz, 1H), 7.80 (dd, $J = 8.3, 2.2$ Hz, 1H), 7.74 (d, $J = 8.3$ Hz, 1H), 4.25-4.32 (m, 1H), 3.94 (dd, $J = 10.2, 2.6$ Hz, 1H), 3.58 (dd, $J = 7.4, 4.3$ Hz, 1H), 3.49 (dd, $J = 10.1, 7.2$ Hz, 1H), 3.34 (dd, $J = 9.9, 7.0$ Hz, 1H), 3.30 (dd, $J = 9.9, 3.1$ Hz, 1H), 2.58-2.66 (m, 2H), 1.87-2.45 (m, 2H), 2.14 (dd, $J = 14.0, 4.4$ Hz, 1H), 1.96-2.04 (m, 1H), 1.82-1.88 (m, 1H), 1.52-1.60 (m, 1H), 1.41 (dd, $J = 13.9, 7.5$ Hz, 1H), 1.30-1.38 (m, 1H), 0.97 (s, 9H); MS (ESI-) m/z 494 (M-H)⁻.

Example 429

***N*¹-((3*aR*,4*S*,6*aS*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-L-leucinamide**

Step A: *tert*-Butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(2-chloro-4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate was prepared by substituting *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamate from Example 226 for (*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide and 2-chloro-4-(trifluoromethyl)benzene-1-sulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in the procedure described in Example 319: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.33 (d, *J* = 8.2, 1H), 8.14 (d, *J* = 8.7, 1H), 7.99 (s, 1H), 7.75 – 7.71 (m, 1H), 4.95 (s, 1H), 4.71 (td, *J* = 8.3, 4.9, 1H), 4.33 – 4.25 (m, 1H), 3.92 (dd, *J* = 10.2, 2.9, 1H), 3.53 (dd, *J* = 10.2, 7.7, 1H), 3.38 (dd, *J* = 9.9, 7.4, 1H), 3.30 (dd, *J* = 10.0, 3.3, 1H), 2.72 – 2.58 (m, 2H), 2.14 (dd, *J* = 14.1, 4.7, 1H), 1.93 (dt, *J* = 18.2, 6.2, 1H), 1.86 – 1.77 (m, 2H), 1.57 (ddd, *J* = 16.4, 12.5, 8.6, 1H), 1.50 (s, 9H), 1.31 (ddd, *J* = 16.0, 13.2, 6.7, 1H), 0.97 (s, 9H); MS (ESI+) *m/z* 596 (M+H)⁺.

Step B: The title compound was prepared by substituting *tert*-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(2-chloro-4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate from Step A for *tert*-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-*d*₅) δ ppm 8.44 (d, *J* = 7.0 Hz, 1H), 8.35 (d, *J* = 8.2 Hz, 1H), 7.99 (d, *J* = 1.7 Hz, 1H), 7.74 (dd, *J* = 8.2, 1.7 Hz, 1H), 4.25-4.32 (m, 1H), 3.94 (dd, *J* = 10.1, 2.8 Hz, 1H), 3.59 (dd, *J* = 7.4, 4.4 Hz, 1H), 3.49 (dd, *J* = 10.2, 7.3 Hz, 1H), 3.31-3.39 (m, 2H), 2.58-2.67 (m, 2H), 1.86-2.48 (m, 2H), 2.15 (dd, *J* = 14.0, 4.4 Hz, 1H), 1.97-2.05 (m, 1H), 1.82-1.88 (m, 1H), 1.53-1.61 (m, 1H), 1.42 (dd, *J* = 14.0, 7.4 Hz, 1H), 1.31-1.39 (m, 1H), 0.98 (s, 9H); MS (ESI-) *m/z* 494 (M-H)⁻.

DEMANDE OU BREVET VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME.

CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 À 313

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets

JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE VOLUME

THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 313


NOTE: For additional volumes, please contact the Canadian Patent Office

NOM DU FICHER / FILE NAME :

NOTE POUR LE TOME / VOLUME NOTE:

We claim

1. A compound of formula (I),



or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, wherein

L^1 is $C(O)$, $S(O)_2$, $SO_2N(R^4)$, $C(O)O$ or $-(CR^aR^b)_m-$;

R^1 is alkyl, G^1 , $-CH(G^1)_2$, $-(CR^aR^b)_m-G^1$, $-(CR^aR^b)_m-CH(G^1)_2$, $-(CR^eR^f)_n-N(R^5)_2$, $-(CR^eR^f)_n-N(R^5)-C(O)O(alkyl)$, $-(CR^eR^f)_n-N(R^5)-C(O)(alkyl)$, or $-(CR^eR^f)_n-N(R^5)-SO_2R^6$; or

L^1-R^1 taken together are hydrogen, alkyl, hydroxyalkyl, G^1 , or $-CH(G^1)_2$;

L^2 is $-(CR^cR^d)_p-$, $C(O)$, $C(O)N(R^4)$, $S(O)_2$, $SO_2N(R^5)$, or $C(O)O$;

R^2 is alkyl, G^2 , $-C(R^c)(G^2)(G^3)$, $-(CR^cR^d)_p-G^2$, $-(CR^cR^d)_p-CH(G^2)(G^3)$, $-(CR^gR^h)_q-N(R^5)-C(O)O(alkyl)$, $-(CR^gR^h)_q-N(R^5)-C(O)O-G^2$, $-(CR^gR^h)_q-N(R^5)-C(O)(alkyl)$, $-(CR^gR^h)_q-N(R^5)-SO_2R^6$, $-(CR^gR^h)_q-N(R^4)(R^5)$, $-(CR^gR^h)_q-N(R^5)-C(O)N(R^5)-(alkyl)$, or $-(CR^gR^h)_q-N(R^5)-C(O)N(R^5)-G^2$; or

L^2-R^2 taken together are alkyl, G^2 , or $-C(R^c)(G^2)(G^3)$;

m and p , at each occurrence, are each independently 1, 2, 3, 4, 5, or 6;

n and q , at each occurrence, are each independently 1, 2, 3, 4, or 5;

R^a , R^b , R^c , and R^d , at each occurrence, are each independently hydrogen, alkyl, arylalkyl, halogen, haloalkyl or OR^7 ; or

R^a and R^b , or R^c and R^d , together with the carbon atom to which they are attached, optionally form a C_{3-6} cycloalkyl ring;

R^e , R^f , R^g , and R^h , at each occurrence, are each independently hydrogen, alkyl, halogen, haloalkyl, OR^7 , cycloalkylalkyl, heteroaryl, arylalkyl, or heteroarylalkyl; wherein the aryl, cycloalkyl and heteroaryl groups of aryl, cycloalkyl and heteroaryl are each independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of alkyl and haloalkyl;

G^1 , G^2 , and G^3 at each occurrence, are each independently aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; wherein G^1 , G^2 , and G^3 at each occurrence are each independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cyano, haloalkyl, halogen, nitro, oxo, phenyl, $N(R^7)_2$, $N(R^7)C(O)R^7$, OR^7 , $C(O)R^7$, $C(O)OR^7$, $C(O)N(R^7)_2$, SO_2R^8 , and $SO_2N(R^7)_2$; and wherein G^1 is other than quinoline, quinazolinone, or pyridopyrimidinone;

R^3 is hydrogen, alkyl, haloalkyl, cycloalkyl, or cycloalkylalkyl;

R^4 , R^5 , and R^7 , at each occurrence, are each independently hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, or haloalkyl; wherein said aryl, the aryl of arylalkyl and cycloalkyl are independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of alkyl, haloalkyl, and halogen;

R^6 is alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; wherein said aryl, heteroaryl, and heterocycle are independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of alkyl, haloalkyl, and halogen;

R^8 is alkyl or haloalkyl;

with the proviso that L^1-R^1 and L^2-R^2 are not both alkyl at the same time;

and with the proviso that when L^1-R^1 is alkyl, L^2-R^2 is other than $C(O)N(R^4)$, wherein R^4 is alkyl;

and with the further proviso that the compound is other than:

N-(2-trityloctahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

N-(octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide

N-methyl-*N*-(2-trityloctahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

N-methyl-*N*-(octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

6-(2-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)methyl-2*H*-pyrido[3,2-*b*][1,4]thiazin-3(4*H*)-one;

tert-butyl 2-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)octahydrocyclopenta[*c*]pyrrol-4-ylcarbamate;

tert-butyl 2-benzyl octahydrocyclopenta[*c*]pyrrol-4-ylcarbamate; or

tert-butyl octahydrocyclopenta[*c*]pyrrol-4-ylcarbamate.

2. The compound according to claim 1, wherein

L^1 is $-(CR^aR^b)_m-$;

- R^a and R^b are each hydrogen;
 m is 1;
 R^1 is G^1 ; wherein G^1 is aryl;
 L^2 is $C(O)$;
 R^2 is $-(CR^cR^d)_p-G^2$; wherein G^2 is aryl;
 p is 1;
 R^c and R^d , together with the carbon atom to which they are attached form a C_{3-6} cycloalkyl ring; and
 R^3 is hydrogen.
3. The compound according to claim 1, wherein
 L^1-R^1 together are alkyl; or
 L^1 is $-(CR^aR^b)_m-$ or $C(O)$;
 R^1 is G^1 ; wherein G^1 is aryl, cycloalkyl, or heteroaryl;
 L^2 is $C(O)$;
 R^2 is $-(CR^cR^d)_p-G^2$; wherein G^2 is aryl and p is 1 or 2;
 R^a , R^b , R^c , and R^d , at each occurrence are independently hydrogen, alkyl, or arylalkyl;
 and
 R^3 is hydrogen or alkyl.
4. The compound according to claim 1, wherein
 L^1 is $-(CR^aR^b)_m-$;
 R^a and R^b at each occurrence are each hydrogen;
 m is 1 or 2;
 R^1 is G^1 ; wherein G^1 is aryl;
 L^2 is $C(O)N(R^4)$, wherein R^4 is alkyl;
 R^2 is G^2 , wherein G^2 is aryl; and
 R^3 is hydrogen.
5. The compound according to claim 1, wherein
 L^1 is $-(CR^aR^b)_m-$, $C(O)$ or $S(O)_2$;
 R^a and R^b at each occurrence are each hydrogen;
 m is 1;
 R^1 is alkyl or G^1 ; wherein G^1 is aryl or cycloalkyl;

L^2 is C(O);

R^2 is $-(CR^cR^d)_p-G^2$; wherein

R^c and R^d at each occurrence are independently hydrogen, alkyl or OR^7 ;

p is 1;

G^2 is cycloalkyl or heterocycle; wherein said cycloalkyl or heterocycle is unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of alkyl, haloalkyl, halogen, oxo and $C(O)OR^7$;

R^7 is hydrogen; and

R^3 is hydrogen.

6. The compound according to claim 1, wherein

L^1 is $-(CR^aR^b)_m$;

R^a and R^b at each occurrence are each hydrogen;

m is 1;

R^1 is G^1 ; wherein G^1 is aryl;

L^2 - R^2 together are cycloalkyl; and

R^3 is hydrogen or cycloalkyl.

7. The compound according to claim 1, wherein

L^1 is $-(CR^aR^b)_m$;

R^a and R^b at each occurrence are each hydrogen;

m is 1;

R^1 is G^1 ; wherein G^1 is aryl;

L^2 is C(O);

R^2 is $-C(R^c)(G^2)(G^3)$, or $-(CR^cR^d)_p-CH(G^2)(G^3)$; wherein G^2 is aryl and G^3 is aryl or cycloalkyl;

R^c and R^d are each hydrogen; and

R^3 is hydrogen.

8. The compound according to claim 1, wherein

L^1 - R^1 together is hydrogen or $-CH(G^1)_2$, wherein each G^1 is aryl or heteroaryl; or

L^1 is $-(CR^aR^b)_m$, C(O), or $S(O)_2$;

R^1 is G^1 , $-CH(G^1)_2$, $-(CR^aR^b)_m-G^1$, $-(CR^aR^b)_m-CH(G^1)_2$, $-(CR^eR^f)_n-N(R^5)_2$; wherein each G^1 is aryl or heteroaryl;

R^a and R^b are each hydrogen;

R^e and R^f at each occurrence, are each independently hydrogen or alkyl;

R^5 at each occurrence, is independently hydrogen or alkyl;

L^2 is C(O);

R^2 is $-C(R^c)(G^2)(G^3)$; wherein G^2 and G^3 are each cycloalkyl;

R^c hydrogen or OR^7 , wherein R^7 is hydrogen; and

R^3 is hydrogen.

9. The compound according to claim 1, wherein

L^1 is $-(CR^aR^b)_m-$ or $S(O)_2$;

R^a and R^b at each occurrence are each hydrogen;

m is 1;

R^1 is G^1 ; wherein G^1 is aryl;

L^2 is C(O); and

R^2 is alkyl or G^2 , wherein G^2 is cycloalkyl or heterocycle; and

R^3 is hydrogen.

10. The compound according to claim 1, wherein

L^1 is $-(CR^aR^b)_m-$, C(O) or $S(O)_2$;

R^a and R^b at each occurrence are each hydrogen;

m , at each occurrence, is 1 or 2;

R^1 is G^1 , $-(CR^aR^b)_m-G^1$, or $-CH(G^1)_2$, wherein G^1 , at each occurrence, is independently aryl or heteroaryl;

L^2 is C(O);

R^2 is $-(CR^gR^h)_q-N(R^5)-C(O)O(alkyl)$, $-(CR^gR^h)_q-N(R^5)-C(O)O-G^2$, $-(CR^gR^h)_q-N(R^5)-C(O)(alkyl)$, $-(CR^gR^h)_q-N(R^5)-SO_2-R^6$, $-(CR^gR^h)_q-N(R^4)(R^5)$, $-(CR^gR^h)_q-N(R^5)-C(O)N(R^5)-(alkyl)$, or $-(CR^gR^h)_q-N(R^5)-C(O)N(R^5)-G^2$;

q is 1 or 2;

R^g and R^h , at each occurrence, are each independently hydrogen, alkyl, arylalkyl, or cycloalkylalkyl;

R^4 and R^5 at each occurrence, are each independently hydrogen, alkyl, arylalkyl, cycloalkyl or cycloalkylalkyl;

R^6 is alkyl, aryl, or cycloalkyl;

- G^2 is aryl or cycloalkyl; and
 R^3 is hydrogen, alkyl, cycloalkyl or cycloalkylalkyl.
11. The compound according to claim 1, wherein
 L^1 - R^1 together are hydrogen or hydroxyalkyl; or
 L^1 is $-(CR^aR^b)_m-$, $C(O)$ or $S(O)_2$;
 R^1 is G^1 , $-(CR^aR^b)_m-G^1$ or $-CH(G^1)_2$, wherein each G^1 is aryl or heteroaryl;
 R^a and R^b , at each occurrence, are each independently hydrogen or alkyl;
 L^2 is $S(O)_2$;
 R^2 is G^2 , wherein G^2 is aryl or heteroaryl; or
 R^3 is hydrogen, alkyl or cycloalkyl.
12. The compound according to claim 1, wherein
 L^1 is $-(CR^aR^b)_m-$;
 R^a and R^b are each hydrogen;
 R^1 is $-CH(G^1)_2$, wherein each G^1 is aryl;
 L^2 is $C(O)$;
 R^2 is $-(CR^cR^d)_p-G^2$; wherein G^2 is aryl;
 p is 1;
 R^c and R^d , at each occurrence, are each independently hydrogen or alkyl; and
 R^3 is hydrogen.
13. The compound according to claim 1, wherein
 L^1 is $C(O)$, $S(O)_2$ or $-(CR^aR^b)_m-$;
 R^a and R^b , at each occurrence, are independently hydrogen or alkyl;
 m is 1;
 R^1 is G^1 or $-(CR^aR^b)_m-G^1$, wherein G^1 is aryl or heteroaryl;
 L^2 is $-(CR^cR^d)_p-$;
 R^c and R^d are each hydrogen;
 p is 1;
 R^2 is G^2 , wherein G^2 is aryl, cycloalkyl or heteroaryl; or
 L^2 - R^2 taken together are alkyl, G^2 , or $-C(R^c)(G^2)(G^3)$, wherein G^2 and G^3 are each aryl or heteroaryl and R^c is hydrogen; and
 R^3 is hydrogen or alkyl.

14. The compound according to claim 1, wherein
 L^1 is C(O);
 R^1 is $-(CR^eR^f)_n-N(R^5)_2$;
 n is 1 or 2;
 R^e and R^f at each occurrence are each independently hydrogen or alkyl;
 R^5 at each occurrence is independently hydrogen or alkyl;
 L^2 is C(O) or S(O)₂;
 R^2 is G^2 or $-C(R^c)(G^2)(G^3)$, wherein G^2 and G^3 are each aryl or heteroaryl and R^c is hydrogen; and
 R^3 is hydrogen, alkyl, or cycloalkyl.
15. The compound according to claim 1, wherein
 L^1 is C(O);
 R^1 is $-(CR^eR^f)_n-N(R^5)_2$ or $-(CR^eR^f)_n-N(R^5)C(O)O(alkyl)$;
 n is 1 or 2;
 R^e and R^f at each occurrence are each independently hydrogen, alkyl, or arylalkyl;
 R^5 at each occurrence is independently hydrogen, alkyl or cycloalkyl;
 L^2 is C(O);
 R^2 is $-(CR^gR^h)_qN(R^4)(R^5)$ or $-(CR^gR^h)_q-N(R^5)C(O)O(alkyl)$;
 q is 1 or 2;
 R^4 is hydrogen or alkyl;
 R^g and R^h at each occurrence are each independently hydrogen or alkyl; and
 R^3 is hydrogen.
16. The compound of claim 1, wherein
 L^1-R^1 taken together are hydrogen, G^1 or $CH(G^1)_2$, wherein G^1 is aryl or heteroaryl;
 L^2 is C(O);
 R^2 is $-(CR^gR^h)_qN(R^4)(R^5)$ or $-(CR^gR^h)_q-N(R^5)C(O)O(alkyl)$;
 q is 1 or 2;
 R^4 is hydrogen, alkyl, or cycloalkylalkyl;
 R^5 is hydrogen or alkyl;
 R^g and R^h at each occurrence are each independently hydrogen or alkyl; and

R³ is hydrogen.

17. The compound of claim 1, wherein

L¹-R¹ taken together are G¹, wherein G¹ is aryl or heteroaryl;

L² is C(O);

R² is G², wherein G² is aryl or heteroaryl; and

R³ is hydrogen or alkyl.

18. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

N-[(3*aS**,4*S**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclopentanecarboxamide;

N-[(3*aS**,4*R**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclopentanecarboxamide;

N-[(3*aR**,4*R**,6*aS**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclohexyl-2-phenylacetamide;

N-[(3*aS**,4*R**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclohexyl-2-phenylacetamide;

N-[(3*aR**,4*R**,6*aS**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aR**,4*S**,6*aS**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aS**,4*S**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide;

N-[(3*aS**,4*R**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide;

N-[(3*aS**,4*S**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide;

N-[(3*aS**,4*R**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide;

N-[(3*aS**,4*S**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

(2*S*)-2-(3-benzoylphenyl)-*N*-[(3*aS**,4*S**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]propanamide;

(2*S*)-2-(3-benzoylphenyl)-*N*-[(3*aS**,4*R**,6*aR**)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]propanamide;

N-[(3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylpropanamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-propylpentanamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]cycloheptanecarboxamide;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(4-isobutylphenyl)propanamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,3-diphenylpropanamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-methyl-3-phenylpropanamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-methyl-2-phenylpropanamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclopropanecarboxamide;

2-benzyl-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethylbutanamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;

(2*R*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;

(2*S*)-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

(2*R*)-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide;

(2*R*)-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylpropanamide;

(2*S*)-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylpropanamide;

(2*S*)-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(4-isobutylphenyl)propanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclopropyl-2-phenylacetamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-cyclobutyl-2-phenylacetamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(4-chlorophenyl)-3-methylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-ethyl-2-phenylpentanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(4-hydroxyphenyl)-3-methylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-methyl-2-phenylpropanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-1-phenylcyclopropanecarboxamide;

2-benzyl-*N*-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2,3-diphenylpropanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-2-methyl-3-phenylpropanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(2-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;

N-{(3*aS*,4*S*,6*aR*)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[2-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(3-methylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(4-methylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethoxy)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(3-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

N-{(3*aS*,4*S*,6*aR*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

N-{(3*aS*,4*S*,6*aR*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

N-{(3*aS*,4*S*,6*aR*)-2-[3-(3-chlorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(3-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(3-phenylpropyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-((3*aS*,4*S*,6*aR*)-2-{3-[4-(trifluoromethyl)phenyl]propyl} octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(pyridin-4-ylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*S*,6*aR*)-2-(pyridin-3-ylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

2,2-dicyclohexyl-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;

N-{(3*aS*,4*R*,6*aR*)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

N-{(3*aS*,4*R*,6*aR*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-2-(3,3-diphenylpropyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

N-{(3*aS*,4*R*,6*aR*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

N-{(3*aS*,4*R*,6*aR*)-2-[4,4-bis(4-fluorophenyl)butyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

3-methyl-2-phenyl-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(cyclohexylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-2-methyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(2-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(3-chlorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(3-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

3-methyl-2-phenyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(3-methoxybenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(3-methylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide;

3-methyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(2-methylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(2,6-dimethylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(2-methoxybenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(4-*tert*-butylbenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(4-methoxybenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(3-cyanobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

3-methyl-2-phenyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;

3-methyl-2-phenyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[2-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(thien-2-ylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide;

3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(pyridin-4-ylmethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide;

3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(2-phenylethyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide;

3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(3-phenylpropyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[3-(4-*tert*-butylphenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

3-methyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[3-(2-methylphenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2-phenylbutanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[3-(3-chlorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

3-methyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[3-(3-methylphenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-2-phenylbutanamide;

3-methyl-2-phenyl-*N*-((3*aR*,4*S*,6*aS*)-2-{3-[3-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[*c*]pyrrol-4-yl)butanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[3-(3-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

3-methyl-2-phenyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(4-phenylbutyl)octahydrocyclopenta[*c*]pyrrol-4-yl]butanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[3-(3-chloro-5-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

3-methyl-2-phenyl-*N*-((3*aR*,4*S*,6*aS*)-2-{3-[4-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[*c*]pyrrol-4-yl)butanamide;

N-[(3*aR*,4*S*,6*aS*)-2-(3,3-diphenylpropyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[4,4-bis(4-fluorophenyl)butyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

N-{(3*aR*,4*S*,6*aS*)-2-[5,5-bis(4-fluorophenyl)pentyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

N-[(3*aS*,4*S*,6*aR*)-2-benzhydryloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzhydryloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

3-methyl-2-phenyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

3,3-dimethyl-2-phenyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

2,2-dicyclohexyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;

2-ethyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

2-propyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}pentanamide;

N-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}cyclohexanecarboxamide;

N-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}cycloheptanecarboxamide;

N-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}cyclopentanecarboxamide;

6,6-bis(4-fluorophenyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}hexanamide;

3,3-diphenyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}propanamide;

5,5-bis(4-fluorophenyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} pentanamide;
 3,3-bis(4-fluorophenyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} propanamide;
 4,4-bis(4-fluorophenyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;
 2,2-diphenyl-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;
 2,2-bis(4-fluorophenyl)-*N*-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;
*N*²-(*tert*-butoxycarbonyl)-*N*¹-{(3*aR**,4*R**,6*aS**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} -L-leucinamide;
*N*²-(*tert*-butoxycarbonyl)-*N*¹-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} -D-leucinamide;
*N*²-(*tert*-butoxycarbonyl)-*N*²-methyl-*N*¹-{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} -D-leucinamide;
 6,6-bis(4-fluorophenyl)-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} hexanamide;
 3,3-diphenyl-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} propanamide;
 5,5-bis(4-fluorophenyl)-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} pentanamide;
 3,3-bis(4-fluorophenyl)-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} propanamide;
 4,4-bis(4-fluorophenyl)-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;
 2,2-diphenyl-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;
 2,2-bis(4-fluorophenyl)-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} acetamide;
 3,3-dimethyl-2-phenyl-*N*-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} butanamide;
*N*²-(*tert*-butoxycarbonyl)-*N*¹-{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} -L-leucinamide;

N^2 -(*tert*-butyloxycarbonyl)- N^1 -{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;
 N^2 -(*tert*-butyloxycarbonyl)- N^2 -methyl- N^1 -{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;
 N^1 -[(3*aS*,4*R*,6*aR*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -(*tert*-butyloxycarbonyl)- N^2 -methyl-L-leucinamide;
2,2-dicyclohexyl-2-hydroxy-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;
 N^2 -(*tert*-butyloxycarbonyl)- N^2 -methyl- N^1 -{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
2,2-dicyclohexyl-2-hydroxy-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;
 N^2 -(*tert*-butyloxycarbonyl)- N^2 -methyl- N^1 -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
2,2-dicyclohexyl-*N*-{(3*aR*,4*S*,6*aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;
2,2-dicyclohexyl-*N*-{(3*aR*,4*R*,6*aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;
 N^1 -{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^1 -{(3*aR**,4*R**,6*aS**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;
 N^2 -methyl- N^1 -{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;
 N^1 -{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^1 -{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;
 N^2 -methyl- N^1 -{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;
 N^2 -methyl- N^1 -{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^1 -[(3*aS*,4*R*,6*aR*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-leucinamide;

N^2 -methyl- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -methyl- N^2 -(methanesulfonyl)- N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^1 -[(3a*S*,4*R*,6a*R*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl- N^2 -(methanesulfonyl)-L-leucinamide;
 N^2 -methyl- N^2 -(methanesulfonyl)- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -(methanesulfonyl)- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -(methanesulfonyl)- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;
 N^2 -(cyclopropylsulfonyl)- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -(isobutylsulfonyl)- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -(cyclopropylsulfonyl)- N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -acetyl- N^2 -methyl- N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -(2,2-dimethylpropanoyl)- N^2 -methyl- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -(2,2-dimethylpropanoyl)- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
isobutyl (*S*)-4-methyl-1-oxo-1-[(3a*S*,4*R*,6a*R*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;
cyclopentyl (*S*)-4-methyl-1-oxo-1-[(3a*S*,4*R*,6a*R*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;
 N^2 -[(*tert*-butylamino)carbonyl]- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -[(cyclopentylamino)carbonyl]- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -methyl- N^1 -[(3a*S*,4*R*,6a*R*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}]octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^2 -methyl- N^1 -((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^1 -((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 3-(trifluoromethyl)- N -{(3*aS**,4*S**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} benzenesulfonamide;
 3-(trifluoromethyl)- N -{(3*aS**,4*R**,6*aR**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} benzenesulfonamide;
 3-(trifluoromethyl)- N -{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} benzenesulfonamide;
 3-(trifluoromethyl)- N -{(3*aR*,4*R*,6*aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} benzenesulfonamide;
 3-(trifluoromethyl)- N -{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl} benzenesulfonamide;
 N -[(3*aS*,4*R*,6*aR*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;
 N -{(3*aS*,4*R*,6*aR*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;
 N -{(3*aS*,4*R*,6*aR*)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;
 N -{(3*aS*,4*R*,6*aR*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;
 N -{(3*aS*,4*R*,6*aR*)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;
 N -[(3*aS*,4*S*,6*aR*)-2-(4-hydroxybutyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;
 (3*aS**,4*S**,6*aR**)- N,N -dicyclopropyl-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-amine;
 (3*aS**,4*R**,6*aR**)-2-benzyl- N -cyclopropyloctahydrocyclopenta[*c*]pyrrol-4-amine;
 (3*aS**,4*S**,6*aR**)-2-benzyl- N -cyclopropyloctahydrocyclopenta[*c*]pyrrol-4-amine;
 N -[(3*aS**,4*S**,6*aR**)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N -cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-[(3a*S**,4*R**,6a*R**)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-cyclopropyl-*N*-[(3a*S**,4*S**,6a*R**)-octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;

N-{(3a*S**,4*S**,6a*R**)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-{(3a*S**,4*S**,6a*R**)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-cyclopropyl-3-(trifluoromethyl)-*N*-{(3a*S**,4*S**,6a*R**)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}benzenesulfonamide;

2,2-dicyclohexyl-*N*-((3a*S*,4*S*,6a*R*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

2,2-dicyclohexyl-*N*-{(3a*S*,4*S*,6a*R*)-2-[(2-phenylethyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-*N*-((3a*S*,4*S*,6a*R*)-2-{[2-(1-naphthyl)ethyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

2,2-dicyclohexyl-*N*-((3a*S*,4*S*,6a*R*)-2-{[3-(trifluoromethyl)benzyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

2,2-dicyclohexyl-*N*-((3a*S*,4*S*,6a*R*)-2-{[2-(4-fluorophenyl)ethyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)acetamide;

(2*S*)-2-phenyl-*N*-{(3a*R*,4*R*,6a*S*)-2-[(1*S*)-1-phenylethyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

(2*S*)-2-phenyl-*N*-{(3a*R*,4*S*,6a*S*)-2-[(1*S*)-1-phenylethyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

(2*S*)-2-phenyl-*N*-{(3a*S*,4*S*,6a*R*)-2-[(1*S*)-1-phenylethyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

(2*S*)-2-phenyl-*N*-{(3a*S*,4*R*,6a*R*)-2-[(1*S*)-1-phenylethyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

N-[(3a*R*,4*S*,6a*S*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*,3-dimethyl-2-phenylbutanamide;

N-[(3a*S**,4*R**,6a*R**)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-*N*,3-dimethyl-2-phenylbutanamide;

(3a*R**,4*S**,6a*S**)-*N*-benzyl-2-(3-methyl-2-phenylbutanoyl)octahydrocyclopenta[*c*]pyrrol-4-amine;

2,2-dicyclohexyl-*N*-[(3*aS*,4*R*,6*aR*)-2-(*N,N*-dimethyl-D-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N'-[(3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*-isopropyl-*N*-phenylurea;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-ylcarbamate;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(ethyl)carbamate;

tert-butyl (2*S*,3*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamate;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxohexan-2-yl(methyl)carbamate;

N-[(3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-bis(4-fluorophenyl)acetamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-isopropyl-3-methylbutanamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methylbutanamide;

tert-butyl (2*S*)-2-({[(3*aS*,4*R*,6*aR*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzoyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-2-isopropyl-3-methylbutanamide;

N-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methylbutanamide;
2-cyclohexyl-2-hydroxy-*N*-{(3*aS*,4*S*,6*aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}acetamide;

tert-butyl (*S*)-1-((3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

S-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-(methylsulfonyl)-L-leucinamide;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-(methylsulfonyl)-L-leucinamide;

*N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-neopentyl-L-leucinamide;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-neopentyl-L-leucinamide;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-neopentyl-L-norvalinamide;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-morpholin-4-ylpentanamide;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-piperidin-1-ylpentanamide;

*N*²-neopentyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*L*-leucinamide;

*N*²-neopentyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*L*-norvalinamide;

*N*²-neopentyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*L*-leucinamide;

*N*²-neopentyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*L*-norvalinamide;

*N*²-neopentyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*L*-leucinamide;

*N*²-neopentyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*L*-norvalinamide;

N-(*tert*-butoxycarbonyl)-*N*-methyl-*N*-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*L*-phenylalaninamide;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

*N*²-neopentyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*L*-norvalinamide;

*N*¹-{(3*aR*,4*S*,6*aS*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*²-neopentyl-*L*-leucinamide;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

isopropyl (*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(6-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

tert-butyl (*S*)-4,4-dimethyl-1-((3*aR*,4*S*,6*aS*)-2-(2-(methylsulfonyl)pyrimidin-5-yl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-ylcarbamate;

(*S*)-*tert*-butyl 2-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylate;

tert-butyl (1*R*)-1-isopropyl-3-oxo-3-[[[(3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]propylcarbamate;

tert-butyl (2*S*)-2-{[[[(3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate;

N-(*tert*-butoxycarbonyl)-*N*-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*L*-phenylalaninamide;

N-(*tert*-butoxycarbonyl)-*N*-methyl-*N*-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*L*-phenylalaninamide;

(*S*)-*tert*-butyl 2-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylate;

tert-butyl (1*R*)-1-isopropyl-3-oxo-3-[[[(3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]propylcarbamate;

tert-butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate;

tert-butyl (2*S*)-2-{[[[(3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate;

tert-butyl (3*S*)-3-{[[[(3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)amino]carbonyl}-3,4-dihydroisoquinoline-2(1*H*)-carboxylate;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)hexan-2-yl)carbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

isopropyl (*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

isopropyl (*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

(3*aS*,4*R*,6*aR*)-*N*-neopentyl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-neopentyl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-isopropyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-*N*-isopropyloctahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aS*,4*R*,6*aR*)-*N*-(4-fluorobenzyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-(4-fluorobenzyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-(4-fluorobenzyl)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-ethyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N,N*-diethyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-propyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N,N*-dipropyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-(cyclopropylmethyl)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-*N*-ethyloctahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-*N,N*-diethyloctahydrocyclopenta[*c*]pyrrol-4-amine;

(3a*R*,4*S*,6a*S*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-*N*-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-amine;

tert-butyl (*S*)-1-(ethyl((3a*R*,4*S*,6a*S*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-(propyl((3a*R*,4*S*,6a*S*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl)amino)pentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((cyclopropylmethyl)((3a*R*,4*S*,6a*S*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;

2-nitro-*N*-((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)benzenesulfonamide;

N-methyl-2-nitro-*N*-((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)benzenesulfonamide;

(3a*R*,4*S*,6a*S*)-*N*-methyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

tert-butyl (*S*)-4,4-dimethyl-1-(methyl((3a*R*,4*S*,6a*S*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl)amino)-1-oxopentan-2-yl(methyl)carbamate;

(2*S*)-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methyl-*N*-{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}pentanamide;

2-isopropyl-3-methyl-*N*-{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

2-isopropyl-3-methyl-*N*-{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}butanamide;

tert-butyl (*S*)-4-methyl-1-oxo-1-((3a*R*,4*S*,6a*S*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

tert-butyl methyl((*S*)-4-methyl-1-oxo-1-((3a*R*,4*S*,6a*S*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((*S*)-4-methyl-1-oxo-1-((3a*R*,4*S*,6a*S*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl (*S*)-1-((3a*R*,4*S*,6a*S*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl ethyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(3-fluoro-4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluoro-3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

(2*S*)-4-methyl-2-morpholin-4-yl-*N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide;

(2*S*)-4-methyl-2-pyrrolidin-1-yl-*N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide;

(2*S*)-4-methyl-2-piperidin-1-yl-*N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide;

tert-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl ethyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluoro-3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*R*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((*S*)-4-methyl-1-oxo-1-((3*aR*,4*R*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl (*S*)-1-((3*aS*,4*R*,6*aR*)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((2*S*,3*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;

tert-butyl methyl((*S*)-3-methyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-yl)carbamate;

tert-butyl (*S*)-3,3-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-ylcarbamate;

tert-butyl (*S*)-3,3-dimethyl-1-oxo-1-((3*aS*,4*R*,6*aR*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-ylcarbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)hexan-2-yl)carbamate;

tert-butyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

(2*S*)-4-methyl-2-pyrrolidin-1-yl-*N*-{(3*aS*,4*R*,6*aR*)-2-[3-(trifluoromethyl)benzoyl]octahydrocyclopenta[*c*]pyrrol-4-yl}pentanamide;

(2*S*)-4-methyl-*N*-[(3*aS*,4*R*,6*aR*)-2-(methylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2-pyrrolidin-1-ylpentanamide;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-(cyclopropylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide;

*N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-leucinamide;

tert-butyl methyl((*S*)-4-methyl-1-((3*aS*,4*R*,6*aR*)-octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl)carbamate;

(2*S*)-*N*-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]piperidine-2-carboxamide;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-valinamide;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-norvalinamide;

*N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-isoleucinamide;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-isoleucinamide;

*N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²,4-dimethyl-L-leucinamide;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-L-valinamide;

*N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-3-methyl-L-valinamide;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²,4-dimethyl-L-leucinamide;

*N*¹-[(3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-norvalinamide;

*N*¹-[(3*aS*,4*S*,6*aR*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-leucinamide;

*N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-L-leucinamide;

*N*¹-[(3*aR*,4*S*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-norleucinamide;

*N*¹-[(3*aR*,4*R*,6*aS*)-2-benzyloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-norvalinamide;

N^1 -[(3a*R*,4*R*,6a*S*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-leucinamide;

N^1 -[(3a*R*,4*S*,6a*S*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-norvalinamide;

N^2 -ethyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^2 -methyl- N^1 -{(3a*S*,4*R*,6a*R*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-valinamide;

(2*S*)- N -[(3a*S*,4*R*,6a*R*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]piperidine-2-carboxamide;

N^1 -[(3a*S*,4*R*,6a*R*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-valinamide;

(2*S*)- N -{(3a*S*,4*R*,6a*R*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}piperidine-2-carboxamide;

N^2 -methyl- N^1 -{(3a*S*,4*R*,6a*R*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide;

N^1 -[(3a*S*,4*R*,6a*R*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-norvalinamide;

N^2 -methyl- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-valinamide;

N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

N^1 -{(3a*S*,4*R*,6a*R*)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

N^2 -methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide;

N^2 -methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide;

N^1 -[(3a*R*,4*S*,6a*S*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-norvalinamide;

N^2 -methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^2 -methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^1 -[(3a*R*,4*S*,6a*S*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-leucinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide;

N^2 -ethyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-phenylalaninamide;

N -methyl- N -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-phenylalaninamide;

N -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-prolinamide;

(3*R*)-3-amino-4-methyl- N -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide;

N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide;

(2*S*)- N -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)piperidine-2-carboxamide;

(3*S*)- N -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;

4-methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norleucinamide;

N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N -((3a*S*,4*R*,6a*R*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-prolinamide;

(3*R*)-3-amino-4-methyl-*N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide;

(2*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)piperidine-2-carboxamide;

(2*S*)-*N*-{(3*aS*,4*R*,6*aR*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}piperidine-2-carboxamide;

*N*¹-{(3*aS*,4*R*,6*aR*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*²-methyl-L-valinamide;

(2*S*)-*N*-((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)piperidine-2-carboxamide;

*N*²-methyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide;

*N*¹-{(3*aS*,4*R*,6*aR*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*²-methyl-L-norvalinamide;

*N*²-methyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

*N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

*N*²-methyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide;

*N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-fluoro-3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*N*²-methyl-L-leucinamide;

3-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide;

3-methyl-*N*¹-((3*aS*,4*R*,6*aR*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide;

*N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-isoleucinamide;

*N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-isoleucinamide;

N^2 -methyl- N^1 -((3a*S*,4*R*,6a*R*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-isoleucinamide;
 N^2 -methyl- N^1 -((3a*S*,4*R*,6a*R*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-isoleucinamide;
 N^2 ,4-dimethyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2 ,4-dimethyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2 ,4-dimethyl- N^1 -((3a*S*,4*R*,6a*R*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2 ,4-dimethyl- N^1 -((3a*S*,4*R*,6a*R*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norleucinamide;
4-methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2 -methyl- N^1 -((3a*R*,4*R*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
 N^2 -methyl- N^1 -((3a*R*,4*R*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
 N^1 -((3a*S*,4*R*,6a*R*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
 N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
 N^1 -((3a*S*,4*R*,6a*R*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
3-cyclohexyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-alaninamide;
3-cyclohexyl- N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-alaninamide;

N^1 -((3a*R*,4*S*,6a*S*)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-L-leucinamide;

N^1 -((3a*R*,4*S*,6a*S*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-4-methyl-L-leucinamide;

N-methyl-*N*-((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-phenylalaninamide;

N^1 -((3a*R*,4*S*,6a*S*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^2 ,4-dimethyl-L-leucinamide;

N-((3a*R*,4*S*,6a*S*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*N*-methyl-L-phenylalaninamide;

N^1 -cyclopropyl- N^2 ,4-dimethyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^1 -ethyl- N^2 ,4-dimethyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^2 ,4-dimethyl- N^1 -propyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^1 -(cyclopropylmethyl)- N^2 ,4-dimethyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^1 , N^2 ,4-trimethyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^1 , N^2 -dimethyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

N^1 -((3a*R*,4*S*,6a*S*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^1 , N^2 ,4-trimethyl-L-leucinamide;

4-methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

4-methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

4-methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[2-(methylsulfonyl)pyrimidin-5-yl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^1 -{(3a*S*,4*R*,6a*R*)-2-[(3-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

N^1 -{(3a*S*,4*R*,6a*R*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

N^1 -{(3a*S*,4*R*,6a*R*)-2-[(3,4-difluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

N^1 -{(3a*S*,4*R*,6a*R*)-2-[(3,5-difluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

N^1 -{(3a*S*,4*R*,6a*R*)-2-[(4-chlorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

N^2 -methyl- N^1 -[(3a*S*,4*R*,6a*R*)-2-(phenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-L-leucinamide;

N^2 -methyl- N^1 -{(3a*S*,4*R*,6a*R*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^1 -[(3a*S*,4*R*,6a*R*)-2-(4-fluorobenzyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-leucinamide;

N^2 -methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-valinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-valinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-4-methyl-L-leucinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norleucinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-leucinamide;

N^2 -methyl- N^1 -{(3a*S*,4*S*,6a*R*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

N^2 -methyl- N^1 -{(3a*S*,4*S*,6a*R*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;

2,2-bis(4-fluorophenyl)-*N*-[(3*aR*,4*S*,6*aS*)-2-(*N*-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

2,2-bis(4-fluorophenyl)-*N*-[(3*aR*,4*S*,6*aS*)-2-(*N*-methyl-L-norvalyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

N-[(3*aR*,4*S*,6*aS*)-2-(*N*,4-dimethyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-2,2-bis(4-fluorophenyl)acetamide;

2,2-bis(4-fluorophenyl)-*N*-[(3*aR*,4*S*,6*aS*)-2-(4-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-4-((*S*)-2-(*tert*-butoxycarbonylamino)-4,4-dimethylpentanamido)hexahydrocyclopenta[*c*]pyrrol-2(1*H*)-yl)-4,4-dimethyl-1-oxopentan-2-ylcarbamate;

4-methyl-*N*¹-[(3*aR*,4*S*,6*aS*)-2-(4-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-L-leucinamide;

4-methyl-*N*¹-[(3*aR*,4*S*,6*aS*)-2-L-phenylalanyloctahydrocyclopenta[*c*]pyrrol-4-yl]-L-leucinamide;

(3*aR*,4*S*,6*aS*)-*N*-benzhydryl-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aS*,4*R*,6*aR*)-*N*-benzhydryl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

(3*aR*,4*S*,6*aS*)-*N*-benzhydryl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-amine;

*N*¹-[(3*aS*,4*R*,6*aR*)-2-benzhydryloctahydrocyclopenta[*c*]pyrrol-4-yl]-*N*²-methyl-L-leucinamide;

4-methyl-*N*²-propyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

*N*²-(cyclopropylmethyl)-4-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

*N*²-(cyclobutylmethyl)-4-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

*N*²-isobutyl-4-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

*N*²-(cyclopentylmethyl)-4-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;

N^2 -(cyclohexylmethyl)-4-methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2 -butyl-4-methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2 -ethyl-4-methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2 -(cyclopropylmethyl)-4-methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -(cyclopropylmethyl)-4-methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -isopropyl-4-methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2 -isopropyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
 N^2 -isopropyl- N^1 -((3a*S*,4*R*,6a*R*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
 N^2 -isopropyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
 N^2 -isopropyl- N^1 -((3a*S*,4*R*,6a*R*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
3-cyclohexyl- N^2 -isopropyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-alaninamide;
 N^1 -((3a*R*,4*S*,6a*S*)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^2 -isopropyl-4-methyl-L-leucinamide;
 N^1 -((3a*R*,4*S*,6a*S*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^2 -isopropyl-4-methyl-L-leucinamide;
 N^2 -isopropyl- N^1 -[(3a*R*,4*S*,6a*S*)-2-(*N*-isopropyl-4-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-L-leucinamide;
 N^2 -isopropyl- N^1 -[(3a*R*,4*S*,6a*S*)-2-(*N*-isopropyl-L-phenylalanyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-L-leucinamide;
 N^2 -isopropyl-4-methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

N^2 -isopropyl-4-methyl- N^1 -{(3*aR*,4*S*,6*aS*)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 2,2-bis(4-fluorophenyl)-*N*-[(3*aR*,4*S*,6*aS*)-2-(*N*-isopropyl-4-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]acetamide;
 N^2 -isopropyl-4-methyl- N^1 -{(3*aR*,4*S*,6*aS*)-2-[2-(methylsulfonyl)pyrimidin-5-yl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^1 -[(3*aR*,4*S*,6*aS*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -isopropyl-L-norvalinamide;
 N^1 -[(3*aS*,4*R*,6*aR*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -isopropyl-L-norvalinamide;
 N^2 -isopropyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2,N^2 -dimethyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 (3*R*)-3-(dimethylamino)-4-methyl-*N*-((3*aR*,4*S*,6*aS*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide;
 N^2 -cyclopropyl-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2,N^2 -dicyclopropyl-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2 -cyclopentyl-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2 -cyclohexyl-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2 -(1-ethylpropyl)-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2 -cyclobutyl-4-methyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 4-methyl- N^2 -neopentyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^2 -cyclopentyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;
 N^2 -cyclohexyl- N^1 -((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

N^2 -cyclopentyl- N^1 -[(3a*R*,4*S*,6a*S*)-2-(*N*-cyclopentyl-4-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-4-methyl-L-leucinamide;
 N^2,N^2 -dimethyl- N^1 -{(3a*S*,4*S*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^1 -[(3a*S*,4*R*,6a*R*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl- N^2 -neopentyl-L-leucinamide;
 N^1 -[(3a*S*,4*R*,6a*R*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -(3,3-dimethylbutyl)- N^2 -methyl-L-leucinamide;
 N^2,N^2 -dimethyl- N^1 -((3a*S*,4*R*,6a*R*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-leucinamide;
 N^1 -[(3a*S*,4*R*,6a*R*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -(4-fluorobenzyl)- N^2 -methyl-L-leucinamide;
(2*S*)-*N*-[(3a*S*,4*R*,6a*R*)-2-benzyl octahydrocyclopenta[*c*]pyrrol-4-yl]-1-(methylsulfonyl)piperidine-2-carboxamide;
(3*R*)-4-methyl-3-[(methylsulfonyl)amino]-*N*-((3a*R*,4*S*,6a*S*)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)pentanamide;
 N^2 -(methylsulfonyl)- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -(methylsulfonyl)- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-D-leucinamide;
 N^2 -ethyl- N^2 -(methylsulfonyl)- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
4-methyl- N^2 -(methylsulfonyl)- N^1 -{(3a*R*,4*S*,6a*S*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
3-methyl- N^2 -(methylsulfonyl)- N^1 -{(3a*R*,4*S*,6a*S*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-valinamide;
 N^2 -(methylsulfonyl)- N^1 -{(3a*R*,4*S*,6a*S*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide;
 N^2 -(isopropylsulfonyl)- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -(phenylsulfonyl)- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;
 N^2 -(cyclopentylsulfonyl)- N^1 -{(3a*S*,4*R*,6a*R*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-leucinamide;

isopropyl (*S*)-4,4-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

isopropyl (*S*)-3,3-dimethyl-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)butan-2-ylcarbamate;

cyclopentyl (*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-ylcarbamate;

*N*²-(2,2-dimethylpropanoyl)-*N*¹-{(3*aR*,4*S*,6*aS*)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide;

tert-butyl (*S*)-1-((3*aR*,4*S*,6*aS*)-2-(3-chloro-4-fluorophenylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(pyridin-3-ylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl methyl((*S*)-1-oxo-1-((3*aR*,4*S*,6*aS*)-2-(thiophen-2-ylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-ylamino)pentan-2-yl)carbamate;

*N*²-methyl-*N*¹-((3*aR*,4*S*,6*aS*)-2-{[4-(trifluoromethoxy)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

*N*²-methyl-*N*¹-[(3*aR*,4*S*,6*aS*)-2-(thien-2-ylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-L-norvalinamide;

*N*¹-{(3*aR*,4*S*,6*aS*)-2-[(3-chloro-4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*²-methyl-L-norvalinamide;

*N*²-methyl-*N*¹-[(3*aR*,4*S*,6*aS*)-2-(pyridin-3-ylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-L-norvalinamide;

*N*¹-{(3*aR*,4*S*,6*aS*)-2-[(4-cyanophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*²-methyl-L-norvalinamide;

*N*¹-{(3*aR*,4*S*,6*aS*)-2-[(4-methoxyphenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*²-methyl-L-norvalinamide;

*N*¹-((3*aR*,4*S*,6*aS*)-2-{[3,5-bis(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-*N*²-methyl-L-norvalinamide;

*N*¹-{(3*aR*,4*S*,6*aS*)-2-[(2-chloro-4-fluorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-*N*²-methyl-L-norvalinamide;

*N*²-methyl-*N*¹-[(3*aR*,4*S*,6*aS*)-2-(1-naphthylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-L-norvalinamide;

N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-bromo-3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^2 -methyl-L-norvalinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(3,4-dichlorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(4-*tert*-butylphenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;

N^1 -[(3a*R*,4*S*,6a*S*)-2-(1,1'-biphenyl-4-ylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-norvalinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(3,4-dimethoxyphenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(3-cyanophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;

N^1 -[(3a*R*,4*S*,6a*S*)-2-(2-furylsulfonyl)octahydrocyclopenta[*c*]pyrrol-4-yl]- N^2 -methyl-L-norvalinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(2,3-dichlorophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;

N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[4-(trifluoromethyl)benzyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

N^2 -methyl- N^1 -((3a*R*,4*S*,6a*S*)-2-{[2-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)-L-norvalinamide;

N^1 -{(3a*R*,4*S*,6a*S*)-2-[(3-bromophenyl)sulfonyl]octahydrocyclopenta[*c*]pyrrol-4-yl}- N^2 -methyl-L-norvalinamide;

N^1 -((3a*R*,4*S*,6a*S*)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^2 -methyl-L-norvalinamide;

N^1 -((3a*R*,4*S*,6a*S*)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[*c*]pyrrol-4-yl)- N^2 -methyl-L-norvalinamide;

N^2 -methyl- N^1 -{(3a*R*,4*S*,6a*S*)-2-[3-(trifluoromethyl)benzoyl]octahydrocyclopenta[*c*]pyrrol-4-yl}-L-norvalinamide;

N -[(3a*R*,4*S*,6a*S*)-2-benzyl]octahydrocyclopenta[*c*]pyrrol-4-yl]- N -isopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-[(3*aR*,4*S*,6*aS*)-2-benzyl-octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;

N-isopropyl-*N*-[(3*aR*,4*S*,6*aS*)-2-(*N*-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;

N-[(3*aR*,4*S*,6*aS*)-2-(*N*-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;

N-cyclopropyl-*N*-[(3*aS**,4*S**,6*aR**)-[2-(*N*-methyl-L-leucyl)octahydrocyclopenta[*c*]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide; and


4-fluoro-*N*-{(3*aR*,4*S*,6*aS*)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[*c*]pyrrol-4-yl} benzamide.

19. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

20. A method of treating pain in a subject in need thereof, comprising: administering to the subject a therapeutically suitable amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein the pain is acute pain, chronic pain, neuropathic pain, inflammatory pain, visceral pain, cancer pain, allodynia, fibromyalgia, sciatica, back pain, and headache pain including migraine, or combinations thereof.

21. A method of treating disorders of the central nervous system in a subject in need thereof, comprising the step of: administering a therapeutically suitable amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein the disorders of the central nervous system include stroke, epilepsy, manic depression, bipolar disorders, depression, anxiety, schizophrenia, migraine, and psychoses; neural degenerative disorders including Alzheimer's disease, AIDS related dementia, Parkinson's disease, neuropathy caused by head injury, and dementia caused by cerebrovascular disorders; disorders of the lower urinary tract including overactive bladder, prostatitis, prostatic dysuria, interstitial cystitis, and benign prostatic hyperplasia; disorders caused by psychogenic stress including bronchial asthma, unstable angina, and hypersensitive colon inflammation; cardiovascular disorders including hypertension, atherosclerosis, heart failure, and cardiac arrhythmias; drug addiction withdrawal symptoms, including ethanol addiction withdrawal symptoms; skin disorders

including pruritis and allergic dermatitis, inflammatory bowel disease; cancer; diabetes; and infertility and sexual dysfunction, or combinations thereof.



(I),